U.S. patent application number 17/246394 was filed with the patent office on 2021-10-28 for compositions and methods for t cell engineering.
The applicant listed for this patent is Gracell Biotechnologies (Shanghai) Co., Ltd., Suzhou Gracell Biotechnologies Co., Ltd.. Invention is credited to Wei CAO, Tao JIN, Liping LIU, Shuyi QIU, Zhongdong SHI, Jing SUN, Xinxin Wang, Chunhui YANG.
Application Number | 20210332101 17/246394 |
Document ID | / |
Family ID | 1000005722858 |
Filed Date | 2021-10-28 |
United States Patent
Application |
20210332101 |
Kind Code |
A1 |
Wang; Xinxin ; et
al. |
October 28, 2021 |
COMPOSITIONS AND METHODS FOR T CELL ENGINEERING
Abstract
The present disclosure relates to an engineered immune cell and
use thereof. The present disclosure provides an engineered immune
cell comprising a CAR or engineered TCR, which CAR or engineered
TCR can comprise a first antigen binding domain and a second
antigen binding domain. The engineered immune cells of the present
disclosure, when administered into a subject, can inhibit the host
immune cells such as T cells and/or NK cells and enhance the
survival and persistence of the engineered immune cells in vivo,
thereby exhibiting more effective tumor killing activity.
Inventors: |
Wang; Xinxin; (Shanghai,
CN) ; JIN; Tao; (Shanghai, CN) ; YANG;
Chunhui; (Shanghai, CN) ; SHI; Zhongdong;
(Shanghai, CN) ; LIU; Liping; (Shanghai, CN)
; SUN; Jing; (Shanghai, CN) ; QIU; Shuyi;
(Shanghai, CN) ; CAO; Wei; (Shanghai, CN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Gracell Biotechnologies (Shanghai) Co., Ltd.
Suzhou Gracell Biotechnologies Co., Ltd. |
Shanghai
Jiangsu |
|
CN
CN |
|
|
Family ID: |
1000005722858 |
Appl. No.: |
17/246394 |
Filed: |
April 30, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
PCT/CN2019/114939 |
Nov 1, 2019 |
|
|
|
17246394 |
|
|
|
|
PCT/CN2019/101651 |
Aug 20, 2019 |
|
|
|
PCT/CN2019/114939 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 14/7051 20130101;
C07K 14/70596 20130101; A61K 38/00 20130101; C07K 14/70507
20130101; A61K 35/17 20130101; A61P 35/00 20180101 |
International
Class: |
C07K 14/725 20060101
C07K014/725; A61K 35/17 20060101 A61K035/17; A61P 35/00 20060101
A61P035/00; C07K 14/705 20060101 C07K014/705 |
Foreign Application Data
Date |
Code |
Application Number |
Nov 1, 2018 |
CN |
201811297174.3 |
Dec 14, 2018 |
CN |
201811535338.1 |
Dec 18, 2018 |
CN |
201811549651.0 |
Jun 6, 2019 |
CN |
201910492882.0 |
Claims
1. An engineered immune cell, comprising: (i) one or more chimeric
polypeptide receptors (CPRs) comprising a binding moiety, wherein
the binding moiety comprises: a first antigen binding domain
exhibiting specific binding to an immune cell antigen, wherein,
upon engaging the immune cell antigen with the first antigen
binding domain, a subject's immune response toward the engineered
immune cell is reduced; and a second antigen binding domain
exhibiting specific binding to a disease-associated antigen,
wherein the disease-associated antigen and the immune cell antigen
are different, wherein each CPR of the one or more CPRs further
comprises a transmembrane domain and an intracellular signaling
domain; and (ii) a heterologous enhancer moiety capable of
enhancing one or more activities of the engineered immune cell,
wherein an endogenous T cell receptor (TCR) of the engineered
immune cell is inactivated, and wherein the engineered immune cell
exhibits: (1) enhanced degree of persistence by remaining viable
for at least about 20 days; (2) enhanced degree of expansion by at
least about 10-fold within 15 days; and/or (3) enhanced
cytotoxicity against a target cell comprising the
disease-associated antigen, as compared to that of a control immune
cell that comprises the one or more CPRs and does not comprise the
heterologous enhancer moiety.
2. The engineered immune cell of claim 1, wherein the engineered
immune cell exhibits two or more of (1) the enhanced degree of
persistence, (2) the enhanced degree of expansion, and (3) the
enhanced cytotoxicity against the target cell.
3. The engineered immune cell of claim 1, wherein (1), (2), and/or
(3) is measured in absence of any exogenous enhancer moiety.
4. The engineered immune cell of claim 1, wherein the engineered
immune cell exhibits (1) the enhanced degree of persistence and/or
(2) the enhanced degree of expansion, in a presence of the
disease-associated antigen.
5. The engineered immune cell of claim 1, wherein the engineered
immune cell exhibits (1) the enhanced degree of persistence and/or
(2) the enhanced degree of expansion, as compared to that of the
control immune cell without the heterologous enhancer moiety.
6. The engineered immune cell of claim 1, wherein the enhanced
cytotoxicity against the target cell is measured in vivo.
7. The engineered immune cell of claim 1, wherein the heterologous
enhancer moiety enhances a cytokine-associated signaling pathway in
the engineered immune cell.
8. The engineered immune cell of claim 7, wherein the cytokine is
selected from the group consisting of IL-2, IL-3, IL-4, IL-6, IL-7,
IL-8, IL-10, IL-11, IL-12, IL-15, IL-17, IL-18, IL-21, IL-23, PD-1,
PD-L1, CD122, CSFIR, CTAL-4, TIM-3, CCL21, CCL19, and TGFR
beta.
9. The engineered immune cell of claim 7, wherein heterologous
enhancer moiety comprises at least a portion of a receptor of the
cytokine.
10. The engineered immune cell of claim 1, wherein the one or more
CPRs are (a) one or more chimeric antigen receptors (CARs) or (b)
one or more engineered T cell receptors (TCRs).
11. The engineered immune cell of claim 1, wherein an endogenous
gene encoding the immune cell antigen is inactivated in the
engineered immune cell.
12. The engineered immune cell of claim 1, wherein the engineered
immune cell further exhibits enhanced expression of endogenous IL-2
and/or endogenous IFN-.gamma., as compared to that of the control
immune cell without the heterologous enhancer moiety.
13. The engineered immune cell of claim 1, wherein a CPR of the one
or more CPRs comprises both the first antigen binding domain and
the second antigen binding domain.
14. The engineered immune cell of claim 1, wherein (a) a CPR of the
one or more CPRs comprises the first antigen binding domain and
does not comprise the second antigen binding domain and (b) an
additional CPR of the one or more CPRs comprises the second antigen
binding domain and does not comprise the first antigen binding
domain.
15. The engineered immune cell of claim 1, wherein the immune cell
is an NK cell, a T cell, a monocyte, a macrophage, or a
granulocyte.
16. The engineered immune cell of claim 1, wherein the engineered
immune cell is allogeneic to the subject.
17. The engineered immune cell of claim 1, wherein the immune cell
antigen is selected from the group consisting of CD2, CD3, CD4,
CD5, CD7, CD8, CD16a, CD16b, CD25, CD27, CD28, CD30, CD38, CD45,
CD48, CD50, CD52, CD56, CD57, CD62L, CD69, CD94, CD100, CD102,
CD122, CD127, CD132, CD137, CD160, CD161, CD178, CD218, CD226,
CD244, CD159a (NKG2A), CD159c (NKG2C), NKG2E, CD279, CD314 (NKG2D),
CD305, CD335 (NKP46), CD337, CD319 (CS1), TCR.alpha., TCR.beta.,
and SLAMF7.
18. The engineered immune cell of claim 1, wherein the disease
associated antigen is selected from the group consisting of CD2,
CD3, CD4, CD5, CD7, CD8, CD19, CD20, CD22, CD25, CD28, CD30, CD33,
CD38, CD40, CD44V6, CD47, CD52, CD56, CD57, CD58, CD79b, CD80,
CD86, CD81, CD123, CD133, CD137, CD151, CD171, CD276, CLL1, B7H4,
BCMA, VEGFR-2, EGFR, GPC3, PMSA, CEACAM6, c-Met, EGFRvIII,
ErbB2/HER2, ErbB3, HER-2, HER3, ErbB4/HER-4, EphA2, IGF1R, GD2,
O-acetyl GD2, O-acetyl GD3, GHRHR, GHR, Flt1, KDR, Flt4, Flt3, CEA,
CA125, CTLA-4, GITR, BTLA, TGFBR1, TGFBR2, TGFBR1, IL6R, gp130,
Lewis, TNFR1, TNFR2, PD1, PD-L1, PD-L2, PSCA, HVEM, MAGE-A, MSLN,
NY-ESO-1, PSMA, RANK, RORl, TNFRSF4, TWEAK-R, LTPR, LIFRP, LRP5,
MUC1, MUC16, TCR.alpha., TCR.beta., TLR7, TLR9, PTCH1, WT-1, Robol,
Frizzled, OX40, Notch-I-4, APRIL, CS1, MAGE3, Claudin 18.2, Folate
receptor .alpha., Folate receptor .beta., GPC2, CD70, BAFF-R, and
TROP-2.
19. The engineered immune cell of claim 1, wherein the immune cell
antigen and the disease-associated antigen are, respectively, (a)
CD7 and CD19, (b) CD2 and CD19, or (c) TCR and CD19.
20. The engineered immune cell of claim 1, wherein an endogenous
gene encoding a subunit of the endogenous TCR is modified, and
wherein the gene is selected from the group consisting of
TCR.alpha., TCR.beta., CD3.epsilon., CD3.delta., CD3.gamma., and
CD3.zeta..
21. The engineered immune cell of claim 1, wherein the engineered
immune cell is derived from an immune cell that is (a) obtained
from peripheral blood or cord blood or (b) derived from a stem
cell.
22. A method of treatment of a subject in need thereof, comprising
administering to the subject a composition comprising an engineered
immune cell, wherein the engineered immune cell comprises: (i) one
or more chimeric polypeptide receptors (CPRs) comprising a binding
moiety, wherein the binding moiety comprises: a first antigen
binding domain exhibiting specific binding to an immune cell
antigen, wherein, upon engaging the immune cell antigen with the
first antigen binding domain, a subject's immune response toward
the engineered immune cell is reduced, and a second antigen binding
domain exhibiting specific binding to a disease-associated antigen,
wherein the disease-associated antigen and the immune cell antigen
are different, wherein each CPR of the one or more CPRs further
comprises a transmembrane domain and an intracellular signaling
domain, (ii) a heterologous enhancer moiety capable of enhancing
one or more activities of the engineered immune cell, wherein an
endogenous T cell receptor (TCR) of the engineered immune cell is
inactivated, and wherein the engineered immune cell exhibits (1)
enhanced degree of persistence by remaining viable for at least
about 20 days; (2) enhanced degree of expansion by at least about
10-fold within 15 days; and/or (3) enhanced cytotoxicity against a
target cell comprising the disease-associated antigen as compared
to that of a control immune cell that comprises the one or more
CPRs and does not comprise the heterologous enhancer moiety.
23. The method of claim 22, wherein the engineered immune cell
exhibits two or more of (1) the enhanced degree of persistence, (2)
the enhanced degree of expansion, and (3) the enhanced cytotoxicity
against the target cell.
24. The method of claim 22, wherein (1), (2), and/or (3) is
measured in absence of any exogenous enhancer moiety.
25. The method of claim 22, wherein the heterologous enhancer
moiety enhances a cytokine-associated signaling pathway in the
engineered immune cell.
26. The method of claim 22, wherein the immune cell antigen and the
disease associated antigen are, respectively, (a) CD7 and CD19, (b)
CD2 and CD19, or (c) TCR and CD19.
Description
CROSS-REFERENCE
[0001] This application is continuation application which claims
priority to International Application No. PCT/CN2019/114939, filed
Nov. 1, 2019, which claims priority to Chinese Patent Application
No. 201811297174.3, filed Nov. 1, 2018; Chinese Patent Application
No. 201811535338.1, filed Dec. 14, 2018; Chinese Patent Application
No. 201811549651.0, filed Dec. 18, 2018; Chinese Patent Application
No. 201910492882.0, filed Jun. 6, 2019; and International
Application No. PCT/CN2019/101651, filed Aug. 20, 2019, each of
which is entirely incorporated herein by reference.
SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing which
has been submitted electronically in ASCII format and is hereby
incorporated by reference in its entirety. Said ASCII copy, created
on Apr. 30, 2021, is named 56758-702(generic)_SL.txt and is 242,531
bytes in size.
BACKGROUND
[0003] The generation of tumor-specific T lymphocytes by genetic
modification to express chimeric antigen receptors (CARs) is
gaining traction as a form of synthetic biology generating powerful
antitumor effects. Because the specificity is conferred by antibody
fragments, the CAR-T cells are not MHC restricted and are therefore
more practical than approaches based on T-cell receptors that
require MHC matching.
[0004] Although early CAR-T cell clinical data obtained in the
treatment of cancer have shown promising results, the risk to
patients is higher, and some patients' T cells are effective even
after TCR or CAR redirection. Treatment is also not sufficiently
effective, which promotes the modification of allogeneic donor T
cells. However, endogenous .alpha..beta. T cell receptors on
infused allogeneic T cells can recognize primary and secondary
histocompatibility antigens in the recipient, which results in
graft versus host disease (GVHD). As a result, most current
clinical trials using autologous CAR-T cell infusion rely on immune
tolerance to prevent TCR-mediated deleterious recognition of normal
tissues following adoptive cell transfer. This approach has
achieved early clinical success, but is limited by the time and
expense of manufacturing patient-specific T cell products.
SUMMARY
[0005] Recognized herein is a need for compositions and methods for
genetically modifying immune cells (e.g., T cells) for allogeneic
cell therapy. Also recognized herein is a need for methods of
modifying immune cells (e.g., T cells) while circumventing the time
and expense of making patient-specific T cell products.
[0006] In an aspect, the present disclosure provides an engineered
immune cell, comprising: a chimeric polypeptide comprising (i) an
enhancer moiety capable of enhancing one or more activities of the
engineered immune cell, and (ii) an inducible cell death moiety
capable of effecting death of the engineered immune cell upon
contacting the chimeric polypeptide with a cell death activator,
wherein the enhancer moiety is linked to the inducible cell death
moiety, and one or more chimeric polypeptide receptors (CPRs)
comprising a binding moiety, wherein the binding moiety comprises
(i) a first antigen binding domain, which first antigen binding
domain suppresses or reduces a subject's immune response toward the
engineered immune cell when administered into the subject and (ii)
a second antigen binding domain capable of binding to a
disease-associated antigen, wherein an individual CPR of the one or
more CPRs comprises (i) the first antigen binding domain, (ii) the
second antigen binding domain, or (iii) both the first antigen
binding domain and the second antigen binding domain, wherein each
CPR of the one or more CPRs further comprises a transmembrane
domain and an intracellular signaling domain.
[0007] In some embodiments, the one or more CPRs are one or more
chimeric antigen receptor (CARs) or engineered T cell receptors
(TCRs). In some embodiments, the first antigen binding domain binds
to an immune cell antigen. In some embodiments, a gene encoding an
endogenous surface marker of the engineered immune cell is
inactivated (e.g., silenced or knocked out), wherein the endogenous
surface marker is capable of binding to the first antigen binding
domain when expressed. In some embodiments, an endogenous T cell
receptor (TCR) of the engineered immune cell is inactivated. In
some embodiments, a function of the endogenous TCR of the
engineered immune cell is inhibited by an inhibitor. In some
embodiments, a gene encoding a subunit of the endogenous TCR is
inactivated such that the endogenous TCR is inactivated. In some
embodiments, the gene encoding the subunit is TCR.alpha.,
TCR.beta., CD3.epsilon., CD3.delta., CD3.gamma., or CD3.zeta.. In
some embodiments, the chimeric polypeptide does not comprise any
self-cleaving peptide flanked by the enhancer moiety and the
inducible cell death moiety. In some embodiments, the enhancer
moiety is configured to constitutively enhance the one or more
activities of the engineered immune cell. In some embodiments, the
enhancer moiety is configured to constitutively upregulate one or
more intracellular signaling pathways of the engineered immune
cell. In some embodiments, the one or more intracellular signaling
pathways are one or more cytokine signaling pathways. In some
embodiments, the enhancer moiety is self-activating through
self-oligomerizing. In some embodiments, the enhancer moiety is
self-activating through self-dimerizing. In some embodiments, the
chimeric polypeptide is a secreted protein. In some embodiments,
the chimeric polypeptide is an intracellular protein. In some
embodiments, the chimeric polypeptide is a transmembrane protein.
In some embodiments, the enhancer moiety or the inducible cell
death moiety is contained in an ectodomain of the transmembrane
protein. In some embodiments, the enhancer moiety or the inducible
cell death moiety is contained in an endodomain of the
transmembrane protein. In some embodiments, (i) the enhancer moiety
is contained in an endodomain of the transmembrane protein and (ii)
the inducible cell death moiety are contained in an ectodomain of
the transmembrane protein. In some embodiments, (i) the enhancer
moiety is contained in an ectodomain of the transmembrane protein,
and (ii) the inducible cell death moiety is contained in an
endodomain of the transmembrane protein. In some embodiments, the
enhancer moiety is a cytokine or a cytokine receptor. In some
embodiments, the enhancer moiety is selected from the group
consisting of IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10, IL-11,
IL-12, IL-15, IL-17, IL-18, IL-21, IL-23, PD-1, PD-L1, CD122,
CSF1R, CTAL-4, TIM-3, CCL21, CCL19, TGFR beta, receptors for the
same, functional fragments thereof, functional variants thereof,
and combinations thereof. In some embodiments, the enhancer moiety
functions as a trans-activating factor or a cis-activating factor.
In some embodiments, the inducible cell death moiety is selected
from the group consisting of rapaCasp9, iCasp9, HSV-TK,
.DELTA.CD20, mTMPK, .DELTA.CD19, RQR8, Her2t, CD30, BCMA and EGFRt.
In some embodiments, the inducible cell death moiety is EGFRt, and
the cell death activator is an antibody or an antigen binding
fragment thereof that binds EGFRt. In some embodiments, the
inducible cell death moiety is HSV-TK, and the cell death activator
is GCV. In some embodiments, the inducible cell death moiety is
iCasp9, and the cell death activator is AP1903. In some
embodiments, the cell death activator comprises a nucleic acid, a
polynucleotide, an amino acid, a polypeptide, lipid, a
carbohydrate, a small molecule, an enzyme, a ribosome, a
proteasome, a variant thereof, or any combination thereof. In some
embodiments, the individual CPR of the one or more CPRs comprises
both the first antigen binding domain and the second antigen
binding domain. In some embodiments, the first antigen binding
domain and the second antigen binding domain is linked via a
linker. In some embodiments, the linker does not comprise a
self-cleaving peptide. In some embodiments, the first antigen
binding domain or the second antigen binding is a scFv. In some
embodiments, the first antigen binding domain and the second
antigen binding domain is arranged, from amino terminus to carboxyl
terminus, as: (i) VL2-VH1-VL1-VH2; (ii) VH2-VL1-VH1-VL2; (iii)
VL1-VH2-VL2-VH1; (iv) VH1-VL2-VH2-VL1; (v) VL2-VL1-VH1-VH2; (vi)
VH2-VH1-VL1-VL2; (vii) VL1-VL2-VH2-VH1; or (viii) VH1-VH2-VL2-VL1;
wherein VH1 is heavy chain variable domain of the first antigen
binding domain, VL1 is light chain variable light domain of the
first antigen binding domain, VH2 is heavy chain variable domain of
the second antigen binding domain, and VL2 is light chain variable
domain of the second antigen binding domain. In some embodiments,
the first antigen binding domain and the second antigen binding
domain is arranged, from amino terminus to carboxyl terminus, as:
(i) VL2-VH2-VL1-VH1; (ii) VL2-VH2-VH1-VL1; (iii) VL1-VH1-VL2-VH2;
(iv) VL1-VH1-VH2-VL2; (v) VH2-VL2-VL1-VH1; (vi) VH2-VL2-VH1-VL1;
(vii) VH1-VL1-VL2-VH2; or (viii) VH1-VL1-VH2-VL2, wherein VH1 is
heavy chain variable domain of the first antigen binding domain,
VL1 is light chain variable light domain of the first antigen
binding domain, VH2 is heavy chain variable domain of the second
antigen binding domain, and VL2 is light chain variable domain of
the second antigen binding domain. In some embodiments, the first
antigen binding domain and the second antigen binding domain bind
to the immune cell antigen and the disease-associated antigen. In
some embodiments, the individual CPR of the one or more CPRs
comprises only the first antigen binding domain and an additional
individual CPR of the one or more CPRs comprises only the second
antigen binding domain. In some embodiments, the immune cell
antigen is a surface protein or a secreted protein of an immune
cell. In some embodiments, the immune cell is an NK cell, a T cell,
a monocyte, an innate lymphocyte, a macrophage or a granulocyte. In
some embodiments, the immune cell is obtained from peripheral
blood, cord blood, or is derived from a stem cell. In some
embodiments, the immune cell antigen is selected from the group
consisting of CD2, CD3, CD4, CD5, CD7, CD8, CD16a, CD16b, CD25,
CD27, CD28, CD30, CD38, CD45, CD48, CD50, CD52, CD56, CD57, CD62L,
CD69, CD94, CD100, CD102, CD122, CD127, CD132, CD137, CD160, CD161,
CD178, CD218, CD226, CD244, CD159a (NKG2A), CD159c (NKG2C), NKG2E,
CD279, CD314 (NKG2D), CD305, CD335 (NKP46), CD337, CD319 (CS1),
TCR.alpha., TCR.beta. and SLAMF7. In some embodiments, the
disease-associated antigen is a tumor-associated antigen. In some
embodiments, the tumor-associated antigen is CD19, CD2, CD3, CD4,
CD5, CD7, CD8, CD19, CD20, CD22, CD25, CD28, CD30, CD33, CD38,
CD40, CD44V6, CD47, CD52, CD56, CD57, CD58, CD79b, CD80, CD86,
CD81, CD123, CD133, CD137, CD151, CD171, CD276, CLL1, B7H4, BCMA,
VEGFR-2, EGFR, GPC3, PMSA, CEACAM6, c-Met, EGFRvIII, ErbB2/HER2,
ErbB3, HER-2, HER3, ErbB4/HER-4, EphA2, IGF1R, GD2, O-acetyl GD2,
O-acetyl GD3, GHRHR, GHR, Flt1, KDR, Flt4, Flt3, CEA, CA125,
CTLA-4, GITR, BTLA, TGFBR1, TGFBR2, TGFBR1, IL6R, gp130, Lewis,
TNFR1, TNFR2, PD1, PD-L1, PD-L2, PSCA, HVEM, MAGE-A, MSLN,
NY-ESO-1, PSMA, RANK, RORl, TNFRSF4, TWEAK-R, LTPR, LIFRP, LRP5,
MUC1, MUC16, TCR.alpha., TCRb, TLR7, TLR9, PTCH1, WT-1, Robol,
Frizzled, OX40, Notch-1-4, APRIL, CS1, MAGE3, Claudin 18.2, Folate
receptor .alpha., Folate receptor .beta., GPC2, CD70, BAFF-R or
TROP-2. In some embodiments, the first antigen binding domain binds
to an immune cell antigen selected from the group consisting of
CD2, CD3, CD5, CD7 and CD137, and the second antigen binding domain
binds to CD19. In some embodiments, the first antigen binding
domain binds to CD3, and the second antigen binding domain binds to
CD19. In some embodiments, the first antigen binding domain binds
to CD7, and the second antigen binding domain binds to CD19. In
some embodiments, the first antigen binding domain binds to CD137,
and the second antigen binding domain binds to CD19. In some
embodiments, expression of one or more endogenous human leukocyte
antigen (HLA) genes of the engineered immune cell remains intact.
In some embodiments, expression of endogenous HLA-I and/or HLA-II
genes of the engineered immune cell remains intact. In some
embodiments, expression of endogenous HLA-E and/or HLA-G and/or
HLA-C genes of the engineered immune cell remains intact. In some
embodiments, expression of one or more endogenous HLA genes of the
engineered immune cell is upregulated. In some embodiments,
expression of endogenous HLA-E and/or HLA-G and/or HLA-C genes of
the engineered immune cell is upregulated. In some embodiments,
expression of an endogenous HLA-I, an endogenous HLA-II, or both of
the engineered immune cell is inhibited. In some embodiments, a
gene encoding endogenous HLA-I, endogenous HLA-II, or both is
inactivated. In some embodiments, HLA-E or HLA-G of the engineered
immune cell is overexpressed. In some embodiments, CD24, CD47, FASL
and/or PD-1 of the engineered immune cell is overexpressed. In some
embodiments, the engineered immune cell is a T cell, an NKT cell or
an NK cell. In some embodiments, the engineered immune cell is
derived from a stem cell. In some embodiments, the stem cell is a
hematopoietic stem cell (HSC) or an induced pluripotent stem cell
(iPSC). In some embodiments, the engineered immune cell is an
autologous cell or an allogeneic cell. In some embodiments, the
engineered immune cell is obtained from a subject having a
condition. In some embodiments, the engineered immune cell is
obtained from a healthy donor.
[0008] In another aspect, the present disclosure provides an
engineered immune cell, comprising: (a) one or more chimeric
antigen receptors (CARs) comprising a binding moiety, wherein the
binding moiety comprises a first antigen binding domain capable of
binding to an immune cell antigen and a second antigen binding
domain capable of binding to a disease-associated antigen, and
wherein each CAR of the one or more CARs further comprises a
transmembrane domain and an intracellular signaling domain; and (b)
an enhancer moiety capable of enhancing one or more activities of
the engineered immune cell, wherein an endogenous T cell receptor
(TCR) of the engineered immune cell is inactivated, and wherein the
engineered immune cell exhibits (i) enhanced degree of persistence
by remaining viable in vitro for at least about 20 days while in
presence of cells that are heterologous to the engineered immune
cell, (ii) enhanced degree of expansion by at least about 10-fold
within 15 days, or (iii) enhanced cytotoxicity against a target
cell comprising the immune cell antigen or the disease-associated
antigen, compared to an additional engineered immune cell
comprising the one or more CARs in (a) but not the enhancer moiety
in (b).
[0009] In some embodiments, the engineered immune cell is
characterized by exhibiting two or more of (i), (ii), and (iii). In
some embodiments, (i), (ii), and/or (iii) is measured in absence of
any exogenous enhancer moiety. In some embodiments, the immune cell
antigen is selected from the group consisting of CD2, CD3, CD4,
CD5, CD7, CD8, CD16a, CD16b, CD25, CD27, CD28, CD30, CD38, CD45,
CD48, CD50, CD52, CD56, CD57, CD62L, CD69, CD94, CD100, CD102,
CD122, CD127, CD132, CD160, CD161 CD178, CD218, CD226, CD244,
CD159a (NKG2A), CD159c (NKG2C), NKG2E, CD314 (NKG2D), CD305, CD335
(NKP46), CD337, CS1, TCR.alpha., TCR.beta., and SLAMF7. In some
embodiments, the immune cell antigen is CD7. In some embodiments,
the enhancer moiety is configured to constitutively enhance the one
or more activities of the engineered immune cell. In some
embodiments, the enhancer moiety is configured to constitutively
upregulate one or more intracellular signaling pathways of the
engineered immune cell. In some embodiments, the one or more
intracellular signaling pathways are one or more cytokine signaling
pathways. In some embodiments, the enhancer moiety is
self-activating through self-oligomerizing. In some embodiments,
the enhancer moiety is self-activating through self-dimerizing. In
some embodiments, the enhancer moiety is a cytokine or a cytokine
receptor. In some embodiments, the enhancer moiety is selected from
the group consisting of IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10,
IL-11, IL-12, IL-15, IL-17, IL-18, IL-21, IL-23, PD-1, PD-L1,
CD122, CSF1R, CTAL-4, TIM-3, CCL21, CCL19, TGFR beta, receptors for
the same, functional fragments thereof, functional variants
thereof, and combinations thereof. In some embodiments, a gene
encoding a subunit of the endogenous TCR is inactivated such that
the endogenous TCR is inactivated. In some embodiments, the gene
encoding the subunit is TCR.alpha., TCR.beta., CD3.epsilon.,
CD3.delta., CD3.gamma., or CD3.zeta.. In some embodiments, the
engineered immune cell further comprises an inducible cell death
moiety, which inducible cell death moiety effects suicide of the
engineered immune cell upon contact with a cell death activator. In
some embodiments, the inducible cell death moiety is selected from
the group consisting of rapaCasp9, iCasp9, HSV-TK, ACD20, mTMPK,
ACD19, RQR8, Her2t, CD30, BCMA, and EGFRt. In some embodiments, the
inducible cell death moiety is EGFRt, and the cell death activator
is an antibody or an antigen binding fragment thereof that binds
EGFRt. In some embodiments, the inducible cell death moiety is
HSV-TK, and the cell death activator is GCV. In some embodiments,
the inducible cell death moiety is iCasp9, and the cell death
activator is AP1903. In some embodiments, the cell death activator
comprises a nucleic acid, a polynucleotide, an amino acid, a
polypeptide, lipid, a carbohydrate, a small molecule, an enzyme, a
ribosome, a proteasome, a variant thereof, or any combination
thereof. In some embodiments, expression of one or more endogenous
human leukocyte antigen (HLA) genes of the engineered immune cell
remains intact. In some embodiments, expression of endogenous HLA-I
and/or HLA-II genes of the engineered immune cell remains intact.
In some embodiments, expression of endogenous HLA-E and/or HLA-G
and/or HLA-C genes of the engineered immune cell remains intact. In
some embodiments, expression of one or more endogenous HLA genes of
the engineered immune cell is upregulated. In some embodiments,
expression of endogenous HLA-E and/or HLA-G and/or HLA-C genes of
the engineered immune cell is upregulated. In some embodiments,
expression of an endogenous HLA-I, an endogenous HLA-II, or both of
the engineered immune cell is inhibited. In some embodiments, a
gene encoding endogenous HLA-I, endogenous HLA-II, or both is
inactivated. In some embodiments, HLA-E or HLA-G of the engineered
immune cell is overexpressed. In some embodiments, CD24, CD47, FASL
and/or PD-1 of the engineered immune cell is overexpressed. In some
embodiments, the disease-associated antigen is a tumor-associated
antigen. In some embodiments, the first antigen binding domain or
the second antigen binding domain is a scFv. In some embodiments, a
gene encoding an endogenous surface marker of the engineered immune
cell is inactivated, wherein the endogenous surface marker is
capable of binding to the first antigen binding domain when
expressed. In some embodiments, the endogenous surface marker is
CD2, CD3, CD4, CD5, CD7, CD8, CD16a, CD16b, CD25, CD27, CD28, CD30,
CD38, CD45, CD48, CD50, CD52, CD56, CD57, CD62L, CD69, CD94, CD100,
CD102, CD122, CD127, CD132, CD137, CD160, CD161, CD178, CD218,
CD226, CD244, CD159a (NKG2A), CD159c (NKG2C), NKG2E, CD279, CD314
(NKG2D), CD305, CD335 (NKP46), CD337, CD319 (CS1), TCR.alpha.,
TCR.beta. or SLAMF7. In some embodiments, the engineered immune
cell is a T cell, an NKT cell or an NK cell. In some embodiments,
the engineered immune cell is derived from a stem cell. In some
embodiments, the stem cell is a hematopoietic stem cell (HSC) or an
induced pluripotent stem cell (iPSC). In some embodiments, the
engineered immune cell is an autologous cell or an allogeneic cell.
In some embodiments, the engineered immune cell is obtained from a
subject having a condition. In some embodiments, the engineered
immune cell is obtained from a healthy donor.
[0010] In another aspect, the present disclosure provides a
pharmaceutical composition for treating a disease, comprising the
engineered immune cell described herein, and a pharmaceutically
acceptable carrier. In another aspect, the present disclosure
provides a method of treating or diagnosing a disease in a subject,
comprising administering the pharmaceutical composition to the
subject. In some embodiments, the engineered immune cell in the
pharmaceutical composition is derived from an allogeneic immune
cell. In some embodiments, the engineered immune cell derived from
the allogeneic immune cell does not induce graft versus host
disease (GvHD) in the subject. In some embodiments, the engineered
immune cell in the pharmaceutical composition is derived from an
autologous immune cell. In some embodiments, an endogenous TCR of
the engineered immune cell in the pharmaceutical composition is
functionally inactive. In some embodiments, the engineered immune
cell reduces GvHD in the subject compared to an additional immune
cell having a functionally active TCR. In some embodiments, the
disease is a cancer. In some embodiments, the cancer is lymphoma or
leukemia.
[0011] In another aspect, the present disclosure provides a cell,
comprising: a functionally inactive T cell receptor (TCR), and one
or more chimeric antigen receptors (CARs), wherein each individual
CAR of the one or more CARs comprises a binding moiety, which
binding moiety comprises (i) a first antigen binding domain, which
first antigen binding domain suppresses or reduces a subject's
immune response toward the engineered immune cell when administered
into the subject and (ii) a second antigen binding domain that
binds to a disease-associated antigen, and wherein each CAR of the
one or more CARs further comprises a transmembrane domain and an
intracellular signaling domain.
[0012] In some embodiments, the first antigen binding domain and
the second antigen binding domain is linked by a linker. In some
embodiments, the linker does not comprise a self-cleaving peptide.
In some embodiments, the first antigen binding domain and the
second antigen binding domain is arranged, from amino terminus to
carboxyl terminus, as: (i) VL2-VH1-VL1-VH2; (ii) VH2-VL1-VH1-VL2;
(iii) VL1-VH2-VL2-VH1; (iv) VH1-VL2-VH2-VL1; (v) VL2-VL1-VH1-VH2;
(vi) VH2-VH1-VL1-VL2; (vii) VL1-VL2-VH2-VH1; or (viii)
VH1-VH2-VL2-VL1, wherein VH1 is heavy chain variable domain of the
first antigen binding domain, VL1 is light chain variable light
domain of the first antigen binding domain, VH2 is heavy chain
variable domain of the second antigen binding domain, and VL2 is
light chain variable domain of the second antigen binding domain.
In some embodiments, the first antigen binding domain and the
second antigen binding domain is arranged, from amino terminus to
carboxyl terminus, as: (i) VL2-VH2-VL1-VH1; (ii) VL2-VH2-VH1-VL1;
(iii) VL1-VH1-VL2-VH2; (iv) VL1-VH1-VH2-VL2; (v) VH2-VL2-VL1-VH1;
(vi) VH2-VL2-VH1-VL1; (vii) VH1-VL1-VL2-VH2; or (viii)
VH1-VL1-VH2-VL2, wherein VH1 is heavy chain variable domain of the
first antigen binding domain, VL1 is light chain variable light
domain of the first antigen binding domain, VH2 is heavy chain
variable domain of the second antigen binding domain, and VL2 is
light chain variable domain of the second antigen binding domain.
In some embodiments, a gene encoding a subunit of an endogenous TCR
of the cell is inactivated, thereby generating the functionally
inactive TCR. In some embodiments, the gene encoding the subunit is
TCR.alpha., TCR.beta., CD3.epsilon., CD3.delta., CD3.gamma., or
CD3.zeta.. In some embodiments, the first antigen binding domain
binds to an immune cell antigen. In some embodiments, the immune
cell antigen is a surface protein or a secreted protein of an
immune cell. In some embodiments, the immune cell is an NK cell, a
T cell, a monocyte, a macrophage, or a granulocyte. In some
embodiments, the immune cell antigen is CD2, CD3, CD4, CD5, CD7,
CD8, CD16a, CD16b, CD25, CD27, CD28, CD30, CD38, CD45, CD48, CD50,
CD52, CD56, CD57, CD62L, CD69, CD94, CD100, CD102, CD122, CD127,
CD132, CD137, CD160, CD161, CD178, CD218, CD226, CD244, CD159a
(NKG2A), CD159c (NKG2C), NKG2E, CD279, CD314 (NKG2D), CD305, CD335
(NKP46), CD337, CD319 (CS1), TCR.alpha., TCR.beta. or SLAMF7. In
some embodiments, the disease-associated antigen is a
tumor-associated antigen. In some embodiments, the tumor-associated
antigen is CD19, CD2, CD3, CD4, CD5, CD7, CD8, CD19, CD20, CD22,
CD25, CD28, CD30, CD33, CD38, CD40, CD44V6, CD47, CD52, CD56, CD57,
CD58, CD79b, CD80, CD86, CD81, CD123, CD133, CD137, CD151, CD171,
CD276, CLL1, B7H4, BCMA, VEGFR-2, EGFR, GPC3, PMSA, CEACAM6, c-Met,
EGFRvIII, ErbB2/HER2, ErbB3, HER-2, HER3, ErbB4/HER-4, EphA2,
IGF1R, GD2, O-acetyl GD2, O-acetyl GD3, GHRHR, GHR, Flt1, KDR,
Flt4, Flt3, CEA, CA125, CTLA-4, GITR, BTLA, TGFBR1, TGFBR2, TGFBR1,
TL6R, gp130, Lewis, TNFR1, TNFR2, PD1, PD-L1, PD-L2, PSCA, HVEM,
MAGE-A, MSLN, NY-ESO-1, PSMA, RANK, RORl, TNFRSF4, TWEAK-R, LTPR,
LIFRP, LRP5, MUC1, MUC16, TCR.alpha., TCRb, TLR7, TLR9, PTCH1,
WT-1, Robol, Frizzled, OX40, Notch-1-4, APRIL, CS1, MAGE3, Claudin
18.2, Folate receptor .alpha., Folate receptor .beta., GPC2, CD70,
BAFF-R or TROP-2. In some embodiments, the first antigen binding
domain binds to an immune cell antigen selected from the group
consisting of CD2, CD3, CD4, CD5, CD7, CD8, CD16a, CD16b, CD25,
CD27, CD28, CD30, CD38, CD45, CD48, CD50, CD52, CD56, CD57, CD62L,
CD69, CD94, CD100, CD102, CD122, CD127, CD132, CD137, CD160, CD161,
CD178, CD218, CD226, CD244, CD159a (NKG2A), CD159c (NKG2C), NKG2E,
CD279, CD314 (NKG2D), CD305, CD335 (NKP46), CD337, CD319 (CS1),
TCR.alpha., TCR.beta. and SLAMF7, and the second antigen binding
domain binds to CD19. In some embodiments, the first antigen
binding domain binds to CD3, and the second antigen binding domain
binds to CD19. In some embodiments, the first antigen binding
domain binds to CD7, and the second antigen binding domain binds to
CD19. In some embodiments, the first antigen binding domain binds
to CD137, and the second antigen binding domain binds to CD19. In
some embodiments, the cell further comprises an enhancer moiety,
which enhancer moiety enhances one or more activities of the
engineered immune cell. In some embodiments, the enhancer moiety is
configured to constitutively enhance the one or more activities of
the engineered immune cell. In some embodiments, the enhancer
moiety is configured to constitutively upregulate one or more
intracellular signaling pathways of the engineered immune cell. In
some embodiments, the one or more intracellular signaling pathways
are one or more cytokine signaling pathways. In some embodiments,
the enhancer moiety is a cytokine or a cytokine receptor. In some
embodiments, the enhancer moiety is selected from the group
consisting of IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10, IL-11,
IL-12, IL-15, IL-17, IL-18, IL-21, IL-23, PD-1, PD-L1, CD122,
CSF1R, CTAL-4, TIM-3, CCL21, CCL19, TGFR beta, receptors for the
same, functional fragments thereof, functional variants thereof,
and combinations thereof. In some embodiments, the cell further
comprises an inducible cell death moiety capable of effecting death
of the cell upon contacting the inducible cell death moiety with a
cell death activator. In some embodiments, the inducible cell death
moiety is selected from the group consisting of rapaCasp9, iCasp9,
HSV-TK, ACD20, mTMPK, ACD19, RQR8, Her2t, CD30, BCMA, and EGFRt. In
some embodiments, the inducible cell death moiety is EGFRt, and the
cell death activator is an antibody or an antigen binding fragment
thereof that binds EGFRt. In some embodiments, the inducible cell
death moiety is HSV-TK, and the cell death activator is GCV. In
some embodiments, the inducible cell death moiety is iCasp9, and
the cell death activator is AP1903.
[0013] In another aspect, the present disclosure provides a nucleic
acid molecule comprising a first sequence encoding a chimeric
antigen receptor (CAR), wherein the CAR comprises a binding moiety,
which binding moiety comprises (i) a first antigen binding domain,
which first antigen binding domain suppresses or reduces a
subject's immune response toward the engineered immune cell when
administered into the subject linked to (ii) a second antigen
binding domain capable of binding to a disease-associated antigen,
and wherein each CAR of the one or more CARs further comprises a
transmembrane domain and an intracellular signaling domain.
[0014] In some embodiments, the first antigen binding domain binds
to an antigen selected from the group consisting of CD2, CD3, CD4,
CD5, CD7, CD8, CD16a, CD16b, CD25, CD27, CD28, CD30, CD38, CD45,
CD48, CD50, CD52, CD56, CD57, CD62L, CD69, CD94, CD100, CD102,
CD122, CD127, CD132, CD137, CD160, CD161, CD178, CD218, CD226,
CD244, CD159a (NKG2A), CD159c (NKG2C), NKG2E, CD279, CD314 (NKG2D),
CD305, CD335 (NKP46), CD337, CD319 (CS1), TCR.alpha., TCR.beta. and
SLAMF7. In some embodiments, the second antigen binding domain
binds to CD19, CD2, CD3, CD4, CD5, CD7, CD8, CD19, CD20, CD22,
CD25, CD28, CD30, CD33, CD38, CD40, CD44V6, CD47, CD52, CD56, CD57,
CD58, CD79b, CD80, CD86, CD81, CD123, CD133, CD137, CD151, CD171,
CD276, CLL1, B7H4, BCMA, VEGFR-2, EGFR, GPC3, PMSA, CEACAM6, c-Met,
EGFRvIII, ErbB2/HER2, ErbB3, HER-2, HER3, ErbB4/HER-4, EphA2,
IGF1R, GD2, O-acetyl GD2, O-acetyl GD3, GHRHR, GHR, Flt1, KDR,
Flt4, Flt3, CEA, CA125, CTLA-4, GITR, BTLA, TGFBR1, TGFBR2, TGFBR1,
IL6R, gp130, Lewis, TNFR1, TNFR2, PD1, PD-L1, PD-L2, PSCA, HVEM,
MAGE-A, MSLN, NY-ESO-1, PSMA, RANK, RORl, TNFRSF4, TWEAK-R, LTPR,
LIFRP, LRP5, MUC1, MUC16, TCR.alpha., TCRb, TLR7, TLR9, PTCH1,
WT-1, Robol, Frizzled, OX40, Notch-1-4, APRIL, CS1, MAGE3, Claudin
18.2, Folate receptor .alpha., Folate receptor .beta., GPC2, CD70,
BAFF-R or TROP-2. In some embodiments, the nucleic acid molecule
further comprises a second sequence encoding an enhancer moiety,
which enhancer moiety enhances one or more activities of the CAR
when expressed in a cell. In some embodiments, the enhancer moiety
is selected from the group consisting of IL-2, IL-3, IL-4, IL-6,
IL-7, IL-8, IL-10, IL-11, IL-12, IL-15, IL-17, IL-18, IL-21, IL-23,
PD-1, PD-L1, CD122, CSF1R, CTAL-4, TIM-3, CCL21, CCL19, TGFR beta,
receptors for the same, functional fragments thereof, functional
variants thereof, and combinations thereof. In some embodiments,
the nucleic acid molecule further comprises a second sequence
encoding an inducible cell death moiety, which inducible cell death
moiety, when expressed in a cell, effects death of the cell upon
contacting the inducible cell death moiety with a cell death
activator. In some embodiments, the inducible cell death moiety is
selected from the group consisting of rapaCasp9, iCasp9, HSV-TK,
.DELTA.CD20, mTMPK, .DELTA.CD19, RQR8, Her2t, CD30, BCMA, and
EGFRt. In some embodiments, the nucleic acid molecule further
comprises a third sequence flanked by the first sequence and the
second sequence, wherein the third sequence encodes a cleavable
linker. In some embodiments, the cleavable linker is a
self-cleaving peptide. In some embodiments, the nucleic acid
molecule further comprises a regulatory sequence regulating
expression of the first sequence and/or the second sequence.
[0015] In another aspect, the present disclosure provides a kit
comprising a nucleic acid molecule described herein.
[0016] In another aspect, the present disclosure provides a method
of generating an engineered cell, comprising (a) delivering the
nucleic acid molecule described herein into a cell; and (b)
expressing the nucleic acid molecule in the cell, thereby
generating the engineered cell.
[0017] In another aspect, the present disclosure provides an
engineered immune cell, comprising: an enhancer moiety capable of
enhancing one or more activities of the engineered immune cell; a
chimeric antigen receptor (CAR) comprising an antigen binding
domain that specifically binds CD7, wherein the CAR further
comprises a transmembrane domain and an intracellular signaling
domain; wherein an endogenous CD7 in the engineered immune cell is
inactivated. In some embodiments, the enhancer moiety is selected
from the group consisting of IL-2, IL-7, IL-12, IL-15, IL-18,
IL-21, PD-1, PD-L1, CSF1R, CTAL-4, TIM-3, CCL21, CCL19, and TGFR
beta, receptors for the same, and a combination thereof. In some
embodiments, an endogenous T cell receptor (TCR) of the engineered
immune cell is inactivated. In some embodiments, the engineered
immune cell further comprises a polypeptide that comprises an
inducible cell death moiety capable of effecting death of the
engineered immune cell upon contacting the polypeptide with a cell
death activator. In some embodiments, the enhancer moiety is part
of the polypeptide. In some embodiments, the enhancer moiety is not
a part of the CAR. In some embodiments, the enhancer moiety is a
part of the CAR. In some embodiments, the engineered immune cell is
a T cell, an NKT cell or an NK cell. In some embodiments, the
engineered immune cell is derived from a stem cell. In some
embodiments, the stem cell is a hematopoietic stem cell (HSC) or an
induced pluripotent stem cell (iPSC). In some embodiments, the
engineered immune cell is an autologous cell or an allogeneic cell.
In some embodiments, the engineered immune cell is obtained from a
subject having a condition. In some embodiments, the engineered
immune cell is obtained from a healthy donor.
[0018] In another aspect, the present disclosure provides a method
of generating the engineered immune cell described herein,
comprising (a) delivering one or more nucleic acid molecules
encoding (i) the enhancer moiety and (ii) the CAR in to an immune
cell; and (b) expressing the one or more nucleic acid molecules in
the immune cell, thereby generating the engineered immune cell. In
some embodiments, a single nucleic acid molecule encodes (i) the
enhancer moiety and (ii) the CAR. In some embodiments, the single
nucleic acid molecule comprises a self-cleaving peptide flanked by
(i) the enhancer moiety and (ii) the CAR. In some embodiments, the
single nucleic acid molecule does not comprise any self-cleaving
peptide flanked by (i) the enhancer moiety and (ii) the CAR. In
some embodiments, (i) a first nucleic acid molecule encodes the
enhancer moiety and (ii) a second nucleic acid molecule encodes the
CAR.
[0019] In another aspect, the present disclosure provides a method
of treating or diagnosing a condition in a subject, comprising
administering the engineered immune cell described herein to the
subject. In some embodiments, the engineered immune cell is derived
from an autologous immune cell of the subject. In some embodiments,
the engineered immune cell is derived from an allogeneic immune
cell. In some embodiments, the condition is cancer (e.g., T cell
and/or NK cell malignancies).
[0020] In another aspect, the present disclosure provides an
engineered immune cell, comprising: a single chimeric antigen
receptor (CAR) comprising (i) a first antigen binding domain that
specifically binds CD7 and (ii) a second antigen binding domain
capable of binding to a disease-associated antigen, the CAR further
comprises a transmembrane domain and an intracellular signaling
domain, wherein a gene encoding endogenous CD7 is inactivated in
the engineered immune cell. In some embodiments, the engineered
immune further comprises an enhancer moiety capable of enhancing
one or more activities of the engineered immune cell. In some
embodiments, the enhancer moiety is selected from the group
consisting of IL-2, IL-7, IL-12, IL-15, IL-18, IL-21, PD-1, PD-L1,
CSF1R, CTAL-4, TIM-3, CCL21, CCL19, and TGFR beta, receptors for
the same, and a combination thereof. In some embodiments, an
endogenous T cell receptor (TCR) of the engineered immune cell is
inactivated. In some embodiments, the engineered immune cell
further comprises a polypeptide that comprises an inducible cell
death moiety capable of effecting death of the engineered immune
cell upon contacting the polypeptide with a cell death activator.
In some embodiments, the enhancer moiety is part of the
polypeptide. In some embodiments, the engineered immune cell is a T
cell, an NKT cell or an NK cell. In some embodiments, the
engineered immune cell is derived from a stem cell. In some
embodiments, the stem cell is a hematopoietic stem cell (HSC) or an
induced pluripotent stem cell (iPSC). In some embodiments, the
engineered immune cell is an autologous cell or an allogeneic cell.
In some embodiments, the engineered immune cell is obtained from a
subject having a condition. In some embodiments, the engineered
immune cell is obtained from a healthy donor.
[0021] In another aspect, the present disclosure provides a method
of generating the engineered immune cell, comprising (a) delivering
one or more nucleic acid molecules encoding the single CAR into an
immune cell; and (b) expressing the one or more nucleic acid
molecules in the immune cell, thereby generating the engineered
immune cell. In some embodiments, a single nucleic acid molecule
encodes the single CAR.
[0022] In another aspect, the present disclosure provides a method
of treating or diagnosing a condition in a subject, comprising
administering the engineered immune cell to the subject. In some
embodiments, the engineered immune cell is derived from an
autologous immune cell of the subject. In some embodiments, the
engineered immune cell is derived from an allogeneic immune cell.
In some embodiments, the condition is cancer (e.g., T cell and/or
NK cell malignancies).
[0023] In another aspect, the present disclosure provides a method
of delivering an allogeneic cell therapy comprising: administering
to a subject in need thereof a population of engineered immune
cells, an individual engineered immune cell of the population
comprises: (a) one or more chimeric antigen receptors (CARs)
comprising a binding moiety, wherein the binding moiety comprises a
first antigen binding domain capable of binding to an immune cell
antigen and a second antigen binding domain capable of binding to a
disease-associated antigen, which first antigen binding domain
suppresses or reduces a subject's immune response toward the
engineered immune cell when administered into the subject; (b) an
enhancer moiety capable of enhancing one or more activities of the
engineered immune cell, wherein an endogenous T cell receptor (TCR)
of the engineered immune cell is inactivated, and wherein the
engineered immune cell exhibits (i) enhanced degree of persistence
by remaining viable in vitro for at least about 20 days while in
presence of cells that are heterologous to the engineered immune
cell, (ii) enhanced degree of expansion by at least about 10-fold
within 15 days, or (iii) enhanced cytotoxicity against a target
cell comprising the immune cell antigen or the disease-associated
antigen.
[0024] In some embodiments, the administering of the population of
the engineered immune cells alone without the use of an additional
proliferation agent yields (i) enhanced degree of persistence by
remaining viable in vitro for at least about 20 days while in
presence of immune cells that are heterologous to the engineered
immune cell, (ii) enhanced degree of expansion by at least about
10-fold within 15 days, or (iii) enhanced cytotoxicity against a
target cell comprising the immune cell antigen or the
disease-associated antigen. In some embodiments, each CAR of the
one or more CARs further comprises a transmembrane domain and an
intracellular signaling domain, wherein the first antigen binding
domain suppresses or reduces a subject's immune response toward the
engineered immune cell when administered into the subject. In some
embodiments, an endogenous CD7 of the individual engineered immune
cell is inactivated. In some embodiments, the immune cell antigen
is CD7.
[0025] In some embodiments, the enhancer moiety is configured to
constitutively enhance the one or more activities of the individual
engineered immune cell. In some embodiments, the enhancer moiety is
configured to constitutively upregulate one or more intracellular
signaling pathways of the engineered immune cell. In some
embodiments, the one or more intracellular signaling pathways are
one or more cytokine signaling pathways. In some embodiments, the
enhancer moiety is self-activating through self-oligomerizing. In
some embodiments, the enhancer moiety is self-activating through
self-dimerizing. In some embodiments, the enhancer moiety is a
cytokine or a cytokine receptor. In some embodiments, the enhancer
moiety is selected from the group consisting of IL-2, IL-3, IL-4,
IL-6, IL-7, IL-8, IL-10, IL-11, IL-12, IL-15, IL-17, IL-18, IL-21,
IL-23, PD-1, PD-L1, CD122, CSF1R, CTAL-4, TIM-3, CCL21, CCL19, TGFR
beta, receptors for the same, functional fragments thereof,
functional variants thereof, and combinations thereof. In some
embodiments, a gene encoding a subunit of the endogenous TCR is
inactivated such that the endogenous TCR is inactivated. In some
embodiments, the gene encoding the subunit is TCR.alpha.,
TCR.beta., CD3.epsilon., CD3.delta., CD3.gamma., or CD3.zeta.. In
some embodiments, the individual engineered immune cell further
comprises an inducible cell death moiety, which inducible cell
death moiety effects suicide of the engineered immune cell upon
contact with a cell death activator. In some embodiments, the
inducible cell death moiety is selected from the group consisting
of rapaCasp9, iCasp9, HSV-TK, ACD20, mTMPK, ACD19, RQR8, Her2t,
CD30, BCMA, and EGFRt. In some embodiments, the inducible cell
death moiety is EGFRt, and the cell death activator is an antibody
or an antigen binding fragment thereof that binds EGFRt. In some
embodiments, the inducible cell death moiety is HSV-TK, and the
cell death activator is GCV. In some embodiments, the inducible
cell death moiety is iCasp9, and the cell death activator is
AP1903. In some embodiments, the cell death activator comprises a
nucleic acid, a polynucleotide, an amino acid, a polypeptide,
lipid, a carbohydrate, a small molecule, an enzyme, a ribosome, a
proteasome, a variant thereof, or any combination thereof. In some
embodiments, expression of one or more endogenous human leukocyte
antigen (HLA) genes of the individual engineered immune cell
remains intact. In some embodiments, expression of endogenous HLA-I
and/or HLA-II genes of the individual engineered immune cell
remains intact. In some embodiments, expression of endogenous HLA-E
and/or HLA-G and/or HLA-C genes of the individual engineered immune
cell remains intact. In some embodiments, expression of one or more
endogenous HLA genes of the individual engineered immune cell is
upregulated. In some embodiments, expression of endogenous HLA-E
and/or HLA-G and/or HLA-C genes of the individual engineered immune
cell is upregulated. In some embodiments, expression of an
endogenous HLA-I, an endogenous HLA-II, or both of the individual
engineered immune cell is inhibited. In some embodiments, a gene
encoding endogenous HLA-I, endogenous HLA-II, or both is
inactivated. In some embodiments, HLA-E or HLA-G of the engineered
immune cell is overexpressed. In some embodiments, CD24, CD47, FASL
and/or PD-1 of the engineered immune cell is overexpressed.
[0026] In some embodiments, the disease-associated antigen is a
tumor-associated antigen. In some embodiments, the first antigen
binding domain or the second antigen binding domain is a scFv. In
some embodiments, the individual engineered immune cell is a T
cell, an NKT cell or an NK cell. In some embodiments, the
individual engineered immune cell is derived from a stem cell. In
some embodiments, the stem cell is a hematopoietic stem cell (HSC)
or an induced pluripotent stem cell (iPSC). In some embodiments,
the individual engineered immune cell is an allogeneic cell. In
some embodiments, the individual engineered immune cell is obtained
from a healthy donor.
[0027] In an aspect, the present disclosure provides a cell
comprising: (a) one or more chimeric antigen receptors (CARs)
comprising a binding moiety, wherein the binding moiety comprises
an antigen binding domain capable of binding to an immune cell
antigen, and wherein each CAR of the one or more CARs further
comprises a transmembrane domain and an intracellular signaling
domain; and (b) an enhancer moiety capable of enhancing one or more
activities of the cell, wherein an endogenous T cell receptor (TCR)
of the cell is inactivated.
[0028] In some embodiments, the enhancer moiety enhances one or
more activities of the cell. In some embodiments, the enhancer
moiety is configured to constitutively enhance the one or more
activities of the cell. In some embodiments, the enhancer moiety is
configured to constitutively upregulate one or more intracellular
signaling pathways of the cell. In some embodiments, the one or
more intracellular signaling pathways are one or more cytokine
signaling pathways. In some embodiments, the enhancer moiety is a
cytokine or a cytokine receptor. In some embodiments, the enhancer
moiety is selected from the group consisting of IL-2, IL-3, IL-4,
IL-6, IL-7, IL-8, IL-10, IL-11, IL-12, IL-15, IL-17, IL-18, IL-21,
IL-23, PD-1, PD-L1, CD122, CSF1R, CTAL-4, TIM-3, CCL21, CCL19, TGFR
beta, receptors for the same, functional fragments thereof,
functional variants thereof, and combinations thereof. In some
embodiments, the method further comprises an inducible cell death
moiety capable of effecting death of the cell upon contacting the
inducible cell death moiety with a cell death activator. In some
embodiments, the inducible cell death moiety is selected from the
group consisting of rapaCasp9, iCasp9, HSV-TK, ACD20, mTMPK, ACD19,
RQR8, Her2t, CD30, BCMA, and EGFRt. In some embodiments, the
inducible cell death moiety is EGFRt, and the cell death activator
is an antibody or an antigen binding fragment thereof that binds
EGFRt. In some embodiments, the inducible cell death moiety is
HSV-TK, and the cell death activator is GCV. In some embodiments,
the inducible cell death moiety is iCasp9, and the cell death
activator is AP1903. In some embodiments, a gene encoding an
endogenous surface marker of the cell is inactivated, wherein the
endogenous surface marker is capable of binding to the first
antigen binding domain when expressed. In some embodiments, the
endogenous surface marker is CD2, CD3, CD4, CD5, CD7, CD8, CD16a,
CD16b, CD25, CD27, CD28, CD30, CD38, CD45, CD48, CD50, CD52, CD56,
CD57, CD62L, CD69, CD94, CD100, CD102, CD122, CD127, CD132, CD137,
CD160, CD161, CD178, CD218, CD226, CD244, CD159a (NKG2A), CD159c
(NKG2C), NKG2E, CD279, CD314 (NKG2D), CD305, CD335 (NKP46), CD337,
CD319 (CS1), TCR.alpha., TCR.beta. or SLAMF7.
[0029] In an aspect, the present disclosure provides a method for
treating a lymphoid malignancy, comprising administering to a
patient in need thereof a population of engineered immune cells,
wherein an individual engineered immune cell of the population
comprises: (a) one or more chimeric antigen receptors (CARs)
comprising a binding moiety, wherein the binding moiety comprises
an antigen binding domain capable of binding to an immune cell
antigen, and wherein each CAR of the one or more CARs further
comprises a transmembrane domain and an intracellular signaling
domain; and (b) an enhancer moiety capable of enhancing one or more
activities of the engineered immune cell, wherein an endogenous T
cell receptor (TCR) of the engineered immune cell is inactivated,
wherein (i) the number of affected cells in peripheral blood or the
number of affected cells in bone marrow is reduced by at least 50%
within 3 weeks after a last dosing of the engineered immune cells,
and (ii) the number of any one or more of autologous T cell,
granulocyte, and NK cell in peripheral blood starts to increase
within 3 weeks after a last dosing of the engineered immune
cells.
[0030] In some embodiments, the enhancer moiety enhances one or
more activities of the engineered immune cell. In some embodiments,
the enhancer moiety is configured to constitutively enhance the one
or more activities of the engineered immune cell. In some
embodiments, the enhancer moiety is configured to constitutively
upregulate one or more intracellular signaling pathways of the
engineered immune cell. In some embodiments, the one or more
intracellular signaling pathways are one or more cytokine signaling
pathways. In some embodiments, the enhancer moiety is a cytokine or
a cytokine receptor. In some embodiments, the enhancer moiety is
selected from the group consisting of IL-2, IL-3, IL-4, IL-6, IL-7,
IL-8, IL-10, IL-11, IL-12, IL-15, IL-17, IL-18, IL-21, IL-23, PD-1,
PD-L1, CD122, CSF1R, CTAL-4, TIM-3, CCL21, CCL19, TGFR beta,
receptors for the same, functional fragments thereof, functional
variants thereof, and combinations thereof. In some embodiments,
the engineered immune cell further comprises an inducible cell
death moiety capable of effecting death of the cell upon contacting
the inducible cell death moiety with a cell death activator.
[0031] In some embodiments, the inducible cell death moiety is
selected from the group consisting of rapaCasp9, iCasp9, HSV-TK,
ACD20, mTMPK, ACD19, RQR8, Her2t, CD30, BCMA, and EGFRt. In some
embodiments, the inducible cell death moiety is EGFRt, and the cell
death activator is an antibody or an antigen binding fragment
thereof that binds EGFRt. In some embodiments, the inducible cell
death moiety is HSV-TK, and the cell death activator is GCV. In
some embodiments, the inducible cell death moiety is iCasp9, and
the cell death activator is AP1903. In some embodiments, a gene
encoding an endogenous surface marker of the cell is inactivated,
wherein the endogenous surface marker is capable of binding to the
first antigen binding domain when expressed. In some embodiments,
the endogenous surface marker is CD2, CD3, CD4, CD5, CD7, CD8,
CD16a, CD16b, CD25, CD27, CD28, CD30, CD38, CD45, CD48, CD50, CD52,
CD56, CD57, CD62L, CD69, CD94, CD100, CD102, CD122, CD127, CD132,
CD137, CD160, CD161, CD178, CD218, CD226, CD244, CD159a (NKG2A),
CD159c (NKG2C), NKG2E, CD279, CD314 (NKG2D), CD305, CD335 (NKP46),
CD337, CD319 (CS1), TCR.alpha., TCR.beta. or SLAMF7. In some
embodiments, the number of any one or more of autologous T cell,
granulocyte, and NK cell in peripheral blood starts to increase
before the number of affected cells in peripheral blood or the
number of affected cells in bone marrow is reduced by at least 50%.
In some embodiments, the number of any one or more of autologous T
cell, granulocyte, and NK cell in peripheral blood starts to
increase after the number of affected cells in peripheral blood or
the number of affected cells in bone marrow is reduced by at least
50%.
[0032] Additional aspects and advantages of the present disclosure
will become readily apparent to those skilled in this art from the
following detailed description, wherein only illustrative
embodiments of the present disclosure are shown and described. As
will be realized, the present disclosure is capable of other and
different embodiments, and its several details are capable of
modifications in various obvious respects, all without departing
from the disclosure. Accordingly, the drawings and description are
to be regarded as illustrative in nature, and not as
restrictive.
INCORPORATION BY REFERENCE
[0033] All publications, patents, and patent applications mentioned
in this specification are herein incorporated by reference to the
same extent as if each individual publication, patent, or patent
application was specifically and individually indicated to be
incorporated by reference. To the extent publications and patents
or patent applications incorporated by reference contradict the
disclosure contained in the specification, the specification is
intended to supersede and/or take precedence over any such
contradictory material.
BRIEF DESCRIPTION OF THE DRAWINGS
[0034] The novel features of the invention are set forth with
particularity in the appended claims. A better understanding of the
features and advantages of the present invention will be obtained
by reference to the following detailed description that sets forth
illustrative embodiments, in which the principles of the invention
are utilized, and the accompanying drawings (also "Figure" and
"FIG." herein), of which:
[0035] FIG. 1 illustrates an example structure of EGFRt-CD3-CD19
CAR.
[0036] FIG. 2 illustrates an example preparation process of
EGFRt-CD3-CD19 universal CAR-T.
[0037] FIG. 3 illustrates expression of Parallel CAR (FMC63-OKT3)
and the tEGFR switch.
[0038] FIG. 4 illustrates expression of Parallel and Loop CARs.
[0039] FIGS. 5A-C illustrate experimental data comparing the UCHT1
vs OKT3.
[0040] FIGS. 6A-C illustrate the anti-cancer function of
parallel-UCHT1.
[0041] FIGS. 7A and 7B illustrate experimental data comparing the
anti-cancer function of parallel CAR vs Loop CAR.
[0042] FIGS. 8A and 8B illustrate that TCR KO CD19 CAR-T cell
showed a proliferation defect in subcutaneous tumor model. 5e5
Raji-luciferase cells were grafted into NOG mice by subcutaneous
injection. 1e6 WT, TCR KO CD19 CAR-T cells were infused (IV) into
Raji grafted mice. Tumor burden was assessed by caliper
measurements of the actual tumor sizes. Although both were Raji
based tumor bearing models, subcutaneous model generates solid
tumors and has much higher requirements on CAR-T cell proliferation
for controlling the tumors than intravenous model. TCR KO CAR-T
cells showed a proliferation defects compared to WT CAR-T cells,
consistent with their tumor control effects.
[0043] FIGS. 9A-C illustrate proliferation and killing efficacy of
CAR-T cells with different enhancers after multiple rounds of
stimulation by cancer cells.
[0044] FIGS. 10A and 10B illustrate the proliferation of CAR-T
cells with different enhancers after multiple rounds of stimulation
by cancer cells.
[0045] FIG. 11 illustrates In vivo comparison of enhancers in TCR
KO CD19 CAR-T cells. 5e5 Raji-luciferase cells were grafted into
NOG mice by intravenous (IV) injection. WT, TCR KO CD19 CAR-T cells
with/without enhancers were infused (IV) into Raji grafted mice.
Tumor burden was assessed by bioluminescence intensity (BLI).
[0046] FIG. 12 illustrates in vivo comparison of enhancers in TCR
KO CD19 CAR-T cells.
[0047] FIG. 13 illustrates an example tissue distribution of CD7
mRNA.
[0048] FIG. 14 illustrates an example tissue distribution of CD2
mRNA.
[0049] FIG. 15 illustrates an example preparation of CD7 CAR-T.
[0050] FIG. 16 illustrates an experimental data of CD7 gRNA
screening.
[0051] FIG. 17 illustrates example structures of CAR7, CAR7-mb15
and CAR7-C7R.
[0052] FIG. 18 illustrates experimental data of CAR expression of
CAR7, CAR7-mb15, CAR7-C7R and control CAR19, expression of IL15Ra
and CD34, and the knockout efficiency of CD7 and CD3.
[0053] FIG. 19 illustrates experimental data of the activation of
STAT5 in UCAR-T cells. Adding IL-2 activated the STAT5 of CAR7 T
cells and remove of IL-2 significantly decreased pSTAT5 level. In
CAR7-C7R, the level of pSTAT5 was at high level with or without
exogenous IL-2.
[0054] FIG. 20 illustrates experimental data of the killing effect
of UCAR-T cells on CCRF-CEM-luc cell line.
[0055] FIG. 21 illustrates experimental data of the killing effect
of UCAR-T cells on alloreactive T (allo-T) cells.
[0056] FIG. 22 illustrates the killing effect of UCAR-T cells on
NK92 cell line in 24 hours.
[0057] FIG. 23A illustrates experimental data of in vitro expansion
of several UCAR-T cells, where the UCAR-T cells expressing
enhancers survived longer. FIG. 23B illustrates experimental data
of comparison of their killing effects on CCRF-CEM tumor cells
after removing IL-2.
[0058] FIG. 24A illustrates experimental data of in vitro expansion
of several UCAR-T cells. FIG. 24B illustrates experimental data of
comparison of their killing effects on CCRF-CEM tumor cells after
removing IL-2 and co-culturing with CCRF-CEM for multiple rounds,
where the UCAR-T cells expressing enhancers showed stronger
expansion under the stimulation of tumor antigens.
[0059] FIG. 25 illustrates experimental data of expansion of UCAR-T
cells expressing enhancers in immuno-deficient mice carrying
CCRF-CEM tumor.
[0060] FIG. 26 illustrates experimental data of the killing effect
of UCAR-T cells expressing enhancers on CCRF-CEM tumor in mice.
[0061] FIG. 27 illustrates in vivo comparison of enhancers in TCR
KO CD7 CAR-T cells.
[0062] FIGS. 28A and 28B illustrate in vivo comparison of enhancers
in TCR KO CD7 CAR-T cells.
[0063] FIG. 29 illustrates an example structure of
RQR8-CD19CAR-MBIL15, RQR8-CD19CAR-MBIL15-IL7, RQR8-CD19CAR-C7R and
RQR8-CD19CAR-MBIL7.
[0064] FIG. 30 illustrates a design of E3: constitutive active
IL7R.alpha. based enhancer+safety switch.
[0065] FIG. 31 illustrates expression of CAR and the enhancer.
[0066] FIGS. 32A and 32B illustrate test of CAR-T function.
[0067] FIGS. 33A and 33B illustrate test of enhancer function.
[0068] FIGS. 34A-C illustrate test of enhancer function.
[0069] FIGS. 35A-C illustrate test of safety switch by ADCC.
[0070] FIGS. 36A and 36B illustrate test of safety switch by ADCC
after repeat stimulations.
[0071] FIG. 37 illustrates examples of the design of CD7-CD19 dual
CARs. L719 represents Loop-CAR, LHLH=VLVH-VLVH, HLHL=VHVL-VHVL;
T197 and T719 are Tandem-CARs, EAAAK is the linker (SEQ ID NO: 92)
between two LH. SP: signaling peptide; H: hinge; TM: transmembrane
domain.
[0072] FIGS. 38A and 38B illustrate an experimental data of the
expression of CD7 single CARs constructed with scFvs of different
antibodies and the knockout efficiencies of CD7/CD3 (TRAC) (FIG.
38A), as well as the killing effects of CARs on CD7+ cells (FIG.
38B). LH represents VLVH, and HL represents VHVL.
[0073] FIG. 39 illustrates experimental data of the expressions of
Loop-CARs and Tandem-CARs. CAR7 and CAR19 are single CAR controls,
and Mock T is negative control.
[0074] FIG. 40 illustrates experimental data of the knockout
efficiencies of CD7 and CD3 (TRAC) and clearances of CD7+ cells by
CARs.
[0075] FIG. 41 illustrates experimental data of the clearance of
HeLa-CD19+ cells by Loop-CARs and Tandem CARs.
[0076] FIGS. 42A and 42B illustrate experimental data of the
complete killing of NK by CD7 single CAR and CD7-CD19 dual CARs.
FIG. 42A shows the experimental data of the clearance efficiencies
of in vitro expanded peripheral blood NK by different CARs. FIG.
42B illustrates experimental data of the in vitro expanded NK
comprises .about.80% CD7+ cells; after killing by L719-LHLH and
T197-LHLH, the remaining NK cells are CD7-cells.
[0077] FIG. 43 illustrates experimental data of the rapid killing
of allogeneic T cells by CD7 single CAR and CD7-CD19 dual CARs.
[0078] FIG. 44 illustrates experimental data of the in vivo
functions of dual CARs. Loop CARs and Tandem CARs both showed
potent killing effects on Raji tumor cells.
[0079] FIGS. 45A and 45B illustrate experimental data comparing two
Tandem CARs. FIG. 45A shows experimental data using L719: L719-LHLH
as a standard control for screening, and CAR7, CAR19 and Mock T as
other controls. FIG. 45B shows experimental data of the clearance
of the remaining CD7+ cells by different CARs after CD7
knockout.
[0080] FIG. 46 illustrates experimental data of the two Tandem CARs
showing similar clearance effects on HeLa-CD19+ cells as L719. 8
FIGS. 47A and 47 B illustrate experimental data of the two Tandem
CARs showing similar clearance effects on allogeneic T cells (FIG.
47A) and NK cells (FIG. 47B) as L719.
[0081] FIG. 48 illustrates experimental data of the in vivo
functional screening of dual CARs. Both Loop and Tandem dual CARs
showed potent killing effects on CCRF-CEM tumor cells in vivo.
[0082] FIG. 49 illustrates the structure of rapaC, L719-C7R, and
L719-E3.
[0083] FIGS. 50A-J illustrate experimental data of the effects of
cytokine signaling on the functions of dual CARs. FIG. 50A
illustrates experimental data of the expressions of L719 and
L719-C7R dual CARs. FIG. 50B illustrates experimental data of the
killing effects of dual CARs on HeLa-CD7+ cells. FIG. 50C
illustrates experimental data of the killing effects of dual CARs
on HeLa-CD19+ cells. FIG. 50D illustrates experimental data of the
expressions of enhancer and CD7 in L718 dual CAR-T cells. FIG. 50E
illustrates experimental data of cytotoxicity of L719 dual CAR-T
cells. FIG. 50F illustrates experimental data of cytotoxicity of
L719 dual CAR-T cells. FIG. 50G illustrates experimental data of
the expressions of phosphorylated STAT5 and the enhancer in L719
dual CAR-T cells. FIG. 50H illustrates experimental data of L719
dual CAR-T cell proliferation. FIG. 50I illustrates experimental
data of the killing effects of dual CARs on HeLa-CD19+ cells. FIG.
50J illustrates experimental data of the killing effects of dual
CARs on HeLa-CD7+ cells.
[0084] FIG. 51 illustrates an example tissue distribution of CD137
mRNA.
[0085] FIG. 52 illustrates an example structural diagram of
CD137-CD19 AAC/CAR.
[0086] FIG. 53 illustrates an example preparing process of
CD137-CD19 universal CAR-T.
[0087] FIGS. 54A-C illustrate experimental data showing defects in
cell expansion of TCR knockout autologous CAR-T cells. FIG. 54A
illustrates FACS data showing fraction of TCR+ cells pre- and
post-infusion. FIG. 54B illustrates bar-graph of the FACS data in
FIG. 54A. FIG. 54C illustrates comparison of expansion differences
of CAR-T cells with or without TCRs.
[0088] FIGS. 55A and 55B illustrate experimental data showing
effects of C7R on TCR knockout (KO) CD7 CAR-T cells (e.g., a CAR-T
cell having a CAR targeting CD7, also referred to as UCART7 cells
or CAR7 cells) expansion and persistence. FIG. 55A illustrates TCR
KO CD7 CAR-T expansion data with or without enhancer C7R. FIG. 55B
illustrates proliferation data of TCR KO CD7 CAR-T cells with or
without enhancer.
[0089] FIGS. 56A-E illustrate experimental data showing STAT5
phosphorylation, cell persistence and cytotoxicity of TCR KO CD7
CAR-T cells expressing enhancer C7R or E3 (EGFRt+IL7Ra). FIG. 56A
illustrates experimental data of fraction of CAR-T cells expressing
enhancer. FIG. 56B illustrates cytotoxicity of TCR KO CD7 CAR-T
cells. FIG. 56C illustrates proliferation data of CAR-T cells in
the absence of IL2. FIG. 56D illustrates experimental data of
fractions of CAR-T cells expressing enhancer and having
phosphorylated STAT5. FIG. 56E illustrates a bar graph of mean
fluorescent index (MFI) of phosphorylated STAT5 of FIG. 56D.
[0090] FIGS. 57A and 57B illustrate experimental data showing
expansion and persistence of UCAR-T GC197 cells (e.g.,
multi-specific CAR-T cells having CARs targeting both CD19 and
CD7). FIG. 57A illustrates proliferation data of UCAR-T GC197 cells
expressing enhancer C7R from two different donors in the presence
of cancer antigen stimulation. FIG. 57B illustrates proliferation
data of UCAR-T GC197 cells expressing enhancer C7R in the absence
of IL2 or antigen stimulation.
[0091] FIGS. 58A-C illustrate experimental data showing expansion
and persistence of UCAR-T GC197 cells. FIG. 58A illustrates
experimental data showing fractions of CAR-T cells expressing CD7
and the enhancer C7R or E3 (EGFRt+IL7Ra). FIG. 58B illustrates
proliferation data of UCAR-T GC197 cells expressing enhancer C7R or
E3 (EGFRt+IL7Ra). FIG. 58C illustrates proliferation data of UCAR-T
GC197 cells expressing enhancer C7R or E3 (EGFRt+IL7R.alpha.) in
the presence of cancer antigen stimulation.
[0092] FIGS. 59A and 59B illustrate experimental data of K562-CAR19
profiling and natural killer (NK) cell killing assay. FIG. 59A
illustrates experimental data of fractions of K562 cells expressing
CAR (e.g., CAR19 or CAR targeting CD19) and enhancer CD47 or E4
(CD47+IL7R.alpha.). FIG. 59B illustrates experimental data of
cytotoxicity of NK cells toward K562-CAR19 expressing the enhancer
CD47 or E4 (CD47+IL7R.alpha.).
[0093] FIGS. 60A and 60B illustrate experimental data showing STAT5
phosphorylation and cell persistence of UCART19 cells (e.g., CAR-T
cells having CARs targeting CD19, also referred to as CD19 CAR-T
cells or CAR19 cells). FIG. 60A illustrates experimental data of
fractions of TCR KO CAR19 cells having phosphorylated STAT5 and
CAR19. FIG. 60B illustrates proliferation data of TCR KO CD19 CAR
expressing enhancer C7R, CD47 or E4 (CD47+IL7R.alpha.).
[0094] FIGS. 61A and 62B illustrate safety switch function of E2
and E3 in L719 cells. FIG. 61A illustrates safety switch function
of E3 in L719-E3 cells. FIG. 61B illustrates safety switch function
of E2 in L719-E2 cells.
[0095] FIGS. 62A and 62B illustrate safety switch function of E3
tested in CAR7-E3 and L719-E3 by Complement dependent cytotoxicity
assay (CDC assay). FIG. 62A illustrates safety switch function of
E3 tested in CAR7-E3 cells. FIG. 62B illustrates safety switch
function of E3 tested in L719-E3 cells.
[0096] FIGS. 63A and 63B illustrate expression of IL2 and
IFN.gamma. in TCR/CD7 double knockout CAR7 cells with no cytokine
signaling enhancement, or with mbIL15, C7R, or E3 expression. FIG.
63A illustrates expression of IL2 in TCR/CD7 double knockout CAR7
cells with no cytokine signaling enhancement, or with mbIL15, C7R,
or E3 expression. FIG. 63B illustrates IFN.gamma. in TCR/CD7 double
knockout CAR7 cells with no cytokine signaling enhancement, or with
mbIL15, C7R, or E3 expression.
[0097] FIG. 64 illustrates expression of IL2 and IFN.gamma. in
TCR/CD7 double knockout CD19/CD7 dual CAR-L719 cells with no
cytokine signaling enhancement, or with C7R, or E3 expression.
[0098] FIG. 65 illustrates CD2 gRNA screening.
[0099] FIGS. 66A-C illustrate the in vivo GvHD study comparing CD19
CAR-T vs TCR KO CD19 CAR-T cells. FIG. 66A illustrates the in vivo
GvHD study of CD19 CAR-T. FIG. 66B illustrates the in vivo GvHD
study of TCR KO CD19 CAR-T cells. FIG. 66C illustrates the in vivo
GvHD study comparing CD19 CAR-T vs TCR KO CD19 CAR-T cells.
[0100] FIGS. 67A-E illustrate the clinical data of CAR7-C7R for
treating T-acute lymphoblastic leukemia (T-ALL) patients. FIG. 67A
shows the kinetics of T-ALL elimination in the peripheral blood.
FIG. 67B shows the CAR7-C7Rcell concentration in the peripheral
blood. FIG. 67C shows CAR7-C7R DNA copy/ug DNA of peripheral blood
cells. FIG. 67D shows the granulocyte and lymphocyte (T and NK
cells) recovery in the bone marrow. FIG. 67E shows the granulocyte
and lymphocyte (T and NK cells) recovery in peripheral blood.
[0101] FIG. 68 illustrates BLI imaging of the in vivo efficacy of
CAR7 and CAR7-E3 UCAR-T cells.
[0102] FIG. 69 illustrates BLI imaging of the in vivo efficacy of
L719 and L719-C7R UCAR-T cells.
DETAILED DESCRIPTION
[0103] While various embodiments of the invention have been shown
and described herein, it will be obvious to those skilled in the
art that such embodiments are provided by way of example only.
Numerous variations, changes, and substitutions may occur to those
skilled in the art without departing from the invention. It should
be understood that various alternatives to the embodiments of the
invention described herein may be employed.
[0104] The term "about," as used herein, refers to a value or
composition within a range of acceptable tolerances for a
particular value or composition as determined, which will depend in
part on how the value or composition is measured or measured, i.e.,
the limitations of the measurement system. For example, "about" can
mean within 1 or more than 1 standard deviation, per the practice
in the art. Alternatively, "about" can mean a range of up to 20%,
up to 10%, up to 5%, or up to 1% of a given value. Alternatively,
particularly with respect to biological systems or processes, the
term can mean within an order of magnitude, preferably within
5-fold, and more preferably within 2-fold, of a value. Where
particular values are described in the application and claims,
unless otherwise stated, the term "about" meaning within an
acceptable error range for the particular value should be
assumed.
[0105] The term "administering," as used herein, refers to
physically introducing a product of the present disclosure into a
subject using any of a variety of methods and delivery systems,
including intravenous, intramuscular, subcutaneous,
intraperitoneal, spinal or other routes of parenteral
administration, for example by injection or infusion.
[0106] The term "antigen," as used herein, refers to a molecule or
a fragment thereof capable of being bound by a selective binding
agent. As an example, an antigen can be a ligand that can be bound
by a selective binding agent such as a receptor. As another
example, an antigen can be an antigenic molecule that can be bound
by a selective binding agent such as an immunological protein
(e.g., an antibody). An antigen can also refer to a molecule or
fragment thereof capable of being used in an animal to produce
antibodies capable of binding to that antigen. In some cases, an
antigen may be bound to a substrate (e.g., a cell membrane).
Alternatively, an antigen may not be bound to a substrate (e.g., a
secreted molecule, such as a secreted polypeptide).
[0107] The term "antibody (Ab)," as used herein, include, but is
not limited to, an immunoglobulin that specifically binds to an
antigen and comprises at least two heavy (H) chains and two light
(L) chains interconnected by disulfide bonds, or an antigen
thereof. Each H chain comprises a heavy chain variable region
(abbreviated herein as VH) and a heavy chain constant region. The
heavy chain constant region comprises three constant domains CH1,
CH2 and CH3. Each light chain comprises a light chain variable
region (abbreviated herein as VL) and a light chain constant
region. The light chain constant region comprises a constant domain
CL. The VH and VL regions can be further subdivided into
hypervariable regions called complementarity determining regions
(CDRs) interspersed with more conserved regions called framework
regions (FR). Each VH and VL contains three CDRs and four FRs,
arranged from the amino terminus to the carboxy terminus in the
following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable
regions of the heavy and light chains contain a binding domain that
interacts with the antigen.
[0108] The term "nucleotide," as used herein, generally refers to a
base-sugar-phosphate combination. A nucleotide can comprise a
synthetic nucleotide. A nucleotide can comprise a synthetic
nucleotide analog. Nucleotides can be monomeric units of a nucleic
acid sequence (e.g. deoxyribonucleic acid (DNA) and ribonucleic
acid (RNA)). The term nucleotide can include ribonucleoside
triphosphates adenosine triphosphate (ATP), uridine triphosphate
(UTP), cytosine triphosphate (CTP), guanosine triphosphate (GTP)
and deoxyribonucleoside triphosphates such as dATP, dCTP, dITP,
dUTP, dGTP, dTTP, or derivatives thereof. Such derivatives can
include, for example, [aS]dATP, 7-deaza-dGTP and 7-deaza-dATP, and
nucleotide derivatives that confer nuclease resistance on the
nucleic acid molecule containing them. The term nucleotide as used
herein can refer to dideoxyribonucleoside triphosphates (ddNTPs)
and their derivatives. Illustrative examples of
dideoxyribonucleoside triphosphates can include, but are not
limited to, ddATP, ddCTP, ddGTP, ddITP, and ddTTP. A nucleotide can
be unlabeled or detectably labeled by well-known techniques.
Labeling can also be carried out with quantum dots. Detectable
labels can include, for example, radioactive isotopes, fluorescent
labels, chemiluminescent labels, bioluminescent labels and enzyme
labels. Fluorescent labels of nucleotides can include but are not
limited fluorescein, 5-carboxyfluorescein (FAM),
2'7'-dimethoxy-4'5-dichloro-6-carboxyfluorescein (JOE), rhodamine,
6-carboxyrhodamine (R6G), N,N,N',N'-tetramethyl-6-carboxyrhodamine
(TAMRA), 6-carboxy-X-rhodamine (ROX), 4-(4'dimethylaminophenylazo)
benzoic acid (DABCYL), Cascade Blue, Oregon Green, Texas Red,
Cyanine and 5-(2'-aminoethyl)aminonaphthalene-1-sulfonic acid
(EDANS). Specific examples of fluorescently labeled nucleotides can
include [R6G]dUTP, [TAMRA]dUTP, [R110]dCTP, [R6G]dCTP, [TAMRA]dCTP,
[JOE]ddATP, [R6G]ddATP, [FAM]ddCTP, [R110]ddCTP, [TAMRA]ddGTP,
[ROX]ddTTP, [dR6G]ddATP, [dR110]ddCTP, [dTAMRA]ddGTP, and
[dROX]ddTTP available from Perkin Elmer, Foster City, Calif.,
FluoroLink DeoxyNucleotides, FluoroLink Cy3-dCTP, FluoroLink
Cy5-dCTP, FluoroLink Fluor X-dCTP, FluoroLink Cy3-dUTP, and
FluoroLink Cy5-dUTP available from Amersham, Arlington Heights,
Ill.; Fluorescein-15-dATP, Fluorescein-12-dUTP,
Tetramethyl-rodamine-6-dUTP, IR770-9-dATP, Fluorescein-12-ddUTP,
Fluorescein-12-UTP, and Fluorescein-15-2'-dATP available from
Boehringer Mannheim, Indianapolis, Ind.; and Chromosome Labeled
Nucleotides, BODIPY-FL-14-UTP, BODIPY-FL-4-UTP, BODIPY-TMR-14-UTP,
BODIPY-TMR-14-dUTP, BODIPY-TR-14-UTP, BODIPY-TR-14-dUTP, Cascade
Blue-7-UTP, Cascade Blue-7-dUTP, fluorescein-12-UTP,
fluorescein-12-dUTP, Oregon Green 488-5-dUTP, Rhodamine
Green-5-UTP, Rhodamine Green-5-dUTP, tetramethylrhodamine-6-UTP,
tetramethylrhodamine-6-dUTP, Texas Red-5-UTP, Texas Red-5-dUTP, and
Texas Red-12-dUTP available from Molecular Probes, Eugene, Oreg.
Nucleotides can also be labeled or marked by chemical modification.
A chemically-modified single nucleotide can be biotin-dNTP. Some
non-limiting examples of biotinylated dNTPs can include,
biotin-dATP (e.g., bio-N6-ddATP, biotin-14-dATP), biotin-dCTP
(e.g., biotin-11-dCTP, biotin-14-dCTP), and biotin-dUTP (e.g.
biotin-11-dUTP, biotin-16-dUTP, biotin-20-dUTP).
[0109] The terms "polynucleotide," "oligonucleotide," and "nucleic
acid" are used interchangeably to refer to a polymeric form of
nucleotides of any length, either deoxyribonucleotides or
ribonucleotides, or analogs thereof, either in single-, double-, or
multi-stranded form. A polynucleotide can be exogenous or
endogenous to a cell. A polynucleotide can exist in a cell-free
environment. A polynucleotide can be a gene or fragment thereof. A
polynucleotide can be DNA. A polynucleotide can be RNA. A
polynucleotide can have any three dimensional structure, and can
perform any function, known or unknown. A polynucleotide can
comprise one or more analogs (e.g. altered backbone, sugar, or
nucleobase). If present, modifications to the nucleotide structure
can be imparted before or after assembly of the polymer. Some
non-limiting examples of analogs include: 5-bromouracil, peptide
nucleic acid, xeno nucleic acid, morpholinos, locked nucleic acids,
glycol nucleic acids, threose nucleic acids, dideoxynucleotides,
cordycepin, 7-deaza-GTP, fluorophores (e.g. rhodamine or
fluorescein linked to the sugar), thiol containing nucleotides,
biotin linked nucleotides, fluorescent base analogs, CpG islands,
methyl-7-guanosine, methylated nucleotides, inosine, thiouridine,
pseudourdine, dihydrouridine, queuosine, and wyosine. Non-limiting
examples of polynucleotides include coding or non-coding regions of
a gene or gene fragment, loci (locus) defined from linkage
analysis, exons, introns, messenger RNA (mRNA), transfer RNA
(tRNA), ribosomal RNA (rRNA), short interfering RNA (siRNA),
short-hairpin RNA (shRNA), micro-RNA (miRNA), ribozymes, cDNA,
recombinant polynucleotides, branched polynucleotides, plasmids,
vectors, isolated DNA of any sequence, isolated RNA of any
sequence, cell-free polynucleotides including cell-free DNA (cfDNA)
and cell-free RNA (cfRNA), nucleic acid probes, and primers. The
sequence of nucleotides can be interrupted by non-nucleotide
components.
[0110] The term "gene," as used herein, refers to a nucleic acid
(e.g., DNA such as genomic DNA and cDNA) and its corresponding
nucleotide sequence that is involved in encoding an RNA transcript.
The term as used herein with reference to genomic DNA includes
intervening, non-coding regions as well as regulatory regions and
can include 5' and 3' ends. In some uses, the term encompasses the
transcribed sequences, including 5' and 3' untranslated regions
(5'-UTR and 3'-UTR), exons and introns. In some genes, the
transcribed region will contain "open reading frames" that encode
polypeptides. In some uses of the term, a "gene" comprises only the
coding sequences (e.g., an "open reading frame" or "coding region")
necessary for encoding a polypeptide. In some cases, genes do not
encode a polypeptide, for example, ribosomal RNA genes (rRNA) and
transfer RNA (tRNA) genes. In some cases, the term "gene" includes
not only the transcribed sequences, but in addition, also includes
non-transcribed regions including upstream and downstream
regulatory regions, enhancers and promoters. A gene can refer to an
"endogenous gene" or a native gene in its natural location in the
genome of an organism. A gene can refer to an "exogenous gene" or a
non-native gene. A non-native gene can refer to a gene not normally
found in the host organism but which is introduced into the host
organism by gene transfer. A non-native gene can also refer to a
gene not in its natural location in the genome of an organism. A
non-native gene can also refer to a naturally occurring nucleic
acid or polypeptide sequence that comprises mutations, insertions
and/or deletions (e.g., non-native sequence).
[0111] The term "endogenous," as used herein, refers to a nucleic
acid molecule or polypeptide normally expressed in a cell or
tissue.
[0112] The term "exogenous," as used herein, refers to the nucleic
acid molecule or polypeptide is not endogenously present in the
cell or is present at a level sufficient to achieve the functional
effects obtained upon overexpression. Thus, the term "exogenous"
includes any recombinant nucleic acid molecule or polypeptide
expressed in a cell, e.g., a foreign, heterologous, and
overexpressed nucleic acid molecule and polypeptide.
[0113] The term "T cell and NK cell consensus marker," as used
herein, refers to a marker co-existing on T cells and NK cells,
including but not limited to: CD2, CD7, CD38, CD45, CD48, CD50,
CD52, CD56, CD69, CD100, CD122, CD132, CD161, CD159a, CD159c,
CD314.
[0114] The term "marker of T cells and/or NK cells," as used
herein, refers to markers present in T cells or NK cells,
respectively, or both T cells and NK cells, including but not
limited to: CD2, CD3, CD4, CD5, CD7, CD8, CD16a, CD16b, CD25, CD27,
CD28, CD38, CD45, CD48, CD50, CD52, CD56, CD57, CD62L, CD69, CD94,
CD100, CD102, CD122, CD127, CD132, CD160, CD161 CD178, CD218,
CD226, CD244, CD159a (NKG2A), CD159c (NKG2C), NKG2E, CD314 (NKG2D),
CD305, CD335 (NKP46), CD337, SLAMF7.
[0115] The term "functionally inactivate" or "functional
inactivation" as used herein refers to that a functional gene or
the product of the gene such as mRNA or protein is prevented or
inhibited. The inactivation may be achieved by deletion, addition
or substitution of the gene or the promoter thereof, so that
expression does not occur, or mutation of the coding sequence of
the gene so that the gene product such as mRNA or protein is
inactive. The functional inactivation may be complete or partial.
Inactivation of a gene can encompass all degrees of inactivation,
including gene silencing, knockout, inhibition and disruption. In
some embodiments, the functional inactivation is introduced by
CRISPR-Cas9 system.
[0116] The terms "subject," "individual," and "patient" are used
interchangeably herein to refer to a vertebrate, preferably a
mammal such as a human. Mammals include, but are not limited to,
murines, simians, humans, farm animals, sport animals, and pets.
Tissues, cells and their progeny of a biological entity obtained in
vivo or cultured in vitro are also encompassed.
[0117] The terms "treatment" and "treating," as used herein, refer
to an approach for obtaining beneficial or desired results
including but not limited to a therapeutic benefit and/or a
prophylactic benefit. For example, a treatment can comprise
administering a system or cell population disclosed herein. By
therapeutic benefit is meant any therapeutically relevant
improvement in or effect on one or more conditions (e.g., diseases
or symptoms) under treatment. For prophylactic benefit, a
composition can be administered to a subject at risk of developing
a particular condition, or to a subject reporting one or more of
the physiological symptoms of a disease, even though the condition
may not have yet been manifested.
Overview
[0118] CARs can comprise an extracellular antigen recognition
region, for example, a scFv (single-chain variable fragment), a
transmembrane region, and an intracellular costimulatory signal
region. The extracellular domain of CARs can recognize a specific
antigen and then transduce the signal through the intracellular
domain, causing T cell activation and proliferation, cytolysis
toxicity, and secretion of cytokines, thereby eliminating target
cells. The patient's autologous T cells (or heterologous donors)
can be first isolated, activated and genetically engineered to
produce CAR-T cells, which can be then injected into the same
patient. In this way, the probability of graft-versus-host disease
may be reduced, and the antigen can be recognized by T cells in a
non-MHC-restricted manner. In addition, a CAR-T can treat all
cancers that express the antigen.
[0119] The present disclosure provides compositions and methods to
engineer a cell, e.g., an immune cell, such that it can target both
disease-associated antigen (e.g., tumor-associated antigen or tumor
cell marker) and immune cell antigen (e.g., CD3, CD7 or CD137)
through bispecific or multivalent CAR(s). For example, the present
disclosure provides an engineered immune cell that can target a
tumor cell marker and an immune cell antigen such as CD3. The
endogenous TCR can be inactivated (e.g., disrupted, inhibited,
knocked out or silenced). The CAR-T of the present disclosure which
targets the tumor cell marker and the immune cell antigen can
eliminate positive tumor cells and clear host immune cell antigen
positive T and NK cells, thereby avoiding host rejection (HVG). In
the present disclosure, the endogenous TCR of the engineered immune
cell can be knocked out, and graft-versus-host disease (GVHD) can
be prevented, thereby preparing a general-purpose or universal
CAR-T (UCAR-T) cell. The engineered immune cell can be derived from
an autologous T cell or an allogeneic T cell.
[0120] Moreover, the engineered immune cell can comprise a cell
suicide element (e.g., inducible cell death moiety), and the CAR-T
can be inactivated/cleared at any time to reduce side effects. In
some cases, the engineered immune cell can further comprise an
enhancer moiety. The enhancer moiety can regulate one or more
activities of the engineered immune cell when the engineered immune
cell is administered to a subject. For example, the enhancer moiety
can be a cytokine (e.g., IL-5 or IL-7) or a cytokine receptor
(e.g., IL-5R or IL-7R). The enhancer moiety can enhance a signaling
pathway within the engineered immune cell, for example, STAT5
signaling pathway. In some embodiments, the engineered immune cell
comprises a bispecific CAR targeting both CD19 and CD3. The
engineered immune cell show in this example can further comprise an
inducible cell death moiety such as a truncated epidermal growth
factor receptor (EGFRt or tEGFR, which can be used interchangeably
herein; see U.S. Pat. No. 9,447,194B2 and PCT Publication No.
WO2018038945).
[0121] The inducible cell death moiety or the enhancer moiety can
be introduced in the immune cell via a separate expression vector.
In some cases, the inducible cell death moiety and the enhancer
moiety may be introduced into the immune cell via an expression
vector comprising sequences encoding both moieties. In some cases,
the inducible cell death moiety and the enhancer moiety are linked
and are expressed as a chimeric polypeptide.
[0122] The application of the engineered immune cells provided
herein in cell therapy can treat the disease (e.g., cancer) of a
patient, be prepared in large-scale in advance to avoid GVHD and
HvG, reduce treatment costs, inactivate CAR-T at any time if
necessary, reduce side effects of immunotherapy, and ensure product
safety. The engineered cells provided herein can be referred to as
universal CAR T cells (UCAR-T cells).
Chimeric Antigen Receptor (CAR)
[0123] The cell (e.g., immune cell or engineered immune cell)
provided herein can comprise one or more CARs. The CAR can include
an extracellular domain, a transmembrane domain, and an
intracellular signaling domain. The extracellular domain can
include a target-specific binding element (also known as an antigen
binding domain). The intracellular domain can include a
costimulatory signaling region and a zeta (.zeta.) chain portion. A
costimulatory signaling region refers to a portion of the CAR
comprising the intracellular domain of a costimulatory molecule.
Costimulatory molecules are cell surface molecules other than
antigens receptors or their ligands that may be needed for an
efficient response of lymphocytes to antigen. Between the
extracellular domain and the transmembrane domain of the CAR, or
between the cytoplasmic domain and the transmembrane domain of the
CAR, there may be incorporated a spacer domain. As used herein, the
term "spacer domain" generally means any oligo- or polypeptide that
functions to link the transmembrane domain to, either the
extracellular domain or, the cytoplasmic domain in the polypeptide
chain. A spacer domain may comprise up to 300 amino acids,
preferably 10 to 100 amino acids and most preferably 25 to 50 amino
acids.
[0124] With respect to the transmembrane domain, the CAR can be
designed to comprise a transmembrane domain that is fused to the
extracellular domain of the CAR. In one embodiment, the
transmembrane domain that naturally is associated with one of the
domains in the CAR is used. In some instances, the transmembrane
domain can be selected or modified by amino acid substitution to
avoid binding of such domains to the transmembrane domains of the
same or different surface membrane proteins to minimize
interactions with other members of the receptor complex.
[0125] The transmembrane domain may be derived either from a
natural or from a synthetic source. Where the source is natural,
the domain may be derived from any membrane-bound or transmembrane
protein. Transmembrane regions of particular use in the present
disclosure may be derived from (e.g., comprise at least the
transmembrane region(s) of) the alpha, beta or zeta chain of the
T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16,
CD22, CD33, CD3.gamma., CD64, CD80, CD86, CD134, CD137, CD154, or
from an immunoglobulin such as IgG4. Alternatively the
transmembrane domain may be synthetic, in which case it will
comprise predominantly hydrophobic residues such as leucine and
valine. Preferably a triplet of phenylalanine, tryptophan and
valine will be found at each end of a synthetic transmembrane
domain. Optionally, a short oligo- or polypeptide linker,
preferably between 2 and 10 amino acids in length may form the
linkage between the transmembrane domain and the cytoplasmic
signaling domain of the CAR. A glycine-serine doublet provides a
particularly suitable linker.
[0126] The cytoplasmic domain or otherwise the intracellular
signaling domain of the CAR of the present disclosure can be
responsible for activation of at least one of the normal effector
functions of the immune cell in which the CAR has been placed in.
The term "effector function" refers to a specialized function of a
cell. Effector function of a T cell, for example, may be cytolytic
activity or helper activity including the secretion of cytokines.
Thus the term "intracellular signaling domain" refers to the
portion of a protein which transduces the effector function signal
and directs the cell to perform a specialized function. While
usually the entire intracellular signaling domain can be employed,
in many cases it is not necessary to use the entire chain. To the
extent that a truncated portion of the intracellular signaling
domain is used, such truncated portion may be used in place of the
intact chain as long as it transduces the effector function signal.
The term intracellular signaling domain is thus meant to include
any truncated portion of the intracellular signaling domain
sufficient to transduce the effector function signal.
[0127] Examples of intracellular signaling domains for use in the
CAR of the present disclosure include the cytoplasmic sequences of
the TCR and co-receptors that act in concert to initiate signal
transduction following antigen receptor engagement, as well as any
derivative or variant of these sequences and any synthetic sequence
that has the same functional capability.
[0128] Signals generated through the TCR alone may be insufficient
for full activation of the T cell and that a secondary or
co-stimulatory signal may be included. Thus, T cell activation can
be said to be mediated by two distinct classes of cytoplasmic
signaling sequence: those that initiate antigen-dependent primary
activation through the TCR (primary cytoplasmic signaling
sequences) and those that act in an antigen-independent manner to
provide a secondary or co-stimulatory signal (secondary cytoplasmic
signaling sequences).
[0129] Primary cytoplasmic signaling sequences can regulate primary
activation of the TCR complex either in a stimulatory way, or in an
inhibitory way. Primary cytoplasmic signaling sequences that act in
a stimulatory manner may contain signaling motifs which are known
as immunoreceptor tyrosine-based activation motifs or ITAMs.
Examples of ITAM containing primary cytoplasmic signaling sequences
that are of particular use in the present disclosure include those
derived from TCR zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta,
CD3 epsilon, CD5, CD22, CD79a, CD79b, and CD66d. It is particularly
preferred that cytoplasmic signaling molecule in the CAR of the
present disclosure comprises a cytoplasmic signaling sequence
derived from CD3-zeta.
[0130] In some embodiments, the cytoplasmic domain of the CAR can
be designed to comprise the CD3-zeta signaling domain by itself or
combined with any other desired cytoplasmic domain(s) useful in the
context of the CAR of the present disclosure. For example, the
cytoplasmic domain of the CAR can comprise a CD3 zeta chain portion
and a costimulatory signaling region. The costimulatory signaling
region refers to a portion of the CAR comprising the intracellular
domain of a costimulatory molecule. A costimulatory molecule is a
cell surface molecule other than an antigen receptor or its ligands
that may be needed for an efficient response of lymphocytes to an
antigen. Examples of such molecules include CD27, CD28, 4-1BB
(CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte
function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C,
B7-H3, and a ligand that specifically binds with CD83, and the
like. Thus, while the present disclosure is, in some cases,
exemplified with 4-1BB as the co-stimulatory signaling element,
other costimulatory elements are within the scope of the present
disclosure.
[0131] The cytoplasmic signaling sequences within the cytoplasmic
signaling portion of the CAR of the present disclosure may be
linked to each other in a random or specified order. Optionally, a
short oligo- or polypeptide linker, preferably between 2 and 10
amino acids in length may form the linkage. A glycine-serine
doublet provides a particularly suitable linker.
[0132] In some embodiments, the cytoplasmic domain is designed to
comprise the signaling domain of CD3-zeta and the signaling domain
of CD28. In another embodiment, the cytoplasmic domain is designed
to comprise the signaling domain of CD3-zeta and the signaling
domain of 4-1BB. In yet another embodiment, the cytoplasmic domain
is designed to comprise the signaling domain of CD3-zeta and the
signaling domain of CD28 and 4-1BB.
[0133] A CAR provided herein can comprise one or more antigen
binding domains. In some cases, a CAR provided herein comprises an
antigen binding domain that can target both an immune cell antigen
(e.g., to inhibit killing activity of a T cell or NK cell) and a
disease-associated antigen (e.g., a tumor-associated antigen). For
example, an antigen binding domain targeting both immune cell
antigens and cancer antigens include, but not limited to, CD2, CD3,
CD4, CD5, CD7, CD8, CD30, CD38, CD45, CD48, CD50, CD52, CD56, CD69,
CD100, CD122, CD132, CD137, CD161, CD159a, CD159c, CD279, CD314,
CD319 (CS1) and TCR.
[0134] In some cases, a CAR provided herein comprises two antigen
binding domains such that one individual CAR is a bispecific CAR,
targeting two different antigens. For bispecific CAR, one antigen
binding domain can target immune cell antigen, and the other
antigen binding domain can target disease-associated antigen. The
two antigen binding domains of a bispecific CAR can have a tandem
structure, a parallel structure or a loop structure.
[0135] For example, a CAR can target a tumor cell marker and CD3.
The CAR can have a structure as formula I.
L-scFv1-I-scFv2-H-TM-C-CD3 (I), wherein each "-" is independently a
linker peptide or a peptide bond; L is optionally a signaling
peptide sequence; I is a flexible linker; H is optionally a hinge
region; TM is a transmembrane domain; C is a costimulatory domain;
CD3.zeta. is a cytoplasmic signaling sequence derived from
CD3.zeta.; one of scFv1 and scFv2 is an antigen binding domain
targeting a tumor cell marker, and the other one is an antigen
binding domain targeting CD3. The CAR can have a structure as
formula II or II': L-VL-scFv-VH-H-TM-C-CD3.zeta. (II),
L-VH-scFv-VL-H-TM-C-CD3.zeta. ((II'), wherein each "-" is
independently a linker peptide or a peptide bond; the elements L,
H, TM, C and CD3.zeta. as described above; scFv is an antigen
binding domain targeting a tumor cell marker, VH is an anti-CD3
antibody heavy chain variable region, and VL is an anti-CD3
antibody light chain variable region; or scFv is an antigen binding
domain targeting CD-3, VH is an anti-tumor cell marker antibody
heavy chain variable region, and VL is an anti-tumor cell marker
antibody light chain variable region.
[0136] In some cases, a CAR can comprise the structure of EGFRt-CD3
scFv-CD19 scFv-Hinge-TM-CD28/41BB-CD33, wherein EGFRt is a
truncated EGFR, as a safety switch (e.g., inducible cell death
moiety), CD3 scFv is the svFCv fragment of the heavy and light
chain variable regions of the monoclonal antibody OKT3 or UCHT1
linked by a GS linker, and the CD19 scFv fragment is the heavy and
light chain variable region of the monoclonal FMC63 antibody linked
by a GS linker. The structure of the CAR can further comprise a
hinge, transmembrane regions, costimulatory signaling region of
CD28 or 41BB, and/or CD3 (intracellular domain. In the present
disclosure, the nucleic acid construct of EGFRt-CD3 scFv-CD19
scFv-Hinge-TM-CD28/41BB-CD3.zeta. can be inserted into a vector
(e.g., a lentiviral vector). The vector can be packaged in 293T
cells. T cells can be sorted from PBMC, and after activation, TCR
and PD-1 genes can be knocked out by CRISPR/CAS technology. T cells
can then be infected with the vectors to express the CARs. The
prepared CAR-T cells can be used to detect the infection efficiency
and gene editing efficiency of CAR by flowcytometry.
[0137] The immune cell marker, e.g., CD3, of the above examples can
be replaced with other immune cell markers such as CD7 and
CD137.
[0138] In some cases, a CAR comprising two antigen binding domains
arranged in a tandem form. In some embodiments, the first antigen
binding domain and the second antigen binding domain is arranged,
from amino terminus to carboxyl terminus, as: (i) VL2-VH2-VL1-VH1;
(ii) VL2-VH2-VH1-VL1; (iii) VL1-VH1-VL2-VH2; (iv) VL1-VH1-VH2-VL2;
(v) VH2-VL2-VL1-VH1; (vi) VH2-VL2-VH1-VL1; (vii) VH1-VL1-VL2-VH2;
or (viii) VH1-VL1-VH2-VL2, wherein VH1 is heavy chain variable
domain of the first antigen binding domain, VL1 is light chain
variable light domain of the first antigen binding domain, VH2 is
heavy chain variable domain of the second antigen binding domain,
and VL2 is light chain variable domain of the second antigen
binding domain. For example, the CAR can have a structure
represented by the following formula IV or IV':
L3-scFv1-R-scFv2-H3-TM3-C3-CD3 (IV);
L3-scFv2-R-scFv1-H3-TM3-C3-CD3.zeta. ((IV'), wherein each "-" is
independently a linker peptide or peptide bond; L3 is an optional
signal peptide sequence; scFv1 is an antigen binding domain that
targets tumor cell markers; R is a rigid or flexible joint; scFv2
is an antigen binding domain (e.g., an antibody single-chain
variable region sequence) that targets T cell and NK cell consensus
markers; H3 is an optional hinge region; TM3 is a transmembrane
domain; C3 is a costimulatory domain; CD3.zeta. is a cytoplasmic
signaling sequence derived from CD3.zeta..
[0139] In some cases, a CAR comprising two antigen binding domains
arranged in a loop form. In some cases, the first antigen binding
domain and the second antigen binding domain is arranged, from
amino terminus to carboxyl terminus, as: (i) VL2-VH1-VL1-VH2; (ii)
VH2-VL1-VH1-VL2; (iii) VL1-VH2-VL2-VH1; (iv) VH1-VL2-VH2-VL1; (v)
VL2-VL1-VH1-VH2; (vi) VH2-VH1-VL1-VL2; (vii) VL1-VL2-VH2-VH1; or
(viii) VH1-VH2-VL2-VL1, wherein VH1 is heavy chain variable domain
of the first antigen binding domain, VL1 is light chain variable
light domain of the first antigen binding domain, VH2 is heavy
chain variable domain of the second antigen binding domain, and VL2
is light chain variable domain of the second antigen binding
domain. For example, the CAR can have the following formula VI,
VI', VI'' or VI''' structure: L8-VL1-VH2-I-VL2-VH1-H8-TM8-C8-CD3
(VI); L8-VH1-VL2-I-VH2-VL1-H8-TM8-C8-CD3.zeta. ((VI');
L8-VL2-VH1-I-VL1-VH2-H8-TM8-C8-CD3 (VI'');
L8-VH2-VL1-I-VH1-VL2-H8-TM8-C8-CD3.zeta. (VI'''), wherein each "-"
is independently a linker peptide or peptide bond; L8 is an
optional signal peptide sequence; VH1 is an anti-tumor cell marker
antibody heavy chain variable region, and VL1 is an anti-tumor cell
marker antibody light chain variable region; VH2 is an anti-T cell
and NK cell consensus marker (such as CD7 or CD2) antibody heavy
chain variable region; and VL2 is an anti-T cell and NK cell
consensus marker (such as CD7 or CD2) antibody light chain variable
region; I is a flexible joint; H8 is an optional hinge region; TM8
is a transmembrane domain; C8 is a costimulatory domain; CD3.zeta.
is a cytoplasmic signaling sequence derived from CD3.zeta..
[0140] In some cases, a CAR comprising two antigen binding domains
are arranged in a parallel form. The parallel form can comprise a
full construct of a first CAR having a first antigen binding domain
linked to a full construct of a second CAR having a second antigen
binding domain. An example of parallel form can be tEGFR-CD19
scFv-CD28-CD3.zeta.-CD3 scFv-41BB-CD3.zeta.. The tEGFR shown here
can function as a safety switch, which can be replaced by other
safety switches as described in the present disclosure. As
described herein, CD19 scFv and CD3 scFv are two examples of
antigen binding domains, which may be replaced with various antigen
binding domains as described in the present disclosure. CD28 can be
an example of transmembrane domain and can be replaced with other
transmembrane domains described herein. 41BB can be an example of
co-stimulatory domain and can be replaced with other co-stimulatory
domains described herein. In some cases, a linker is used to link
the first CAR and the second CAR. The linker can be a cleavable
linker. The cleavable linker can be self-cleaving peptide such as
2A self-cleaving peptide.
[0141] Also contemplated in the present disclosure is a nucleic
acid molecule encoding a CAR or a bispecific CAR. The nucleic acid
can comprise a first sequence encoding a chimeric antigen receptor
(CAR), wherein the CAR can comprise a binding moiety, which binding
moiety comprises (i) a first antigen binding domain, which first
antigen binding domain suppresses or reduces a subject's immune
response toward the engineered immune cell when administered into
the subject linked to (ii) a second antigen binding domain capable
of binding to a disease-associated antigen, and wherein each CAR of
the one or more CARs can further comprise a transmembrane domain
and an intracellular signaling domain. The first antigen binding
domain can target an immune cell antigen selected from the group
consisting of CD2, CD3, CD4, CD5, CD7, CD8, CD16a, CD16b, CD25,
CD27, CD28, CD30, CD38, CD45, CD48, CD50, CD52, CD56, CD57, CD62L,
CD69, CD94, CD100, CD102, CD122, CD127, CD132, CD137, CD160, CD161,
CD178, CD218, CD226, CD244, CD159a (NKG2A), CD159c (NKG2C), NKG2E,
CD279, CD314 (NKG2D), CD305, CD335 (NKP46), CD337, CD319 (CS1),
TCR.alpha., TCR.beta. and SLAMF7. The second antigen binding domain
can target a disease-associated antigen such as CD19. Other
non-limiting examples of disease-associated antigen includes BCMA,
VEGFR2, CD19, CD20, CD30, CD22, CD25, CD28, CD30, CD33, CD52, CD56,
CD80, CD86, CD81, CD123, cd171, CD276, B7H4, CD133, EGFR, GPC3;
PMSA, CD 3, CEACAM6, c-Met, EGFRvIII, ErbB2, ErbB3 HER-2, HER3,
ErbB4/HER-4, EphA2, IGF1R, GD2, O-acetyl GD2, O-acetyl GD3, GHRHR,
GHR, Flt1, KDR, Flt4, CD44V6, CEA, CA125, CD151, CTLA-4, GITR,
BTLA, TGFBR2, TGFBR1, IL6R, gp130, Lewis, TNFR1, TNFR2, PD1, PD-L1,
PD-L2, HVEM, MAGE-A, Mesothelin, NY-ESO-1, PSMA, RANK, RORl,
TNFRSF4, CD40, CD137, TWEAK-R, LTPR, LIFRP, LRP5, MUC1, TCRa, TCRp,
TLR7, TLR9, PTCH1, WT-1, Robl, Frizzled, OX40, CD79b, Claudin 18.2,
Folate receptor .alpha., Folate receptor .beta., GPC2, CD70, BAFF-R
and Notch-1-4.
[0142] The nucleic acid molecule can further comprise a second
sequence encoding an enhancer moiety, which enhancer moiety can
enhance one or more activities of the CAR when expressed in a cell.
The enhancer moiety can be selected from the group consisting of
IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10, IL-11, IL-12, IL-15,
IL-17, IL-18, IL-21, IL-23, PD-1, PD-L1, CD122, CSF1R, CTAL-4,
TIM-3, CCL21, CCL19, TGFR beta, receptors for the same, functional
fragments thereof, functional variants thereof, and combinations
thereof. The nucleic acid molecule can further comprise a second
sequence encoding an inducible cell death moiety, which inducible
cell death moiety, when expressed in a cell, can effect death of
the cell upon contacting the inducible cell death moiety with a
cell death activator. The inducible cell death moiety can be
selected from the group consisting of rapaCasp9, iCasp9, HSV-TK,
.DELTA.CD20, mTMPK, .DELTA.CD19, RQR8, and EGFRt.
[0143] The nuclei acid molecule can further comprise a third
sequence flanked by the first sequence and the second sequence,
wherein the third sequence can encode a cleavable linker. The
cleavable linker can be a self-cleaving peptide.
[0144] The nucleic acid molecule can further comprise a regulatory
sequence regulating expression of the first sequence and/or the
second sequence.
[0145] Also contemplated in the present disclosure is a kit
comprising the nucleic acid molecule described herein.
[0146] In some cases, the nucleic acid encoding the CAR described
herein can be delivered into an immune cell for expression of the
CAR to generate an engineered cell.
Source Cell
[0147] The present disclosure provides an engineered cell, such as
an engineered immune cell. The engineered immune cell can be
prepared from a cell (e.g., an immune cell) isolated from a sample
obtained from a subject. The engineered immune cell can be prepared
from a cell line cell. The immune cell used to prepare the
engineered immune cell can be a T cell, a B cell, a natural killer
(NK) cell or a macrophage. The immune cell used to prepare the
engineered immune cell can be an innate lymphocyte (ILC).
[0148] The immune cell used to prepare the engineered immune cell
can be a stem cell. The stem cell can be a hematopoietic stem cell
(HSC) or an induced pluripotent stem cell (iPSC).
[0149] The immune cell may comprise a T-cell receptor (TCR). The
TCR can be endogenous TCR of the immune cell. In some cases, the
endogenous TCR can be inactivated. For example, a gene encoding a
subunit of the TCR can be inactivated. For example, the immune cell
can be an alpha beta T cells with impaired TCRs such that the
immune cells can avoid GVHD. For another example, the function of
the endogenous TCR can be inhibited by an inhibitor such as
TCR-derived peptides, peptides derived from amino acid sequences of
fusion and other protein regions of various viruses, antibodies and
small molecule inhibitors. The viruses from which the TCR
inhibiting peptides can be derived from include, but are not
limited to, severe acute respiratory syndrome coronavirus
(SARS-CoV), herpesvirus saimiri (HVS), human herpesvirus 6 (HHV-6),
Lassa virus (LASV), lymphocytic choriomeningitis virus (LCMV),
Mopeia virus (MOPV), Tacaribe virus (TACV), Friend murine leukemia
virus (MLV); human T lymphotropic virus type 1 (HTLV-1);
herpesvirus ateles (HVA); Marburg virus (MARV); Sudan Ebola virus
(SEBOV); and Zaire Ebola virus (ZEBOV).
[0150] In some cases, the immune cells can be T cells containing
TCRs that may not cause GVHD responses. For example, the immune
cell can be an alpha beta T cell with TCRs that can recognize
specific antigens such as viral specific antigen, tumor-associated
antigens (TAAs) or tumor-specific antigens (TSAs). For another
example, the immune cell can be a gamma delta T cell or a natural
killer T (NKT) cell. For another example, the immune cell can be
induced pluripotent stem cells produced from antigen-specific T
cells (e.g., antigen-specific cytotoxic T cells). The immune cell
can be cord-blood T cells.
[0151] The immune cell may comprise a cell surface marker. The cell
surface marker can be an immune cell antigen. The gene encoding the
immune cell antigen of the immune cell used for preparing the
engineered immune cell can be inactivated. Examples of immune cell
antigens include, but are not limited to, CD2, CD3, CD4, CD5, CD7,
CD8, CD16a, CD16b, CD25, CD27, CD28, CD30, CD38, CD45, CD48, CD50,
CD52, CD56, CD57, CD62L, CD69, CD94, CD100, CD102, CD122, CD127,
CD132, CD137, CD160, CD161, CD178, CD218, CD226, CD244, CD159a
(NKG2A), CD159c (NKG2C), NKG2E, CD279, CD314 (NKG2D), CD305, CD335
(NKP46), CD337, CD319 (CS1), TCR.alpha., TCR.beta. and SLAMF7. For
example, in some cases, the gene encoding CD7 of the immune cell is
inactivated. In some cases, the gene encoding CD3 of the immune
cell is inactivated. In some cases, the gene encoding CD137 of the
immune cell is inactivated.
[0152] The immune cells can be isolated from a sample from a
subject. The subject can be a healthy donor. The subject can have a
condition (e.g., a disease such as cancer). The sample can be a
bodily fluid or a tissue, including but not limited to, peripheral
blood mononuclear cells, bone marrow, lymph node tissue, cord
blood, thymus tissue, tissue from a site of infection, ascites,
pleural effusion, spleen tissue, and tumors. In some cases, a
sample comprises NK cells, NKT cells, T-cells or T-cell progenitor
cells. For example, in some cases, the sample is an umbilical cord
blood sample, a peripheral blood sample (e.g., a mononuclear cell
fraction) or a sample from the subject comprising pluripotent
cells. In some aspects, a sample from the subject can be cultured
to generate induced pluripotent stem (iPS) cells and these cells
used to produce NK cells, NKT cells or T-cells. Cell samples may be
cultured directly from the subject or may be cryopreserved prior to
use. In some aspects, obtaining a cell sample comprises collecting
a cell sample. In other aspects, the sample is obtained by a third
party. In still further aspects, a sample from a subject can be
treated to purify or enrich the T-cells or T-cell progenitors in
the sample. For example, the sample can be subjected to gradient
purification, cell culture selection and/or cell sorting (e.g., via
fluorescence-activated cell sorting (FACS)).
[0153] The immune cell can be an NK cell. The NK cells can be
obtained from peripheral blood, cord-blood, or other sources
described herein. The NK cells can be derived from induced
pluripotent stem cells.
[0154] In some embodiments, a cell that can be utilized in a method
provided herein can be positive or negative for a given factor. In
some embodiments, a cell utilized in a method provided herein can
be a CD3+ cell, CD3- cell, a CD5+ cell, CD5- cell, a CD7+ cell,
CD7- cell, a CD14+ cell, CD14- cell, CD8+ cell, a CD8- cell, a
CD103+ cell, CD103- cell, CD11b+ cell, CD11b- cell, a BDCA1+ cell,
a BDCA1- cell, an L-selectin+ cell, an L-selectin- cell, a CD25+, a
CD25- cell, a CD27+, a CD27- cell, a CD28+ cell, CD28- cell, a
CD44+ cell, a CD44- cell, a CD56+ cell, a CD56- cell, a CD57+ cell,
a CD57- cell, a CD62L+ cell, a CD62L- cell, a CD69+ cell, a CD69-
cell, a CD45RO+ cell, a CD45RO- cell, a CD127+ cell, a CD127- cell,
a CD132+ cell, a CD132- cell, an IL-7+ cell, an IL-7- cell, an
IL-15+ cell, an IL-15- cell, a lectin-like receptor G1 positive
cell, a lectin-like receptor G1 negative cell, or an differentiated
or de-differentiated cell thereof. The examples of factors
expressed by cells is not intended to be limiting, and a person
having skill in the art will appreciate that a cell may be positive
or negative for any factor known in the art. In some embodiments, a
cell may be positive for two or more factors. For example, a cell
may be CD4+ and CD8+. In some embodiments, a cell may be negative
for two or more factors. For example, a cell may be CD25-, CD44-,
and CD69-. In some embodiments, a cell may be positive for one or
more factors, and negative for one or more factors. For example, a
cell may be CD4+ and CD8-. In some aspects, a cellular marker
provided herein can be utilized to select, enrich, or deplete a
population of cells. In some aspects, enriching comprises selecting
a monocyte fraction. In some aspects, enriching comprises sorting a
population of immune cells from a monocyte fraction. In some
embodiments, the cells may be selected for having or not having one
or more given factors (e.g., cells may be separated based on the
presence or absence of one or more factors). In some embodiments,
the selected cells can also be transduced and/or expanded in vitro.
The selected cells can be expanded in vitro prior to infusion. In
some embodiments, selected cells can be transduced with a vector
provided herein. It should be understood that cells used in any of
the methods disclosed herein may be a mixture (e.g., two or more
different cells) of any of the cells disclosed herein. For example,
a method of the present disclosure may comprise cells, and the
cells are a mixture of CD4+ cells and CD8+ cells. In another
example, a method of the present disclosure may comprise cells, and
the cells are a mixture of CD4+ cells and naive cells. In some
cases, a cell can be a stem memory TSCM cell comprised of CD45RO
(-), CCR7(+), CD45RA (+), CD62L+(L-selectin), CD27+, CD28+ and
IL-7Ra+, stem memory cells can also express CD95, IL-2RP, CXCR3,
and LFA-1, and show numerous functional attributes distinctive of
stem memory cells. Cells provided herein can also be central memory
TCM cells comprising L-selectin and CCR7, where the central memory
cells can secrete, for example, IL-2, but not IFN.gamma. or IL-4.
Cells can also be effector memory TEM cells comprising L-selectin
or CCR7 and produce, for example, effector cytokines such as
IFN.gamma. and IL-4. In some cases, a population of cells can be
introduced to a subject. For example, a population of cells can be
a combination of T cells and NK cells. In other cases, a population
can be a combination of naive cells and effector cells. A
population of cells can be TILs.
[0155] The source immune cells can be T cells. The T cells can be
alpha beta T cells or gamma delta T cells. T cells can be obtained
from a number of sources, including peripheral blood mononuclear
cells, bone marrow, lymph node tissue, cord blood, thymus tissue,
tissue from a site of infection, ascites, pleural effusion, spleen
tissue, and tumors. In certain embodiments of the present
disclosure, various T cell lines may be used. In certain
embodiments of the present disclosure, T cells can be obtained from
a unit of blood collected from a subject using any number of
techniques known to the skilled artisan, such as Ficoll.TM.
separation. In some embodiments, cells from the circulating blood
of an individual are obtained by apheresis. The apheresis product
typically contains lymphocytes, including T cells, monocytes,
granulocytes, B cells, other nucleated white blood cells, red blood
cells, and platelets. In some embodiments, the cells collected by
apheresis may be washed to remove the plasma fraction and to place
the cells in an appropriate buffer or media for subsequent
processing steps. In some embodiments of the present disclosure,
the cells are washed with phosphate buffered saline (PBS). In an
alternative embodiment, the wash solution lacks calcium and may
lack magnesium or may lack many if not all divalent cations.
Initial activation steps in the absence of calcium may lead to
magnified activation. A washing step may be accomplished by methods
such as by using a semi-automated "flow-through" centrifuge (for
example, the Cobe 2991 cell processor, the Baxter CytoMate, or the
Haemonetics Cell Saver 5) according to the manufacturer's
instructions. After washing, the cells may be resuspended in a
variety of biocompatible buffers, such as, for example, Ca2+-free,
Mg2+-free PBS, PlasmaLyte A, or other saline solution with or
without buffer. Alternatively, the undesirable components of the
apheresis sample may be removed and the cells directly resuspended
in culture media.
[0156] In another embodiment, T cells are isolated from peripheral
blood lymphocytes by lysing the red blood cells and depleting the
monocytes, for example, by centrifugation through a PERCOLL.TM.
gradient or by counterflow centrifugal elutriation. A specific
subpopulation of T cells, such as CD3+, CD28+, CD4+, CD8+, CD45RA+,
and CD45RO+ T cells, can be further isolated by positive or
negative selection techniques. For example, in one embodiment, T
cells are isolated by incubation with anti-CD3/anti-CD28 (i.e.,
3.times.28)-conjugated beads, such as DYNABEADS.RTM. M-450 CD3/CD28
T, for a time period sufficient for positive selection of the
desired T cells. In one embodiment, the time period is about 30
minutes. In a further embodiment, the time period ranges from 30
minutes to 36 hours or longer and all integer values there between.
In a further embodiment, the time period is at least 1, 2, 3, 4, 5,
or 6 hours. In yet another preferred embodiment, the time period is
10 to 24 hours. In some embodiments, the incubation time period is
24 hours. For isolation of T cells from patients with leukemia, use
of longer incubation times, such as 24 hours, can increase cell
yield. Longer incubation times may be used to isolate T cells in
any situation where there are few T cells as compared to other cell
types. Further, use of longer incubation times can increase the
efficiency of capture of CD8+ T cells. Thus, by simply shortening
or lengthening the time T cells are allowed to bind to the CD3/CD28
beads and/or by increasing or decreasing the ratio of beads to T
cells (as described further herein), subpopulations of T cells can
be preferentially selected for or against at culture initiation or
at other time points during the process. Additionally, by
increasing or decreasing the ratio of anti-CD3 and/or anti-CD28
antibodies on the beads or other surface, subpopulations of T cells
can be preferentially selected for or against at culture initiation
or at other desired time points. In some cases, multiple rounds of
selection can also be used. In certain embodiments, it may be
useful to perform the selection procedure and use the "unselected"
cells in the activation and expansion process. "Unselected" cells
can also be subjected to further rounds of selection.
[0157] Enrichment of a T cell population by negative selection can
be accomplished with a combination of antibodies directed to
surface markers unique to the negatively selected cells. An example
method can be cell sorting and/or selection via negative magnetic
immunoadherence or flow cytometry that uses a cocktail of
monoclonal antibodies directed to cell surface markers present on
the cells negatively selected. For example, to enrich for CD4+
cells by negative selection, a monoclonal antibody cocktail
typically includes antibodies to CD14, CD20, CD11b, CD16, HLA-DR,
and CD8. In certain embodiments, it may be desirable to enrich for
or positively select for regulatory T cells which typically express
CD4+, CD25+, CD62Lhi, GITR+, and FoxP3+. Alternatively, in certain
embodiments, T regulatory cells are depleted by anti-C25 conjugated
beads or other similar method of selection.
[0158] For isolation of a desired population of cells by positive
or negative selection, the concentration of cells and surface
(e.g., particles such as beads) can be varied. In certain
embodiments, it may be desirable to significantly decrease the
volume in which beads and cells are mixed together (i.e., increase
the concentration of cells), to ensure maximum contact of cells and
beads. For example, in one embodiment, a concentration of 2 billion
cells/ml is used. In one embodiment, a concentration of 1 billion
cells/ml is used. In a further embodiment, greater than 100 million
cells/ml is used. In a further embodiment, a concentration of cells
of 10, 15, 20, 25, 30, 35, 40, 45, or 50 million cells/ml is used.
In yet another embodiment, a concentration of cells from 75, 80,
85, 90, 95, or 100 million cells/ml is used. In further
embodiments, concentrations of 125 or 150 million cells/ml can be
used. Using high concentrations can result in increased cell yield,
cell activation, and cell expansion. Further, use of high cell
concentrations allows more efficient capture of cells that may
weakly express target antigens of interest, such as CD28-negative T
cells, or from samples where there are many tumor cells present
(i.e., leukemic blood, tumor tissue, etc.). Such populations of
cells may have therapeutic value and would be desirable to obtain.
For example, using high concentration of cells allows more
efficient selection of CD8+ T cells that normally have weaker CD28
expression.
[0159] In a related embodiment, lower concentrations of cells may
be used. By significantly diluting the mixture of T cells and
surface (e.g., particles such as beads), interactions between the
particles and cells is minimized. This method can select for cells
that express high amounts of desired antigens to be bound to the
particles. For example, CD4+ T cells express higher levels of CD28
and are more efficiently captured than CD8+ T cells in dilute
concentrations. In some embodiments, the concentration of cells
used is 5.times.10.sup.6/ml. In other embodiments, the
concentration used can be from about 1.times.10.sup.5/ml to
1.times.10.sup.6/ml, and any integer value in between. In other
embodiments, the cells may be incubated on a rotator for varying
lengths of time at varying speeds at either 2-10.degree. C. or at
room temperature.
[0160] T cells for stimulation can also be frozen after a washing
step. Wishing not to be bound by theory, the freeze and subsequent
thaw step provides a more uniform product by removing granulocytes
and to some extent monocytes in the cell population. After the
washing step that removes plasma and platelets, the cells may be
suspended in a freezing solution. While many freezing solutions and
parameters are known in the art and will be useful in this context,
one method involves using PBS containing 20% DMSO and 8% human
serum albumin, or culture media containing 10% Dextran 40 and 5%
Dextrose, 20% Human Serum Albumin and 7.5% DMSO, or 31.25%
Plasmalyte-A, 31.25% Dextrose 5%, 0.45% NaCl, 10% Dextran 40 and 5%
Dextrose, 20% Human Serum Albumin, and 7.5% DMSO or other suitable
cell freezing media containing for example, Hespan and PlasmaLyte
A, the cells then are frozen to -80.degree. C. at a rate of
1.degree. per minute and stored in the vapor phase of a liquid
nitrogen storage tank. Other methods of controlled freezing may be
used as well as uncontrolled freezing immediately at -20.degree. C.
or in liquid nitrogen.
[0161] In some embodiments, cryopreserved cells are thawed and
washed as described herein and allowed to rest for one hour at room
temperature prior to activation using the methods of the present
disclosure.
[0162] In some embodiments, the cells are isolated from a blood
sample or an apheresis from a subject prior to any number of
relevant treatment modalities, including but not limited to
treatment with agents such as natalizumab, efalizumab, antiviral
agents, chemotherapy, radiation, immunosuppressive agents, such as
cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506,
antibodies, or other immunoablative agents such as CAMPATH,
anti-CD3 antibodies, cytoxan, fludarabine, cyclosporin, FK506,
rapamycin, mycophenolic acid, steroids, FR901228, and irradiation.
These drugs inhibit either the calcium dependent phosphatase
calcineurin (cyclosporine and FK506) or inhibit the p70S6 kinase
that is important for growth factor induced signaling (rapamycin)
(Liu et al., Cell 66:807-815, 1991; Henderson et al., Immun.
73:316-321, 1991; Bierer et al., Curr. Opin. Immun. 5:763-773,
1993). In a further embodiment, the cells are isolated for a
patient and frozen for later use in conjunction with (e.g., before,
simultaneously or following) bone marrow or stem cell
transplantation, T cell ablative therapy using either chemotherapy
agents such as, fludarabine, external-beam radiation therapy (XRT),
cyclophosphamide, or antibodies such as OKT3 or CAMPATH. In another
embodiment, the cells are isolated prior to and can be frozen for
later use for treatment following B-cell ablative therapy such as
agents that react with CD20, e.g., Rituxan.
Engineered Immune Cell
[0163] The engineered immune cell provided herein can exhibit
enhanced activity toward tumor cells, but with reduced side effects
such as GVHD. The engineered immune cell can target a
disease-associated antigen (e.g., tumor-associated antigen, or
tumor cell marker) and at the same time suppress host immune cells.
One or more endogenous genes (e.g., a gene encoding a subunit of a
TCR, or a gene encoding a cell surface marker) of the engineered
immune cell can be inactivated. In some cases, the engineered
immune cell comprises a first CAR and a second CAR, each targeting
a different antigen. In some cases, the engineered immune cell
comprises a CAR having a first antigen binding domain and a second
antigen binding domain.
[0164] The engineered immune cell can comprise one or more chimeric
antigen receptors (CARs) comprising a binding moiety. The binding
moiety can comprise a first antigen binding domain capable of
binding to an immune cell antigen and a second antigen binding
domain capable of binding to a disease-associated antigen. Each CAR
of the one or more CARs may further comprise a transmembrane domain
and an intracellular signaling domain. The engineered immune cell
can also comprise an enhancer moiety capable of enhancing one or
more activities of the engineered immune cell. The endogenous T
cell receptor (TCR) of the engineered immune cell can be
inactivated. In some cases, the engineered immune cell can exhibit
(i) enhanced degree of persistence by remaining viable in vitro for
at least about 20 days while in presence of cells that are
heterologous to the engineered immune cell, (ii) enhanced degree of
expansion by at least about 10-fold within 15 days, or (iii)
enhanced cytotoxicity against a target cell comprising the immune
cell antigen or the disease-associated antigen, compared to an
additional engineered immune cell comprising the one or more CARs
but not the enhancer moiety. In some cases, the engineered immune
cell can be characterized by exhibiting two or more of (i) enhanced
degree of persistence, (ii) enhanced degree of expansion, and (iii)
enhanced cytotoxicity. The (i), (ii), and/or (iii) characteristics
can be measured in absence of any exogenous enhancer moiety such as
exogenous cytokines.
[0165] The engineered immune cell can comprise a multi-specific
CAR. In some cases, the engineered immune cell comprises a
bispecific CAR targeting an immune cell antigen and a
disease-associated antigen. The two antigen binding domains of the
bispecific CAR can be arranged in any form as described in the
present disclosure, for example, parallel form, loop form, and
tandem form. For example, an engineered immune cell described
herein can comprise comprising a single chimeric antigen receptor
(CAR) comprising (i) a first antigen binding domain that
specifically binds CD7 and (ii) a second antigen binding domain
capable of binding to a disease-associated antigen. The CAR can
further comprise a transmembrane domain and an intracellular
signaling domain. In various cases, a gene encoding endogenous CD7
can be inactivated (e.g., silenced or knocked out) in the
engineered immune cell.
[0166] The immune cell antigen can be selected from the group
consisting of CD2, CD3, CD4, CD5, CD7, CD8, CD16a, CD16b, CD25,
CD27, CD28, CD30, CD38, CD45, CD48, CD50, CD52, CD56, CD57, CD62L,
CD69, CD94, CD100, CD102, CD122, CD127, CD132, CD137, CD160, CD161,
CD178, CD218, CD226, CD244, CD159a (NKG2A), CD159c (NKG2C), NKG2E,
CD279, CD314 (NKG2D), CD305, CD335 (NKP46), CD337, CD319 (CS1),
TCR.alpha., TCR.beta. and SLAMF7. In some cases, the immune cell
antigen is CD2, CD3, CD4, CD5, CD7, CD8, CD30, CD38, CD45, CD48,
CD50, CD52, CD56, CD69, CD100, CD122, CD132, CD137, CD161, CD159a,
CD159c, CD279, CD314, CD319 (CS1), TCR.alpha. or TCR.beta.. In some
cases, the immune cell antigen is CD2, CD3, CD5, CD7, or CD137. In
some cases, the immune cell antigen is CD7. The enhancer moiety can
be configured to constitutively enhance the one or more activities
of the engineered immune cell. The enhancer moiety can be
configured to constitutively upregulate one or more intracellular
signaling pathways of the engineered immune cell. The one or more
intracellular signaling pathways can be one or more cytokine
signaling pathways. The enhancer moiety can be self-activating
through self-oligomerizing. The enhancer moiety can be
self-activating through self-dimerizing.
[0167] The enhancer moiety can be a cytokine or a cytokine
receptor. The enhancer moiety can be selected from the group
consisting of IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10, IL-11,
IL-12, IL-15, IL-17, IL-18, IL-21, IL-23, PD-1, PD-L1, CD122,
CSF1R, CTAL-4, TIM-3, CCL21, CCL19, TGFR beta, receptors for the
same, functional fragments thereof, functional variants thereof,
and combinations thereof.
[0168] In some cases, a gene encoding a subunit of the endogenous
TCR of the engineered immune cell can be inactivated such that the
endogenous TCR is inactivated. The gene encoding the subunit can be
TCR.alpha., TCR.beta., CD3.epsilon., CD3.delta., CD3.gamma., or
CD3.zeta..
[0169] The engineered immune cell can further comprise an inducible
cell death moiety, which inducible cell death moiety can effect
suicide of the engineered immune cell upon contact with a cell
death activator. The inducible cell death moiety can be selected
from the group consisting of rapaCasp9, iCasp9, HSV-TK, ACD20,
mTMPK, ACD19, RQR8, and EGFRt. In some cases, the inducible cell
death moiety is EGFRt, and the cell death activator is an antibody
or an antigen binding fragment thereof that binds EGFRt. In some
cases, the inducible cell death moiety is HSV-TK, and the cell
death activator is GCV. In some cases, the inducible cell death
moiety is iCasp9, and the cell death activator is AP1903. The cell
death activator can comprise a nucleic acid, a polynucleotide, an
amino acid, a polypeptide, lipid, a carbohydrate, a small molecule,
an enzyme, a ribosome, a proteasome, a variant thereof, or any
combination thereof.
[0170] The expression of one or more endogenous human leukocyte
antigen (HLA) genes of the engineered immune cell may remain
intact. In some cases, the expression of endogenous HLA-I and/or
HLA-II genes of the engineered immune cell may remain intact. The
expression of endogenous HLA-E and/or HLA-G and/or HLA-C genes of
the engineered immune cell may remain intact.
[0171] The expression of one or more endogenous HLA genes of the
engineered immune cell can be upregulated. In some cases, the
expressions of endogenous HLA-E and/or HLA-G and/or HLA-C genes of
the engineered immune cell are upregulated.
[0172] The expression of one or more endogenous HLA genes of the
engineered immune cell may be knocked out or partially knocked out.
For example, HLA-I, HLA-II or both can be knocked out. In some
cases, HLA-I, HLA-2, or both can be partially knocked out. In some
cases, HLA-I/II can be partially knockout. In some cases, an
endogenous HLA can be knocked out to reduce T cell killing activity
but keep anti-NK killer function. For example, HLA-A/B can be
knocked out while keeping HLA-C/E in the engineered immune cell. In
some cases, HLA-A, HLA-B, or both is knocked out. In some cases,
HLA-C, HLA-E, or both remains intact. In some cases, a
killer/phagocyte inhibitor of the engineered immune cell can be
overexpressed. In some other cases, an endogenous HLA can be
knocked out with co-expression of killer/phagocyte inhibitor(s).
For example, HLA-I, HLA-II, or both can be knocked out with
co-expression of killer/phagocyte inhibitors. The killer/phagocyte
inhibitor may suppress immune response toward the engineered immune
cell. The killer/phagocyte inhibitors include, but are not limited
to, CD47, CD24, FASL, PDL1, or functional domains thereof.
[0173] The disease-associated antigen described herein can be a
tumor-associated antigen or a tumor-specific antigen. The first
antigen binding domain or the second antigen binding domain can be
an antibody or fragment thereof, for example, a scFv or a single
domain antibody.
[0174] A gene encoding an endogenous surface marker of the
engineered immune cell can be inactivated, wherein the endogenous
surface marker is capable of binding to the first antigen binding
domain when expressed. The endogenous surface marker can be the
antigen that CAR targets. In various embodiments, when a CAR of the
engineered immune cell targets an antigen that is endogenously
expressed by the engineered immune cell, the endogenous antigen or
the gene encoding such antigen may be inactivated (e.g., disrupted,
inhibited, silenced or knocked out). Various gene editing methods
described herein can be used. The endogenous surface marker can be,
for example, CD2, CD3, CD4, CD5, CD7, CD8, CD16a, CD16b, CD25,
CD27, CD28, CD30, CD38, CD45, CD48, CD50, CD52, CD56, CD57, CD62L,
CD69, CD94, CD100, CD102, CD122, CD127, CD132, CD137, CD160, CD161,
CD178, CD218, CD226, CD244, CD159a (NKG2A), CD159c (NKG2C), NKG2E,
CD279, CD314 (NKG2D), CD305, CD335 (NKP46), CD337, CD319 (CS1),
TCR.alpha., TCR.beta. and SLAMF7.
[0175] The engineered immune cell provided herein can comprise a
chimeric polypeptide comprising (i) an enhancer moiety capable of
enhancing one or more activities of the engineered immune cell, and
(ii) an inducible cell death moiety capable of effecting death of
the engineered immune cell upon contacting the chimeric polypeptide
with a cell death activator, wherein the enhancer moiety is linked
to the inducible cell death moiety. In some cases, the enhancer
moiety and the inducible moiety may be linked by a linker. The
linker can be a cleavable linker, for example, a self-cleaving
peptide. The engineered immune cell can further comprise one or
more chimeric polypeptide receptors (CPRs) comprising a binding
moiety, wherein the binding moiety comprises (i) a first antigen
binding domain, which first antigen binding domain suppresses or
reduces a subject's immune response toward the engineered immune
cell when administered into the subject and (ii) a second antigen
binding domain capable of binding to a disease-associated antigen.
An individual CPR of the one or more CPRs can comprise (i) the
first antigen binding domain, (ii) the second antigen binding
domain, or (iii) both the first antigen binding domain and the
second antigen binding domain. A CPR of the one or more CPRs can
further comprise a transmembrane domain and an intracellular
signaling domain. In some cases, the one or more CPRs in the
engineered immune cell are one or more chimeric antigen receptors
(CARs) or engineered T cell receptors (TCRs). In some cases, the
engineered immune cells comprise both CARs and engineered TCRs. The
engineered TCR can be a TCR fusion protein. For example, the TCR
fusion protein can comprise a heterologous antigen binding domain
fused to one or more subunits of a TCR complex. In some cases, the
TCR fusion protein can comprise a TCR subunit comprising at least a
portion of a TCR extracellular domain and a TCR intracellular
domain; and an antibody domain comprising an antigen binding
domain, where the TCR subunit and the antibody domain are linked.
The TCR fusion protein can incorporate into a TCR complex when
expressed in a T cell. In some cases, the TCR fusion protein can
further comprise a TCR transmembrane domain. The TCR extracellular
domain, the TCR intracellular domain, or the TCR transmembrane
domain can be derived from TCR alpha chain, TCR beta chain, TCR
gamma chain, TCR delta chain, CD3 epsilon, CD3 gamma, CD3 delta or
CD3 zeta. In some cases, an endogenous TCR of the engineered immune
cell comprising an engineered TCR is inactivated. In some cases,
the engineered immune cell comprising inactivated endogenous TCR
may not cause GVHD. For example, a gene encoding an endogenous TCR
subunit can be inactivated. For another example, a gene encoding an
endogenous TCR subunit may be mutated such that an endogenous TCR
may not be formed.
[0176] The engineered immune cell provided herein can comprise a
chimeric polypeptide comprising (i) an enhancer moiety capable of
enhancing one or more activities of the engineered immune cell, and
(ii) an inducible cell death moiety capable of effecting death of
the engineered immune cell upon contacting the chimeric polypeptide
with a cell death activator. In some cases, the enhancer moiety is
linked to the inducible cell death moiety. The one or more chimeric
antigen receptors (CARs) can comprise a binding moiety. The binding
moiety can comprise (i) a first antigen binding domain, which first
antigen binding domain suppresses or reduces a subject's immune
response toward the engineered immune cell when administered into
the subject and (ii) a second antigen binding domain capable of
binding to a disease-associated antigen. In some cases, an
individual CAR of the one or more CARs comprises (i) the first
antigen binding domain or (ii) the second antigen binding domain.
In some cases, an individual CAR of the one or more CARs comprises
both the first antigen binding domain and the second antigen
binding domain. In some cases, each CAR of the one or more CARs
further comprises a transmembrane domain and an intracellular
signaling domain.
[0177] The first antigen binding domain of the engineered immune
cell can bind to an immune cell antigen. In some cases, endogenous
T cell receptors (TCRs) of the engineered immune cell is
inactivated. Various methods can be used to inactivate endogenous
TCRs. For example, a gene encoding a subunit of the endogenous TCR
can be inactivated such that the endogenous TCR is inactivated. The
gene encoding the subunit can be TCR.alpha., TCR.beta.,
CD3.epsilon., CD3.delta., CD3.gamma., or CD3.zeta..
[0178] The chimeric polypeptide may or may not comprise any
self-cleaving peptide flanked by the enhancer moiety and the
inducible cell death moiety. The enhancer moiety can be configured
to constitutively enhance the one or more activities of the
engineered immune cell. The enhancer moiety can be configured to
constitutively upregulate one or more intracellular signaling
pathways of the engineered immune cell. The one or more
intracellular signaling pathways can be one or more cytokine
signaling pathways. The enhancer moiety can be self-activating
through self-oligomerizing. The enhancer moiety can be
self-activating through self-dimerizing.
[0179] The chimeric polypeptide described herein can be a secreted
protein. The chimeric polypeptide can be an intracellular protein.
The chimeric polypeptide can be a transmembrane protein. The
enhancer moiety or the inducible cell death moiety can be contained
in an ectodomain of the transmembrane protein. The enhancer moiety
or the inducible cell death moiety is contained in an endodomain of
the transmembrane protein. The enhancer moiety can be contained in
an endodomain of the transmembrane protein and the inducible cell
death moiety can be contained in an ectodomain of the transmembrane
protein. The enhancer moiety can be contained in an ectodomain of
the transmembrane protein, and the inducible cell death moiety can
be contained in an endodomain of the transmembrane protein. The
enhancer moiety can be a cytokine or a cytokine receptor. For
example, the enhancer moiety can be selected from the group
consisting of IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10, IL-11,
IL-12, IL-15, IL-17, IL-18, IL-21, IL-23, PD-1, PD-L1, CD122,
CSF1R, CTAL-4, TIM-3, CCL21, CCL19, TGFR beta, receptors for the
same, functional fragments thereof, functional variants thereof,
and combinations thereof. The inducible cell death moiety can be
selected from the group consisting of rapaCasp9, iCasp9, HSV-TK,
ACD20, mTMPK, ACD19, RQR8, and EGFRt. In some cases, the inducible
cell death moiety is EGFRt, and the cell death activator is an
antibody or an antigen binding fragment thereof that binds EGFRt.
In some cases, the inducible cell death moiety is HSV-TK, and the
cell death activator is GCV. In some cases, the inducible cell
death moiety is iCasp9, and the cell death activator is AP1903. The
cell death activator may comprise a nucleic acid, a polynucleotide,
an amino acid, a polypeptide, lipid, a carbohydrate, a small
molecule, an enzyme, a ribosome, a proteasome, a variant thereof,
or any combination thereof.
[0180] The engineered immune cell can be a CAR-T cell. The CAR-T
cell can express a CAR targeting a tumor cell marker and CD3. The
expression of endogenous CD3 gene can be silenced in the CAR-T
cell. The CAR can be a single CAR targeting both a tumor cell
marker and CD3. The CAR can comprise a first CAR targeting a tumor
cell marker and a second CAR targeting CD3. The CAR-T cell can have
one or more of the following characteristics: (a) expression of
PD-1 gene is silenced in the CAR-T cell; (b) expression of TCR gene
is silenced in the CAR-T cell; (c) the CAR-T cell expresses an
exogenous cellular suicide element (e.g., inducible cell death
moiety).
[0181] The engineered immune cell can express a CAR and/or an
exogenous TCR, and the CAR and/or exogenous TCR target a tumor cell
marker. The engineered immune cell can comprise a cytokine-related
signaling pathway that is enhanced. The cytokine-related signaling
pathway can comprise a related signaling pathway of a cytokine
selected from a group consisting of IL-2, IL-3, IL-4, IL-6, IL-7,
IL-8, IL-10, IL-11, IL-12, IL-15, IL-17, IL-18, IL-21, or a
combination thereof. Enhancing the cytokine-related signaling
pathway can comprise introducing a gene encoding a cytokine and/or
a receptor thereof, up-regulating a gene encoding a cytokine and/or
a receptor thereof, or exogenously adding a cytokine, a receptor of
cytokine that is introduced, or a combination thereof. The
engineered immune cell can be a CAR-T cell having one or more
characteristics selected from a group consisting of (a) gene
expression an endogenous TCR being silenced; (b) expressing an
element for cellular suicide; (c) normal expression of endogenous
HLA-I and HLA-II genes; (d) normal expression or overexpression of
endogenous HLA-E and/or HLA-G.
[0182] The engineered immune cell can comprise a CAR or an
exogenous TCR targeting a tumor cell marker. The engineered immune
cell can comprise a substance targeting a T cell or NK cell. For
example, the engineered immune cell can comprise a CAR targeting a
T cell and/or NK cell. The engineered immune cell can comprise a
bispecific CAR targeting both (i) a tumor cell marker and (ii) a T
cell and/or NK cell marker. In some cases, the substance is an
antibody. The antibody target both T cell and NK cell can be H-69,
3Ale, 3Alf, T3-3A1, RFT2, SDZ214-380 (SDZCHH380), CD7-6B7, 124-1D1,
4H9, RPA-2.10, TS1/8, OKT11, AB75, 3E11, BH1, or Lo-CD2a.
[0183] The CAR-T cell provided herein can be a universal CAR-T
cell. The CAR-T cell can express a chimeric antigen receptor CAR
that targets a tumor cell marker and the binding of the T cell
receptor to PD-1 is inhibited. The CAR-T cell can target a tumor
cell marker and an immune cell marker such as CD2 or CD7. The
endogenous TCR expression in the CAR-T cells provided herein can be
knocked out by gene editing technology. Upon knocking out the
endogenous TCRs of the CAR-T cells, the normal cells may not be
recognized and killed by the CAR-T cells during the allogeneic
infusion. The GVHD reaction may be inhibited. Moreover, targeting
tumor cells through CD19 while eliminating host T cells and/or NK
cells through CD2 or CD7 can avoid host versus graft (HVG) and/or
NK killing and improve the survival and anti-tumor effect of the
allogeneic CAR-T cells in the recipient. The CAR-T can further
comprise a suicide gene switch (e.g., an inducible cell death
moiety). The CAR-T cells can be inactivated or removed by turning
on the suicide gene switch (e.g., binding of an activator to the
inducible cell death moiety) to reduce the side effects of the
CAR-T cell therapy. For example, a CAR provided herein can have a
structure of CD19 scFv-CD7 scFv-Hinge-TM-CD28/41BB-CD3.zeta.,
wherein the CD7 scFv fragment is a monoclonal 3Ale antibody, the
heavy and light chain variable regions are joined by a GS linker,
and the CD19 scFV fragment is the heavy and light chain variable
region of the monoclonal FMC63 antibody linked by a GS linker. The
CAR can also include a hinge region and a transmembrane region in
tandem, human CD28 and/or 41BB intracellular co-stimulatory
elements, as well as human CD3 intracellular domain. In some cases
of the present disclosure, a gene fragment of a CAR construct CD19
scFv-CD7 scFv-Hinge-TM-CD28/41BB-CD3.zeta. can be inserted into a
lentiviral vector, and the recombinant vector can be packaged into
viral particles in 293T cells. To prepare universal CAR-T cells, T
cells can be isolated from peripheral blood mononuclear cells, and
after activation, some endogenous genes (e.g., CD7, TCR and PD-1
genes) can be knocked out by gene editing technologies such as
CRISPR/CAS technology. Next, T cells can be infected by the viral
particles containing the CAR construct describe herein to express
the CAR. The prepared CAR-T cells can be used to detect the
infection efficiency and gene editing efficiency of CAR by
flowcytometry.
[0184] The engineered immune cell may have one or more
characteristics described herein: (a) the expression of the
endogenous CD7 or CD2 gene of the engineered immune cell is
silenced; (b) the PD-1 gene expression of the engineered immune
cell is silenced; (c) the TCR gene expression of the engineered
immune cell is silenced; (d) the engineered immune cell expresses a
cytokine or cytokine receptor complex and the pSTAT5 signaling
level is up-regulated; (e) the engineered immune cell expresses an
exogenous inducible cell death moiety; (f) the first CAR, and/or
the second CAR in the engineered immune cell is co-expressed with
the inducible cell death moiety.
[0185] The engineered immune cell may comprise two different CARs,
each having a different antigen binding domain target a different
antigen. The engineered immune cell may comprise a single CAR,
which further comprises two antigen binding domains targeting two
different antigens. In some cases, a first CAR, and/or a second CAR
is linked to an inducible cell death moiety and/or an enhancer
moiety by a self-cleaving element. In some cases, the enhancer
moiety is a cytokine or cytokine complex. Examples of cytokines or
cytokine complexes include IL2, IL7, IL15, membrane-bound IL15
(mbIL15 or mb15), and a constitutive activating cytokine receptor
such as an IL7 receptor (C7R). As used herein, "mbIL" and "mb" are
used interchangeably to refer to a membrane-bound interleukin
factor, for example, mbIL7 or mb7, and mbIL17 or mb17.
[0186] The engineered immune cell described herein may have the
following characteristics: (a) the engineered immune cell expresses
a CAR and/or an exogenous TCR, and the CAR and/or exogenous TCR
targets tumor cell markers; and (b) the cytokine-associated
signaling pathway is enhanced. The engineered immune cell may be
(i) chimeric antigen receptor T cells (CAR-T cells); (ii) chimeric
antigen receptor NK cells (CAR-NK cells); or (iii) Exogenous T cell
receptor (TCR) T cells (TCR-T cells). The engineered immune cell
can be a CAR-T cell, preferably a universal CAR-T cell (UCAR-T
cell). The "cytokine-related signaling pathway," as used herein,
refers to a signaling pathway initiated by the cytokine binding to
the corresponding receptor, converting the extracellular signal
into an intracellular signal, which is then amplified, dispersed,
and regulated by a signal cascade. A series of cellular responses
can be produced. In some cases, the cytokine-related signaling
pathway comprises a related signaling pathway of a cytokine
selected from the group consisting of IL-2, IL-3, IL-4, IL-6, IL-7,
IL-8, IL-10, IL-11, IL-12, IL-15, IL-17, IL-18, IL-21, 25 or a
combination thereof.
[0187] The engineered immune cell can comprise a bispecific CAR (or
a dual CAR). For example, the bispecific CAR can comprise both a
first antigen binding domain and a second antigen binding domain.
The first antigen binding domain and the second antigen binding
domain can be linked via a linker. The linker may not comprise a
self-cleaving peptide. The first antigen binding domain or the
second antigen binding can be a scFv.
[0188] The first antigen binding domain and the second antigen
binding domain can be arranged, from amino terminus to carboxyl
terminus, as: (i) VL2-VH1-VL1-VH2; (ii) VH2-VL1-VH1-VL2; (iii)
VL1-VH2-VL2-VH1; or (iv) VH1-VL2-VH2-VL1, wherein VH1 is heavy
chain variable domain of the first antigen binding domain, VL1 is
light chain variable light domain of the first antigen binding
domain, VH2 is heavy chain variable domain of the second antigen
binding domain, and VL2 is light chain variable domain of the
second antigen binding domain.
[0189] The first antigen binding domain and the second antigen
binding domain can be arranged, from amino terminus to carboxyl
terminus, as: (i) VL2-VH2-VL1-VH1; (ii) VL2-VH2-VH1-VL1; (iii)
VL1-VH1-VL2-VH2; or (iv) VL1-VH1-VH2-VL1, wherein VH1 is heavy
chain variable domain of the first antigen binding domain, VL1 is
light chain variable light domain of the first antigen binding
domain, VH2 is heavy chain variable domain of the second antigen
binding domain, and VL2 is light chain variable domain of the
second antigen binding domain. The first antigen binding domain and
the second antigen binding domain can bind to the immune cell
antigen and the disease-associated antigen.
[0190] In some cases, the engineered immune cell may not comprise a
bispecific CAR. For example, an individual CAR of the engineered
immune cell can comprise only the first antigen binding domain and
an additional individual CAR of the engineered immune cell can
comprise only the second antigen binding domain.
[0191] The immune cell antigen can be a surface protein or a
secreted protein of an immune cell. The immune cell can be an NK
cell, a T cell, a monocyte, a macrophage or a granulocyte. The
immune cell antigen can be selected from the group consisting of
CD2, CD3, CD4, CD5, CD7, CD8, CD16a, CD16b, CD25, CD27, CD28, CD30,
CD38, CD45, CD48, CD50, CD52, CD56, CD57, CD62L, CD69, CD94, CD100,
CD102, CD122, CD127, CD132, CD137, CD160, CD161, CD178, CD218,
CD226, CD244, CD159a (NKG2A), CD159c (NKG2C), NKG2E, CD279, CD314
(NKG2D), CD305, CD335 (NKP46), CD337, CD319 (CS1), TCR.alpha.,
TCR.beta. and SLAMF7.
[0192] The disease-associated antigen can be a tumor-associated
antigen. The tumor-associated antigen can be CD19 or other antigens
described herein. In some cases, the first antigen binding domain
can bind to an immune cell antigen selected from the group
consisting of CD2, CD3, CD5, CD7 and CD137, and the second antigen
binding domain can bind to CD19. In some cases, the first antigen
binding domain can bind to CD3, and the second antigen binding
domain can bind to CD19. In some cases, the first antigen binding
domain can bind to CD7, and the second antigen binding domain can
bind to CD19. In some cases, the first antigen binding domain can
bind to CD137, and the second antigen binding domain can bind to
CD19. The expression of one or more endogenous human leukocyte
antigen (HLA) genes of the engineered immune cell can remain
intact. The expression of endogenous HLA-I and/or HLA-II genes of
the engineered immune cell can remain intact. The expression of
endogenous HLA-E and/or HLA-G and/or HLA-C genes of the engineered
immune cell can remain intact. The expression of one or more
endogenous HLA genes of the engineered immune cell can be
upregulated. The expression of endogenous HLA-E and/or HLA-G and/or
HLA-C genes of the engineered immune cell can be upregulated.
[0193] In various embodiments, the engineered immune cell is a T
cell, an NKT cell or an NK cell. In some cases, the engineered
immune cell is derived from a stem cell. The stem cell can be a
hematopoietic stem cell (HSC) or an induced pluripotent stem cell
(iPSC).
[0194] A cell (e.g., an engineered immune cell) provided herein can
comprise one or more chimeric antigen receptors (CARs) comprising a
binding moiety, where the binding moiety can comprise an antigen
binding domain capable of binding to an immune cell antigen. Each
CAR of the one or more CARs can further comprise a transmembrane
domain and an intracellular signaling domain. The cell can further
comprise an enhancer moiety capable of enhancing one or more
activities of the cell, where an endogenous T cell receptor (TCR)
of the cell may be inactivated.
[0195] The enhancer moiety can enhance one or more activities of
the cell. The enhancer moiety can be configured to constitutively
enhance the one or more activities of the cell. The enhancer moiety
can be configured to constitutively upregulate one or more
intracellular signaling pathways of the cell. For example, the one
or more intracellular signaling pathways can be one or more
cytokine signaling pathways. The enhancer moiety can be a cytokine
or a cytokine receptor. The enhancer moiety can be selected from
the group consisting of IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10,
IL-11, IL-12, IL-15, IL-17, IL-18, IL-21, IL-23, PD-1, PD-L1,
CD122, CSF1R, CTAL-4, TIM-3, CCL21, CCL19, TGFR beta, receptors for
the same, functional fragments thereof, functional variants
thereof, and combinations thereof.
[0196] The cell can further comprise an inducible cell death moiety
capable of effecting death of the cell upon contacting the
inducible cell death moiety with a cell death activator. The
inducible cell death moiety can be selected from the group
consisting of rapaCasp9, iCasp9, HSV-TK, ACD20, mTMPK, ACD19, RQR8,
Her2t, CD30, BCMA, and EGFRt. For example, the inducible cell death
moiety can be EGFRt, and the cell death activator can be an
antibody or an antigen binding fragment thereof that binds EGFRt.
For another example, the inducible cell death moiety can be HSV-TK,
and the cell death activator can be GCV. For another example, the
inducible cell death moiety can be iCasp9, and the cell death
activator can be AP1903.
[0197] A gene encoding an endogenous surface marker of the cell can
be inactivated, where the endogenous surface marker may be capable
of binding to the first antigen binding domain when expressed. The
endogenous surface marker can be CD2, CD3, CD4, CD5, CD7, CD8,
CD16a, CD16b, CD25, CD27, CD28, CD30, CD38, CD45, CD48, CD50, CD52,
CD56, CD57, CD62L, CD69, CD94, CD100, CD102, CD122, CD127, CD132,
CD137, CD160, CD161, CD178, CD218, CD226, CD244, CD159a (NKG2A),
CD159c (NKG2C), NKG2E, CD279, CD314 (NKG2D), CD305, CD335 (NKP46),
CD337, CD319 (CS1), TCR.alpha., TCR.beta. or SLAMF7.
Antigen Binding Domain
[0198] The engineered immune cell can comprise a first antigen
binding domain and a second antigen binding domain. In some cases,
a single or individual CAR of the engineered immune cell comprises
both the first antigen binding domain and the second antigen
binding domain. In some cases, two CARs of the engineered immune
cell comprise the first antigen binding domain and the second
antigen binding domain with each CAR contains only one antigen
binding domain. In some cases, two engineered immune cells comprise
the first antigen binding domain and the second antigen binding
domain with each engineered immune cell comprises only one type of
antigen binding domain. In some cases, the first antigen binding
domain can target an immune cell antigen and the second antigen
binding domain can target a disease-associated antigen. The antigen
binding domain can be a Fab, F(ab').sub.2, single domain antibody,
single chain Fv (scFv), centyrin, darpin, or other polypeptides
with antigen binding specificities.
[0199] The antigen binding domain can target an immune cell
antigen. Examples of immune cell antigen include, but are not
limited to, CD2, CD3, CD4, CD5, CD7, CD8, CD16a, CD16b, CD25, CD27,
CD28, CD30, CD38, CD45, CD48, CD50, CD52, CD56, CD57, CD62L, CD69,
CD94, CD100, CD102, CD122, CD127, CD132, CD137, CD160, CD161,
CD178, CD218, CD226, CD244, CD159a (NKG2A), CD159c (NKG2C), NKG2E,
CD279, CD314 (NKG2D), CD305, CD335 (NKP46), CD337, CD319 (CS1),
TCR.alpha., TCR.beta. and SLAMF7. In some cases, the immune cell
antigen is a cell marker expressed on both T cells and NK cells,
including, but not limited to, CD2, CD7, CD38, CD45, CD48, CD50,
CD52, CD56, CD69, CD100, CD122, CD132, CD134 (OX40), CD137 (4-1BB),
CD178 (ICOS), CD161, CD159a, CD159c and CD314.
[0200] CD3 is a marker present on the surface of T lymphocytes.
There are three subtypes, CD 3.delta., CD 3.epsilon. and CD
3.gamma.. CD 3.delta. and CD 3.epsilon. have a molecular weight of
20 kDa, and CD37 has a molecular weight of 26 kDa, which is
expressed on the surface of T lymphocytes, thymocytes and NK cell
membranes. CD3 can be expressed in 61% to 85% of normal peripheral
blood lymphocytes and 60% to 85% in thymocytes. It belongs to the
immunoglobulin superfamily. CD3 is a component of the T-lymphocyte
receptor (TCR) complex and forms a complex with the .alpha.-.beta.
and .gamma./.delta. T-lymphocyte receptors (TCRs), which can be the
main membrane protein for conducting TCR signals upon TCR binding
to peptide/MHC. TCR can be essential for cell surface expression,
antigen recognition, and signaling. CD3 is a surface-specific
molecule of T lymphocytes through which T lymphocytes with killing
effects can be recruited. Monoclonal antibodies to CD3 can induce
or prevent T lymphocyte activation. Anti-CD3 antibodies induce
apoptosis of T lymphocytes in the presence of anti-CD28 antibodies
or IL-2. CD3 is one of the markers of mature T lymphocytes in
peripheral blood. Determination of CD3+ T lymphocytes for
evaluation of immunodeficiency (T lymphocyte deficiency), leukemia,
lymphoma (T lymphocyte type) classification diagnosis. Anti-CD3
monoclonal antibodies can be used for immunosuppressive therapy in
organ transplantation or bone marrow transplantation, and can also
be used for immunomodulatory treatment of severe autoimmune
diseases to remove T lymphocytes.
[0201] In some cases, the antigen binding domain can target CD7.
CD7 is a transmembrane protein and is a member of the
immunoglobulin superfamily. CD7 proteins are expressed on the
surface of mature T cells and NK cells as well as their precursor
cells. CD7 can bind to its ligand K12/SECTM1 and function as a
co-stimulatory effecter on T cell activation. In mice, CD7 knockout
T cell precursors can develop into normal T cells with only a
slight effect on T cell effector function. More than 90% of T-cell
acute lymphoblastic leukemia (T-ALL) can express CD7, and therefore
CD7 can be a marker for T-ALL. Moreover, CD7 can also be expressed
in NK lymphoma, T-cell lymphoma/leukemia, chronic myelogenous
leukemia, acute myeloid leukemia, and lymphocyte-rich thymoma. An
example tissue distribution of CD7 expression is shown in FIG.
13.
[0202] In some cases, the antigen binding domain can target CD2.
Similar to CD7, CD2 adhesion molecules may expressed on all
peripheral blood T cells and natural killer cells, but not on B
lymphocytes. The CD2 extracellular domain contains an
immunoglobulin-like domain that mediates homodimerization. Binding
of CD2 to CD58 (LFA-3) or CD48 can help T cells adhere to antigen
presenting cells, triggering signal transduction of T cell
receptors for antigen binding. The function of CD2 may be similar
to other T cell costimulatory receptors (such as CD28). CD2
knockout mice can have normal immune function. CD2 expression in
cells of T-ALL, T-cell lymphoma/leukemia, acute promyelocytic
leukemia (microparticle variant), systemic mastocytosis, mast cell
disease, thymoma, and acute myeloid lymphoma and NK cell leukemia.
An example tissue distribution of CD2 expression is shown in FIG.
14.
[0203] The antigen binding domain can target CD137. CD137, also
known as 4-1BB, is a member of the TNF receptor superfamily. CD137
protein can be an activation-induced co-stimulatory receptor, which
can be widely expressed in activated T cells, NK cells, dendritic
cells, granulocytes and other immune cell types and certain tumor
cells. CD137 expression was found on activated T and NK cells with
little expression in naive T cells and inactivated T and NK cells.
In T cells, CD137 can initiate NF-.kappa.B pathway through TRAF2
and participate in T cell proliferation, cytokine secretion and
anti-apoptosis. In clinical applications, CD137 can be used as a
marker for reactive T cells. Activation of CD137 signaling pathway
by CD137 natural ligand or agonistic antibody can increase cytokine
secretion and antitumor activity of cytotoxic lymphocytes.
Inhibition of reactive T cells with specific inhibitory CD137
antibodies can reduce autologous rejection in transplant rejection
or reduce GVHD response caused by autoreactive T cells of an
allogeneic origin. CD137 expression can be regulated by TCR
signaling and downstream signaling of cytokine TL-2/TL-15. Knockout
of CD137 molecule may have no effect on the function of mature T
cells in a non-activated state. The endogenous CD137 of the
engineered immune cell can be knocked out to avoid fratricide. The
endogenous TCRs of the engineered immune cell can be inactivated to
prevent GVHD. An example tissue distribution of CD137 expression is
shown in FIG. 51.
[0204] The antigen binding domain can target a disease-associated
antigen, for example, tumor-associated antigen. Examples of the
tumor-associated antigens include, but are not limited to, BCMA,
VEGFR2, CD19, CD20, CD30, CD22, CD25, CD28, CD30, CD33, CD52, CD56,
CD80, CD86, CD81, CD123, cd171, CD276, B7H4, CD133, EGFR, GPC3;
PMSA, CD 3, CEACAM6, c-Met, EGFRvIII, ErbB2, ErbB3 HER-2, HER3,
ErbB4/HER-4, EphA2, IGF1R, GD2, O-acetyl GD2, O-acetyl GD3, GHRHR,
GHR, Flt1, KDR, Flt4, CD44V6, CEA, CA125, CD151, CTLA-4, GITR,
BTLA, TGFBR2, TGFBR1, IL6R, gp130, Lewis, TNFR1, TNFR2, PD1, PD-L1,
PD-L2, HVEM, MAGE-A, Mesothelin, NY-ESO-1, PSMA, RANK, RORl,
TNFRSF4, CD40, CD137, TWEAK-R, LTPR, LIFRP, LRP5, MUC1, TCRa, TCRp,
TLR7, TLR9, PTCH1, WT-1, Robl, Frizzled, OX40, CD79b, Claudin 18.2,
Folate receptor .alpha., Folate receptor .beta., GPC2, CD70, BAFF-R
and Notch-1-4. In some cases, the tumor-associated antigens
comprise CD19, CD2, CD3, CD4, CD5, CD7, CD8, CD19, CD20, CD22,
CD25, CD28, CD30, CD33, CD38, CD40, CD44V6, CD47, CD52, CD56, CD57,
CD58, CD79b, CD80, CD86, CD81, CD123, CD133, CD137, CD151, CD171,
CD276, CLL1, B7H4, BCMA, VEGFR-2, EGFR, GPC3, PMSA, CEACAM6, c-Met,
EGFRvIII, ErbB2/HER2, ErbB3, HER-2, HER3, ErbB4/HER-4, EphA2,
IGF1R, GD2, O-acetyl GD2, O-acetyl GD3, GHRHR, GHR, Flt1, KDR,
Flt4, Flt3, CEA, CA125, CTLA-4, GITR, BTLA, TGFBR1, TGFBR2, TGFBR1,
IL6R, gp130, Lewis, TNFR1, TNFR2, PD1, PD-L1, PD-L2, PSCA, HVEM,
MAGE-A, MSLN, NY-ESO-1, PSMA, RANK, RORl, TNFRSF4, TWEAK-R, LTPR,
LIFRP, LRP5, MUC1, MUC16, TCR.alpha., TCRb, TLR7, TLR9, PTCH1,
WT-1, Robol, Frizzled, OX40, Notch-1-4, APRIL, CS1, MAGE3, Claudin
18.2, Folate receptor .alpha., Folate receptor .beta., GPC2, CD70,
BAFF-R or TROP-2.
[0205] In some cases, the tumor-associated antigen is CD19. CD19 is
a 95 kDa glycoprotein on the surface of B cells that begins to
express from the early development of B cells until it
differentiates into plasma cells. CD19 is a member of the
immunoglobulin (Ig) superfamily and is involved in the regulation
of the signal transduction process of B cell receptors as one of
the constituent elements of the B cell surface signal transduction
complex. In a CD19-deficient mouse model, the number of B cells in
peripheral lymphoid tissue can be significantly reduced, and the
response to vaccines and mitogens is also reduced, accompanied by a
decrease in serum Ig levels. It can be generally believed that the
expression of CD19 is restricted to the B-cell lineage and not to
the surface of pluripotent hematopoietic stem cells. CD19 can also
be expressed on the surface of most B cell lymphomas, mantle cell
lymphomas, ALLs, CLLs, hairy cell leukemias, and some acute myeloid
leukemia cells. CD19 can be a target for immunotherapy in the
treatment of leukemia/lymphoma. CD19 may not be expressed on most
normal cell surfaces other than B cells, including pluripotent
hematopoietic stem cells. This feature can make CD19 a safe
therapeutic target for autoimmune diseases because the risk of
irreversible bone marrow toxicity damage can be minimized.
[0206] The antigen binding domain provided herein can have a
structure shown as V.sub.H-V.sub.L or VL-VH, wherein VH is a heavy
chain variable region of an antibody; V.sub.L is a light chain
variable region of an antibody; "-" is a linker peptide (or
flexible linker) or a peptide bond. In some embodiments, the
antigen binding domain targets a tumor-associated antigen. In some
embodiments, the tumor-associated antigen comprises CD19. In some
embodiments, the antigen binding domain that targets CD19 comprises
the heavy chain variable region and the light chain variable region
of the monoclonal FMC63 antibody. In some embodiments, the sequence
of the linker peptide or flexible linker comprises 2-6, preferably
3-4 consecutive (GGGGS) amino acid sequences (SEQ ID NO: 93). In
some embodiments, the amino acid sequence of V.sub.L1 is as shown
in SEQ ID NO.: 87, and the amino acid sequence of VH1 is shown in
SEQ ID NO.: 88. An example amino acid sequence of CAR targeting
CD19 is shown in SEQ ID NO.: 89. In some embodiments, the antigen
binding domain targets an immune cell antigen. In some embodiments,
the immune cell antigen targets CD7. In some other embodiments, the
immune cell antigen targets CD2. In some embodiments, the
monoclonal antibody of CD7 is selected from the group consisting of
TH-69, 3Ale, 3Alf, T3-3A1, RFT2, CD7-6B7, 124-1D1, 4H9, SDZ214-380,
or a combination thereof. In some other embodiments, the monoclonal
antibody to CD2 is selected from the group consisting of RPA-2.10,
TS1/8, OKT11, AB75, 3E11, BH1, or a combination thereof. In some
embodiments, the amino acid sequence of V.sub.L is as shown in SEQ
ID NO.: 90, and the amino acid sequence of VH is shown in SEQ ID
NO.: 91.
Enhancer Moiety
[0207] The engineered immune cell provided herein can comprise an
enhancer moiety. The enhancer moiety can regulate one or more
activities of the engineered immune cell, for example, enhance or
upregulate one or more signaling pathways to enhance or upregulate
effector functions of the engineered immune cell. The signaling
pathways can be a cytokine-related signaling pathway. The enhancer
moiety can be a cytokine. The enhancer moiety can be a cytokine
receptor.
[0208] The cytokine-related signaling pathway can comprise a
related signaling pathway of a cytokine. Examples of cytokines
include, but are not limited to, IL-2, IL-3, IL-4, IL-6, IL-7,
IL-8, IL-10, IL-11, IL-12, IL-15, IL-17, IL-18, IL-21 and IL25. In
some cases, the cytokine-related signaling pathway comprises a
related signaling pathway of two or more cytokines, wherein the
cytokines include: IL-2 and IL-7, IL-2 and IL-15. IL-7 and IL-15,
IL15 and IL21. The cellular response can include regulation of
downstream gene expression, changes in intracellular enzyme
activity, changes in cellular bone architecture, changes in DNA
synthesis, promotion of gene transcription, regulation of immune
cell differentiation, proliferation, and resistance to cell death.
In some cases, the cytokine-related signaling pathway is enhanced
comprising: introducing or up-regulating a gene encoding a cytokine
and/or a receptor thereof, exogenously adding a cytokine, being
introduced into a cytokine receptor, or a combination thereof. In
some cases, up-regulating the gene encoding the cytokine and/or its
receptor comprises up-regulating the level of transcription and/or
translation of the encoding gene. In some cases, the enhanced
cytokine-related signaling pathway can be achieved by one or more
of the following methods: expressing a gene encoding the cytokine
and/or its receptor in the immune cell, increasing the copy number
of the gene encoding the cytokine and/or its receptor in the immune
cell, engineering a regulatory sequence (e.g., a promoter) of the
encoding gene to enhance transcription speed (e.g., transcriptional
initiation rate), modifying a translational regulatory region of a
messenger RNA carrying the encoded gene to enhance translational
strength, modifying the coding gene itself to enhance mRNA
stability, protein stability and to release protein feedback
inhibition.
[0209] The cytokine-related signaling pathway can be enhanced by
membrane expression of a cytokine and its receptor, secretion of a
cytokine, enhancement of transcriptional regulation of a cytokine
and/or its receptor, or a combination thereof. The
membrane-expressed cytokine and its receptors can include: IL-15
and its receptor (e.g., mbIL15 fusion protein), IL-7 and its
receptor (e.g., mbIL7 fusion protein), IL-17 and its receptor
(e.g., mbIL17 fusion protein), IL-2 and its receptor (e.g., mbTL2
fusion protein), IL-21 and its receptor (e.g., mbIL21 fusion
protein), constitute the activated IL-7 receptor (C7R), or a
combination thereof. In some cases, the enhancer moiety comprised
in the engineered immune cell is a secretive cytokine. The
secretive cytokine can function with various mechanisms, for
example, the secretive cytokine can be a trans-activating factor or
a cis-activating factor. The secretive cytokines can include IL-2,
IL-3, IL-4, IL-6, IL-7, IL-8, IL-10, IL-11, IL-12, IL-15, IL-17,
IL-18, IL-21, or a combination thereof. In some cases, the enhancer
is a membrane bound protein such as mbIL15, mbIL7, mbIL21 and
mbIL2. In some cases, the enhancer moiety is constitutively active
cytokine receptor downstream signaling protein such as STAT5 and
STAT3. In some cases, the enhancer moiety is a constitutively
active cytokine receptor such as constitutively active IL-7
receptor (C7R) or derivatives thereof. For example, the
constitutively active cytokine receptor can be an engineered
protein (e.g., referred to as "E3" in the present disclosure) where
the ecto domain of C7R is replaced by a safety switch, such as
EGFRt or truncated form of human epidermal growth factor receptor 2
(Her2t; see U.S. Patent Application Publication No. 20170267742A1)
or other peptides described in the present disclosure. For another
example, the constitutively active cytokine receptor can be an
engineered protein (e.g., referred to as "E4" in the present
disclosure) where the ectodomain of C7R is replaced by an immune
cell inhibitor, such as CD47, CD24 or other peptides that inhibit
killer or phagocytic immune cell function and protect therapeutic
cells (e.g., the engineered immune cells described herein). In some
cases, the cytokine can be a chemokine such as CCL21 and CCL19.
Other non-limiting examples of chemokines that may be used include
CCL27, CCL28, CCL20, CXCL9, CXCL10, CXCL11, CXCL16, CXCL13, CXCL5,
CXCL6, CXCL8, CXCL12, CCL2, CCL8, CCL13, CCL25, CCL3, CCL4, CCL5,
CCL7, CCL14, CCL15, CCL16, CCL23, CX3CL1, XCL1, XCL2, CCL1, CCL17,
CCL22, CCL11, CCL24, CCL26, CXCL1, CXCL2, CXCL3 and CXCL7. In some
cases, the enhancer moiety is a ligand of CCR7, which can function
to enhance infiltration of T cells, NK cells or dendritic cells.
CCR7 ligand includes, but not limited to, CCL21 and CCL19. In some
cases, the enhancer moiety comprises co-expression of chemokines
CCL21 and CCL19 for therapeutic use to treat lymphomas or other
solid tumors.
[0210] In some situations, the engineered immune cell is used as a
therapeutic agent to treat liquid tumors, and in such situations,
the enhancer moiety can comprise any cytokine in any form as
described herein. In some situations, the engineered immune cell is
used as a therapeutic agent to treat solid tumors, and in such
situations, the enhancer moiety can comprise any cytokine in any
form and further comprise one or more chemokines.
[0211] In some cases, two cytokines may be used to enhance the
cytokine-related signaling pathway in the engineered immune cell,
including IL-2 and IL-7, IL-2 and IL-15, IL-7 and IL-15, and TL15
and IL21. The cytokine-related signaling pathway enhancement can
comprise the expression of a polypeptide selected from the group
consisting of a mbTL fusion protein, a constitutively active IL-7
receptor (C7R), an interleukin, or a combination thereof.
[0212] The enhancer moiety described herein can be interleukin 15
(IL-15) or IL-15 receptor. IL-15 is a 14-15kDs glycoprotein
composed of 114 amino acids and belongs to the family of four helix
bundle cytokines. IL-15 is structurally homologous to interleukin 2
(IL-2). IL-15 receptor comprises a high affinity IL-15 receptor
alpha chain, an IL2/15 receptor beta chain, and a common gamma
chain. Therefore, IL-15 may have some functions similar to IL-2,
such as stimulating T cell activation and proliferation, enhancing
NK cell killing activity and promoting B cell production of
immunoglobulin. Recent studies have found that IL-15 may play a
role in the differentiation, proliferation and activation of NK
cells, NKT cells and intestinal epithelial cells. IL-15 and IL-17
may play a role in the regulation of CD8+ memory T cells. Studies
have also shown that IL-15 can regulate the proliferation of CD8+
memory T cells and the survival cycle of NK cells through a
mechanism, in which a cell expressing IL-15a chain receptor can
present IL-15 to a cell expressing an IL-150 chain and a common
gamma chain. IL-15 may also play a role in the non-immune system,
such as regulation of skeletal muscle anabolism. The enhancer
moiety described herein can be interleukin 7 (IL-7). IL-7 can
promote the growth of pre-B cells, pro-B cells, B cells, and T
cells. It can also promote growth and anti-apoptosis of B cells and
T cells. IL-7 can play a role in the early differentiation and
proliferation of thymus and the development and differentiation of
dendritic cells. However, IL-7 may not have an enhanced effect on
the killing activity of antigen-specific cytotoxic T lymphocytes.
It can first transfer from the thymus to the peripheral blood, then
induce thymocytes or peripheral blood lymphocytes to produce
lymphokines, activate and enhance lymphokine-activated killer cell
activity of LAK cells. CD8+ subpopulation can be the main effector
cell of IL-7, and IL-7 Can also support memory CD8+ T cell
expansion and survival. IL-7 can promote bone marrow tissue
production. IL-7 not only can stimulate myeloid precursor cells and
megakaryocytes to produce colony forming units and platelets, but
also can restore the body from the immunosuppression of
cyclophosphamide. At higher concentrations, it can also induce
cytotoxicity that enhances macrophages, function as a synergistic
factor for the production of CTL cells, NK cells, and activated
monocytes, induce monocyte-macrophages to secrete various cytokines
and promote the expression of inflammatory factors such as
macrophage inflammatory protein alpha (MIP-alpha), MIP-P, IL-8 and
monocyte chemoattractant protein-1 (MCP-1) and the like. By
activating a large number of inflammatory factors produced by
inflammatory cells, IL-7 not only can regulate the interaction
between the components of the inflammatory process, but also
enhance the inflammatory cytokine receptors (CCR) such as CCR1,
CCR2 and CCR5. In addition, IL-7 can play a role in inducing immune
responses. IL-7 can induce type I immune responses and increase the
production of IFN-.gamma. and IL2. IL-7 can synergize with IL12 to
induce IFN-.gamma. and T cell proliferation. IL-7 and transforming
growth factor beta (TGF.beta.) can play a regulatory role and can
be part of the immune regulatory mechanism. IL-7 not only can
promote immune reconstitution of T cells, but also can induce
up-regulation of T cell cycle and BCL-2 expression, which broadens
the diversity and persistence of circulating T cell receptor pools
and increases the number of CD4+ and CD8+ T cells. Moreover, for
HIV antigens, expanded T cells can also secrete IL2 and
IFN-.gamma., and have good antiviral function. Therefore, IL-7 can
reverse the defects of HIV-specific T lymphocytes in proliferation,
cytokine secretion and cell function.
[0213] The enhance moiety can regulate (e.g., activate) signal
transducer and activator of transcription 5 (STAT5)-mediated
signaling pathway. STAT5 can be widely present in the cytoplasm.
When cytokines (e.g., IL2, IL7, IL15 and IL21) bind to the cytokine
receptors, the receptor-coupled JAK is activated, thereby
phosphorylating the Tyr residue at the C-terminus of the STAT5
protein. The phosphorylated STAT5 can form homologous or
heterologous dimers through its SH2 region. The homologous or
heterodimer can be transferred to the nucleus and bind to the
target gene, thereby regulating the expression of the target gene
including the cell regulatory factor and the anti-apoptotic gene.
Activation of STAT5 can play a role in maintaining normal cell
function and regulating cell proliferation and differentiation.
Therefore, regulating the activity of STAT5 signaling pathway may
regulate the survival and persistence of CAR-T cells described
herein.
[0214] The enhancer moiety can be introduced into a cell (e.g., an
immune cell or an engineered immune cell) by delivering a nucleic
acid molecule encoding the enhancer moiety into the cell. The
nucleic acid molecule can be a vector. The enhancer moiety can be a
part of a fusion construct. A fusion protein or corresponding
nucleic acid construct can have a structure as presented by a
formula selected from:
S-2A-L1-scFv-H-TM-C-CD3.zeta.-2A-L2-IL15-IL15Ra (A);
S-2A-L1-scFv-H-TM-C-CD3.zeta.-2A-L2-IL15-IL15Ra-2A-L3-IL7 (B);
S-2A-L1-scFv-H-TM-C-CD3.zeta.-2A-L2-C7R (C);
S-2A-L1-scFv-H-TM-C-CD3.zeta.-2A-L2-IL7-IL7Ra (D); wherein: each
"-" is independently a linker peptide or a peptide bond; S is a
safety switch; 2A is an optional self-cleaving peptide; each of L1,
L2 and L3 is independently null or a signal peptide sequence; C7R
is as described above; scFv is an antigen binding domain; H is null
or a hinge region; TM is a transmembrane domain; C is a
costimulatory signaling molecule; CD3.zeta. is a cytoplasmic
signaling sequence derived from CD3.zeta.; IL15 is interleukin 15,
IL15Ra is IL-15 receptor .alpha.; IL7 is interleukin 7, IL7Ra is
IL-7 receptor .alpha.; C7R is a constitutively activated IL-7
receptor.
[0215] The enhancer moiety can be part of a chimeric polypeptide.
For example, the enhancer moiety can be linked to an inducible cell
death moiety. The enhancer moiety can be linked to the inducible
cell death moiety by a linker. The linker may not be cleaved. The
linker may not comprise a self-cleaving peptide. In some other
cases, the enhancer moiety and the inducible cell death moiety can
be expressed in a cell from a same nucleic acid molecule and can be
cleaved to form two polypeptides.
Inducible Cell Death Moiety
[0216] The engineered immune cell described herein may comprise an
inducible cell death moiety, also referred to as "suicide gene
switch." "suicide switch," "safety switch," or "cell suicide
element." The inducible cell death moiety can be used to
effectively remove of the engineered immune cells (e.g., CAR-T
cells) in vivo under the action of exogenous factors (e.g., drugs).
The inducible cell death moiety described herein may be rapaCasp9,
iCasp9, CD20 (and its mimotope), RQR8, Her2t, CD30, BCMA, EGFRt,
HSV-TK, mTMPK and the like. iCasp9, CD20 (and its mimotope), RQR8,
and HSV-TK may have the same ability to clear T cells, but
rapaCasp9, iCasp9, RQR8, and CD20 (and their mimotope) may be
faster in comparison with HSV-TK.
[0217] In some cases, an inducible cell death moiety is capable of
effecting death of said cell upon contacting said inducible cell
death moiety with a cell death activator. The inducible cell death
moiety can be, for example, rapaCasp9, iCasp9, HSV-TK, ACD20,
mTMPK, ACD19, RQR8, or EGFRt. In some cases, the inducible cell
death moiety is EGFRt, and said cell death activator is an antibody
or an antigen binding fragment thereof that binds EGFRt. In some
cases, the inducible cell death moiety is HSV-TK, and said cell
death activator is GCV. In some cases, the inducible cell death
moiety is iCasp9, and said cell death activator is AP1903.
[0218] The inducible cell death moiety can be linked to an enhancer
moiety and can be co-expressed in a cell as a chimeric polypeptide
as described above.
Graft Versus Host Disease (GVHD)
[0219] To prepare "off-the-shelf" allogeneic T cells for the
treatment of malignant and infectious diseases, cell therapy by
infusion of T cells can be designed to re-establish immunity
against pathogens and malignancies. The amount of time required to
produce the T cells with tumor-targeting properties with a
sufficient number of T cells in vitro can be generally incompatible
with the patient's therapeutic window. Furthermore, autologous T
cells from patients with advanced disease may have impaired
function and are tolerant to the desired antigen.
[0220] To address these issues, patients can be administered with
allogeneic T cells but need to be prevented from immune-mediated
rejection by host T cells by recognizing different major or minor
histocompatibility antigens on the infused cells. Infusion of T
cells without the expression of TCR alpha and beta chains and HLA-A
molecules may not cause GVHD and HVG. Thus the T cells edited with
CRISPR/CAS9 to delete TCR alpha chain and HLA-A molecular can serve
as a source of universal effector donor cells.
[0221] Although knockdown of Beta-2-Microglobulin (B2M) may prevent
donor CAR-T cells from being attacked by the host T cells. The
donor CAR-T cells may be attacked by host NK cells and affect the
survival of CAR-T cells. Therefore, the present disclosure provides
engineered immune cells which target tumor cells and host T cells
and/or NK cells. The engineered immune cells described herein can
scavenge host T cells and/or NK cells, and enhance the survival,
persistence and expansion ability of CAR-T cells, thereby being
more effective against tumor cells.
Gene Editing
[0222] Various gene editing methods can be used in the present
disclosure to make the engineered immune cells, including CRISPR,
RNA interference technology, TALENs (transcription activator-like
(TAL) effector nucleases) and Zinc finger nucleases (ZFNs).
[0223] In some cases, CRISPR/Cas9 system is used to edit the genes
of the immune cells. For example, CRISPR/Cas9 system can be used to
knockout endogenous TCRs or cell surface markers (e.g., CD7) of the
immune cells to generate the engineered immune cells for T cell
therapy. The CRISPR/Cas9 (clustered regular interspaced short
palindromic repeats)/Cas (CRISPR-associated) system is a natural
immune system unique to prokaryotes that is resistant to viruses or
exogenous plasmids. The Type II CRISPR/Cas system has been applied
in many eukaryotic and prokaryotic organisms as a direct
genome-directed genome editing tool. The development of the
CRISPR/Cas9 system has revolutionized the ability of people to edit
DNA sequences and regulate the expression levels of target genes,
providing a powerful tool for accurate genome editing of organisms.
The simplified CRISPR/Cas9 system can comprise Cas9 protein and
gRNA. The principle of action is that gRNA forms a Cas9-gRNA
complex with Cas9 protein through its own Cas9 handle, and the base
complementary pairing sequence of gRNA in the Cas9-gRNA complex is
paired with the target sequence of the target gene by the principle
of base complementary pairing. Cas9 uses its own endonuclease
activity to cleave the target DNA sequence. Compared to traditional
genome editing techniques, the CRISPR/Cas9 system has several
distinct advantages: ease of use, simplicity, low cost,
programmability, and the ability to edit multiple genes
simultaneously.
Pharmaceutical Composition
[0224] The present disclosure also provides a pharmaceutical
composition comprising an engineered immune cell described herein
and a pharmaceutically acceptable carrier, diluent or excipient. In
some embodiments, the pharmaceutical composition is a liquid
composition. The pharmaceutical composition can be administered
into a subject, for example, by injection. The concentration of the
engineered immune cells in the preparation can be at least about
10.sup.2, 10.sup.3, 10.sup.4, 10.sup.5, 10.sup.6, 10.sup.7,
10.sup.8, 10.sup.9, or more cells/ml. In some case, the
concentration of the engineered immune cells in the preparation can
be 1.times.10.sup.3-1.times.10.sup.8 cells/ml, or
1.times.10.sup.4-1.times.10.sup.7 cells/ml.
[0225] The pharmaceutical compositions of the present disclosure
may comprise engineered immune cells as described herein, in
combination with one or more pharmaceutically or physiologically
acceptable carriers, diluents or excipients. Such compositions may
comprise buffers such as neutral buffered saline, phosphate
buffered saline and the like; carbohydrates such as glucose,
mannose, sucrose or dextrans, mannitol; proteins; polypeptides or
amino acids such as glycine; antioxidants; chelating agents such as
EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and
preservatives. Compositions of the present disclosure may be
formulated for intravenous administration.
[0226] Pharmaceutical compositions of the present disclosure may be
administered in a manner appropriate to the disease to be treated
(or prevented). The quantity and frequency of administration will
be determined by such factors as the condition of the patient, and
the type and severity of the patient's disease, although
appropriate dosages may be determined by clinical trials.
[0227] When "an immunologically effective amount", "an anti-tumor
effective amount", "an tumor-inhibiting effective amount", or
"therapeutic amount" is indicated, the precise amount of the
compositions of the present disclosure to be administered can be
determined by a physician with consideration of individual
differences in age, weight, tumor size, extent of infection or
metastasis, and condition of the patient (subject). It can
generally be stated that a pharmaceutical composition comprising
the engineered immune cells (e.g., CAR-T cells) described herein
may be administered at a dosage of 10.sup.4 to 10.sup.9 cells/kg
body weight, or in some cases, 10.sup.5 to 10.sup.6 cells/kg body
weight, including all integer values within those ranges. T cell
compositions may also be administered multiple times at these
dosages. The cells can be administered by using infusion
techniques. The optimal dosage and treatment regime for a
particular patient can readily be determined by monitoring the
patient for signs of disease and adjusting the treatment
accordingly.
[0228] The administration of the subject compositions may be
carried out in any convenient manner, including by aerosol
inhalation, injection, ingestion, transfusion, implantation or
transplantation. The compositions described herein may be
administered to a patient subcutaneously, intradermally,
intratumorally, intranodally, intramedullary, intramuscularly, by
intravenous (i.v.) injection, or intraperitoneally. In some
embodiments, the T cell compositions of the present disclosure are
administered to a patient by intradermal or subcutaneous injection.
In some other embodiments, the T cell compositions of the present
disclosure are preferably administered by i.v. injection. The
compositions of T cells may be injected directly into a tumor,
lymph node, or site of infection.
Therapeutics
[0229] The present disclosure provides therapeutic applications
with engineered immune cells (e.g., T cells or NK cells) transduced
with a lentiviral vector (LV) encoding an expression cassette
described herein. Transduced T cells or NK cells can target tumor
cell markers (such as CD19) and activated T cell and/or NK cell
consensus markers (such as CD3, CD7, CD137, etc.). The engineered
immune cells can be used for allogeneic tumor treatment and can be
prepared on a large scale.
[0230] Accordingly, the present disclosure also provides a method
of stimulating a T cell mediated immune response to a target cell
population or tissue of a subject (e.g., a mammal) comprising the
step of administering to the subject an engineered immune cell
(e.g., CAR-T cell) of the disclosure.
[0231] In some embodiments, the present disclosure provides a type
of cell therapy comprising directly administering engineered
universal CAR-T cells of the present disclosure to a patient in
need thereof. The CAR-T cells of the present disclosure may have
the endogenous TCR expression knocked out or silenced in the cells
by gene editing technology. Inactivation of the endogenous TCRs can
prevent killing of normal cells by the TCRs during the allogeneic
infusion. The GVHD reaction may be prevented. The CAR-T cells
targeting a tumor cell marker (such as CD19) and a marker for
activated T cells and/or NK cells (such as CD137) can remove
activated T cells and/or NK cells while scavenging tumor cells. In
addition, host versus graft response (HVG) can also be prevented.
The cell therapy provided herein can also improve the survival and
anti-tumor effect of allogeneic CAR-T cells in the subject.
[0232] In some embodiments, provided herein is a method of treating
or diagnosing a disease in a subject, comprising administering the
pharmaceutical composition described herein to said subject.
[0233] The engineered immune cell in said pharmaceutical
composition can be derived from an allogeneic immune cell. The
engineered immune cell derived from said allogeneic immune cell may
not induce graft versus host disease (GvHD) in said subject. The
engineered immune cell in said pharmaceutical composition can be
derived from an autologous immune cell.
[0234] The endogenous TCR of said engineered immune cell in said
pharmaceutical composition may be functionally inactive. The
engineered immune cell can reduce GVHD in said subject compared to
an additional immune cell having a functionally active TCR. The
disease can be a cancer. The cancer can be, for example, lymphoma
or leukemia.
[0235] The CAR-T cells of the present disclosure can undergo robust
in vivo cell expansion and can be extended. The CAR-mediated immune
response can be part of a step of adoptive immunotherapy in which
CAR-modified T cells can induce an immune response specific for the
antigen-binding domain in the CAR. For example, anti-CD19 CAR-T
cells elicit a specific immune response against cells expressing
CD19.
[0236] The engineered immune cells provided herein can be used to
treat cancers. Cancers that may be treated include tumors that are
not vascularized, or not yet substantially vascularized, as well as
vascularized tumors. The cancers may comprise non-solid tumors
(such as hematological tumors, for example, leukemias and
lymphomas) or may comprise solid tumors. Types of cancers to be
treated with the CARs of the present disclosure include, but are
not limited to, carcinoma, blastoma, and sarcoma, and certain
leukemia or lymphoid malignancies, benign and malignant tumors, and
malignancies e.g., sarcomas, carcinomas, and melanomas. Adult
tumors/cancers and pediatric tumors/cancers are also included.
[0237] Hematologic cancers are cancers of the blood or bone marrow.
Examples of hematological (or hematogenous) cancers include
leukemias, including acute leukemias (such as acute lymphocytic
leukemia, acute myelocytic leukemia, acute myelogenous leukemia and
myeloblastic, promyelocytic, myelomonocytic, monocytic and
erythroleukemia), chronic leukemias (such as chronic myelocytic
(granulocytic) leukemia, chronic myelogenous leukemia, and chronic
lymphocytic leukemia), polycythemia vera, lymphoma, Hodgkin's
disease, non-Hodgkin's lymphoma (indolent and high grade forms),
multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain
disease, myelodysplastic syndrome, hairy cell leukemia and
myelodysplasia.
[0238] Solid tumors are abnormal masses of tissue that usually do
not contain cysts or liquid areas. Solid tumors can be benign or
malignant. Different types of solid tumors are named for the type
of cells that form them (such as sarcomas, carcinomas, and
lymphomas). Examples of solid tumors, such as sarcomas and
carcinomas, include fibrosarcoma, myxosarcoma, liposarcoma,
chondrosarcoma, osteosarcoma, and other sarcomas, synovioma,
mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma,
colon carcinoma, lymphoid malignancy, pancreatic cancer, breast
cancer, lung cancers, ovarian cancer, prostate cancer,
hepatocellular carcinoma, squamous cell carcinoma, basal cell
carcinoma, adenocarcinoma, sweat gland carcinoma, medullary thyroid
carcinoma, papillary thyroid carcinoma, pheochromocytomas sebaceous
gland carcinoma, papillary carcinoma, papillary adenocarcinomas,
medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma,
hepatoma, bile duct carcinoma, choriocarcinoma, Wilms' tumor,
cervical cancer, testicular tumor, seminoma, bladder carcinoma,
melanoma, and CNS tumors (such as a glioma (such as brainstem
glioma and mixed gliomas), glioblastoma (also known as glioblastoma
multiforme) astrocytoma, CNS lymphoma, germinoma, medulloblastoma,
Schwannoma craniopharyogioma, ependymoma, pinealoma,
hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma,
neuroblastoma, retinoblastoma and brain metastases).
[0239] In some embodiments, the antigen bind moiety portion of the
CAR of the present disclosure is designed to treat a particular
cancer. For example, the CAR designed to target CD19 can be used to
treat cancers and disorders including but are not limited to pre-B
ALL (pediatric indication), adult ALL, mantle cell lymphoma,
diffuse large B-cell lymphoma, salvage post allogeneic bone marrow
transplantation, and the like. In some embodiments, the CAR can be
designed to target CD22 to treat diffuse large B-cell lymphoma. In
some embodiments, cancers and disorders include but are not limited
to pre-B ALL (pediatric indication), adult ALL, mantle cell
lymphoma, diffuse large B-cell lymphoma, salvage post allogeneic
bone marrow transplantation, and the like can be treated using a
combination of CARs that target CD19, CD20, CD22, and RORl. In some
embodiments, the CAR can be designed to target mesothelin to treat
mesothelioma, pancreatic cancer, ovarian cancer, and the like. In
some embodiments, the CAR can be designed to target CD33/IL3Ra to
treat acute myelogenous leukemia and the like. In some embodiments,
the CAR can be designed to target c-Met to treat triple negative
breast cancer, non-small cell lung cancer, and the like. In some
embodiments, the CAR can be designed to target PSMA to treat
prostate cancer and the like. In some embodiments, the CAR can be
designed to target Glycolipid F77 to treat prostate cancer and the
like. In some embodiments, the CAR can be designed to target
EGFRvIII to treat gliobastoma and the like. In some embodiments,
the CAR can be designed to target GD-2 to treat neuroblastoma,
melanoma, and the like. In some embodiments, the CAR can be
designed to target NY-ESO-1 TCR to treat myeloma, sarcoma,
melanoma, and the like. In some embodiments, the CAR can be
designed to target MAGE A3 TCR to treat myeloma, sarcoma, melanoma,
and the like.
[0240] The present disclosure should not be construed to be limited
to solely to the antigen targets and diseases disclosed herein.
Rather, the present disclosure should be construed to include any
antigenic target that is associated with a disease where a CAR can
be used to treat the disease.
[0241] The cell therapy disclosed herein can be co-formulated with,
and/or co-administered with, one or more additional therapeutic
agents, e.g., one or more anti-cancer agents, cytotoxic or
cytostatic agents, hormone treatment, vaccines, and/or other
immunotherapies. In some embodiments, the engineered immune cells
are administered in combination with other therapeutic treatment
modalities, including surgery, radiation, cryosurgery, and/or
thermotherapy. Such combination therapies may advantageously
utilize lower dosages of the administered therapeutic agents, thus
avoiding possible toxicities or complications associated with the
various monotherapies.
[0242] In certain embodiments, the methods and compositions
described herein are administered in combination with one or more
antibody molecules, chemotherapy, other anti-cancer therapy (e.g.,
targeted anti-cancer therapies, or oncolytic drugs), cytotoxic
agents, immune-based therapies (e.g., cytokines), surgical and/or
radiation procedures. Exemplary cytotoxic agents that can be
administered in combination with include antimicrotubule agents,
topoisomerase inhibitors, anti-metabolites, mitotic inhibitors,
alkylating agents, anthracyclines, vinca alkaloids, intercalating
agents, agents capable of interfering with a signal transduction
pathway, agents that promote apoptosis, proteasome inhibitors, and
radiation (e.g., local or whole body ir-radiation).
[0243] In certain embodiments, the combination therapy, is used in
combination with a standard of cancer care chemotherapeutic agent
including, but not limited to, anastrozole (Arimidex.RTM.),
bicalu-tamide (Casodex.RTM.), bleomycin sulfate (Blenoxane.RTM.),
busulfan (Myleran.RTM.), busulfan injection (Busulfex.RTM.),
capecitabine (Xeloda.RTM.),
N4-pentoxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin
(Paraplatin.RTM.), carmustine (BiCNU.RTM.), chlorambucil
(Leukeran.RTM.), cisplatin (Platinol.RTM.), cladribine
(Leustatin.RTM.), cyclophosphamide (Cytoxan.RTM. or Neosar.RTM.),
cytarabine, cytosine arabinoside (Cy-tosar-U.RTM.), cytarabine
liposome injection (DepoCyt.RTM.), dacarbazine (DTIC-Dome.RTM.),
dactinomy-cin (Actinomycin D, Cosmegan), daunorubicin hydrochloride
(Cerubidine.RTM.), daunorubicin citrate liposome injection
(DaunoXome.RTM.), dexamethasone, docetaxel (Taxotere.RTM.),
doxorubicin hydro-chloride (Adriamycin.RTM., Rubex.RTM.), etoposide
(Vepesid.RTM.), fludarabine phosphate (Fludara.RTM.),
5-fluorouracil (Adrucil.RTM., Efudex.RTM.), flutamide
(Eulexin.RTM.), tezacitibine, Gemcitabine (difluorodeox-ycitidine),
hydroxyurea (Hydrea.RTM.), Idarubicin (Idamycin.RTM.), ifosfamide
(IFEX.RTM.), irinotecan (Camptosar.RTM.), L-asparaginase
(ELSPAR.RTM.), leucovorin calcium, melphalan (Alkeran.RTM.),
6-mercaptopurine (Purinethol.RTM.), methotrexate (Folex.RTM.),
mitoxantrone (Novantrone.RTM.), mylotarg, paclitaxel (Taxol.RTM.),
nab-paclitaxel (Abraxane.RTM.), phoenix (Yttrium90/MX-DTPA),
pentostatin, polifeprosan 20 with carmustine implant
(Gliadel.RTM.), tamoxifen citrate (Nolvadex.RTM.), teniposide
(Vumon.RTM.), 6-thioguanine, thiotepa, tirapazamine
(Tirazone.RTM.), topotecan hydrochloride for injec-tion
(Hycamptin.RTM.), vinblastine (Velban.RTM.), vincristine
(Oncovin.RTM.), and vinorelbine (Navelbine.RTM.).
[0244] Examples of alkylating agents include, without limitation,
nitrogen mustards, ethylenimine deriva-tives, alkyl sulfonates,
nitrosoureas and triazenes): uracil mustard (Aminouracil
Mustard.RTM., Chlorethaminacil.RTM., Demethyldopan.RTM.,
Desmethyldopan.RTM., Haemanthamine.RTM., Nordopan.RTM., Uracil
nitrogen Mustard.RTM., Uracillost.RTM., Uracilmostaza.RTM.,
Uramustin.RTM., Uramustine.RTM.), chlormethine (Mustargen.RTM.),
cyclophosphamide (Cytoxan.RTM., Neosar.RTM., Clafen.RTM.,
Endoxan.RTM., Procytox.RTM., Revimmune.TM.), ifosfamide
(Mitoxana.RTM.), melphalan (Alkeran.RTM.), Chlorambucil
(Leukeran.RTM.), pi-pobroman (Amedel.RTM., Vercyte.RTM.),
triethylenemelamine (Hemel.RTM., Hexalen.RTM., Hexastat.RTM.),
triethy-lenethiophosphoramine, Temozolomide (Temodar.RTM.),
thiotepa (Thioplex.RTM.), busulfan (Busilvex.RTM., Myleran.RTM.),
carmustine (BiCNU.RTM.), lomustine (CeeNU.RTM.), streptozocin
(Zanosar.RTM.), and Dacarbazine (DTIC-Dome.RTM.). Additional
exemplary alkylating agents include, without limitation,
Oxaliplatin (Eloxatin.RTM.); Temozolomide (Temodar.RTM. and
Temodal.RTM.); Dactinomycin (also known as actinomycin-D,
Cosmegen.RTM.); Melphalan (also known as L-PAM, L-sarcolysin, and
phenylal-anine mustard, Alkeran.RTM.); Altretamine (also known as
hexamethylmelamine (HMM), Hexalen.RTM.); Carmustine (BiCNU.RTM.);
Bendamustine (Treanda.RTM.); Busulfan (Busulfex.RTM. and
Myleran.RTM.); Car-boplatin (Paraplatin.RTM.); Lomustine (also
known as CCNU, CeeNU.RTM.); Cisplatin (also known as CDDP,
Platinol.RTM. and Platinol.RTM.-AQ); Chlorambucil (Leukeran.RTM.);
Cyclophosphamide (Cytoxan.RTM. and Neosar.RTM.); Dacarbazine (also
known as DTIC, DIC and imidazole carboxamide, DTIC-Dome.RTM.);
Altretamine (also known as hexamethylmelamine (HMM), Hexalen.RTM.);
Ifosfamide (Ifex.RTM.); Prednumustine; Procarbazine
(Matulane.RTM.); Mechlorethamine (also known as nitrogen mustard,
mustine and mechloroethamine hydrochloride, Mustargen.RTM.);
Streptozocin (Zanosar.RTM.); Thiotepa (also known as
thiophosphoamide, TESPA and TSPA, Thioplex.RTM.); Cyclophosphamide
(Endoxan.RTM., Cytoxan.RTM., Neosar.RTM., Procytox.RTM.,
Revimmune.RTM.); and Bendamustine HCl (Treanda.RTM.).
[0245] Examples of anthracyclines include, e.g., doxorubicin
(Adriamycin.RTM. and Rubex.RTM.); bleomycin (Lenoxane.RTM.);
daunorubicin (dauorubicin hydrochloride, daunomycin, and
rubidomycin hydro-chloride, Cerubidine.RTM.); daunorubicin
liposomal (daunorubicin citrate liposome, DaunoXome.RTM.);
mitoxantrone (DHAD, Novantrone.RTM.); epirubicin (Ellence.TM.);
idarubicin (Idamycin.RTM., Idamycin PFS.RTM.); mitomycin C
(Mutamycin.RTM.); geldanamycin; herbimycin; ravidomycin; and
desacetyl-ravidomycin.
[0246] Examples of vinca alkaloids that can be used in combination
with the cell therapy described herein, include, but are not
limited to, vinorelbine tartrate (Navelbine.RTM.), Vincristine
(Oncovin.RTM.), and Vindesine (Eldisine.RTM.)); vinblastine (also
known as vinblastine sulfate, vincaleukoblastine and VLB,
Alkaban-AQ.RTM. and Velban.RTM.); and vinorelbine
(Navelbine.RTM.).
[0247] Examples of proteasome inhibitors that can be used in
combination with the cell therapy described herein, include, but
are not limited to, bortezomib (Velcade.RTM.); carfilzomib
(PX-171-007,
(S)-4-Methyl-N--((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxope-
ntan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamid-
o)-4-phenylbutanamido)-pentanamide); marizomib (NPI-0052); ixazomib
citrate (MLN-9708); delanzomib (CEP-18770);
0-Methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(-
2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-L-serinamide
(ONX-0912); danoprevir (RG7227, CAS 850876-88-9); ixazomib
(MHLN2238, CAS 1072833-77-2); and (S)
N-[(phenylmethoxy)carbonyl]-L-leucyl-N-(1-formyl-3-methylbutyl)-L-Leucina-
mide (MG-132, CAS 133407-82-6).
[0248] In some embodiments, the cell therapy may be used in
combination with a tyrosine kinase inhibitor (e.g., a receptor
tyrosine kinase (RTK) inhibitor). Exemplary tyrosine kinase
inhibitor include, but are not limited to, an epidermal growth
factor (EGF) pathway inhibitor (e.g., an epidermal growth factor
receptor (EGFR) inhibitor), a vascular endothelial growth factor
(VEGF) pathway inhibitor (e.g., a vascular endothelial growth
factor receptor (VEGFR) inhibitor (e.g., a VEGFR-1 inhibitor, a
VEGFR-2 inhibitor, a VEGFR-3 inhibitor)), a platelet derived growth
factor (PDGF) pathway inhibitor (e.g., a platelet derived growth
factor receptor (PDGFR) inhibitor (e.g., a PDGFR-P inhibitor)), a
RAF-1 inhibitor, a KIT inhibitor and a RET inhibitor. In some
embodiments, the anti-cancer agent used in combination with the
hedgehog inhibitor is selected from the group consisting of:
axitinib (AG013736), bosutinib (SKI-606), cediranib (RE-CENTIN,
AZD2171), dasatinib (SPRYCEL.RTM., BMS-354825), erlotinib
(TARCEVA.RTM.), gefitinib (IRESSA.RTM.), imatinib (Gleevec.RTM.,
CGP57148B, STI-571), lapatinib (TYKERB.RTM., TYVERB.RTM.),
lestaurtinib (CEP-701), neratinib (HKI-272), nilotinib
(TASIGNA.RTM.), semaxanib (semaxinib, SU5416), sunitinib
(SUTENT.RTM., SU11248), toceranib (PALLADIA.RTM.), vandetanib
(ZACTIMA.RTM., ZD6474), vatalanib (PTK787, PTK/ZK), trastuzumab
(HERCEPTIN.RTM.), bevacizumab (AVAS-TIN.RTM.), rituximab
(RITUXAN.RTM.), cetuximab (ERBITUX.RTM.), panitumumab
(VECTIBIX.RTM.), ranibizumab (Lucentis.RTM.), nilotinib
(TASIGNA.RTM.), sorafenib (NEXAVAR.RTM.), alemtuzumab
(CAM-PATH.RTM.), gemtuzumab ozogamicin (MYLOTARG.RTM.), ENMD-2076,
PCI-32765, AC220, dovitinib lactate (TK1258, CHIR-258), BIBW 2992
(TOVOK.TM.), SGX523, PF-04217903, PF-02341066, PF-299804,
BMS-777607, ABT-869, MP470, BIBF 1120 (VARGATEF.RTM.), AP24534,
JNJ-26483327, MGCD265, DCC-2036, BMS-690154, CEP-11981, tivozanib
(AV-951), 0SI-930, MM-121, XL-184, XL-647, XL228, AEE788, AG-490,
AST-6, BMS-599626, CUDC-101, PD153035, pelitinib (EKB-569),
vandetanib (zactima), WZ3146, WZ4002, WZ8040, ABT-869 (linifanib),
AEE788, AP24534 (ponatinib), AV-951 (tivozanib), axitinib, BAY
73-4506 (regorafenib), brivanib alaninate (BMS-582664), brivanib
(BMS-540215), cediranib (AZD2171), CHIR-258 (dovitinib), CP 673451,
CYC116, E7080, Ki8751, masitinib (AB1010), MGCD-265, motesanib
diphosphate (AMG-706), MP-470, OSI-930, Pazopanib Hydrochloride,
PD173074, Sorafenib Tosylate (Bay 43-9006), SU 5402, TSU-68
(SU6668), vatalanib, XL880 (GSK1363089, EXEL-2880). Further
examples of hedgehog inhibitors include, but are not limited to,
vismodegib
(2-chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)-benzamide-
, GDC-0449);
1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-((3-(4-fluorophenyl)-3,4-dihydro-
-4-oxo-2-quinazolinyl)methyl)-urea (CAS 330796-24-2);
N-[(2S,3R,3'R,3aS,4'aR,6S,6'aR,6'bS,7aR,12'aS,12'bS)-2', 3',
3a,4,4', 4'a,5,5', 6,6', 6'a,6'b,7,7', 7a,8', 10', 12',
12'a,12'b-Eicosahydro-3,6,11',
12'b-tetramethylspiro[furo[3,2-b]pyridine-2(3H),9'(1'H)-naphth[2,1-a]azul-
en]-3'-yl]-methanesulfonamide (IPI926, CAS 1037210-93-7); and
4-Fluoro-N-methyl-N-[1-[4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl]-4-pi-
peridinyl]-2-(trifluoromethyl)-benzamide (LY2940680, CAS
1258861-20-9); and Erismodegib (LDE225). Selected tyrosine kinase
inhibitors are chosen from sunitinib, erlotinib, gefitinib, or
sorafenib erlotinib hydrochloride (Tarceva.RTM.); linifanib
(N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N'-(2-fluoro-5-methylphenyl)urea,
also known as ABT 869, avail-able from Genentech); sunitinib malate
(Sutent.RTM.); bosutinib
(4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazi-
n-1-yl)propoxy]quinoline-3-carbonitrile, also known as SKI-606,
described in U.S. Pat. No. 6,780,996); dasatinib (Sprycel.RTM.);
pazopanib (Votrient.RTM.); sorafenib (Nexavar.RTM.); zactima
(ZD6474); and imatinib or imatinib mesylate (Gil-vec.RTM. and
Gleevec.RTM.).
[0249] In certain embodiments, the cell therapy can be used in
combination with a Vascular Endothelial Growth Factor (VEGF)
receptor inhibitors, including but not limited to, Bevacizumab
(Avastin.RTM.), axitinib (Inlyta.RTM.); Brivanib alaninate
(BMS-582664,
(S)--((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f-
][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate); Sorafenib
(Nexavar.RTM.); Pazopanib (Votrient.RTM.); Sunitinib malate
(Sutent.RTM.); Cediranib (AZD2171, CAS 288383-20-1); Vargatef
(BIBF1120, CAS 928326-83-4); Foretinib (GSK1363089); Telatinib
(BAY57-9352, CAS 332012-40-5); Apatinib (YN968D1, CAS 811803-05-1);
Imatinib (Gleevec.RTM.); Ponatinib (AP24534, CAS 943319-70-8);
Tivozanib (AV951, CAS 475108-18-0); Regorafenib (BAY73-4506, CAS
755037-03-7); Vatalanib dihydrochloride (PTK787, CAS 212141-51-0);
Brivanib (BMS-540215, CAS 649735-46-6); Vandetanib (Caprelsa.RTM.
or AZD6474); Motesanib diphosphate (AMG706, CAS 857876-30-3,
N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-
-pyridinecarboxamide, described in PCT Publication No. WO
02/066470); Dovitinib dilactic acid (TK1258, CAS 852433-84-2);
Linfan-ib (ABT869, CAS 796967-16-3); Cabozantinib (XL184, CAS
849217-68-1); Lestaurtinib (CAS 111358-88-4);
N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-pipe-
ridinecarboxamide (BMS38703, CAS 345627-80-7);
(3R,4R)-4-Amino-1((4-((3-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-
-5-yl)methyl)piperidin-3-ol (BMS690514);
N-(3,4-Dichloro-2-fluorophenyl)-6-methoxy-7-[[(3aa,50,6aa)-octahydro-2-me-
thylcyclopenta[c]pyrrol-5-yl]methoxy]-4-quinazolinamine (XL647, CAS
781613-23-8);
4-Methyl-3-[[1-methyl-6-(3-pyridinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]am-
ino]-N-[3-(trifluoromethyl)phenyl]-benzamide (BHG712, CAS
940310-85-0); and Aflibercept (Eylea.RTM.).
[0250] In some embodiments, the cell therapy described herein can
be used in combination with a PI3K inhibitor. The PI3K inhibitor
can be an inhibitor of delta and gamma isoforms of PI3K. Examples
of PI3K inhibitors include, but are not limited to,
4-[2-(1H-Indazol-4-yl)-6-[[4-(methylsulfonyl)piperazin-1-yl]methyl]thieno-
[3,2-d]pyrimidin-4-yl]morpholine;
2-Methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]-
quinolin-1-yl]phenyl]propionitrile;
4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine;
Tozasertib (VX680 or MK-0457, CAS 639089-54-6);
(5Z)-5-[[4-(4-Pyridinyl)-6-quinolinyl]methylene]-2,4-thiazolidinedione
(GSK1059615, CAS 958852-01-2);
(1E,4S,4aR,5R,6aS,9aR)-5-(Acetyloxy)-1-[(di-2-propenylamino)methylene]-4,-
4a,5,6,6a,8,9,9a-octahydro-11-hydroxy-4-(methoxymethyl)-4a,6a-dimethyl-cyc-
lopenta[5,6]naphtho[1,2-c]pyran-2,7,10(1H)-trione (PX866, CAS
502632-66-8); 8-Phenyl-2-(morpholin-4-yl)-chromen-4-one (LY294002,
CAS 154447-36-6);
2-Amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7(8H)--
one (SAR 245409 or XL 765);
1,3-Dihydro-8-(6-methoxy-3-pyridinyl)-3-methyl-1-[4-(1-piperazinyl)-3-(tr-
ifluoromethyl)phenyl]-2H-imidazo[4,5-c]quinolin-2-one,
(2Z)-2-butenedioate (1:1) (BGT 226);
5-Fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)ethyl]-4(3H)-quinazolinon-
e (CAL101);
2-Amino-N-[3-[N-[3-[(2-chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]sulfa-
moyl]phenyl]-2-methylpropanamide (SAR 245408 or XL 147); and
(S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide
1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thia-
zol-2-yl}-amide) (BYL719).
[0251] In some embodiments, the cell therapy described herein can
be used in combination with a mTOR inhibitor, e.g., one or more
mTOR inhibitors chosen from one or more of rapamycin, temsirolimus
(TORISEL.RTM.), AZD8055, BEZ235, BGT226, XL765, PF-4691502,
GDC0980, SF1126, OSI-027, GSK1059615, KU-0063794, WYE-354, Palomid
529 (P529), PF-04691502, or PKI-587. ridaforolimus (formally known
as deferolimus, (1R,2R,4S)-4-[(2R)-2
[(1R,9S,12S,15R,16E,18R,19R,21R,
23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,
29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0-
4,9]
hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl
di-methylphosphinate, also known as AP23573 and MK8669, and
described in PCT Publication No. WO 03/064383); everolimus
(Afinitor.RTM. or RAD001); rapamycin (AY22989, Sirolimus.RTM.);
simapi-mod (CAS 164301-51-3); emsirolimus,
(5-{2,4-Bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl}-2-me-
thoxyphenyl)methanol (AZD8055);
2-Amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-
-4-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one (PF04691502, CAS
1013101-36-4); and
N2-[1,4-dioxo-4-[[4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-
-4-yl]methoxy]butyl]-L-arginylglycyl-L-a-aspartylL-serine-(SEQ ID
NO: 94), inner salt (SF1126, CAS 936487-67-1),
(lr,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[1,5-f][1,2,4]triazi-
n-7-yl)cyclohexanecarboxylic acid (OSI-027); and XL765.
[0252] In some embodiments, the cell therapy can be used in
combination with a BRAF inhibitor, e.g., GSK2118436, RG7204,
PLX4032, GDC-0879, PLX4720, and sorafenib tosylate (Bay 43-9006).
In further embodiments, a BRAF inhibitor includes, but is not
limited to, regorafenib (BAY73-4506, CAS 755037-03-7); tuvizanib
(AV951, CAS 475108-18-0); vemurafenib (Zel-boraf.RTM., PLX-4032,
CAS 918504-65-1); encorafenib (also known as LGX818);
1-Methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridiny-
l]oxy]-N-[4-(trifluoromethyl)phenyl-1H-benzimidazol-2-amine
(RAF265, CAS 927880-90-8);
5-[1-(2-Hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2,3-dihydroinden--
1-one oxime (GDC-0879, CAS 905281-76-7);
5-[2-[4-[2-(Dimethylamino)ethoxy]phenyl]-5-(4-pyridinyl)-1H-imidazol-4-yl-
]-2,3-dihydro-1H-Inden-1-one ox-ime (GSK2118436 or SB590885);
(+/-)-Methyl
(5-(2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-
-yl)-1H-benzimidazol-2-yl)carbamate (also known as XL-281 and
BMS908662) and
N-(3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophen-
yl)propane-1-sulfonamide (also known as PLX4720).
[0253] In some embodiments, the cell therapy described herein can
be used in combination with a MEK inhibitor. Any MEK inhibitor can
be used in combination including, but not limited to, selumetinib
(5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl--
1H-benzimidazole-6-carboxamide, also known as AZD6244 or ARRY
142886);ARRY-142886 trametinib dimethyl sulfoxide (GSK-1120212, CAS
1204531-25-80); G02442104 (also known as GSK1120212), RDEA436;
N-[3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl]-1-[(2R)-
-2,3-dihydroxypropyl]-cyclopropanesulfonamide (also known as
RDEA119 or BAY869766); RDEA119/BAY 869766, AS703026; G00039805
(also known as AZD-6244 or selumetinib), BIX 02188; BIX 02189;
2-[(2-Chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro-benz-
amide (also known as CI-1040 or PD184352); CI-1040 (PD-184352),
N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amin-
o]-benzamide (also known as PD0325901);
PD03259012'-amino-3'-methoxyflavone (also known as PD98059
available from Biaffin GmbH & Co., KG, Germany); PD98059,
2,3-bis[amino[(2-aminophenyl)thio]methylene]-butanedinitrile (also
known as U0126); U0126, XL-518 (also known as GDC-0973, Cas No.
1029872-29-4, available from ACC Corp.); GDC-0973 (Methanone,
[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-(25)-2--
piperidinyl-1-azetidinyl]-), G-38963; and G02443714 (also known as
AS703206), or a pharmaceutically acceptable salt or solvate
thereof. Further examples of MEK inhibitors include, but are not
limited to, benimetinib
(6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-ca-
rboxylic acid (2-hydroxyethyoxy)-amide, also known as MEK162, CAS
1073666-70-2);
2,3-Bis[amino[(2-aminophenyl)thio]methylene]-butanedinitrile (also
known as U0126 and described in U.S. Pat. No. 2,779,780);
(3S,4R,5Z,8S,9S,11E)-14-(Ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9-
, 19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione] (also
known as E6201); vemurafenib (PLX-4032, CAS 918504-65-1);
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (TAK-733, CAS
1035555-63-5); pimasertib (AS-703026, CAS 1204531-26-9);
2-(2-Fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-
-dihydropyridine-3-carboxamide (AZD 8330); and
3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-5-[(3-o-
xo-[1,2]oxazinan-2-yl)methyl]benzamide (CH 4987655 or Ro
4987655).
[0254] In some embodiments, the cell therapy described herein can
be used in combination with a JAK2 inhibitor, e.g., CEP-701,
INCB18424, CP-690550 (tasocitinib). Example JAK inhibitors include,
but are not limited to, ruxolitinib (Jakafi.RTM.); tofacitinib
(CP690550); axitinib (AG013736, CAS 319460-85-0);
5-Chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazo-
l-3-y)-12,4-pyrimidinediamine (AZD1480, CAS 935666-88-9);
(9E)-15-[2-(1-Pyrrolidinyl)ethoxy]-7,12,26-trioxa-19,21,24-triazatetracyc-
lo[18.3.1.12,5.114,18]-hexacosa-1(24),2,4,9,14,16,18(25),20,22-nonaene
(SB-1578, CAS 937273-04-6); momelotinib (CYT 387); baricitinib
(INCB-028050 or LY-3009104); pacritinib (SB1518);
(16E)-14-Methyl-20-oxa-5,7,14,27-tetraazatetracyclo[19.3.1.12,6.18,12]hep-
tacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene (SB 1317);
gandotinib (LY 2784544); and
N,N-cicyclopropyl-4-[(1,5-dimethyl-1H-pyrazol-3-yl)amino]-6-ethyl-1,6-dih-
ydro-1-methyl-imidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide
(BMS 911543).
[0255] In some embodiments, the combination therapies disclosed
herein include paclitaxel or a paclitaxel agent, e.g., TAXOL.RTM.,
protein-bound paclitaxel (e.g., ABRAXANE.RTM.). Exemplary
paclitaxel agents include, but are not limited to, nanoparticle
albumin-bound paclitaxel (ABRAX-ANE, marketed by Abraxis
Bioscience), docosahexaenoic acid bound-paclitaxel (DHA-paclitaxel,
Taxoprexin, marketed by Protarga), polyglutamate bound-paclitaxel
(PG-paclitaxel, paclitaxel poliglumex, CT-2103, XYOTAX, marketed by
Cell Therapeutic), the tumor-activated prodrug (TAP), ANG105
(Angiopep-2 bound to three molecules of paclitaxel, marketed by
Im-munoGen), paclitaxel-EC-1 (paclitaxel bound to the
erbB2-recognizing peptide EC-1; see Li et al., Biopolymers (2007)
87:225-230), and glucose-conjugated paclitaxel (e.g., 2'-paclitaxel
me-thyl 2-glucopyranosyl succinate).
Methods
[0256] The present disclosure provides methods for generating an
engineered cell. In some aspects, the method can comprise (a)
delivering a nucleic acid molecule expressing a chimeric
polypeptide into a cell; and (b) expressing the nucleic acid
molecule in the cell, thereby generating the engineered cell. The
chimeric polypeptide can be a chimeric antigen receptor as
described herein.
[0257] The present disclosure also provides methods for
administering an engineered cell as described herein. The
engineered cell can be an engineered immune cell. The engineered
immune cell can be a T cell. The engineered immune cell can be
derived from an autologous T cell. The engineered immune cell can
be derived from an allogeneic T cell.
[0258] In some aspects, provided herein is a method for
administering an engineered immune cell comprising a chimeric
polypeptide comprising (i) an enhancer moiety capable of enhancing
one or more activities of the engineered immune cell, and (ii) an
inducible cell death moiety capable of effecting death of the
engineered immune cell upon contacting the chimeric polypeptide
with a cell death activator. The enhancer moiety can be linked to
the inducible cell death moiety. The engineered immune cell can
further comprise one or more chimeric antigen receptors (CARs)
comprising a binding moiety. The binding moiety can comprise a
first antigen binding domain, which first antigen binding domain
suppresses or reduces a subject's immune response toward the
engineered immune cell when administered into the subject. The
binding moiety can further comprise a second antigen binding domain
capable of binding to a disease-associated antigen. An individual
CAR of the one or more CARs can comprise (i) the first antigen
binding domain, (ii) the second antigen binding domain, or (iii)
both the first antigen binding domain and the second antigen
binding domain. Each CAR of the one or more CARs can further
comprise a transmembrane domain and an intracellular signaling
domain.
[0259] In some aspects, provided herein is a method of
administering an engineered immune cell comprising one or more
chimeric antigen receptors (CARs) comprising a binding moiety. The
binding moiety can comprise a first antigen binding domain capable
of binding to an immune cell antigen and a second antigen binding
domain capable of binding to a disease-associated antigen. Each CAR
of the one or more CARs can further comprise a transmembrane domain
and an intracellular signaling domain. The engineered immune cell
can further comprise an enhancer moiety capable of enhancing one or
more activities of the engineered immune cell. In some cases, an
endogenous T cell receptor (TCR) of the engineered immune cell can
be inactivated. The engineered immune cell can exhibit (i) enhanced
degree of persistence by remaining viable in vitro for at least
about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75,
80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, or
more days while in presence of cells (e.g., cancer cells, immune
cells, or both) that are heterologous to the engineered immune
cell, (ii) enhanced degree of expansion by at least about 2-fold,
3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold,
15-fold, 20-fold, 25-fold, 30-fold, 35-fold, 40-fold, 45-fold,
50-fold, 55-fold, 60-fold, 65-fold, 70-fold, 75-fold, 80-fold,
85-fold, 90-fold, 95-fold, 100-fold, 110-fold, 120-fold, 130-fold,
140-fold, 150-fold, 200-fold, 250-fold, 300-fold, or more within 15
days, or (iii) enhanced cytotoxicity against a target cell
comprising the immune cell antigen or the disease-associated
antigen, compared to an additional engineered immune cell
comprising the one or more CARs but not the enhancer moiety. In
some cases, the engineered immune cell can exhibit enhanced degree
of expansion by at least about 50-fold, 60-fold, 70-fold, 80-fold,
90-fold, 100-fold, 110-fold, 120-fold, 130-fold, 140-fold,
150-fold, 160-fold, 170-fold, 180-fold, 190-fold, 200-fold,
210-fold, 220-fold, 230-fold, 240-fold, 250-fold, 260-fold,
270-fold, 280-fold, 290-fold, 300-fold, 350-fold, 400-fold,
450-fold, 500-fold, or more within 30 days. In some cases, the
engineered immune cell can exhibit enhanced degree of expansion by
at least about 100-fold, 200-fold, 300-fold, 400-fold, 500-fold,
600-fold, 700-fold, 800-fold, 900-fold, 1,000-fold, 2,000-fold,
3,000-fold, 4,000-fold, 5,000-fold, 6,000-fold, 7,000-fold,
8,000-fold, 9,000-fold, 10,000-fold, 20,000-fold, 30,000-fold,
40,000-fold, 50,000-fold, 60,000-fold, 70,000-fold, 80,000-fold,
90,000-fold, 100,000-fold, 200,000-fold, 300,000-fold,
400,000-fold, 500,000-fold, 600,000-fold, 700,000-fold,
800,000-fold, 900,000-fold, 1,000,000-fold, or more within 60 days.
The viability or expansion can be measured in the presence of
stimulation, for example, stimulation by a cancer antigen or a
cancer cell. The viability or expansion can be measured in the
presence of multiple rounds or repeated stimulations.
[0260] In some aspects, provided herein is a method of
administering a cell (e.g., an engineered immune cell), comprising
a functionally inactive T cell receptor (TCR). The cell can further
comprise one or more chimeric antigen receptors (CARs). Each
individual CAR of the one or more CARs can comprise a binding
moiety. The binding moiety can comprise (i) a first antigen binding
domain, which first antigen binding domain suppresses or reduces a
subject's immune response toward the engineered immune cell when
administered into the subject and (ii) a second antigen binding
domain that binds to a disease-associated antigen. Each CAR of the
one or more CARs can further comprise a transmembrane domain and an
intracellular signaling domain.
[0261] In some aspects, provided herein is a method of
administering an engineered immune cell comprising an enhancer
moiety capable of enhancing one or more activities of the
engineered immune cell. The engineered cell can further comprise a
chimeric antigen receptor (CAR) comprising an antigen binding
domain that specifically binds CD7. The CAR can further comprise a
transmembrane domain and an intracellular signaling domain. The
endogenous CD7 in the engineered immune cell can be inactivated. In
some embodiments, the engineered cell can comprise a CAR comprising
an antigen binding domain that specifically binds an immune cell
antigen. The immune cell antigen can be any immune cell antigen
described herein such as CD2, CD3, CD4, CD5, CD8, CD16a, CD16b,
CD25, CD27, CD28, CD30, CD38, CD45, CD48, CD50, CD52, CD56, CD57,
CD62L, CD69, CD94, CD100, CD102, CD122, CD127, CD132, CD137, CD160,
CD161, CD178, CD218, CD226, CD244, CD159a (NKG2A), CD159c (NKG2C),
NKG2E, CD279, CD314 (NKG2D), CD305, CD335 (NKP46), CD337, CD319
(CS1), TCR.alpha., TCR.beta. and SLAMF7. The endogenous immune cell
antigen of the engineered cell, which the antigen binding domain
binds, can be inactivated in the engineered cell.
[0262] In some aspects, provided herein is a method of
administering an engineered immune cell comprising a single
chimeric antigen receptor (CAR) comprising (i) a first antigen
binding domain that specifically binds CD7 and (ii) a second
antigen binding domain capable of binding to a disease-associated
antigen. The CAR can further comprise a transmembrane domain and an
intracellular signaling domain. A gene encoding endogenous CD7 can
be inactivated in the engineered immune cell.
[0263] The present disclosure also provides methods of treating or
diagnosing a disease in a subject. In some cases, the method
comprises administering a pharmaceutical composition comprising an
engineered immune cell into a subject. The engineered immune cell
in the pharmaceutical composition can be derived from an allogeneic
immune cell. The engineered immune cell derived from the allogeneic
immune cell may not induce graft versus host disease (GVHD) in the
subject. The engineered immune cell in the pharmaceutical
composition can be derived from an autologous immune cell. In some
cases, an endogenous TCR of the engineered immune cell in the
pharmaceutical composition is functionally inactive. The engineered
immune cell can reduce GVHD in the subject compared to an immune
cell having a functionally active TCR. The disease can be a cancer.
For example, the cancer can be lymphoma or leukemia.
[0264] The present disclosure also provides a method of delivering
an allogeneic cell therapy comprising administering to a subject in
need thereof a population of engineered immune cells. An individual
engineered immune cell of the population can comprise one or more
chimeric antigen receptors (CARs) comprising a binding moiety. The
binding moiety can comprise a first antigen binding domain capable
of binding to an immune cell antigen. The binding moiety can
further comprise a second antigen binding domain capable of binding
to a disease-associated antigen. The first antigen binding domain
can suppress or reduce a subject's immune response toward the
engineered immune cell when administered into the subject. The
engineered immune cell can further comprise an enhancer moiety
capable of enhancing one or more activities of the engineered
immune cell. The endogenous T cell receptor (TCR) of the engineered
immune cell can be inactivated. For example, a gene encoding a
subunit of TCR can be inactivated. Various gene editing methods
described herein can be used to inactivate endogenous TCRs of a T
cell.
[0265] In some embodiments, a method provided herein can include
activation of a population of cells. In some cases, the cell used
to prepare the engineered immune cell can be activated before
preparing the engineered immune cell. In some cases, the engineered
immune cell can be activated. Activation as used herein can refer
to a process whereby a cell transitions from a resting state to an
active state. This process can comprise a response to an antigen,
migration, and/or a phenotypic or genetic change to a functionally
active state. In some aspects, activation can refer to the stepwise
process of T cell activation. In some cases, a T cell can require
one or more signals to become activated. For example, a T cell can
require at least two signals to become fully activated. The first
signal can occur after engagement of a TCR by the antigen-MHC
complex, and the second signal can occur by engagement of
co-stimulatory molecules. Anti-CD3 antibody (or a functional
variant thereof) can mimic the first signal and anti-CD28 antibody
(or a functional variant thereof) can mimic the second signal in
vitro.
[0266] In some aspects, a method provided herein can comprise
activation of a population of cells. Activation can be performed by
contacting a population of cells with a surface having attached
thereto an agent that can stimulate a CD3 TCR complex associated
signal and a ligand that can stimulate a co-stimulatory molecule on
the surface of the cells. In particular, T cell populations can be
stimulated in vitro such as by contact with an anti-CD3 antibody or
antigen-binding fragment thereof, or an anti-CD2 antibody
immobilized on a surface, or by contact with a protein kinase C
activator (e.g., bryostatin) sometimes in conjunction with a
calcium ionophore. For co-stimulation of an accessory molecule on
the surface of the T cells, a ligand that binds the accessory
molecule can be used. For example, a population of cells can be
contacted with an anti-CD3 antibody and an anti-CD28 antibody,
under conditions that can stimulate proliferation of the T cells.
In some cases, 4-1BB can be used to stimulate cells. For example,
cells can be stimulated with 4-1BB and IL-21 or another cytokine.
For activation of either CD4 T cells or CD8 T cells, an anti-CD3
antibody and an anti-CD28 antibody can be used. For example, the
agents providing a signal may be in solution or conjugated to a
solid phase surface. The ratio of particles to cells may depend on
particle size relative to the target cell. In further embodiments,
the cells, such as T cells, can be combined with agent-coated
beads, where the beads and the cells can be subsequently separated,
and optionally cultured. Each bead can be coated with either
anti-CD3 antibody or an anti-CD28 antibody, or in some cases, a
combination of the two. In an alternative embodiment, prior to
culture, the agent-coated beads and cells are not separated but are
cultured together. Cell surface proteins may be conjugated by
allowing paramagnetic beads to which anti-CD3 antibody and
anti-CD28 antibody can be attached (3.times.28 beads) to contact
the T cells. In one embodiment the cells and beads (for example,
DYNABEADS.RTM. M-450 CD3/CD28 T paramagnetic beads at a ratio of
1:1) are combined in a buffer, for example, phosphate buffered
saline (PBS) (e.g., without divalent cations such as, calcium and
magnesium). Any cell concentration may be used. The mixture may be
cultured for or for about several hours (e.g., about 3 hours) to or
to about 14 days or any hourly integer value in between. In another
embodiment, the mixture may be cultured for or for about 21 days or
for up to or for up to about 21 days. Conditions appropriate for T
cell culture can include an appropriate media (e.g., Minimal
Essential Media or RPMI Media 1640 or, X-vivo 5, (Lonza)) that may
contain factors necessary for proliferation and viability,
including serum (e.g., fetal bovine or human serum), interleukin-2
(IL-2), insulin, IFN-g, TL-4, TL-7, GM-CSF, IL-10, IL-21, IL-15,
TGF beta, and TNF alpha or any other additives for the growth of
cells. Other additives for the growth of cells include, but are not
limited to, surfactant, plasmanate, and reducing agents such as
N-acetyl-cysteine and 2-mercaptoethanol. Media can include RPMI
1640, Al M-V, DMEM, MEM, a-MEM, F-12, X-Vivo 1, and X-Vivo 20,
Optimizer, with added amino acids, sodium pyruvate, and vitamins,
either serum-free or supplemented with an appropriate amount of
serum (or plasma) or a defined set of hormones, and/or an amount of
cytokine(s) sufficient for the growth and expansion of T cells.
Antibiotics, e.g., penicillin and streptomycin, can be included
only in experimental cultures, possibly not in cultures of cells
that are to be infused into a subject. The target cells can be
maintained under conditions necessary to support growth; for
example, an appropriate temperature (e.g., 37.theta.C) and
atmosphere (e.g., air plus 5% CO.sub.2). In some instances, T cells
that have been exposed to varied stimulation times may exhibit
different characteristics. In some cases, a soluble monospecific
tetrameric antibody against human CD3, CD28, CD2, or any
combination thereof may be used. In some embodiments, activation
can utilize an activation moiety, a costimulatory agent, and any
combination thereof. In some aspects, an activation moiety binds: a
CD3/T cell receptor complex and/or provides costimulation. In some
aspects, an activation moiety is any one of anti-CD3 antibody
and/or anti-CD28 antibody. In some aspects, a solid phase is at
least one of a bead, plate, and/or matrix. In some aspects, a solid
phase is a bead. Alternatively or in addition to, the activation
moiety may be not be conjugated a substrate, e.g., the activation
moiety may be free-floating in a medium.
[0267] In some cases, a population of cells can be activated or
expanded by co-culturing with tissue or cells. A cell can be an
antigen presenting cell. An artificial antigen presenting cells
(aAPCs) can express ligands for T cell receptor and costimulatory
molecules and can activate and expand T cells for transfer, while
improving their potency and function in some cases. An aAPC can be
engineered to express any gene for T cell activation. An aAPC can
be engineered to express any gene for T cell expansion. An aAPC can
be a bead, a cell, a protein, an antibody, a cytokine, or any
combination. An aAPC can deliver signals to a cell population that
may undergo genomic transplant. For example, an aAPC can deliver a
signal 1, signal, 2, signal 3 or any combination. A signal 1 can be
an antigen recognition signal. For example, signal 1 can be
ligation of a TCR by a peptide-MHC complex or binding of agonistic
antibodies directed towards CD3 that can lead to activation of the
CD3 signal-transduction complex. Signal 2 can be a co-stimulatory
signal. For example, a co-stimulatory signal can be anti-CD28,
inducible co-stimulator (ICOS), CD27, and 4-1BB (CD137), which bind
to ICOS-L, CD70, and 4-1BBL, respectively. Signal 3 can be a
cytokine signal. A cytokine can be any cytokine. A cytokine can be
IL-2, IL-7, IL-12, IL-15, IL-21, or any combination thereof. In
some cases an artificial antigen presenting cell (aAPC) may be used
to activate and/or expand a cell population. In some cases, an
artificial may not induce allospecificity. An aAPC may not express
HLA in some cases. An aAPC may be genetically modified to stably
express genes that can be used to activation and/or stimulation. In
some cases, a K562 cell may be used for activation. A K562 cell may
also be used for expansion. A K562 cell can be a human
erythroleukemic cell line. A K562 cell may be engineered to express
genes of interest. K562 cells may not endogenously express HLA
class I, II, or CD1d molecules but may express ICAM-1 (CD54) and
LFA-3 (CD58). K562 may be engineered to deliver a signal 1 to T
cells. For example, K562 cells may be engineered to express HLA
class I. In some cases, K562 cells may be engineered to express
additional molecules such as B7, CD80, CD83, CD86, CD32, CD64,
4-1BBL, anti-CD3, anti-CD3 mAb, anti-CD28, anti-CD28mAb, CD1d,
anti-CD2, membrane-bound IL-15, membrane-bound IL-17,
membrane-bound IL-21, membrane-bound IL-2, truncated CD19, or any
combination. In some cases, an engineered K562 cell can expresses a
membranous form of anti-CD3 mAb, clone OKT3, in addition to CD80
and CD83. In some cases, an engineered K562 cell can expresses a
membranous form of anti-CD3 mAb, clone OKT3, membranous form of
anti-CD28 mAb in addition to CD80 and CD83.
[0268] An aAPC can be a bead. A spherical polystyrene bead can be
coated with antibodies against CD3 and CD28 and be used for T cell
activation. A bead can be of any size. In some cases, a bead can be
or can be about 3 and 6 micrometers. A bead can be or can be about
4.5 micrometers in size. A bead can be utilized at any cell to bead
ratio. For example, a 3 to 1 bead to cell ratio at 1 million cells
per milliliter can be used. An aAPC can also be a rigid spherical
particle, a polystyrene latex microbeads, a magnetic nano- or
micro-particles, a nanosized quantum dot, a 4,
poly(lactic-co-glycolic acid) (PLGA) microsphere, a nonspherical
particle, a 5, carbon nanotube bundle, a 6, ellipsoid PLGA
microparticle, a 7, nanoworms, a fluidic lipid bilayer-containing
system, an 8, 2D-supported lipid bilayer (2D-SLBs), a 9, liposome,
a 10, RAFTsomes/microdomain liposome, an 11, SLB particle, or any
combination thereof. In some cases, an aAPC can expand CD4 T cells.
For example, an aAPC can be engineered to mimic an antigen
processing and presentation pathway of HLA class II-restricted CD4
T cells. A K562 can be engineered to express HLA-D, DP a, DP R
chains, Ii, DM .alpha., DM .beta., CD80, CD83, or any combination
thereof. For example, engineered K562 cells can be pulsed with an
HLA-restricted peptide in order to expand HLA-restricted
antigen-specific CD4 T cells. In some cases, the use of aAPCs can
be combined with exogenously introduced cytokines for T cell
activation, expansion, or any combination. Cells can also be
expanded in vivo, for example in the subject's blood after
administration of genomically transplanted cells into a
subject.
[0269] In some embodiments, a method provided herein can comprise
transduction of a population of cells. In some embodiments, a
method comprises introducing a polynucleotide encoding for a
cellular receptor such as a chimeric antigen receptor and/or a T
cell receptor. In some cases, a transfection of a cell can be
performed.
[0270] In some embodiments, a viral supernatant comprising a
polynucleotide encoding for a cellular receptor such as a CAR
and/or TCR is generated. In some embodiments, a viral vector can be
a retroviral vector, a lentiviral vector and/or an adeno-associated
viral vector. Packaging cells can be used to form virus particles
capable of infecting a host cell. Such cells can include 293 cells,
(e.g., for packaging adenovirus), and Psi2 cells or PA317 cells
(e.g., for packaging retrovirus). Viral vectors can be generated by
producing a cell line that packages a nucleic acid vector into a
viral particle. The vectors can contain the minimal viral sequences
required for packaging and subsequent integration into a host. The
vectors can contain other viral sequences being replaced by an
expression cassette for the polynucleotide(s) to be expressed. The
missing viral functions can be supplied in trans by the packaging
cell line. For example, AAV vectors can comprise ITR sequences from
the AAV genome which are required for packaging and integration
into the host genome. Viral DNA can be packaged in a cell line,
which can contain a helper plasmid encoding the other AAV genes,
namely rep and cap, while lacking ITR sequences. The cell line can
also be infected with adenovirus as a helper. The helper virus can
promote replication of the AAV vector and expression of AAV genes
from the helper plasmid. Contamination with adenovirus can be
reduced by, e.g., heat treatment to which adenovirus is more
sensitive than AAV. Additional methods for the delivery of nucleic
acids to cells can be used, for example, as described in
US20030087817, incorporated herein by reference.
[0271] In some embodiments, a host cell can be transiently or
non-transiently transfected with one or more vectors described
herein. A cell can be transfected as it naturally occurs in a
subject. A cell can be taken or derived from a subject and
transfected. A cell can be derived from cells taken from a subject,
such as a cell line. In some embodiments, a cell transfected with
one or more vectors described herein is used to establish a new
cell line comprising one or more vector-derived sequences.
Non-limiting examples of vectors for eukaryotic host cells include
but are not limited to: pBs, pQE-9 (Qiagen), phagescript, PsiX174,
pBluescript SK, pBsKS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene);
pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia). Eukaryotic:
pWL-neo, pSv2cat, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPv, pMSG,
pSVL (Pharmiacia). Also, any other plasmids and vectors can be used
as long as they are replicable and viable in a selected host. Any
vector and those commercially available (and variants or
derivatives thereof) can be engineered to include one or more
recombination sites for use in the methods. Such vectors can be
obtained from, for example, Vector Laboratories Inc., Invitrogen,
Promega, Novagen, NEB, Clontech, Boehringer Mannheim, Pharmacia,
EpiCenter, OriGenes Technologies Inc., Stratagene, PerkinElmer,
Pharmingen, and Research Genetics. Other vectors of interest
include eukaryotic expression vectors such as pFastBac, pFastBacHT,
pFastBacDUAL, pSFV, and pTet-Splice (Invitrogen), pEUK-C1, pPUR,
pMAM, pMAMneo, pBI101, pBIl21, pDR2, pCMVEBNA, and pYACneo
(Clontech), pSVK3, pSVL, pMSG, pCH110, and pKK232-8 (Pharmacia,
Inc.), p3'SS, pXT1, pSG5, pPbac, pMbac, pMClneo, and pOG44
(Stratagene, Inc.), and pYES2, pAC360, pBlueBa-cHis A, B, and C,
pVL1392, pBlueBac111, pCDM8, pcDNA1, pZeoSV, pcDNA3 pREP4, pCEP4,
and pEBVHis (Invitrogen, Corp.), and variants or derivatives
thereof. Other vectors include pUC18, pUC19, pBlueScript, pSPORT,
cosmids, phagemids, YAC's (yeast artificial chromosomes), BAC's
(bacterial artificial chromosomes), P1 (Escherichia coli phage),
pQE70, pQE60, pQE9 (quagan), pBS vectors, PhageScript vectors,
BlueScript vectors, pNH8A, pNH16A, pNH18A, pNH46A (Stratagene),
pcDNA3 (Invitrogen), pGEX, pTrsfus, pTrc99A, pET-5, pET-9,
pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia), pSPORT1, pSPORT2,
pCMVSPORT2.0 and pSYSPORTI (Invitrogen) and variants or derivatives
thereof. Additional vectors of interest can also include pTrxFus,
pThioHis, pLEX, pTrcHis, pTrcHis2, pRSET, pBlueBa-cHis2,
pcDNA3.1/His, pcDNA3.1(-)/Myc-His, pSecTag, pEBVHis, pPIC9K,
pPIC3.5K, pA081S, pPICZ, pPICZA, pPICZB, pPICZC, pGAPZA, pGAPZB,
pGAPZC, pBlue-Bac4.5, pBlueBacHis2, pMelBac, pSinRep5, pSinHis,
pIND, pIND(SP1), pVgRXR, pcDNA2.1, pYES2, pZEr01.1, pZErO-2.1,
pCR-Blunt, pSE280, pSE380, pSE420, pVL1392, pVL1393, pCDM8,
pcDNA1.1, pcDNA1.1/Amp, pcDNA3.1, pcDNA3.1/Zeo, pSe, SV2, pRc/CMV2,
pRc/RSV, pREP4, pREP7, pREP8, pREP9, pREP 10, pCEP4, pEBVHis,
pCR3.1, pCR2.1, pCR3.1-Uni, and pCRBac from Invitrogen; X ExCell, X
gtl1, pTrc99A, pKK223-3, pGEX-1X T, pGEX-2T, pGEX-2TK, pGEX-4T-1,
pGEX-4T-2, pGEX-4T-3, pGEX-3X, pGEX-5X-1, pGEX-5X-2, pGEX-5X-3,
pEZZ18, pRIT2T, pMC1871, pSVK3, pSVL, pMSG, pCH110, pKK232-8,
pSL1180, pNEO, and pUC4K from Pharmacia; pSCREEN-lb(+), pT7Blue(R),
pT7Blue-2, pCITE-4-abc(+), pOCUS-2, pTAg, pET-32L1C, pET-30LIC,
pBAC-2 cp LIC, pBACgus-2 cp LIC, pT7Blue-2 LIC, pT7Blue-2, X
SCREEN-1, XB1ueSTAR, pET-3abcd, pET-7abc, pET9abcd, pET 11 abcd,
pET12abc, pET-14b, pET-15b, pET-16b, pET-17b-pET-17xb, pET-19b,
pET-20b(+), pET-21abcd(+), pET-22b(+), pET-23abcd(+), pET-24abcd
(+), pET-25b(+), pET-26b(+), pET-27b(+), pET-28abc(+),
pET-29abc(+), pET-30abc(+), pET-31b(+), pET-32abc(+), pET-33b(+),
pBAC-1, pBACgus-1, pBAC4x-1, pBACgus4x-1, pBAC-3 cp, pBACgus-2 cp,
pBACsurf-1, plg, Signal plg, pYX, Selecta Vecta-Neo, Selecta
Vecta-Hyg, and Selecta Vecta-Gpt from Novagen; pLexA, pB42AD,
pGBT9, pAS2-1, pGAD424, pACT2, pGAD GL, pGAD GH, pGAD10, pGilda,
pEZM3, pEGFP, pEGFP-1, pEGFPN, pEGFP-C, pEBFP, pGFPuv, pGFP,
p6xHis-GFP, pSEAP2-Basic, pSEAP2-Contral, pSEAP2-Promoter,
pSEAP2-Enhancer, p I3 gal-Basic, pl3 gal-Control, p I3
gal-Promoter, p I3 gal-Enhancer, pCMV, pTet-Off, pTet-On, pTK-Hyg,
pRetro-Off, pRetro-On, pIRESlneo, pIRESlhyg, pLXSN, pLNCX, pLAPSN,
pMAMneo, pMAMneo-CAT, pMAMneo-LUC, pPUR, pSV2neo, pYEX4T-1/2/3,
pYEX-S1, pBacPAK-His, pBacPAK8/9, pAcUW31, BacPAK6, pTriplEx,
2Xgt10, Xgt11, pWE15, and X TriplEx from Clontech; Lambda ZAP II,
pBK-CMV, pBK-RSV, pBluescript II KS+/-, pBluescript II SK+/-,
pAD-GAL4, pBD-GAL4 Cam, pSurfscript, Lambda FIX II, Lambda DASH,
Lambda EMBL3, Lambda EMBL4, SuperCos, pCR-Scrigt Amp, pCR-Script
Cam, pCR-Script Direct, pBS+/-, pBC KS+/-, pBC SK+/-, Phag-escript,
pCAL-n-EK, pCAL-n, pCAL-c, pCAL-kc, pET-3abcd, pET-llabcd, pSPUTK,
pESP-1, pCMVLacI, pOPRSVI/MCS, pOPI3 CAT, pXT1, pSG5, pPbac, pMbac,
pMClneo, pMClneo Poly A, pOG44, p0G45, pFRTI3GAL, pNE0I3GAL,
pRS403, pRS404, pRS405, pRS406, pRS413, pRS414, pRS415, and pRS416
from Stratagene, pPC86, pDBLeu, pDBTrp, pPC97, p2.5, pGAD1-3,
pGAD10, pACt, pACT2, pGADGL, pGADGH, pAS2-1, pGAD424, pGBT8, pGBT9,
pGAD-GAL4, pLexA, pBD-GAL4, pHISi, pHISi-1, placZi, pB42AD, pDG202,
pJK202, pJG4-5, pNLexA, pYESTrp, and variants or derivatives
thereof. In some embodiments, a vector can be a minicircle vector.
A vector provided herein can be used to deliver a polypeptide
coding for a CAR and/or TCR.
[0272] Transduction and/or transfection can be performed by any one
of: non-viral transfection, biolistics, chemical transfection,
electroporation, nucleofection, heat-shock transfection,
lipofection, microinjection, or viral transfection. In some
embodiments a provided method comprises viral transduction, and the
viral transduction comprises a lentivirus. Viral particles can be
used to deliver a viral vector comprising a polypeptide sequence
coding for a cellular receptor into a cell ex vivo or in vivo. In
some cases, a viral vector as disclosed herein may be measured as
pfu (plaque forming units). In some cases, the pfu of recombinant
virus or viral vector of the compositions and methods of the
disclosure may be about 10.sup.8 to about 5.times.10.sup.10 pfu. In
some cases, recombinant viruses of this disclosure are at least
about 1.times.10.sup.8, 2.times.10.sup.8, 3.times.10.sup.8,
4.times.10.sup.8, 5.times.10.sup.8, 6.times.10.sup.8,
7.times.10.sup.8, 8.times.10.sup.8, 9.times.10.sup.8,
1.times.10.sup.9, 2.times.10.sup.9, 3.times.10.sup.9,
4.times.10.sup.9, 5.times.10.sup.9, 6.times.10.sup.9,
7.times.10.sup.9, 8.times.10.sup.9, 9.times.10.sup.9,
1.times.10.sup.10, 2.times.10.sup.10, 3.times.10.sup.10,
4.times.10.sup.10, and 5.times.10.sup.10 pfu. In some cases,
recombinant viruses of this disclosure are at most about
1.times.10.sup.8, 2.times.10.sup.8, 3.times.10.sup.8,
4.times.10.sup.8, 5.times.10.sup.8, 6.times.10.sup.8,
7.times.10.sup.8, 8.times.10.sup.8, 9.times.10.sup.8,
1.times.10.sup.9, 2.times.10.sup.9, 3.times.10.sup.9,
4.times.10.sup.9, 5.times.10.sup.9, 6.times.10.sup.9,
7.times.10.sup.9, 8.times.10.sup.9, 9.times.10.sup.9,
1.times.10.sup.10, 2.times.10.sup.10, 3.times.10.sup.10,
4.times.10.sup.10, and 5.times.10.sup.10 pfu. In some aspects, the
viral vector of the disclosure may be measured as vector genomes.
In some cases, recombinant viruses of this disclosure are
1.times.10.sup.10 to 3.times.10.sup.12 vector genomes, or
1.times.10.sup.9 to 3.times.10.sup.13 vector genomes, or
1.times.10.sup.8 to 3.times.10.sup.14 vector genomes, or at least
about 1.times.10.sup.1, 1.times.10.sup.2, 1.times.10.sup.3,
1.times.10.sup.4, 1.times.10.sup.5, 1.times.10.sup.6,
1.times.10.sup.7, 1.times.10.sup.8, 1.times.10.sup.9,
1.times.10.sup.10, 1.times.10.sup.11, 1.times.10.sup.12,
1.times.10.sup.13, 1.times.10.sup.14, 1.times.10.sup.15,
1.times.10.sup.16, 1.times.10.sup.17, and 1.times.10.sup.18 vector
genomes, or are 1.times.10.sup.8 to 3.times.10.sup.14 vector
genomes, or are at most about 1.times.10.sup.1, 1.times.10.sup.2,
1.times.10.sup.3, 1.times.10.sup.4, 1.times.10.sup.5,
1.times.10.sup.6, 1.times.10.sup.7, 1.times.10.sup.8,
1.times.10.sup.9, 1.times.10.sup.10, 1.times.10.sup.11,
1.times.10.sup.12, 1.times.10.sup.13, 1.times.10.sup.14,
1.times.10.sup.15, 1.times.10.sup.16, 1.times.10.sup.17, and
1.times.10.sup.18 vector genomes. In some cases, a viral vector
provided herein can be measured using multiplicity of infection
(MOI). In some cases, MOI may refer to the ratio, or multiple of
vector or viral genomes to the cells to which the nucleic may be
delivered. In some cases, the MOI may be 1.times.10.sup.6. In some
cases, the MOI may be 1.times.10.sup.5 to 1.times.10.sup.7. In some
cases, the MOI may be 1.times.10.sup.4 to 1.times.10.sup.8. In some
cases, recombinant viruses of the disclosure are at least about
1.times.10.sup.1, 1.times.10.sup.2, 1.times.10.sup.3,
1.times.10.sup.4, 1.times.10.sup.5, 1.times.10.sup.6,
1.times.10.sup.7, 1.times.10.sup.8, 1.times.10.sup.9,
1.times.10.sup.10, 1.times.10.sup.11, 1.times.10.sup.12,
1.times.10.sup.13, 1.times.10.sup.14, 1.times.10.sup.15,
1.times.10.sup.16, 1.times.10.sup.17, and 1.times.10.sup.18 MOI. In
some cases, recombinant viruses of this disclosure are
1.times.10.sup.8 to 3.times.10.sup.14 MOI, or are at most about
1.times.10.sup.1, 1.times.10.sup.2, 1.times.10.sup.3,
1.times.10.sup.4, 1.times.10.sup.5, 1.times.10.sup.6,
1.times.10.sup.7, 1.times.10.sup.8, 1.times.10.sup.9,
1.times.10.sup.10, 1.times.10.sup.11, 1.times.10.sup.12,
1.times.10.sup.13, 1.times.10.sup.14, 1.times.10.sup.15,
1.times.10.sup.16, 1.times.10.sup.17, and 1.times.10.sup.18 MOI. In
some cases, a viral vector is introduced at a multiplicity of
infection (MOI) from about 1.times.10.sup.5, 2.times.10.sup.5,
3.times.10.sup.5, 4.times.10.sup.5, 5.times.10.sup.5,
6.times.10.sup.5, 7.times.10.sup.5, 8.times.10.sup.5,
9.times.10.sup.5, 1.times.10.sup.6, 2.times.10.sup.6,
3.times.10.sup.6 4.times.10.sup.6, 5.times.10.sup.6,
6.times.10.sup.6, 7.times.10.sup.6, 8.times.10.sup.6,
9.times.10.sup.6, 1.times.10.sup.7, 2.times.10.sup.7,
3.times.10.sup.7, or up to about 9.times.10.sup.9 genome
copies/virus particles per cell.
[0273] The transfection efficiency of cells with any of the nucleic
acid delivery platforms described herein, for example,
transduction, can be or can be about 20%, 25%, 30%, 35%, 40%, 45%,
50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or more than 99.9%. In some
embodiments, a method can comprise adding an infective agent to a
composition comprising a population of cells. An infective agent
can comprise polybrene. In some aspects, an infective agent can
enhance efficiency of viral infection. An infective agent can
enhance viral infectivity from about 100 to 1,000 fold. Polybrene
can be added to a composition at a concentration from about 5 ug to
10 ug per ml.
[0274] In some embodiments, a method provided herein can comprise a
non-viral approach of introducing a cellular receptor to a cell.
Non-viral approaches can include but are not limited to: CRISPR
associated proteins (Cas proteins, e.g., Cas9), Zinc finger
nuclease (ZFN), Transcription Activator-Like Effector Nuclease
(TALEN), Argonaute nucleases, and meganucleases. Nucleases can be
naturally existing nucleases, genetically modified, and/or
recombinant. Non-viral approaches can also be performed using a
transposon-based system (e.g. PiggyBac, Sleeping beauty).
[0275] In some embodiments, a method provided herein can utilize a
PiggyBac system to introduce an exogenous polypeptide to a cell. A
PiggyBac system comprises two components, a transposon and a
transposase. The PiggyBac transposase facilitates the integration
of the transposon specifically at `TTAA` sites randomly dispersed
in the genome. The predicted frequency of `TTAA` in the genome is
approximately 1 in every 256 base-pairs of DNA sequence. Unlike
other transposons, the PB transposase also enables the excision of
the transposon in a completely seamless manner, leaving no
sequences or mutations behind. Furthermore, PiggyBac offers a large
cargo-carrying capacity (over 200 kb has been demonstrated) with no
known upper limit. PB performance levels can be increased by
codon-optimization strategies, mutations, deletions, additions,
substitutions, and any combination thereof. In some cases, PB can
have a larger cargo (approximately 9.1-14.3 kb), a higher
transposition activity, and its footprint-free characteristic can
make it appealing as a gene editing tool. In some aspects, PB can
comprise a few features: high efficiency transposition; large
cargo; steady long-term expression; the trans-gene is integrated as
a single copy; tracking the target gene in vivo by a noninvasive
mark instead of traditional method such as PCR; easy to determine
the integration site, and combinations thereof.
[0276] In some aspects, a method provided herein can utilize a
Sleeping Beauty (SB) System to introduce a polypeptide coding for a
cellular receptor to a cell. SB was engineered from ancient
Tc1/mariner transposon fossils found within the Salmonid genomes by
in vitro evolution. The SB ITRs (230 bp) contain imperfect direct
repeats (DRs) of 32 bp in length that can serve as recognition
signals for the transposase. Binding affinity and spacing between
the DR elements within ITR has involved in transpositional
activities. The SB transposase can be a 39 kDa protein that possess
DNA binding polypeptide, a nuclear localization signal (NLS) and
the catalytic domain, featured by a conserved amino acid motif
(DDE). Various screens mutagenizing the primary amino acid sequence
of the SB transposase resulted in hyperactive transposase versions.
In some cases, a modified SB can be utilized. Modified SBs can
contain mutations, deletions and additions within ITRs of the
original SB transposon. Modified SBs can comprise: pT2, pT3, pT2B,
pT4, SB100X, and combinations thereof. Non-limited examples of
modified SBs can be selected from: SB10, SB11 (3-fold higher than
SB10), SB12 (4-fold higher than SB10), HSB1-HSB5 (up to 10-fold
higher than SB10), HSB13-HSB17 (HSB17 is 17-fold higher than SB10),
SB100X (100-fold higher than SB10), SB150X (130-fold higher than
SB10), and any combination thereof. In some cases, SB100X is
100-fold hyperactive compared to the originally resurrected
transposase (SB10). In some aspects, SB transposition excision
leaves a footprint (3 bp) at the cargo site. Integration occurs
into TA dinucleotides of the genome, and results in target site
duplications, generated by the host repair machinery. In some
cases, SB appears to possess a nearly unbiased, close-to-random
integration profile. Transposon integration can be artificially
targeted (.about.10%) to a predetermined genomic locus in wildtype
systems, however in chimeric systems provided herein, SB transposon
integration can be directed to a predetermined locus with
efficiencies over 10%.
[0277] In some aspects, a non-viral approach may be taken to
introduce an exogenous polynucleic acid to a population of cells.
In some aspects, a non-viral vector or nucleic acid may be
delivered without the use of a virus and may be measured according
to the quantity of nucleic acid. Generally, any suitable amount of
nucleic acid can be used with the compositions and methods of this
disclosure. In some cases, nucleic acid may be at least about 1 pg,
10 pg, 100 pg, 1 pg, 10 pg, 100 pg, 200 pg, 300 pg, 400 pg, 500 pg,
600 pg, 700 pg, 800 pg, 900 pg, 1 .mu.g, g, 100 .mu.g, 200 .mu.g,
300 .mu.g, 400 .mu.g, 500 .mu.g, 600 .mu.g, 700 .mu.g, 800 .mu.g,
900 .mu.g, 1 ng, 10 ng, 100 ng, 200 ng, 300 ng, 400 ng, 500 ng, 600
ng, 700 ng, 800 ng, 900 ng, 1 mg, 10 mg, 100 mg, 200 mg, 300 mg,
400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1 g, 2 g, 3 g, 4 g,
or 5 g. In some cases, nucleic acid may be at most about 1 pg, 10
pg, 100 pg, 1 pg, 10 pg, 100 pg, 200 pg, 300 pg, 400 pg, 500 pg,
600 pg, 700 pg, 800 pg, 900 pg, 1 .mu.g, 10 pg, 100 ag, 200 ag, 300
ag, 400 ag, 500 ag, 600 ag, 700 ag, 800 ag, 900 ag, 1 ng, 10 ng,
100 ng, 200 ng, 300 ng, 400 ng, 500 ng, 600 ng, 700 ng, 800 ng, 900
ng, 1 mg, 10 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg,
700 mg, 800 mg, 900 mg, 1 g, 2 g, 3 g, 4 g, or 5 g.
[0278] In some embodiments, a non-viral approach of introducing a
CAR and/or TCR sequence to a cell can include electroporation.
Electroporation can be performed using, for example, the Neon.RTM.
Transfection System (ThermoFisher Scientific) or the AMAXA.RTM.
Nucleofector (AMAXA.RTM. Biosystems). Electroporation parameters
may be adjusted to optimize transfection efficiency and/or cell
viability. Electroporation devices can have multiple electrical
wave form pulse settings such as exponential decay, time constant
and square wave. Every cell type has a unique optimal Field
Strength (E) that is dependent on the pulse parameters applied
(e.g., voltage, capacitance and resistance). Application of optimal
field strength causes electropermeabilization through induction of
transmembrane voltage, which allows nucleic acids to pass through
the cell membrane. In some cases, the electroporation pulse
voltage, the electroporation pulse width, number of pulses, cell
density, and tip type may be adjusted to optimize transfection
efficiency and/or cell viability.
[0279] In some embodiments, electroporation pulse voltage may be
varied to optimize transfection efficiency and/or cell viability.
In some cases, the electroporation voltage may be less than about
500 volts. In some cases, the electroporation voltage may be at
least about 500 volts, at least about 600 volts, at least about 700
volts, at least about 800 volts, at least about 900 volts, at least
about 1000 volts, at least about 1100 volts, at least about 1200
volts, at least about 1300 volts, at least about 1400 volts, at
least about 1500 volts, at least about 1600 volts, at least about
1700 volts, at least about 1800 volts, at least about 1900 volts,
at least about 2000 volts, at least about 2100 volts, at least
about 2200 volts, at least about 2300 volts, at least about 2400
volts, at least about 2500 volts, at least about 2600 volts, at
least about 2700 volts, at least about 2800 volts, at least about
2900 volts, or at least about 3000 volts. In some cases, the
electroporation pulse voltage required for optimal transfection
efficiency and/or cell viability may be specific to the cell type.
For example, an electroporation voltage of 1900 volts may optimal
(e.g., provide the highest viability and/or transfection
efficiency) for macrophage cells. In another example, an
electroporation voltage of about 1350 volts may optimal (e.g.,
provide the highest viability and/or transfection efficiency) for
Jurkat cells or primary human cells such as T cells. In some cases,
a range of electroporation voltages may be optimal for a given cell
type. For example, an electroporation voltage between about 1000
volts and about 1300 volts may optimal (e.g., provide the highest
viability and/or transfection efficiency) for human 578T cells. In
some cases, a primary cell can be a primary lymphocyte. In some
cases, a population of primary cells can be a population of
lymphocytes.
[0280] In some embodiments, electroporation pulse width may be
varied to optimize transfection efficiency and/or cell viability.
In some cases, the electroporation pulse width may be less than
about 5 milliseconds. In some cases, the electroporation width may
be at least about 5 milliseconds, at least about 6 milliseconds, at
least about 7 milliseconds, at least about 8 milliseconds, at least
about 9 milliseconds, at least about 10 milliseconds, at least
about 11 milliseconds, at least about 12 milliseconds, at least
about 13 milliseconds, at least about 14 milliseconds, at least
about 15 milliseconds, at least about 16 milliseconds, at least
about 17 milliseconds, at least about 18 milliseconds, at least
about 19 milliseconds, at least about 20 milliseconds, at least
about 21 milliseconds, at least about 22 milliseconds, at least
about 23 milliseconds, at least about 24 milliseconds, at least
about 25 milliseconds, at least about 26 milliseconds, at least
about 27 milliseconds, at least about 28 milliseconds, at least
about 29 milliseconds, at least about 30 milliseconds, at least
about 31 milliseconds, at least about 32 milliseconds, at least
about 33 milliseconds, at least about 34 milliseconds, at least
about 35 milliseconds, at least about 36 milliseconds, at least
about 37 milliseconds, at least about 38 milliseconds, at least
about 39 milliseconds, at least about 40 milliseconds, at least
about 41 milliseconds, at least about 42 milliseconds, at least
about 43 milliseconds, at least about 44 milliseconds, at least
about 45 milliseconds, at least about 46 milliseconds, at least
about 47 milliseconds, at least about 48 milliseconds, at least
about 49 milliseconds, or at least about 50 milliseconds. In some
cases, the electroporation pulse width required for optimal
transfection efficiency and/or cell viability may be specific to
the cell type. For example, an electroporation pulse width of 30
milliseconds may optimal (e.g., provide the highest viability
and/or transfection efficiency) for macrophage cells. In another
example, an electroporation width of about 10 milliseconds may
optimal (e.g., provide the highest viability and/or transfection
efficiency) for Jurkat cells. In some cases, a range of
electroporation widths may be optimal for a given cell type. For
example, an electroporation width between about 20 milliseconds and
about 30 milliseconds may optimal (e.g., provide the highest
viability and/or transfection efficiency) for human 578T cells.
[0281] In some embodiments, the number of electroporation pulses
may be varied to optimize transfection efficiency and/or cell
viability. In some cases, electroporation may comprise a single
pulse. In some cases, electroporation may comprise more than one
pulse. In some cases, electroporation may comprise 2 pulses, 3
pulses, 4 pulses, 5 pulses 6 pulses, 7 pulses, 8 pulses, 9 pulses,
or 10 or more pulses. In some cases, the number of electroporation
pulses required for optimal transfection efficiency and/or cell
viability may be specific to the cell type. For example,
electroporation with a single pulse may be optimal (e.g., provide
the highest viability and/or transfection efficiency) for
macrophage cells. In another example, electroporation with a 3
pulses may be optimal (e.g., provide the highest viability and/or
transfection efficiency) for primary cells. In some cases, a range
of electroporation widths may be optimal for a given cell type. For
example, electroporation with between about 1 to about 3 pulses may
be optimal (e.g., provide the highest viability and/or transfection
efficiency) for human cells.
[0282] In some cases, the starting cell density for electroporation
may be varied to optimize transfection efficiency and/or cell
viability. In some cases, the starting cell density for
electroporation may be less than about 1.times.105 cells. In some
cases, the starting cell density for electroporation may be at
least about 1.times.10.sup.5 cells, at least about 2.times.10.sup.5
cells, at least about 3.times.10.sup.5 cells, at least about
4.times.10.sup.5 cells, at least about 5.times.10.sup.5 cells, at
least about 6.times.10.sup.5 cells, at least about 7.times.10.sup.5
cells, at least about 8.times.10.sup.5 cells, at least about
9.times.10.sup.5 cells, at least about 1.times.10.sup.6 cells, at
least about 1.5.times.10.sup.6 cells, at least about
2.times.10.sup.6 cells, at least about 2.5.times.10.sup.6 cells, at
least about 3.times.10.sup.6 cells, at least about
3.5.times.10.sup.6 cells, at least about 4.times.10.sup.6 cells, at
least about 4.5.times.10.sup.6 cells, at least about
5.times.10.sup.6 cells, at least about 5.5.times.10.sup.6 cells, at
least about 6.times.10.sup.6 cells, at least about
6.5.times.10.sup.6 cells, at least about 7.times.10.sup.6 cells, at
least about 7.5.times.10.sup.6 cells, at least about
8.times.10.sup.6 cells, at least about 8.5.times.10.sup.6 cells, at
least about 9.times.10.sup.6 cells, at least about
9.5.times.10.sup.6 cells, at least about 1.times.10.sup.7 cells, at
least about 1.2.times.10.sup.7 cells, at least about
1.4.times.10.sup.7 cells, at least about 1.6.times.10.sup.7 cells,
at least about 1.8.times.10.sup.7 cells, at least about
2.times.10.sup.7 cells, at least about 2.2.times.10.sup.7 cells, at
least about 2.4.times.10.sup.7 cells, at least about
2.6.times.10.sup.7 cells, at least about 2.8.times.10.sup.7 cells,
at least about 3.times.10.sup.7 cells, at least about
3.2.times.10.sup.7 cells, at least about 3.4.times.10.sup.7 cells,
at least about 3.6.times.10.sup.7 cells, at least about
3.8.times.10.sup.7 cells, at least about 4.times.10.sup.7 cells, at
least about 4.2.times.10.sup.7 cells, at least about
4.4.times.10.sup.7 cells, at least about 4.6.times.10.sup.7 cells,
at least about 4.8.times.10.sup.7 cells, or at least about
5.times.10.sup.7 cells. In some cases, the starting cell density
for electroporation required for optimal transfection efficiency
and/or cell viability may be specific to the cell type. For
example, a starting cell density for electroporation of
1.5.times.10.sup.6 cells may optimal (e.g., provide the highest
viability and/or transfection efficiency) for macrophage cells. In
another example, a starting cell density for electroporation of
5.times.10.sup.6 cells may optimal (e.g., provide the highest
viability and/or transfection efficiency) for human cells. In some
cases, a range of starting cell densities for electroporation may
be optimal for a given cell type. For example, a starting cell
density for electroporation between of 5.6.times.10.sup.6 and
5.times.10.sup.7 cells may optimal (e.g., provide the highest
viability and/or transfection efficiency) for human cells such as T
cells.
[0283] A method for treating a lymphoid malignancy is provided. The
method can comprise administering to a patient in need thereof a
population of engineered immune cells. An individual engineered
immune cell of the population can comprise one or more chimeric
antigen receptors (CARs) comprising a binding moiety, where the
binding moiety can comprise an antigen binding domain capable of
binding to an immune cell antigen, and where each CAR of the one or
more CARs can further comprise a transmembrane domain and an
intracellular signaling domain. An individual engineered immune
cell of the population can further comprise an enhancer moiety
capable of enhancing one or more activities of the engineered
immune cell. An endogenous T cell receptor (TCR) of the engineered
immune cell may be inactivated. In some cases, the number of
affected cells in peripheral blood or the number of affected cells
in bone marrow of the patient can be reduced by at least about 10%,
15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%,
80%, 85%, 90%, 95% or more within a period (e.g., 3 weeks) after a
last dosing of the engineered immune cells. In some cases, the
period after a last dosing of the engineered immune cell can be
about 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks or more. The
number of any one or more of autologous T cell, granulocyte, and NK
cell in peripheral blood of the patient can start to increase
within a period (e.g., 3 weeks) after a last dosing of the
engineered immune cells. In some cases, the period after a last
dosing of the engineered immune cell can be about 1 week, 2 weeks,
3 weeks, 4 weeks, 5 weeks or more.
[0284] The enhancer moiety can enhance one or more activities of
the engineered immune cell. The enhancer moiety can be configured
to constitutively enhance the one or more activities of the
engineered immune cell. The enhancer moiety can be configured to
constitutively upregulate one or more intracellular signaling
pathways of the engineered immune cell. The one or more
intracellular signaling pathways can be one or more cytokine
signaling pathways. The enhancer moiety can be a cytokine or a
cytokine receptor. The enhancer moiety can be selected from the
group consisting of IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10,
IL-11, IL-12, IL-15, IL-17, IL-18, IL-21, IL-23, PD-1, PD-L1,
CD122, CSF1R, CTAL-4, TIM-3, CCL21, CCL19, TGFR beta, receptors for
the same, functional fragments thereof, functional variants
thereof, and combinations thereof.
[0285] The engineered immune cell can further comprise an inducible
cell death moiety capable of effecting death of the cell upon
contacting the inducible cell death moiety with a cell death
activator. The inducible cell death moiety can be selected from the
group consisting of rapaCasp9, iCasp9, HSV-TK, ACD20, mTMPK, ACD19,
RQR8, Her2t, CD30, BCMA, and EGFRt. For example, the inducible cell
death moiety can be EGFRt, and the cell death activator can be an
antibody or an antigen binding fragment thereof that binds EGFRt.
For another example, the inducible cell death moiety can be HSV-TK,
and the cell death activator can be GCV. For another example, the
inducible cell death moiety can be iCasp9, and the cell death
activator can be AP1903.
[0286] A gene encoding an endogenous surface marker of the cell can
be inactivated. The endogenous surface marker can be capable of
binding to the first antigen binding domain when expressed. The
endogenous surface marker can be CD2, CD3, CD4, CD5, CD7, CD8,
CD16a, CD16b, CD25, CD27, CD28, CD30, CD38, CD45, CD48, CD50, CD52,
CD56, CD57, CD62L, CD69, CD94, CD100, CD102, CD122, CD127, CD132,
CD137, CD160, CD161, CD178, CD218, CD226, CD244, CD159a (NKG2A),
CD159c (NKG2C), NKG2E, CD279, CD314 (NKG2D), CD305, CD335 (NKP46),
CD337, CD319 (CS1), TCR.alpha., TCR.beta. or SLAMF7.
[0287] The number of any one or more of autologous T cell,
granulocyte, and NK cell in peripheral blood of the patient may
start to increase before the number of affected cells in peripheral
blood or the number of affected cells in bone marrow is reduced by
at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%,
60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more. The number of any
one or more of autologous T cell, granulocyte, and NK cell in
peripheral blood may start to increase after the number of affected
cells in peripheral blood or the number of affected cells in bone
marrow is reduced by at least about 10%, 15%, 20%, 25%, 30%, 35%,
40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or
more.
EXAMPLES
Example 1 Study of the U-CAR T Cells Expressing CD3+ CD19 Dual CAR
and EGFRt Switch with TCR Knockout
General Materials and Methods
[0288] Isolation of Peripheral Blood Mononuclear Cells (PBMCs) from
Donor Blood and Expansion of T Cells
[0289] Peripheral blood mononuclear cells (PBMCs) were isolated
from donor blood by using Histopaque-1077 (Sigma-Aldrich) through
density gradient centrifuge. Then T cells were enriched, activated
by magnetic beads coupled with anti-CD3/anti-CD28, cultured and
expanded.
[0290] Cell Lines and the Culture of PBMCs
[0291] Rap cells (Burkitt's lymphoma cells, ATCC-CCL86);
[0292] K562 cells (Human erythroleukemia cell line,
ATCC-CCL243);
[0293] Raji-ffluc cell line (obtained by screening Raji cells
transfected with lentivirus having firefly luciferase);
[0294] 293T cells (ATCC-CRL3216).
[0295] Raji cells, K562 cells and Raji-ffluc cell line were
cultured in RPMI1640 medium, and 293T cells were cultured in DMEM
medium. Both RPMI1640 and DMEM were supplemented with 10% (v/v)
fetal bovine serum and 100 U/ml penicillin and streptomycin, 2 mM
glutamine and 1 mM sodium pyruvate. All of the cells were cultured
in an incubator at 37.degree. C., 5% Co.sub.2.
[0296] T cells and the obtained CAR-T cells were cultured in
X-vivo15 medium (containing 5% FBS, 2 mM L-glutamine, 1 mM sodium
pyruvate and 300 IU/ml rhIL2). The culture medium for CAR-T cells
was further supplemented with rhIL-2 (ThermoFisher Scientific) at a
final concentration of 300 IU/ml every two days. All of the cells
were cultured in an incubator at 37.degree. C., 5% CO.sub.2.
1.1 Design of CAR and Package of the Virus
[0297] The structure of the chimeric antigen receptor is EGFRt-CD3
scFv-CD19 scFv-Hinge-TM-CD28-CD3.zeta. (tandem), tEGFR-CD19
scFv-CD28-CD3.zeta.-CD3 scFv-41BB-CD3.zeta. (Parallel), tEGFR-CD3
scFv-CD19 scFv41BB-CD3.zeta. (Tandem), and
CD19VL-CD3VL-CD3VH-CD19VH-41BB-CD3.zeta. (Loop), wherein EGFRt (or
tEGFR) is a truncated EGFR as a switch, CD3 scFv fragment is the
heavy chain and light chain variable region of monoclonal antibody
OKT3 or UCHT1 (connected by a GS linker), CD 19 scFv fragment is
the heavy chain and light chain variable region of monoclonal
antibody FMC63 (connected by a GS linker) containing a beacon
sequence for CAR detection, and also included are hinge region,
transmembrane region, human CD 28 intracellular co-stimulatory
element and human CD3.zeta. intracellular region in tandem. An
example construct of the chimeric antigen receptor is shown in FIG.
1.
[0298] The amino acid sequence of EGFRt-OKT3-FMC63-CD28z (SEQ ID
NO.: 1) is as set forth below:
TABLE-US-00001 ##STR00001##
[0299] In the EGFRt-OKT3-FMC63-CD28z amino acid sequence, the
underlined part is the safety switch signal peptide region, the
italic part is tEGFR, the italic underlined part is tEGFR TM, the
curve underlined part is P2A, the italic curve underlined part is
CAR signal peptide, the bold part is OKT3 VH, the dashed underlined
part is a linking peptide, the bold underlined part is OKT3 VL, the
bold italic part is FMC63 VL, the bold italic underlined part is
FMC63 VH, the boxed part is CD28 hinge region transmembrane region
and costimulatory domain, and the boxed italic part is CD3z.
[0300] The nucleotide acid sequence of EGFRt-OKT3-FMC63-CD28z is as
set forth in SEQ ID NO.: 2.
TABLE-US-00002 SEQ ID NO.: 2:
ATGTTGCTCCTTGTGACGAGCCTCCTGCTCTGCGAGCTGCCCCATCCAGC
CTTCCTCCTCATCCCGCGGAAGGTGTGCAATGGCATAGGCATTGGCGAGT
TTAAAGATTCTCTGAGCATAAATGCTACGAATATTAAGCATTTCAAGAAT
TGTACTTCTATTAGTGGCGACCTCCATATTCTTCCGGTTGCCTTCAGGGG
TGACTCTTTCACCCACACACCTCCATTGGATCCACAAGAACTTGACATCC
TGAAGACGGTTAAAGAGATTACAGGCTTCCTCCTTATCCAAGCGTGGCCC
GAGAACAGAACGGACTTGCACGCCTTTGAGAACCTCGAAATAATACGGGG
TCGGACGAAGCAACACGGCCAATTTAGCCTTGCGGTTGTTAGTCTGAACA
TTACTTCTCTCGGCCTTCGCTCTTTGAAAGAAATCAGCGACGGAGATGTC
ATCATTAGTGGAAACAAGAACCTGTGCTACGCGAACACAATCAACTGGAA
GAAGCTCTTCGGTACTTCAGGCCAAAAGACAAAGATTATTAGTAACAGAG
GAGAGAATAGCTGTAAGGCTACCGGACAAGTTTGTCACGCCTTGTGTAGT
CCAGAGGGTTGCTGGGGACCGGAACCAAGGGATTGCGTCAGTTGCCGGAA
CGTGAGTCGCGGACGCGAGTGTGTGGATAAGTGCAATCTTCTGGAAGGGG
AACCGCGAGAGTTTGTAGAAAATTCCGAATGTATACAGTGTCATCCCGAG
TGTCTTCCACAAGCAATGAATATCACATGTACAGGGAGGGGTCCTGATAA
CTGTATCCAATGTGCACACTACATAGATGGTCCTCACTGTGTAAAGACGT
GCCCCGCCGGAGTAATGGGTGAAAACAACACCCTCGTGTGGAAGTACGCC
GATGCCGGGCATGTCTGTCATTTGTGTCATCCCAACTGCACATATGGCTG
TACCGGTCCTGGATTGGAGGGCTGTCCAACAAACGGGCCGAAAATACCGA
GTATCGCAACAGGCATGGTGGGAGCACTTTTGCTTCTCCTCGTTGTCGCC
CTGGGCATCGGCTTGTTCATGCGAGCTAAACGAGGCTCAGGCGCGACGAA
CTTTAGTTTGCTGAAGCAAGCTGGGGATGTAGAGGAAAATCCGGGTCCCA
TGGCCCTTCCAGTGACAGCCTTGTTGTTGCCACTTGCTCTGCTGCTCCAC
GCTGCGCGGCCACAGGTCCAGTTGCAGCAGTCAGGCGCCGAATTGGCGCG
ACCAGGGGCAAGCGTAAAGATGAGCTGTAAGGCATCCGGGTACACGTTCA
CTCGCTATACCATGCATTGGGTTAAACAACGGCCTGGGCAGGGCCTTGAG
TGGATTGGGTATATCAACCCATCCCGGGGCTACACTAACTATAATCAAAA
GTTTAAAGATAAAGCAACCCTTACGACCGACAAATCATCTTCTACCGCAT
ACATGCAGCTCAGCTCCCTCACCAGTGAAGATTCTGCCGTTTATTATTGT
GCACGATACTATGACGATCACTATTGCCTGGACTACTGGGGTCAAGGCAC
CACACTTACTGTCAGTTCCGGAAGTACCAGTGGGGGAGGTTCTGGCGGTG
GCAGCGGGGGTGGGGGTAGCTCACAAATCGTGCTGACCCAGAGTCCCGCT
ATCATGAGCGCCTCCCCAGGGGAAAAGGTGACGATGACATGCTCAGCCAG
CTCCAGTGTATCCTACATGAATTGGTATCAACAGAAGAGTGGGACGTCAC
CCAAAAGATGGATTTATGACACCAGCAAATTGGCCAGCGGAGTACCAGCG
CATTTCAGAGGCAGTGGGAGTGGAACATCTTATTCTCTCACCATTAGCGG
CATGGAAGCAGAGGATGCAGCAACGTACTATTGTCAACAATGGAGCTCTA
ATCCCTTTACGTTCGGCAGCGGCACTAAGCTCGAAATTAATAGGGGTGGC
GGCGGCTCCGGCGGTGGCGGGTCTGGAGGTGGGGGCAGTGACATCCAGAT
GACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCA
TCAGTTGCAGGGCAAGTCAGGACATTAGTAAATATTTAAATTGGTATCAG
CAGAAACCAGATGGAACTGTTAAACTCCTGATCTACCATACATCAAGATT
ACACTCAGGAGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGAACAGATT
ATTCTCTCACCATTAGCAACCTGGAGCAAGAAGATATTGCCACTTACTTT
TGCCAACAGGGTAATACGCTTCCGTACACGTTCGGAGGGGGGACTAAGTT
GGAAATAACAGGCTCCACCTCTGGATCCGGCAAGCCCGGATCTGGCGAGG
GATCCACCAAGGGCGAGGTGAAACTGCAGGAGTCAGGACCTGGCCTGGTG
GCGCCCTCACAGAGCCTGTCCGTCACATGCACTGTCTCAGGGGTCTCATT
ACCCGACTATGGTGTAAGCTGGATTCGCCAGCCTCCACGAAAGGGTCTGG
AGTGGCTGGGAGTAATATGGGGTAGTGAAACCACATACTATAATTCAGCT
CTCAAATCCAGACTGACCATCATCAAGGACAACTCCAAGAGCCAAGTTTT
CTTAAAAATGAACAGTCTGCAAACTGATGACACAGCCATTTACTACTGTG
CCAAACATTATTACTACGGTGGTAGCTATGCTATGGACTACTGGGGTCAA
GGAACCTCAGTCACCGTCTCCTCAGCGGCCGCAGACTACAAAGACGATGA
CGACAAGATTGAAGTTATGTATCCTCCTCCTTACCTAGACAATGAGAAGA
GCAATGGAACCATTATCCATGTGAAAGGGAAACACCTTTGTCCAAGTCCC
CTATTTCCCGGACCTTCTAAGCCCTTTTGGGTGCTGGTGGTGGTTGGGGG
AGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCT
GGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATG
ACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCC
ACCACGCGACTTCGCAGCCTATCGCTCCAGAGTGAAGTTCAGCAGGAGCG
CAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTC
AATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCG
GGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCC
TGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATT
GGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCA
GGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGG
CCCTGCCCCCTCGCTAA
[0301] The amino acid sequence of EGFRt-UCHT1-FMC63-CD28z (SEQ ID
NO.: 3) is as set forth below:
TABLE-US-00003 ##STR00002##
[0302] In the amino acid sequence of EGFRt-UCHT1-FMC63-CD28z, the
underlined part is the safety switch signal peptide (GMCSFR-L), the
italic part is tEGFR, the italic underlined part is tEGFR TM, the
curve underlined part is P2A, the italic curve underlined part is
CAR signal peptide (CD8 L), the bold part is UCHT1 VL, the dashed
underlined part is the linking peptide, the bold underlined part is
UCHT1 VH, the bold italic part is FMC63 VH, the bold italic
underlined part is FMC63 VL, the boxed part is CD28 hinge region
transmembrane region and costimulatory domain, and the boxed italic
part is CD3z.
[0303] The nucleotide acid sequence of EGFRt-UCHT1-FMC63-CD28z is
as set forth in SEQ ID NO.: 4.
TABLE-US-00004 SEQ ID NO.: 4:
ATGCTGCTGCTCGTGACATCCCTCTTATTATGCGAACTCCCTCACCCCGC
TTTTCTGCTGATCCCCAGAAAGGTGTGCAACGGCATCGGCATTGGAGAGT
TCAAGGATTCTTTAAGCATCAACGCTACCAACATCAAACATTTCAAGAAC
TGTACCTCCATTTCCGGCGATTTACACATCCTCCCCGTTGCCTTTCGTGG
CGATAGCTTCACACACACACCCCCTCTGGACCCTCAAGAACTGGACATTT
TAAAGACCGTGAAGGAGATCACTGGTTTTTTACTGATCCAAGCTTGGCCC
GAAAATAGGACAGATCTCCACGCTTTCGAGAATTTAGAGATCATTCGTGG
CAGAACCAAGCAGCACGGACAGTTCTCTTTAGCCGTCGTGTCTTTAAATA
TCACCTCTTTAGGTTTAAGATCTTTAAAAGAGATCAGCGATGGCGACGTC
ATCATCTCCGGCAACAAGAACCTCTGTTACGCCAACACCATTAATTGGAA
AAAGCTGTTTGGCACCTCCGGACAGAAGACCAAGATCATCAGCAACAGAG
GCGAGAACAGCTGCAAAGCTACCGGCCAAGTTTGCCACGCTCTGTGTAGC
CCCGAAGGCTGCTGGGGACCCGAACCTCGTGACTGTGTGAGCTGTAGGAA
CGTGTCTCGTGGTCGTGAGTGTGTGGATAAGTGCAATTTACTCGAGGGCG
AGCCCAGAGAGTTTGTGGAAAATAGCGAGTGCATCCAGTGCCACCCCGAA
TGTCTGCCCCAAGCTATGAACATTACTTGTACTGGTCGTGGCCCCGATAA
CTGTATCCAGTGCGCTCACTACATTGACGGCCCCCACTGCGTCAAGACAT
GCCCCGCTGGCGTGATGGGAGAAAACAACACACTGGTGTGGAAGTATGCC
GATGCCGGCCACGTCTGTCATCTGTGCCACCCTAACTGTACCTACGGCTG
TACCGGACCCGGACTGGAGGGCTGTCCCACCAACGGACCCAAGATCCCTA
GCATCGCCACCGGCATGGTGGGAGCCTTACTGCTGTTACTGGTGGTGGCT
CTGGGCATTGGTTTATTCATGAGGGCCAAGAGAGGATCCGGCGCCACCAA
CTTTTCTTTACTGAAACAAGCTGGAGACGTCGAGGAAAACCCCGGACCCA
TGGCTCTCCCCGTGACAGCTCTGCTGCTGCCTCTCGCTTTATTACTGCAC
GCCGCTAGGCCCGATATTCAGATGACCCAAAGCCCTAGCTCTTTATCCGC
CAGCGTCGGAGATAGAGTCACAATCACTTGTAGAGCCAGCCAAGATATTC
GTAATTATCTCAACTGGTACCAGCAGAAGCCCGGTAAAGCCCCCAAGCTG
CTCATCTATTACACCTCTCGTCTGGAGAGCGGCGTGCCTTCCAGATTCAG
CGGCTCCGGCAGCGGCACCGACTATACACTCACCATTAGCTCTTTACAGC
CCGAAGATTTCGCTACCTACTACTGCCAGCAAGGTAATACTTTACCTTGG
ACCTTCGGCCAAGGTACCAAGGTCGAAATCAAGGGCGGCGGCGGATCCGG
CGGCGGTGGATCTGGTGGCGGCGGCTCCGAAGTCCAGCTGGTCGAATCCG
GAGGCGGACTGGTCCAGCCCGGTGGATCCCTCAGACTGAGCTGCGCCGCT
AGCGGCTATTCCTTCACCGGCTACACCATGAACTGGGTGAGACAAGCTCC
CGGCAAAGGACTGGAATGGGTGGCCCTCATCAACCCCTACAAGGGCGTGT
CCACATATAATCAAAAGTTTAAGGACAGATTCACCATCAGCGTCGACAAG
TCCAAGAACACCGCTTATTTACAGATGAACTCTTTAAGAGCTGAGGATAC
CGCCGTGTACTATTGTGCTAGGTCCGGCTACTACGGCGACAGCGACTGGT
ATTTTGACGTCTGGGGACAAGGTACCCTCGTGACAGTGAGCAGCGGCGGT
GGCGGTTCTGGCGGCGGAGGCTCCGGAGGAGGCGGCAGCGAGGTGAAGCT
GCAAGAAAGCGGACCCGGTCTCGTGGCTCCCTCCCAATCTTTATCCGTGA
CTTGTACCGTGTCCGGAGTCTCTTTACCCGACTACGGCGTGAGCTGGATT
AGACAGCCCCCCAGAAAAGGTTTAGAGTGGCTGGGCGTGATCTGGGGATC
CGAGACCACATACTACAACAGCGCTTTAAAGTCTCGTCTGACAATCATCA
AAGACAATTCCAAAAGCCAAGTTTTCCTCAAGATGAACTCTTTACAGACC
GACGACACAGCCATTTACTACTGCGCCAAGCATTATTACTACGGCGGCAG
CTACGCTATGGACTACTGGGGCCAAGGTACAAGCGTCACAGTGAGCTCCG
GCAGCACATCCGGAAGCGGAAAGCCCGGCAGCGGAGAGGGCAGCACAAAG
GGAGACATCCAGATGACCCAGACCACCTCCTCTTTAAGCGCCTCTTTAGG
AGATAGGGTGACCATTAGCTGCAGAGCCTCCCAAGACATCAGCAAGTATC
TCAATTGGTACCAGCAAAAGCCCGATGGCACCGTCAAGCTGCTGATCTAC
CACACCTCTCGTCTCCATTCCGGCGTGCCCAGCAGATTTAGCGGAAGCGG
ATCCGGAACAGACTATTCTTTAACAATCAGCAATTTAGAGCAAGAAGACA
TCGCCACATATTTCTGCCAACAAGGTAACACTTTACCCTACACCTTCGGA
GGCGGCACCAAACTGGAGATTACAGCGGCCGCAGACTACAAAGACGATGA
CGACAAGATTGAAGTTATGTATCCTCCTCCTTACCTAGACAATGAGAAGA
GCAATGGAACCATTATCCATGTGAAAGGGAAACACCTTTGTCCAAGTCCC
CTATTTCCCGGACCTTCTAAGCCCTTTTGGGTGCTGGTGGTGGTTGGGGG
AGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCT
GGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATG
ACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCC
ACCACGCGACTTCGCAGCCTATCGCTCCAGAGTGAAGTTCAGCAGGAGCG
CAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTC
AATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCG
GGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCC
TGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATT
GGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCA
GGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGG
CCCTGCCCCCTCGCTAA
[0304] The CAR gene was cloned into the FUW lentiviral vector
backbone under the promoter of EF1.alpha. (EF-1.alpha.) to form
Fuw-EF1.alpha.-CAR. Fuw-EF1.alpha.-CAR, lentiviral envelope plasmid
pMD2.G (Addgene, Plasmid #12259) and lentiviral packaging plasmid
psPAX2 (Addgene, Plasmid #12260) were transfected into 293 T cells
by using Lipofectamine3000 to prepare the whole lentiviral
expression vector. The supernatant was collected at 48 and 72 h and
subject to ultra-centrifuge (Merck Millipore) for concentration.
The concentrated virus was ready for the transfection of T
cells.
[0305] The result shows that the lentiviral vector was successfully
constructed and expression of EGFRt and CD19+CD3 CAR were both
detected as expected.
1.2 Design and Construction of CRISPR
[0306] First, gRNA sequences targeting the first exon of the TCR
conserved region were designed at http://crispr.mit.edu, and two
gRNA sequences with scores above 80 were selected for higher
knockout efficiency. For the gRNA primer, the forward primer
comprises a T7 promotor followed by 20 bp of the target sequence,
and the reverse primer has 20 bp of the complementary sequence.
pX330 plasmid was used as the PCR template. After purification,
T7-PCR product was further used as the template for MEGAshortscript
T7 kit to obtain RNA. The RNA was purified with a MEGAclear column
and eluted with RNA-free water. Cas9 plasmid was purchased from
Addgene.
[0307] The gRNA targeting sequences are as below:
TABLE-US-00005 TRAC-gRNA: TGTGCTAGACATGAGGTCTA,; SEQ ID NO: 5
[0308] Meanwhile, the knockout efficiency of the gRNA was analyzed
by Surveyor assay, TIDE.
1.3 Preparation of CAR-T Cells
[0309] Cell Isolation and Activation
[0310] After apheresis, monocytes were isolated by using
Histopaque-1077 (Sigma-Aldrich) through density gradient
centrifugation. Then T cells were enriched, activated by magnetic
beads coupled with anti-CD3/anti-CD28, cultured and expanded.
[0311] X-vivo 15 with 5% FBS, 2 mM L-glutamine, 1 mM sodium
pyruvate and 300 IU/ml rhIL2 was used as CAR-T cell medium. The
cells were incubated and cultured at 37.degree. C., 5%
CO.sub.2.
[0312] Cell line expressing CD 19: Raji (Burkitt's lymphoma cell
line, ATCC-CCL86); K562 cells (Human erythroleukemia cell line,
ATCC-CCL243); Raji-ffluc cell line was obtained by screening Raji
cells transfected with lentivirus having firefly luciferase;
[0313] Cell line expressing CD3: Jurkat cell.
[0314] All of the cells were cultured in RPMI1640 medium and 293T
cells (ATCC-CRL3216) were cultured in DMEM medium. Both RPMI1640
and DMEM were supplemented with 10% (v/v) fetal bovine serum and
100 U/ml penicillin and streptomycin, 2 mM glutamine and 1 mM
sodium pyruvate.
[0315] Electroporation
[0316] Two days after enriching and activating T cells, the
anti-CD3/anti-CD28 magnetic beads and the cells were collected into
a tube and subject to centrifuge at 300 g for 5 min, and then
washed twice with DPBS and re-suspended in opti-mem at a cell
density of 1-3.times.10.sup.8/ml. The amount of cas9/gRNA required
was calculated based on the density of the cells, 30 .mu.g/ml each.
Cas9 and gRNA were 1:1 mixed, and incubated at room temperature for
10 mins and then transferred to electroporation buffer to further
mix with the cells for electroporation by 4D-Nucleofector System N
(Lonza) system. Then the cells were re-suspended in a pre-warmed
medium to a density of 1-2.times.10.sup.6/ml, transferred to a
plate and then cultured in an incubator at 37.degree. C., 5%
CO.sub.2.
[0317] Lentiviral Transfection
[0318] 1 day after electroporation, the cells were transfected by
lentiviral vector at MOI of 2-8, transferred to a flask and
cultured at 37.degree. C., 5% Co.sub.2.
[0319] Cell Proliferation and Detection of CAR Positive Ratio
[0320] 3 days after the transfection, the number of cells and CAR
positive cells were detected, and the positive ratio of CAR in T
cells was calculated. The positive ratio of CD3 and PD1 was also
detected to determine the knockout efficiency. Then the cells were
continuously cultured in the incubator and half of the medium was
replaced every 2-3 days till day 14, when the cells were ready for
cryopreservation. An example workflow is shown in FIG. 2.
[0321] FIG. 3 shows flow cytometry data of fractions of the
engineered immune cells expressing dual-CARs or control cells with
or without specified markers. For example, CD3 can be a marker
indictive of endogenous TCR knockout efficiency, 3CAR (CAR
targeting CD3) can be a marker indictive of CAR-T cells targeting
CD3, 19CAR (CAR targeting CD19) can be a marker indicative of CAR-T
cells targeting CD19, and EGFR can be a marker indictive of CAR-T
expressing EGFRt. FIG. 4 shows another flow cytometry data of
fractions of the engineered immune cells expressing dual-CARs or
control cells with or without specified markers. In FIG. 4, the CAR
targeting CD19 was a scFv of monoclonal antibody FMC63, and the CAR
targeting CD3 was a scFv of monoclonal antibody OKT3 or UCHT1. The
result shows that positive ratio of EGFR and CAR and negative ratio
of CD3 were high in the prepared EGFRt-CD3-CD19 CAR-T cells,
indicating the gene knockout dual CAR-T cells (e.g.,
parallel-EGFRt) with safety switch (e.g., EGFRt) were successfully
prepared.
1.4 Release of the Cytokines
[0322] The dual CAR-T cells prepared in Example 1.3 and CD19
positive tumor cells (Raji), CD3 positive tumor cells (Jurkat) or
primary allogeneic PBMCs, 100 ul each, were mixed in RPMI medium at
1:1 ratio to a density of 1.times.10.sup.6/ml for each cell, and
then cultured overnight in a 96-well plate. The medium was then
collected and subject to centrifuge and the released cytokine
IFN-.gamma. and IL-2 were detected by Cytokine bead array kit (CBA
kit, BD Biosciences).
[0323] The result shows that co-incubation of EGFRt-CD3-CD19 CAR-T
cells with Raji, Jurkat or primary allogeneic PBMCs produce a large
amount of IFN-.gamma. and IL-2, indicating function of CAR-T
against CD19 positive or CD3 positive target cells.
1.5 In Vitro Killing Activity
[0324] A stably transfected cell line was obtained by introducing
the luciferase gene into the target cell followed by screening.
After adding fluorescein, luciferase could react with the
fluorescein to produce fluorescence. By detecting the intensity of
the fluorescence, the activity of luciferase can be measured, and
the survival of the cells can be detected so that to evaluate the
killing effect of CART cells.
[0325] FIG. 5A shows bar-graphs of cytotoxicity of CAR-T cells,
including CAR-T cells targeting CD3 with scFv of monoclonal
antibody OKT3 or UCHT1, dual-specific CAR-T cells targeting CD19
and CD3 (para193-O and para193-U), CD19 CAR with endogenous TCR
knocked out (TCR KO CD19 CAR), and T cells controls with endogenous
TCR knocked out (TCR KO T cell control), toward CD19+ NALM6-Luc
cells and CD3+ Jurkat-Luc cells at 1:1 E:T (Effector CAR-T cells to
Target cancer cells) ratio for 6 hours and 24 hours, respectively.
FIG. 5B shows cytotoxicity of CAR-T cells toward Jurket cells
measured from Day 1 to Day3 of co-culture of Jurkat cells and CAR-T
cells at 1:1 E:T ratio. FIG. 5C shows cytotoxicity of CAR-T cells
toward T cells expressing CD3 measured from Day1 to Day 3 of
co-culture of NALM6 cells and CAR-T cells at 1:1 E:T ratio.
[0326] The cytotoxicity of the dual-specific CAR-T cells targeting
CD19 and CD3 (e.g., dual-specific CAR-T cells in parallel form with
scFv from monoclonal antibody UCHT1: GC193-para-U) were also tested
against NALM6-LucG, Jurkat-LucG, Raji, allogeneic NTcells
(non-treated T cells), and autologous NT cells. FIG. 6A shows 40
hour cytotoxicity of CAR-T cells toward NALM6 cells at different
effector: target ratios. FIG. 6B shows 6 hour cytotoxicity of CAR-T
cells toward Jurkat cells at different effector: target ratios.
FIG. 6C shows 40 hour cytotoxicity of CAR-T cells toward Jurkat,
allogeneic NT cells, autologous NT cells, Raji cells, and NALM6
cells. FIG. 7A shows 16 hour cytotoxicity of dual-specific CAR-T
cells in parallel or loop form toward NALM6 cells. CD19-CD3
dual-specific CAR-T cells showed comparable anti-tumor efficacy to
single CD19 CAR-T cells. FIG. 7B shows 16 hour cytotoxicity of
dual-specific CAR-T cells in parallel or loop form toward Jurkat
cells. CD19-CD3 dual-specific CAR-T cells showed comparable
anti-tumor efficacy to single CD3 CAR-T cells. The result shows
that EGFRt-CD3-CD19 CAR-T cells significantly killed Nalm6, Raji,
Jurkat and primary allogeneic PBMCs, indicating the function of
CAR-T against CD19-positive or CD3-positive target cells, and their
capabilities of simultaneous targeting both CD19+ cancer cells and
CD3+ killer T cells.
1.6 In Vivo Efficacy
[0327] 6-12 weeks NOD-Prkdcscid Il2rgnull (NPG) mice were selected
and intraperitoneally injected with 2.times.10.sup.5 Raji-ffluc
cells or Jurkat-ffluc cells, 50 .mu.L DPBS and 50 .mu.L matrigel
matrix (Corning). Two days later, the tumor graft burden of the
mice was measured, and the mice were divided into 4 groups based on
the tumor burden. One day later, 200 .mu.L DPBS, 5.times.10.sup.6
NT cells and 5.times.10.sup.6 EGFRt-CD3-CD19 CAR-T cells were
respectively injected to each mouse. The tumor burden of the mice
was further evaluated 7 days after the CAR-T treatment. Then each
mouse was injected intraperitoneally with 3 mg d-luciferin for a
4-minutes reaction, and subsequently photographed by using a
Xenogen IVIS Imaging System with 30 s exposure.
[0328] The result shows that EGFRt-CD3-CD19 CAR-T significantly
decreased the tumor burden compared to NT cells for tumors from by
both Raji-ffluc and Jurkat-ffluc cells, indicating EGFRt-CD3-CD19
CAR-T can clear CD19 positive or CD3 positive target cells in
vivo.
1.7 In Vivo GVHD Study
[0329] The mice were systemically treated with a sub-lethal dose of
irradiation (175 cGy) first. Then CAR-T cells were re-suspended in
PBS and injected into the thorax of the treated mice. The mice were
observed 2-3 times a week by using GVHD clinical criteria including
weight loss, arch-back, activity, fur texture, and skin
integrity.
[0330] The result shows that mice without TCR knockout showed GVHD
symptoms, however, no GVHD was detected in the EGFRt-CD3-CD19
CAR-T+TCR dual knockout group.
[0331] FIGS. 66A-C show the in vivo GvHD study comparing CD19 CAR-T
vs TCR KO CD19 CAR-T cells. 2e7 CD19 CAR-T or TCR KO CD19 CAR-T
cells were infused into each Raji-tumor bearing NOG mice to compare
GvHD response. Mice from CD19 CAR-T group showed significant CAR-T
expansion along with severe weight loss (>20%), arch-back,
ruffled fur, and early death compared with TCR KO CAR-T cells. No
GVHD was detected in any TCR KO CD19 CAR-T infused mice.
1.8 In Vitro HVG Study
[0332] EGFRt-CD3-CD19 CAR-T+TCR knockout and EGFRt-CD3-CD19
CAR-T+TCR/B2M dual knockout cells were 1:1 incubated with NK cells
overnight to detect apoptosis and cytokine release
(IFN-.gamma.).
[0333] The results show that compared to the control group,
EGFRt-CD3-CD19 CAR-T+TCR knockout group had almost no apoptosis,
and the cytokine released was significantly less, indicating that
the product of the present disclosure will not cause HVG reaction
by NK cells. Meanwhile, the TCR/B2M dual knockout cells were
significantly killed by NK cell and were not able to survive
long.
[0334] HVG can also induce allogeneic T cells against HLA intact
CAR-T cells. FIG. 6C shows that dual CAR-T cells can target
allogeneic T cells within 40 hours, preventing CAR-T rejection by
host allogeneic T cells, which usually takes 72 hours.
1.9 Clearance of EGFRt Gene-Mediated CAR-T Cells
[0335] NK cells were isolated from PBMCs as effector cells, and 1:1
co-cultured with CD19-28z CART or EGFRt-CD3-CD19 CAR-T, with or
without Cetuximab at a final concentration of 10 .mu.g/mL. 4 h and
24 h later, the expression of CD3 and CAR was detected by flow
cytometry.
ADCC percentage=(1-monoclonal antibody group CAR positive ratio/no
antibody group CAR positive ratio)*100%
[0336] The results show that, 4 h and 24 h later, in the presence
of Cetuximab, NK cells significantly cleared EGFRt-CD3-CD19 CAR-T
cells, but failed to clear CD19-28z CART. Without Cetuximab, NK
failed to kill either of the cells. This indicates that Cetuximab
functions as a safety switch, which binds to EGFRt-CD3-CD19 CAR-T,
and allows NK to mediate the ADCC function so that to clear CART
cells.
Example 2 Study of U-CAR-T Cells Expressing CAR19 and the Enhancer
with TCR Knockout
[0337] In this example, 5.times.10.sup.5 Raji-luciferase cells were
grafted into NOG mice by subcutaneous injection and grew till reach
100 mm.sup.3. 1.times.10.sup.6 wildtype or TCR KO CD19 CAR-T cells
were intravenously infused (IV) into Raji grafted mice. Tumor
burden was assessed by caliper measurements of the actual tumor
sizes. CAR-T cell expansion in the peripheral blood was measured by
flow cytometry analysis. FIG. 8A shows tumor burden post CAR-T
treatment. TCR intact CD19 CAR-T cells were able to eliminate
tumors, but TCR KO CD19 CAR-T wasn't able to control Raji tumor
growth. Although both were Raji based tumor bearing models,
subcutaneous model generates solid tumors and has much higher
requirements on CAR-T cell proliferation for controlling the tumors
than intravenous model. FIG. 8B shows CAR-T proliferation in
peripheral blood. TCR KO CAR-T cells showed a proliferation defects
compared to WT CAR-T cells, the peak of CAR-T cell expansion is
much weaker than that of WT cells, which is consistent with their
tumor control effects.
[0338] FIGS. 9A-9C show proliferation of CD19 CAR-T cells with TCR
knockout. FIG. 9A shows an experimental timeline of repeated
stimulations by NALM6 cells and measurements of residual tumor
cells. FIG. 9B shows the proliferation data of CD19 CAR-T cells
with TCR knockout and expression of different enhancers in
comparison to CD19 CAR-T cells without TCR knockout and CD19 CAR-T
cells with TCR knockout but without expression of the enhancers.
Additions of NALM6 cells are indicated by arrows according to the
experimental trimline in FIG. 9A. FIG. 9B shows the clearing
activity of various CD19 CAR-T cells as indicated by the amount of
residual tumor cells measured at the indicated days according to
the experimental timeline in FIG. 9A. Under multiple rounds or
repeated stimulations by NALM6 cells, the CD19 CAR-T cells with TCR
knockout and C7R or IL7 exhibited persistent expansion and enhanced
expansion ability compared with other cells tested in this
experiment.
[0339] FIGS. 10A and 10B show additional proliferation data
comparing expansion ability of engineered CAR-T cells. FIG. 10A
shows proliferation data of CD19 CAR-T cells with TCR knockout and
two different enhancers (C7R and IL2) in comparison to cells
without the expression of the enhancer. The results showed that
under multiple rounds or repeated stimulation by NALM6 cells, CD19
CAR-T cells with TCR knockout and C7R or IL2 exhibited persistent
expansion and enhanced expansion ability compared with the cell
without the expression of any enhancer. FIG. 10B shows
proliferation data of CD7 CAR-T cells with TCR knockout and two
different enhancers (C7R and mbIL15) in comparison to cells without
the expression of the enhancer. The results showed that under
multiple rounds or repeated stimulation by CCRF-CEM cells, CD7
CAR-T cells with TCR knockout and C7R or mbIL15 exhibited
persistent expansion and enhanced expansion ability compared with
the cell without the expression of any enhancer. The cells with the
expression of C7R exhibited better expansion ability than the cells
expressing mbIL15.
[0340] FIG. 11 shows an example of in vivo comparison of enhancers
in TCR KO CD19 CAR-T cells. In this example, 5.times.10.sup.5
Raji-luciferase cells were grafted into NOG mice by intravenous
(IV) injection and grew for 5 days. TCR KO CD19 CAR-T cells (CD19
CAR-T cells with TCR knockout) with/without enhancers as well as
vehicle and T cell controls were intravenously infused (IV) into
Raji grafted mice. Tumor burden was assessed by bioluminescence
intensity (BLI). The TCR KO CD19 CAR-T cells expressing enhancer
C7R, IL7 exhibited the better tumor control in comparison to the
cells without the expression of enhancers or with expression of
mbIL15 or other control cells. FIG. 12 shows corresponding images
of the NOG mice indicating tumor burden assessed by BLI.
Example 3 Study of U-CAR-T Cells Expressing CAR7 and the Enhancer
with TCR and CD 7 Double Knockout, as Well as U-CAR-T Cells
Expressing CD2 CAR and the Enhancer with TCR and CD 2 Double
Knockout
General Materials and Methods
[0341] Isolation of Peripheral Blood Mononuclear Cells (PBMCs) from
Donor Blood and Expansion of T Cells
[0342] Peripheral blood mononuclear cells (PBMCs) were isolated
from donor blood by using Histopaque-1077 (Sigma-Aldrich) through
density gradient centrifuge. Then T cells were enriched, activated
by magnetic beads coupled with anti-CD3/anti-CD28, cultured and
expanded.
[0343] Cell Lines and Culture of T Cells
[0344] CCRF-CEM (T lymphoblast, ATCC.RTM. CCL-119.TM.);
[0345] CCRF-CEM-luc cells (obtained by screening CCRF-CEM cells
transfected with lentivirus having firefly luciferase);
[0346] K562 cells (Human erythroleukemia cell line,
ATCC-CCL243);
[0347] 293T cells (ATCC-CRL3216);
[0348] NK92 cells (ATCC-CRL2407).
[0349] The CCRF-CEM-luc cell line was cultured in RPMI1640 medium,
and 293T cells were cultured in DMEM medium. Both RPMI1640 and DMEM
were supplemented with 10% (v/v) fetal bovine serum and 100 U/ml
penicillin and streptomycin, 2 mM glutamine and 1 mM sodium
pyruvate. All of the cells were cultured in an incubator at
37.degree. C., 5% Co.sub.2.
[0350] NK92 cells were cultured in RPMI1640 medium supplemented
with 10% (v/v) fetal bovine serum, 2 mM glutamine, 1 mM sodium
pyruvate, 1% NEAA, 0.1 mM mercaptoethanol and 200 IU/ml rhIL2.
[0351] T cells and the obtained CAR-T cells were cultured in
X-vivo15 medium (containing 5% FBS, 2 mM L-glutamine, 1 mM sodium
pyruvate and 300 IU/ml rhIL2). The culture medium for CAR-T cells
was further supplemented with rhIL-2 (ThermoFisher Scientific) at a
final concentration of 300 IU/ml every two days. All of the cells
were cultured in an incubator at 37.degree. C., 5% CO.sub.2.
3.1 Design and Construction of CRISPR
[0352] CD7 and TCR gRNAs for gene editing were selected after
evaluating gene editing efficiency and off-target risk at website
http://crispr.mit.edu, www.idtdna.com and https://www.synthego.com.
gRNAs and HiFi-Cas9 protein used in the present disclosure were
purchased from Integrated DNA Technologies, Inc (IDT).
[0353] For gene editing, 3 .mu.g Cas9 protein and 1.5 .mu.g gRNA
were mixed in 20 .mu.l and incubated at 37.degree. C. or room
temperature for 15 minutes to form ribonucleoprotein (RNP). Then
RNP was transfected into T cells by Lonza 4D Nucleofector. Gene
knockout efficiency was determined by the ratio of the cells
expressing the protein as detected by flow cytometry (FACS).
[0354] Our previous study indicated that TRAC-gRNA1 has a higher
knockout efficiency for TCR (the sequence is set forth as SEQ ID
NO.: 20). When gRNA of CD7 and TRAC-gRNA were used together to
knockout CD7 and TCR simultaneously, three of four CD7-gRNAs showed
high efficiencies (as shown in FIG. 16). CD7-gRNA1 (SEQ ID NO.: 34)
was selected as the gRNA to knockout CD7.
TABLE-US-00006 TRAC-gRNA1: TTCGGAACCCAATCACTGAC,; SEQ ID NO 20
CD7-gRNA1: GAGGTCAATGTCTACGGCTC,. SEQ ID NO 25
[0355] The gDNA of CD2 were designed as below, and CD2 gRNA2 showed
the highest CD2 knockout efficiencies (as shown in FIG. 65).
TABLE-US-00007 CD2-gRNA1: CAAAGAGATTACGAATGCCT (SEQ ID NO: 29)
CD2-gRNA2: GTGCCACAAAGACCATCAAG (SEQ ID NO: 30) CD2-gRNA3:
AGAGGGTCATCACACACAAG (SEQ ID NO: 31) CD2-gRNA4:
CTTGTAGATATCCTGATCAT (SEQ ID NO: 32)
3.2 Design of CAR and Cytokine and Package of the Virus
[0356] The structure of the chimeric antigen receptor and the
cytokines are: CAR7, CAR7-mb15 and CAR7-C7R (as shown in FIG. 17).
The nucleotide sequences and amino acid sequences are set forth as
SEQ ID NO.: 35-40.
TABLE-US-00008 CAR7 (SEQ ID NO 35):
atggcactccctgtaactgcacttcttttgccacttgccttgctcctgcacgcagcgcggccggacatc
gagctgacccagagccccgccatcatgagcgccagcctgggcgaggagatcaccctgacctgcagcgcc
agcagcagcgtgagctacatgcactggtaccagcagaagagcggcaccagccccaagctgctgatctac
agcaccagcaacctggccagcggcgtgcccagcaggttcagcggcagcggcagcggcaccttctacagc
ctgaccatcagcagcgtggaggccgaggacgccgccgactactactgccaccagtggagcagctacacc
ttcggcggcggcaccaagctggagatcaagaggggcggcggcggcagcggcggcggcggcagcggcggc
ggcggcagccaggtgaagctgcaggagagcggcggcggcctggtgaagcccggcggcagcctgaagctg
agctgcgccgccagcggcttcaccttcagcagctacgccatgagctgggtgaggcagacccccgagaag
aggctggagtgggtggccaccatcagcagcggcggcagctacacctactaccccgacagcgtgaagggc
aggttcaccatcagcagggacaacgccaagaacaccctgtacctgcagatgagcagcctgaggagcgag
gacaccgccatgtactactgcgccaggcaggacggctactaccccggctggttcgccaactggggccag
ggcaccaccgtgaccgtgagcagctccggaacaacgacaccagcaccacggccacccactcctgctccg
acaattgcgtctcagcccctttcccttcgacccgaagcttgtcgccctgctgcgggaggagcggtccac
acgcgcgggcttgacttcgcttgcgacatctacatttgggcacccttggccgggacatgcggcgtcttg
ctcctgagtctggttataacgctgtattgtaagcgaggtcggaagaagcttttgtatatctttaaacag
ccctttatgaggcccgtacaaaccacacaagaggaggatgggtgctcatgcagatttcctgaagaggaa
gagggcggttgcgaacttagagtcaaattcagccgctccgcagatgcacctgcttataaacagggtcag
aatcaattgtataatgaacttaatctcgggaggcgcgaggagtatgatgtgctggacaagcgacggggt
cgagacccagagatgggcggtaaaccccgccgaaagaacccccaggagggactgtataatgagctgcaa
aaggacaaaatggcagaagcctattccgaaatagggatgaagggagagcggcggcgaggtaagggacat
gacggtctttatcaaggtcttagtactgcaactaaggacacctatgacgcgctgcatatgcaggctctc
ccacctagataa CAR7 (SEQ ID NO 36):
MALPVTALLLPLALLLHAARPDIELTQSPAIMSASLGEEITLTCSASSSVSYMHW
YQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFYSLTISSVEAEDAADYYCHQWSSYT
FGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQESGGGLVKPGGSLKLSCAASGFTFSSY
AMSWVRQTPEKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSED
TAMYYCARQDGYYPGWFANWGQGTTVTVSSSGTTTPAPRPPTPAPTIASQPLSLRPEAC
RPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMR
PVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYD
VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGL
YQGLSTATKDTYDALHMQALPPR CAR7-mb15 (SEQ ID NO 37):
atggcactccctgtaactgcacttcttttgccacttgccttgctcctgcacgcagcgcggccggacatc
gagctgacccagagccccgccatcatgagcgccagcctgggcgaggagatcaccctgacctgcagcgcc
agcagcagcgtgagctacatgcactggtaccagcagaagagcggcaccagccccaagctgctgatctac
agcaccagcaacctggccagcggcgtgcccagcaggttcagcggcagcggcagcggcaccttctacagc
ctgaccatcagcagcgtggaggccgaggacgccgccgactactactgccaccagtggagcagctacacc
ttcggcggcggcaccaagctggagatcaagaggggcggcggcggcagcggcggcggcggcagcggcggc
ggcggcagccaggtgaagctgcaggagagcggcggcggcctggtgaagcccggcggcagcctgaagctg
agctgcgccgccagcggcttcaccttcagcagctacgccatgagctgggtgaggcagacccccgagaag
aggctggagtgggtggccaccatcagcagcggcggcagctacacctactaccccgacagcgtgaagggc
aggttcaccatcagcagggacaacgccaagaacaccctgtacctgcagatgagcagcctgaggagcgag
gacaccgccatgtactactgcgccaggcaggacggctactaccccggctggttcgccaactggggccag
ggcaccaccgtgaccgtgagcagctccggaacaacgacaccagcaccacggccacccactcctgctccg
acaattgcgtctcagcccctttcccttcgacccgaagcttgtcgccctgctgcgggaggagcggtccac
acgcgcgggcttgacttcgcttgcgacatctacatttgggcacccttggccgggacatgcggcgtcttg
ctcctgagtctggttataacgctgtattgtaagcgaggtcggaagaagcttttgtatatctttaaacag
ccctttatgaggcccgtacaaaccacacaagaggaggatgggtgctcatgcagatttcctgaagaggaa
gagggcggttgcgaacttagagtcaaattcagccgctccgcagatgcacctgcttataaacagggtcag
aatcaattgtataatgaacttaatctcgggaggcgcgaggagtatgatgtgctggacaagcgacggggt
cgagacccagagatgggcggtaaaccccgccgaaagaacccccaggagggactgtataatgagctgcaa
aaggacaaaatggcagaagcctattccgaaatagggatgaagggagagcggcggcgaggtaagggacat
gacggtctttatcaaggtcttagtactgcaactaaggacacctatgacgcgctgcatatgcaggctctc
ccacctagacgagctaaacgaggctcaggcgcgacgaactttagtttgctgaagcaagctggggatgta
gaggaaaatccgggtcccatggattggacttggattttgttcctcgttgccgcagcgactcgcgtccat
agtaattgggtgaacgtaattagtgacttgaaaaaaattgaggaccttatacaaagtatgcatatcgat
gcaacactgtacacggagtccgacgtgcacccaagctgcaaggtcaccgcaatgaaatgctttttgctc
gaattgcaagttatctcacttgagtcaggggacgcttcaatccatgatactgtggagaatttgataatc
ctggcgaacaatagccttagttcaaatggcaacgtcactgagtcaggctgcaaggaatgtgaggaattg
gaagaaaaaaatatcaaggaatttttgcaatcttttgttcacatagttcagatgttcattaacactagt
tccgggggcggcagtggaggtggcggtagcggcgggggtggctctggtggaggcggctctgggggcgga
agtctgcagataacatgccccccacctatgagtgttgaacatgctgatatctgggttaaatcttactcc
ctttacagtcgagaaaggtacatttgcaactccggctttaaacgcaaagccgggactagttcactgact
gaatgtgtattgaataaagcgacaaatgtcgcacactggactaccccttccctcaaatgcattcgcgat
cctgccttggtgcatcagcgaccagcaccgccgtccacggtaactaccgcaggagtaacaccgcagccc
gagagcctttccccctcaggcaaagagccggccgcatcctccccatcttccaataataccgcagctacc
accgcagcaatcgtacccggatcccagctgatgcccagcaaaagtccgagtactggaacgactgaaatc
tccagtcacgagtcttctcatggaactccgagtcaaactacagcaaagaattgggagctgactgcttcc
gcttcacaccagccgccaggcgtttatcctcagggacactcagataccacggtggcgattagcacaagc
accgtcctcctgtgtgggctgagtgcagtgtcacttctcgcctgctaccttaagtccagacagacaccc
cctttggcaagcgttgaaatggaagccatggaagccttgcctgtcacatgggggacttcatcccgcgat
gaagacttggagaactgctcacaccatctt CAR7-mb15 (SEQ ID NO 38):
MALPVTALLLPLALLLHAARPDIELTQSPAIMSASLGEEITLTCSASSSVSYMHW
YQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFYSLTISSVEAEDAADYYCHQWSSYT
FGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQESGGGLVKPGGSLKLSCAASGFTFSSY
AMSWVRQTPEKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSED
TAMYYCARQDGYYPGWFANWGQGTTVTVSSSGTTTPAPRPPTPAPTIASQPLSLRPEAC
RPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMR
PVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYD
VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGL
YQGLSTATKDTYDALHMQALPPRRAKRGSGATNFSLLKQAGDVEENPGPMDWTWILF
LVAAATRVHSNWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQV
ISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFI
NTSSGGGSGGGGSGGGGSGGGGSGGGSLQITCPPPMSVEHADIWVKSYSLYSRERYICN
SGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRDPALVHQRPAPPSTVTTAGVTPQP
ESLSPSGKEPAASSPSSNNTAATTAAIVPGSQLMPSKSPSTGTTEISSHESSHGTPSQTTAK
NWELTASASHQPPGVYPQGHSDTTVAISTSTVLLCGLSAVSLLACYLKSRQTPPLASVE
MEAMEALPVTWGTSSRDEDLENCSHHL CAR7-C7R (SEQ ID NO 39):
atggcactccctgtaactgcacttcttttgccacttgccttgctcctgcacgcagcgcggccggacatc
gagctgacccagagccccgccatcatgagcgccagcctgggcgaggagatcaccctgacctgcagcgcc
agcagcagcgtgagctacatgcactggtaccagcagaagagcggcaccagccccaagctgctgatctac
agcaccagcaacctggccagcggcgtgcccagcaggttcagcggcagcggcagcggcaccttctacagc
ctgaccatcagcagcgtggaggccgaggacgccgccgactactactgccaccagtggagcagctacacc
ttcggcggcggcaccaagctggagatcaagaggggcggcggcggcagcggcggcggcggcagcggcggc
ggcggcagccaggtgaagctgcaggagagcggcggcggcctggtgaagcccggcggcagcctgaagctg
agctgcgccgccagcggcttcaccttcagcagctacgccatgagctgggtgaggcagacccccgagaag
aggctggagtgggtggccaccatcagcagcggcggcagctacacctactaccccgacagcgtgaagggc
aggttcaccatcagcagggacaacgccaagaacaccctgtacctgcagatgagcagcctgaggagcgag
gacaccgccatgtactactgcgccaggcaggacggctactaccccggctggttcgccaactggggccag
ggcaccaccgtgaccgtgagcagctccggaacaacgacaccagcaccacggccacccactcctgctccg
acaattgcgtctcagcccctttcccttcgacccgaagcttgtcgccctgctgcgggaggagcggtccac
acgcgcgggcttgacttcgcttgcgacatctacatttgggcacccttggccgggacatgcggcgtcttg
ctcctgagtctggttataacgctgtattgtaagcgaggtcggaagaagcttttgtatatctttaaacag
ccctttatgaggcccgtacaaaccacacaagaggaggatgggtgctcatgcagatttcctgaagaggaa
gagggcggttgcgaacttagagtcaaattcagccgctccgcagatgcacctgcttataaacagggtcag
aatcaattgtataatgaacttaatctcgggaggcgcgaggagtatgatgtgctggacaagcgacggggt
cgagacccagagatgggcggtaaaccccgccgaaagaacccccaggagggactgtataatgagctgcaa
aaggacaaaatggcagaagcctattccgaaatagggatgaagggagagcggcggcgaggtaagggacat
gacggtctttatcaaggtcttagtactgcaactaaggacacctatgacgcgctgcatatgcaggctctc
ccacctagaggctcaggcgcgacgaactttagtttgctgaagcaagctggggatgtagaggaaaatccg
ggtcccatgttggtgcgccgaggcgcacgagcaggacctcggatgccgcgaggctggacagccctctgt
ctcctctctttgcttccatccgggttcatgagtctcgacaataatggtacggcaaccccggaactcccg
acccaaggaacctttagtaacgtttcaaccaatgtgtcctatcaggagacaacaaccccttctacactg
ggcagtaccagcttgcatcccgtcagccaacacggcaacgaggcaacaactaacatcacagagactacg
gtcaagtttactagtacttccgtaatcacgtctgtgtacgggaatacaaattcatcagttcagagtcaa
acgtcagttatatctacagtcttcactactcccgcgaatgtatccaccccagaaaccaccctcaaacct
tctcttagtccaggaaatgttagcgatttgtcaacgacgagcacgagtttggcgactagtccaacgaaa
ccgtacacttccagcagtcccatactgtccgacattaaggcagaaataaaatgttctgggatcagggag
gtcaagcttacgcagggaatatgtcttgagcaaaataagacgtcctcatgcgcagaattcaagaaagat
cgcggcgaaggtctggccagagtcctctgtggagaggagcaggcggatgctgacgcaggagcgcaggtt
tgtagtctcctgctcgcgcaaagtgaagttaggccccaatgtctcttgttggtactggctaaccgaact
gaaattagcagcaagcttcaactcatgaaaaaacaccagagtgatttgaaaaaacttgggatacttgac
ttcacggagcaagacgttgcgtctcaccaatcctactcacagaaaaccccgatactgttgacatgcccc
accatatcaatcttgtctttcttcagtgtggctcttctggtgatcttggcgtgcgtgctgtggaaaaaa
aggattaaaccgatcgtttggcctagtctgccggatcacaaaaagacactggagcacctctgcaagaag
ccacgaaaaaacctgaatgtgagctttaaccccgagtcttttttggactgtcagatacaccgagtcgac
gatatacaggcaagagatgaggttgagggtttcctgcaagacacattcccgcaacaactcgaagaatcc
gagaaacagcgccttggtggagatgtccagtctccgaactgtccgagcgaggacgtagtaattacccca
gaaagcttcggtcgagatagtagccttacgtgtctcgccgggaacgtgtcagcgtgtgacgcgcctatt
ctttcaagttcacgcagtttggactgtcgagaatcagggaaaaacggacctcacgtgtatcaggatctc
cttctcagcctgggcacgacaaacagtaccttgcctcctccgttttccctgcagtcaggtattctgacg
ctcaatccagtcgcacaagggcaacctatcctgacctccttgggttctaaccaggaagaggcatacgtc
actatgtccagcttctatcagaatcag CAR-C7R (SEQ ID NO 40):
MALPVTALLLPLALLLHAARPDIELTQSPAIMSASLGEEITLTCSASSSVSYMHW
YQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFYSLTISSVEAEDAADYYCHQWSSYT
FGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQESGGGLVKPGGSLKLSCAASGFTFSSY
AMSWVRQTPEKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSED
TAMYYCARQDGYYPGWFANWGQGTTVTVSSSGTTTPAPRPPTPAPTIASQPLSLRPEAC
RPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMR
PVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYD
VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGL
YQGLSTATKDTYDALHMQALPPRGSGATNFSLLKQAGDVEENPGPMLVRRGARAGPR
MPRGWTALCLLSLLPSGFMSLDNNGTATPELPTQGTFSNVSTNVSYQETTTPSTLGSTSL
HPVSQHGNEATTNITETTVKFTSTSVITSVYGNTNSSVQSQTSVISTVFTTPANVSTPETT
LKPSLSPGNVSDLSTTSTSLATSPTKPYTSSSPILSDIKAEIKCSGIREVKLTQGICLEQNKT
SSCAEFKKDRGEGLARVLCGEEQADADAGAQVCSLLLAQSEVRPQCLLLVLANRTEISS
KLQLMKKHQSDLKKLGILDFTEQDVASHQSYSQKTPILLTCPTISILSFFSVALLVILACV
LWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQIHRVDDIQARDEVE
GFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPI
LSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLG
SNQEEAYVTMSSFYQNQ
[0357] The amino acid sequence of two CD2 scFv constructed to
single or a dual CAR are as below:
TABLE-US-00009 CD2 scFv1 VH: (SEQ ID NO: 95)
QLQQPGAELVRPGSSVKLSCKASGYTFTRYWIHWVKQRPIQGLEWIGNID
PSDSETHYNQKFKDKATLTVDKSSGTAYMQLSSLTSEDSAVYYCATEDLY YAMEYWGQGTSVTVSS
CD2 scFv1 VL: (SEQ ID NO: 96)
DIMMTQSPSSLAVSAGEKVTMTCKSSQSVLYSSNQKNYLAWYQQKPGQSP
KLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQPEDLAVYYCHQYLSS HTFGGGTKLEIKR
CD2 scFv2 VH: (SEQ ID NO: 97)
QVQLQQPGTELVRPGSSVKLSCKASGYTFTSYWVNWVKQRPDQGLEWIGR
IDPYDSETHYNQKFTDKAISTIDTSSNTAYMQLSTLTSDASAVYYCSRSP
RDSSTNLADWGQGTLVTVSS CD2 scFv2 VL: (SEQ ID NO: 98)
DIVMTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKY
ASQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSFPLTFGA GTKLELRR
[0358] The CAR genes were cloned into the FUW lentiviral vector
backbone under the promoter of EF a (EF-1.alpha.) to form
Fuw-EF1.alpha.-CAR. Fuw-EF1.alpha.-CAR, lentiviral envelope plasmid
pMD2.G (Addgene, Plasmid #12259) and lentiviral packaging plasmid
psPAX2 (Addgene, Plasmid #12260) were transfected into 293 T cells
by using Lipofectamine3000 to prepare the whole lentiviral
expression vector. The supernatant was collected at 48 and 72 h and
subject to ultra-centrifuge (Merck Millipore) for
concentration.
3.3 Preparation of UCAR-T Cells
[0359] The whole preparation process is illustrated in FIG. 15.
[0360] Cell Isolation and Activation
[0361] After apheresis, monocytes were isolated using
Histopaque-1077 (Sigma-Aldrich) by density gradient centrifugation.
T cells were then enriched, activated by magnetic beads coupled
with anti-CD3/anti-CD28, cultured and expanded.
[0362] X-vivo 15 with 5% FBS, 2 mM L-glutamine, 1 mM sodium
pyruvate and 300 IU/ml rhIL2 was used as UCAR-T cell medium. The
cells were incubated and cultured at 37.degree. C., 5%
CO.sub.2.
[0363] Electroporation and Lentivirus Infection
[0364] Two days after enriching and activating the T cells, the
anti-CD3/anti-CD28 magnetic beads were removed and the cells were
collected into a tube and subject to centrifuge at 300 g for 5 min,
and then washed twice with DPBS and re-suspended in opti-mem at a
cell density of 50.times.10.sup.6/ml. The amount of cas9/gRNA RNP
required was calculated based on the density of the cells, and then
mixed with cells and transferred for electroporation by
4D-Nucleofector System N (Lonza) system. Then the cells were
re-suspended in a pre-warmed medium to a density of
2.times.10.sup.6/ml. The cells were further subject to lentiviral
transfection at MOI of 2-8, transferred to a flask and cultured in
an incubator at 37.degree. C., 5% Co.sub.2.
[0365] Cell Proliferation and Detection of CAR Positive Ratio
[0366] 3 days after the transfection, the number of cells and CAR
positive cells were detected, and the positive ratio of CAR in T
cells was calculated. The positive ratio of TCR (or CD3) and CD7
was also detected to determine the knockout efficiency. Then cells
were continuously cultured in the incubator for 10 days and then
the cells were ready for cryopreservation.
[0367] The result shows that (FIG. 18) the expression of CAR,
IL15R.alpha. or C7R (CD34) was successfully detected by flow
cytometry for CAR7, CAR7-mb15 and CAR7-C7R, and the positive ratio
was higher than 30%. The negative ratio of CD3/CD7 was up to about
98%, indicating that the TCR knockout enhanced and universal UCAR-T
cells were successfully prepared.
[0368] As shown in FIG. 19, after removing exogenous IL-2, pSTAT5
level of CAR7 went down to basal level. However, the level of
pSTAT5 in CAR7-C7R T cells (CD34+ cells) or CAR7-T cells with
exogenous IL2 addition were at quite high levels, indicating
expression of C7R and exogenously added IL-2 can both enhance the
activation of STAT5 signaling pathway.
3.4 In Vitro Killing Effect
[0369] A stably transfected CCRF-CEM-luc cell line was obtained by
introducing the luciferase gene into the target cell CCRF-CEM
followed by screening. After adding fluorescein, luciferase could
react with the fluorescein to produce fluorescence. By detecting
the intensity of the fluorescence, the activity of luciferase can
be measured, and the survival of the cells can be detected so that
to evaluate the killing effect of UCAR-T cells.
[0370] The UCAR-T cells prepared in Example 3.3 were mixed with
CD-7 positive T cell CCRF-CEM-luc, 100 ul each, in RPMI medium at
1:1 ratio to a density of 1.times.106/ml for each cell, and then
cultured for a certain period of time in a 96-well plate. The
medium was then collected and subject to centrifuge and the
cytokine IFN-.gamma. and IL-2 were detected by Cytokine bead array
kit (CBA kit, BD Biosciences). In addition, fluorescein substrate
was added to the cell culture to detect the killing effect of the
UCAR-T cells. The result shows that UCAR-T has a significant
killing effect on CCRF-CEM tumor within 24 hours (FIG. 20).
[0371] The killing effect of UCAR-T on allogeneic T cells:
allogeneic T cells were labeled with CFSE and incubated with CAR-T
for a predetermined period of time. Then changes in the number of
CFSE positive cells were analyzed by flow cytometry. The result
shows that CAR-T cells efficiently killed allogeneic T cells within
24 hours, which is much shorter than the time for allo-T cell
mediated HVG to happen, and thus CAR7 can effectively protect CAR-T
cells from allogeneic T cell killing (FIG. 21).
[0372] The 24 hour killing effect of UCAR-T on NK tumor cell line
(NK92): NK92 was labeled with carboxyfluorescein succinimidyl ester
(CFSE) and incubated with UCAR-T for a predetermined period of
time. Then changes in the number of CFSE positive cells were
analyzed by flow cytometry, so that to calculate the in vitro
killing effect of UCAR-T on NK92 tumor cell line (FIG. 22).
3.5 Proliferation of CAR-T Cells
[0373] IL-2 was removed from CAR-T. CAR-T cells were continuously
cultured for 2 weeks and counted twice a week to measure the
proliferation.
[0374] The result in FIGS. 23A and 23B shows that CAR7-mb15 and
CAR7-C7R CAR-T cells had stronger proliferation rate than CAR7
CAR-T cells, and in absence of IL-2, they still had higher survival
ratio within 2 weeks. CAR7-C7R showed better survival than
CAR7-mb15. In vitro killing assay indicates that the UCAR-T cells
have superior killing effect against T-ALL cell line CCRF-CEM
within 7 hours.
3.6 Re-Activation of Cells In Vitro
[0375] IL-2 was removed from UCAR-T. CCRF-CEM was added twice a
week at 1:1 effector: target ratio and counted twice a week to
measure the proliferation.
[0376] FIGS. 24A and 24B show that after adding CCRF-CEM, CAR7-mb15
and CAR7-C7R UCAR-T cells showed significantly stronger
proliferation than CAR7 UCAR-T and CAR7-C7R UCAR-T cells
proliferated better than CAR7-mbIL15 UCAR-T cells. After repeated
stimulation, UCAR-T cells still showed significant ability to
remove tumor cells, indicating after repeated antigen stimulation,
the cytokine-related signaling pathway enhanced UCAR-T cells has a
higher proliferation rate, and can survive better.
3.7 Proliferation and Efficacy of UCAR-T Cells in Tumor Bearing
Mice
[0377] 6-12 weeks NOD/Shi-scid/IL-2R.gamma.null (NOG) mice were
selected and intraperitoneally injected with 2.times.10.sup.6
CCRF-CEM-luc cells. Two days later, the tumor graft burden of the
mice was measured, and the mice were divided into 5 groups based on
the tumor burden. 6 days after the tumor implantation,
1.times.10.sup.6 UCAR-T or control was injected intravenously to
each mouse, and the tumor burden was further evaluated every 1-2
weeks. Each mouse was injected intraperitoneally with 3 mg
D-luciferin for a 4-minutes reaction, and then photographed using a
Xenogen IVIS Imaging System with 30 s exposure (BLI). UCAR-T cell
number in peripheral blood was counted every week.
[0378] FIG. 25 shows that CAR7-mb15 and CAR7-C7R UCAR-T had
significant expansion, and CAR7 UCAR-T did not show any significant
expansion. FIG. 26 shows the result of BLI imaging, and it can be
seen that CAR7-mb15 and CAR7-C7R UCAR-T cells had better effect on
tumor clearance than CAR7 UCAR-T cells.
[0379] FIG. 27 shows BLI images of the mice treated with vehicle
control or CAR7 UCAR-T cells with TCR knockout and with or without
expression of enhancers. CAR7 UCAR-T cells with TCR knockout and
the expression of C7R or mbIL15 exhibited better efficiency on
tumor clearance in comparison to vehicle control and TCR KO CAR7
UCAR-T cells without the expression of any enhancers. C7R
expressing CAR7 cells showed better tumor control and mouse
survival than that expressing mbIL15. As used herein, "CAR7," "CAR7
UCAR-T," or CD7 CAR-T" can be used interchangeably to indicate an
engineered CAR-T cell comprising a CAR targeting CD7.
[0380] FIG. 28A BLI imaging shows in vivo function of CD7 CAR-T
cells in clearing tumor cells. TCR KO CD7 CAR-T cells with the
expression C7R or mbIL15 exhibited better in vivo efficiency on
tumor clearance in comparison to vehicle control and TCR KO CD7
CAR-T cells without the expression of any enhancers. FIG. 28B shows
animal survival data of the NOG mice treated with TCR KO CD7 CAR-T
with or without the expression of enhancer and vehicle control.
Percentage of survived mice were measured against days after CAR-T
cell infusion. Mice treated with TCR KO CD7 CAR-T with expression
of C7R or mbIL15 had a better survival rate in comparison to mice
treated with CAR-T cells without the expression enhancer or vehicle
control. C7R expressing CAR7 cells showed better tumor control and
mouse survival than that expressing mbIL15.
[0381] FIG. 55A shows expansion data of CAR-T cells. Freshly
prepared CD7 CAR-T cells expressing C7R were cultured in T cell
culture media without supplement of IL2 or antigen stimulation,
compared to control cells that do not have C7R or any enhancer
expression, CD7 CAR-T cells expressing C7R maintained better
expansion and persisted in culture. FIG. 55B shows proliferation of
CAR-T cells in the presence of stimulation. CD7 CAR-T (or UCART7),
CD7 CAR-T expressing mbIL15 or C7R were repetitively stimulated by
CCRF-CEM (CD7+ T-ALL cells). The CD7 CAR-T expressing C7R showed
the best persistence and proliferation. CD7 CAR-T expressing
mbIL15/C7R stopped proliferation when antigen stimulation was
removed at round 6 of stimulation (CC6). "CC," as used herein,
indicates co-culture with cancer cells.
3.8 In Vivo GVHD Study
[0382] The mice were systemically treated with a sub-lethal dose of
irradiation (175 cGy) first. Then CAR-T cells were re-suspended in
PBS and injected into the thorax of the treated mice. The mice were
observed 2-3 times a week by using GVHD clinical criteria including
weight loss, arch-back, activity, fur texture, and skin
integrity.
[0383] The result shows that mice in groups without TCR knockout
all showed symptoms of GVHD, however, no GVHD was detected in TCR
knockout group.
3.9 Effect of TCR Knockout
[0384] FIGS. 54A-C show the effect of TCR knockout in the CAR-T
cells. In an investigator initiated clinical trial, TCR expression
in Mesothelin CAR-T cells were impaired to avoid TCR related
adverse event. However, TCR KO CAR-T cells unexpectedly showed
significant expansion defects after infusion into the patients.
FIG. 54A shows example of TCR KO efficiency in autologous
Mesothelin (MSLN) CAR+ T cells (left), and CAR+ T cells in
patient's peripheral blood CAR-T cells at 13 days post infusion
(right). FIG. 54B shows TCR disruption efficiencies in autologous
MSLN CAR-T products were highly effective, with less than 5% TCR+
cells remaining in the product. However, after infusion into
patients, majority of the CAR-T cells detected in the peripheral
blood were TCR+ cells. FIG. 54C shows that TCR+ cells showed 40 to
.about.1000 fold more expansion than TCR-cells in cancer patients.
Therefore, even in autologous CAR-T applications, where there is no
cell survival and expansion pressure from allogeneic killer cells,
TCR disruption dramatically impaired CAR-T cell expansion.
3.10 Sequences of Construct Designs
[0385] CD7CAR-mbIL15 construct design: CD7CAR-mbIL15 amino acid
sequence (mbIL15=IgE signal peptide+IL15+IL15R.alpha.)
TABLE-US-00010 (SEQ ID NO: 99)
MALPVTALLLPLALLLHAARPDIELTQSPAIMSASLGEEITLTCSASSSV
SYMHWYQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFYSLTISSVEA
EDAADYYCHQWSSYTFGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQESGG
GLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVATISSGGSYTY
YPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARQDGYYPGWFAN
WGQGTTVTVSSSGTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHT
RGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRP
VQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNL
GRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGM
KGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRGSGATNFSLLKQAG
DVEENPGPMDWTWILFLVAAATRVHSNWVNVISDLKKIEDLIQSMHIDAT
LYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSL
SSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTSSGGGSGGGGS
GGGGSGGGGSGGGSLQITCPPPMSVEHADIWVKSYSLYSRERYICNSGFK
RKAGTSSLTECVLNKATNVAHWTTPSLKCIRDPALVHQRPAPPSTVTTAG
VTPQPESLSPSGKEPAASSPSSNNTAATTAAIVPGSQLMPSKSPSTGTTE
ISSHESSHGTPSQTTAKNWELTASASHQPPGVYPQGHSDTTVAISTSTVL
LCGLSAVSLLACYLKSRQTPPLASVEMEAMEALPVTWGTSSRDEDLENCS HHL
[0386] CD7CAR-C7R construct design: CD7CAR-C7R amino acid sequence
(C7R=CD34 ecto domain+constitutively active IL7R.alpha.)
TABLE-US-00011 (SEQ ID NO: 40)
MALPVTALLLPLALLLHAARPDIELTQSPAIMSASLGEEITLTCSASSSV
SYMHWYQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFYSLTISSVEA
EDAADYYCHQWSSYTFGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQESGG
GLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVATISSGGSYTY
YPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARQDGYYPGWFAN
WGQGTTVTVSSSGTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHT
RGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRP
VQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNL
GRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGM
KGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRGSGATNFSLLKQAG
DVEENPGPMLVRRGARAGPRMPRGWTALCLLSLLPSGFMSLDNNGTATPE
LPTQGTFSNVSTNVSYQETTTPSTLGSTSLHPVSQHGNEATTNITETTVK
FTSTSVITSVYGNTNSSVQSQTSVISTVFTTPANVSTPETTLKPSLSPGN
VSDLSTTSTSLATSPTKPYTSSSPILSDIKAEIKCSGIREVKLTQGICLE
QNKTSSCAEFKKDRGEGLARVLCGEEQADADAGAQVCSLLLAQSEVRPQC
LLLVLANRTEISSKLQLMKKHQSDLKKLGILDFTEQDVASHQSYSQKTPI
LLTCPTISILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCK
KPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQ
RLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSL
DCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPIL
TSLGSNQEEAYVTMSSFYQNQ
Example 4 Study of U-CAR T Cells Expressing the Enhancer Together
with the Safety-Switch
4.1 Design of CAR and Package of the Virus
[0387] The structure of the chimeric antigen receptor is:
[0388] 1) RQR8-CD19CAR-mbIL15;
[0389] 2) RQR8-CD19CAR-mbIL15-IL7;
[0390] 3) RQR8-CD19CAR-C7R;
[0391] 4) RQR8-CD19CAR-mbIL7;
[0392] wherein RQR8 is a safety switch, and the CD19CAR fragment is
the heavy chain and light chain variable region of monoclonal
antibody FMC63 (connected by a GS linker), and also included are
hinge region and transmembrane region, human CD 28 intracellular
co-stimulatory element, and human CD3.zeta. intracellular region in
tandem; mbIL15 consists of IL15+IL15R.alpha. in tandem; C7R is a
constitutively activated IL7 receptor consisting of CD34
extracellular domain and IL7 receptor transmembrane and
intracellular domains; IL7 consists of IL7 signal peptide and
mature peptide; mbIL7 consists of IL7+IL7Ra in tandem. Examples of
the constructs described herein are shown in FIG. 29.
[0393] The amino acid sequence of RQR8 is as set forth below (SEQ
ID NO.: 7):
TABLE-US-00012 MGTSLLCWMALCLLGADHADACPYSNPSLCSGGGGSELPTQGTFSNVSTN
VSPAKPTTTACPYSNPSLCSGGGGSPAPRPPTPAPTIASQPLSLRPEACR
PAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRRRVC KCPRPVV
[0394] The DNA sequence of RQR8 is as set forth below (SEQ ID NO.:
8):
TABLE-US-00013 ATGGGCACCTCTCTGCTGTGCTGGATGGCTCTGTGTCTGCTGGGCGCTGA
CCATGCTGATGCTTGCCCCTATTCCAACCCCTCTCTGTGCTCCGGAGGAG
GAGGATCCGAACTGCCTACCCAAGGCACCTTCAGCAACGTGTCCACCAAC
GTGAGCCCCGCTAAGCCTACCACCACCGCTTGCCCTTACTCCAATCCCAG
CCTCTGCTCCGGAGGCGGAGGATCCCCCGCCCCCAGACCTCCTACACCCG
CTCCCACAATCGCCAGCCAGCCTCTGTCTCTGAGACCCGAAGCTTGCAGA
CCCGCTGCCGGAGGAGCTGTGCATACAAGAGGACTGGATTTCGCTTGCGA
CATCTACATCTGGGCCCCTCTGGCTGGCACATGTGGCGTGCTGCTGCTGT
CTCTGGTCATTACACTGTACTGCAACCATAGAAATAGAAGAAGGGTGTGC
AAGTGTCCCAGACCCGTGGTGGGCAGCGGAGAAGGAAGAGGCTCTCTGCT
GACATGCGGAGACGTGGAAGAGAACCCCGGCCCC
[0395] The amino acid sequence of CD19CAR is as set forth below
(SEQ ID NO.: 9):
TABLE-US-00014 MLLLVTSLLLCELPHPAELLIPDIQMTQTTSSLSASLGDRVTISCRASQD
ISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNL
EQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVK
LQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWG
SETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGG
SYAMDYWGQGTSVTVSSAAADYKDDDDKIEVMYPPPYLDNEKSNGTIIHV
KGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSR
LLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQ
GQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKD
KMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
[0396] The DNA sequence of CD19CAR is as set forth below (SEQ ID
NO.: 10):
TABLE-US-00015 ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGC
ATTCCTCCTGATCCCAGACATCCAGATGACACAGACTACATCCTCCCTGT
CTGCCTCTCTGGGAGACAGAGTCACCATCAGTTGCAGGGCAAGTCAGGAC
ATTAGTAAATATTTAAATTGGTATCAGCAGAAACCAGATGGAACTGTTAA
ACTCCTGATCTACCATACATCAAGATTACACTCAGGAGTCCCATCAAGGT
TCAGTGGCAGTGGGTCTGGAACAGATTATTCTCTCACCATTAGCAACCTG
GAGCAAGAAGATATTGCCACTTACTTTTGCCAACAGGGTAATACGCTTCC
GTACACGTTCGGAGGGGGGACTAAGTTGGAAATAACAGGCTCCACCTCTG
GATCCGGCAAGCCCGGATCTGGCGAGGGATCCACCAAGGGCGAGGTGAAA
CTGCAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGTCCGT
CACATGCACTGTCTCAGGGGTCTCATTACCCGACTATGGTGTAAGCTGGA
TTCGCCAGCCTCCACGAAAGGGTCTGGAGTGGCTGGGAGTAATATGGGGT
AGTGAAACCACATACTATAATTCAGCTCTCAAATCCAGACTGACCATCAT
CAAGGACAACTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTGCAAA
CTGATGACACAGCCATTTACTACTGTGCCAAACATTATTACTACGGTGGT
AGCTATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTC
AGCGGCCGCAGACTACAAAGACGATGACGACAAGATTGAAGTTATGTATC
CTCCTCCTTACCTAGACAATGAGAAGAGCAATGGAACCATTATCCATGTG
AAAGGGAAACACCTTTGTCCAAGTCCCCTATTTCCCGGACCTTCTAAGCC
CTTTTGGGTGCTGGTGGTGGTTGGGGGAGTCCTGGCTTGCTATAGCTTGC
TAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGG
CTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCAC
CCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATC
GCTCCAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAG
GGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTA
CGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGC
CGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGAT
AAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAG
GGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGG
ACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC
[0397] The amino acid sequence of mbIL15 is as set forth below (SEQ
ID NO.: 11):
TABLE-US-00016 ##STR00003##
[0398] In the amino acid sequence of mbIL15, the underlined part is
the signal peptide region, the italic part is IL-15, the bold part
is the linking region, and the dashed underlined part is IL-15
receptor .alpha..
[0399] The DNA sequence of mbIL15 is as set forth below (SEQ ID
NO.: 12):
TABLE-US-00017 ATGGATTGGACTTGGATTTTGTTCCTCGTTGCCGCAGCGACTCGCGTCCA
TAGTAATTGGGTGAACGTAATTAGTGACTTGAAAAAAATTGAGGACCTTA
TACAAAGTATGCATATCGATGCAACACTGTACACGGAGTCCGACGTGCAC
CCAAGCTGCAAGGTCACCGCAATGAAATGCTTTTTGCTCGAATTGCAAGT
TATCTCACTTGAGTCAGGGGACGCTTCAATCCATGATACTGTGGAGAATT
TGATAATCCTGGCGAACAATAGCCTTAGTTCAAATGGCAACGTCACTGAG
TCAGGCTGCAAGGAATGTGAGGAATTGGAAGAAAAAAATATCAAGGAATT
TTTGCAATCTTTTGTTCACATAGTTCAGATGTTCATTAACACTAGTTCCG
GGGGCGGCAGTGGAGGTGGCGGTAGCGGCGGGGGTGGCTCTGGTGGAGGC
GGCTCTGGGGGCGGAAGTCTGCAGATAACATGCCCCCCACCTATGAGTGT
TGAACATGCTGATATCTGGGTTAAATCTTACTCCCTTTACAGTCGAGAAA
GGTACATTTGCAACTCCGGCTTTAAACGCAAAGCCGGGACTAGTTCACTG
ACTGAATGTGTATTGAATAAAGCGACAAATGTCGCACACTGGACTACCCC
TTCCCTCAAATGCATTCGCGATCCTGCCTTGGTGCATCAGCGACCAGCAC
CGCCGTCCACGGTAACTACCGCAGGAGTAACACCGCAGCCCGAGAGCCTT
TCCCCCTCAGGCAAAGAGCCGGCCGCATCCTCCCCATCTTCCAATAATAC
CGCAGCTACCACCGCAGCAATCGTACCCGGGTCCCAGCTGATGCCCAGCA
AAAGTCCGAGTACTGGAACGACTGAAATCTCCAGTCACGAGTCTTCTCAT
GGAACTCCGAGTCAAACTACAGCAAAGAATTGGGAGCTGACTGCTTCCGC
TTCACACCAGCCGCCAGGCGTTTATCCTCAGGGACACTCAGATACCACGG
TGGCGATTAGCACAAGCACCGTCCTCCTGTGTGGGCTGAGTGCAGTGTCA
CTTCTCGCCTGCTACCTTAAGTCCAGACAGACACCCCCTTTGGCAAGCGT
TGAAATGGAAGCCATGGAAGCCTTGCCTGTCACATGGGGGACTTCATCCC
GCGATGAAGACTTGGAGAACTGCTCACACCATCTTTGA
[0400] The amino acid sequence of IL7 is as set forth below (SEQ ID
NO.: 13):
TABLE-US-00018 MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDGKQYESVLMVSIDQLLD
SMKEIGSNCLNNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDF
DLHLLKVSEGTTILLNCTGQVKGRKPAALGEAQPTKSLEENKSLKEQKKL
NDLCFLKRLLQEIKTCWNKILMGTKEH
[0401] The DNA sequence of IL7 is as set forth below (SEQ ID NO.:
14):
TABLE-US-00019 GAATTCGGCAGCGGCGTCAAGCAGACACTGAACTTCGATCTGCTGAAGCT
GGCCGGAGACGTCGAGAGCAACCCCGGCCCTATGTTCCACGTGAGCTTTA
GATACATCTTCGGACTGCCCCCTCTGATTCTGGTGCTGCTGCCCGTGGCC
AGCAGCGACTGCGATATCGAGGGCAAGGACGGCAAGCAGTATGAGTCCGT
GCTGATGGTCTCCATCGATCAGCTGCTGGACAGCATGAAGGAGATCGGCT
CCAACTGCCTCAACAACGAGTTCAACTTTTTCAAGAGGCACATCTGCGAC
GCCAACAAGGAGGGCATGTTTCTGTTTAGAGCCGCTAGAAAGCTGAGGCA
GTTTCTGAAGATGAACAGCACCGGCGACTTTGATCTGCATCTGCTGAAAG
TGAGCGAGGGCACCACCATTCTGCTGAACTGCACCGGCCAAGTGAAAGGA
AGAAAGCCCGCCGCTCTGGGCGAGGCTCAGCCTACCAAGTCTCTGGAAGA
GAACAAGTCTCTGAAGGAGCAGAAGAAGCTCAACGATCTGTGCTTCCTCA
AGAGGCTGCTGCAAGAGATCAAGACATGCTGGAACAAGATCCTCATGGGC
ACCAAGGAACACTG
[0402] The amino acid sequence of C7R is as set forth below (SEQ ID
NO.: 15):
TABLE-US-00020 MLVRRGARAGPRMPRGWTALCLLSLLPSGFMSLDNNGTATPELPTQGTFS
NVSTNVSYQETTTPSTLGSTSLHPVSQHGNEATTNITETTVKFTSTSVIT
SVYGNTNSSVQSQTSVISTVFTTPANVSTPETTLKPSLSPGNVSDLSTTS
TSLATSPTKPYTSSSPILSDIKAEIKCSGIREVKLTQGICLEQNKTSSCA
EFKKDRGEGLARVLCGEEQADADAGAQVCSLLLAQSEVRPQCLLLVLANR
TEISSKLQLMKKHQSDLKKLGILDFTEQDVASHQSYSQKTPILLTCPTIS
ILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNV
SFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQS
PNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKN
GPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQE
EAYVTMSSFYQNQ.
[0403] In the amino acid sequence of the constitutively activated
IL-7 receptor (C7R), the underlined part is CD34 extracellular
region, the italic part is IL-7 receptor .alpha. transmembrane
region, and the bold part is IL-7 receptor a intracellular
region.
[0404] The DNA sequence of C7R is as set forth below (SEQ ID NO.:
16):
TABLE-US-00021 GGAAGCGGCGCCACAAACTTTTCTCTGCTGAAGCAAGCCGGCGACGTCGA
AGAGAACCCCGGCCCTATGCTGGTGAGGAGAGGCGCTAGGGCTGGACCCA
GAATGCCCAGAGGCTGGACCGCTCTGTGTCTGCTGTCTCTGCTGCCCAGC
GGCTTCATGAGCCTCGATAATAACGGCACCGCTACCCCCGAGCTGCCCAC
ACAAGGCACCTTCTCCAATGTGAGCACCAACGTGTCCTACCAAGAGACCA
CCACCCCTTCCACACTGGGAAGCACATCTCTGCATCCCGTCTCCCAGCAC
GGCAATGAAGCCACCACAAACATCACCGAGACCACCGTGAAGTTCACCAG
CACCTCCGTCATTACCAGCGTGTACGGCAACACCAATAGCTCCGTGCAAA
GCCAGACATCCGTGATTTCCACCGTGTTTACCACCCCCGCCAATGTCAGC
ACACCCGAGACAACACTGAAACCTTCTCTGTCCCCCGGAAACGTGAGCGA
TCTGAGCACAACCAGCACCAGCCTCGCCACCAGCCCCACAAAGCCTTACA
CAAGCAGCAGCCCCATTCTGAGCGACATCAAGGCCGAAATCAAGTGCTCC
GGAATTAGAGAGGTCAAGCTGACCCAAGGAATCTGTCTGGAGCAGAATAA
GACCAGCAGCTGCGCCGAGTTCAAGAAAGACAGAGGCGAAGGACTGGCCA
GAGTGCTCTGCGGCGAGGAACAAGCCGATGCCGATGCCGGAGCTCAAGTG
TGCAGCCTCCTCCTCGCTCAGAGCGAGGTCAGACCCCAATGTCTGCTGCT
CGTGCTGGCCAATAGGACCGAGATCTCCTCCAAACTGCAGCTGATGAAGA
AGCACCAGAGCGACCTCAAGAAGCTCGGCATCCTCGACTTTACCGAGCAA
GACGTGGCCTCCCATCAATCCTATAGCCAGAAGACCCCCATTCTGCTGAC
ATGTCCCACAATCAGCATCCTCAGCTTCTTCAGCGTCGCTCTGCTCGTCA
TTCTGGCTTGTGTGCTGTGGAAGAAGAGGATCAAGCCTATTGTGTGGCCC
TCTCTGCCCGACCACAAGAAGACCCTCGAACACCTCTGCAAGAAACCTAG
AAAGAACCTCAACGTGAGCTTCAACCCCGAGTCCTTTCTGGACTGTCAAA
TCCATAGGGTGGATGACATCCAAGCTAGAGACGAGGTCGAGGGCTTTCTG
CAAGACACCTTCCCTCAGCAGCTGGAAGAAAGCGAGAAGCAAAGACTGGG
CGGAGATGTGCAGTCCCCTAATTGCCCCTCCGAGGACGTGGTGATTACCC
CCGAGAGCTTCGGAAGAGACAGCTCTCTGACATGTCTGGCCGGAAATGTG
TCCGCTTGCGATGCCCCTATTCTGAGCAGCTCCAGATCTCTGGACTGCAG
AGAGTCCGGCAAGAACGGCCCTCATGTGTACCAAGATCTGCTGCTGTCTC
TGGGAACCACAAACTCCACACTGCCTCCCCCCTTTAGCCTCCAGTCCGGC
ATTCTGACACTGAACCCCGTGGCTCAAGGCCAACCTATCCTCACATCCCT
CGGCTCCAATCAAGAGGAAGCCTACGTGACCATGAGCTCCTTCTATCAGA ACCAGTGA
[0405] The amino acid sequence of mbIL7 is as set forth below (SEQ
ID NO.: 17):
TABLE-US-00022 ##STR00004##
[0406] In the amino acid sequence of mbIL7, the underlined part is
the signal peptide region, the italic part is IL-7, the bold part
is the linking region and the dashed underlined part is IL-7
receptor .alpha..
[0407] The DNA sequence of mbIL7 is as set forth below (SEQ ID NO.:
18):
TABLE-US-00023 ATGGCTCTGCCTGTTACAGCTCTGCTGCTGCCTCTGGCTCTGCTTCTGCA
TGCCGCCAGACCTGACTGTGACATCGAGGGCAAAGACGGCAAGCAGTACG
AGAGCGTGCTGATGGTGTCCATCGACCAGCTGCTGGACAGCATGAAGGAA
ATCGGCAGCAACTGCCTGAACAACGAGTTCAACTTCTTCAAGCGGCACAT
CTGCGACGCCAACAAAGAAGGCATGTTCCTGTTCAGAGCCGCCAGAAAGC
TGCGGCAGTTCCTGAAGATGAACAGCACCGGCGACTTCGACCTGCATCTG
CTGAAAGTGTCTGAGGGCACCACCATCCTGCTGAATTGCACCGGCCAAGT
GAAGGGCAGAAAGCCTGCTGCTCTGGGAGAAGCCCAGCCTACCAAGAGCC
TGGAAGAGAACAAGTCCCTGAAAGAGCAGAAGAAGCTGAACGACCTCTGC
TTCCTGAAGCGGCTGCTGCAAGAGATCAAGACCTGCTGGAACAAGATCCT
GATGGGCACCAAAGAGCACGGCGGAGGATCTGGCGGAGGTGGAAGCGGCG
GAGGCGGTAGCGGTGGCGGAGGAAGTGGTGGCGGATCTGAATCTGGCTAC
GCCCAGAACGGCGACCTGGAAGATGCCGAGCTGGACGACTACAGCTTCAG
CTGCTACAGCCAGCTGGAAGTGAACGGCAGCCAGCACTCTCTGACCTGCG
CCTTTGAAGATCCCGACGTGAACATCACCAACCTTGAGTTCGAGATTTGT
GGCGCCCTGGTGGAAGTCAAGTGCCTGAATTTCCGGAAGCTGCAAGAAAT
CTACTTTATCGAGACAAAGAAGTTCCTGCTGATCGGCAAGAGCAACATCT
GTGTGAAAGTGGGCGAGAAAAGCCTGACCTGCAAGAAGATCGACCTGACC
ACCATCGTGAAGCCCGAGGCTCCTTTCGATCTGAGCGTGGTGTATAGAGA
GGGCGCCAACGACTTCGTGGTCACCTTCAACACCAGCCACCTCCAAAAGA
AATACGTGAAGGTGCTGATGCACGACGTGGCCTACCGGCAAGAGAAGGAC
GAGAACAAATGGACCCACGTGAACCTGAGCAGCACCAAGCTGACCCTGCT
GCAGAGAAAACTGCAGCCTGCCGCTATGTACGAGATCAAAGTGCGGAGCA
TCCCCGACCACTACTTTAAAGGCTTTTGGAGCGAGTGGTCCCCTAGCTAC
TACTTCAGAACCCCTGAGATCAACAACTCCAGCGGCGAGATGGACCCCAT
TCTGCTGACAATCAGCATCCTGAGCTTTTTCAGCGTGGCCCTGCTGGTCA
TCCTGGCCTGTGTGCTGTGGAAGAAGCGGATCAAGCCCATCGTGTGGCCC
AGCCTGCCTGACCACAAGAAAACCCTGGAACACCTGTGCAAGAAGCCCCG
GAAAAACCTGAACGTGTCCTTCAATCCCGAGAGCTTCCTGGACTGCCAGA
TCCACAGAGTGGACGACATCCAGGCCAGGGACGAAGTGGAAGGATTTCTG
CAGGACACATTCCCTCAGCAGCTCGAAGAGAGCGAGAAGCAAAGACTCGG
AGGCGACGTGCAGAGCCCTAATTGCCCTTCTGAGGACGTGGTCATCACCC
CAGAGAGCTTCGGCAGAGATAGCAGCCTGACATGTCTGGCCGGCAATGTG
TCCGCCTGTGATGCCCCTATCCTGTCCTCTAGCAGAAGCCTGGATTGCAG
AGAGAGCGGCAAGAACGGCCCTCACGTGTACCAGGATCTGCTCCTGTCTC
TGGGCACCACAAACAGCACACTGCCTCCACCATTCAGCCTGCAGAGCGGC
ATCCTGACACTGAACCCTGTTGCTCAGGGCCAGCCTATCCTGACAAGCCT
GGGCAGCAATCAAGAAGAGGCCTACGTCACCATGAGCAGCTTCTACCAGA ACCAG
[0408] The above CAR genes were cloned into the FUW lentiviral
vector backbone under the promoter of EF1.alpha. (EF-1.alpha.) to
form Fuw-EF1.alpha.-CAR. Fuw-EF1.alpha.-CAR, lentiviral envelope
plasmid pMD2.G (Addgene, Plasmid #12259) and lentiviral packaging
plasmid psPAX2 (Addgene, Plasmid #12260) were transfected into 293
T cells by using Lipofectamine3000 to prepare the whole lentiviral
expression vector. The supernatant was collected at 48 and 72 h and
subject to ultra-centrifuge (Merck Millipore) for concentration.
The concentrated virus was ready for the transfection of T
cells.
[0409] The result shows that expression of RQR8, CAR, IL15R.alpha.
or C7R was successfully detected by flow cytometry for
RQR8-CD19CAR-MBIL15, RQR8-CD19CAR-MBIL15-IL7, RQR8-CD19CAR-C7R
cells; secretion of IL-7 was detected by ELISA. The lentiviral
vectors were successfully constructed. All of the structures could
be expressed simultaneously without interference with each
other.
4.2 Design and Construction of CRISPR
[0410] First, gRNA sequences targeting the exon of the TCR
conserved region were designed at http://crispr.mit.edu, and two
gRNA sequences with scores above 80 were selected for higher
knockout efficiency. For the gRNA primer, the forward primer
comprises a T7 promotor followed by 20 bp of the target sequence,
and the reverse primer has 20 bp of the complementary sequence.
Plasmids were used as PCR template. After purification, T7-PCR
product was further used as the template for MEGAshortscript T7 kit
to obtain RNA. The RNA was purified with a MEGAclear column and
eluted with RNA-free water. Cas9 plasmid was purchased from
Addgene.
[0411] The gRNA targeting sequences are as below:
TABLE-US-00024 TRAC-gRNA: SEQ ID NO.: 5 TGTGCTAGACATGAGGTCTA,
[0412] Meanwhile, the knockout efficiency of the gRNA was analyzed
by T7E1, TIDE and flow cytometry.
[0413] The result shows that the TCR gene was successfully knocked
out with a knockout efficiency of higher than 90%.
4.3 Preparation of CAR-T Cells
[0414] Cell Isolation and Activation
[0415] After apheresis, monocytes were isolated using
Histopaque-1077 (Sigma-Aldrich) by density gradient centrifugation.
Then T cells were enriched, activated by magnetic beads coupled
with anti-CD3/anti-CD28, cultured and expanded.
[0416] X-vivo 15 with 5% FBS, 2 mM L-glutamine, 1 mM sodium
pyruvate and 300 IU/ml rhIL2 was used as CAR-T cell medium. The
cells were incubated and cultured at 37.degree. C., 5% CO2.
[0417] Cell line expressing CD 19: Raji (Burkitt's lymphoma cell
line, ATCC-CCL86); K562 cells (Human erythroleukemia cell line,
ATCC-CCL243); Raji-ffluc cell line was obtained by screening Raji
cells transfected with lentivirus having firefly luciferase;
[0418] All of the cells were cultured in RPMI1640 medium and 293T
cells (ATCC-CRL3216) were cultured in DMEM medium. Both RPMI1640
and DMEM were supplemented with 10% (v/v) fetal bovine serum and
100 U/ml penicillin and streptomycin, 2 mM glutamine and 1 mM
sodium pyruvate.
[0419] Electroporation
[0420] Two days after enriching and activating the T cells, the
anti-CD3/anti-CD28 magnetic beads were removed and the cells were
collected into a tube. Cas9 and gRNA as needed were mixed,
incubated at room temperature and then transferred to
electroporation buffer to further mix with the cells for
electroporation by 4D-Nucleofector System N (Lonza) system. Then
the cells were re-suspended in a pre-warmed medium to a density of
1-2.times.10.sup.6/ml, transferred to a plate and cultured in an
incubator at 37.degree. C., 5% CO.sub.2.
[0421] Lentiviral Transfection
[0422] 1 day after electroporation, the cells were transfected by
lentiviral vector at MOI of 2-8, transferred to a flask and
cultured at 37.degree. C., 5% CO.sub.2.
[0423] Cell Proliferation and Detection of CAR Positive Ratio
[0424] 3 days after the transfection, the number of cells and CAR
positive cells were detected, and the positive ratio of CAR in T
cells was calculated. The positive ratio of CD3 was also detected
to determine the knockout efficiency. Then cells were continuously
cultured in the incubator and half of the medium was replaced every
2-3 days till day 14 when the cells were ready for
cryopreservation.
[0425] The result shows that that expression of RQR8, CAR,
IL15R.alpha. or C7R was successfully detected by flow cytometry for
RQR8-CD19CAR-mbIL15, RQR8-CD19CAR-mbIL15-IL7, RQR8-CD19CAR-C7R
CAR-T; secretion of IL-7 was detected by ELISA. The CD3 negative
ratio was higher than 90%, indicating that the TCR knockout CAR-T
with enhanced cytokine-related signaling pathway and the safety
switch was successfully constructed, and each of the elements does
not interfere with each other.
4.4 Release of the Cytokines
[0426] The CAR-T cells prepared in Example 3 and CD19 positive
tumor cells (Raji, NALM6), 100 ul each, were mixed in RPMI medium
at 1:1 ratio to a density of 1.times.10.sup.6/ml for each cell, and
then cultured overnight in a 96-well plate. The medium was
collected and subject to centrifuge and the released cytokine
IFN-.gamma. and IL-2 were detected by Cytokine bead array kit (CBA
kit, BD Biosciences).
[0427] The result shows that incubation of RQR8-CD19CAR-MBIL15,
RQR8-CD19CAR-MBIL15-IL7, RQR8-CD19CAR-C7R CAR-T cells with Raji,
NALM6 produced a large amount of IFN-.gamma. and IL-2, indicating
function of the cytokine-related signaling pathway enhanced CART
against CD19 positive target cells, and the secretion of cytokines
by the cytokine-related signaling pathway enhanced CART was
increased compared to conventional CAR-T.
4.5 Expression of CD107a after Co-Culture of CAR-T Cells with the
Target Cells
[0428] 2*10.sup.5 CAR-T/NT cells and 2*10.sup.5 target cells (Raji,
NALM6)/control cells (K562) were added to a v-bottom 96 well plate,
and re-suspended in 200 .mu.l X-VIVO complete medium without IL-2.
11 BD GolgiStop(containing monesin) was added to each 1 ml medium
and 2 .mu.l CD107a antibody (1:50) was added to each well. The
cells were then cultured at 37.degree. C. for 4 hours and further
subject to collection.
[0429] The sample was centrifuged to remove the medium, washed once
with PBS, and then centrifuged at 400 g, 4.degree. C. for 5
minutes. The supernatant was removed and specific surface
antibodies CAR, CD3, CD4, and CD8 were added to each tube. Then the
cells were re-suspended in 100 .mu.l and put on ice for 30 minutes
in dark.
[0430] Each tube was washed once with 3 mL PBS, and then the sample
was centrifuged at 400 g for 5 minutes. The supernatant was
carefully removed and the pellet was re-suspended in PBS. CAR, CD3,
CD4, CD8, and CD107a were detected by flow cytometry.
[0431] The result shows that incubation of RQR8-CD19CAR-MBIL15,
RQR8-CD19CAR-MBIL15-IL7, RQR8-CD19CAR-C7R CAR-T cells with Raji,
NALM6 produced a large amount of CD107a, indicating function of the
cytokine-related signaling pathway enhanced CART against CD19
positive target cells in vitro.
4.6 In Vitro Killing Activity
[0432] A stably transfected cell line was obtained by introducing
the luciferase gene into the target cell followed by screening. The
CAR-T cells prepared in Example 3 were mixed with CD19-positive
tumor cells (Raji-luc, NALM6-luc) at different effector: target
ratios. After adding fluorescein, luciferase could react with the
fluorescein to produce fluorescence. By detecting the intensity of
the fluorescence, the activity of luciferase can be measured, and
the survival of the cells can be detected so that to evaluate the
killing effect of CART cells.
[0433] The result shows that RQR8-CD19CAR-MBIL15,
RQR8-CD19CAR-MBIL15-IL7, RQR8-CD19CAR-C7R CAR-T cells significantly
killed Raji and NALM6, and the cytokine-related signaling pathway
enhanced CART showed a more significant killing effect, which is
correlated with the effector: target ratio.
4.7 Proliferation of CAR-T Cells
[0434] IL-2 was removed from CAR-T. CAR-T cells were continuously
cultured for 2 weeks and counted twice a week to measure the
proliferation.
[0435] The result shows that RQR8-CD19CAR-MBIL15,
RQR8-CD19CAR-MBIL15-IL7, RQR8-CD19CAR-C7R CAR-T cells had stronger
proliferation rate than CD19 CAR-T. Without IL-2, they still had
high survival ratio after 2 weeks. CFSE showed certain
proliferation and CD19 CAR-T could not survive after 2 weeks.
4.8 Re-Activation of Cells In Vitro
[0436] IL-2 was removed from CAR-T. K562-CD19 was added twice a
week at 2:1 effector: target ratio. The cells were cultured for 2
weeks and counted twice a week to measure cell proliferation
[0437] The result shows that after adding K562-CD19,
RQR8-CD19CAR-MBIL15, RQR8-CD19CAR-MBIL15-IL7, RQR8-CD19CAR-C7R
CAR-T cells showed significantly stronger proliferation rate than
CD19 CAR-T. After the stimulation, the cell survival ratio was
higher than CD19 CAR-T, indicating the cytokine-related signaling
pathway enhanced CART has a higher proliferation rate, and can
survive better.
4.9 In Vivo Efficacy
[0438] 6-12 weeks NOD-Prkdcscid Il2rgnull (NOG) mice were selected
and intraperitoneally injected with 2.times.10.sup.5 Raji-ffluc
cells, 50 .mu.L DPBS and 50 .mu.L matrigel matrix (Corning). Two
days later, the tumor graft burden of the mice was measured, and
the mice were divided into 4 groups based on the tumor burden. One
day later, 200 .mu.L DPBS, 5.times.10.sup.6 NT cells,
5.times.10.sup.6 CD19 CAR-T cells, RQR8-CD19CAR-MBIL15,
RQR8-CD19CAR-MBIL15-IL7, RQR8-CD19CAR-C7R CAR-T cells were
respectively injected to each mouse. The tumor burden of the mice
was further evaluated 7 days after the CAR-T treatment. Each mouse
was injected intraperitoneally with 3 mg d-luciferin for a
4-minutes reaction, and then photographed by using a Xenogen IVIS
Imaging System with 30 s exposure.
[0439] The result shows that after two weeks, RQR8-CD19CAR-MBIL15,
RQR8-CD19CAR-MBIL15-IL7 and RQR8-CD19CAR-C7R CAR-T cells
significantly decreased the tumor burden compared to NT and CD19
CAR-T cells, and T cells could still be detected in peripheral
blood. Mice in the cytokine-related signaling pathway enhanced CART
groups overall had longer survival.
4.10 In Vivo GVHD Study
[0440] The mice were systemically treated with a sub-lethal dose of
irradiation (175 cGy) first. Then CAR-T cells were re-suspended in
PBS and injected into the thorax of the treated mice. The mice were
observed 2-3 times a week by using GVHD clinical criteria including
weight loss, arch-back, activity, fur texture, and skin
integrity.
[0441] The result shows that mice in the group without TCR knockout
all showed symptoms of GVHD reaction, and no GVHD reaction was
detected in TCR single knockout CAR-T cell groups.
4.11 Clearance of 11 RQR8 Gene-Mediated CAR-T Cells
[0442] NK cells were isolated from PBMCs as effector cells, and 1:1
co-cultured with CAR-T, with or without rituximab (Rutiximab) at a
final concentration of 10 g/mL. 4 h and 24 h later, the expression
CAR was detected by flow cytometry.
ADCC percentage=(1-monoclonal antibody group CAR positive ratio/no
antibody group CAR positive ratio)*100%
[0443] The results show that, 4 h and 24 h later, NK cells
significantly cleared RQR8-CD19CAR-MBIL15, RQR8-CD19CAR-MBIL15-IL7
and RQR8-CD19CAR-C7R CAR-T cells in the presence of Rutiximab, but
failed to clear CD19 CAR-T. Without Rutiximab, NK failed to kill
any of the cells. This indicates that Rutiximab can function as a
safety switch, which binds to RQR8, and allows NK to mediate the
ADCC function so that to clear CART cells.
Example 5 Study of U-CAR T Cells Expressing E3
[0444] FIG. 30 shows an example design of CAR-T cells expressing of
enhancer E3. In E3, the ecto domain of C7R is replaced by a safety
switch, such as EGFRt or Her2t or other peptides described in the
present disclosure.
[0445] FIG. 31 shows flow cytometry data of fractions of CAR-T
cells expressing CD19 CAR and the enhancer C7R or E3.
[0446] FIGS. 32A and 32B show in vitro killing activity of CAR-T
cells toward HeLa cells expressing a CD19 antigen. FIG. 32A shows
in vitro killing activity of CD19 CAR-T cells expressing C7R or E3
in comparison with target only or T cell controls. The effector:
target ratio in this experiment is 5:1. FIG. 32B shows in vitro
killing activity of CD19 CAR-T cells expressing C7R or E3 in
comparison with target only or T cell controls. The effector:
target ratio in this experiment is 1:1.
[0447] FIGS. 33A and 33B show expression of phosphorylated STAT5
(pSTAT5) and CD19 CAR in the tested engineered cells. FIG. 33A
shows flow cytometry data of fractions of CAR-T cells expressing
CD19 CAR and pSTAT5. FIG. 33B shows corresponding mean fluorescent
index (MFI) of pSTAT5 of the data in FIG. 33A.
[0448] FIGS. 34A-C show proliferation data of CD19 CAR-T cells
expressing C7R or E3 in comparison to CD19 CAR-T without enhancer.
FIG. 34A shows cytokine independent proliferation of the three
different cells. FIG. 34B shows proliferation under repeated NALM6
stimulations. FIG. 34C shows percentage of CAR-T cells before and
after the stimulation by NALM6. CAR stimulation enriched CAR+
cells.
[0449] FIG. 35A shows flow cytometry data of fractions of CAR-T
cells co-cultured with NK cells at different effector: target
ratios in the presence or absence of Cetuximab (CTX, anti-EGFR
Antibody). The data showed that in the presence of CTX, the CD19
CAR-T expressing E3 can be effectively killed by NK cells via NK
Cell-Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC),
indicating that E3 functions as an effective safety switch and has
been effectively turned off. FIG. 35B shows the total killing
activity of NK cells toward other cells. FIG. 35C shows the killing
activity of NK cells toward CAR-T cells.
[0450] FIGS. 36A and 36B show test of safety switch by ADCC after
repeated stimulation. FIG. 36A shows flow cytometry data of
fractions of CAR-T cells co-cultured with NK cells at different
effector: target ratios in the presence or absence of CTX. The
cells shown in this example were repeated stimulated. FIG. 36B
shows killing activity of NK cells toward CAR-T cells.
[0451] FIG. 56A shows flow cytometry data of fractions of TCR KO
CD7 CAR-T cells expressing CD7 CAR and enhancer C7R or E3
(EGFRt+IL7R.alpha.) at day 12 of cell culture. FIG. 56B shows
6-hour cytotoxicity of TCR KO CD7 CAR-T cells expressing CD7 CAR
and enhancer C7R or E3 (EGFRt+IL7R.alpha.) toward CCRF-CEM cells.
The effector: target ratios tested in this experiment are 5:1 and
1:1. FIG. 56C shows proliferation of TCR KO CD7 CART cells
expressing C7R or E3 (EGFRt+IL7R.alpha.). The CAR-T cells were
cultured in T cell culture media without supplement of IL2 and
monitored for fold of cell expansion. The results show that TCR KO
CD7 CART cells expressing C7R or E3 displayed better cell expansion
and cell stability than control T cells. E3 (EGFRt+IL7R.alpha.) has
better enhancer expression and thus maintained better cell
persistence and expansion than C7R. FIG. 56D shows flow cytometry
data of fractions of TCR KO CD7 CAR-T cells expressing
phosphorylated STAT5 (pSTAT5) and C7R or E3. pSTAT5 was highly
upregulated in TCR KO CD7 CAR-T cells expressing C7R or E3. CAR19
plus IL2 stimulation were used as positive control for pSTAT5. FIG.
56E shows corresponding mean fluorescent index (MFI) of pSTAT5 of
the data in FIG. 56D.
[0452] Sequence of construct design: The etcodomain of C7R can
replaced by a safety switch, such as truncated EGFR or truncated
Her2.
[0453] CD7CAR-E3 amino acid sequence (E3=EGFRt+ constitutively
active IL7R.alpha. TM and endo domain)
TABLE-US-00025 (SEQ ID NO: 100)
MALPVTALLLPLALLLHAARPDIELTQSPAIMSASLGEEITLTCSASSSV
SYMHWYQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFYSLTISSVEA
EDAADYYCHQWSSYTFGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQESGG
GLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVATISSGGSYTY
YPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARQDGYYPGWFAN
WGQGTTVTVSSSGTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHT
RGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRP
VQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNL
GRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGM
KGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRGSGATNFSLLKQAG
DVEENPGPMLLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINA
TNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILTVKEITGF
LLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLK
EISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQ
VCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSE
CIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENN
TLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSPILLTCPTI
SILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLN
VSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQ
SPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGK
NGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQ
EEAYVTMSSFYQNQ
[0454] CD7CAR-E3 (E3=Her2t+constitutively active IL7R.alpha. TM and
endo domain)
TABLE-US-00026 (SEQ ID NO: 101)
MALPVTALLLPLALLLHAARPDIELTQSPAIMSASLGEEITLTCSASSSV
SYMHWYQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFYSLTISSVEA
EDAADYYCHQWSSYTFGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQESGG
GLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVATISSGGSYTY
YPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARQDGYYPGWFAN
WGQGTTVTVSSSGTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHT
RGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRP
VQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNL
GRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGM
KGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRGSGATNFSLLKQAG
DVEENPGPMLLLVTSLLLCELPHPAFLLIPCHPECQPQNGSVTCFGPEAD
QCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGACQPCPINCTH
SCVDLDDKGCPAEQRASPLTGGGSGGGSPILLTCPTISILSFFSVALLVI
LACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQI
HRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITP
ESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSL
GTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQN Q
[0455] FIG. 68 shows BLI imaging of the in vivo efficacy of CAR7
and CAR7-E3 UCAR-T in CCRF-CEM (T-ALL) murine xenograft model. Each
mouse was inoculated intravenously with 3.times.10.sup.5 CCRF-CEM
cells. Four days later, CAR-T cells were intravenously infused
(1.times.10.sup.6 cells per mouse). BLI imaging indicates CAR7-E3
UCAR-T cells had better effect on tumor clearance than CAR7 UCAR-T
cells.
Example 6 Study of U-CAR T Cells Expressing Dual CAR
General Materials and Methods
[0456] Isolation of Peripheral Blood Mononuclear Cells (PBMCs) from
Donor Blood and Expansion of T Cells
[0457] Peripheral blood mononuclear cells (PBMCs) were isolated
from donor blood by using Histopaque-1077 (Sigma-Aldrich) through
density gradient centrifuge. Then T cells were enriched, activated
by magnetic beads coupled with anti-CD3/anti-CD28, cultured and
expanded.
[0458] Cell Lines and Culture of PBMCs
[0459] Raji cells (Burkitt's lymphoma cells, ATCC-CCL86);
[0460] K562 cells (Human erythroleukemia cell line,
ATCC-CCL243);
[0461] Raji-ffluc cell line (obtained by screening Raji cells
transfected with lentivirus having firefly luciferase);
[0462] 293T cells (ATCC-CRL3216);
[0463] CCRF-CEM cells (ATCC-CCL119);
[0464] PBNK: peripheral blood NK sorted from PBMC by using CD56
microbeads and cultured in NK serum free medium kit II (Cyagen
Biosciences)+10% FBS+900 IU/ml IL2 (PeproTech);
[0465] NK92 cells (ATCC-CRL2407);
[0466] NK92-ffluc cells (obtained by screening NK92 cells
transfected with lentivirus having firefly luciferase);
[0467] Raji cells, Raji-ffluc cell line, and K562 cells were
cultured in RPMI1640 medium, and 293T cells were cultured in DMEM
medium. Both RPMI1640 and DMEM were supplemented with 10% (v/v)
fetal bovine serum and 100 U/ml penicillin and streptomycin, 2 mM
glutamine and 1 mM sodium pyruvate. All of the cells were cultured
in an incubator at 37.degree. C., 5% Co.sub.2.
[0468] NK92 cells were cultured in RPMI1640 medium supplemented
with 10% (v/v) fetal bovine serum, 2 mM glutamine, 1 mM sodium
pyruvate, 1% NEAA, 0.1 mM mercaptoethanol and 200 IU/ml rhIL2.
[0469] T cells and the obtained CAR-T cells were cultured in
X-vivo15 medium (containing 5% FBS, 2 mM L-glutamine, 1 mM sodium
pyruvate and 300 IU/ml rhIL2). The culture medium for CAR-T cells
was further supplemented with rhIL-2 (ThermoFisher Scientific) at a
final concentration of 300 IU/ml every two days. All of the cells
were cultured in an incubator at 37.degree. C., 5% CO2.
6.1 Design and Construction of CRISPR
[0470] CD7, CD2, TCR gRNAs for gene editing were selected after
evaluating gene editing efficiency and off-target risk at website
http://crispr.mit.edu, www.idtdna.com and https://www.synthego.com.
gRNAs used in the present disclosure were either synthesized by
Integrated DNA Technologies, Inc (IDT) or prepared by in vitro
transcription (See Shi et al., 2017, J Vis Exp. doi:
10.3791/55267). HiFi-Cas9 was purchased from IDT.
[0471] For gene editing, 3 .mu.g Cas9 protein and 1.5 .mu.g gRNA
were mixed in 20 .mu.l and incubated at 37.degree. C. or room
temperature for 15 minutes to form ribonucleoprotein (RNP). Then
RNP was transfected into T cells by Lonza 4D Nucleofector. Gene
knockout efficiency was determined by the ratio of the cells
expressing the protein as detected by flow cytometry.
[0472] gRNA targeting sequences used are as below:
TABLE-US-00027 SEQ ID NO: 20 TRAC-gRNA1: TTCGGAACCCAATCACTGAC, SEQ
ID NO: 21 TRAC-gRNA2: TCAGGGTTCTGGATATCTGT, SEQ ID NO: 22
TRAC-gRNA3: AAGTTCCTGTGATGTCAAGC, SEQ ID NO: 25 CD7-gRNA1:
GAGGTCAATGTCTACGGCTC, SEQ ID NO: 26 CD7-gRNA2:
ATCACGGAGGTCAATGTCTA, SEQ ID NO: 27 CD7-gRNA3:
GTAGACATTGACCTCCGTGA, SEQ ID NO: 28 CD7-gRNA4:
GGAGCAGGTGATGTTGACGG, SEQ ID NO: 29 CD2-gRNA1:
CAAAGAGATTACGAATGCCT, SEQ ID NO: 30 CD2-gRNA2:
GTGCCACAAAGACCATCAAG, SEQ ID NO: 31 CD2-gRNA3:
AGAGGGTCATCACACACAAG, SEQ ID NO: 32 CD2-gRNA4:
CTTGTAGATATCCTGATCAT,
[0473] After screening, gRNA with high knockout efficiency was
found for each gene and high efficiency was also observed when
knocking out two genes, TCR/CD7 or TCR/CD2, wherein TRAC-gRNA2 and
CD7-gRNA1 are gRNAs with high knockout efficiencies. FIG. 16 shows
efficiencies of CD7 knockout by using different CD7-gRNAs with
TRAC-gRNA1, and CD7-gRNA1 and CD7-gRNA4 were obviously better, and
CD7-gRNA1 was used in subsequent experiments.
6.2 Design of CD7 CAR and Package of the Virus
[0474] The scFv of the CD7 single CAR is derived from TH69, 3Ale
and SDZCHH380 antibodies. The scFv in the CAR is designed as
3Ale-LH, TH69-LH, SDZ-LH, SDZ-HL. The amino acid sequence of the
CAR is as set forth in SEQ ID NO: 75-78.
TABLE-US-00028 3A1e-LH (SEQ ID NO 75)
MALPVTALLLPLALLLHAARPDIELTQSPAIMSASLGEEITLTCSASSSVSYMHW
YQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFYSLTISSVEAEDAADYYCHQWSSYT
FGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQESGGGLVKPGGSLKLSCAASGFTFSSY
AMSWVRQTPEKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSED
TAMYYCARQDGYYPGWFANWGQGTTVTVSSSGTTTPAPRPPTPAPTIASQPLSLRPEAC
RPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMR
PVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYD
VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGL
YQGLSTATKDTYDALHMQALPPR* TH69-LH (SEQ ID NO 76)
MALPVTALLLPLALLLHAARPAAYKDIQMTQTTSSLSASLGDRVTISCSASQGIS
NYLNWYQQKPDGTVKLLIYYTSSLHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYYCQQ
YSKLPYTFGGGTKLEIKRGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLKLSCAAS
GLTFSSYAMSWVRQTPEKRLEWVASISSGGFTYYPDSVKGRFTISRDNARNILYLQMSS
LRSEDTAMYYCARDEVRGYLDVWGAGTTVTVSSSGTTTPAPRPPTPAPTIASQPLSLRP
EACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQP
FMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRRE
EYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGH
DGLYQGLSTATKDTYDALHMQALPPR* SDZ-LH (SEQ ID NO 77)
MALPVTALLLPLALLLHAARPDIQMTQSPASLSASVGETVTITCRASGNIHNYL
AWYQQKQGKSPQLLVYNAKTLADGVPSRFSGSGSGTQYSLKINSLQPEDFGSYYCQHF
WTTPPWTFGGGTKLEIKGGGGSGGGGSGGGGSQIQLVQSGPELKKPGETVKISCKASGY
TFTNYGMNWVKQAPGKGLKWMGWINTYNGEPTYADDFKGRFDFSLETSASTAYLQIN
NLKNEDTATYFCARRGYYYGSRYGAMDYWGQGTSVTVSSSGTTTPAPRPPTPAPTIAS
QPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKL
LYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNEL
NLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERR
RGKGHDGLYQGLSTATKDTYDALHMQALPPR* SDZ-HL (SEQ ID NO 78)
MALPVTALLLPLALLLHAARPQIQLVQSGPELKKPGETVKISCKASGYTFTNYG
MNWVKQAPGKGLKWMGWINTYNGEPTYADDFKGRFDFSLETSASTAYLQINNLKNED
TATYFCARRGYYYGSRYGAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIQMTQSP
ASLSASVGETVTITCRASGNIHNYLAWYQQKQGKSPQLLVYNAKTLADGVPSRFSGSGS
GTQYSLKINSLQPEDFGSYYCQHFWTTPPWTFGGGTKLEIKSGTTTPAPRPPTPAPTIASQ
PLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLL
YIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELN
LGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRR
GKGHDGLYQGLSTATKDTYDALHMQALPPR*
[0475] The CAR gene was cloned into the FUW lentiviral vector
backbone under the promoter of EF1.alpha. (EF-1.alpha.) to form
Fuw-EF1.alpha.-CAR. Fuw-EF1.alpha.-CAR, lentiviral envelope plasmid
pMD2.G (Addgene, Plasmid #12259) and lentiviral packaging plasmid
psPAX2 (Addgene, Plasmid #12260) were transfected into 293 T cells
by using Lipofectamine3000 or PEI to prepare the whole expression
vector. The supernatant was collected at 48 and 72 h and subject to
ultra-centrifuge (Merck Millipore) for concentration. The
concentrated virus was ready for the transfection of T cells.
6.3 Preparation of CAR-T Cells
[0476] Cell Isolation and Activation
[0477] After apheresis, monocytes were isolated using
Histopaque-1077 (Sigma-Aldrich) by density gradient centrifugation.
Then T cells were enriched, activated by magnetic beads coupled
with anti-CD3/anti-CD28, cultured and expanded.
[0478] X-vivo 15 with 5% FBS, 2 mM L-glutamine, 1 mM sodium
pyruvate and 300 IU/ml rhIL2 was used as CAR-T cell medium. The
cells were incubated and cultured at 37.degree. C., 5% CO2.
[0479] Cell line expressing CD 19: Raji (Burkitt's lymphoma cell
line, ATCC-CCL86); K562 (ATCC-CCL243); Raji-ffluc and NK92 cell
lines was obtained by screening cells transfected with lentivirus
having firefly luciferase;
[0480] Cell line expressing CD7 and CD2: Jurkat cell, CCRF-CEM and
NK92 cells.
[0481] All of the cells were cultured in RPMI1640 medium and 293T
cells (ATCC-CRL3216) were cultured in DMEM medium. Both RPMI1640
and DMEM were supplemented with 10% (v/v) fetal bovine serum and
100 U/ml penicillin and streptomycin, 2 mM glutamine and 1 mM
sodium pyruvate.
[0482] Electroporation and Lentivirus Infection
[0483] Two days after enriching and activating the T cells, the
anti-CD3/anti-CD28 magnetic beads were removed and the cells were
collected into a tube and subject to centrifuge at 300 g for 5 min,
and then washed twice with DPBS and re-suspended in opti-mem at a
cell density of 50.times.10.sup.6/ml. The amount of cas9/gRNA RNP
required was calculated based on the density of the cells, and then
mixed with cells and transferred for electroporation by
4D-Nucleofector System N (Lonza) system. Then the cells were
re-suspended in a pre-warmed medium to a density of
1-2.times.10.sup.6/ml. The cells were further subject to lentiviral
transfection at MOI of 2-8, transferred to a flask and cultured in
an incubator at 37.degree. C., 5% Co.sub.2.
[0484] Cell Proliferation and Detection of CAR Positive Ratio
[0485] 3 days after the transfection, the number of cells and CAR
positive cells were detected, and the positive ratio of CAR in T
cells was calculated. The positive ratio of TCR (or CD3), and CD7
was also detected to determine the knockout efficiency. Then the
cells were continuously cultured in the incubator and half of the
medium was replaced every 2-3 days till day 10 when the cells were
ready for cryopreservation.
6.4 Screening of CD7 CAR Structure
[0486] As shown in FIG. 38A, the expression of anti-CD7 CAR was
successfully detected, among which TH69-LH shows the strongest
expression, followed by 3Ale-LH, then SDZ-LH, and SDZ-HL. In terms
of function, as shown in FIG. 38B, 3Ale-LH, CARs all showed the
best killing effects on CD7-positive T cells, while TH69-LH, SDZ-LH
and SDZ-HL CARs were less effective. Therefore, the scFv of 3Ale
was selected for CD7 CAR in the dual CAR.
6.5 Design of CD19-CD7 Dual CAR Structure
[0487] The structure of CD19-CD7 dual CAR targeting CD19 and CD7 is
as illustrated in FIG. 37 and below:
[0488] Loop: L719-LHLH and L719-HLHL, sequence as set forth in SEQ
ID NO 79 and 80;
TABLE-US-00029 L719-LHLH (SEQ ID NO. 79)
MALPVTALLLPLALLLHAARPDIQMTQTTSSLSASLGDRVTISCRASQDISKYLN
WYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTL
PYTFGGGTKLEITGGGGSQVKLQESGGGLVKPGGSLKLSCAASGETFSSYAMSWVRQT
PEKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCAR
QDGYYPGWFANWGQGTTVTVSSGSTSGSGKPGSGEGSTKGDIELTQSPAIMSASLGEEI
TLTCSASSSVSYMHWYQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFYSLTISSVEAE
DAADYYCHQWSSYTFGGGTKLEIKRGGGGSEVKLQESGPGLVAPSQSLSVTCTVSGVS
LPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQT
DDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSSGTTTPAPRPPTPAPTIASQPLSLRP
EACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQP
FMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRRE
EYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGH
DGLYQGLSTATKDTYDALHMQALPPR* L719-HLHL (SEQ ID NO. 80)
MALPVTALLLPLALLLHAARPEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYG
VSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAI
YYCAKHYYYGGSYAMDYWGQGTSVTVSSGGGGSDIELTQSPAIMSASLGEEITLTCSA
SSSVSYME1WYQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFYSLTISSVEAEDAADY
YCHQWSSYTFGGGTKLEIKRGSTSGSGKPGSGEGSTKGQVKLQESGGGLVKPGGSLKL
SCAASGFTFSSYAMSWVRQTPEKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTL
YLQMSSLRSEDTAMYYCARQDGYYPGWFANWGQGTTVTVSSGGGGSDIQMTQTTSSL
SASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDY
SLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITSGTTTPAPRPPTPAPTIASQPLSLRPE
ACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPF
MRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREE
YDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHD
GLYQGLSTATKDTYDALHMQALPPR*
[0489] Tandem: T197-LHLH, T197-LHLH-EAAAK3 (by using a linker with
three connected EAAAK (SEQ ID NO: 102)), T719-LHLH, T719-LHHL,
sequence as set forth in SEQ ID NO 81-84;
TABLE-US-00030 T197-LHLH (SEQ ID NO. 81)
MALPVTALLLPLALLLHAARPDIQMTQTTSSLSASLGDRVTISCRASQDISKYLN
WYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTL
PYTFGGGTKLEITGGGGSGGGGSGGGGSEVKLQESGPGLVAPSQSLSVTCTVSGVSLPD
YGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDT
AIYYCAKHYYYGGSYAMDYWGQGTSVTVSSGSTSGSGKPGSGEGSTKGDIELTQSPAT
MSASLGEEITLTCSASSSVSYMHWYQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFY
SLTISSVEAEDAADYYCHQWSSYTFGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQESG
GGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVATISSGGSYTYYPDSVKG
RFTISRDNAKNTLYLQMSSLRSEDTAMYYCARQDGYYPGWFANWGQGTTVTVSSSGT
TTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLL
SLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADA
PAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK
MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR* T197-LHLH-(EAAAK)3
(SEQ ID NO. 82)
MALPVTALLLPLALLLHAARPDIQMTQTTSSLSASLGDRVTISCRASQDISKYLN
WYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTL
PYTFGGGTKLEITGGGGSGGGGSGGGGSEVKLQESGPGLVAPSQSLSVTCTVSGVSLPD
YGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDT
AIYYCAKHYYYGGSYAMDYWGQGTSVTVSSEAAAKEAAAKEAAAKDIELTQSPAIMS
ASLGEEITLTCSASSSVSYMHWYQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFYSLT
ISSVEAEDAADYYCHQWSSYTFGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQESGGGL
VKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVATISSGGSYTYYPDSVKGRFTI
SRDNAKNTLYLQMSSLRSEDTAMYYCARQDGYYPGWFANWGQGTTVTVSSSGTTTPA
PRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVIT
LYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYK
QGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA
YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR* T719-LHLH (SEQ ID NO.
83) MALPVTALLLPLALLLHAARPDIELTQSPAIMSASLGEEITLTCSASSSVSYMHW
YQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFYSLTISSVEAEDAADYYCHQWSSYT
FGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQESGGGLVKPGGSLKLSCAASGFTFSSY
AMSWVRQTPEKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSED
TAMYYCARQDGYYPGWFANWGQGTTVTVSSGSTSGSGKPGSGEGSTKGDIQMTQTTS
SLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGT
DYSLTISNLEQEDIATYFCQQGNTLPYTEGGGTKLEITGGGGSGGGGSGGGGSEVKLQE
SGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKS
RLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSSGT
TTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLL
SLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADA
PAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK
MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR* T719-LHHL (SEQ ID
NO. 84) MALPVTALLLPLALLLHAARPDIELTQSPAIMSASLGEEITLTCSASSSVSYMHW
YQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFYSLTISSVEAEDAADYYCHQWSSYT
FGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQESGGGLVKPGGSLKLSCAASGFTFSSY
AMSWVRQTPEKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSED
TAMYYCARQDGYYPGWFANWGQGTTVTVSSGSTSGSGKPGSGEGSTKGEVKLQESGP
GLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLT
IIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSGGGGS
GGGGSGGGGSDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIY
HTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITSGT
TTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLL
SLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADA
PAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK
MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR*
[0490] Loop dual CAR connected with a constitutively activated IL7
receptor C7R: L719-C7R, amino acid sequence as set forth in SEQ ID
NO 85.
TABLE-US-00031 L719-C7R (SEQ ID NO 85)
MALPVTALLLPLALLLHAARPDIQMTQTTSSLSASLGDRVTISCRASQDISKYLN
WYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTL
PYTEGGGTKLEITGGGGSQVKLQESGGGLVKPGGSLKLSCAASGFTESSYAMSWVRQT
PEKRLEWVATISSGGSYTYYPDSVKGRETISRDNAKNTLYLQMSSLRSEDTAMYYCAR
QDGYYPGWFANWGQGTTVTVSSGSTSGSGKPGSGEGSTKGDIELTQSPAEVISASLGEEI
TLTCSASSSVSYMHWYQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFYSLTISSVEAE
DAADYYCHQWSSYTEGGGTKLEIKRGGGGSEVKLQESGPGLVAPSQSLSVTCTVSGVS
LPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQT
DDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSSGTTTPAPRPPTPAPTIASQPLSLRP
EACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQP
FMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRRE
EYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGH
DGLYQGLSTATKDTYDALHMQALPPRGSGATNFSLLKQAGDVEENPGPMLVRRGARA
GPRMPRGWTALCLLSLLPSGFMSLDNNGTATPELPTQGTFSNVSTNVSYQETTTPSTLG
STSLHPVSQHGNEATTNITETTVKFTSTSVITSVYGNTNSSVQSQTSVISTVFTTPANVSTP
ETTLKPSLSPGNVSDLSTTSTSLATSPTKPYTSSSPILSDIKAEIKCSGIREVKLTQGICLEQ
NKTSSCAEFKKDRGEGLARVLCGEEQADADAGAQVCSLLLAQSEVRPQCLLLVLANRT
EISSKLQLMKKHQSDLKKLGILDFTEQDVASHQSYSQKTPILLTCPTISILSFFSVALLVIL
ACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSENPESELDCQIHRVDDIQARD
EVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESEGRDSSLTCLAGNVSACD
APILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTS
LGSNQEEAYVTMSSFYQNQ*
6.6 Test for the Dual CAR Structure-1
[0491] 1) Expression of the dual CARs and the knockout
efficiency
[0492] We compared two Loop CARs (L719-LHLH and L719-HLHL) and two
Tandem CARs (T197-LHLH and T197-LHLH-(EAAAK3)3), where CAR7 and
CAR19 were used as single CAR control, and Mock T was a negative
control. As shown in FIG. 39, the expression of the two Loop dual
CARs was diagonally distributed, indicating successful expression
of the dual CARs. CD19 CAR of the Tandem dual CARs showed strong
expression, however, CD7 CAR was weakly detected. FIG. 40 shows the
knockout efficiencies of CD7 and CD3 (TRAC), and it can be seen
that in Mock T and CAR19, the knockout efficiencies were up to 98%.
In the other two groups including CD7 single CAR and CD7/CD19 dual
CAR, the ratio of CD7+ cells was significantly lower than those in
Mock T and CAR 19 groups, indicating the function of CD7 CAR.
[0493] 2) In vitro killing effects of dual CARs on CD19+ cells and
CD7+ cells
[0494] First, we compared the killing effects of different CARs on
CD 19 target. xCELLigence Real-Time Cell Analyzer (RTCA) experiment
showed that two Loop CARs and two Tandem CARs both had potent
killing effects on HeLa-CD19+ cells, similar as CD19 single CAR
(CAR19) (FIG. 41).
[0495] Subsequently, we compared the killing effects of different
CARs on CD7+NK cells from peripheral blood (FIG. 42A). In vivo
expanded PBNK cells (ratio of CD7+ cell was .about.80%) were
labelled with carboxyfluorescein succinimidyl ester (CFSE), and
incubated with CAR-T cells for 1 day. Then the cells were subject
to flow cytometry to analyze the change in ratio of CFSE positive
cells. FIG. 42A shows that dual CARs and CD7 single CAR had
significant killing effects on NK cells, and CD19 single CAR and
Mock T did not show any killing effect. FIG. 42B shows that CD7+
cells in NK almost disappeared after co-culturing with dual CARs
(L719-LHLH and T197-LHLH), indicating CAR7 and dual CARs completely
killed the CD7+ cells in NK.
[0496] Furthermore, we compared the killing effects of different
CARs on allogeneic T cells (CD7+) (FIG. 43). The result shows that
the allogeneic T cells were completely killed by CAR7 and dual
CARs, while CAR19 did not show any killing effect on allogeneic T
cells.
[0497] 3) In vivo clearance of CD19+ Raji tumor by dual CARs
[0498] Each mouse was inoculated intravenously with
3.times.10.sup.5 tumor cells. 6 days later, CAR-T cells were
intravenously infused (3.times.10.sup.6 cells per mouse). BLI
imaging indicates that Loop CARs and Tandem CARs both cleared Raji
tumors to certain extent, and L719-LHLH showed the best in vivo
tumor control (FIG. 44).
6.7 Test for Dual CAR Structure-2
[0499] Two other Tandem dual CAR structures: T719-LHLH and
T719-LHHL were designed and compared with Loop CAR (L719-LHLH, also
named as L719).
[0500] FIGS. 45A and 45B show that new Tandem dual CARs were
successfully expressed (FIG. 45A), and also had significant killing
effects on the remaining CD7+ cells after gene knockout (FIG.
45B).
[0501] Real-time Cell Analysis (RTCA) shows that (FIG. 46), Tandem
dual CARs had similar killing effects on HeLa-CD19 cells as
L719.
[0502] FIGS. 47A and 47B shows that, Tandem dual CARs also had
similar strong killing effects on allogeneic T cells and NK cells
as L719 over 24 hours.
[0503] FIG. 48 shows that L719 and Tandem (T719-LHLH and T719-LHHL)
dual CARs both greatly cleared the CCRF-CEM tumors in vivo
(CCRF-CEM intravenous model in NOG mice).
6.8 Release of the Cytokines
[0504] The dual CAR-T cells prepared in Example 6.3 and CD19
positive tumor cells (Raji), CD7 positive tumor cells (Jurkat) or
primary allogeneic PBMCs or NK, 100 ul each, were mixed in RPMI
medium at 1: 1 ratio to a density of 1.times.10.sup.6/ml for each
cell, and then cultured overnight in a 96-well plate. The medium
was then collected and subject to centrifuge and the released
cytokine IFN-.gamma. and IL-2 were detected by Cytokine bead array
kit (CBA kit, BD Biosciences).
[0505] The result shows that incubation of CD19-CD7 CAR-T cells
with Raji, Jurka, primary allogeneic PBMCs or NK cells produces a
large amount of IFN-.gamma. and IL-2, indicating function of CAR-T
against CD19 positive or CD7 positive target cells.
6.9 In Vivo GVHD Study
[0506] The mice were systemically treated with a sub-lethal dose of
irradiation (175 cGy) first. Then CAR-T cells were re-suspended in
PBS and injected into the thorax of the treated mice. The mice were
observed 2-3 times a week by using GVHD clinical criteria including
weight loss, arch-back, activity, fur texture, and skin
integrity.
[0507] The result shows that mice without TCR knockout showed GVHD
symptoms, however, no GVHD was detected in the CD7-CD19
CAR-T+TCR/CD7double knockout group.
6.10 In Vitro HVG Study
[0508] CD7 CAR can effectively and rapidly clear CD7+ cells, and in
vitro experiments showed that allogeneic T cells did not display
significant rejection on CAR-T cells expressing CD7 CAR, but
displayed strong rejection on CAR-T cells expressing CAR19
only.
[0509] The allogeneic NK cells showed significantly less rejection
on CAR-T cells expressing CD7 CAR than CAR-T cells without CD7
CAR.
6.11 Clearance of CAR-T Cells by AP1903 or Rapamycin
[0510] 10 nM AP1903 or Rapamycin was added to the medium of
rapaCasp9-L719 CAR-T (sequence as set forth in SEQ ID NO: 86)
cells. 1, 6 and 24 hours later, apoptosis and survival of the CAR-T
cells were detected by flow cytometry.
[0511] The result shows that AP1903 and Rapamycin rapidly cleared
rapaCasp9-L719 CAR-T cells but fails to clear CD19 control CART,
indicating the specificity of the safety switch.
TABLE-US-00032 rapaC9-L719 (SEQ ID NO. 86)
MASRILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKET
SFNQAYGRDLMEAQEWCRKYMKSGNVKDLLQAWDLYYHVFRRISKLEYSGGGSLEG
VQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGW
EEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLESGGGGSGGGGS
GGGGSGVDGFGDVGALESLRGNADLAYILSMEPCGHCLIINNVNFCRESGLRTRTGSNI
DCEKLRRRFSSLHFMVEVKGDLTAKKMVLALLELAQQDHGALDCCVVVILSHGCQAS
HLQFPGAVYGTDGCPVSVEKIVNIFNGTSCPSLGGKPKLFFIQACGGEQKDHGFEVASTS
PEDESPGSNPEPDATPFQEGLRTFDQLDAISSLPTPSDIFVSYSTFPGFVSWRDPKSGSWY
VETLDDIFEQWAHSEDLQSLLLRVANAVSVKGIYKQMPGCFNFLRKKLFFKTSGSGATN
FSLLKQAGDVEENPGPMALPVTALLLPLALLLHAARPDIQMTQTTSSLSASLGDRVTISC
RASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDI
ATYFCQQGNTLPYTFGGGTKLEITGGGGSQVKLQESGGGLVKPGGSLKLSCAASGFTFS
SYAMSWVRQTPEKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRS
EDTAMYYCARQDGYYPGWFANWGQGTTVTVSSGSTSGSGKPGSGEGSTKGDIELTQSP
AIMSASLGEEITLTCSASSSVSYMHWYQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTF
YSLTISSVEAEDAADYYCHQWSSYTFGGGTKLEIKRGGGGSEVKLQESGPGLVAPSQSL
SVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQ
VFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSSGTTTPAPRPPTPAP
TIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGR
KKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLY
NELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKG
ERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR*
[0512] Safety switch functions of E3 in L719-E3 cells were
determined by 24 hr Complement dependent cytotoxicity assay (CDC
assay). Briefly, TCR/CD7 double knockout L719-E3 cells or L718-E2
cells were incubated in media containing 0%, 5% or 25% donor serum.
24 hr CDC effects were examined by adding 5 or 50 ug/ml of
Cetuximab(CTX). Rituximab (RTX), which targeting CD20, was used as
negative control. As shown in FIGS. 61A and 61B, L719-E3 cells were
specifically lysed by cetuximab in the presence of serum (FIG.
61A), and no CDC effect was observed in L719-E2 cells without EGFRt
or CD20 extracellular domain (FIG. 61B).
[0513] Safety switch functions of E3 in TCR/CD7 double knockout
CAR7-E3 cells or L719-E3 cells were further determined by
Complement dependent cytotoxicity assay (CDC assay). Cells were
incubated in media containing 0%, 5% or 25% Guinea pig serum. Then
CDC effects were detected in the presence of 5 ug/ml of Cetuximab.
As shown in FIG. 62A, the CDC effects corresponded to the
concentrations of the serum (complement), and were specific for E3
expressing CAR7-E3 cells but not control T cells. The CDC effects
were also examined on L719-E3 cells in the presence of either 5
ug/ml Cetuximab or Herceptin. As shown in FIG. 62B, the CDC effects
were only observed in the presence of Cetuximab.
6.12 Cytokine Receptor C7R or E3 Enhanced the Function of Dual
CAR
[0514] To further enhance the survival of the universal CAR-T cells
in vivo, a constitutive signal factor IL7 receptor (C7R) or E3 was
linked to the L719 dual CAR by 2A to activate the pSTAT5 signaling
pathway. FIG. 50A shows the expression of CD19 and CD7 antigen
binding domains in L719 and L719-C7R dual CAR-T cells. FIG. 50B
shows cytotoxicity of L719 dual CAR-T cells with or without C7R
expression toward HeLa cells expressing CD7 (HeLa-CD7). FIG. 50C
show cytotoxicity of L719 dual CAR-T cells with or without C7R
expression toward HeLa cells expressing CD19 (HeLa-CD19). The
effector: target ratio tested in FIGS. 50B and 50C is 4:1. FIGS.
50B and 50C show that both L719 and L719-C7R effectively killed
HeLa-CD7 and HeLa-CD19. FIG. 50D shows flow cytometry data of
fractions of L719 dual CAR-T cells expressing both an enhancer (C7R
or E3) and CD7. FIG. 50E shows 6-hour cytotoxicity data of L719
dual CAR-T cells expressing C7R or E3 toward NALM6 cells. The
effector: target ratios tested in this experiment are 5:1 and 1:1.
FIG. 50F shows 6-hour cytotoxicity data of L719 dual CAR-T cells
expressing C7R or E3 toward CCRF-CEM cells. The effector: target
ratios tested in this experiment are 5:1 and 1:1. FIG. 50G shows
flow cytometry data of fractions of L719 dual CAR-T cells
expressing phosphorylated STAT5 (pSTAT5) and C7R or E3. pSTAT5 was
highly upregulated in L719 dual CAR-T cells expressing C7R or E3.
CAR19 plus IL2 stimulation were used as positive control for
pSTAT5. Non-engineered T cells were used as negative control for
pSTAT5. FIG. 50H shows proliferation of L719 dual CAR-T cells
expressing C7R or E3 after IL-2 removal. The CAR-T cells were
treated with two rounds of stimulations by NALM6 cells.
[0515] FIG. 50I shows cytotoxicity of L719 dual CAR-T cells
expressing E3 (L719-E3) toward CD19 expressing HeLa cells
(HeLa-CD19). The L719-E3 cells were compared with control groups
including target cells only, non-transduced TCR/CD7 double knockout
cells (NT-DKO), and CD19 CAR-T cells, and L719-E3 showed better
cytotoxicity toward HeLa-CD19 cells. The effector: target ratio
tested in this experiment is 5:1. FIG. 50J shows cytotoxicity of
L719 dual CAR-T cells expressing E3 (L719-E3) toward CD7 expressing
HeLa cells (HeLa-CD7). The L719-E3 cells were compared with control
groups including target cells only, non-transduced TCR/CD7 double
knockout cells (NT-DKO), and CD19 CAR-T cells, and L719-E3 showed
better cytotoxicity toward HeLa-CD7 cells. The effector: target
ratio tested in this experiment is 5:1.
[0516] FIGS. 63A and 63B show the expression of IL2 and IFN-.gamma.
in TCR/CD7 double knockout CAR7 cells with no cytokine signaling
enhancement, or with mbIL15, C7R, or E3 expression. Cells were
stimulated by CCRF-CEM cells at 1:1 effector: target cell ratio for
24 hours. Supernatant were collected and measured for IL12 and
IFN.gamma. expression by cytokine bead array. As shown in FIG. 63A,
CAR7 cells expressing C7R and E3 showed enhanced IL-2
production.
[0517] FIG. 64 shows the expression of IL2 and IFN-.gamma. in
TCR/CD7 double knockout CD19/CD7 dual CAR-L719 cells with no
cytokine signaling enhancement, or with C7R, or E3 expression.
[0518] Cells were stimulated by CCRF-CEM cells at 1:2 effector:
target cell ratio for 24 hours. Supernatant were collected and
measured for IL12 and IFN.gamma. expression by cytokine bead array.
As shown in FIG. 64, CAR7 cells expressing C7R showed enhanced IL-2
production.
6.13 Additional Sequences Used to Construct CARs as Described
Herein
TABLE-US-00033 [0519] FMC63 scFv V.sub.L (SEQ ID NO 87)
DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRL
HSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEIT FMC63 scFv
V.sub.H (SEQ ID NO 88)
EVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGS
ETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWG QGTSVTVSS
FMC63 CD19CAR (SEQ ID NO 89)
MALPVTALLLPLALLLHAARPDIQMTQTTSSLSASLGDRVTISCRASQDISKYLN
WYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTL
PYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSL
PDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTD
DTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSSGTTTPAPRPPTPAPTIASQPLSLRPE
ACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPF
MRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREE
YDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHD
GLYQGLSTATKDTYDALHMQALPPR* 3A1e CD7 scFv V.sub.L (SEQ ID NO 90)
DIELTQSPAIMSASLGEEITLTCSASSSVSYMEIWYQQKSGTSPKWYSTSNLASG
VPSRFSGSGSGTFYSLTISSVEAEDAADYYCHQWSSYTFGGGTKLEIKR 3A1e CD7 scFv
V.sub.H (SEQ ID NO 91)
QVKLQESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVATISS
GGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARQDGYYPGWFANW
GQGTTVTVSS
6.14 Proliferation of CD19 and CD7 Dual Specific CAR-T Cells
[0520] FIG. 57A shows proliferation of CD19 and CD7 dual specific
CAR-T cells expressing C7R (GC197-C7R). The engineered dual
specific CAR-T cells were prepared from two different T cell
donors. CAR-T cells from both donors displayed superior persistence
and proliferation in response to repetitive cancer antigen
stimulation. FIG. 57B shows proliferation of GC197-C7R cells
without stimulation. Freshly prepared GC197-C7R were cultured in T
cell culture media without supplement of IL2 or antigen
stimulation, compared to control T cells, GC197-C7R maintained
better expansion, and persisted in culture.
[0521] FIG. 58A shows expression of CD7 CAR and enhancer in
GC197-C7R and GC197-E3 at day 12 of cell culture. FIG. 58B shows
proliferation of GC197 cells expressing C7R (GC197-C7R) or E3
(GC197-E3) without stimulation. GC197-C7R or GC197-E3 cells were
cultured in T cell culture media without supplement of IL2 and
monitored for fold of cell expansion and persistence. FIG. 58C
shows proliferation of GC197-C7R and GC197-E3 in the presence of
antigen stimulation. The cells were repeated stimulated by Nalm6
(CD19+ B-ALL cell line) and monitored for fold of cell expansion.
The data showed that GC197-C7R/E3 displayed comparably superior
cell expansion and cell stability either with or without cytokine
or antigen stimulation.
6.15 In Vivo Efficacy
[0522] FIG. 69 shows BLI imaging of the in vivo efficacy of L719
and L719-C7R UCAR-T in Nalm6 (B-ALL) murine xenograft model. Each
mouse was inoculated intravenously with 1.times.10.sup.6 Nalm6
cells. Four days later, CAR-T cells were intravenously infused
(high dose: 1.times.10.sup.6 or low dose: 3.times.10.sup.5 cells
per mouse). BLI imaging indicates L719-C7R UCAR-T cells had better
effect on tumor clearance than L719 UCAR-T cells.
Example 7 Study of U-CAR T Cells with CD137 and CD19 Dual CAR
General Materials and Methods
[0523] Isolation of Peripheral Blood Mononuclear Cells (PBMCs) from
Donor Blood and Expansion of T Cells
[0524] Peripheral blood mononuclear cells (PBMCs) were isolated
from donor blood by using Histopaque-1077 (Sigma-Aldrich) through
density gradient centrifuge. Then T cells were enriched, activated
by magnetic beads coupled with anti-CD3/anti-CD28, cultured and
expanded.
[0525] Cell Lines and Culture of PBMC and Peripheral Blood Primary
NK (PBNK) Cells
[0526] Raji cells (Burkitt's lymphoma cells, ATCC-CCL86);
[0527] K562 cells (Human erythroleukemia cell line,
ATCC-CCL243);
[0528] Raji-ffluc cell line (obtained by screening Raji cells
transfected with lentivirus having firefly luciferase);
[0529] 293T cells (ATCC-CRL3216);
[0530] NK92 cells (ATCC-CRL2407);
[0531] NK92-ffluc cells (obtained by screening NK92 cells
transfected with lentivirus having firefly luciferase)
[0532] Raji cells, K562 cells and Raji-ffluc cell line were
cultured in RPMI1640 medium, and 293T cells were cultured in DMEM
medium. Both RPMI1640 and DMEM were supplemented with 10% (v/v)
fetal bovine serum and 100 U/ml penicillin and streptomycin, 2 mM
glutamine and 1 mM sodium pyruvate. All of the cells were cultured
in an incubator at 37.degree. C., 5% Co.sub.2.
[0533] NK92 cells and NK92-ffluc cells were cultured in RPMI1640
medium supplemented with 10% (v/v) fetal bovine serum, 2 mM
glutamine, 1 mM sodium pyruvate, 1% NEAA, 0.1 mM mercaptoethanol
and 200 IU/ml rhIL2. PBNKs was sorted from PBMCs by using CD56
microbeads, and then cultured in above medium and expanded under
the stimulation of K562 expressing 4-1BBL-mbIL15.
[0534] T cells and the obtained CAR-T cells were cultured in
X-vivo15 medium (containing 5% FBS, 2 mM L-glutamine, 1 mM sodium
pyruvate and 300 IU/ml rhIL2). The culture medium for CAR-T cells
was supplemented with rhIL-2 (ThermoFisher Scientific) at a final
concentration of 300 IU/ml every two days. All of the cells were
cultured in an incubator at 37.degree. C., 5% CO.sub.2.
7.1 Design of CD19-CD137 Dual CAR and Package of the Virus
[0535] The structure of CD19 CAR is SP-CD19 scFv VL-Linker-CD19
scFv VH-Hinge-TM-4-1BB-CD3.zeta.; and the loop of CD19 and CD137
targeting dual CAR (CD19-CD7 dual-CAR) is SP-CD19 scFv
VL-Linker-CD137 scFv VH-linker-CD137 scFv VL-Linker-CD19 scFv
VH-Hinge-TM-4-1BB-CD3.zeta. (as shown in FIG. 52). The nucleotide
sequence of CD19-CD137-loop-CAR is set forth as SEQ ID NO.: 41.
TABLE-US-00034 CD19-CD137-Loop-CAR (SEQ ID NO 41):
ATGGCACTCCCTGTAACTGCACTTCTTTTGCCACTTGCCTTGCTCCTGCACGC
AGCGCGGCCGGATATTCAAATGACACAAACTACCAGCTCCCTTTCAGCATCTTTGGG
CGATAGAGTAACTATAAGTTGCCGCGCGTCCCAAGACATCTCTAAGTACCTTAACTG
GTATCAACAAAAACCGGACGGGACGGTCAAACTGTTGATCTATCACACATCCAGAT
TGCACTCAGGCGTGCCGAGCAGGTTCAGTGGGAGTGGGTCAGGAACGGATTACAGC
TTGACGATTAGTAACCTGGAGCAAGAAGACATTGCCACCTACTTCTGCCAGCAAGG
TAACACTCTCCCATATACGTTCGGGGGTGGCACCAAGCTGGAAATCACTGGCGGCG
GAGGATCCGAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGA
GAGCCTGAGGATCAGCTGCAAGGGCAGCGGCTACAGCTTCAGCACCTACTGGATCA
GCTGGGTGAGGCAGATGCCCGGCAAGGGCCTGGAGTGGATGGGCAAGATCTACCCC
GGCGACAGCTACACCAACTACAGCCCCAGCTTCCAGGGCCAGGTGACCATCAGCGC
CGACAAGAGCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCAGCGAC
ACCGCCATGTACTACTGCGCCAGGGGCTACGGCATCTTCGACTACTGGGGCCAGGG
CACCCTGGTGACCGTGAGCAGCGGCAGCACAAGCGGCTCTGGCAAGCCTGGATCTG
GCGAGGGCTCTACCAAGGGCATGAGCTACGAGCTGACCCAGCCCCCCAGCGTGAGC
GTGAGCCCCGGCCAGACCGCCAGCATCACCTGCAGCGGCGACAACATCGGCGACCA
GTACGCCCACTGGTACCAGCAGAAGCCCGGCCAGAGCCCCGTGCTGGTGATCTACC
AGGACAAGAACAGGCCCAGCGGCATCCCCGAGAGGTTCAGCGGCAGCAACAGCGG
CAACACCGCCACCCTGACCATCAGCGGCACCCAGGCCATGGACGAGGCCGACTACT
ACTGCGCCACCTACACCGGCTTCGGCAGCCTGGCCGTGTTCGGCGGCGGCACCAAG
CTGACCGTGCTGGGGGGAGGCGGCAGCGAGGTGAAACTGCAGGAGTCCGGGCCCG
GTCTCGTGGCACCTTCCCAGTCACTGTCCGTGACCTGCACCGTATCTGGGGTAAGTC
TGCCGGATTATGGGGTTTCATGGATCCGGCAACCTCCGAGGAAAGGGTTGGAATGG
CTGGGAGTCATCTGGGGAAGCGAGACAACTTATTATAATTCTGCTTTGAAGAGCCG
CTTGACGATAATCAAGGACAACAGTAAGAGTCAGGTTTTCTTGAAGATGAATTCTCT
TCAGACAGATGACACCGCTATTTATTATTGTGCAAAACATTATTATTACGGAGGATC
CTACGCGATGGACTATTGGGGACAGGGTACCTCTGTTACGGTGTCCTCATCCGGAAC
AACGACACCAGCACCACGGCCACCCACTCCTGCTCCGACAATTGCGTCTCAGCCCCT
TTCCCTTCGACCCGAAGCTTGTCGCCCTGCTGCGGGAGGAGCGGTCCACACGCGCG
GGCTTGACTTCGCTTGCGACATCTACATTTGGGCACCCTTGGCCGGGACATGCGGCG
TCTTGCTCCTGAGTCTGGTTATAACGCTGTATTGTAAGCGAGGTCGGAAGAAGCTTT
TGTATATCTTTAAACAGCCCTTTATGAGGCCCGTACAAACCACACAAGAGGAGGAT
GGGTGCTCATGCAGATTTCCTGAAGAGGAAGAGGGCGGTTGCGAACTTAGAGTCAA
ATTCAGCCGCTCCGCAGATGCACCTGCTTATAAACAGGGTCAGAATCAATTGTATA
ATGAACTTAATCTCGGGAGGCGCGAGGAGTATGATGTGCTGGACAAGCGACGGGGT
CGAGACCCAGAGATGGGCGGTAAACCCCGCCGAAAGAACCCCCAGGAGGGACTGT
ATAATGAGCTGCAAAAGGACAAAATGGCAGAAGCCTATTCCGAAATAGGGATGAA
GGGAGAGCGGCGGCGAGGTAAGGGACATGACGGTCTTTATCAAGGTCTTAGTACTG
CAACTAAGGACACCTATGACGCGCTGCATATGCAGGCTCTCCCACCTAGATAA
[0536] The CAR gene was cloned into the FUW lentiviral vector
backbone under the promoter of EF1.alpha. (EF-1.alpha.) to form
Fuw-EF1.alpha.-CAR. Fuw-EF1.alpha.-CAR, lentiviral envelope plasmid
pMD2.G (Addgene, Plasmid #12259) and lentiviral packaging plasmid
psPAX2 (Addgene, Plasmid #12260) were transfected into 293 T cells
by using Lipofectamine3000 to prepare the whole lentiviral
expression vector. The supernatant was collected at 48 and 72 h and
subject to ultra-centrifuge (Merck Millipore) for concentration.
The concentrated virus was ready for the transfection of T
cells.
[0537] The result shows that the lentiviral vector was successfully
constructed and expressions of anti-CD19 and anti-CD19/CD137 of the
dual CAR were detected as expected.
7.2 Design and Construction of CRISPR
[0538] CD137 and TCR gRNAs for gene editing were selected after
evaluating gene editing efficiency and off-target risk at website
http://crispr.mit.edu, www.idtdna.com and https://www.synthego.com.
gRNAs used in the present disclosure were synthesized by Integrated
DNA Technologies, Inc (IDT). HiFi-Cas9 was purchased from IDT.
[0539] For gene editing, 3 .mu.g Cas9 protein and 1.5 .mu.g gRNA
were mixed in 20 .mu.l and incubated at 37.degree. C. or room
temperature for 15 minutes to form ribonucleoprotein (RNP). Then
RNP was transfected into T cells by Lonza 4D Nucleofector. Gene
knockout efficiency was determined by the ratio of the cells
expressing the protein as detected by flow cytometry.
[0540] gRNA targeting sequences used are as below:
TABLE-US-00035 SEQ ID NO: 20 TRAC-gRNA1: TTCGGAACCCAATCACTGAC, SEQ
ID NO: 21 TRAC-gRNA2: TCAGGGTTCTGGATATCTGT, SEQ ID NO: 22
TRAC-gRNA3: AAGTTCCTGTGATGTCAAGC, SEQ ID NO: 45 CD137-gRNA1:
AACGTGGCATCTGTCGACCC, SEQ ID NO: 46 CD137-gRNA2:
GCGCTGGAGAAACTATTTGG, SEQ ID NO: 47 CD137-gRNA3:
ACATTTAACGATCAGAAACG, SEQ ID NO: 48 CD137-gRNA4:
GGTCCTTTGTCCACCTGCGC, SEQ ID NO: 49 CD137-gRNA5:
GAGAAACTATTTGGAGGACA, SEQ ID NO: 50 CD137-gRNA6:
GGAGAAACTATTTGGAGGAC,
[0541] After screening, gRNA with high knockout efficiency was
found for each gene and high efficiency was also observed when
knocking out two genes, TCR/CD137.
7.3 Preparation of CAR-T Cells
[0542] Cell Isolation and Activation
[0543] After apheresis, monocytes were isolated using
Histopaque-1077 (Sigma-Aldrich) by density gradient centrifugation.
Then T cells were enriched, activated by magnetic beads coupled
with anti-CD3/anti-CD28, cultured and expanded.
[0544] X-vivo 15 with 5% FBS, 2 mM L-glutamine, 1 mM sodium
pyruvate and 300 IU/ml rhIL2 was used as CAR-T cell medium. The
cells were incubated and cultured at 37.degree. C., 5% CO2.
[0545] Allogeneic T cells were activated by using
anti-CD3/anti-CD28 magnetic beads.
[0546] Allogeneic PBNK cells were activated by co-culturing K562
cells with PBNKs.
[0547] The expression of CD137 on the cell surface before and after
the activation was determined by flow cytometry.
[0548] Electroporation and Lentivirus Infection
[0549] Two days after enriching and activating the T cells, the
anti-CD3/anti-CD28 magnetic beads were removed and the cells were
collected into a tube and subject to centrifuge at 300 g for 5 min,
and then washed twice with DPBS and re-suspended in opti-mem at a
cell density of 50.times.10.sup.6/ml. The amount of cas9/gRNA RNP
required was calculated based on the density of the cells, and then
mixed with cells and transferred for electroporation by
4D-Nucleofector System N (Lonza) system. Then the cells were
re-suspended in a pre-warmed medium to a density of
1-2.times.106/ml. The cells were further subject to lentiviral
transfection at MOI of 2-8, and then transferred to a flask and
cultured in an incubator at 37.degree. C., 5% CO.sub.2.
[0550] Cell Proliferation and Detection of CAR Positive Ratio
[0551] 4 days after the transfection, the number of cells and CAR
positive cells were detected, and the positive ratio of CAR in T
cells was calculated. The positive ratio of TCR (or CD3) and CD137
was also detected to determine the knockout efficiency. Then cells
were continuously cultured in the incubator and half of the medium
was replaced every 2-3 days till day 10 when the cells were ready
for cryopreservation. An example workflow is shown in FIG. 53.
[0552] The result shows that positive ratio of CAR and negative
ratio of CD3 were both high in the prepared CD19-CD137 CAR-T
cells.
7.4 In Vitro Killing Effect and Release of the Cytokines
[0553] The dual CAR-T cells prepared in Example 7.3 and CFSE
labeled CD19 positive tumor cells (Raji) and CD137 positive cells
(activated allogeneic T cells or activated allogeneic PBNK or
NK92), 100 ul each, were mixed in RPMI medium at 1:1 ratio to a
density of 1.times.10.sup.6/ml for each cell, and then cultured
from overnight to 1 week in a 96-well plate. The number of CAR-T
cells and CFSE-labeled target cells was detected by flow cytometry,
so that to determine the killing effect between CAR-T cells and
target cells during co-culture. Furthermore, the co-culture medium
was also collected and subject to centrifuge and the released
cytokine IFN-.gamma. and IL-2 were detected by Cytokine bead array
kit (CBA kit, BD Biosciences).
[0554] The result shows that incubation of CD19-CD137 CAR-T cells
with Raji, allo-T or allo-NK cells produces a large amount of
IFN-.gamma. and IL-2, indicating function of CAR-T against CD19
positive or CD137 positive target cells. The flowcytometry result
also indicates that the killing effects of allo-T and allo-NK on
CD19-CD137 dual CAR T cells were significantly less than that on
CD19 single CAR T cells.
[0555] Additional experiments show that CD19-CD137 dual CAR T cells
only clear CD137 positive cells and NK cells, but fails to show any
significant killing effect on CD137 negative inactivated T cells or
NK cells, indicating the specificity of CD137 CAR.
7.5 In Vivo Efficacy
[0556] 6-12 weeks NOD/Shi-scid/IL-2R.gamma.null (NOG) mice were
selected and intravenously injected with 2.times.10.sup.5
Raji-ffluc cells and allo-T cells. 5 days later, the tumor graft
burden of the mice was measured, and the mice were divided into 4
groups based on the tumor burden. One day later, 200 .mu.L DPBS,
0.5.times.10.sup.6 CD19 CAR-T cells and 0.5.times.10.sup.6
CD19-CD137 CAR-T cells were respectively injected to each mouse.
The tumor burden of the mice was further evaluated every 7 days
after the CAR-T treatment. Each mouse was injected
intraperitoneally with 3 mg d-luciferin for a 4-minutes reaction,
and then photographed using a Xenogen IVIS Imaging System with 30 s
exposure.
[0557] The result shows that CD19-CD137 CAR-T significantly
decreased the tumor burden compared to CD19 CAR-T cells, and
CD19-CD137 CAR-T cells showed significant better in vivo expansion
than CD19 CAR-T cells, indicating the CD19-CD137 CAR-T cells
survive better and have a stronger ability to clear CD19 positive
tumor cells in vivo.
7.6 In Vivo GVHD Study
[0558] The mice were systemically treated with a sub-lethal dose of
irradiation (175 cGy) first. Then CAR-T cells were re-suspended in
PBS and injected into the thorax of the treated mice. The mice were
observed 2-3 times a week by using GVHD clinical criteria including
weight loss, arch-back, activity, fur texture, and skin
integrity.
[0559] The result shows that mice without TCR knockout all showed
GVHD symptoms, however, no GVHD was detected in the TCR/CD137 dual
knockout CD19-CD137 CAR-T cell group.
7.7 Additional Sequences Used in Constructing CARs as Described
Herein
TABLE-US-00036 [0560] 4-1BB-L (SEQ ID NO: 51)
MEYASDASLDPEAPWPPAPRARACRVLPWALVAGLLLLLLLAAACAVFLACP
WAVSGARASPGSAASPRLREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWY
SDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQ
PLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAW
QLTQGATVLGLFRVTPEIPAGLPSPRSE 4-1BB PF-05082566 scFv VH (SEQ ID NO:
52) EVQLVQSGAEVKKPGESLRISCKGSGYSFSTYWISWVRQMPGKGLEWMGKIYP
GDSYTNYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGYGIFDYWGQGTL VTVSS
4-1BB PF-05082566 scFv VL (SEQ ID NO: 53)
MSYELTQPPSVSVSPGQTASITCSGDNIGDQYAHWYQQKPGQSPVLVIYQDKN
RPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYTGFGSLAVFGGGTKLTVL 4-1BB
BMS-663513 scFv VH (SEQ ID NO: 54)
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPEKGLEWIGE
INHGGYVTYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYG
PGNYDWYFDLWGRGTLVTVSS 4-1BB BMS-663513 scFv VL (SEQ ID NO: 55)
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYD
ASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTF CGGTKVEIKR AAC
VL-VH (SEQ ID NO: 56)
MALPVTALLLPLALLLHAARPMSYELTQPPSVSVSPGQTASITCSGDNIGDQYA
HWYQQKPGQSPVLVIYQDKNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYT
GFGSLAVFGGGTKLTVLGSTSGSGKPGSGEGSTKGEVQLVQSGAEVKKPGESLRISCKG
SGYSFSTYWISWVRQMPGKGLEWMGKIYPGDSYTNYSPSFQGQVTISADKSISTAYLQ
WSSLKASDTAMYYCARGYGIFDYWGQGTLVTVSSSGTTTPAPRPPTPAPTIASQPLSLRP
EACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQP
FMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRRE
EYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGH
DGLYQGLSTATKDTYDALHMQALPPR* AAC DNA sequence VL-VH (SEQ ID NO: 57)
ATGGCCCTGCCCGTGACCGCCCTGCTGCTGCCCCTGGCCCTGCTGCTGCACG
CCGCCAGGCCCATGAGCTACGAGCTGACCCAGCCCCCCAGCGTGAGCGTGAGCCCC
GGCCAGACCGCCAGCATCACCTGCAGCGGCGACAACATCGGCGACCAGTACGCCCA
CTGGTACCAGCAGAAGCCCGGCCAGAGCCCCGTGCTGGTGATCTACCAGGACAAGA
ACAGGCCCAGCGGCATCCCCGAGAGGTTCAGCGGCAGCAACAGCGGCAACACCGC
CACCCTGACCATCAGCGGCACCCAGGCCATGGACGAGGCCGACTACTACTGCGCCA
CCTACACCGGCTTCGGCAGCCTGGCCGTGTTCGGCGGCGGCACCAAGCTGACCGTG
CTGGGCAGCACCAGCGGCAGCGGCAAGCCCGGCAGCGGCGAGGGCAGCACCAAGG
GCGAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGAGAGCCT
GAGGATCAGCTGCAAGGGCAGCGGCTACAGCTTCAGCACCTACTGGATCAGCTGGG
TGAGGCAGATGCCCGGCAAGGGCCTGGAGTGGATGGGCAAGATCTACCCCGGCGA
CAGCTACACCAACTACAGCCCCAGCTTCCAGGGCCAGGTGACCATCAGCGCCGACA
AGAGCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCAGCGACACCGCC
ATGTACTACTGCGCCAGGGGCTACGGCATCTTCGACTACTGGGGCCAGGGCACCCT
GGTGACCGTGAGCAGCAGCGGCACCACCACCCCCGCCCCCAGGCCCCCCACCCCCG
CCCCCACCATCGCCAGCCAGCCCCTGAGCCTGAGGCCCGAGGCCTGCAGGCCCGCC
GCCGGCGGCGCCGTGCACACCAGGGGCCTGGACTTCGCCTGCGACATCTACATCTG
GGCCCCCCTGGCCGGCACCTGCGGCGTGCTGCTGCTGAGCCTGGTGATCACCCTGTA
CTGCAAGAGGGGCAGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGAGGC
CCGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGA
GGAGGGCGGCTGCGAGCTGAGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCCGCC
TACAAGCAGGGCCAGAACCAGCTGTACAACGAGCTGAACCTGGGCAGGAGGGAGG
AGTACGACGTGCTGGACAAGAGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC
CAGGAGGAAGAACCCCCAGGAGGGCCTGTACAACGAGCTGCAGAAGGACAAGATG
GCCGAGGCCTACAGCGAGATCGGCATGAAGGGCGAGAGGAGGAGGGGCAAGGGCC
ACGACGGCCTGTACCAGGGCCTGAGCACCGCCACCAAGGACACCTACGACGCCCTG
CACATGCAGGCCCTGCCCCCCAGGTGA AAC VH-VL (SEQ ID NO: 58) S01
ATGGCCCTGCCCGTGACCGCCCTGCTGCTGCCCCTGGCCCTGCTGCTGCACG
CCGCCAGGCCCGAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGG
CGAGAGCCTGAGGATCAGCTGCAAGGGCAGCGGCTACAGCTTCAGCACCTACTGGA
TCAGCTGGGTGAGGCAGATGCCCGGCAAGGGCCTGGAGTGGATGGGCAAGATCTAC
CCCGGCGACAGCTACACCAACTACAGCCCCAGCTTCCAGGGCCAGGTGACCATCAG
CGCCGACAAGAGCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCAGCG
ACACCGCCATGTACTACTGCGCCAGGGGCTACGGCATCTTCGACTACTGGGGCCAG
GGCACCCTGGTGACCGTGAGCAGCGGCAGCACCAGCGGCAGCGGCAAGCCCGGCA
GCGGCGAGGGCAGCACCAAGGGCATGAGCTACGAGCTGACCCAGCCCCCCAGCGT
GAGCGTGAGCCCCGGCCAGACCGCCAGCATCACCTGCAGCGGCGACAACATCGGCG
ACCAGTACGCCCACTGGTACCAGCAGAAGCCCGGCCAGAGCCCCGTGCTGGTGATC
TACCAGGACAAGAACAGGCCCAGCGGCATCCCCGAGAGGTTCAGCGGCAGCAACA
GCGGCAACACCGCCACCCTGACCATCAGCGGCACCCAGGCCATGGACGAGGCCGAC
TACTACTGCGCCACCTACACCGGCTTCGGCAGCCTGGCCGTGTTCGGCGGCGGCACC
AAGCTGACCGTGCTGAGCGGCACCACCACCCCCGCCCCCAGGCCCCCCACCCCCGC
CCCCACCATCGCCAGCCAGCCCCTGAGCCTGAGGCCCGAGGCCTGCAGGCCCGCCG
CCGGCGGCGCCGTGCACACCAGGGGCCTGGACTTCGCCTGCGACATCTACATCTGG
GCCCCCCTGGCCGGCACCTGCGGCGTGCTGCTGCTGAGCCTGGTGATCACCCTGTAC
TGCAAGAGGGGCAGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGAGGCC
CGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAG
GAGGGCGGCTGCGAGCTGAGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCCGCCT
ACAAGCAGGGCCAGAACCAGCTGTACAACGAGCTGAACCTGGGCAGGAGGGAGGA
GTACGACGTGCTGGACAAGAGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCC
AGGAGGAAGAACCCCCAGGAGGGCCTGTACAACGAGCTGCAGAAGGACAAGATGG
CCGAGGCCTACAGCGAGATCGGCATGAAGGGCGAGAGGAGGAGGGGCAAGGGCCA
CGACGGCCTGTACCAGGGCCTGAGCACCGCCACCAAGGACACCTACGACGCCCTGC
ACATGCAGGCCCTGCCCCCCAGGTGA FMC63 VH (SEQ ID NO: 59)
EVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGS
ETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWG QGTSVTVSS
FMC63 VL (SEQ ID NO: 60)
DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRL
HSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEIT FMC63 CD19
CAR (SEQ ID NO: 61)
MALPVTALLLPLALLLHAARPDIQMTQTTSSLSASLGDRVTISCRASQDISKYLN
WYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTL
PYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSL
PDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTD
DTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSSGTTTPAPRPPTPAPTIASQPLSLRPE
ACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPF
MRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREE
YDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHD
GLYQGLSTATKDTYDALHMQALPPR*
Example 8 Study of U-CAR T Cells Expressing E4
[0561] FIG. 59A shows flow cytometry data of fractions of CD19
CAR-T cells expressing enhancer CD47 (CAR19-CD47) or E4 (CAR19-E4).
In the E4 design, the ecto domain of C7R is replaced by the ecto
domain from an immune cell inhibitor, such as CD47, CD24 or other
peptides that inhibit killer or phagocytic immune cell function and
protect therapeutic cells. The CAR19-CD47 or CAR19-E4 was expressed
in K562 cells, which lacks MHCI/II expression and are very
sensitive to NK cell killing due to lack of MHC expression.
Expression of CAR19 and CD47 were analyzed by flow cytometry. FIG.
59B shows NK cell killing activity toward CAR19-CD47 and CAR19-E4
cells. Both CD47 and E4 were able to reduce the extent of NK cell
killing for K562 cells. The data show that E4 may protect MHCI
negative cells from killing by NK cells, which may be used in
protection of MHCI KO CAR-T cells.
[0562] FIG. 60A shows flow cytometry data of fractions of TCR KO
CD19 CAR-T cells expressing CD19 and phosphorylated STAT5 (pSTAT5).
The CAR19-CD47 or CAR19-E4 was expressed in TCR knockout T cells
and accessed for CAR expression and STAT5 phosphorylation. CAR19-E2
and CAR19-CD47 plus IL2 stimulation were used as positive controls.
E4 mediates up-regulation of pSTAT5. FIG. 60B shows proliferation
of TCR KO CD19 CAR-T cells expressing enhancer CD47 (CAR19-CD47) or
E4 (CAR19-E4). The CAR19-CD47, CAR19-E4, CAR19-C7R expressing TCR
knockout T cells were compared for cell proliferation and cell
survival without IL12 supplement. E4 can mediate stronger cell
proliferation as well as maintenance of cell number after removal
of IL2 in culture media. The E4 maintains better CAR-T cell
stability without IL2 addition. E4 may protect therapeutic cells,
such as cells that with HLA-I KO, from NK cell killing or killing
by phagocytes and T killer cells.
[0563] Sequence of construct design: the etco domain of C7R can
replaced by an immune cell inhibitor, such as truncated CD47, CD24,
that can inhibit a killer or phagocytic immune cell function and
protect the CAR-T/NK cells from being attached by patient's immune
system.
[0564] CD7CAR-E4 amino acid sequence:
TABLE-US-00037 (SEQ ID NO: 103)
MLLLVTSLLLCELPHPAFLLIPQLLFNKTKSVEFTFCNDTVVIPCFVTNM
EAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDA
SLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSPNEPILLT
CPTISILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPR
KNLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLG
GDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCR
ESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSL
GSNQEEAYVTMSSFYQNQ.
Example 9 Clinical Data of CAR7-C7R for Treating T-Acute
Lymphoblastic Leukemia (T-ALL) Patients
[0565] This example provides clinical study designs and clinical
data using CAR7-C7R. Patients were enrolled with tumor burden at
the enrollment that 38.2% of bone marrow cells were T-ALL cells.
Before infusing the CAR7-C7R cells, the patients were treated with
pre-conditional regimen. The pre-conditional regimen used
chemotherapy drug including fludarabine, cyclophosphamide and
etoposide for lymphodepletion. The pre-conditional regimen can
provide better CAR-T engraftment and tumor clearance. Two days
after completion of lymphodepletion regimen, CAR7-C7R cells were
intravenously infused into patients at 1.5.times.10.sup.7/kg.
CAR7-C7R rapidly eliminated cancer cells (T-ALL cells) and expanded
to the peak around 7-10 days, without affecting innate immune cell
subsets such as granulocytes and monocytes. Once cancer cells were
completely cleared in both the peripheral blood and in the bone
marrow, CAR7-C7R cells very quickly return to minimal level, which
allows patients' own immune system to start recovery immediately
after cancer cell clearance. T cells and NK cells then gradually
recover to normal levels.
[0566] FIGS. 67A-E show the clinical data of CAR7-C7R for treating
T-acute lymphoblastic leukemia (T-ALL) patients. The construct of
CAR7-C7R used in the clinical studies is shown in FIG. 17. FIG. 67A
shows the kinetics of T-ALL elimination in the peripheral blood.
T-ALL cells were quickly eliminated within 7-10 days. T-ALL cell
concentration were measured in the peripheral blood by flow
cytometry. FIGS. 67B and 67C shows the CAR7-C7R cell expansion
kinetics, where FIG. 67B shows the CAR7-C7Rcell concentration in
the peripheral blood and FIG. 67C shows CAR7-C7R DNA copy/ug DNA of
peripheral blood cells. FIGS. 67D and 67E show the granulocyte and
lymphocyte (T and NK cells) recovery in the bone marrow and in
peripheral blood.
[0567] While preferred embodiments of the present invention have
been shown and described herein, it will be obvious to those
skilled in the art that such embodiments are provided by way of
example only. It is not intended that the invention be limited by
the specific examples provided within the specification. While the
invention has been described with reference to the aforementioned
specification, the descriptions and illustrations of the
embodiments herein are not meant to be construed in a limiting
sense. Numerous variations, changes, and substitutions will now
occur to those skilled in the art without departing from the
invention. Furthermore, it shall be understood that all aspects of
the invention are not limited to the specific depictions,
configurations or relative proportions set forth herein which
depend upon a variety of conditions and variables. It should be
understood that various alternatives to the embodiments of the
invention described herein may be employed in practicing the
invention. It is therefore contemplated that the invention shall
also cover any such alternatives, modifications, variations or
equivalents. It is intended that the following claims define the
scope of the invention and that methods and structures within the
scope of these claims and their equivalents be covered thereby.
Sequence CWU 1 SEQUENCE LISTING <160> NUMBER OF SEQ ID
NOS: 103 <210> SEQ ID NO 1 <211> LENGTH: 1138
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 1
Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro 1 5
10 15 Ala Phe Leu Leu Ile Pro Arg Lys Val Cys Asn Gly Ile Gly Ile
Gly 20 25 30 Glu Phe Lys Asp Ser Leu Ser Ile Asn Ala Thr Asn Ile
Lys His Phe 35 40 45 Lys Asn Cys Thr Ser Ile Ser Gly Asp Leu His
Ile Leu Pro Val Ala 50 55 60 Phe Arg Gly Asp Ser Phe Thr His Thr
Pro Pro Leu Asp Pro Gln Glu 65 70 75 80 Leu Asp Ile Leu Lys Thr Val
Lys Glu Ile Thr Gly Phe Leu Leu Ile 85 90 95 Gln Ala Trp Pro Glu
Asn Arg Thr Asp Leu His Ala Phe Glu Asn Leu 100 105 110 Glu Ile Ile
Arg Gly Arg Thr Lys Gln His Gly Gln Phe Ser Leu Ala 115 120 125 Val
Val Ser Leu Asn Ile Thr Ser Leu Gly Leu Arg Ser Leu Lys Glu 130 135
140 Ile Ser Asp Gly Asp Val Ile Ile Ser Gly Asn Lys Asn Leu Cys Tyr
145 150 155 160 Ala Asn Thr Ile Asn Trp Lys Lys Leu Phe Gly Thr Ser
Gly Gln Lys 165 170 175 Thr Lys Ile Ile Ser Asn Arg Gly Glu Asn Ser
Cys Lys Ala Thr Gly 180 185 190 Gln Val Cys His Ala Leu Cys Ser Pro
Glu Gly Cys Trp Gly Pro Glu 195 200 205 Pro Arg Asp Cys Val Ser Cys
Arg Asn Val Ser Arg Gly Arg Glu Cys 210 215 220 Val Asp Lys Cys Asn
Leu Leu Glu Gly Glu Pro Arg Glu Phe Val Glu 225 230 235 240 Asn Ser
Glu Cys Ile Gln Cys His Pro Glu Cys Leu Pro Gln Ala Met 245 250 255
Asn Ile Thr Cys Thr Gly Arg Gly Pro Asp Asn Cys Ile Gln Cys Ala 260
265 270 His Tyr Ile Asp Gly Pro His Cys Val Lys Thr Cys Pro Ala Gly
Val 275 280 285 Met Gly Glu Asn Asn Thr Leu Val Trp Lys Tyr Ala Asp
Ala Gly His 290 295 300 Val Cys His Leu Cys His Pro Asn Cys Thr Tyr
Gly Cys Thr Gly Pro 305 310 315 320 Gly Leu Glu Gly Cys Pro Thr Asn
Gly Pro Lys Ile Pro Ser Ile Ala 325 330 335 Thr Gly Met Val Gly Ala
Leu Leu Leu Leu Leu Val Val Ala Leu Gly 340 345 350 Ile Gly Leu Phe
Met Arg Ala Lys Arg Gly Ser Gly Ala Thr Asn Phe 355 360 365 Ser Leu
Leu Lys Gln Ala Gly Asp Val Glu Glu Asn Pro Gly Pro Met 370 375 380
Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu His 385
390 395 400 Ala Ala Arg Pro Gln Val Gln Leu Gln Gln Ser Gly Ala Glu
Leu Ala 405 410 415 Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala
Ser Gly Tyr Thr 420 425 430 Phe Thr Arg Tyr Thr Met His Trp Val Lys
Gln Arg Pro Gly Gln Gly 435 440 445 Leu Glu Trp Ile Gly Tyr Ile Asn
Pro Ser Arg Gly Tyr Thr Asn Tyr 450 455 460 Asn Gln Lys Phe Lys Asp
Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser 465 470 475 480 Ser Thr Ala
Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala 485 490 495 Val
Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr 500 505
510 Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Gly Ser Thr Ser Gly
515 520 525 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Gln
Ile Val 530 535 540 Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro
Gly Glu Lys Val 545 550 555 560 Thr Met Thr Cys Ser Ala Ser Ser Ser
Val Ser Tyr Met Asn Trp Tyr 565 570 575 Gln Gln Lys Ser Gly Thr Ser
Pro Lys Arg Trp Ile Tyr Asp Thr Ser 580 585 590 Lys Leu Ala Ser Gly
Val Pro Ala His Phe Arg Gly Ser Gly Ser Gly 595 600 605 Thr Ser Tyr
Ser Leu Thr Ile Ser Gly Met Glu Ala Glu Asp Ala Ala 610 615 620 Thr
Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Phe Thr Phe Gly Ser 625 630
635 640 Gly Thr Lys Leu Glu Ile Asn Arg Gly Gly Gly Gly Ser Gly Gly
Gly 645 650 655 Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln
Thr Thr Ser 660 665 670 Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr
Ile Ser Cys Arg Ala 675 680 685 Ser Gln Asp Ile Ser Lys Tyr Leu Asn
Trp Tyr Gln Gln Lys Pro Asp 690 695 700 Gly Thr Val Lys Leu Leu Ile
Tyr His Thr Ser Arg Leu His Ser Gly 705 710 715 720 Val Pro Ser Arg
Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu 725 730 735 Thr Ile
Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln 740 745 750
Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu 755
760 765 Ile Thr Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu
Gly 770 775 780 Ser Thr Lys Gly Glu Val Lys Leu Gln Glu Ser Gly Pro
Gly Leu Val 785 790 795 800 Ala Pro Ser Gln Ser Leu Ser Val Thr Cys
Thr Val Ser Gly Val Ser 805 810 815 Leu Pro Asp Tyr Gly Val Ser Trp
Ile Arg Gln Pro Pro Arg Lys Gly 820 825 830 Leu Glu Trp Leu Gly Val
Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn 835 840 845 Ser Ala Leu Lys
Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser 850 855 860 Gln Val
Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile 865 870 875
880 Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp
885 890 895 Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ala
Ala Asp 900 905 910 Tyr Lys Asp Asp Asp Asp Lys Ile Glu Val Met Tyr
Pro Pro Pro Tyr 915 920 925 Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile
Ile His Val Lys Gly Lys 930 935 940 His Leu Cys Pro Ser Pro Leu Phe
Pro Gly Pro Ser Lys Pro Phe Trp 945 950 955 960 Val Leu Val Val Val
Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val 965 970 975 Thr Val Ala
Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu 980 985 990 Leu
His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr 995
1000 1005 Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala
Ala 1010 1015 1020 Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp
Ala Pro Ala 1025 1030 1035 Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
Glu Leu Asn Leu Gly 1040 1045 1050 Arg Arg Glu Glu Tyr Asp Val Leu
Asp Lys Arg Arg Gly Arg Asp 1055 1060 1065 Pro Glu Met Gly Gly Lys
Pro Arg Arg Lys Asn Pro Gln Glu Gly 1070 1075 1080 Leu Tyr Asn Glu
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser 1085 1090 1095 Glu Ile
Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp 1100 1105 1110
Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp 1115
1120 1125 Ala Leu His Met Gln Ala Leu Pro Pro Arg 1130 1135
<210> SEQ ID NO 2 <211> LENGTH: 3417 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polynucleotide <400> SEQUENCE: 2 atgttgctcc
ttgtgacgag cctcctgctc tgcgagctgc cccatccagc cttcctcctc 60
atcccgcgga aggtgtgcaa tggcataggc attggcgagt ttaaagattc tctgagcata
120 aatgctacga atattaagca tttcaagaat tgtacttcta ttagtggcga
cctccatatt 180 cttccggttg ccttcagggg tgactctttc acccacacac
ctccattgga tccacaagaa 240 cttgacatcc tgaagacggt taaagagatt
acaggcttcc tccttatcca agcgtggccc 300 gagaacagaa cggacttgca
cgcctttgag aacctcgaaa taatacgggg tcggacgaag 360 caacacggcc
aatttagcct tgcggttgtt agtctgaaca ttacttctct cggccttcgc 420
tctttgaaag aaatcagcga cggagatgtc atcattagtg gaaacaagaa cctgtgctac
480 gcgaacacaa tcaactggaa gaagctcttc ggtacttcag gccaaaagac
aaagattatt 540 agtaacagag gagagaatag ctgtaaggct accggacaag
tttgtcacgc cttgtgtagt 600 ccagagggtt gctggggacc ggaaccaagg
gattgcgtca gttgccggaa cgtgagtcgc 660 ggacgcgagt gtgtggataa
gtgcaatctt ctggaagggg aaccgcgaga gtttgtagaa 720 aattccgaat
gtatacagtg tcatcccgag tgtcttccac aagcaatgaa tatcacatgt 780
acagggaggg gtcctgataa ctgtatccaa tgtgcacact acatagatgg tcctcactgt
840 gtaaagacgt gccccgccgg agtaatgggt gaaaacaaca ccctcgtgtg
gaagtacgcc 900 gatgccgggc atgtctgtca tttgtgtcat cccaactgca
catatggctg taccggtcct 960 ggattggagg gctgtccaac aaacgggccg
aaaataccga gtatcgcaac aggcatggtg 1020 ggagcacttt tgcttctcct
cgttgtcgcc ctgggcatcg gcttgttcat gcgagctaaa 1080 cgaggctcag
gcgcgacgaa ctttagtttg ctgaagcaag ctggggatgt agaggaaaat 1140
ccgggtccca tggcccttcc agtgacagcc ttgttgttgc cacttgctct gctgctccac
1200 gctgcgcggc cacaggtcca gttgcagcag tcaggcgccg aattggcgcg
accaggggca 1260 agcgtaaaga tgagctgtaa ggcatccggg tacacgttca
ctcgctatac catgcattgg 1320 gttaaacaac ggcctgggca gggccttgag
tggattgggt atatcaaccc atcccggggc 1380 tacactaact ataatcaaaa
gtttaaagat aaagcaaccc ttacgaccga caaatcatct 1440 tctaccgcat
acatgcagct cagctccctc accagtgaag attctgccgt ttattattgt 1500
gcacgatact atgacgatca ctattgcctg gactactggg gtcaaggcac cacacttact
1560 gtcagttccg gaagtaccag tgggggaggt tctggcggtg gcagcggggg
tgggggtagc 1620 tcacaaatcg tgctgaccca gagtcccgct atcatgagcg
cctccccagg ggaaaaggtg 1680 acgatgacat gctcagccag ctccagtgta
tcctacatga attggtatca acagaagagt 1740 gggacgtcac ccaaaagatg
gatttatgac accagcaaat tggccagcgg agtaccagcg 1800 catttcagag
gcagtgggag tggaacatct tattctctca ccattagcgg catggaagca 1860
gaggatgcag caacgtacta ttgtcaacaa tggagctcta atccctttac gttcggcagc
1920 ggcactaagc tcgaaattaa taggggtggc ggcggctccg gcggtggcgg
gtctggaggt 1980 gggggcagtg acatccagat gacacagact acatcctccc
tgtctgcctc tctgggagac 2040 agagtcacca tcagttgcag ggcaagtcag
gacattagta aatatttaaa ttggtatcag 2100 cagaaaccag atggaactgt
taaactcctg atctaccata catcaagatt acactcagga 2160 gtcccatcaa
ggttcagtgg cagtgggtct ggaacagatt attctctcac cattagcaac 2220
ctggagcaag aagatattgc cacttacttt tgccaacagg gtaatacgct tccgtacacg
2280 ttcggagggg ggactaagtt ggaaataaca ggctccacct ctggatccgg
caagcccgga 2340 tctggcgagg gatccaccaa gggcgaggtg aaactgcagg
agtcaggacc tggcctggtg 2400 gcgccctcac agagcctgtc cgtcacatgc
actgtctcag gggtctcatt acccgactat 2460 ggtgtaagct ggattcgcca
gcctccacga aagggtctgg agtggctggg agtaatatgg 2520 ggtagtgaaa
ccacatacta taattcagct ctcaaatcca gactgaccat catcaaggac 2580
aactccaaga gccaagtttt cttaaaaatg aacagtctgc aaactgatga cacagccatt
2640 tactactgtg ccaaacatta ttactacggt ggtagctatg ctatggacta
ctggggtcaa 2700 ggaacctcag tcaccgtctc ctcagcggcc gcagactaca
aagacgatga cgacaagatt 2760 gaagttatgt atcctcctcc ttacctagac
aatgagaaga gcaatggaac cattatccat 2820 gtgaaaggga aacacctttg
tccaagtccc ctatttcccg gaccttctaa gcccttttgg 2880 gtgctggtgg
tggttggggg agtcctggct tgctatagct tgctagtaac agtggccttt 2940
attattttct gggtgaggag taagaggagc aggctcctgc acagtgacta catgaacatg
3000 actccccgcc gccccgggcc cacccgcaag cattaccagc cctatgcccc
accacgcgac 3060 ttcgcagcct atcgctccag agtgaagttc agcaggagcg
cagacgcccc cgcgtaccag 3120 cagggccaga accagctcta taacgagctc
aatctaggac gaagagagga gtacgatgtt 3180 ttggacaaga gacgtggccg
ggaccctgag atggggggaa agccgagaag gaagaaccct 3240 caggaaggcc
tgtacaatga actgcagaaa gataagatgg cggaggccta cagtgagatt 3300
gggatgaaag gcgagcgccg gaggggcaag gggcacgatg gcctttacca gggtctcagt
3360 acagccacca aggacaccta cgacgccctt cacatgcagg ccctgccccc tcgctaa
3417 <210> SEQ ID NO 3 <211> LENGTH: 1138 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic polypeptide <400> SEQUENCE: 3 Met Leu Leu
Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro 1 5 10 15 Ala
Phe Leu Leu Ile Pro Arg Lys Val Cys Asn Gly Ile Gly Ile Gly 20 25
30 Glu Phe Lys Asp Ser Leu Ser Ile Asn Ala Thr Asn Ile Lys His Phe
35 40 45 Lys Asn Cys Thr Ser Ile Ser Gly Asp Leu His Ile Leu Pro
Val Ala 50 55 60 Phe Arg Gly Asp Ser Phe Thr His Thr Pro Pro Leu
Asp Pro Gln Glu 65 70 75 80 Leu Asp Ile Leu Lys Thr Val Lys Glu Ile
Thr Gly Phe Leu Leu Ile 85 90 95 Gln Ala Trp Pro Glu Asn Arg Thr
Asp Leu His Ala Phe Glu Asn Leu 100 105 110 Glu Ile Ile Arg Gly Arg
Thr Lys Gln His Gly Gln Phe Ser Leu Ala 115 120 125 Val Val Ser Leu
Asn Ile Thr Ser Leu Gly Leu Arg Ser Leu Lys Glu 130 135 140 Ile Ser
Asp Gly Asp Val Ile Ile Ser Gly Asn Lys Asn Leu Cys Tyr 145 150 155
160 Ala Asn Thr Ile Asn Trp Lys Lys Leu Phe Gly Thr Ser Gly Gln Lys
165 170 175 Thr Lys Ile Ile Ser Asn Arg Gly Glu Asn Ser Cys Lys Ala
Thr Gly 180 185 190 Gln Val Cys His Ala Leu Cys Ser Pro Glu Gly Cys
Trp Gly Pro Glu 195 200 205 Pro Arg Asp Cys Val Ser Cys Arg Asn Val
Ser Arg Gly Arg Glu Cys 210 215 220 Val Asp Lys Cys Asn Leu Leu Glu
Gly Glu Pro Arg Glu Phe Val Glu 225 230 235 240 Asn Ser Glu Cys Ile
Gln Cys His Pro Glu Cys Leu Pro Gln Ala Met 245 250 255 Asn Ile Thr
Cys Thr Gly Arg Gly Pro Asp Asn Cys Ile Gln Cys Ala 260 265 270 His
Tyr Ile Asp Gly Pro His Cys Val Lys Thr Cys Pro Ala Gly Val 275 280
285 Met Gly Glu Asn Asn Thr Leu Val Trp Lys Tyr Ala Asp Ala Gly His
290 295 300 Val Cys His Leu Cys His Pro Asn Cys Thr Tyr Gly Cys Thr
Gly Pro 305 310 315 320 Gly Leu Glu Gly Cys Pro Thr Asn Gly Pro Lys
Ile Pro Ser Ile Ala 325 330 335 Thr Gly Met Val Gly Ala Leu Leu Leu
Leu Leu Val Val Ala Leu Gly 340 345 350 Ile Gly Leu Phe Met Arg Ala
Lys Arg Gly Ser Gly Ala Thr Asn Phe 355 360 365 Ser Leu Leu Lys Gln
Ala Gly Asp Val Glu Glu Asn Pro Gly Pro Met 370 375 380 Ala Leu Pro
Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu His 385 390 395 400
Ala Ala Arg Pro Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser 405
410 415 Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
Asp 420 425 430 Ile Arg Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly
Lys Ala Pro 435 440 445 Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu Glu
Ser Gly Val Pro Ser 450 455 460 Arg Phe Ser Gly Ser Gly Ser Gly Thr
Asp Tyr Thr Leu Thr Ile Ser 465 470 475 480 Ser Leu Gln Pro Glu Asp
Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asn 485 490 495 Thr Leu Pro Trp
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly 500 505 510 Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val 515 520 525
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu 530
535 540 Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Thr
Met 545 550 555 560 Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val Ala Leu 565 570 575 Ile Asn Pro Tyr Lys Gly Val Ser Thr Tyr
Asn Gln Lys Phe Lys Asp 580 585 590 Arg Phe Thr Ile Ser Val Asp Lys
Ser Lys Asn Thr Ala Tyr Leu Gln 595 600 605 Met Asn Ser Leu Arg Ala
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 610 615 620 Ser Gly Tyr Tyr
Gly Asp Ser Asp Trp Tyr Phe Asp Val Trp Gly Gln 625 630 635 640 Gly
Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 645 650
655 Gly Ser Gly Gly Gly Gly Ser Glu Val Lys Leu Gln Glu Ser Gly Pro
660 665 670 Gly Leu Val Ala Pro Ser Gln Ser Leu Ser Val Thr Cys Thr
Val Ser 675 680 685 Gly Val Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile
Arg Gln Pro Pro 690 695 700 Arg Lys Gly Leu Glu Trp Leu Gly Val Ile
Trp Gly Ser Glu Thr Thr 705 710 715 720 Tyr Tyr Asn Ser Ala Leu Lys
Ser Arg Leu Thr Ile Ile Lys Asp Asn 725 730 735 Ser Lys Ser Gln Val
Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp 740 745 750 Thr Ala Ile
Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr 755 760 765 Ala
Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly 770 775
780 Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys
785 790 795 800 Gly Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser
Ala Ser Leu 805 810 815 Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser
Gln Asp Ile Ser Lys 820 825 830 Tyr Leu Asn Trp Tyr Gln Gln Lys Pro
Asp Gly Thr Val Lys Leu Leu 835 840 845 Ile Tyr His Thr Ser Arg Leu
His Ser Gly Val Pro Ser Arg Phe Ser 850 855 860 Gly Ser Gly Ser Gly
Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu 865 870 875 880 Gln Glu
Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro 885 890 895
Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr Ala Ala Ala Asp 900
905 910 Tyr Lys Asp Asp Asp Asp Lys Ile Glu Val Met Tyr Pro Pro Pro
Tyr 915 920 925 Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val
Lys Gly Lys 930 935 940 His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro
Ser Lys Pro Phe Trp 945 950 955 960 Val Leu Val Val Val Gly Gly Val
Leu Ala Cys Tyr Ser Leu Leu Val 965 970 975 Thr Val Ala Phe Ile Ile
Phe Trp Val Arg Ser Lys Arg Ser Arg Leu 980 985 990 Leu His Ser Asp
Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr 995 1000 1005 Arg
Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala 1010 1015
1020 Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala
1025 1030 1035 Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
Leu Gly 1040 1045 1050 Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
Arg Gly Arg Asp 1055 1060 1065 Pro Glu Met Gly Gly Lys Pro Arg Arg
Lys Asn Pro Gln Glu Gly 1070 1075 1080 Leu Tyr Asn Glu Leu Gln Lys
Asp Lys Met Ala Glu Ala Tyr Ser 1085 1090 1095 Glu Ile Gly Met Lys
Gly Glu Arg Arg Arg Gly Lys Gly His Asp 1100 1105 1110 Gly Leu Tyr
Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp 1115 1120 1125 Ala
Leu His Met Gln Ala Leu Pro Pro Arg 1130 1135 <210> SEQ ID NO
4 <211> LENGTH: 3417 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polynucleotide <400> SEQUENCE: 4 atgctgctgc tcgtgacatc
cctcttatta tgcgaactcc ctcaccccgc ttttctgctg 60 atccccagaa
aggtgtgcaa cggcatcggc attggagagt tcaaggattc tttaagcatc 120
aacgctacca acatcaaaca tttcaagaac tgtacctcca tttccggcga tttacacatc
180 ctccccgttg cctttcgtgg cgatagcttc acacacacac cccctctgga
ccctcaagaa 240 ctggacattt taaagaccgt gaaggagatc actggttttt
tactgatcca agcttggccc 300 gaaaatagga cagatctcca cgctttcgag
aatttagaga tcattcgtgg cagaaccaag 360 cagcacggac agttctcttt
agccgtcgtg tctttaaata tcacctcttt aggtttaaga 420 tctttaaaag
agatcagcga tggcgacgtc atcatctccg gcaacaagaa cctctgttac 480
gccaacacca ttaattggaa aaagctgttt ggcacctccg gacagaagac caagatcatc
540 agcaacagag gcgagaacag ctgcaaagct accggccaag tttgccacgc
tctgtgtagc 600 cccgaaggct gctggggacc cgaacctcgt gactgtgtga
gctgtaggaa cgtgtctcgt 660 ggtcgtgagt gtgtggataa gtgcaattta
ctcgagggcg agcccagaga gtttgtggaa 720 aatagcgagt gcatccagtg
ccaccccgaa tgtctgcccc aagctatgaa cattacttgt 780 actggtcgtg
gccccgataa ctgtatccag tgcgctcact acattgacgg cccccactgc 840
gtcaagacat gccccgctgg cgtgatggga gaaaacaaca cactggtgtg gaagtatgcc
900 gatgccggcc acgtctgtca tctgtgccac cctaactgta cctacggctg
taccggaccc 960 ggactggagg gctgtcccac caacggaccc aagatcccta
gcatcgccac cggcatggtg 1020 ggagccttac tgctgttact ggtggtggct
ctgggcattg gtttattcat gagggccaag 1080 agaggatccg gcgccaccaa
cttttcttta ctgaaacaag ctggagacgt cgaggaaaac 1140 cccggaccca
tggctctccc cgtgacagct ctgctgctgc ctctcgcttt attactgcac 1200
gccgctaggc ccgatattca gatgacccaa agccctagct ctttatccgc cagcgtcgga
1260 gatagagtca caatcacttg tagagccagc caagatattc gtaattatct
caactggtac 1320 cagcagaagc ccggtaaagc ccccaagctg ctcatctatt
acacctctcg tctggagagc 1380 ggcgtgcctt ccagattcag cggctccggc
agcggcaccg actatacact caccattagc 1440 tctttacagc ccgaagattt
cgctacctac tactgccagc aaggtaatac tttaccttgg 1500 accttcggcc
aaggtaccaa ggtcgaaatc aagggcggcg gcggatccgg cggcggtgga 1560
tctggtggcg gcggctccga agtccagctg gtcgaatccg gaggcggact ggtccagccc
1620 ggtggatccc tcagactgag ctgcgccgct agcggctatt ccttcaccgg
ctacaccatg 1680 aactgggtga gacaagctcc cggcaaagga ctggaatggg
tggccctcat caacccctac 1740 aagggcgtgt ccacatataa tcaaaagttt
aaggacagat tcaccatcag cgtcgacaag 1800 tccaagaaca ccgcttattt
acagatgaac tctttaagag ctgaggatac cgccgtgtac 1860 tattgtgcta
ggtccggcta ctacggcgac agcgactggt attttgacgt ctggggacaa 1920
ggtaccctcg tgacagtgag cagcggcggt ggcggttctg gcggcggagg ctccggagga
1980 ggcggcagcg aggtgaagct gcaagaaagc ggacccggtc tcgtggctcc
ctcccaatct 2040 ttatccgtga cttgtaccgt gtccggagtc tctttacccg
actacggcgt gagctggatt 2100 agacagcccc ccagaaaagg tttagagtgg
ctgggcgtga tctggggatc cgagaccaca 2160 tactacaaca gcgctttaaa
gtctcgtctg acaatcatca aagacaattc caaaagccaa 2220 gttttcctca
agatgaactc tttacagacc gacgacacag ccatttacta ctgcgccaag 2280
cattattact acggcggcag ctacgctatg gactactggg gccaaggtac aagcgtcaca
2340 gtgagctccg gcagcacatc cggaagcgga aagcccggca gcggagaggg
cagcacaaag 2400 ggagacatcc agatgaccca gaccacctcc tctttaagcg
cctctttagg agatagggtg 2460 accattagct gcagagcctc ccaagacatc
agcaagtatc tcaattggta ccagcaaaag 2520 cccgatggca ccgtcaagct
gctgatctac cacacctctc gtctccattc cggcgtgccc 2580 agcagattta
gcggaagcgg atccggaaca gactattctt taacaatcag caatttagag 2640
caagaagaca tcgccacata tttctgccaa caaggtaaca ctttacccta caccttcgga
2700 ggcggcacca aactggagat tacagcggcc gcagactaca aagacgatga
cgacaagatt 2760 gaagttatgt atcctcctcc ttacctagac aatgagaaga
gcaatggaac cattatccat 2820 gtgaaaggga aacacctttg tccaagtccc
ctatttcccg gaccttctaa gcccttttgg 2880 gtgctggtgg tggttggggg
agtcctggct tgctatagct tgctagtaac agtggccttt 2940 attattttct
gggtgaggag taagaggagc aggctcctgc acagtgacta catgaacatg 3000
actccccgcc gccccgggcc cacccgcaag cattaccagc cctatgcccc accacgcgac
3060 ttcgcagcct atcgctccag agtgaagttc agcaggagcg cagacgcccc
cgcgtaccag 3120 cagggccaga accagctcta taacgagctc aatctaggac
gaagagagga gtacgatgtt 3180 ttggacaaga gacgtggccg ggaccctgag
atggggggaa agccgagaag gaagaaccct 3240 caggaaggcc tgtacaatga
actgcagaaa gataagatgg cggaggccta cagtgagatt 3300 gggatgaaag
gcgagcgccg gaggggcaag gggcacgatg gcctttacca gggtctcagt 3360
acagccacca aggacaccta cgacgccctt cacatgcagg ccctgccccc tcgctaa 3417
<210> SEQ ID NO 5 <211> LENGTH: 20 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic oligonucleotide <400> SEQUENCE: 5 tgtgctagac
atgaggtcta 20 <210> SEQ ID NO 6 <400> SEQUENCE: 6 000
<210> SEQ ID NO 7 <211> LENGTH: 157 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 7 Met Gly Thr Ser Leu
Leu Cys Trp Met Ala Leu Cys Leu Leu Gly Ala 1 5 10 15 Asp His Ala
Asp Ala Cys Pro Tyr Ser Asn Pro Ser Leu Cys Ser Gly 20 25 30 Gly
Gly Gly Ser Glu Leu Pro Thr Gln Gly Thr Phe Ser Asn Val Ser 35 40
45 Thr Asn Val Ser Pro Ala Lys Pro Thr Thr Thr Ala Cys Pro Tyr Ser
50 55 60 Asn Pro Ser Leu Cys Ser Gly Gly Gly Gly Ser Pro Ala Pro
Arg Pro 65 70 75 80 Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
Ser Leu Arg Pro 85 90 95 Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala
Val His Thr Arg Gly Leu 100 105 110 Asp Phe Ala Cys Asp Ile Tyr Ile
Trp Ala Pro Leu Ala Gly Thr Cys 115 120 125 Gly Val Leu Leu Leu Ser
Leu Val Ile Thr Leu Tyr Cys Asn His Arg 130 135 140 Asn Arg Arg Arg
Val Cys Lys Cys Pro Arg Pro Val Val 145 150 155 <210> SEQ ID
NO 8 <211> LENGTH: 534 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polynucleotide <400> SEQUENCE: 8 atgggcacct ctctgctgtg
ctggatggct ctgtgtctgc tgggcgctga ccatgctgat 60 gcttgcccct
attccaaccc ctctctgtgc tccggaggag gaggatccga actgcctacc 120
caaggcacct tcagcaacgt gtccaccaac gtgagccccg ctaagcctac caccaccgct
180 tgcccttact ccaatcccag cctctgctcc ggaggcggag gatcccccgc
ccccagacct 240 cctacacccg ctcccacaat cgccagccag cctctgtctc
tgagacccga agcttgcaga 300 cccgctgccg gaggagctgt gcatacaaga
ggactggatt tcgcttgcga catctacatc 360 tgggcccctc tggctggcac
atgtggcgtg ctgctgctgt ctctggtcat tacactgtac 420 tgcaaccata
gaaatagaag aagggtgtgc aagtgtccca gacccgtggt gggcagcgga 480
gaaggaagag gctctctgct gacatgcgga gacgtggaag agaaccccgg cccc 534
<210> SEQ ID NO 9 <211> LENGTH: 497 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 9 Met Leu Leu Leu Val
Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro 1 5 10 15 Ala Phe Leu
Leu Ile Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser 20 25 30 Leu
Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser 35 40
45 Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly
50 55 60 Thr Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser
Gly Val 65 70 75 80 Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
Tyr Ser Leu Thr 85 90 95 Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala
Thr Tyr Phe Cys Gln Gln 100 105 110 Gly Asn Thr Leu Pro Tyr Thr Phe
Gly Gly Gly Thr Lys Leu Glu Ile 115 120 125 Thr Gly Ser Thr Ser Gly
Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser 130 135 140 Thr Lys Gly Glu
Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala 145 150 155 160 Pro
Ser Gln Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu 165 170
175 Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu
180 185 190 Glu Trp Leu Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr
Asn Ser 195 200 205 Ala Leu Lys Ser Arg Leu Thr Ile Ile Lys Asp Asn
Ser Lys Ser Gln 210 215 220 Val Phe Leu Lys Met Asn Ser Leu Gln Thr
Asp Asp Thr Ala Ile Tyr 225 230 235 240 Tyr Cys Ala Lys His Tyr Tyr
Tyr Gly Gly Ser Tyr Ala Met Asp Tyr 245 250 255 Trp Gly Gln Gly Thr
Ser Val Thr Val Ser Ser Ala Ala Ala Asp Tyr 260 265 270 Lys Asp Asp
Asp Asp Lys Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu 275 280 285 Asp
Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His 290 295
300 Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val
305 310 315 320 Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu
Leu Val Thr 325 330 335 Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys
Arg Ser Arg Leu Leu 340 345 350 His Ser Asp Tyr Met Asn Met Thr Pro
Arg Arg Pro Gly Pro Thr Arg 355 360 365 Lys His Tyr Gln Pro Tyr Ala
Pro Pro Arg Asp Phe Ala Ala Tyr Arg 370 375 380 Ser Arg Val Lys Phe
Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln 385 390 395 400 Gly Gln
Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu 405 410 415
Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly 420
425 430 Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
Gln 435 440 445 Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met
Lys Gly Glu 450 455 460 Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr
Gln Gly Leu Ser Thr 465 470 475 480 Ala Thr Lys Asp Thr Tyr Asp Ala
Leu His Met Gln Ala Leu Pro Pro 485 490 495 Arg <210> SEQ ID
NO 10 <211> LENGTH: 1491 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polynucleotide <400> SEQUENCE: 10 atgcttctcc tggtgacaag
ccttctgctc tgtgagttac cacacccagc attcctcctg 60 atcccagaca
tccagatgac acagactaca tcctccctgt ctgcctctct gggagacaga 120
gtcaccatca gttgcagggc aagtcaggac attagtaaat atttaaattg gtatcagcag
180 aaaccagatg gaactgttaa actcctgatc taccatacat caagattaca
ctcaggagtc 240 ccatcaaggt tcagtggcag tgggtctgga acagattatt
ctctcaccat tagcaacctg 300 gagcaagaag atattgccac ttacttttgc
caacagggta atacgcttcc gtacacgttc 360 ggagggggga ctaagttgga
aataacaggc tccacctctg gatccggcaa gcccggatct 420 ggcgagggat
ccaccaaggg cgaggtgaaa ctgcaggagt caggacctgg cctggtggcg 480
ccctcacaga gcctgtccgt cacatgcact gtctcagggg tctcattacc cgactatggt
540 gtaagctgga ttcgccagcc tccacgaaag ggtctggagt ggctgggagt
aatatggggt 600 agtgaaacca catactataa ttcagctctc aaatccagac
tgaccatcat caaggacaac 660 tccaagagcc aagttttctt aaaaatgaac
agtctgcaaa ctgatgacac agccatttac 720 tactgtgcca aacattatta
ctacggtggt agctatgcta tggactactg gggtcaagga 780 acctcagtca
ccgtctcctc agcggccgca gactacaaag acgatgacga caagattgaa 840
gttatgtatc ctcctcctta cctagacaat gagaagagca atggaaccat tatccatgtg
900 aaagggaaac acctttgtcc aagtccccta tttcccggac cttctaagcc
cttttgggtg 960 ctggtggtgg ttgggggagt cctggcttgc tatagcttgc
tagtaacagt ggcctttatt 1020 attttctggg tgaggagtaa gaggagcagg
ctcctgcaca gtgactacat gaacatgact 1080 ccccgccgcc ccgggcccac
ccgcaagcat taccagccct atgccccacc acgcgacttc 1140 gcagcctatc
gctccagagt gaagttcagc aggagcgcag acgcccccgc gtaccagcag 1200
ggccagaacc agctctataa cgagctcaat ctaggacgaa gagaggagta cgatgttttg
1260 gacaagagac gtggccggga ccctgagatg gggggaaagc cgagaaggaa
gaaccctcag 1320 gaaggcctgt acaatgaact gcagaaagat aagatggcgg
aggcctacag tgagattggg 1380 atgaaaggcg agcgccggag gggcaagggg
cacgatggcc tttaccaggg tctcagtaca 1440 gccaccaagg acacctacga
cgcccttcac atgcaggccc tgccccctcg c 1491 <210> SEQ ID NO 11
<211> LENGTH: 395 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 11 Met Asp Trp Thr Trp Ile Leu
Phe Leu Val Ala Ala Ala Thr Arg Val 1 5 10 15 His Ser Asn Trp Val
Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp 20 25 30 Leu Ile Gln
Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp 35 40 45 Val
His Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu 50 55
60 Leu Gln Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr
65 70 75 80 Val Glu Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser
Asn Gly 85 90 95 Asn Val Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu
Leu Glu Glu Lys 100 105 110 Asn Ile Lys Glu Phe Leu Gln Ser Phe Val
His Ile Val Gln Met Phe 115 120 125 Ile Asn Thr Ser Ser Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly 130 135 140 Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Ser Leu Gln Ile Thr 145 150 155 160 Cys Pro Pro
Pro Met Ser Val Glu His Ala Asp Ile Trp Val Lys Ser 165 170 175 Tyr
Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly Phe Lys 180 185
190 Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn Lys Ala
195 200 205 Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile
Arg Asp 210 215 220 Pro Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser
Thr Val Thr Thr 225 230 235 240 Ala Gly Val Thr Pro Gln Pro Glu Ser
Leu Ser Pro Ser Gly Lys Glu 245 250 255 Pro Ala Ala Ser Ser Pro Ser
Ser Asn Asn Thr Ala Ala Thr Thr Ala 260 265 270 Ala Ile Val Pro Gly
Ser Gln Leu Met Pro Ser Lys Ser Pro Ser Thr 275 280 285 Gly Thr Thr
Glu Ile Ser Ser His Glu Ser Ser His Gly Thr Pro Ser 290 295 300 Gln
Thr Thr Ala Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser His Gln 305 310
315 320 Pro Pro Gly Val Tyr Pro Gln Gly His Ser Asp Thr Thr Val Ala
Ile 325 330 335 Ser Thr Ser Thr Val Leu Leu Cys Gly Leu Ser Ala Val
Ser Leu Leu 340 345 350 Ala Cys Tyr Leu Lys Ser Arg Gln Thr Pro Pro
Leu Ala Ser Val Glu 355 360 365 Met Glu Ala Met Glu Ala Leu Pro Val
Thr Trp Gly Thr Ser Ser Arg 370 375 380 Asp Glu Asp Leu Glu Asn Cys
Ser His His Leu 385 390 395 <210> SEQ ID NO 12 <211>
LENGTH: 1188 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polynucleotide
<400> SEQUENCE: 12 atggattgga cttggatttt gttcctcgtt
gccgcagcga ctcgcgtcca tagtaattgg 60 gtgaacgtaa ttagtgactt
gaaaaaaatt gaggacctta tacaaagtat gcatatcgat 120 gcaacactgt
acacggagtc cgacgtgcac ccaagctgca aggtcaccgc aatgaaatgc 180
tttttgctcg aattgcaagt tatctcactt gagtcagggg acgcttcaat ccatgatact
240 gtggagaatt tgataatcct ggcgaacaat agccttagtt caaatggcaa
cgtcactgag 300 tcaggctgca aggaatgtga ggaattggaa gaaaaaaata
tcaaggaatt tttgcaatct 360 tttgttcaca tagttcagat gttcattaac
actagttccg ggggcggcag tggaggtggc 420 ggtagcggcg ggggtggctc
tggtggaggc ggctctgggg gcggaagtct gcagataaca 480 tgccccccac
ctatgagtgt tgaacatgct gatatctggg ttaaatctta ctccctttac 540
agtcgagaaa ggtacatttg caactccggc tttaaacgca aagccgggac tagttcactg
600 actgaatgtg tattgaataa agcgacaaat gtcgcacact ggactacccc
ttccctcaaa 660 tgcattcgcg atcctgcctt ggtgcatcag cgaccagcac
cgccgtccac ggtaactacc 720 gcaggagtaa caccgcagcc cgagagcctt
tccccctcag gcaaagagcc ggccgcatcc 780 tccccatctt ccaataatac
cgcagctacc accgcagcaa tcgtacccgg gtcccagctg 840 atgcccagca
aaagtccgag tactggaacg actgaaatct ccagtcacga gtcttctcat 900
ggaactccga gtcaaactac agcaaagaat tgggagctga ctgcttccgc ttcacaccag
960 ccgccaggcg tttatcctca gggacactca gataccacgg tggcgattag
cacaagcacc 1020 gtcctcctgt gtgggctgag tgcagtgtca cttctcgcct
gctaccttaa gtccagacag 1080 acaccccctt tggcaagcgt tgaaatggaa
gccatggaag ccttgcctgt cacatggggg 1140 acttcatccc gcgatgaaga
cttggagaac tgctcacacc atctttga 1188 <210> SEQ ID NO 13
<211> LENGTH: 177 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 13 Met Phe His Val Ser Phe Arg
Tyr Ile Phe Gly Leu Pro Pro Leu Ile 1 5 10 15 Leu Val Leu Leu Pro
Val Ala Ser Ser Asp Cys Asp Ile Glu Gly Lys 20 25 30 Asp Gly Lys
Gln Tyr Glu Ser Val Leu Met Val Ser Ile Asp Gln Leu 35 40 45 Leu
Asp Ser Met Lys Glu Ile Gly Ser Asn Cys Leu Asn Asn Glu Phe 50 55
60 Asn Phe Phe Lys Arg His Ile Cys Asp Ala Asn Lys Glu Gly Met Phe
65 70 75 80 Leu Phe Arg Ala Ala Arg Lys Leu Arg Gln Phe Leu Lys Met
Asn Ser 85 90 95 Thr Gly Asp Phe Asp Leu His Leu Leu Lys Val Ser
Glu Gly Thr Thr 100 105 110 Ile Leu Leu Asn Cys Thr Gly Gln Val Lys
Gly Arg Lys Pro Ala Ala 115 120 125 Leu Gly Glu Ala Gln Pro Thr Lys
Ser Leu Glu Glu Asn Lys Ser Leu 130 135 140 Lys Glu Gln Lys Lys Leu
Asn Asp Leu Cys Phe Leu Lys Arg Leu Leu 145 150 155 160 Gln Glu Ile
Lys Thr Cys Trp Asn Lys Ile Leu Met Gly Thr Lys Glu 165 170 175 His
<210> SEQ ID NO 14 <211> LENGTH: 614 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polynucleotide <400> SEQUENCE: 14 gaattcggca
gcggcgtcaa gcagacactg aacttcgatc tgctgaagct ggccggagac 60
gtcgagagca accccggccc tatgttccac gtgagcttta gatacatctt cggactgccc
120 cctctgattc tggtgctgct gcccgtggcc agcagcgact gcgatatcga
gggcaaggac 180 ggcaagcagt atgagtccgt gctgatggtc tccatcgatc
agctgctgga cagcatgaag 240 gagatcggct ccaactgcct caacaacgag
ttcaactttt tcaagaggca catctgcgac 300 gccaacaagg agggcatgtt
tctgtttaga gccgctagaa agctgaggca gtttctgaag 360 atgaacagca
ccggcgactt tgatctgcat ctgctgaaag tgagcgaggg caccaccatt 420
ctgctgaact gcaccggcca agtgaaagga agaaagcccg ccgctctggg cgaggctcag
480 cctaccaagt ctctggaaga gaacaagtct ctgaaggagc agaagaagct
caacgatctg 540 tgcttcctca agaggctgct gcaagagatc aagacatgct
ggaacaagat cctcatgggc 600 accaaggaac actg 614 <210> SEQ ID NO
15 <211> LENGTH: 513 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 15 Met Leu Val Arg Arg Gly Ala
Arg Ala Gly Pro Arg Met Pro Arg Gly 1 5 10 15 Trp Thr Ala Leu Cys
Leu Leu Ser Leu Leu Pro Ser Gly Phe Met Ser 20 25 30 Leu Asp Asn
Asn Gly Thr Ala Thr Pro Glu Leu Pro Thr Gln Gly Thr 35 40 45 Phe
Ser Asn Val Ser Thr Asn Val Ser Tyr Gln Glu Thr Thr Thr Pro 50 55
60 Ser Thr Leu Gly Ser Thr Ser Leu His Pro Val Ser Gln His Gly Asn
65 70 75 80 Glu Ala Thr Thr Asn Ile Thr Glu Thr Thr Val Lys Phe Thr
Ser Thr 85 90 95 Ser Val Ile Thr Ser Val Tyr Gly Asn Thr Asn Ser
Ser Val Gln Ser 100 105 110 Gln Thr Ser Val Ile Ser Thr Val Phe Thr
Thr Pro Ala Asn Val Ser 115 120 125 Thr Pro Glu Thr Thr Leu Lys Pro
Ser Leu Ser Pro Gly Asn Val Ser 130 135 140 Asp Leu Ser Thr Thr Ser
Thr Ser Leu Ala Thr Ser Pro Thr Lys Pro 145 150 155 160 Tyr Thr Ser
Ser Ser Pro Ile Leu Ser Asp Ile Lys Ala Glu Ile Lys 165 170 175 Cys
Ser Gly Ile Arg Glu Val Lys Leu Thr Gln Gly Ile Cys Leu Glu 180 185
190 Gln Asn Lys Thr Ser Ser Cys Ala Glu Phe Lys Lys Asp Arg Gly Glu
195 200 205 Gly Leu Ala Arg Val Leu Cys Gly Glu Glu Gln Ala Asp Ala
Asp Ala 210 215 220 Gly Ala Gln Val Cys Ser Leu Leu Leu Ala Gln Ser
Glu Val Arg Pro 225 230 235 240 Gln Cys Leu Leu Leu Val Leu Ala Asn
Arg Thr Glu Ile Ser Ser Lys 245 250 255 Leu Gln Leu Met Lys Lys His
Gln Ser Asp Leu Lys Lys Leu Gly Ile 260 265 270 Leu Asp Phe Thr Glu
Gln Asp Val Ala Ser His Gln Ser Tyr Ser Gln 275 280 285 Lys Thr Pro
Ile Leu Leu Thr Cys Pro Thr Ile Ser Ile Leu Ser Phe 290 295 300 Phe
Ser Val Ala Leu Leu Val Ile Leu Ala Cys Val Leu Trp Lys Lys 305 310
315 320 Arg Ile Lys Pro Ile Val Trp Pro Ser Leu Pro Asp His Lys Lys
Thr 325 330 335 Leu Glu His Leu Cys Lys Lys Pro Arg Lys Asn Leu Asn
Val Ser Phe 340 345 350 Asn Pro Glu Ser Phe Leu Asp Cys Gln Ile His
Arg Val Asp Asp Ile 355 360 365 Gln Ala Arg Asp Glu Val Glu Gly Phe
Leu Gln Asp Thr Phe Pro Gln 370 375 380 Gln Leu Glu Glu Ser Glu Lys
Gln Arg Leu Gly Gly Asp Val Gln Ser 385 390 395 400 Pro Asn Cys Pro
Ser Glu Asp Val Val Ile Thr Pro Glu Ser Phe Gly 405 410 415 Arg Asp
Ser Ser Leu Thr Cys Leu Ala Gly Asn Val Ser Ala Cys Asp 420 425 430
Ala Pro Ile Leu Ser Ser Ser Arg Ser Leu Asp Cys Arg Glu Ser Gly 435
440 445 Lys Asn Gly Pro His Val Tyr Gln Asp Leu Leu Leu Ser Leu Gly
Thr 450 455 460 Thr Asn Ser Thr Leu Pro Pro Pro Phe Ser Leu Gln Ser
Gly Ile Leu 465 470 475 480 Thr Leu Asn Pro Val Ala Gln Gly Gln Pro
Ile Leu Thr Ser Leu Gly 485 490 495 Ser Asn Gln Glu Glu Ala Tyr Val
Thr Met Ser Ser Phe Tyr Gln Asn 500 505 510 Gln <210> SEQ ID
NO 16 <211> LENGTH: 1608 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polynucleotide <400> SEQUENCE: 16 ggaagcggcg ccacaaactt
ttctctgctg aagcaagccg gcgacgtcga agagaacccc 60 ggccctatgc
tggtgaggag aggcgctagg gctggaccca gaatgcccag aggctggacc 120
gctctgtgtc tgctgtctct gctgcccagc ggcttcatga gcctcgataa taacggcacc
180 gctacccccg agctgcccac acaaggcacc ttctccaatg tgagcaccaa
cgtgtcctac 240 caagagacca ccaccccttc cacactggga agcacatctc
tgcatcccgt ctcccagcac 300 ggcaatgaag ccaccacaaa catcaccgag
accaccgtga agttcaccag cacctccgtc 360 attaccagcg tgtacggcaa
caccaatagc tccgtgcaaa gccagacatc cgtgatttcc 420 accgtgttta
ccacccccgc caatgtcagc acacccgaga caacactgaa accttctctg 480
tcccccggaa acgtgagcga tctgagcaca accagcacca gcctcgccac cagccccaca
540 aagccttaca caagcagcag ccccattctg agcgacatca aggccgaaat
caagtgctcc 600 ggaattagag aggtcaagct gacccaagga atctgtctgg
agcagaataa gaccagcagc 660 tgcgccgagt tcaagaaaga cagaggcgaa
ggactggcca gagtgctctg cggcgaggaa 720 caagccgatg ccgatgccgg
agctcaagtg tgcagcctcc tcctcgctca gagcgaggtc 780 agaccccaat
gtctgctgct cgtgctggcc aataggaccg agatctcctc caaactgcag 840
ctgatgaaga agcaccagag cgacctcaag aagctcggca tcctcgactt taccgagcaa
900 gacgtggcct cccatcaatc ctatagccag aagaccccca ttctgctgac
atgtcccaca 960 atcagcatcc tcagcttctt cagcgtcgct ctgctcgtca
ttctggcttg tgtgctgtgg 1020 aagaagagga tcaagcctat tgtgtggccc
tctctgcccg accacaagaa gaccctcgaa 1080 cacctctgca agaaacctag
aaagaacctc aacgtgagct tcaaccccga gtcctttctg 1140 gactgtcaaa
tccatagggt ggatgacatc caagctagag acgaggtcga gggctttctg 1200
caagacacct tccctcagca gctggaagaa agcgagaagc aaagactggg cggagatgtg
1260 cagtccccta attgcccctc cgaggacgtg gtgattaccc ccgagagctt
cggaagagac 1320 agctctctga catgtctggc cggaaatgtg tccgcttgcg
atgcccctat tctgagcagc 1380 tccagatctc tggactgcag agagtccggc
aagaacggcc ctcatgtgta ccaagatctg 1440 ctgctgtctc tgggaaccac
aaactccaca ctgcctcccc cctttagcct ccagtccggc 1500 attctgacac
tgaaccccgt ggctcaaggc caacctatcc tcacatccct cggctccaat 1560
caagaggaag cctacgtgac catgagctcc ttctatcaga accagtga 1608
<210> SEQ ID NO 17 <211> LENGTH: 635 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 17 Met Ala Leu Pro Val
Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala
Arg Pro Asp Cys Asp Ile Glu Gly Lys Asp Gly Lys Gln 20 25 30 Tyr
Glu Ser Val Leu Met Val Ser Ile Asp Gln Leu Leu Asp Ser Met 35 40
45 Lys Glu Ile Gly Ser Asn Cys Leu Asn Asn Glu Phe Asn Phe Phe Lys
50 55 60 Arg His Ile Cys Asp Ala Asn Lys Glu Gly Met Phe Leu Phe
Arg Ala 65 70 75 80 Ala Arg Lys Leu Arg Gln Phe Leu Lys Met Asn Ser
Thr Gly Asp Phe 85 90 95 Asp Leu His Leu Leu Lys Val Ser Glu Gly
Thr Thr Ile Leu Leu Asn 100 105 110 Cys Thr Gly Gln Val Lys Gly Arg
Lys Pro Ala Ala Leu Gly Glu Ala 115 120 125 Gln Pro Thr Lys Ser Leu
Glu Glu Asn Lys Ser Leu Lys Glu Gln Lys 130 135 140 Lys Leu Asn Asp
Leu Cys Phe Leu Lys Arg Leu Leu Gln Glu Ile Lys 145 150 155 160 Thr
Cys Trp Asn Lys Ile Leu Met Gly Thr Lys Glu His Gly Gly Gly 165 170
175 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
180 185 190 Gly Gly Gly Ser Glu Ser Gly Tyr Ala Gln Asn Gly Asp Leu
Glu Asp 195 200 205 Ala Glu Leu Asp Asp Tyr Ser Phe Ser Cys Tyr Ser
Gln Leu Glu Val 210 215 220 Asn Gly Ser Gln His Ser Leu Thr Cys Ala
Phe Glu Asp Pro Asp Val 225 230 235 240 Asn Ile Thr Asn Leu Glu Phe
Glu Ile Cys Gly Ala Leu Val Glu Val 245 250 255 Lys Cys Leu Asn Phe
Arg Lys Leu Gln Glu Ile Tyr Phe Ile Glu Thr 260 265 270 Lys Lys Phe
Leu Leu Ile Gly Lys Ser Asn Ile Cys Val Lys Val Gly 275 280 285 Glu
Lys Ser Leu Thr Cys Lys Lys Ile Asp Leu Thr Thr Ile Val Lys 290 295
300 Pro Glu Ala Pro Phe Asp Leu Ser Val Val Tyr Arg Glu Gly Ala Asn
305 310 315 320 Asp Phe Val Val Thr Phe Asn Thr Ser His Leu Gln Lys
Lys Tyr Val 325 330 335 Lys Val Leu Met His Asp Val Ala Tyr Arg Gln
Glu Lys Asp Glu Asn 340 345 350 Lys Trp Thr His Val Asn Leu Ser Ser
Thr Lys Leu Thr Leu Leu Gln 355 360 365 Arg Lys Leu Gln Pro Ala Ala
Met Tyr Glu Ile Lys Val Arg Ser Ile 370 375 380 Pro Asp His Tyr Phe
Lys Gly Phe Trp Ser Glu Trp Ser Pro Ser Tyr 385 390 395 400 Tyr Phe
Arg Thr Pro Glu Ile Asn Asn Ser Ser Gly Glu Met Asp Pro 405 410 415
Ile Leu Leu Thr Ile Ser Ile Leu Ser Phe Phe Ser Val Ala Leu Leu 420
425 430 Val Ile Leu Ala Cys Val Leu Trp Lys Lys Arg Ile Lys Pro Ile
Val 435 440 445 Trp Pro Ser Leu Pro Asp His Lys Lys Thr Leu Glu His
Leu Cys Lys 450 455 460 Lys Pro Arg Lys Asn Leu Asn Val Ser Phe Asn
Pro Glu Ser Phe Leu 465 470 475 480 Asp Cys Gln Ile His Arg Val Asp
Asp Ile Gln Ala Arg Asp Glu Val 485 490 495 Glu Gly Phe Leu Gln Asp
Thr Phe Pro Gln Gln Leu Glu Glu Ser Glu 500 505 510 Lys Gln Arg Leu
Gly Gly Asp Val Gln Ser Pro Asn Cys Pro Ser Glu 515 520 525 Asp Val
Val Ile Thr Pro Glu Ser Phe Gly Arg Asp Ser Ser Leu Thr 530 535 540
Cys Leu Ala Gly Asn Val Ser Ala Cys Asp Ala Pro Ile Leu Ser Ser 545
550 555 560 Ser Arg Ser Leu Asp Cys Arg Glu Ser Gly Lys Asn Gly Pro
His Val 565 570 575 Tyr Gln Asp Leu Leu Leu Ser Leu Gly Thr Thr Asn
Ser Thr Leu Pro 580 585 590 Pro Pro Phe Ser Leu Gln Ser Gly Ile Leu
Thr Leu Asn Pro Val Ala 595 600 605 Gln Gly Gln Pro Ile Leu Thr Ser
Leu Gly Ser Asn Gln Glu Glu Ala 610 615 620 Tyr Val Thr Met Ser Ser
Phe Tyr Gln Asn Gln 625 630 635 <210> SEQ ID NO 18
<211> LENGTH: 1905 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polynucleotide <400> SEQUENCE: 18 atggctctgc ctgttacagc
tctgctgctg cctctggctc tgcttctgca tgccgccaga 60 cctgactgtg
acatcgaggg caaagacggc aagcagtacg agagcgtgct gatggtgtcc 120
atcgaccagc tgctggacag catgaaggaa atcggcagca actgcctgaa caacgagttc
180 aacttcttca agcggcacat ctgcgacgcc aacaaagaag gcatgttcct
gttcagagcc 240 gccagaaagc tgcggcagtt cctgaagatg aacagcaccg
gcgacttcga cctgcatctg 300 ctgaaagtgt ctgagggcac caccatcctg
ctgaattgca ccggccaagt gaagggcaga 360 aagcctgctg ctctgggaga
agcccagcct accaagagcc tggaagagaa caagtccctg 420 aaagagcaga
agaagctgaa cgacctctgc ttcctgaagc ggctgctgca agagatcaag 480
acctgctgga acaagatcct gatgggcacc aaagagcacg gcggaggatc tggcggaggt
540 ggaagcggcg gaggcggtag cggtggcgga ggaagtggtg gcggatctga
atctggctac 600 gcccagaacg gcgacctgga agatgccgag ctggacgact
acagcttcag ctgctacagc 660 cagctggaag tgaacggcag ccagcactct
ctgacctgcg cctttgaaga tcccgacgtg 720 aacatcacca accttgagtt
cgagatttgt ggcgccctgg tggaagtcaa gtgcctgaat 780 ttccggaagc
tgcaagaaat ctactttatc gagacaaaga agttcctgct gatcggcaag 840
agcaacatct gtgtgaaagt gggcgagaaa agcctgacct gcaagaagat cgacctgacc
900 accatcgtga agcccgaggc tcctttcgat ctgagcgtgg tgtatagaga
gggcgccaac 960 gacttcgtgg tcaccttcaa caccagccac ctccaaaaga
aatacgtgaa ggtgctgatg 1020 cacgacgtgg cctaccggca agagaaggac
gagaacaaat ggacccacgt gaacctgagc 1080 agcaccaagc tgaccctgct
gcagagaaaa ctgcagcctg ccgctatgta cgagatcaaa 1140 gtgcggagca
tccccgacca ctactttaaa ggcttttgga gcgagtggtc ccctagctac 1200
tacttcagaa cccctgagat caacaactcc agcggcgaga tggaccccat tctgctgaca
1260 atcagcatcc tgagcttttt cagcgtggcc ctgctggtca tcctggcctg
tgtgctgtgg 1320 aagaagcgga tcaagcccat cgtgtggccc agcctgcctg
accacaagaa aaccctggaa 1380 cacctgtgca agaagccccg gaaaaacctg
aacgtgtcct tcaatcccga gagcttcctg 1440 gactgccaga tccacagagt
ggacgacatc caggccaggg acgaagtgga aggatttctg 1500 caggacacat
tccctcagca gctcgaagag agcgagaagc aaagactcgg aggcgacgtg 1560
cagagcccta attgcccttc tgaggacgtg gtcatcaccc cagagagctt cggcagagat
1620 agcagcctga catgtctggc cggcaatgtg tccgcctgtg atgcccctat
cctgtcctct 1680 agcagaagcc tggattgcag agagagcggc aagaacggcc
ctcacgtgta ccaggatctg 1740 ctcctgtctc tgggcaccac aaacagcaca
ctgcctccac cattcagcct gcagagcggc 1800 atcctgacac tgaaccctgt
tgctcagggc cagcctatcc tgacaagcct gggcagcaat 1860 caagaagagg
cctacgtcac catgagcagc ttctaccaga accag 1905 <210> SEQ ID NO
19 <400> SEQUENCE: 19 000 <210> SEQ ID NO 20
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide <400> SEQUENCE: 20 ttcggaaccc aatcactgac 20
<210> SEQ ID NO 21 <211> LENGTH: 20 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic oligonucleotide <400> SEQUENCE: 21 tcagggttct
ggatatctgt 20 <210> SEQ ID NO 22 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic oligonucleotide <400>
SEQUENCE: 22 aagttcctgt gatgtcaagc 20 <210> SEQ ID NO 23
<400> SEQUENCE: 23 000 <210> SEQ ID NO 24 <400>
SEQUENCE: 24 000 <210> SEQ ID NO 25 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic oligonucleotide <400>
SEQUENCE: 25 gaggtcaatg tctacggctc 20 <210> SEQ ID NO 26
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide <400> SEQUENCE: 26 atcacggagg tcaatgtcta 20
<210> SEQ ID NO 27 <211> LENGTH: 20 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic oligonucleotide <400> SEQUENCE: 27 gtagacattg
acctccgtga 20 <210> SEQ ID NO 28 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic oligonucleotide <400>
SEQUENCE: 28 ggagcaggtg atgttgacgg 20 <210> SEQ ID NO 29
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide <400> SEQUENCE: 29 caaagagatt acgaatgcct 20
<210> SEQ ID NO 30 <211> LENGTH: 20 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic oligonucleotide <400> SEQUENCE: 30 gtgccacaaa
gaccatcaag 20 <210> SEQ ID NO 31 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic oligonucleotide <400>
SEQUENCE: 31 agagggtcat cacacacaag 20 <210> SEQ ID NO 32
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide <400> SEQUENCE: 32 cttgtagata tcctgatcat 20
<210> SEQ ID NO 33 <400> SEQUENCE: 33 000 <210>
SEQ ID NO 34 <211> LENGTH: 20 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic oligonucleotide <400> SEQUENCE: 34 gaggtcaatg
tctacggctc 20 <210> SEQ ID NO 35 <211> LENGTH: 1461
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polynucleotide <400> SEQUENCE:
35 atggcactcc ctgtaactgc acttcttttg ccacttgcct tgctcctgca
cgcagcgcgg 60 ccggacatcg agctgaccca gagccccgcc atcatgagcg
ccagcctggg cgaggagatc 120 accctgacct gcagcgccag cagcagcgtg
agctacatgc actggtacca gcagaagagc 180 ggcaccagcc ccaagctgct
gatctacagc accagcaacc tggccagcgg cgtgcccagc 240 aggttcagcg
gcagcggcag cggcaccttc tacagcctga ccatcagcag cgtggaggcc 300
gaggacgccg ccgactacta ctgccaccag tggagcagct acaccttcgg cggcggcacc
360 aagctggaga tcaagagggg cggcggcggc agcggcggcg gcggcagcgg
cggcggcggc 420 agccaggtga agctgcagga gagcggcggc ggcctggtga
agcccggcgg cagcctgaag 480 ctgagctgcg ccgccagcgg cttcaccttc
agcagctacg ccatgagctg ggtgaggcag 540 acccccgaga agaggctgga
gtgggtggcc accatcagca gcggcggcag ctacacctac 600 taccccgaca
gcgtgaaggg caggttcacc atcagcaggg acaacgccaa gaacaccctg 660
tacctgcaga tgagcagcct gaggagcgag gacaccgcca tgtactactg cgccaggcag
720 gacggctact accccggctg gttcgccaac tggggccagg gcaccaccgt
gaccgtgagc 780 agctccggaa caacgacacc agcaccacgg ccacccactc
ctgctccgac aattgcgtct 840 cagccccttt cccttcgacc cgaagcttgt
cgccctgctg cgggaggagc ggtccacacg 900 cgcgggcttg acttcgcttg
cgacatctac atttgggcac ccttggccgg gacatgcggc 960 gtcttgctcc
tgagtctggt tataacgctg tattgtaagc gaggtcggaa gaagcttttg 1020
tatatcttta aacagccctt tatgaggccc gtacaaacca cacaagagga ggatgggtgc
1080 tcatgcagat ttcctgaaga ggaagagggc ggttgcgaac ttagagtcaa
attcagccgc 1140 tccgcagatg cacctgctta taaacagggt cagaatcaat
tgtataatga acttaatctc 1200 gggaggcgcg aggagtatga tgtgctggac
aagcgacggg gtcgagaccc agagatgggc 1260 ggtaaacccc gccgaaagaa
cccccaggag ggactgtata atgagctgca aaaggacaaa 1320 atggcagaag
cctattccga aatagggatg aagggagagc ggcggcgagg taagggacat 1380
gacggtcttt atcaaggtct tagtactgca actaaggaca cctatgacgc gctgcatatg
1440 caggctctcc cacctagata a 1461 <210> SEQ ID NO 36
<211> LENGTH: 486 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 36 Met Ala Leu Pro Val Thr Ala
Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro
Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met 20 25 30 Ser Ala Ser
Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser 35 40 45 Ser
Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro 50 55
60 Lys Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser
65 70 75 80 Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr
Ile Ser 85 90 95 Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys
His Gln Trp Ser 100 105 110 Ser Tyr Thr Phe Gly Gly Gly Thr Lys Leu
Glu Ile Lys Arg Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gln Val Lys 130 135 140 Leu Gln Glu Ser Gly Gly
Gly Leu Val Lys Pro Gly Gly Ser Leu Lys 145 150 155 160 Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser 165 170 175 Trp
Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile 180 185
190 Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg
195 200 205 Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu
Gln Met 210 215 220 Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr
Cys Ala Arg Gln 225 230 235 240 Asp Gly Tyr Tyr Pro Gly Trp Phe Ala
Asn Trp Gly Gln Gly Thr Thr 245 250 255 Val Thr Val Ser Ser Ser Gly
Thr Thr Thr Pro Ala Pro Arg Pro Pro 260 265 270 Thr Pro Ala Pro Thr
Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu 275 280 285 Ala Cys Arg
Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp 290 295 300 Phe
Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly 305 310
315 320 Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly
Arg 325 330 335 Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg
Pro Val Gln 340 345 350 Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg
Phe Pro Glu Glu Glu 355 360 365 Glu Gly Gly Cys Glu Leu Arg Val Lys
Phe Ser Arg Ser Ala Asp Ala 370 375 380 Pro Ala Tyr Lys Gln Gly Gln
Asn Gln Leu Tyr Asn Glu Leu Asn Leu 385 390 395 400 Gly Arg Arg Glu
Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp 405 410 415 Pro Glu
Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 420 425 430
Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile 435
440 445 Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
Tyr 450 455 460 Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala
Leu His Met 465 470 475 480 Gln Ala Leu Pro Pro Arg 485 <210>
SEQ ID NO 37 <211> LENGTH: 2721 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polynucleotide <400> SEQUENCE: 37 atggcactcc
ctgtaactgc acttcttttg ccacttgcct tgctcctgca cgcagcgcgg 60
ccggacatcg agctgaccca gagccccgcc atcatgagcg ccagcctggg cgaggagatc
120 accctgacct gcagcgccag cagcagcgtg agctacatgc actggtacca
gcagaagagc 180 ggcaccagcc ccaagctgct gatctacagc accagcaacc
tggccagcgg cgtgcccagc 240 aggttcagcg gcagcggcag cggcaccttc
tacagcctga ccatcagcag cgtggaggcc 300 gaggacgccg ccgactacta
ctgccaccag tggagcagct acaccttcgg cggcggcacc 360 aagctggaga
tcaagagggg cggcggcggc agcggcggcg gcggcagcgg cggcggcggc 420
agccaggtga agctgcagga gagcggcggc ggcctggtga agcccggcgg cagcctgaag
480 ctgagctgcg ccgccagcgg cttcaccttc agcagctacg ccatgagctg
ggtgaggcag 540 acccccgaga agaggctgga gtgggtggcc accatcagca
gcggcggcag ctacacctac 600 taccccgaca gcgtgaaggg caggttcacc
atcagcaggg acaacgccaa gaacaccctg 660 tacctgcaga tgagcagcct
gaggagcgag gacaccgcca tgtactactg cgccaggcag 720 gacggctact
accccggctg gttcgccaac tggggccagg gcaccaccgt gaccgtgagc 780
agctccggaa caacgacacc agcaccacgg ccacccactc ctgctccgac aattgcgtct
840 cagccccttt cccttcgacc cgaagcttgt cgccctgctg cgggaggagc
ggtccacacg 900 cgcgggcttg acttcgcttg cgacatctac atttgggcac
ccttggccgg gacatgcggc 960 gtcttgctcc tgagtctggt tataacgctg
tattgtaagc gaggtcggaa gaagcttttg 1020 tatatcttta aacagccctt
tatgaggccc gtacaaacca cacaagagga ggatgggtgc 1080 tcatgcagat
ttcctgaaga ggaagagggc ggttgcgaac ttagagtcaa attcagccgc 1140
tccgcagatg cacctgctta taaacagggt cagaatcaat tgtataatga acttaatctc
1200 gggaggcgcg aggagtatga tgtgctggac aagcgacggg gtcgagaccc
agagatgggc 1260 ggtaaacccc gccgaaagaa cccccaggag ggactgtata
atgagctgca aaaggacaaa 1320 atggcagaag cctattccga aatagggatg
aagggagagc ggcggcgagg taagggacat 1380 gacggtcttt atcaaggtct
tagtactgca actaaggaca cctatgacgc gctgcatatg 1440 caggctctcc
cacctagacg agctaaacga ggctcaggcg cgacgaactt tagtttgctg 1500
aagcaagctg gggatgtaga ggaaaatccg ggtcccatgg attggacttg gattttgttc
1560 ctcgttgccg cagcgactcg cgtccatagt aattgggtga acgtaattag
tgacttgaaa 1620 aaaattgagg accttataca aagtatgcat atcgatgcaa
cactgtacac ggagtccgac 1680 gtgcacccaa gctgcaaggt caccgcaatg
aaatgctttt tgctcgaatt gcaagttatc 1740 tcacttgagt caggggacgc
ttcaatccat gatactgtgg agaatttgat aatcctggcg 1800 aacaatagcc
ttagttcaaa tggcaacgtc actgagtcag gctgcaagga atgtgaggaa 1860
ttggaagaaa aaaatatcaa ggaatttttg caatcttttg ttcacatagt tcagatgttc
1920 attaacacta gttccggggg cggcagtgga ggtggcggta gcggcggggg
tggctctggt 1980 ggaggcggct ctgggggcgg aagtctgcag ataacatgcc
ccccacctat gagtgttgaa 2040 catgctgata tctgggttaa atcttactcc
ctttacagtc gagaaaggta catttgcaac 2100 tccggcttta aacgcaaagc
cgggactagt tcactgactg aatgtgtatt gaataaagcg 2160 acaaatgtcg
cacactggac taccccttcc ctcaaatgca ttcgcgatcc tgccttggtg 2220
catcagcgac cagcaccgcc gtccacggta actaccgcag gagtaacacc gcagcccgag
2280 agcctttccc cctcaggcaa agagccggcc gcatcctccc catcttccaa
taataccgca 2340 gctaccaccg cagcaatcgt acccggatcc cagctgatgc
ccagcaaaag tccgagtact 2400 ggaacgactg aaatctccag tcacgagtct
tctcatggaa ctccgagtca aactacagca 2460 aagaattggg agctgactgc
ttccgcttca caccagccgc caggcgttta tcctcaggga 2520 cactcagata
ccacggtggc gattagcaca agcaccgtcc tcctgtgtgg gctgagtgca 2580
gtgtcacttc tcgcctgcta ccttaagtcc agacagacac cccctttggc aagcgttgaa
2640 atggaagcca tggaagcctt gcctgtcaca tgggggactt catcccgcga
tgaagacttg 2700 gagaactgct cacaccatct t 2721 <210> SEQ ID NO
38 <211> LENGTH: 907 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 38 Met Ala Leu Pro Val Thr Ala
Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro
Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met 20 25 30 Ser Ala Ser
Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser 35 40 45 Ser
Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro 50 55
60 Lys Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser
65 70 75 80 Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr
Ile Ser 85 90 95 Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys
His Gln Trp Ser 100 105 110 Ser Tyr Thr Phe Gly Gly Gly Thr Lys Leu
Glu Ile Lys Arg Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gln Val Lys 130 135 140 Leu Gln Glu Ser Gly Gly
Gly Leu Val Lys Pro Gly Gly Ser Leu Lys 145 150 155 160 Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser 165 170 175 Trp
Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile 180 185
190 Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg
195 200 205 Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu
Gln Met 210 215 220 Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr
Cys Ala Arg Gln 225 230 235 240 Asp Gly Tyr Tyr Pro Gly Trp Phe Ala
Asn Trp Gly Gln Gly Thr Thr 245 250 255 Val Thr Val Ser Ser Ser Gly
Thr Thr Thr Pro Ala Pro Arg Pro Pro 260 265 270 Thr Pro Ala Pro Thr
Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu 275 280 285 Ala Cys Arg
Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp 290 295 300 Phe
Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly 305 310
315 320 Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly
Arg 325 330 335 Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg
Pro Val Gln 340 345 350 Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg
Phe Pro Glu Glu Glu 355 360 365 Glu Gly Gly Cys Glu Leu Arg Val Lys
Phe Ser Arg Ser Ala Asp Ala 370 375 380 Pro Ala Tyr Lys Gln Gly Gln
Asn Gln Leu Tyr Asn Glu Leu Asn Leu 385 390 395 400 Gly Arg Arg Glu
Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp 405 410 415 Pro Glu
Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 420 425 430
Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile 435
440 445 Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
Tyr 450 455 460 Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala
Leu His Met 465 470 475 480 Gln Ala Leu Pro Pro Arg Arg Ala Lys Arg
Gly Ser Gly Ala Thr Asn 485 490 495 Phe Ser Leu Leu Lys Gln Ala Gly
Asp Val Glu Glu Asn Pro Gly Pro 500 505 510 Met Asp Trp Thr Trp Ile
Leu Phe Leu Val Ala Ala Ala Thr Arg Val 515 520 525 His Ser Asn Trp
Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp 530 535 540 Leu Ile
Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp 545 550 555
560 Val His Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu
565 570 575 Leu Gln Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His
Asp Thr 580 585 590 Val Glu Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu
Ser Ser Asn Gly 595 600 605 Asn Val Thr Glu Ser Gly Cys Lys Glu Cys
Glu Glu Leu Glu Glu Lys 610 615 620 Asn Ile Lys Glu Phe Leu Gln Ser
Phe Val His Ile Val Gln Met Phe 625 630 635 640 Ile Asn Thr Ser Ser
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 645 650 655 Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Ser Leu Gln Ile Thr 660 665 670 Cys
Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val Lys Ser 675 680
685 Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly Phe Lys
690 695 700 Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn
Lys Ala 705 710 715 720 Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu
Lys Cys Ile Arg Asp 725 730 735 Pro Ala Leu Val His Gln Arg Pro Ala
Pro Pro Ser Thr Val Thr Thr 740 745 750 Ala Gly Val Thr Pro Gln Pro
Glu Ser Leu Ser Pro Ser Gly Lys Glu 755 760 765 Pro Ala Ala Ser Ser
Pro Ser Ser Asn Asn Thr Ala Ala Thr Thr Ala 770 775 780 Ala Ile Val
Pro Gly Ser Gln Leu Met Pro Ser Lys Ser Pro Ser Thr 785 790 795 800
Gly Thr Thr Glu Ile Ser Ser His Glu Ser Ser His Gly Thr Pro Ser 805
810 815 Gln Thr Thr Ala Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser His
Gln 820 825 830 Pro Pro Gly Val Tyr Pro Gln Gly His Ser Asp Thr Thr
Val Ala Ile 835 840 845 Ser Thr Ser Thr Val Leu Leu Cys Gly Leu Ser
Ala Val Ser Leu Leu 850 855 860 Ala Cys Tyr Leu Lys Ser Arg Gln Thr
Pro Pro Leu Ala Ser Val Glu 865 870 875 880 Met Glu Ala Met Glu Ala
Leu Pro Val Thr Trp Gly Thr Ser Ser Arg 885 890 895 Asp Glu Asp Leu
Glu Asn Cys Ser His His Leu 900 905 <210> SEQ ID NO 39
<211> LENGTH: 3063 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polynucleotide <400> SEQUENCE: 39 atggcactcc ctgtaactgc
acttcttttg ccacttgcct tgctcctgca cgcagcgcgg 60 ccggacatcg
agctgaccca gagccccgcc atcatgagcg ccagcctggg cgaggagatc 120
accctgacct gcagcgccag cagcagcgtg agctacatgc actggtacca gcagaagagc
180 ggcaccagcc ccaagctgct gatctacagc accagcaacc tggccagcgg
cgtgcccagc 240 aggttcagcg gcagcggcag cggcaccttc tacagcctga
ccatcagcag cgtggaggcc 300 gaggacgccg ccgactacta ctgccaccag
tggagcagct acaccttcgg cggcggcacc 360 aagctggaga tcaagagggg
cggcggcggc agcggcggcg gcggcagcgg cggcggcggc 420 agccaggtga
agctgcagga gagcggcggc ggcctggtga agcccggcgg cagcctgaag 480
ctgagctgcg ccgccagcgg cttcaccttc agcagctacg ccatgagctg ggtgaggcag
540 acccccgaga agaggctgga gtgggtggcc accatcagca gcggcggcag
ctacacctac 600 taccccgaca gcgtgaaggg caggttcacc atcagcaggg
acaacgccaa gaacaccctg 660 tacctgcaga tgagcagcct gaggagcgag
gacaccgcca tgtactactg cgccaggcag 720 gacggctact accccggctg
gttcgccaac tggggccagg gcaccaccgt gaccgtgagc 780 agctccggaa
caacgacacc agcaccacgg ccacccactc ctgctccgac aattgcgtct 840
cagccccttt cccttcgacc cgaagcttgt cgccctgctg cgggaggagc ggtccacacg
900 cgcgggcttg acttcgcttg cgacatctac atttgggcac ccttggccgg
gacatgcggc 960 gtcttgctcc tgagtctggt tataacgctg tattgtaagc
gaggtcggaa gaagcttttg 1020 tatatcttta aacagccctt tatgaggccc
gtacaaacca cacaagagga ggatgggtgc 1080 tcatgcagat ttcctgaaga
ggaagagggc ggttgcgaac ttagagtcaa attcagccgc 1140 tccgcagatg
cacctgctta taaacagggt cagaatcaat tgtataatga acttaatctc 1200
gggaggcgcg aggagtatga tgtgctggac aagcgacggg gtcgagaccc agagatgggc
1260 ggtaaacccc gccgaaagaa cccccaggag ggactgtata atgagctgca
aaaggacaaa 1320 atggcagaag cctattccga aatagggatg aagggagagc
ggcggcgagg taagggacat 1380 gacggtcttt atcaaggtct tagtactgca
actaaggaca cctatgacgc gctgcatatg 1440 caggctctcc cacctagagg
ctcaggcgcg acgaacttta gtttgctgaa gcaagctggg 1500 gatgtagagg
aaaatccggg tcccatgttg gtgcgccgag gcgcacgagc aggacctcgg 1560
atgccgcgag gctggacagc cctctgtctc ctctctttgc ttccatccgg gttcatgagt
1620 ctcgacaata atggtacggc aaccccggaa ctcccgaccc aaggaacctt
tagtaacgtt 1680 tcaaccaatg tgtcctatca ggagacaaca accccttcta
cactgggcag taccagcttg 1740 catcccgtca gccaacacgg caacgaggca
acaactaaca tcacagagac tacggtcaag 1800 tttactagta cttccgtaat
cacgtctgtg tacgggaata caaattcatc agttcagagt 1860 caaacgtcag
ttatatctac agtcttcact actcccgcga atgtatccac cccagaaacc 1920
accctcaaac cttctcttag tccaggaaat gttagcgatt tgtcaacgac gagcacgagt
1980 ttggcgacta gtccaacgaa accgtacact tccagcagtc ccatactgtc
cgacattaag 2040 gcagaaataa aatgttctgg gatcagggag gtcaagctta
cgcagggaat atgtcttgag 2100 caaaataaga cgtcctcatg cgcagaattc
aagaaagatc gcggcgaagg tctggccaga 2160 gtcctctgtg gagaggagca
ggcggatgct gacgcaggag cgcaggtttg tagtctcctg 2220 ctcgcgcaaa
gtgaagttag gccccaatgt ctcttgttgg tactggctaa ccgaactgaa 2280
attagcagca agcttcaact catgaaaaaa caccagagtg atttgaaaaa acttgggata
2340 cttgacttca cggagcaaga cgttgcgtct caccaatcct actcacagaa
aaccccgata 2400 ctgttgacat gccccaccat atcaatcttg tctttcttca
gtgtggctct tctggtgatc 2460 ttggcgtgcg tgctgtggaa aaaaaggatt
aaaccgatcg tttggcctag tctgccggat 2520 cacaaaaaga cactggagca
cctctgcaag aagccacgaa aaaacctgaa tgtgagcttt 2580 aaccccgagt
cttttttgga ctgtcagata caccgagtcg acgatataca ggcaagagat 2640
gaggttgagg gtttcctgca agacacattc ccgcaacaac tcgaagaatc cgagaaacag
2700 cgccttggtg gagatgtcca gtctccgaac tgtccgagcg aggacgtagt
aattacccca 2760 gaaagcttcg gtcgagatag tagccttacg tgtctcgccg
ggaacgtgtc agcgtgtgac 2820 gcgcctattc tttcaagttc acgcagtttg
gactgtcgag aatcagggaa aaacggacct 2880 cacgtgtatc aggatctcct
tctcagcctg ggcacgacaa acagtacctt gcctcctccg 2940 ttttccctgc
agtcaggtat tctgacgctc aatccagtcg cacaagggca acctatcctg 3000
acctccttgg gttctaacca ggaagaggca tacgtcacta tgtccagctt ctatcagaat
3060 cag 3063 <210> SEQ ID NO 40 <211> LENGTH: 1021
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 40
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5
10 15 His Ala Ala Arg Pro Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile
Met 20 25 30 Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser
Ala Ser Ser 35 40 45 Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys
Ser Gly Thr Ser Pro 50 55 60 Lys Leu Leu Ile Tyr Ser Thr Ser Asn
Leu Ala Ser Gly Val Pro Ser 65 70 75 80 Arg Phe Ser Gly Ser Gly Ser
Gly Thr Phe Tyr Ser Leu Thr Ile Ser 85 90 95 Ser Val Glu Ala Glu
Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser 100 105 110 Ser Tyr Thr
Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Gly Gly 115 120 125 Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Lys 130 135
140 Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys
145 150 155 160 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
Ala Met Ser 165 170 175 Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu
Trp Val Ala Thr Ile 180 185 190 Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr
Pro Asp Ser Val Lys Gly Arg 195 200 205 Phe Thr Ile Ser Arg Asp Asn
Ala Lys Asn Thr Leu Tyr Leu Gln Met 210 215 220 Ser Ser Leu Arg Ser
Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gln 225 230 235 240 Asp Gly
Tyr Tyr Pro Gly Trp Phe Ala Asn Trp Gly Gln Gly Thr Thr 245 250 255
Val Thr Val Ser Ser Ser Gly Thr Thr Thr Pro Ala Pro Arg Pro Pro 260
265 270 Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro
Glu 275 280 285 Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg
Gly Leu Asp 290 295 300 Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
Ala Gly Thr Cys Gly 305 310 315 320 Val Leu Leu Leu Ser Leu Val Ile
Thr Leu Tyr Cys Lys Arg Gly Arg 325 330 335 Lys Lys Leu Leu Tyr Ile
Phe Lys Gln Pro Phe Met Arg Pro Val Gln 340 345 350 Thr Thr Gln Glu
Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu 355 360 365 Glu Gly
Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala 370 375 380
Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu 385
390 395 400 Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly
Arg Asp 405 410 415 Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
Gln Glu Gly Leu 420 425 430 Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
Glu Ala Tyr Ser Glu Ile 435 440 445 Gly Met Lys Gly Glu Arg Arg Arg
Gly Lys Gly His Asp Gly Leu Tyr 450 455 460 Gln Gly Leu Ser Thr Ala
Thr Lys Asp Thr Tyr Asp Ala Leu His Met 465 470 475 480 Gln Ala Leu
Pro Pro Arg Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu 485 490 495 Lys
Gln Ala Gly Asp Val Glu Glu Asn Pro Gly Pro Met Leu Val Arg 500 505
510 Arg Gly Ala Arg Ala Gly Pro Arg Met Pro Arg Gly Trp Thr Ala Leu
515 520 525 Cys Leu Leu Ser Leu Leu Pro Ser Gly Phe Met Ser Leu Asp
Asn Asn 530 535 540 Gly Thr Ala Thr Pro Glu Leu Pro Thr Gln Gly Thr
Phe Ser Asn Val 545 550 555 560 Ser Thr Asn Val Ser Tyr Gln Glu Thr
Thr Thr Pro Ser Thr Leu Gly 565 570 575 Ser Thr Ser Leu His Pro Val
Ser Gln His Gly Asn Glu Ala Thr Thr 580 585 590 Asn Ile Thr Glu Thr
Thr Val Lys Phe Thr Ser Thr Ser Val Ile Thr 595 600 605 Ser Val Tyr
Gly Asn Thr Asn Ser Ser Val Gln Ser Gln Thr Ser Val 610 615 620 Ile
Ser Thr Val Phe Thr Thr Pro Ala Asn Val Ser Thr Pro Glu Thr 625 630
635 640 Thr Leu Lys Pro Ser Leu Ser Pro Gly Asn Val Ser Asp Leu Ser
Thr 645 650 655 Thr Ser Thr Ser Leu Ala Thr Ser Pro Thr Lys Pro Tyr
Thr Ser Ser 660 665 670 Ser Pro Ile Leu Ser Asp Ile Lys Ala Glu Ile
Lys Cys Ser Gly Ile 675 680 685 Arg Glu Val Lys Leu Thr Gln Gly Ile
Cys Leu Glu Gln Asn Lys Thr 690 695 700 Ser Ser Cys Ala Glu Phe Lys
Lys Asp Arg Gly Glu Gly Leu Ala Arg 705 710 715 720 Val Leu Cys Gly
Glu Glu Gln Ala Asp Ala Asp Ala Gly Ala Gln Val 725 730 735 Cys Ser
Leu Leu Leu Ala Gln Ser Glu Val Arg Pro Gln Cys Leu Leu 740 745 750
Leu Val Leu Ala Asn Arg Thr Glu Ile Ser Ser Lys Leu Gln Leu Met 755
760 765 Lys Lys His Gln Ser Asp Leu Lys Lys Leu Gly Ile Leu Asp Phe
Thr 770 775 780 Glu Gln Asp Val Ala Ser His Gln Ser Tyr Ser Gln Lys
Thr Pro Ile 785 790 795 800 Leu Leu Thr Cys Pro Thr Ile Ser Ile Leu
Ser Phe Phe Ser Val Ala 805 810 815 Leu Leu Val Ile Leu Ala Cys Val
Leu Trp Lys Lys Arg Ile Lys Pro 820 825 830 Ile Val Trp Pro Ser Leu
Pro Asp His Lys Lys Thr Leu Glu His Leu 835 840 845 Cys Lys Lys Pro
Arg Lys Asn Leu Asn Val Ser Phe Asn Pro Glu Ser 850 855 860 Phe Leu
Asp Cys Gln Ile His Arg Val Asp Asp Ile Gln Ala Arg Asp 865 870 875
880 Glu Val Glu Gly Phe Leu Gln Asp Thr Phe Pro Gln Gln Leu Glu Glu
885 890 895 Ser Glu Lys Gln Arg Leu Gly Gly Asp Val Gln Ser Pro Asn
Cys Pro 900 905 910 Ser Glu Asp Val Val Ile Thr Pro Glu Ser Phe Gly
Arg Asp Ser Ser 915 920 925 Leu Thr Cys Leu Ala Gly Asn Val Ser Ala
Cys Asp Ala Pro Ile Leu 930 935 940 Ser Ser Ser Arg Ser Leu Asp Cys
Arg Glu Ser Gly Lys Asn Gly Pro 945 950 955 960 His Val Tyr Gln Asp
Leu Leu Leu Ser Leu Gly Thr Thr Asn Ser Thr 965 970 975 Leu Pro Pro
Pro Phe Ser Leu Gln Ser Gly Ile Leu Thr Leu Asn Pro 980 985 990 Val
Ala Gln Gly Gln Pro Ile Leu Thr Ser Leu Gly Ser Asn Gln Glu 995
1000 1005 Glu Ala Tyr Val Thr Met Ser Ser Phe Tyr Gln Asn Gln 1010
1015 1020 <210> SEQ ID NO 41 <211> LENGTH: 2181
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polynucleotide <400> SEQUENCE:
41 atggcactcc ctgtaactgc acttcttttg ccacttgcct tgctcctgca
cgcagcgcgg 60 ccggatattc aaatgacaca aactaccagc tccctttcag
catctttggg cgatagagta 120 actataagtt gccgcgcgtc ccaagacatc
tctaagtacc ttaactggta tcaacaaaaa 180 ccggacggga cggtcaaact
gttgatctat cacacatcca gattgcactc aggcgtgccg 240 agcaggttca
gtgggagtgg gtcaggaacg gattacagct tgacgattag taacctggag 300
caagaagaca ttgccaccta cttctgccag caaggtaaca ctctcccata tacgttcggg
360 ggtggcacca agctggaaat cactggcggc ggaggatccg aggtgcagct
ggtgcagagc 420 ggcgccgagg tgaagaagcc cggcgagagc ctgaggatca
gctgcaaggg cagcggctac 480 agcttcagca cctactggat cagctgggtg
aggcagatgc ccggcaaggg cctggagtgg 540 atgggcaaga tctaccccgg
cgacagctac accaactaca gccccagctt ccagggccag 600 gtgaccatca
gcgccgacaa gagcatcagc accgcctacc tgcagtggag cagcctgaag 660
gccagcgaca ccgccatgta ctactgcgcc aggggctacg gcatcttcga ctactggggc
720 cagggcaccc tggtgaccgt gagcagcggc agcacaagcg gctctggcaa
gcctggatct 780 ggcgagggct ctaccaaggg catgagctac gagctgaccc
agccccccag cgtgagcgtg 840 agccccggcc agaccgccag catcacctgc
agcggcgaca acatcggcga ccagtacgcc 900 cactggtacc agcagaagcc
cggccagagc cccgtgctgg tgatctacca ggacaagaac 960 aggcccagcg
gcatccccga gaggttcagc ggcagcaaca gcggcaacac cgccaccctg 1020
accatcagcg gcacccaggc catggacgag gccgactact actgcgccac ctacaccggc
1080 ttcggcagcc tggccgtgtt cggcggcggc accaagctga ccgtgctggg
gggaggcggc 1140 agcgaggtga aactgcagga gtccgggccc ggtctcgtgg
caccttccca gtcactgtcc 1200 gtgacctgca ccgtatctgg ggtaagtctg
ccggattatg gggtttcatg gatccggcaa 1260 cctccgagga aagggttgga
atggctggga gtcatctggg gaagcgagac aacttattat 1320 aattctgctt
tgaagagccg cttgacgata atcaaggaca acagtaagag tcaggttttc 1380
ttgaagatga attctcttca gacagatgac accgctattt attattgtgc aaaacattat
1440 tattacggag gatcctacgc gatggactat tggggacagg gtacctctgt
tacggtgtcc 1500 tcatccggaa caacgacacc agcaccacgg ccacccactc
ctgctccgac aattgcgtct 1560 cagccccttt cccttcgacc cgaagcttgt
cgccctgctg cgggaggagc ggtccacacg 1620 cgcgggcttg acttcgcttg
cgacatctac atttgggcac ccttggccgg gacatgcggc 1680 gtcttgctcc
tgagtctggt tataacgctg tattgtaagc gaggtcggaa gaagcttttg 1740
tatatcttta aacagccctt tatgaggccc gtacaaacca cacaagagga ggatgggtgc
1800 tcatgcagat ttcctgaaga ggaagagggc ggttgcgaac ttagagtcaa
attcagccgc 1860 tccgcagatg cacctgctta taaacagggt cagaatcaat
tgtataatga acttaatctc 1920 gggaggcgcg aggagtatga tgtgctggac
aagcgacggg gtcgagaccc agagatgggc 1980 ggtaaacccc gccgaaagaa
cccccaggag ggactgtata atgagctgca aaaggacaaa 2040 atggcagaag
cctattccga aatagggatg aagggagagc ggcggcgagg taagggacat 2100
gacggtcttt atcaaggtct tagtactgca actaaggaca cctatgacgc gctgcatatg
2160 caggctctcc cacctagata a 2181 <210> SEQ ID NO 42
<400> SEQUENCE: 42 000 <210> SEQ ID NO 43 <400>
SEQUENCE: 43 000 <210> SEQ ID NO 44 <400> SEQUENCE: 44
000 <210> SEQ ID NO 45 <211> LENGTH: 20 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic oligonucleotide <400> SEQUENCE: 45
aacgtggcat ctgtcgaccc 20 <210> SEQ ID NO 46 <211>
LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic oligonucleotide
<400> SEQUENCE: 46 gcgctggaga aactatttgg 20 <210> SEQ
ID NO 47 <211> LENGTH: 20 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide <400> SEQUENCE: 47 acatttaacg atcagaaacg 20
<210> SEQ ID NO 48 <211> LENGTH: 20 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic oligonucleotide <400> SEQUENCE: 48 ggtcctttgt
ccacctgcgc 20 <210> SEQ ID NO 49 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic oligonucleotide <400>
SEQUENCE: 49 gagaaactat ttggaggaca 20 <210> SEQ ID NO 50
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide <400> SEQUENCE: 50 ggagaaacta tttggaggac 20
<210> SEQ ID NO 51 <211> LENGTH: 254 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 51 Met Glu Tyr Ala Ser
Asp Ala Ser Leu Asp Pro Glu Ala Pro Trp Pro 1 5 10 15 Pro Ala Pro
Arg Ala Arg Ala Cys Arg Val Leu Pro Trp Ala Leu Val 20 25 30 Ala
Gly Leu Leu Leu Leu Leu Leu Leu Ala Ala Ala Cys Ala Val Phe 35 40
45 Leu Ala Cys Pro Trp Ala Val Ser Gly Ala Arg Ala Ser Pro Gly Ser
50 55 60 Ala Ala Ser Pro Arg Leu Arg Glu Gly Pro Glu Leu Ser Pro
Asp Asp 65 70 75 80 Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe
Ala Gln Leu Val 85 90 95 Ala Gln Asn Val Leu Leu Ile Asp Gly Pro
Leu Ser Trp Tyr Ser Asp 100 105 110 Pro Gly Leu Ala Gly Val Ser Leu
Thr Gly Gly Leu Ser Tyr Lys Glu 115 120 125 Asp Thr Lys Glu Leu Val
Val Ala Lys Ala Gly Val Tyr Tyr Val Phe 130 135 140 Phe Gln Leu Glu
Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser 145 150 155 160 Val
Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala 165 170
175 Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala
180 185 190 Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu
Ser Ala 195 200 205 Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala
Arg Ala Arg His 210 215 220 Ala Trp Gln Leu Thr Gln Gly Ala Thr Val
Leu Gly Leu Phe Arg Val 225 230 235 240 Thr Pro Glu Ile Pro Ala Gly
Leu Pro Ser Pro Arg Ser Glu 245 250 <210> SEQ ID NO 52
<211> LENGTH: 116 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 52 Glu Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Arg Ile Ser
Cys Lys Gly Ser Gly Tyr Ser Phe Ser Thr Tyr 20 25 30 Trp Ile Ser
Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly
Lys Ile Tyr Pro Gly Asp Ser Tyr Thr Asn Tyr Ser Pro Ser Phe 50 55
60 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr
Tyr Cys 85 90 95 Ala Arg Gly Tyr Gly Ile Phe Asp Tyr Trp Gly Gln
Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> SEQ ID
NO 53 <211> LENGTH: 109 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 53 Met Ser Tyr Glu Leu Thr Gln
Pro Pro Ser Val Ser Val Ser Pro Gly 1 5 10 15 Gln Thr Ala Ser Ile
Thr Cys Ser Gly Asp Asn Ile Gly Asp Gln Tyr 20 25 30 Ala His Trp
Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile 35 40 45 Tyr
Gln Asp Lys Asn Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly 50 55
60 Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala
65 70 75 80 Met Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Tyr Thr Gly Phe
Gly Ser 85 90 95 Leu Ala Val Phe Gly Gly Gly Thr Lys Leu Thr Val
Leu 100 105 <210> SEQ ID NO 54 <211> LENGTH: 121
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 54
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 1 5
10 15 Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly
Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Ser Pro Glu Lys Gly Leu
Glu Trp Ile 35 40 45 Gly Glu Ile Asn His Gly Gly Tyr Val Thr Tyr
Asn Pro Ser Leu Glu 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr
Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala
Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Tyr Gly Pro
Gly Asn Tyr Asp Trp Tyr Phe Asp Leu Trp Gly 100 105 110 Arg Gly Thr
Leu Val Thr Val Ser Ser 115 120 <210> SEQ ID NO 55
<211> LENGTH: 110 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 55 Glu Ile Val Leu Thr Gln Ser
Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu
Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr
Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55
60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp
Pro Pro 85 90 95 Ala Leu Thr Phe Cys Gly Gly Thr Lys Val Glu Ile
Lys Arg 100 105 110 <210> SEQ ID NO 56 <211> LENGTH:
489 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 56
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5
10 15 His Ala Ala Arg Pro Met Ser Tyr Glu Leu Thr Gln Pro Pro Ser
Val 20 25 30 Ser Val Ser Pro Gly Gln Thr Ala Ser Ile Thr Cys Ser
Gly Asp Asn 35 40 45 Ile Gly Asp Gln Tyr Ala His Trp Tyr Gln Gln
Lys Pro Gly Gln Ser 50 55 60 Pro Val Leu Val Ile Tyr Gln Asp Lys
Asn Arg Pro Ser Gly Ile Pro 65 70 75 80 Glu Arg Phe Ser Gly Ser Asn
Ser Gly Asn Thr Ala Thr Leu Thr Ile 85 90 95 Ser Gly Thr Gln Ala
Met Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Tyr 100 105 110 Thr Gly Phe
Gly Ser Leu Ala Val Phe Gly Gly Gly Thr Lys Leu Thr 115 120 125 Val
Leu Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly 130 135
140 Ser Thr Lys Gly Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys
145 150 155 160 Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser
Gly Tyr Ser 165 170 175 Phe Ser Thr Tyr Trp Ile Ser Trp Val Arg Gln
Met Pro Gly Lys Gly 180 185 190 Leu Glu Trp Met Gly Lys Ile Tyr Pro
Gly Asp Ser Tyr Thr Asn Tyr 195 200 205 Ser Pro Ser Phe Gln Gly Gln
Val Thr Ile Ser Ala Asp Lys Ser Ile 210 215 220 Ser Thr Ala Tyr Leu
Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala 225 230 235 240 Met Tyr
Tyr Cys Ala Arg Gly Tyr Gly Ile Phe Asp Tyr Trp Gly Gln 245 250 255
Gly Thr Leu Val Thr Val Ser Ser Ser Gly Thr Thr Thr Pro Ala Pro 260
265 270 Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser
Leu 275 280 285 Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val
His Thr Arg 290 295 300 Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp
Ala Pro Leu Ala Gly 305 310 315 320 Thr Cys Gly Val Leu Leu Leu Ser
Leu Val Ile Thr Leu Tyr Cys Lys 325 330 335 Arg Gly Arg Lys Lys Leu
Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg 340 345 350 Pro Val Gln Thr
Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro 355 360 365 Glu Glu
Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser 370 375 380
Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu 385
390 395 400 Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys
Arg Arg 405 410 415 Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg
Lys Asn Pro Gln 420 425 430 Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
Lys Met Ala Glu Ala Tyr 435 440 445 Ser Glu Ile Gly Met Lys Gly Glu
Arg Arg Arg Gly Lys Gly His Asp 450 455 460 Gly Leu Tyr Gln Gly Leu
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala 465 470 475 480 Leu His Met
Gln Ala Leu Pro Pro Arg 485 <210> SEQ ID NO 57 <211>
LENGTH: 1470 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polynucleotide
<400> SEQUENCE: 57 atggccctgc ccgtgaccgc cctgctgctg
cccctggccc tgctgctgca cgccgccagg 60 cccatgagct acgagctgac
ccagcccccc agcgtgagcg tgagccccgg ccagaccgcc 120 agcatcacct
gcagcggcga caacatcggc gaccagtacg cccactggta ccagcagaag 180
cccggccaga gccccgtgct ggtgatctac caggacaaga acaggcccag cggcatcccc
240 gagaggttca gcggcagcaa cagcggcaac accgccaccc tgaccatcag
cggcacccag 300 gccatggacg aggccgacta ctactgcgcc acctacaccg
gcttcggcag cctggccgtg 360 ttcggcggcg gcaccaagct gaccgtgctg
ggcagcacca gcggcagcgg caagcccggc 420 agcggcgagg gcagcaccaa
gggcgaggtg cagctggtgc agagcggcgc cgaggtgaag 480 aagcccggcg
agagcctgag gatcagctgc aagggcagcg gctacagctt cagcacctac 540
tggatcagct gggtgaggca gatgcccggc aagggcctgg agtggatggg caagatctac
600 cccggcgaca gctacaccaa ctacagcccc agcttccagg gccaggtgac
catcagcgcc 660 gacaagagca tcagcaccgc ctacctgcag tggagcagcc
tgaaggccag cgacaccgcc 720 atgtactact gcgccagggg ctacggcatc
ttcgactact ggggccaggg caccctggtg 780 accgtgagca gcagcggcac
caccaccccc gcccccaggc cccccacccc cgcccccacc 840 atcgccagcc
agcccctgag cctgaggccc gaggcctgca ggcccgccgc cggcggcgcc 900
gtgcacacca ggggcctgga cttcgcctgc gacatctaca tctgggcccc cctggccggc
960 acctgcggcg tgctgctgct gagcctggtg atcaccctgt actgcaagag
gggcaggaag 1020 aagctgctgt acatcttcaa gcagcccttc atgaggcccg
tgcagaccac ccaggaggag 1080 gacggctgca gctgcaggtt ccccgaggag
gaggagggcg gctgcgagct gagggtgaag 1140 ttcagcagga gcgccgacgc
ccccgcctac aagcagggcc agaaccagct gtacaacgag 1200 ctgaacctgg
gcaggaggga ggagtacgac gtgctggaca agaggagggg cagggacccc 1260
gagatgggcg gcaagcccag gaggaagaac ccccaggagg gcctgtacaa cgagctgcag
1320 aaggacaaga tggccgaggc ctacagcgag atcggcatga agggcgagag
gaggaggggc 1380 aagggccacg acggcctgta ccagggcctg agcaccgcca
ccaaggacac ctacgacgcc 1440 ctgcacatgc aggccctgcc ccccaggtga 1470
<210> SEQ ID NO 58 <211> LENGTH: 1470 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polynucleotide <400> SEQUENCE: 58 atggccctgc
ccgtgaccgc cctgctgctg cccctggccc tgctgctgca cgccgccagg 60
cccgaggtgc agctggtgca gagcggcgcc gaggtgaaga agcccggcga gagcctgagg
120 atcagctgca agggcagcgg ctacagcttc agcacctact ggatcagctg
ggtgaggcag 180 atgcccggca agggcctgga gtggatgggc aagatctacc
ccggcgacag ctacaccaac 240 tacagcccca gcttccaggg ccaggtgacc
atcagcgccg acaagagcat cagcaccgcc 300 tacctgcagt ggagcagcct
gaaggccagc gacaccgcca tgtactactg cgccaggggc 360 tacggcatct
tcgactactg gggccagggc accctggtga ccgtgagcag cggcagcacc 420
agcggcagcg gcaagcccgg cagcggcgag ggcagcacca agggcatgag ctacgagctg
480 acccagcccc ccagcgtgag cgtgagcccc ggccagaccg ccagcatcac
ctgcagcggc 540 gacaacatcg gcgaccagta cgcccactgg taccagcaga
agcccggcca gagccccgtg 600 ctggtgatct accaggacaa gaacaggccc
agcggcatcc ccgagaggtt cagcggcagc 660 aacagcggca acaccgccac
cctgaccatc agcggcaccc aggccatgga cgaggccgac 720 tactactgcg
ccacctacac cggcttcggc agcctggccg tgttcggcgg cggcaccaag 780
ctgaccgtgc tgagcggcac caccaccccc gcccccaggc cccccacccc cgcccccacc
840 atcgccagcc agcccctgag cctgaggccc gaggcctgca ggcccgccgc
cggcggcgcc 900 gtgcacacca ggggcctgga cttcgcctgc gacatctaca
tctgggcccc cctggccggc 960 acctgcggcg tgctgctgct gagcctggtg
atcaccctgt actgcaagag gggcaggaag 1020 aagctgctgt acatcttcaa
gcagcccttc atgaggcccg tgcagaccac ccaggaggag 1080 gacggctgca
gctgcaggtt ccccgaggag gaggagggcg gctgcgagct gagggtgaag 1140
ttcagcagga gcgccgacgc ccccgcctac aagcagggcc agaaccagct gtacaacgag
1200 ctgaacctgg gcaggaggga ggagtacgac gtgctggaca agaggagggg
cagggacccc 1260 gagatgggcg gcaagcccag gaggaagaac ccccaggagg
gcctgtacaa cgagctgcag 1320 aaggacaaga tggccgaggc ctacagcgag
atcggcatga agggcgagag gaggaggggc 1380 aagggccacg acggcctgta
ccagggcctg agcaccgcca ccaaggacac ctacgacgcc 1440 ctgcacatgc
aggccctgcc ccccaggtga 1470 <210> SEQ ID NO 59 <211>
LENGTH: 120 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 59 Glu Val Lys Leu Gln Glu Ser Gly Pro Gly
Leu Val Ala Pro Ser Gln 1 5 10 15 Ser Leu Ser Val Thr Cys Thr Val
Ser Gly Val Ser Leu Pro Asp Tyr 20 25 30 Gly Val Ser Trp Ile Arg
Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu 35 40 45 Gly Val Ile Trp
Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys 50 55 60 Ser Arg
Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 65 70 75 80
Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala 85
90 95 Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly
Gln 100 105 110 Gly Thr Ser Val Thr Val Ser Ser 115 120 <210>
SEQ ID NO 60 <211> LENGTH: 107 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 60 Asp Ile Gln Met Thr
Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val
Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu
Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40
45 Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu
Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn
Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
Thr 100 105 <210> SEQ ID NO 61 <211> LENGTH: 491
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 61
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5
10 15 His Ala Ala Arg Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser
Leu 20 25 30 Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg
Ala Ser Gln 35 40 45 Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln
Lys Pro Asp Gly Thr 50 55 60 Val Lys Leu Leu Ile Tyr His Thr Ser
Arg Leu His Ser Gly Val Pro 65 70 75 80 Ser Arg Phe Ser Gly Ser Gly
Ser Gly Thr Asp Tyr Ser Leu Thr Ile 85 90 95 Ser Asn Leu Glu Gln
Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly 100 105 110 Asn Thr Leu
Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr 115 120 125 Gly
Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr 130 135
140 Lys Gly Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro
145 150 155 160 Ser Gln Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val
Ser Leu Pro 165 170 175 Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro
Arg Lys Gly Leu Glu 180 185 190 Trp Leu Gly Val Ile Trp Gly Ser Glu
Thr Thr Tyr Tyr Asn Ser Ala 195 200 205 Leu Lys Ser Arg Leu Thr Ile
Ile Lys Asp Asn Ser Lys Ser Gln Val 210 215 220 Phe Leu Lys Met Asn
Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr 225 230 235 240 Cys Ala
Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp 245 250 255
Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ser Gly Thr Thr Thr Pro 260
265 270 Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro
Leu 275 280 285 Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly
Ala Val His 290 295 300 Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr
Ile Trp Ala Pro Leu 305 310 315 320 Ala Gly Thr Cys Gly Val Leu Leu
Leu Ser Leu Val Ile Thr Leu Tyr 325 330 335 Cys Lys Arg Gly Arg Lys
Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe 340 345 350 Met Arg Pro Val
Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg 355 360 365 Phe Pro
Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser 370 375 380
Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr 385
390 395 400 Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
Asp Lys 405 410 415 Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
Arg Arg Lys Asn 420 425 430 Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln
Lys Asp Lys Met Ala Glu 435 440 445 Ala Tyr Ser Glu Ile Gly Met Lys
Gly Glu Arg Arg Arg Gly Lys Gly 450 455 460 His Asp Gly Leu Tyr Gln
Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr 465 470 475 480 Asp Ala Leu
His Met Gln Ala Leu Pro Pro Arg 485 490 <210> SEQ ID NO 62
<400> SEQUENCE: 62 000 <210> SEQ ID NO 63 <400>
SEQUENCE: 63 000 <210> SEQ ID NO 64 <400> SEQUENCE: 64
000 <210> SEQ ID NO 65 <400> SEQUENCE: 65 000
<210> SEQ ID NO 66 <400> SEQUENCE: 66 000 <210>
SEQ ID NO 67 <400> SEQUENCE: 67 000 <210> SEQ ID NO 68
<400> SEQUENCE: 68 000 <210> SEQ ID NO 69 <400>
SEQUENCE: 69 000 <210> SEQ ID NO 70 <400> SEQUENCE: 70
000 <210> SEQ ID NO 71 <400> SEQUENCE: 71 000
<210> SEQ ID NO 72 <400> SEQUENCE: 72 000 <210>
SEQ ID NO 73 <400> SEQUENCE: 73 000 <210> SEQ ID NO 74
<400> SEQUENCE: 74 000 <210> SEQ ID NO 75 <211>
LENGTH: 486 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 75 Met Ala Leu Pro Val Thr Ala Leu Leu Leu
Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Asp Ile Glu
Leu Thr Gln Ser Pro Ala Ile Met 20 25 30 Ser Ala Ser Leu Gly Glu
Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser 35 40 45 Ser Val Ser Tyr
Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro 50 55 60 Lys Leu
Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser 65 70 75 80
Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser 85
90 95 Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp
Ser 100 105 110 Ser Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
Arg Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gln Val Lys 130 135 140 Leu Gln Glu Ser Gly Gly Gly Leu Val
Lys Pro Gly Gly Ser Leu Lys 145 150 155 160 Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser 165 170 175 Trp Val Arg Gln
Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile 180 185 190 Ser Ser
Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg 195 200 205
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met 210
215 220 Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg
Gln 225 230 235 240 Asp Gly Tyr Tyr Pro Gly Trp Phe Ala Asn Trp Gly
Gln Gly Thr Thr 245 250 255 Val Thr Val Ser Ser Ser Gly Thr Thr Thr
Pro Ala Pro Arg Pro Pro 260 265 270 Thr Pro Ala Pro Thr Ile Ala Ser
Gln Pro Leu Ser Leu Arg Pro Glu 275 280 285 Ala Cys Arg Pro Ala Ala
Gly Gly Ala Val His Thr Arg Gly Leu Asp 290 295 300 Phe Ala Cys Asp
Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly 305 310 315 320 Val
Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg 325 330
335 Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln
340 345 350 Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu
Glu Glu 355 360 365 Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg
Ser Ala Asp Ala 370 375 380 Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu
Tyr Asn Glu Leu Asn Leu 385 390 395 400 Gly Arg Arg Glu Glu Tyr Asp
Val Leu Asp Lys Arg Arg Gly Arg Asp 405 410 415 Pro Glu Met Gly Gly
Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 420 425 430 Tyr Asn Glu
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile 435 440 445 Gly
Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr 450 455
460 Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met
465 470 475 480 Gln Ala Leu Pro Pro Arg 485 <210> SEQ ID NO
76 <211> LENGTH: 490 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 76 Met Ala Leu Pro Val Thr Ala
Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro
Ala Ala Tyr Lys Asp Ile Gln Met Thr Gln Thr 20 25 30 Thr Ser Ser
Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys 35 40 45 Ser
Ala Ser Gln Gly Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys 50 55
60 Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Ser Leu His
65 70 75 80 Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
Asp Tyr 85 90 95 Ser Leu Thr Ile Ser Asn Leu Glu Pro Glu Asp Ile
Ala Thr Tyr Tyr 100 105 110 Cys Gln Gln Tyr Ser Lys Leu Pro Tyr Thr
Phe Gly Gly Gly Thr Lys 115 120 125 Leu Glu Ile Lys Arg Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly 130 135 140 Gly Gly Gly Ser Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val 145 150 155 160 Lys Pro Gly
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Leu Thr 165 170 175 Phe
Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg 180 185
190 Leu Glu Trp Val Ala Ser Ile Ser Ser Gly Gly Phe Thr Tyr Tyr Pro
195 200 205 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
Arg Asn 210 215 220 Ile Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu
Asp Thr Ala Met 225 230 235 240 Tyr Tyr Cys Ala Arg Asp Glu Val Arg
Gly Tyr Leu Asp Val Trp Gly 245 250 255 Ala Gly Thr Thr Val Thr Val
Ser Ser Ser Gly Thr Thr Thr Pro Ala 260 265 270 Pro Arg Pro Pro Thr
Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser 275 280 285 Leu Arg Pro
Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr 290 295 300 Arg
Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala 305 310
315 320 Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
Cys 325 330 335 Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln
Pro Phe Met 340 345 350 Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly
Cys Ser Cys Arg Phe 355 360 365 Pro Glu Glu Glu Glu Gly Gly Cys Glu
Leu Arg Val Lys Phe Ser Arg 370 375 380 Ser Ala Asp Ala Pro Ala Tyr
Lys Gln Gly Gln Asn Gln Leu Tyr Asn 385 390 395 400 Glu Leu Asn Leu
Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg 405 410 415 Arg Gly
Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro 420 425 430
Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala 435
440 445 Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly
His 450 455 460 Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp
Thr Tyr Asp 465 470 475 480 Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490 <210> SEQ ID NO 77 <211> LENGTH: 492
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 77
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5
10 15 His Ala Ala Arg Pro Asp Ile Gln Met Thr Gln Ser Pro Ala Ser
Leu 20 25 30 Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg
Ala Ser Gly 35 40 45 Asn Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln
Lys Gln Gly Lys Ser 50 55 60 Pro Gln Leu Leu Val Tyr Asn Ala Lys
Thr Leu Ala Asp Gly Val Pro 65 70 75 80 Ser Arg Phe Ser Gly Ser Gly
Ser Gly Thr Gln Tyr Ser Leu Lys Ile 85 90 95 Asn Ser Leu Gln Pro
Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe 100 105 110 Trp Thr Thr
Pro Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 115 120 125 Lys
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 130 135
140 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
145 150 155 160 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe
Thr Asn Tyr 165 170 175 Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys
Gly Leu Lys Trp Met 180 185 190 Gly Trp Ile Asn Thr Tyr Asn Gly Glu
Pro Thr Tyr Ala Asp Asp Phe 195 200 205 Lys Gly Arg Phe Asp Phe Ser
Leu Glu Thr Ser Ala Ser Thr Ala Tyr 210 215 220 Leu Gln Ile Asn Asn
Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 225 230 235 240 Ala Arg
Arg Gly Tyr Tyr Tyr Gly Ser Arg Tyr Gly Ala Met Asp Tyr 245 250 255
Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ser Gly Thr Thr Thr 260
265 270 Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln
Pro 275 280 285 Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly
Gly Ala Val 290 295 300 His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile
Tyr Ile Trp Ala Pro 305 310 315 320 Leu Ala Gly Thr Cys Gly Val Leu
Leu Leu Ser Leu Val Ile Thr Leu 325 330 335 Tyr Cys Lys Arg Gly Arg
Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro 340 345 350 Phe Met Arg Pro
Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys 355 360 365 Arg Phe
Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe 370 375 380
Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu 385
390 395 400 Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
Leu Asp 405 410 415 Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
Pro Arg Arg Lys 420 425 430 Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
Gln Lys Asp Lys Met Ala 435 440 445 Glu Ala Tyr Ser Glu Ile Gly Met
Lys Gly Glu Arg Arg Arg Gly Lys 450 455 460 Gly His Asp Gly Leu Tyr
Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr 465 470 475 480 Tyr Asp Ala
Leu His Met Gln Ala Leu Pro Pro Arg 485 490 <210> SEQ ID NO
78 <211> LENGTH: 492 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 78 Met Ala Leu Pro Val Thr Ala
Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro
Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu 20 25 30 Lys Lys Pro
Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr 35 40 45 Thr
Phe Thr Asn Tyr Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys 50 55
60 Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Asn Gly Glu Pro Thr
65 70 75 80 Tyr Ala Asp Asp Phe Lys Gly Arg Phe Asp Phe Ser Leu Glu
Thr Ser 85 90 95 Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys
Asn Glu Asp Thr 100 105 110 Ala Thr Tyr Phe Cys Ala Arg Arg Gly Tyr
Tyr Tyr Gly Ser Arg Tyr 115 120 125 Gly Ala Met Asp Tyr Trp Gly Gln
Gly Thr Ser Val Thr Val Ser Ser 130 135 140 Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp 145 150 155 160 Ile Gln Met
Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly Glu 165 170 175 Thr
Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile His Asn Tyr Leu 180 185
190 Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr
195 200 205 Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser
Gly Ser 210 215 220 Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser
Leu Gln Pro Glu 225 230 235 240 Asp Phe Gly Ser Tyr Tyr Cys Gln His
Phe Trp Thr Thr Pro Pro Trp 245 250 255 Thr Phe Gly Gly Gly Thr Lys
Leu Glu Ile Lys Ser Gly Thr Thr Thr 260 265 270 Pro Ala Pro Arg Pro
Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro 275 280 285 Leu Ser Leu
Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val 290 295 300 His
Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro 305 310
315 320 Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr
Leu 325 330 335 Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe
Lys Gln Pro 340 345 350 Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu
Asp Gly Cys Ser Cys 355 360 365 Arg Phe Pro Glu Glu Glu Glu Gly Gly
Cys Glu Leu Arg Val Lys Phe 370 375 380 Ser Arg Ser Ala Asp Ala Pro
Ala Tyr Lys Gln Gly Gln Asn Gln Leu 385 390 395 400 Tyr Asn Glu Leu
Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp 405 410 415 Lys Arg
Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys 420 425 430
Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala 435
440 445 Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly
Lys 450 455 460 Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
Lys Asp Thr 465 470 475 480 Tyr Asp Ala Leu His Met Gln Ala Leu Pro
Pro Arg 485 490 <210> SEQ ID NO 79 <211> LENGTH: 726
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 79
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5
10 15 His Ala Ala Arg Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser
Leu 20 25 30 Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg
Ala Ser Gln 35 40 45 Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln
Lys Pro Asp Gly Thr 50 55 60 Val Lys Leu Leu Ile Tyr His Thr Ser
Arg Leu His Ser Gly Val Pro 65 70 75 80 Ser Arg Phe Ser Gly Ser Gly
Ser Gly Thr Asp Tyr Ser Leu Thr Ile 85 90 95 Ser Asn Leu Glu Gln
Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly 100 105 110 Asn Thr Leu
Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr 115 120 125 Gly
Gly Gly Gly Ser Gln Val Lys Leu Gln Glu Ser Gly Gly Gly Leu 130 135
140 Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe
145 150 155 160 Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Thr
Pro Glu Lys 165 170 175 Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly
Gly Ser Tyr Thr Tyr 180 185 190 Tyr Pro Asp Ser Val Lys Gly Arg Phe
Thr Ile Ser Arg Asp Asn Ala 195 200 205 Lys Asn Thr Leu Tyr Leu Gln
Met Ser Ser Leu Arg Ser Glu Asp Thr 210 215 220 Ala Met Tyr Tyr Cys
Ala Arg Gln Asp Gly Tyr Tyr Pro Gly Trp Phe 225 230 235 240 Ala Asn
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Ser Thr 245 250 255
Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Asp 260
265 270 Ile Glu Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly
Glu 275 280 285 Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser
Tyr Met His 290 295 300 Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys
Leu Leu Ile Tyr Ser 305 310 315 320 Thr Ser Asn Leu Ala Ser Gly Val
Pro Ser Arg Phe Ser Gly Ser Gly 325 330 335 Ser Gly Thr Phe Tyr Ser
Leu Thr Ile Ser Ser Val Glu Ala Glu Asp 340 345 350 Ala Ala Asp Tyr
Tyr Cys His Gln Trp Ser Ser Tyr Thr Phe Gly Gly 355 360 365 Gly Thr
Lys Leu Glu Ile Lys Arg Gly Gly Gly Gly Ser Glu Val Lys 370 375 380
Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser 385
390 395 400 Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly
Val Ser 405 410 415 Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp
Leu Gly Val Ile 420 425 430 Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser
Ala Leu Lys Ser Arg Leu 435 440 445 Thr Ile Ile Lys Asp Asn Ser Lys
Ser Gln Val Phe Leu Lys Met Asn 450 455 460 Ser Leu Gln Thr Asp Asp
Thr Ala Ile Tyr Tyr Cys Ala Lys His Tyr 465 470 475 480 Tyr Tyr Gly
Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 485 490 495 Val
Thr Val Ser Ser Ser Gly Thr Thr Thr Pro Ala Pro Arg Pro Pro 500 505
510 Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu
515 520 525 Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly
Leu Asp 530 535 540 Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala
Gly Thr Cys Gly 545 550 555 560 Val Leu Leu Leu Ser Leu Val Ile Thr
Leu Tyr Cys Lys Arg Gly Arg 565 570 575 Lys Lys Leu Leu Tyr Ile Phe
Lys Gln Pro Phe Met Arg Pro Val Gln 580 585 590 Thr Thr Gln Glu Glu
Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu 595 600 605 Glu Gly Gly
Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala 610 615 620 Pro
Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu 625 630
635 640 Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
Asp 645 650 655 Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln
Glu Gly Leu 660 665 670 Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu
Ala Tyr Ser Glu Ile 675 680 685 Gly Met Lys Gly Glu Arg Arg Arg Gly
Lys Gly His Asp Gly Leu Tyr 690 695 700 Gln Gly Leu Ser Thr Ala Thr
Lys Asp Thr Tyr Asp Ala Leu His Met 705 710 715 720 Gln Ala Leu Pro
Pro Arg 725 <210> SEQ ID NO 80 <211> LENGTH: 726
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 80
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5
10 15 His Ala Ala Arg Pro Glu Val Lys Leu Gln Glu Ser Gly Pro Gly
Leu 20 25 30 Val Ala Pro Ser Gln Ser Leu Ser Val Thr Cys Thr Val
Ser Gly Val 35 40 45 Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg
Gln Pro Pro Arg Lys 50 55 60 Gly Leu Glu Trp Leu Gly Val Ile Trp
Gly Ser Glu Thr Thr Tyr Tyr 65 70 75 80 Asn Ser Ala Leu Lys Ser Arg
Leu Thr Ile Ile Lys Asp Asn Ser Lys 85 90 95 Ser Gln Val Phe Leu
Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala 100 105 110 Ile Tyr Tyr
Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met 115 120 125 Asp
Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly Gly Gly 130 135
140 Gly Ser Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser
145 150 155 160 Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser
Ser Val Ser 165 170 175 Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr
Ser Pro Lys Leu Leu 180 185 190 Ile Tyr Ser Thr Ser Asn Leu Ala Ser
Gly Val Pro Ser Arg Phe Ser 195 200 205 Gly Ser Gly Ser Gly Thr Phe
Tyr Ser Leu Thr Ile Ser Ser Val Glu 210 215 220 Ala Glu Asp Ala Ala
Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Thr 225 230 235 240 Phe Gly
Gly Gly Thr Lys Leu Glu Ile Lys Arg Gly Ser Thr Ser Gly 245 250 255
Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln Val Lys 260
265 270 Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu
Lys 275 280 285 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
Ala Met Ser 290 295 300 Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu
Trp Val Ala Thr Ile 305 310 315 320 Ser Ser Gly Gly Ser Tyr Thr Tyr
Tyr Pro Asp Ser Val Lys Gly Arg 325 330 335 Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met 340 345 350 Ser Ser Leu Arg
Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gln 355 360 365 Asp Gly
Tyr Tyr Pro Gly Trp Phe Ala Asn Trp Gly Gln Gly Thr Thr 370 375 380
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln 385
390 395 400 Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr
Ile Ser 405 410 415 Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr Leu Asn
Trp Tyr Gln Gln 420 425 430 Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
Tyr His Thr Ser Arg Leu 435 440 445 His Ser Gly Val Pro Ser Arg Phe
Ser Gly Ser Gly Ser Gly Thr Asp 450 455 460 Tyr Ser Leu Thr Ile Ser
Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr 465 470 475 480 Phe Cys Gln
Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr 485 490 495 Lys
Leu Glu Ile Thr Ser Gly Thr Thr Thr Pro Ala Pro Arg Pro Pro 500 505
510 Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu
515 520 525 Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly
Leu Asp 530 535 540 Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala
Gly Thr Cys Gly 545 550 555 560 Val Leu Leu Leu Ser Leu Val Ile Thr
Leu Tyr Cys Lys Arg Gly Arg 565 570 575 Lys Lys Leu Leu Tyr Ile Phe
Lys Gln Pro Phe Met Arg Pro Val Gln 580 585 590 Thr Thr Gln Glu Glu
Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu 595 600 605 Glu Gly Gly
Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala 610 615 620 Pro
Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu 625 630
635 640 Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
Asp 645 650 655 Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln
Glu Gly Leu 660 665 670 Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu
Ala Tyr Ser Glu Ile 675 680 685 Gly Met Lys Gly Glu Arg Arg Arg Gly
Lys Gly His Asp Gly Leu Tyr 690 695 700 Gln Gly Leu Ser Thr Ala Thr
Lys Asp Thr Tyr Asp Ala Leu His Met 705 710 715 720 Gln Ala Leu Pro
Pro Arg 725 <210> SEQ ID NO 81 <211> LENGTH: 746
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 81
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5
10 15 His Ala Ala Arg Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser
Leu 20 25 30 Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg
Ala Ser Gln 35 40 45 Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln
Lys Pro Asp Gly Thr 50 55 60 Val Lys Leu Leu Ile Tyr His Thr Ser
Arg Leu His Ser Gly Val Pro 65 70 75 80 Ser Arg Phe Ser Gly Ser Gly
Ser Gly Thr Asp Tyr Ser Leu Thr Ile 85 90 95 Ser Asn Leu Glu Gln
Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly 100 105 110 Asn Thr Leu
Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr 115 120 125 Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu 130 135
140 Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser
145 150 155 160 Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro
Asp Tyr Gly 165 170 175 Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly
Leu Glu Trp Leu Gly 180 185 190 Val Ile Trp Gly Ser Glu Thr Thr Tyr
Tyr Asn Ser Ala Leu Lys Ser 195 200 205 Arg Leu Thr Ile Ile Lys Asp
Asn Ser Lys Ser Gln Val Phe Leu Lys 210 215 220 Met Asn Ser Leu Gln
Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys 225 230 235 240 His Tyr
Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly 245 250 255
Thr Ser Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro 260
265 270 Gly Ser Gly Glu Gly Ser Thr Lys Gly Asp Ile Glu Leu Thr Gln
Ser 275 280 285 Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Glu Ile Thr
Leu Thr Cys 290 295 300 Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp
Tyr Gln Gln Lys Ser 305 310 315 320 Gly Thr Ser Pro Lys Leu Leu Ile
Tyr Ser Thr Ser Asn Leu Ala Ser 325 330 335 Gly Val Pro Ser Arg Phe
Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser 340 345 350 Leu Thr Ile Ser
Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys 355 360 365 His Gln
Trp Ser Ser Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 370 375 380
Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 385
390 395 400 Ser Gln Val Lys Leu Gln Glu Ser Gly Gly Gly Leu Val Lys
Pro Gly 405 410 415 Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe
Thr Phe Ser Ser 420 425 430 Tyr Ala Met Ser Trp Val Arg Gln Thr Pro
Glu Lys Arg Leu Glu Trp 435 440 445 Val Ala Thr Ile Ser Ser Gly Gly
Ser Tyr Thr Tyr Tyr Pro Asp Ser 450 455 460 Val Lys Gly Arg Phe Thr
Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu 465 470 475 480 Tyr Leu Gln
Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr 485 490 495 Cys
Ala Arg Gln Asp Gly Tyr Tyr Pro Gly Trp Phe Ala Asn Trp Gly 500 505
510 Gln Gly Thr Thr Val Thr Val Ser Ser Ser Gly Thr Thr Thr Pro Ala
515 520 525 Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro
Leu Ser 530 535 540 Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly
Ala Val His Thr 545 550 555 560 Arg Gly Leu Asp Phe Ala Cys Asp Ile
Tyr Ile Trp Ala Pro Leu Ala 565 570 575 Gly Thr Cys Gly Val Leu Leu
Leu Ser Leu Val Ile Thr Leu Tyr Cys 580 585 590 Lys Arg Gly Arg Lys
Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met 595 600 605 Arg Pro Val
Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe 610 615 620 Pro
Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg 625 630
635 640 Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr
Asn 645 650 655 Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
Asp Lys Arg 660 665 670 Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
Arg Arg Lys Asn Pro 675 680 685 Gln Glu Gly Leu Tyr Asn Glu Leu Gln
Lys Asp Lys Met Ala Glu Ala 690 695 700 Tyr Ser Glu Ile Gly Met Lys
Gly Glu Arg Arg Arg Gly Lys Gly His 705 710 715 720 Asp Gly Leu Tyr
Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp 725 730 735 Ala Leu
His Met Gln Ala Leu Pro Pro Arg 740 745 <210> SEQ ID NO 82
<211> LENGTH: 743 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 82 Met Ala Leu Pro Val Thr Ala
Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro
Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu 20 25 30 Ser Ala Ser
Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln 35 40 45 Asp
Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr 50 55
60 Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Val Pro
65 70 75 80 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu
Thr Ile 85 90 95 Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe
Cys Gln Gln Gly 100 105 110 Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly
Thr Lys Leu Glu Ile Thr 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Glu 130 135 140 Val Lys Leu Gln Glu Ser
Gly Pro Gly Leu Val Ala Pro Ser Gln Ser 145 150 155 160 Leu Ser Val
Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly 165 170 175 Val
Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly 180 185
190 Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser
195 200 205 Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe
Leu Lys 210 215 220 Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr
Tyr Cys Ala Lys 225 230 235 240 His Tyr Tyr Tyr Gly Gly Ser Tyr Ala
Met Asp Tyr Trp Gly Gln Gly 245 250 255 Thr Ser Val Thr Val Ser Ser
Glu Ala Ala Ala Lys Glu Ala Ala Ala 260 265 270 Lys Glu Ala Ala Ala
Lys Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile 275 280 285 Met Ser Ala
Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser 290 295 300 Ser
Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser 305 310
315 320 Pro Lys Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val
Pro 325 330 335 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser
Leu Thr Ile 340 345 350 Ser Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr
Tyr Cys His Gln Trp 355 360 365 Ser Ser Tyr Thr Phe Gly Gly Gly Thr
Lys Leu Glu Ile Lys Arg Gly 370 375 380 Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gln Val 385 390 395 400 Lys Leu Gln Glu
Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu 405 410 415 Lys Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met 420 425 430
Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr 435
440 445 Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys
Gly 450 455 460 Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu
Tyr Leu Gln 465 470 475 480 Met Ser Ser Leu Arg Ser Glu Asp Thr Ala
Met Tyr Tyr Cys Ala Arg 485 490 495 Gln Asp Gly Tyr Tyr Pro Gly Trp
Phe Ala Asn Trp Gly Gln Gly Thr 500 505 510 Thr Val Thr Val Ser Ser
Ser Gly Thr Thr Thr Pro Ala Pro Arg Pro 515 520 525 Pro Thr Pro Ala
Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro 530 535 540 Glu Ala
Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu 545 550 555
560 Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys
565 570 575 Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys
Arg Gly 580 585 590 Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe
Met Arg Pro Val 595 600 605 Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser
Cys Arg Phe Pro Glu Glu 610 615 620 Glu Glu Gly Gly Cys Glu Leu Arg
Val Lys Phe Ser Arg Ser Ala Asp 625 630 635 640 Ala Pro Ala Tyr Lys
Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn 645 650 655 Leu Gly Arg
Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg 660 665 670 Asp
Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly 675 680
685 Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
690 695 700 Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
Gly Leu 705 710 715 720 Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr
Tyr Asp Ala Leu His 725 730 735 Met Gln Ala Leu Pro Pro Arg 740
<210> SEQ ID NO 83 <211> LENGTH: 746 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 83 Met Ala Leu Pro Val
Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala
Arg Pro Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met 20 25 30 Ser
Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser 35 40
45 Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro
50 55 60 Lys Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val
Pro Ser 65 70 75 80 Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser
Leu Thr Ile Ser 85 90 95 Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr
Tyr Cys His Gln Trp Ser 100 105 110 Ser Tyr Thr Phe Gly Gly Gly Thr
Lys Leu Glu Ile Lys Arg Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gln Val Lys 130 135 140 Leu Gln Glu Ser
Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys 145 150 155 160 Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser 165 170
175 Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile
180 185 190 Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys
Gly Arg 195 200 205 Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu
Tyr Leu Gln Met 210 215 220 Ser Ser Leu Arg Ser Glu Asp Thr Ala Met
Tyr Tyr Cys Ala Arg Gln 225 230 235 240 Asp Gly Tyr Tyr Pro Gly Trp
Phe Ala Asn Trp Gly Gln Gly Thr Thr 245 250 255 Val Thr Val Ser Ser
Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser 260 265 270 Gly Glu Gly
Ser Thr Lys Gly Asp Ile Gln Met Thr Gln Thr Thr Ser 275 280 285 Ser
Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala 290 295
300 Ser Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp
305 310 315 320 Gly Thr Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu
His Ser Gly 325 330 335 Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly
Thr Asp Tyr Ser Leu 340 345 350 Thr Ile Ser Asn Leu Glu Gln Glu Asp
Ile Ala Thr Tyr Phe Cys Gln 355 360 365 Gln Gly Asn Thr Leu Pro Tyr
Thr Phe Gly Gly Gly Thr Lys Leu Glu 370 375 380 Ile Thr Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 385 390 395 400 Ser Glu
Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser 405 410 415
Gln Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp 420
425 430 Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu
Trp 435 440 445 Leu Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn
Ser Ala Leu 450 455 460 Lys Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser
Lys Ser Gln Val Phe 465 470 475 480 Leu Lys Met Asn Ser Leu Gln Thr
Asp Asp Thr Ala Ile Tyr Tyr Cys 485 490 495 Ala Lys His Tyr Tyr Tyr
Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly 500 505 510 Gln Gly Thr Ser
Val Thr Val Ser Ser Ser Gly Thr Thr Thr Pro Ala 515 520 525 Pro Arg
Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser 530 535 540
Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr 545
550 555 560 Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro
Leu Ala 565 570 575 Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile
Thr Leu Tyr Cys 580 585 590 Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile
Phe Lys Gln Pro Phe Met 595 600 605 Arg Pro Val Gln Thr Thr Gln Glu
Glu Asp Gly Cys Ser Cys Arg Phe 610 615 620 Pro Glu Glu Glu Glu Gly
Gly Cys Glu Leu Arg Val Lys Phe Ser Arg 625 630 635 640 Ser Ala Asp
Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn 645 650 655 Glu
Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg 660 665
670 Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
675 680 685 Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
Glu Ala 690 695 700 Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
Gly Lys Gly His 705 710 715 720 Asp Gly Leu Tyr Gln Gly Leu Ser Thr
Ala Thr Lys Asp Thr Tyr Asp 725 730 735 Ala Leu His Met Gln Ala Leu
Pro Pro Arg 740 745 <210> SEQ ID NO 84 <211> LENGTH:
746 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 84
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5
10 15 His Ala Ala Arg Pro Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile
Met 20 25 30 Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser
Ala Ser Ser 35 40 45 Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys
Ser Gly Thr Ser Pro 50 55 60 Lys Leu Leu Ile Tyr Ser Thr Ser Asn
Leu Ala Ser Gly Val Pro Ser 65 70 75 80 Arg Phe Ser Gly Ser Gly Ser
Gly Thr Phe Tyr Ser Leu Thr Ile Ser 85 90 95 Ser Val Glu Ala Glu
Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser 100 105 110 Ser Tyr Thr
Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Gly Gly 115 120 125 Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Lys 130 135
140 Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys
145 150 155 160 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
Ala Met Ser 165 170 175 Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu
Trp Val Ala Thr Ile 180 185 190 Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr
Pro Asp Ser Val Lys Gly Arg 195 200 205 Phe Thr Ile Ser Arg Asp Asn
Ala Lys Asn Thr Leu Tyr Leu Gln Met 210 215 220 Ser Ser Leu Arg Ser
Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gln 225 230 235 240 Asp Gly
Tyr Tyr Pro Gly Trp Phe Ala Asn Trp Gly Gln Gly Thr Thr 245 250 255
Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser 260
265 270 Gly Glu Gly Ser Thr Lys Gly Glu Val Lys Leu Gln Glu Ser Gly
Pro 275 280 285 Gly Leu Val Ala Pro Ser Gln Ser Leu Ser Val Thr Cys
Thr Val Ser 290 295 300 Gly Val Ser Leu Pro Asp Tyr Gly Val Ser Trp
Ile Arg Gln Pro Pro 305 310 315 320 Arg Lys Gly Leu Glu Trp Leu Gly
Val Ile Trp Gly Ser Glu Thr Thr 325 330 335 Tyr Tyr Asn Ser Ala Leu
Lys Ser Arg Leu Thr Ile Ile Lys Asp Asn 340 345 350 Ser Lys Ser Gln
Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp 355 360 365 Thr Ala
Ile Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr 370 375 380
Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly 385
390 395 400 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Asp Ile 405 410 415 Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser
Leu Gly Asp Arg 420 425 430 Val Thr Ile Ser Cys Arg Ala Ser Gln Asp
Ile Ser Lys Tyr Leu Asn 435 440 445 Trp Tyr Gln Gln Lys Pro Asp Gly
Thr Val Lys Leu Leu Ile Tyr His 450 455 460 Thr Ser Arg Leu His Ser
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly 465 470 475 480 Ser Gly Thr
Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp 485 490 495 Ile
Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr Thr Phe 500 505
510 Gly Gly Gly Thr Lys Leu Glu Ile Thr Ser Gly Thr Thr Thr Pro Ala
515 520 525 Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro
Leu Ser 530 535 540 Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly
Ala Val His Thr 545 550 555 560 Arg Gly Leu Asp Phe Ala Cys Asp Ile
Tyr Ile Trp Ala Pro Leu Ala 565 570 575 Gly Thr Cys Gly Val Leu Leu
Leu Ser Leu Val Ile Thr Leu Tyr Cys 580 585 590 Lys Arg Gly Arg Lys
Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met 595 600 605 Arg Pro Val
Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe 610 615 620 Pro
Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg 625 630
635 640 Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr
Asn 645 650 655 Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
Asp Lys Arg 660 665 670 Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
Arg Arg Lys Asn Pro 675 680 685 Gln Glu Gly Leu Tyr Asn Glu Leu Gln
Lys Asp Lys Met Ala Glu Ala 690 695 700 Tyr Ser Glu Ile Gly Met Lys
Gly Glu Arg Arg Arg Gly Lys Gly His 705 710 715 720 Asp Gly Leu Tyr
Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp 725 730 735 Ala Leu
His Met Gln Ala Leu Pro Pro Arg 740 745 <210> SEQ ID NO 85
<211> LENGTH: 1261 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 85 Met Ala Leu Pro Val Thr Ala
Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro
Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu 20 25 30 Ser Ala Ser
Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln 35 40 45 Asp
Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr 50 55
60 Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Val Pro
65 70 75 80 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu
Thr Ile 85 90 95 Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe
Cys Gln Gln Gly 100 105 110 Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly
Thr Lys Leu Glu Ile Thr 115 120 125 Gly Gly Gly Gly Ser Gln Val Lys
Leu Gln Glu Ser Gly Gly Gly Leu 130 135 140 Val Lys Pro Gly Gly Ser
Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe 145 150 155 160 Thr Phe Ser
Ser Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys 165 170 175 Arg
Leu Glu Trp Val Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr 180 185
190 Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
195 200 205 Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu
Asp Thr 210 215 220 Ala Met Tyr Tyr Cys Ala Arg Gln Asp Gly Tyr Tyr
Pro Gly Trp Phe 225 230 235 240 Ala Asn Trp Gly Gln Gly Thr Thr Val
Thr Val Ser Ser Gly Ser Thr 245 250 255 Ser Gly Ser Gly Lys Pro Gly
Ser Gly Glu Gly Ser Thr Lys Gly Asp 260 265 270 Ile Glu Leu Thr Gln
Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu 275 280 285 Glu Ile Thr
Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His 290 295 300 Trp
Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr Ser 305 310
315 320 Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
Gly 325 330 335 Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu
Ala Glu Asp 340 345 350 Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser
Tyr Thr Phe Gly Gly 355 360 365 Gly Thr Lys Leu Glu Ile Lys Arg Gly
Gly Gly Gly Ser Glu Val Lys 370 375 380 Leu Gln Glu Ser Gly Pro Gly
Leu Val Ala Pro Ser Gln Ser Leu Ser 385 390 395 400 Val Thr Cys Thr
Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser 405 410 415 Trp Ile
Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly Val Ile 420 425 430
Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu 435
440 445 Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met
Asn 450 455 460 Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
Lys His Tyr 465 470 475 480 Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr
Trp Gly Gln Gly Thr Ser 485 490 495 Val Thr Val Ser Ser Ser Gly Thr
Thr Thr Pro Ala Pro Arg Pro Pro 500 505 510 Thr Pro Ala Pro Thr Ile
Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu 515 520 525 Ala Cys Arg Pro
Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp 530 535 540 Phe Ala
Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly 545 550 555
560 Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg
565 570 575 Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro
Val Gln 580 585 590 Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe
Pro Glu Glu Glu 595 600 605 Glu Gly Gly Cys Glu Leu Arg Val Lys Phe
Ser Arg Ser Ala Asp Ala 610 615 620 Pro Ala Tyr Lys Gln Gly Gln Asn
Gln Leu Tyr Asn Glu Leu Asn Leu 625 630 635 640 Gly Arg Arg Glu Glu
Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp 645 650 655 Pro Glu Met
Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 660 665 670 Tyr
Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile 675 680
685 Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr
690 695 700 Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu
His Met 705 710 715 720 Gln Ala Leu Pro Pro Arg Gly Ser Gly Ala Thr
Asn Phe Ser Leu Leu 725 730 735 Lys Gln Ala Gly Asp Val Glu Glu Asn
Pro Gly Pro Met Leu Val Arg 740 745 750 Arg Gly Ala Arg Ala Gly Pro
Arg Met Pro Arg Gly Trp Thr Ala Leu 755 760 765 Cys Leu Leu Ser Leu
Leu Pro Ser Gly Phe Met Ser Leu Asp Asn Asn 770 775 780 Gly Thr Ala
Thr Pro Glu Leu Pro Thr Gln Gly Thr Phe Ser Asn Val 785 790 795 800
Ser Thr Asn Val Ser Tyr Gln Glu Thr Thr Thr Pro Ser Thr Leu Gly 805
810 815 Ser Thr Ser Leu His Pro Val Ser Gln His Gly Asn Glu Ala Thr
Thr 820 825 830 Asn Ile Thr Glu Thr Thr Val Lys Phe Thr Ser Thr Ser
Val Ile Thr 835 840 845 Ser Val Tyr Gly Asn Thr Asn Ser Ser Val Gln
Ser Gln Thr Ser Val 850 855 860 Ile Ser Thr Val Phe Thr Thr Pro Ala
Asn Val Ser Thr Pro Glu Thr 865 870 875 880 Thr Leu Lys Pro Ser Leu
Ser Pro Gly Asn Val Ser Asp Leu Ser Thr 885 890 895 Thr Ser Thr Ser
Leu Ala Thr Ser Pro Thr Lys Pro Tyr Thr Ser Ser 900 905 910 Ser Pro
Ile Leu Ser Asp Ile Lys Ala Glu Ile Lys Cys Ser Gly Ile 915 920 925
Arg Glu Val Lys Leu Thr Gln Gly Ile Cys Leu Glu Gln Asn Lys Thr 930
935 940 Ser Ser Cys Ala Glu Phe Lys Lys Asp Arg Gly Glu Gly Leu Ala
Arg 945 950 955 960 Val Leu Cys Gly Glu Glu Gln Ala Asp Ala Asp Ala
Gly Ala Gln Val 965 970 975 Cys Ser Leu Leu Leu Ala Gln Ser Glu Val
Arg Pro Gln Cys Leu Leu 980 985 990 Leu Val Leu Ala Asn Arg Thr Glu
Ile Ser Ser Lys Leu Gln Leu Met 995 1000 1005 Lys Lys His Gln Ser
Asp Leu Lys Lys Leu Gly Ile Leu Asp Phe 1010 1015 1020 Thr Glu Gln
Asp Val Ala Ser His Gln Ser Tyr Ser Gln Lys Thr 1025 1030 1035 Pro
Ile Leu Leu Thr Cys Pro Thr Ile Ser Ile Leu Ser Phe Phe 1040 1045
1050 Ser Val Ala Leu Leu Val Ile Leu Ala Cys Val Leu Trp Lys Lys
1055 1060 1065 Arg Ile Lys Pro Ile Val Trp Pro Ser Leu Pro Asp His
Lys Lys 1070 1075 1080 Thr Leu Glu His Leu Cys Lys Lys Pro Arg Lys
Asn Leu Asn Val 1085 1090 1095 Ser Phe Asn Pro Glu Ser Phe Leu Asp
Cys Gln Ile His Arg Val 1100 1105 1110 Asp Asp Ile Gln Ala Arg Asp
Glu Val Glu Gly Phe Leu Gln Asp 1115 1120 1125 Thr Phe Pro Gln Gln
Leu Glu Glu Ser Glu Lys Gln Arg Leu Gly 1130 1135 1140 Gly Asp Val
Gln Ser Pro Asn Cys Pro Ser Glu Asp Val Val Ile 1145 1150 1155 Thr
Pro Glu Ser Phe Gly Arg Asp Ser Ser Leu Thr Cys Leu Ala 1160 1165
1170 Gly Asn Val Ser Ala Cys Asp Ala Pro Ile Leu Ser Ser Ser Arg
1175 1180 1185 Ser Leu Asp Cys Arg Glu Ser Gly Lys Asn Gly Pro His
Val Tyr 1190 1195 1200 Gln Asp Leu Leu Leu Ser Leu Gly Thr Thr Asn
Ser Thr Leu Pro 1205 1210 1215 Pro Pro Phe Ser Leu Gln Ser Gly Ile
Leu Thr Leu Asn Pro Val 1220 1225 1230 Ala Gln Gly Gln Pro Ile Leu
Thr Ser Leu Gly Ser Asn Gln Glu 1235 1240 1245 Glu Ala Tyr Val Thr
Met Ser Ser Phe Tyr Gln Asn Gln 1250 1255 1260 <210> SEQ ID
NO 86 <211> LENGTH: 1263 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 86 Met Ala Ser Arg Ile Leu Trp
His Glu Met Trp His Glu Gly Leu Glu 1 5 10 15 Glu Ala Ser Arg Leu
Tyr Phe Gly Glu Arg Asn Val Lys Gly Met Phe 20 25 30 Glu Val Leu
Glu Pro Leu His Ala Met Met Glu Arg Gly Pro Gln Thr 35 40 45 Leu
Lys Glu Thr Ser Phe Asn Gln Ala Tyr Gly Arg Asp Leu Met Glu 50 55
60 Ala Gln Glu Trp Cys Arg Lys Tyr Met Lys Ser Gly Asn Val Lys Asp
65 70 75 80 Leu Leu Gln Ala Trp Asp Leu Tyr Tyr His Val Phe Arg Arg
Ile Ser 85 90 95 Lys Leu Glu Tyr Ser Gly Gly Gly Ser Leu Glu Gly
Val Gln Val Glu 100 105 110 Thr Ile Ser Pro Gly Asp Gly Arg Thr Phe
Pro Lys Arg Gly Gln Thr 115 120 125 Cys Val Val His Tyr Thr Gly Met
Leu Glu Asp Gly Lys Lys Phe Asp 130 135 140 Ser Ser Arg Asp Arg Asn
Lys Pro Phe Lys Phe Met Leu Gly Lys Gln 145 150 155 160 Glu Val Ile
Arg Gly Trp Glu Glu Gly Val Ala Gln Met Ser Val Gly 165 170 175 Gln
Arg Ala Lys Leu Thr Ile Ser Pro Asp Tyr Ala Tyr Gly Ala Thr 180 185
190 Gly His Pro Gly Ile Ile Pro Pro His Ala Thr Leu Val Phe Asp Val
195 200 205 Glu Leu Leu Lys Leu Glu Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly 210 215 220 Ser Gly Gly Gly Gly Ser Gly Val Asp Gly Phe Gly
Asp Val Gly Ala 225 230 235 240 Leu Glu Ser Leu Arg Gly Asn Ala Asp
Leu Ala Tyr Ile Leu Ser Met 245 250 255 Glu Pro Cys Gly His Cys Leu
Ile Ile Asn Asn Val Asn Phe Cys Arg 260 265 270 Glu Ser Gly Leu Arg
Thr Arg Thr Gly Ser Asn Ile Asp Cys Glu Lys 275 280 285 Leu Arg Arg
Arg Phe Ser Ser Leu His Phe Met Val Glu Val Lys Gly 290 295 300 Asp
Leu Thr Ala Lys Lys Met Val Leu Ala Leu Leu Glu Leu Ala Gln 305 310
315 320 Gln Asp His Gly Ala Leu Asp Cys Cys Val Val Val Ile Leu Ser
His 325 330 335 Gly Cys Gln Ala Ser His Leu Gln Phe Pro Gly Ala Val
Tyr Gly Thr 340 345 350 Asp Gly Cys Pro Val Ser Val Glu Lys Ile Val
Asn Ile Phe Asn Gly 355 360 365 Thr Ser Cys Pro Ser Leu Gly Gly Lys
Pro Lys Leu Phe Phe Ile Gln 370 375 380 Ala Cys Gly Gly Glu Gln Lys
Asp His Gly Phe Glu Val Ala Ser Thr 385 390 395 400 Ser Pro Glu Asp
Glu Ser Pro Gly Ser Asn Pro Glu Pro Asp Ala Thr 405 410 415 Pro Phe
Gln Glu Gly Leu Arg Thr Phe Asp Gln Leu Asp Ala Ile Ser 420 425 430
Ser Leu Pro Thr Pro Ser Asp Ile Phe Val Ser Tyr Ser Thr Phe Pro 435
440 445 Gly Phe Val Ser Trp Arg Asp Pro Lys Ser Gly Ser Trp Tyr Val
Glu 450 455 460 Thr Leu Asp Asp Ile Phe Glu Gln Trp Ala His Ser Glu
Asp Leu Gln 465 470 475 480 Ser Leu Leu Leu Arg Val Ala Asn Ala Val
Ser Val Lys Gly Ile Tyr 485 490 495 Lys Gln Met Pro Gly Cys Phe Asn
Phe Leu Arg Lys Lys Leu Phe Phe 500 505 510 Lys Thr Ser Gly Ser Gly
Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala 515 520 525 Gly Asp Val Glu
Glu Asn Pro Gly Pro Met Ala Leu Pro Val Thr Ala 530 535 540 Leu Leu
Leu Pro Leu Ala Leu Leu Leu His Ala Ala Arg Pro Asp Ile 545 550 555
560 Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg
565 570 575 Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr
Leu Asn 580 585 590 Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu
Leu Ile Tyr His 595 600 605 Thr Ser Arg Leu His Ser Gly Val Pro Ser
Arg Phe Ser Gly Ser Gly 610 615 620 Ser Gly Thr Asp Tyr Ser Leu Thr
Ile Ser Asn Leu Glu Gln Glu Asp 625 630 635 640 Ile Ala Thr Tyr Phe
Cys Gln Gln Gly Asn Thr Leu Pro Tyr Thr Phe 645 650 655 Gly Gly Gly
Thr Lys Leu Glu Ile Thr Gly Gly Gly Gly Ser Gln Val 660 665 670 Lys
Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu 675 680
685 Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
690 695 700 Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
Ala Thr 705 710 715 720 Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro
Asp Ser Val Lys Gly 725 730 735 Arg Phe Thr Ile Ser Arg Asp Asn Ala
Lys Asn Thr Leu Tyr Leu Gln 740 745 750 Met Ser Ser Leu Arg Ser Glu
Asp Thr Ala Met Tyr Tyr Cys Ala Arg 755 760 765 Gln Asp Gly Tyr Tyr
Pro Gly Trp Phe Ala Asn Trp Gly Gln Gly Thr 770 775 780 Thr Val Thr
Val Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly 785 790 795 800
Ser Gly Glu Gly Ser Thr Lys Gly Asp Ile Glu Leu Thr Gln Ser Pro 805
810 815 Ala Ile Met Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys
Ser 820 825 830 Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln
Lys Ser Gly 835 840 845 Thr Ser Pro Lys Leu Leu Ile Tyr Ser Thr Ser
Asn Leu Ala Ser Gly 850 855 860 Val Pro Ser Arg Phe Ser Gly Ser Gly
Ser Gly Thr Phe Tyr Ser Leu 865 870 875 880 Thr Ile Ser Ser Val Glu
Ala Glu Asp Ala Ala Asp Tyr Tyr Cys His 885 890 895 Gln Trp Ser Ser
Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 900 905 910 Arg Gly
Gly Gly Gly Ser Glu Val Lys Leu Gln Glu Ser Gly Pro Gly 915 920 925
Leu Val Ala Pro Ser Gln Ser Leu Ser Val Thr Cys Thr Val Ser Gly 930
935 940 Val Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro
Arg 945 950 955 960 Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Gly Ser
Glu Thr Thr Tyr 965 970 975 Tyr Asn Ser Ala Leu Lys Ser Arg Leu Thr
Ile Ile Lys Asp Asn Ser 980 985 990 Lys Ser Gln Val Phe Leu Lys Met
Asn Ser Leu Gln Thr Asp Asp Thr 995 1000 1005 Ala Ile Tyr Tyr Cys
Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr 1010 1015 1020 Ala Met Asp
Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 1025 1030 1035 Ser
Gly Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro 1040 1045
1050 Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg
1055 1060 1065 Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp
Phe Ala 1070 1075 1080 Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly
Thr Cys Gly Val 1085 1090 1095 Leu Leu Leu Ser Leu Val Ile Thr Leu
Tyr Cys Lys Arg Gly Arg 1100 1105 1110 Lys Lys Leu Leu Tyr Ile Phe
Lys Gln Pro Phe Met Arg Pro Val 1115 1120 1125 Gln Thr Thr Gln Glu
Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu 1130 1135 1140 Glu Glu Glu
Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser 1145 1150 1155 Ala
Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn 1160 1165
1170 Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys
1175 1180 1185 Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
Arg Lys 1190 1195 1200 Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln
Lys Asp Lys Met 1205 1210 1215 Ala Glu Ala Tyr Ser Glu Ile Gly Met
Lys Gly Glu Arg Arg Arg 1220 1225 1230 Gly Lys Gly His Asp Gly Leu
Tyr Gln Gly Leu Ser Thr Ala Thr 1235 1240 1245 Lys Asp Thr Tyr Asp
Ala Leu His Met Gln Ala Leu Pro Pro Arg 1250 1255 1260 <210>
SEQ ID NO 87 <211> LENGTH: 107 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 87 Asp Ile Gln Met Thr
Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val
Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu
Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40
45 Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu
Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn
Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
Thr 100 105 <210> SEQ ID NO 88 <211> LENGTH: 120
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 88
Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 1 5
10 15 Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp
Tyr 20 25 30 Gly Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu
Glu Trp Leu 35 40 45 Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr
Asn Ser Ala Leu Lys 50 55 60 Ser Arg Leu Thr Ile Ile Lys Asp Asn
Ser Lys Ser Gln Val Phe Leu 65 70 75 80 Lys Met Asn Ser Leu Gln Thr
Asp Asp Thr Ala Ile Tyr Tyr Cys Ala 85 90 95 Lys His Tyr Tyr Tyr
Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Ser
Val Thr Val Ser Ser 115 120 <210> SEQ ID NO 89 <211>
LENGTH: 491 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 89 Met Ala Leu Pro Val Thr Ala Leu Leu Leu
Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Asp Ile Gln
Met Thr Gln Thr Thr Ser Ser Leu 20 25 30 Ser Ala Ser Leu Gly Asp
Arg Val Thr Ile Ser Cys Arg Ala Ser Gln 35 40 45 Asp Ile Ser Lys
Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr 50 55 60 Val Lys
Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Val Pro 65 70 75 80
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile 85
90 95 Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln
Gly 100 105 110 Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu
Glu Ile Thr 115 120 125 Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser
Gly Glu Gly Ser Thr 130 135 140 Lys Gly Glu Val Lys Leu Gln Glu Ser
Gly Pro Gly Leu Val Ala Pro 145 150 155 160 Ser Gln Ser Leu Ser Val
Thr Cys Thr Val Ser Gly Val Ser Leu Pro 165 170 175 Asp Tyr Gly Val
Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu 180 185 190 Trp Leu
Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala 195 200 205
Leu Lys Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val 210
215 220 Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr
Tyr 225 230 235 240 Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala
Met Asp Tyr Trp 245 250 255 Gly Gln Gly Thr Ser Val Thr Val Ser Ser
Ser Gly Thr Thr Thr Pro 260 265 270 Ala Pro Arg Pro Pro Thr Pro Ala
Pro Thr Ile Ala Ser Gln Pro Leu 275 280 285 Ser Leu Arg Pro Glu Ala
Cys Arg Pro Ala Ala Gly Gly Ala Val His 290 295 300 Thr Arg Gly Leu
Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu 305 310 315 320 Ala
Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr 325 330
335 Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe
340 345 350 Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser
Cys Arg 355 360 365 Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg
Val Lys Phe Ser 370 375 380 Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln
Gly Gln Asn Gln Leu Tyr 385 390 395 400 Asn Glu Leu Asn Leu Gly Arg
Arg Glu Glu Tyr Asp Val Leu Asp Lys 405 410 415 Arg Arg Gly Arg Asp
Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn 420 425 430 Pro Gln Glu
Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu 435 440 445 Ala
Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly 450 455
460 His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr
465 470 475 480 Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 485 490
<210> SEQ ID NO 90 <211> LENGTH: 105 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 90 Asp Ile Glu Leu Thr
Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 1 5 10 15 Glu Glu Ile
Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 20 25 30 His
Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr 35 40
45 Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60 Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu
Ala Glu 65 70 75 80 Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser
Tyr Thr Phe Gly 85 90 95 Gly Gly Thr Lys Leu Glu Ile Lys Arg 100
105 <210> SEQ ID NO 91 <211> LENGTH: 120 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic polypeptide <400> SEQUENCE: 91 Gln Val
Lys Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20
25 30 Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp
Val 35 40 45 Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro
Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Arg Ser Glu
Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Gln Asp Gly Tyr Tyr
Pro Gly Trp Phe Ala Asn Trp Gly Gln 100 105 110 Gly Thr Thr Val Thr
Val Ser Ser 115 120 <210> SEQ ID NO 92 <211> LENGTH: 5
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 92 Glu
Ala Ala Ala Lys 1 5 <210> SEQ ID NO 93 <211> LENGTH: 30
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <220> FEATURE:
<221> NAME/KEY: SITE <222> LOCATION: (1)..(30)
<223> OTHER INFORMATION: This sequence may encompass 2-6 "Gly
Gly Gly Gly Ser" repeating units <400> SEQUENCE: 93 Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1 5 10 15
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 20 25 30
<210> SEQ ID NO 94 <211> LENGTH: 4 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 94 Arg Gly Asp Ser 1
<210> SEQ ID NO 95 <211> LENGTH: 116 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 95 Gln Leu Gln Gln Pro
Gly Ala Glu Leu Val Arg Pro Gly Ser Ser Val 1 5 10 15 Lys Leu Ser
Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr Trp Ile 20 25 30 His
Trp Val Lys Gln Arg Pro Ile Gln Gly Leu Glu Trp Ile Gly Asn 35 40
45 Ile Asp Pro Ser Asp Ser Glu Thr His Tyr Asn Gln Lys Phe Lys Asp
50 55 60 Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Gly Thr Ala Tyr
Met Gln 65 70 75 80 Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
Tyr Cys Ala Thr 85 90 95 Glu Asp Leu Tyr Tyr Ala Met Glu Tyr Trp
Gly Gln Gly Thr Ser Val 100 105 110 Thr Val Ser Ser 115 <210>
SEQ ID NO 96 <211> LENGTH: 113 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 96 Asp Ile Met Met Thr
Gln Ser Pro Ser Ser Leu Ala Val Ser Ala Gly 1 5 10 15 Glu Lys Val
Thr Met Thr Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser 20 25 30 Ser
Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40
45 Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr
Leu Thr 65 70 75 80 Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Val Tyr
Tyr Cys His Gln 85 90 95 Tyr Leu Ser Ser His Thr Phe Gly Gly Gly
Thr Lys Leu Glu Ile Lys 100 105 110 Arg <210> SEQ ID NO 97
<211> LENGTH: 120 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 97 Gln Val Gln Leu Gln Gln Pro
Gly Thr Glu Leu Val Arg Pro Gly Ser 1 5 10 15 Ser Val Lys Leu Ser
Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Val Asn
Trp Val Lys Gln Arg Pro Asp Gln Gly Leu Glu Trp Ile 35 40 45 Gly
Arg Ile Asp Pro Tyr Asp Ser Glu Thr His Tyr Asn Gln Lys Phe 50 55
60 Thr Asp Lys Ala Ile Ser Thr Ile Asp Thr Ser Ser Asn Thr Ala Tyr
65 70 75 80 Met Gln Leu Ser Thr Leu Thr Ser Asp Ala Ser Ala Val Tyr
Tyr Cys 85 90 95 Ser Arg Ser Pro Arg Asp Ser Ser Thr Asn Leu Ala
Asp Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120
<210> SEQ ID NO 98 <211> LENGTH: 108 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 98 Asp Ile Val Met Thr
Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly 1 5 10 15 Asp Arg Val
Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Asp Tyr 20 25 30 Leu
His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile 35 40
45 Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly
50 55 60 Ser Gly Ser Gly Ser Asp Phe Thr Leu Ser Ile Asn Ser Val
Glu Pro 65 70 75 80 Glu Asp Val Gly Val Tyr Tyr Cys Gln Asn Gly His
Ser Phe Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu
Arg Arg 100 105 <210> SEQ ID NO 99 <211> LENGTH: 903
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 99
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5
10 15 His Ala Ala Arg Pro Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile
Met 20 25 30 Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser
Ala Ser Ser 35 40 45 Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys
Ser Gly Thr Ser Pro 50 55 60 Lys Leu Leu Ile Tyr Ser Thr Ser Asn
Leu Ala Ser Gly Val Pro Ser 65 70 75 80 Arg Phe Ser Gly Ser Gly Ser
Gly Thr Phe Tyr Ser Leu Thr Ile Ser 85 90 95 Ser Val Glu Ala Glu
Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser 100 105 110 Ser Tyr Thr
Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Gly Gly 115 120 125 Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Lys 130 135
140 Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys
145 150 155 160 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
Ala Met Ser 165 170 175 Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu
Trp Val Ala Thr Ile 180 185 190 Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr
Pro Asp Ser Val Lys Gly Arg 195 200 205 Phe Thr Ile Ser Arg Asp Asn
Ala Lys Asn Thr Leu Tyr Leu Gln Met 210 215 220 Ser Ser Leu Arg Ser
Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gln 225 230 235 240 Asp Gly
Tyr Tyr Pro Gly Trp Phe Ala Asn Trp Gly Gln Gly Thr Thr 245 250 255
Val Thr Val Ser Ser Ser Gly Thr Thr Thr Pro Ala Pro Arg Pro Pro 260
265 270 Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro
Glu 275 280 285 Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg
Gly Leu Asp 290 295 300 Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
Ala Gly Thr Cys Gly 305 310 315 320 Val Leu Leu Leu Ser Leu Val Ile
Thr Leu Tyr Cys Lys Arg Gly Arg 325 330 335 Lys Lys Leu Leu Tyr Ile
Phe Lys Gln Pro Phe Met Arg Pro Val Gln 340 345 350 Thr Thr Gln Glu
Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu 355 360 365 Glu Gly
Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala 370 375 380
Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu 385
390 395 400 Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly
Arg Asp 405 410 415 Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
Gln Glu Gly Leu 420 425 430 Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
Glu Ala Tyr Ser Glu Ile 435 440 445 Gly Met Lys Gly Glu Arg Arg Arg
Gly Lys Gly His Asp Gly Leu Tyr 450 455 460 Gln Gly Leu Ser Thr Ala
Thr Lys Asp Thr Tyr Asp Ala Leu His Met 465 470 475 480 Gln Ala Leu
Pro Pro Arg Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu 485 490 495 Lys
Gln Ala Gly Asp Val Glu Glu Asn Pro Gly Pro Met Asp Trp Thr 500 505
510 Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val His Ser Asn Trp
515 520 525 Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile
Gln Ser 530 535 540 Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp
Val His Pro Ser 545 550 555 560 Cys Lys Val Thr Ala Met Lys Cys Phe
Leu Leu Glu Leu Gln Val Ile 565 570 575 Ser Leu Glu Ser Gly Asp Ala
Ser Ile His Asp Thr Val Glu Asn Leu 580 585 590 Ile Ile Leu Ala Asn
Asn Ser Leu Ser Ser Asn Gly Asn Val Thr Glu 595 600 605 Ser Gly Cys
Lys Glu Cys Glu Glu Leu Glu Glu Lys Asn Ile Lys Glu 610 615 620 Phe
Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile Asn Thr Ser 625 630
635 640 Ser Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly 645 650 655 Gly Gly Gly Ser Gly Gly Gly Ser Leu Gln Ile Thr Cys
Pro Pro Pro 660 665 670 Met Ser Val Glu His Ala Asp Ile Trp Val Lys
Ser Tyr Ser Leu Tyr 675 680 685 Ser Arg Glu Arg Tyr Ile Cys Asn Ser
Gly Phe Lys Arg Lys Ala Gly 690 695 700 Thr Ser Ser Leu Thr Glu Cys
Val Leu Asn Lys Ala Thr Asn Val Ala 705 710 715 720 His Trp Thr Thr
Pro Ser Leu Lys Cys Ile Arg Asp Pro Ala Leu Val 725 730 735 His Gln
Arg Pro Ala Pro Pro Ser Thr Val Thr Thr Ala Gly Val Thr 740 745 750
Pro Gln Pro Glu Ser Leu Ser Pro Ser Gly Lys Glu Pro Ala Ala Ser 755
760 765 Ser Pro Ser Ser Asn Asn Thr Ala Ala Thr Thr Ala Ala Ile Val
Pro 770 775 780 Gly Ser Gln Leu Met Pro Ser Lys Ser Pro Ser Thr Gly
Thr Thr Glu 785 790 795 800 Ile Ser Ser His Glu Ser Ser His Gly Thr
Pro Ser Gln Thr Thr Ala 805 810 815 Lys Asn Trp Glu Leu Thr Ala Ser
Ala Ser His Gln Pro Pro Gly Val 820 825 830 Tyr Pro Gln Gly His Ser
Asp Thr Thr Val Ala Ile Ser Thr Ser Thr 835 840 845 Val Leu Leu Cys
Gly Leu Ser Ala Val Ser Leu Leu Ala Cys Tyr Leu 850 855 860 Lys Ser
Arg Gln Thr Pro Pro Leu Ala Ser Val Glu Met Glu Ala Met 865 870 875
880 Glu Ala Leu Pro Val Thr Trp Gly Thr Ser Ser Arg Asp Glu Asp Leu
885 890 895 Glu Asn Cys Ser His His Leu 900 <210> SEQ ID NO
100 <211> LENGTH: 1065 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 100 Met Ala Leu Pro Val Thr Ala
Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro
Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met 20 25 30 Ser Ala Ser
Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser 35 40 45 Ser
Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro 50 55
60 Lys Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser
65 70 75 80 Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr
Ile Ser 85 90 95 Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys
His Gln Trp Ser 100 105 110 Ser Tyr Thr Phe Gly Gly Gly Thr Lys Leu
Glu Ile Lys Arg Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gln Val Lys 130 135 140 Leu Gln Glu Ser Gly Gly
Gly Leu Val Lys Pro Gly Gly Ser Leu Lys 145 150 155 160 Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser 165 170 175 Trp
Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile 180 185
190 Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg
195 200 205 Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu
Gln Met 210 215 220 Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr
Cys Ala Arg Gln 225 230 235 240 Asp Gly Tyr Tyr Pro Gly Trp Phe Ala
Asn Trp Gly Gln Gly Thr Thr 245 250 255 Val Thr Val Ser Ser Ser Gly
Thr Thr Thr Pro Ala Pro Arg Pro Pro 260 265 270 Thr Pro Ala Pro Thr
Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu 275 280 285 Ala Cys Arg
Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp 290 295 300 Phe
Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly 305 310
315 320 Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly
Arg 325 330 335 Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg
Pro Val Gln 340 345 350 Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg
Phe Pro Glu Glu Glu 355 360 365 Glu Gly Gly Cys Glu Leu Arg Val Lys
Phe Ser Arg Ser Ala Asp Ala 370 375 380 Pro Ala Tyr Lys Gln Gly Gln
Asn Gln Leu Tyr Asn Glu Leu Asn Leu 385 390 395 400 Gly Arg Arg Glu
Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp 405 410 415 Pro Glu
Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 420 425 430
Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile 435
440 445 Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
Tyr 450 455 460 Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala
Leu His Met 465 470 475 480 Gln Ala Leu Pro Pro Arg Gly Ser Gly Ala
Thr Asn Phe Ser Leu Leu 485 490 495 Lys Gln Ala Gly Asp Val Glu Glu
Asn Pro Gly Pro Met Leu Leu Leu 500 505 510 Val Thr Ser Leu Leu Leu
Cys Glu Leu Pro His Pro Ala Phe Leu Leu 515 520 525 Ile Pro Arg Lys
Val Cys Asn Gly Ile Gly Ile Gly Glu Phe Lys Asp 530 535 540 Ser Leu
Ser Ile Asn Ala Thr Asn Ile Lys His Phe Lys Asn Cys Thr 545 550 555
560 Ser Ile Ser Gly Asp Leu His Ile Leu Pro Val Ala Phe Arg Gly Asp
565 570 575 Ser Phe Thr His Thr Pro Pro Leu Asp Pro Gln Glu Leu Asp
Ile Leu 580 585 590 Lys Thr Val Lys Glu Ile Thr Gly Phe Leu Leu Ile
Gln Ala Trp Pro 595 600 605 Glu Asn Arg Thr Asp Leu His Ala Phe Glu
Asn Leu Glu Ile Ile Arg 610 615 620 Gly Arg Thr Lys Gln His Gly Gln
Phe Ser Leu Ala Val Val Ser Leu 625 630 635 640 Asn Ile Thr Ser Leu
Gly Leu Arg Ser Leu Lys Glu Ile Ser Asp Gly 645 650 655 Asp Val Ile
Ile Ser Gly Asn Lys Asn Leu Cys Tyr Ala Asn Thr Ile 660 665 670 Asn
Trp Lys Lys Leu Phe Gly Thr Ser Gly Gln Lys Thr Lys Ile Ile 675 680
685 Ser Asn Arg Gly Glu Asn Ser Cys Lys Ala Thr Gly Gln Val Cys His
690 695 700 Ala Leu Cys Ser Pro Glu Gly Cys Trp Gly Pro Glu Pro Arg
Asp Cys 705 710 715 720 Val Ser Cys Arg Asn Val Ser Arg Gly Arg Glu
Cys Val Asp Lys Cys 725 730 735 Asn Leu Leu Glu Gly Glu Pro Arg Glu
Phe Val Glu Asn Ser Glu Cys 740 745 750 Ile Gln Cys His Pro Glu Cys
Leu Pro Gln Ala Met Asn Ile Thr Cys 755 760 765 Thr Gly Arg Gly Pro
Asp Asn Cys Ile Gln Cys Ala His Tyr Ile Asp 770 775 780 Gly Pro His
Cys Val Lys Thr Cys Pro Ala Gly Val Met Gly Glu Asn 785 790 795 800
Asn Thr Leu Val Trp Lys Tyr Ala Asp Ala Gly His Val Cys His Leu 805
810 815 Cys His Pro Asn Cys Thr Tyr Gly Cys Thr Gly Pro Gly Leu Glu
Gly 820 825 830 Cys Pro Thr Asn Gly Pro Lys Ile Pro Ser Pro Ile Leu
Leu Thr Cys 835 840 845 Pro Thr Ile Ser Ile Leu Ser Phe Phe Ser Val
Ala Leu Leu Val Ile 850 855 860 Leu Ala Cys Val Leu Trp Lys Lys Arg
Ile Lys Pro Ile Val Trp Pro 865 870 875 880 Ser Leu Pro Asp His Lys
Lys Thr Leu Glu His Leu Cys Lys Lys Pro 885 890 895 Arg Lys Asn Leu
Asn Val Ser Phe Asn Pro Glu Ser Phe Leu Asp Cys 900 905 910 Gln Ile
His Arg Val Asp Asp Ile Gln Ala Arg Asp Glu Val Glu Gly 915 920 925
Phe Leu Gln Asp Thr Phe Pro Gln Gln Leu Glu Glu Ser Glu Lys Gln 930
935 940 Arg Leu Gly Gly Asp Val Gln Ser Pro Asn Cys Pro Ser Glu Asp
Val 945 950 955 960 Val Ile Thr Pro Glu Ser Phe Gly Arg Asp Ser Ser
Leu Thr Cys Leu 965 970 975 Ala Gly Asn Val Ser Ala Cys Asp Ala Pro
Ile Leu Ser Ser Ser Arg 980 985 990 Ser Leu Asp Cys Arg Glu Ser Gly
Lys Asn Gly Pro His Val Tyr Gln 995 1000 1005 Asp Leu Leu Leu Ser
Leu Gly Thr Thr Asn Ser Thr Leu Pro Pro 1010 1015 1020 Pro Phe Ser
Leu Gln Ser Gly Ile Leu Thr Leu Asn Pro Val Ala 1025 1030 1035 Gln
Gly Gln Pro Ile Leu Thr Ser Leu Gly Ser Asn Gln Glu Glu 1040 1045
1050 Ala Tyr Val Thr Met Ser Ser Phe Tyr Gln Asn Gln 1055 1060 1065
<210> SEQ ID NO 101 <211> LENGTH: 851 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 101 Met Ala Leu Pro Val
Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala
Arg Pro Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met 20 25 30 Ser
Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser 35 40
45 Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro
50 55 60 Lys Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val
Pro Ser 65 70 75 80 Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser
Leu Thr Ile Ser 85 90 95 Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr
Tyr Cys His Gln Trp Ser 100 105 110 Ser Tyr Thr Phe Gly Gly Gly Thr
Lys Leu Glu Ile Lys Arg Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gln Val Lys 130 135 140 Leu Gln Glu Ser
Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys 145 150 155 160 Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser 165 170
175 Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile
180 185 190 Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys
Gly Arg 195 200 205 Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu
Tyr Leu Gln Met 210 215 220 Ser Ser Leu Arg Ser Glu Asp Thr Ala Met
Tyr Tyr Cys Ala Arg Gln 225 230 235 240 Asp Gly Tyr Tyr Pro Gly Trp
Phe Ala Asn Trp Gly Gln Gly Thr Thr 245 250 255 Val Thr Val Ser Ser
Ser Gly Thr Thr Thr Pro Ala Pro Arg Pro Pro 260 265 270 Thr Pro Ala
Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu 275 280 285 Ala
Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp 290 295
300 Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly
305 310 315 320 Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys
Arg Gly Arg 325 330 335 Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe
Met Arg Pro Val Gln 340 345 350 Thr Thr Gln Glu Glu Asp Gly Cys Ser
Cys Arg Phe Pro Glu Glu Glu 355 360 365 Glu Gly Gly Cys Glu Leu Arg
Val Lys Phe Ser Arg Ser Ala Asp Ala 370 375 380 Pro Ala Tyr Lys Gln
Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu 385 390 395 400 Gly Arg
Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp 405 410 415
Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 420
425 430 Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
Ile 435 440 445 Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
Gly Leu Tyr 450 455 460 Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr
Asp Ala Leu His Met 465 470 475 480 Gln Ala Leu Pro Pro Arg Gly Ser
Gly Ala Thr Asn Phe Ser Leu Leu 485 490 495 Lys Gln Ala Gly Asp Val
Glu Glu Asn Pro Gly Pro Met Leu Leu Leu 500 505 510 Val Thr Ser Leu
Leu Leu Cys Glu Leu Pro His Pro Ala Phe Leu Leu 515 520 525 Ile Pro
Cys His Pro Glu Cys Gln Pro Gln Asn Gly Ser Val Thr Cys 530 535 540
Phe Gly Pro Glu Ala Asp Gln Cys Val Ala Cys Ala His Tyr Lys Asp 545
550 555 560 Pro Pro Phe Cys Val Ala Arg Cys Pro Ser Gly Val Lys Pro
Asp Leu 565 570 575 Ser Tyr Met Pro Ile Trp Lys Phe Pro Asp Glu Glu
Gly Ala Cys Gln 580 585 590 Pro Cys Pro Ile Asn Cys Thr His Ser Cys
Val Asp Leu Asp Asp Lys 595 600 605 Gly Cys Pro Ala Glu Gln Arg Ala
Ser Pro Leu Thr Gly Gly Gly Ser 610 615 620 Gly Gly Gly Ser Pro Ile
Leu Leu Thr Cys Pro Thr Ile Ser Ile Leu 625 630 635 640 Ser Phe Phe
Ser Val Ala Leu Leu Val Ile Leu Ala Cys Val Leu Trp 645 650 655 Lys
Lys Arg Ile Lys Pro Ile Val Trp Pro Ser Leu Pro Asp His Lys 660 665
670 Lys Thr Leu Glu His Leu Cys Lys Lys Pro Arg Lys Asn Leu Asn Val
675 680 685 Ser Phe Asn Pro Glu Ser Phe Leu Asp Cys Gln Ile His Arg
Val Asp 690 695 700 Asp Ile Gln Ala Arg Asp Glu Val Glu Gly Phe Leu
Gln Asp Thr Phe 705 710 715 720 Pro Gln Gln Leu Glu Glu Ser Glu Lys
Gln Arg Leu Gly Gly Asp Val 725 730 735 Gln Ser Pro Asn Cys Pro Ser
Glu Asp Val Val Ile Thr Pro Glu Ser 740 745 750 Phe Gly Arg Asp Ser
Ser Leu Thr Cys Leu Ala Gly Asn Val Ser Ala 755 760 765 Cys Asp Ala
Pro Ile Leu Ser Ser Ser Arg Ser Leu Asp Cys Arg Glu 770 775 780 Ser
Gly Lys Asn Gly Pro His Val Tyr Gln Asp Leu Leu Leu Ser Leu 785 790
795 800 Gly Thr Thr Asn Ser Thr Leu Pro Pro Pro Phe Ser Leu Gln Ser
Gly 805 810 815 Ile Leu Thr Leu Asn Pro Val Ala Gln Gly Gln Pro Ile
Leu Thr Ser 820 825 830 Leu Gly Ser Asn Gln Glu Glu Ala Tyr Val Thr
Met Ser Ser Phe Tyr 835 840 845 Gln Asn Gln 850 <210> SEQ ID
NO 102 <211> LENGTH: 15 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide <400> SEQUENCE: 102 Glu Ala Ala Ala Lys Glu Ala Ala
Ala Lys Glu Ala Ala Ala Lys 1 5 10 15 <210> SEQ ID NO 103
<211> LENGTH: 368 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 103 Met Leu Leu Leu Val Thr Ser
Leu Leu Leu Cys Glu Leu Pro His Pro 1 5 10 15 Ala Phe Leu Leu Ile
Pro Gln Leu Leu Phe Asn Lys Thr Lys Ser Val 20 25 30 Glu Phe Thr
Phe Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr 35 40 45 Asn
Met Glu Ala Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe 50 55
60 Lys Gly Arg Asp Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr
65 70 75 80 Val Pro Thr Asp Phe Ser Ser Ala Lys Ile Glu Val Ser Gln
Leu Leu 85 90 95 Lys Gly Asp Ala Ser Leu Lys Met Asp Lys Ser Asp
Ala Val Ser His 100 105 110 Thr Gly Asn Tyr Thr Cys Glu Val Thr Glu
Leu Thr Arg Glu Gly Glu 115 120 125 Thr Ile Ile Glu Leu Lys Tyr Arg
Val Val Ser Trp Phe Ser Pro Asn 130 135 140 Glu Pro Ile Leu Leu Thr
Cys Pro Thr Ile Ser Ile Leu Ser Phe Phe 145 150 155 160 Ser Val Ala
Leu Leu Val Ile Leu Ala Cys Val Leu Trp Lys Lys Arg 165 170 175 Ile
Lys Pro Ile Val Trp Pro Ser Leu Pro Asp His Lys Lys Thr Leu 180 185
190 Glu His Leu Cys Lys Lys Pro Arg Lys Asn Leu Asn Val Ser Phe Asn
195 200 205 Pro Glu Ser Phe Leu Asp Cys Gln Ile His Arg Val Asp Asp
Ile Gln 210 215 220 Ala Arg Asp Glu Val Glu Gly Phe Leu Gln Asp Thr
Phe Pro Gln Gln 225 230 235 240 Leu Glu Glu Ser Glu Lys Gln Arg Leu
Gly Gly Asp Val Gln Ser Pro 245 250 255 Asn Cys Pro Ser Glu Asp Val
Val Ile Thr Pro Glu Ser Phe Gly Arg 260 265 270 Asp Ser Ser Leu Thr
Cys Leu Ala Gly Asn Val Ser Ala Cys Asp Ala 275 280 285 Pro Ile Leu
Ser Ser Ser Arg Ser Leu Asp Cys Arg Glu Ser Gly Lys 290 295 300 Asn
Gly Pro His Val Tyr Gln Asp Leu Leu Leu Ser Leu Gly Thr Thr 305 310
315 320 Asn Ser Thr Leu Pro Pro Pro Phe Ser Leu Gln Ser Gly Ile Leu
Thr 325 330 335 Leu Asn Pro Val Ala Gln Gly Gln Pro Ile Leu Thr Ser
Leu Gly Ser 340 345 350 Asn Gln Glu Glu Ala Tyr Val Thr Met Ser Ser
Phe Tyr Gln Asn Gln 355 360 365
1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 103
<210> SEQ ID NO 1 <211> LENGTH: 1138 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 1 Met Leu Leu Leu Val
Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro 1 5 10 15 Ala Phe Leu
Leu Ile Pro Arg Lys Val Cys Asn Gly Ile Gly Ile Gly 20 25 30 Glu
Phe Lys Asp Ser Leu Ser Ile Asn Ala Thr Asn Ile Lys His Phe 35 40
45 Lys Asn Cys Thr Ser Ile Ser Gly Asp Leu His Ile Leu Pro Val Ala
50 55 60 Phe Arg Gly Asp Ser Phe Thr His Thr Pro Pro Leu Asp Pro
Gln Glu 65 70 75 80 Leu Asp Ile Leu Lys Thr Val Lys Glu Ile Thr Gly
Phe Leu Leu Ile 85 90 95 Gln Ala Trp Pro Glu Asn Arg Thr Asp Leu
His Ala Phe Glu Asn Leu 100 105 110 Glu Ile Ile Arg Gly Arg Thr Lys
Gln His Gly Gln Phe Ser Leu Ala 115 120 125 Val Val Ser Leu Asn Ile
Thr Ser Leu Gly Leu Arg Ser Leu Lys Glu 130 135 140 Ile Ser Asp Gly
Asp Val Ile Ile Ser Gly Asn Lys Asn Leu Cys Tyr 145 150 155 160 Ala
Asn Thr Ile Asn Trp Lys Lys Leu Phe Gly Thr Ser Gly Gln Lys 165 170
175 Thr Lys Ile Ile Ser Asn Arg Gly Glu Asn Ser Cys Lys Ala Thr Gly
180 185 190 Gln Val Cys His Ala Leu Cys Ser Pro Glu Gly Cys Trp Gly
Pro Glu 195 200 205 Pro Arg Asp Cys Val Ser Cys Arg Asn Val Ser Arg
Gly Arg Glu Cys 210 215 220 Val Asp Lys Cys Asn Leu Leu Glu Gly Glu
Pro Arg Glu Phe Val Glu 225 230 235 240 Asn Ser Glu Cys Ile Gln Cys
His Pro Glu Cys Leu Pro Gln Ala Met 245 250 255 Asn Ile Thr Cys Thr
Gly Arg Gly Pro Asp Asn Cys Ile Gln Cys Ala 260 265 270 His Tyr Ile
Asp Gly Pro His Cys Val Lys Thr Cys Pro Ala Gly Val 275 280 285 Met
Gly Glu Asn Asn Thr Leu Val Trp Lys Tyr Ala Asp Ala Gly His 290 295
300 Val Cys His Leu Cys His Pro Asn Cys Thr Tyr Gly Cys Thr Gly Pro
305 310 315 320 Gly Leu Glu Gly Cys Pro Thr Asn Gly Pro Lys Ile Pro
Ser Ile Ala 325 330 335 Thr Gly Met Val Gly Ala Leu Leu Leu Leu Leu
Val Val Ala Leu Gly 340 345 350 Ile Gly Leu Phe Met Arg Ala Lys Arg
Gly Ser Gly Ala Thr Asn Phe 355 360 365 Ser Leu Leu Lys Gln Ala Gly
Asp Val Glu Glu Asn Pro Gly Pro Met 370 375 380 Ala Leu Pro Val Thr
Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu His 385 390 395 400 Ala Ala
Arg Pro Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala 405 410 415
Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr 420
425 430 Phe Thr Arg Tyr Thr Met His Trp Val Lys Gln Arg Pro Gly Gln
Gly 435 440 445 Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser Arg Gly Tyr
Thr Asn Tyr 450 455 460 Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr
Thr Asp Lys Ser Ser 465 470 475 480 Ser Thr Ala Tyr Met Gln Leu Ser
Ser Leu Thr Ser Glu Asp Ser Ala 485 490 495 Val Tyr Tyr Cys Ala Arg
Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr 500 505 510 Trp Gly Gln Gly
Thr Thr Leu Thr Val Ser Ser Gly Ser Thr Ser Gly 515 520 525 Gly Gly
Ser Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Gln Ile Val 530 535 540
Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val 545
550 555 560 Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Asn
Trp Tyr 565 570 575 Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile
Tyr Asp Thr Ser 580 585 590 Lys Leu Ala Ser Gly Val Pro Ala His Phe
Arg Gly Ser Gly Ser Gly 595 600 605 Thr Ser Tyr Ser Leu Thr Ile Ser
Gly Met Glu Ala Glu Asp Ala Ala 610 615 620 Thr Tyr Tyr Cys Gln Gln
Trp Ser Ser Asn Pro Phe Thr Phe Gly Ser 625 630 635 640 Gly Thr Lys
Leu Glu Ile Asn Arg Gly Gly Gly Gly Ser Gly Gly Gly 645 650 655 Gly
Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Thr Thr Ser 660 665
670 Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala
675 680 685 Ser Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys
Pro Asp 690 695 700 Gly Thr Val Lys Leu Leu Ile Tyr His Thr Ser Arg
Leu His Ser Gly 705 710 715 720 Val Pro Ser Arg Phe Ser Gly Ser Gly
Ser Gly Thr Asp Tyr Ser Leu 725 730 735 Thr Ile Ser Asn Leu Glu Gln
Glu Asp Ile Ala Thr Tyr Phe Cys Gln 740 745 750 Gln Gly Asn Thr Leu
Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu 755 760 765 Ile Thr Gly
Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly 770 775 780 Ser
Thr Lys Gly Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val 785 790
795 800 Ala Pro Ser Gln Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val
Ser 805 810 815 Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro
Arg Lys Gly 820 825 830 Leu Glu Trp Leu Gly Val Ile Trp Gly Ser Glu
Thr Thr Tyr Tyr Asn 835 840 845 Ser Ala Leu Lys Ser Arg Leu Thr Ile
Ile Lys Asp Asn Ser Lys Ser 850 855 860 Gln Val Phe Leu Lys Met Asn
Ser Leu Gln Thr Asp Asp Thr Ala Ile 865 870 875 880 Tyr Tyr Cys Ala
Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp 885 890 895 Tyr Trp
Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ala Ala Asp 900 905 910
Tyr Lys Asp Asp Asp Asp Lys Ile Glu Val Met Tyr Pro Pro Pro Tyr 915
920 925 Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly
Lys 930 935 940 His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys
Pro Phe Trp 945 950 955 960 Val Leu Val Val Val Gly Gly Val Leu Ala
Cys Tyr Ser Leu Leu Val 965 970 975 Thr Val Ala Phe Ile Ile Phe Trp
Val Arg Ser Lys Arg Ser Arg Leu 980 985 990 Leu His Ser Asp Tyr Met
Asn Met Thr Pro Arg Arg Pro Gly Pro Thr 995 1000 1005 Arg Lys His
Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala 1010 1015 1020 Tyr
Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala 1025 1030
1035 Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly
1040 1045 1050 Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly
Arg Asp 1055 1060 1065 Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn
Pro Gln Glu Gly 1070 1075 1080 Leu Tyr Asn Glu Leu Gln Lys Asp Lys
Met Ala Glu Ala Tyr Ser 1085 1090 1095 Glu Ile Gly Met Lys Gly Glu
Arg Arg Arg Gly Lys Gly His Asp 1100 1105 1110 Gly Leu Tyr Gln Gly
Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp 1115 1120 1125 Ala Leu His
Met Gln Ala Leu Pro Pro Arg 1130 1135 <210> SEQ ID NO 2
<211> LENGTH: 3417 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polynucleotide <400> SEQUENCE: 2 atgttgctcc ttgtgacgag
cctcctgctc tgcgagctgc cccatccagc cttcctcctc 60 atcccgcgga
aggtgtgcaa tggcataggc attggcgagt ttaaagattc tctgagcata 120
aatgctacga atattaagca tttcaagaat tgtacttcta ttagtggcga cctccatatt
180
cttccggttg ccttcagggg tgactctttc acccacacac ctccattgga tccacaagaa
240 cttgacatcc tgaagacggt taaagagatt acaggcttcc tccttatcca
agcgtggccc 300 gagaacagaa cggacttgca cgcctttgag aacctcgaaa
taatacgggg tcggacgaag 360 caacacggcc aatttagcct tgcggttgtt
agtctgaaca ttacttctct cggccttcgc 420 tctttgaaag aaatcagcga
cggagatgtc atcattagtg gaaacaagaa cctgtgctac 480 gcgaacacaa
tcaactggaa gaagctcttc ggtacttcag gccaaaagac aaagattatt 540
agtaacagag gagagaatag ctgtaaggct accggacaag tttgtcacgc cttgtgtagt
600 ccagagggtt gctggggacc ggaaccaagg gattgcgtca gttgccggaa
cgtgagtcgc 660 ggacgcgagt gtgtggataa gtgcaatctt ctggaagggg
aaccgcgaga gtttgtagaa 720 aattccgaat gtatacagtg tcatcccgag
tgtcttccac aagcaatgaa tatcacatgt 780 acagggaggg gtcctgataa
ctgtatccaa tgtgcacact acatagatgg tcctcactgt 840 gtaaagacgt
gccccgccgg agtaatgggt gaaaacaaca ccctcgtgtg gaagtacgcc 900
gatgccgggc atgtctgtca tttgtgtcat cccaactgca catatggctg taccggtcct
960 ggattggagg gctgtccaac aaacgggccg aaaataccga gtatcgcaac
aggcatggtg 1020 ggagcacttt tgcttctcct cgttgtcgcc ctgggcatcg
gcttgttcat gcgagctaaa 1080 cgaggctcag gcgcgacgaa ctttagtttg
ctgaagcaag ctggggatgt agaggaaaat 1140 ccgggtccca tggcccttcc
agtgacagcc ttgttgttgc cacttgctct gctgctccac 1200 gctgcgcggc
cacaggtcca gttgcagcag tcaggcgccg aattggcgcg accaggggca 1260
agcgtaaaga tgagctgtaa ggcatccggg tacacgttca ctcgctatac catgcattgg
1320 gttaaacaac ggcctgggca gggccttgag tggattgggt atatcaaccc
atcccggggc 1380 tacactaact ataatcaaaa gtttaaagat aaagcaaccc
ttacgaccga caaatcatct 1440 tctaccgcat acatgcagct cagctccctc
accagtgaag attctgccgt ttattattgt 1500 gcacgatact atgacgatca
ctattgcctg gactactggg gtcaaggcac cacacttact 1560 gtcagttccg
gaagtaccag tgggggaggt tctggcggtg gcagcggggg tgggggtagc 1620
tcacaaatcg tgctgaccca gagtcccgct atcatgagcg cctccccagg ggaaaaggtg
1680 acgatgacat gctcagccag ctccagtgta tcctacatga attggtatca
acagaagagt 1740 gggacgtcac ccaaaagatg gatttatgac accagcaaat
tggccagcgg agtaccagcg 1800 catttcagag gcagtgggag tggaacatct
tattctctca ccattagcgg catggaagca 1860 gaggatgcag caacgtacta
ttgtcaacaa tggagctcta atccctttac gttcggcagc 1920 ggcactaagc
tcgaaattaa taggggtggc ggcggctccg gcggtggcgg gtctggaggt 1980
gggggcagtg acatccagat gacacagact acatcctccc tgtctgcctc tctgggagac
2040 agagtcacca tcagttgcag ggcaagtcag gacattagta aatatttaaa
ttggtatcag 2100 cagaaaccag atggaactgt taaactcctg atctaccata
catcaagatt acactcagga 2160 gtcccatcaa ggttcagtgg cagtgggtct
ggaacagatt attctctcac cattagcaac 2220 ctggagcaag aagatattgc
cacttacttt tgccaacagg gtaatacgct tccgtacacg 2280 ttcggagggg
ggactaagtt ggaaataaca ggctccacct ctggatccgg caagcccgga 2340
tctggcgagg gatccaccaa gggcgaggtg aaactgcagg agtcaggacc tggcctggtg
2400 gcgccctcac agagcctgtc cgtcacatgc actgtctcag gggtctcatt
acccgactat 2460 ggtgtaagct ggattcgcca gcctccacga aagggtctgg
agtggctggg agtaatatgg 2520 ggtagtgaaa ccacatacta taattcagct
ctcaaatcca gactgaccat catcaaggac 2580 aactccaaga gccaagtttt
cttaaaaatg aacagtctgc aaactgatga cacagccatt 2640 tactactgtg
ccaaacatta ttactacggt ggtagctatg ctatggacta ctggggtcaa 2700
ggaacctcag tcaccgtctc ctcagcggcc gcagactaca aagacgatga cgacaagatt
2760 gaagttatgt atcctcctcc ttacctagac aatgagaaga gcaatggaac
cattatccat 2820 gtgaaaggga aacacctttg tccaagtccc ctatttcccg
gaccttctaa gcccttttgg 2880 gtgctggtgg tggttggggg agtcctggct
tgctatagct tgctagtaac agtggccttt 2940 attattttct gggtgaggag
taagaggagc aggctcctgc acagtgacta catgaacatg 3000 actccccgcc
gccccgggcc cacccgcaag cattaccagc cctatgcccc accacgcgac 3060
ttcgcagcct atcgctccag agtgaagttc agcaggagcg cagacgcccc cgcgtaccag
3120 cagggccaga accagctcta taacgagctc aatctaggac gaagagagga
gtacgatgtt 3180 ttggacaaga gacgtggccg ggaccctgag atggggggaa
agccgagaag gaagaaccct 3240 caggaaggcc tgtacaatga actgcagaaa
gataagatgg cggaggccta cagtgagatt 3300 gggatgaaag gcgagcgccg
gaggggcaag gggcacgatg gcctttacca gggtctcagt 3360 acagccacca
aggacaccta cgacgccctt cacatgcagg ccctgccccc tcgctaa 3417
<210> SEQ ID NO 3 <211> LENGTH: 1138 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 3 Met Leu Leu Leu Val
Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro 1 5 10 15 Ala Phe Leu
Leu Ile Pro Arg Lys Val Cys Asn Gly Ile Gly Ile Gly 20 25 30 Glu
Phe Lys Asp Ser Leu Ser Ile Asn Ala Thr Asn Ile Lys His Phe 35 40
45 Lys Asn Cys Thr Ser Ile Ser Gly Asp Leu His Ile Leu Pro Val Ala
50 55 60 Phe Arg Gly Asp Ser Phe Thr His Thr Pro Pro Leu Asp Pro
Gln Glu 65 70 75 80 Leu Asp Ile Leu Lys Thr Val Lys Glu Ile Thr Gly
Phe Leu Leu Ile 85 90 95 Gln Ala Trp Pro Glu Asn Arg Thr Asp Leu
His Ala Phe Glu Asn Leu 100 105 110 Glu Ile Ile Arg Gly Arg Thr Lys
Gln His Gly Gln Phe Ser Leu Ala 115 120 125 Val Val Ser Leu Asn Ile
Thr Ser Leu Gly Leu Arg Ser Leu Lys Glu 130 135 140 Ile Ser Asp Gly
Asp Val Ile Ile Ser Gly Asn Lys Asn Leu Cys Tyr 145 150 155 160 Ala
Asn Thr Ile Asn Trp Lys Lys Leu Phe Gly Thr Ser Gly Gln Lys 165 170
175 Thr Lys Ile Ile Ser Asn Arg Gly Glu Asn Ser Cys Lys Ala Thr Gly
180 185 190 Gln Val Cys His Ala Leu Cys Ser Pro Glu Gly Cys Trp Gly
Pro Glu 195 200 205 Pro Arg Asp Cys Val Ser Cys Arg Asn Val Ser Arg
Gly Arg Glu Cys 210 215 220 Val Asp Lys Cys Asn Leu Leu Glu Gly Glu
Pro Arg Glu Phe Val Glu 225 230 235 240 Asn Ser Glu Cys Ile Gln Cys
His Pro Glu Cys Leu Pro Gln Ala Met 245 250 255 Asn Ile Thr Cys Thr
Gly Arg Gly Pro Asp Asn Cys Ile Gln Cys Ala 260 265 270 His Tyr Ile
Asp Gly Pro His Cys Val Lys Thr Cys Pro Ala Gly Val 275 280 285 Met
Gly Glu Asn Asn Thr Leu Val Trp Lys Tyr Ala Asp Ala Gly His 290 295
300 Val Cys His Leu Cys His Pro Asn Cys Thr Tyr Gly Cys Thr Gly Pro
305 310 315 320 Gly Leu Glu Gly Cys Pro Thr Asn Gly Pro Lys Ile Pro
Ser Ile Ala 325 330 335 Thr Gly Met Val Gly Ala Leu Leu Leu Leu Leu
Val Val Ala Leu Gly 340 345 350 Ile Gly Leu Phe Met Arg Ala Lys Arg
Gly Ser Gly Ala Thr Asn Phe 355 360 365 Ser Leu Leu Lys Gln Ala Gly
Asp Val Glu Glu Asn Pro Gly Pro Met 370 375 380 Ala Leu Pro Val Thr
Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu His 385 390 395 400 Ala Ala
Arg Pro Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser 405 410 415
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp 420
425 430 Ile Arg Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala
Pro 435 440 445 Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu Glu Ser Gly
Val Pro Ser 450 455 460 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr
Thr Leu Thr Ile Ser 465 470 475 480 Ser Leu Gln Pro Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Gly Asn 485 490 495 Thr Leu Pro Trp Thr Phe
Gly Gln Gly Thr Lys Val Glu Ile Lys Gly 500 505 510 Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val 515 520 525 Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu 530 535 540
Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Thr Met 545
550 555 560 Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
Ala Leu 565 570 575 Ile Asn Pro Tyr Lys Gly Val Ser Thr Tyr Asn Gln
Lys Phe Lys Asp 580 585 590 Arg Phe Thr Ile Ser Val Asp Lys Ser Lys
Asn Thr Ala Tyr Leu Gln 595 600 605 Met Asn Ser Leu Arg Ala Glu Asp
Thr Ala Val Tyr Tyr Cys Ala Arg 610 615 620 Ser Gly Tyr Tyr Gly Asp
Ser Asp Trp Tyr Phe Asp Val Trp Gly Gln 625 630 635 640 Gly Thr Leu
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 645 650 655 Gly
Ser Gly Gly Gly Gly Ser Glu Val Lys Leu Gln Glu Ser Gly Pro 660 665
670 Gly Leu Val Ala Pro Ser Gln Ser Leu Ser Val Thr Cys Thr Val Ser
675 680 685 Gly Val Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln
Pro Pro
690 695 700 Arg Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Gly Ser Glu
Thr Thr 705 710 715 720 Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu Thr
Ile Ile Lys Asp Asn 725 730 735 Ser Lys Ser Gln Val Phe Leu Lys Met
Asn Ser Leu Gln Thr Asp Asp 740 745 750 Thr Ala Ile Tyr Tyr Cys Ala
Lys His Tyr Tyr Tyr Gly Gly Ser Tyr 755 760 765 Ala Met Asp Tyr Trp
Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly 770 775 780 Ser Thr Ser
Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys 785 790 795 800
Gly Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu 805
810 815 Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser
Lys 820 825 830 Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val
Lys Leu Leu 835 840 845 Ile Tyr His Thr Ser Arg Leu His Ser Gly Val
Pro Ser Arg Phe Ser 850 855 860 Gly Ser Gly Ser Gly Thr Asp Tyr Ser
Leu Thr Ile Ser Asn Leu Glu 865 870 875 880 Gln Glu Asp Ile Ala Thr
Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro 885 890 895 Tyr Thr Phe Gly
Gly Gly Thr Lys Leu Glu Ile Thr Ala Ala Ala Asp 900 905 910 Tyr Lys
Asp Asp Asp Asp Lys Ile Glu Val Met Tyr Pro Pro Pro Tyr 915 920 925
Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys 930
935 940 His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
Trp 945 950 955 960 Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr
Ser Leu Leu Val 965 970 975 Thr Val Ala Phe Ile Ile Phe Trp Val Arg
Ser Lys Arg Ser Arg Leu 980 985 990 Leu His Ser Asp Tyr Met Asn Met
Thr Pro Arg Arg Pro Gly Pro Thr 995 1000 1005 Arg Lys His Tyr Gln
Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala 1010 1015 1020 Tyr Arg Ser
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala 1025 1030 1035 Tyr
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly 1040 1045
1050 Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp
1055 1060 1065 Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln
Glu Gly 1070 1075 1080 Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
Glu Ala Tyr Ser 1085 1090 1095 Glu Ile Gly Met Lys Gly Glu Arg Arg
Arg Gly Lys Gly His Asp 1100 1105 1110 Gly Leu Tyr Gln Gly Leu Ser
Thr Ala Thr Lys Asp Thr Tyr Asp 1115 1120 1125 Ala Leu His Met Gln
Ala Leu Pro Pro Arg 1130 1135 <210> SEQ ID NO 4 <211>
LENGTH: 3417 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polynucleotide
<400> SEQUENCE: 4 atgctgctgc tcgtgacatc cctcttatta tgcgaactcc
ctcaccccgc ttttctgctg 60 atccccagaa aggtgtgcaa cggcatcggc
attggagagt tcaaggattc tttaagcatc 120 aacgctacca acatcaaaca
tttcaagaac tgtacctcca tttccggcga tttacacatc 180 ctccccgttg
cctttcgtgg cgatagcttc acacacacac cccctctgga ccctcaagaa 240
ctggacattt taaagaccgt gaaggagatc actggttttt tactgatcca agcttggccc
300 gaaaatagga cagatctcca cgctttcgag aatttagaga tcattcgtgg
cagaaccaag 360 cagcacggac agttctcttt agccgtcgtg tctttaaata
tcacctcttt aggtttaaga 420 tctttaaaag agatcagcga tggcgacgtc
atcatctccg gcaacaagaa cctctgttac 480 gccaacacca ttaattggaa
aaagctgttt ggcacctccg gacagaagac caagatcatc 540 agcaacagag
gcgagaacag ctgcaaagct accggccaag tttgccacgc tctgtgtagc 600
cccgaaggct gctggggacc cgaacctcgt gactgtgtga gctgtaggaa cgtgtctcgt
660 ggtcgtgagt gtgtggataa gtgcaattta ctcgagggcg agcccagaga
gtttgtggaa 720 aatagcgagt gcatccagtg ccaccccgaa tgtctgcccc
aagctatgaa cattacttgt 780 actggtcgtg gccccgataa ctgtatccag
tgcgctcact acattgacgg cccccactgc 840 gtcaagacat gccccgctgg
cgtgatggga gaaaacaaca cactggtgtg gaagtatgcc 900 gatgccggcc
acgtctgtca tctgtgccac cctaactgta cctacggctg taccggaccc 960
ggactggagg gctgtcccac caacggaccc aagatcccta gcatcgccac cggcatggtg
1020 ggagccttac tgctgttact ggtggtggct ctgggcattg gtttattcat
gagggccaag 1080 agaggatccg gcgccaccaa cttttcttta ctgaaacaag
ctggagacgt cgaggaaaac 1140 cccggaccca tggctctccc cgtgacagct
ctgctgctgc ctctcgcttt attactgcac 1200 gccgctaggc ccgatattca
gatgacccaa agccctagct ctttatccgc cagcgtcgga 1260 gatagagtca
caatcacttg tagagccagc caagatattc gtaattatct caactggtac 1320
cagcagaagc ccggtaaagc ccccaagctg ctcatctatt acacctctcg tctggagagc
1380 ggcgtgcctt ccagattcag cggctccggc agcggcaccg actatacact
caccattagc 1440 tctttacagc ccgaagattt cgctacctac tactgccagc
aaggtaatac tttaccttgg 1500 accttcggcc aaggtaccaa ggtcgaaatc
aagggcggcg gcggatccgg cggcggtgga 1560 tctggtggcg gcggctccga
agtccagctg gtcgaatccg gaggcggact ggtccagccc 1620 ggtggatccc
tcagactgag ctgcgccgct agcggctatt ccttcaccgg ctacaccatg 1680
aactgggtga gacaagctcc cggcaaagga ctggaatggg tggccctcat caacccctac
1740 aagggcgtgt ccacatataa tcaaaagttt aaggacagat tcaccatcag
cgtcgacaag 1800 tccaagaaca ccgcttattt acagatgaac tctttaagag
ctgaggatac cgccgtgtac 1860 tattgtgcta ggtccggcta ctacggcgac
agcgactggt attttgacgt ctggggacaa 1920 ggtaccctcg tgacagtgag
cagcggcggt ggcggttctg gcggcggagg ctccggagga 1980 ggcggcagcg
aggtgaagct gcaagaaagc ggacccggtc tcgtggctcc ctcccaatct 2040
ttatccgtga cttgtaccgt gtccggagtc tctttacccg actacggcgt gagctggatt
2100 agacagcccc ccagaaaagg tttagagtgg ctgggcgtga tctggggatc
cgagaccaca 2160 tactacaaca gcgctttaaa gtctcgtctg acaatcatca
aagacaattc caaaagccaa 2220 gttttcctca agatgaactc tttacagacc
gacgacacag ccatttacta ctgcgccaag 2280 cattattact acggcggcag
ctacgctatg gactactggg gccaaggtac aagcgtcaca 2340 gtgagctccg
gcagcacatc cggaagcgga aagcccggca gcggagaggg cagcacaaag 2400
ggagacatcc agatgaccca gaccacctcc tctttaagcg cctctttagg agatagggtg
2460 accattagct gcagagcctc ccaagacatc agcaagtatc tcaattggta
ccagcaaaag 2520 cccgatggca ccgtcaagct gctgatctac cacacctctc
gtctccattc cggcgtgccc 2580 agcagattta gcggaagcgg atccggaaca
gactattctt taacaatcag caatttagag 2640 caagaagaca tcgccacata
tttctgccaa caaggtaaca ctttacccta caccttcgga 2700 ggcggcacca
aactggagat tacagcggcc gcagactaca aagacgatga cgacaagatt 2760
gaagttatgt atcctcctcc ttacctagac aatgagaaga gcaatggaac cattatccat
2820 gtgaaaggga aacacctttg tccaagtccc ctatttcccg gaccttctaa
gcccttttgg 2880 gtgctggtgg tggttggggg agtcctggct tgctatagct
tgctagtaac agtggccttt 2940 attattttct gggtgaggag taagaggagc
aggctcctgc acagtgacta catgaacatg 3000 actccccgcc gccccgggcc
cacccgcaag cattaccagc cctatgcccc accacgcgac 3060 ttcgcagcct
atcgctccag agtgaagttc agcaggagcg cagacgcccc cgcgtaccag 3120
cagggccaga accagctcta taacgagctc aatctaggac gaagagagga gtacgatgtt
3180 ttggacaaga gacgtggccg ggaccctgag atggggggaa agccgagaag
gaagaaccct 3240 caggaaggcc tgtacaatga actgcagaaa gataagatgg
cggaggccta cagtgagatt 3300 gggatgaaag gcgagcgccg gaggggcaag
gggcacgatg gcctttacca gggtctcagt 3360 acagccacca aggacaccta
cgacgccctt cacatgcagg ccctgccccc tcgctaa 3417 <210> SEQ ID NO
5 <211> LENGTH: 20 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide <400> SEQUENCE: 5 tgtgctagac atgaggtcta 20
<210> SEQ ID NO 6 <400> SEQUENCE: 6 000 <210> SEQ
ID NO 7 <211> LENGTH: 157 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 7 Met Gly Thr Ser Leu Leu Cys Trp
Met Ala Leu Cys Leu Leu Gly Ala 1 5 10 15 Asp His Ala Asp Ala Cys
Pro Tyr Ser Asn Pro Ser Leu Cys Ser Gly 20 25 30
Gly Gly Gly Ser Glu Leu Pro Thr Gln Gly Thr Phe Ser Asn Val Ser 35
40 45 Thr Asn Val Ser Pro Ala Lys Pro Thr Thr Thr Ala Cys Pro Tyr
Ser 50 55 60 Asn Pro Ser Leu Cys Ser Gly Gly Gly Gly Ser Pro Ala
Pro Arg Pro 65 70 75 80 Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro
Leu Ser Leu Arg Pro 85 90 95 Glu Ala Cys Arg Pro Ala Ala Gly Gly
Ala Val His Thr Arg Gly Leu 100 105 110 Asp Phe Ala Cys Asp Ile Tyr
Ile Trp Ala Pro Leu Ala Gly Thr Cys 115 120 125 Gly Val Leu Leu Leu
Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg 130 135 140 Asn Arg Arg
Arg Val Cys Lys Cys Pro Arg Pro Val Val 145 150 155 <210> SEQ
ID NO 8 <211> LENGTH: 534 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polynucleotide <400> SEQUENCE: 8 atgggcacct ctctgctgtg
ctggatggct ctgtgtctgc tgggcgctga ccatgctgat 60 gcttgcccct
attccaaccc ctctctgtgc tccggaggag gaggatccga actgcctacc 120
caaggcacct tcagcaacgt gtccaccaac gtgagccccg ctaagcctac caccaccgct
180 tgcccttact ccaatcccag cctctgctcc ggaggcggag gatcccccgc
ccccagacct 240 cctacacccg ctcccacaat cgccagccag cctctgtctc
tgagacccga agcttgcaga 300 cccgctgccg gaggagctgt gcatacaaga
ggactggatt tcgcttgcga catctacatc 360 tgggcccctc tggctggcac
atgtggcgtg ctgctgctgt ctctggtcat tacactgtac 420 tgcaaccata
gaaatagaag aagggtgtgc aagtgtccca gacccgtggt gggcagcgga 480
gaaggaagag gctctctgct gacatgcgga gacgtggaag agaaccccgg cccc 534
<210> SEQ ID NO 9 <211> LENGTH: 497 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 9 Met Leu Leu Leu Val
Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro 1 5 10 15 Ala Phe Leu
Leu Ile Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser 20 25 30 Leu
Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser 35 40
45 Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly
50 55 60 Thr Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser
Gly Val 65 70 75 80 Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
Tyr Ser Leu Thr 85 90 95 Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala
Thr Tyr Phe Cys Gln Gln 100 105 110 Gly Asn Thr Leu Pro Tyr Thr Phe
Gly Gly Gly Thr Lys Leu Glu Ile 115 120 125 Thr Gly Ser Thr Ser Gly
Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser 130 135 140 Thr Lys Gly Glu
Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala 145 150 155 160 Pro
Ser Gln Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu 165 170
175 Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu
180 185 190 Glu Trp Leu Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr
Asn Ser 195 200 205 Ala Leu Lys Ser Arg Leu Thr Ile Ile Lys Asp Asn
Ser Lys Ser Gln 210 215 220 Val Phe Leu Lys Met Asn Ser Leu Gln Thr
Asp Asp Thr Ala Ile Tyr 225 230 235 240 Tyr Cys Ala Lys His Tyr Tyr
Tyr Gly Gly Ser Tyr Ala Met Asp Tyr 245 250 255 Trp Gly Gln Gly Thr
Ser Val Thr Val Ser Ser Ala Ala Ala Asp Tyr 260 265 270 Lys Asp Asp
Asp Asp Lys Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu 275 280 285 Asp
Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His 290 295
300 Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val
305 310 315 320 Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu
Leu Val Thr 325 330 335 Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys
Arg Ser Arg Leu Leu 340 345 350 His Ser Asp Tyr Met Asn Met Thr Pro
Arg Arg Pro Gly Pro Thr Arg 355 360 365 Lys His Tyr Gln Pro Tyr Ala
Pro Pro Arg Asp Phe Ala Ala Tyr Arg 370 375 380 Ser Arg Val Lys Phe
Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln 385 390 395 400 Gly Gln
Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu 405 410 415
Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly 420
425 430 Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
Gln 435 440 445 Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met
Lys Gly Glu 450 455 460 Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr
Gln Gly Leu Ser Thr 465 470 475 480 Ala Thr Lys Asp Thr Tyr Asp Ala
Leu His Met Gln Ala Leu Pro Pro 485 490 495 Arg <210> SEQ ID
NO 10 <211> LENGTH: 1491 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polynucleotide <400> SEQUENCE: 10 atgcttctcc tggtgacaag
ccttctgctc tgtgagttac cacacccagc attcctcctg 60 atcccagaca
tccagatgac acagactaca tcctccctgt ctgcctctct gggagacaga 120
gtcaccatca gttgcagggc aagtcaggac attagtaaat atttaaattg gtatcagcag
180 aaaccagatg gaactgttaa actcctgatc taccatacat caagattaca
ctcaggagtc 240 ccatcaaggt tcagtggcag tgggtctgga acagattatt
ctctcaccat tagcaacctg 300 gagcaagaag atattgccac ttacttttgc
caacagggta atacgcttcc gtacacgttc 360 ggagggggga ctaagttgga
aataacaggc tccacctctg gatccggcaa gcccggatct 420 ggcgagggat
ccaccaaggg cgaggtgaaa ctgcaggagt caggacctgg cctggtggcg 480
ccctcacaga gcctgtccgt cacatgcact gtctcagggg tctcattacc cgactatggt
540 gtaagctgga ttcgccagcc tccacgaaag ggtctggagt ggctgggagt
aatatggggt 600 agtgaaacca catactataa ttcagctctc aaatccagac
tgaccatcat caaggacaac 660 tccaagagcc aagttttctt aaaaatgaac
agtctgcaaa ctgatgacac agccatttac 720 tactgtgcca aacattatta
ctacggtggt agctatgcta tggactactg gggtcaagga 780 acctcagtca
ccgtctcctc agcggccgca gactacaaag acgatgacga caagattgaa 840
gttatgtatc ctcctcctta cctagacaat gagaagagca atggaaccat tatccatgtg
900 aaagggaaac acctttgtcc aagtccccta tttcccggac cttctaagcc
cttttgggtg 960 ctggtggtgg ttgggggagt cctggcttgc tatagcttgc
tagtaacagt ggcctttatt 1020 attttctggg tgaggagtaa gaggagcagg
ctcctgcaca gtgactacat gaacatgact 1080 ccccgccgcc ccgggcccac
ccgcaagcat taccagccct atgccccacc acgcgacttc 1140 gcagcctatc
gctccagagt gaagttcagc aggagcgcag acgcccccgc gtaccagcag 1200
ggccagaacc agctctataa cgagctcaat ctaggacgaa gagaggagta cgatgttttg
1260 gacaagagac gtggccggga ccctgagatg gggggaaagc cgagaaggaa
gaaccctcag 1320 gaaggcctgt acaatgaact gcagaaagat aagatggcgg
aggcctacag tgagattggg 1380 atgaaaggcg agcgccggag gggcaagggg
cacgatggcc tttaccaggg tctcagtaca 1440 gccaccaagg acacctacga
cgcccttcac atgcaggccc tgccccctcg c 1491 <210> SEQ ID NO 11
<211> LENGTH: 395 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 11 Met Asp Trp Thr Trp Ile Leu
Phe Leu Val Ala Ala Ala Thr Arg Val 1 5 10 15 His Ser Asn Trp Val
Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp 20 25 30 Leu Ile Gln
Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp 35 40 45 Val
His Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu 50 55
60 Leu Gln Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr
65 70 75 80 Val Glu Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser
Asn Gly
85 90 95 Asn Val Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu
Glu Lys 100 105 110 Asn Ile Lys Glu Phe Leu Gln Ser Phe Val His Ile
Val Gln Met Phe 115 120 125 Ile Asn Thr Ser Ser Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly 130 135 140 Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Ser Leu Gln Ile Thr 145 150 155 160 Cys Pro Pro Pro Met
Ser Val Glu His Ala Asp Ile Trp Val Lys Ser 165 170 175 Tyr Ser Leu
Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly Phe Lys 180 185 190 Arg
Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn Lys Ala 195 200
205 Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile Arg Asp
210 215 220 Pro Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser Thr Val
Thr Thr 225 230 235 240 Ala Gly Val Thr Pro Gln Pro Glu Ser Leu Ser
Pro Ser Gly Lys Glu 245 250 255 Pro Ala Ala Ser Ser Pro Ser Ser Asn
Asn Thr Ala Ala Thr Thr Ala 260 265 270 Ala Ile Val Pro Gly Ser Gln
Leu Met Pro Ser Lys Ser Pro Ser Thr 275 280 285 Gly Thr Thr Glu Ile
Ser Ser His Glu Ser Ser His Gly Thr Pro Ser 290 295 300 Gln Thr Thr
Ala Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser His Gln 305 310 315 320
Pro Pro Gly Val Tyr Pro Gln Gly His Ser Asp Thr Thr Val Ala Ile 325
330 335 Ser Thr Ser Thr Val Leu Leu Cys Gly Leu Ser Ala Val Ser Leu
Leu 340 345 350 Ala Cys Tyr Leu Lys Ser Arg Gln Thr Pro Pro Leu Ala
Ser Val Glu 355 360 365 Met Glu Ala Met Glu Ala Leu Pro Val Thr Trp
Gly Thr Ser Ser Arg 370 375 380 Asp Glu Asp Leu Glu Asn Cys Ser His
His Leu 385 390 395 <210> SEQ ID NO 12 <211> LENGTH:
1188 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polynucleotide
<400> SEQUENCE: 12 atggattgga cttggatttt gttcctcgtt
gccgcagcga ctcgcgtcca tagtaattgg 60 gtgaacgtaa ttagtgactt
gaaaaaaatt gaggacctta tacaaagtat gcatatcgat 120 gcaacactgt
acacggagtc cgacgtgcac ccaagctgca aggtcaccgc aatgaaatgc 180
tttttgctcg aattgcaagt tatctcactt gagtcagggg acgcttcaat ccatgatact
240 gtggagaatt tgataatcct ggcgaacaat agccttagtt caaatggcaa
cgtcactgag 300 tcaggctgca aggaatgtga ggaattggaa gaaaaaaata
tcaaggaatt tttgcaatct 360 tttgttcaca tagttcagat gttcattaac
actagttccg ggggcggcag tggaggtggc 420 ggtagcggcg ggggtggctc
tggtggaggc ggctctgggg gcggaagtct gcagataaca 480 tgccccccac
ctatgagtgt tgaacatgct gatatctggg ttaaatctta ctccctttac 540
agtcgagaaa ggtacatttg caactccggc tttaaacgca aagccgggac tagttcactg
600 actgaatgtg tattgaataa agcgacaaat gtcgcacact ggactacccc
ttccctcaaa 660 tgcattcgcg atcctgcctt ggtgcatcag cgaccagcac
cgccgtccac ggtaactacc 720 gcaggagtaa caccgcagcc cgagagcctt
tccccctcag gcaaagagcc ggccgcatcc 780 tccccatctt ccaataatac
cgcagctacc accgcagcaa tcgtacccgg gtcccagctg 840 atgcccagca
aaagtccgag tactggaacg actgaaatct ccagtcacga gtcttctcat 900
ggaactccga gtcaaactac agcaaagaat tgggagctga ctgcttccgc ttcacaccag
960 ccgccaggcg tttatcctca gggacactca gataccacgg tggcgattag
cacaagcacc 1020 gtcctcctgt gtgggctgag tgcagtgtca cttctcgcct
gctaccttaa gtccagacag 1080 acaccccctt tggcaagcgt tgaaatggaa
gccatggaag ccttgcctgt cacatggggg 1140 acttcatccc gcgatgaaga
cttggagaac tgctcacacc atctttga 1188 <210> SEQ ID NO 13
<211> LENGTH: 177 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 13 Met Phe His Val Ser Phe Arg
Tyr Ile Phe Gly Leu Pro Pro Leu Ile 1 5 10 15 Leu Val Leu Leu Pro
Val Ala Ser Ser Asp Cys Asp Ile Glu Gly Lys 20 25 30 Asp Gly Lys
Gln Tyr Glu Ser Val Leu Met Val Ser Ile Asp Gln Leu 35 40 45 Leu
Asp Ser Met Lys Glu Ile Gly Ser Asn Cys Leu Asn Asn Glu Phe 50 55
60 Asn Phe Phe Lys Arg His Ile Cys Asp Ala Asn Lys Glu Gly Met Phe
65 70 75 80 Leu Phe Arg Ala Ala Arg Lys Leu Arg Gln Phe Leu Lys Met
Asn Ser 85 90 95 Thr Gly Asp Phe Asp Leu His Leu Leu Lys Val Ser
Glu Gly Thr Thr 100 105 110 Ile Leu Leu Asn Cys Thr Gly Gln Val Lys
Gly Arg Lys Pro Ala Ala 115 120 125 Leu Gly Glu Ala Gln Pro Thr Lys
Ser Leu Glu Glu Asn Lys Ser Leu 130 135 140 Lys Glu Gln Lys Lys Leu
Asn Asp Leu Cys Phe Leu Lys Arg Leu Leu 145 150 155 160 Gln Glu Ile
Lys Thr Cys Trp Asn Lys Ile Leu Met Gly Thr Lys Glu 165 170 175 His
<210> SEQ ID NO 14 <211> LENGTH: 614 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polynucleotide <400> SEQUENCE: 14 gaattcggca
gcggcgtcaa gcagacactg aacttcgatc tgctgaagct ggccggagac 60
gtcgagagca accccggccc tatgttccac gtgagcttta gatacatctt cggactgccc
120 cctctgattc tggtgctgct gcccgtggcc agcagcgact gcgatatcga
gggcaaggac 180 ggcaagcagt atgagtccgt gctgatggtc tccatcgatc
agctgctgga cagcatgaag 240 gagatcggct ccaactgcct caacaacgag
ttcaactttt tcaagaggca catctgcgac 300 gccaacaagg agggcatgtt
tctgtttaga gccgctagaa agctgaggca gtttctgaag 360 atgaacagca
ccggcgactt tgatctgcat ctgctgaaag tgagcgaggg caccaccatt 420
ctgctgaact gcaccggcca agtgaaagga agaaagcccg ccgctctggg cgaggctcag
480 cctaccaagt ctctggaaga gaacaagtct ctgaaggagc agaagaagct
caacgatctg 540 tgcttcctca agaggctgct gcaagagatc aagacatgct
ggaacaagat cctcatgggc 600 accaaggaac actg 614 <210> SEQ ID NO
15 <211> LENGTH: 513 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 15 Met Leu Val Arg Arg Gly Ala
Arg Ala Gly Pro Arg Met Pro Arg Gly 1 5 10 15 Trp Thr Ala Leu Cys
Leu Leu Ser Leu Leu Pro Ser Gly Phe Met Ser 20 25 30 Leu Asp Asn
Asn Gly Thr Ala Thr Pro Glu Leu Pro Thr Gln Gly Thr 35 40 45 Phe
Ser Asn Val Ser Thr Asn Val Ser Tyr Gln Glu Thr Thr Thr Pro 50 55
60 Ser Thr Leu Gly Ser Thr Ser Leu His Pro Val Ser Gln His Gly Asn
65 70 75 80 Glu Ala Thr Thr Asn Ile Thr Glu Thr Thr Val Lys Phe Thr
Ser Thr 85 90 95 Ser Val Ile Thr Ser Val Tyr Gly Asn Thr Asn Ser
Ser Val Gln Ser 100 105 110 Gln Thr Ser Val Ile Ser Thr Val Phe Thr
Thr Pro Ala Asn Val Ser 115 120 125 Thr Pro Glu Thr Thr Leu Lys Pro
Ser Leu Ser Pro Gly Asn Val Ser 130 135 140 Asp Leu Ser Thr Thr Ser
Thr Ser Leu Ala Thr Ser Pro Thr Lys Pro 145 150 155 160 Tyr Thr Ser
Ser Ser Pro Ile Leu Ser Asp Ile Lys Ala Glu Ile Lys 165 170 175 Cys
Ser Gly Ile Arg Glu Val Lys Leu Thr Gln Gly Ile Cys Leu Glu 180 185
190 Gln Asn Lys Thr Ser Ser Cys Ala Glu Phe Lys Lys Asp Arg Gly Glu
195 200 205 Gly Leu Ala Arg Val Leu Cys Gly Glu Glu Gln Ala Asp Ala
Asp Ala 210 215 220 Gly Ala Gln Val Cys Ser Leu Leu Leu Ala Gln Ser
Glu Val Arg Pro 225 230 235 240 Gln Cys Leu Leu Leu Val Leu Ala Asn
Arg Thr Glu Ile Ser Ser Lys 245 250 255
Leu Gln Leu Met Lys Lys His Gln Ser Asp Leu Lys Lys Leu Gly Ile 260
265 270 Leu Asp Phe Thr Glu Gln Asp Val Ala Ser His Gln Ser Tyr Ser
Gln 275 280 285 Lys Thr Pro Ile Leu Leu Thr Cys Pro Thr Ile Ser Ile
Leu Ser Phe 290 295 300 Phe Ser Val Ala Leu Leu Val Ile Leu Ala Cys
Val Leu Trp Lys Lys 305 310 315 320 Arg Ile Lys Pro Ile Val Trp Pro
Ser Leu Pro Asp His Lys Lys Thr 325 330 335 Leu Glu His Leu Cys Lys
Lys Pro Arg Lys Asn Leu Asn Val Ser Phe 340 345 350 Asn Pro Glu Ser
Phe Leu Asp Cys Gln Ile His Arg Val Asp Asp Ile 355 360 365 Gln Ala
Arg Asp Glu Val Glu Gly Phe Leu Gln Asp Thr Phe Pro Gln 370 375 380
Gln Leu Glu Glu Ser Glu Lys Gln Arg Leu Gly Gly Asp Val Gln Ser 385
390 395 400 Pro Asn Cys Pro Ser Glu Asp Val Val Ile Thr Pro Glu Ser
Phe Gly 405 410 415 Arg Asp Ser Ser Leu Thr Cys Leu Ala Gly Asn Val
Ser Ala Cys Asp 420 425 430 Ala Pro Ile Leu Ser Ser Ser Arg Ser Leu
Asp Cys Arg Glu Ser Gly 435 440 445 Lys Asn Gly Pro His Val Tyr Gln
Asp Leu Leu Leu Ser Leu Gly Thr 450 455 460 Thr Asn Ser Thr Leu Pro
Pro Pro Phe Ser Leu Gln Ser Gly Ile Leu 465 470 475 480 Thr Leu Asn
Pro Val Ala Gln Gly Gln Pro Ile Leu Thr Ser Leu Gly 485 490 495 Ser
Asn Gln Glu Glu Ala Tyr Val Thr Met Ser Ser Phe Tyr Gln Asn 500 505
510 Gln <210> SEQ ID NO 16 <211> LENGTH: 1608
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polynucleotide <400> SEQUENCE:
16 ggaagcggcg ccacaaactt ttctctgctg aagcaagccg gcgacgtcga
agagaacccc 60 ggccctatgc tggtgaggag aggcgctagg gctggaccca
gaatgcccag aggctggacc 120 gctctgtgtc tgctgtctct gctgcccagc
ggcttcatga gcctcgataa taacggcacc 180 gctacccccg agctgcccac
acaaggcacc ttctccaatg tgagcaccaa cgtgtcctac 240 caagagacca
ccaccccttc cacactggga agcacatctc tgcatcccgt ctcccagcac 300
ggcaatgaag ccaccacaaa catcaccgag accaccgtga agttcaccag cacctccgtc
360 attaccagcg tgtacggcaa caccaatagc tccgtgcaaa gccagacatc
cgtgatttcc 420 accgtgttta ccacccccgc caatgtcagc acacccgaga
caacactgaa accttctctg 480 tcccccggaa acgtgagcga tctgagcaca
accagcacca gcctcgccac cagccccaca 540 aagccttaca caagcagcag
ccccattctg agcgacatca aggccgaaat caagtgctcc 600 ggaattagag
aggtcaagct gacccaagga atctgtctgg agcagaataa gaccagcagc 660
tgcgccgagt tcaagaaaga cagaggcgaa ggactggcca gagtgctctg cggcgaggaa
720 caagccgatg ccgatgccgg agctcaagtg tgcagcctcc tcctcgctca
gagcgaggtc 780 agaccccaat gtctgctgct cgtgctggcc aataggaccg
agatctcctc caaactgcag 840 ctgatgaaga agcaccagag cgacctcaag
aagctcggca tcctcgactt taccgagcaa 900 gacgtggcct cccatcaatc
ctatagccag aagaccccca ttctgctgac atgtcccaca 960 atcagcatcc
tcagcttctt cagcgtcgct ctgctcgtca ttctggcttg tgtgctgtgg 1020
aagaagagga tcaagcctat tgtgtggccc tctctgcccg accacaagaa gaccctcgaa
1080 cacctctgca agaaacctag aaagaacctc aacgtgagct tcaaccccga
gtcctttctg 1140 gactgtcaaa tccatagggt ggatgacatc caagctagag
acgaggtcga gggctttctg 1200 caagacacct tccctcagca gctggaagaa
agcgagaagc aaagactggg cggagatgtg 1260 cagtccccta attgcccctc
cgaggacgtg gtgattaccc ccgagagctt cggaagagac 1320 agctctctga
catgtctggc cggaaatgtg tccgcttgcg atgcccctat tctgagcagc 1380
tccagatctc tggactgcag agagtccggc aagaacggcc ctcatgtgta ccaagatctg
1440 ctgctgtctc tgggaaccac aaactccaca ctgcctcccc cctttagcct
ccagtccggc 1500 attctgacac tgaaccccgt ggctcaaggc caacctatcc
tcacatccct cggctccaat 1560 caagaggaag cctacgtgac catgagctcc
ttctatcaga accagtga 1608 <210> SEQ ID NO 17 <211>
LENGTH: 635 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 17 Met Ala Leu Pro Val Thr Ala Leu Leu Leu
Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Asp Cys Asp
Ile Glu Gly Lys Asp Gly Lys Gln 20 25 30 Tyr Glu Ser Val Leu Met
Val Ser Ile Asp Gln Leu Leu Asp Ser Met 35 40 45 Lys Glu Ile Gly
Ser Asn Cys Leu Asn Asn Glu Phe Asn Phe Phe Lys 50 55 60 Arg His
Ile Cys Asp Ala Asn Lys Glu Gly Met Phe Leu Phe Arg Ala 65 70 75 80
Ala Arg Lys Leu Arg Gln Phe Leu Lys Met Asn Ser Thr Gly Asp Phe 85
90 95 Asp Leu His Leu Leu Lys Val Ser Glu Gly Thr Thr Ile Leu Leu
Asn 100 105 110 Cys Thr Gly Gln Val Lys Gly Arg Lys Pro Ala Ala Leu
Gly Glu Ala 115 120 125 Gln Pro Thr Lys Ser Leu Glu Glu Asn Lys Ser
Leu Lys Glu Gln Lys 130 135 140 Lys Leu Asn Asp Leu Cys Phe Leu Lys
Arg Leu Leu Gln Glu Ile Lys 145 150 155 160 Thr Cys Trp Asn Lys Ile
Leu Met Gly Thr Lys Glu His Gly Gly Gly 165 170 175 Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 180 185 190 Gly Gly
Gly Ser Glu Ser Gly Tyr Ala Gln Asn Gly Asp Leu Glu Asp 195 200 205
Ala Glu Leu Asp Asp Tyr Ser Phe Ser Cys Tyr Ser Gln Leu Glu Val 210
215 220 Asn Gly Ser Gln His Ser Leu Thr Cys Ala Phe Glu Asp Pro Asp
Val 225 230 235 240 Asn Ile Thr Asn Leu Glu Phe Glu Ile Cys Gly Ala
Leu Val Glu Val 245 250 255 Lys Cys Leu Asn Phe Arg Lys Leu Gln Glu
Ile Tyr Phe Ile Glu Thr 260 265 270 Lys Lys Phe Leu Leu Ile Gly Lys
Ser Asn Ile Cys Val Lys Val Gly 275 280 285 Glu Lys Ser Leu Thr Cys
Lys Lys Ile Asp Leu Thr Thr Ile Val Lys 290 295 300 Pro Glu Ala Pro
Phe Asp Leu Ser Val Val Tyr Arg Glu Gly Ala Asn 305 310 315 320 Asp
Phe Val Val Thr Phe Asn Thr Ser His Leu Gln Lys Lys Tyr Val 325 330
335 Lys Val Leu Met His Asp Val Ala Tyr Arg Gln Glu Lys Asp Glu Asn
340 345 350 Lys Trp Thr His Val Asn Leu Ser Ser Thr Lys Leu Thr Leu
Leu Gln 355 360 365 Arg Lys Leu Gln Pro Ala Ala Met Tyr Glu Ile Lys
Val Arg Ser Ile 370 375 380 Pro Asp His Tyr Phe Lys Gly Phe Trp Ser
Glu Trp Ser Pro Ser Tyr 385 390 395 400 Tyr Phe Arg Thr Pro Glu Ile
Asn Asn Ser Ser Gly Glu Met Asp Pro 405 410 415 Ile Leu Leu Thr Ile
Ser Ile Leu Ser Phe Phe Ser Val Ala Leu Leu 420 425 430 Val Ile Leu
Ala Cys Val Leu Trp Lys Lys Arg Ile Lys Pro Ile Val 435 440 445 Trp
Pro Ser Leu Pro Asp His Lys Lys Thr Leu Glu His Leu Cys Lys 450 455
460 Lys Pro Arg Lys Asn Leu Asn Val Ser Phe Asn Pro Glu Ser Phe Leu
465 470 475 480 Asp Cys Gln Ile His Arg Val Asp Asp Ile Gln Ala Arg
Asp Glu Val 485 490 495 Glu Gly Phe Leu Gln Asp Thr Phe Pro Gln Gln
Leu Glu Glu Ser Glu 500 505 510 Lys Gln Arg Leu Gly Gly Asp Val Gln
Ser Pro Asn Cys Pro Ser Glu 515 520 525 Asp Val Val Ile Thr Pro Glu
Ser Phe Gly Arg Asp Ser Ser Leu Thr 530 535 540 Cys Leu Ala Gly Asn
Val Ser Ala Cys Asp Ala Pro Ile Leu Ser Ser 545 550 555 560 Ser Arg
Ser Leu Asp Cys Arg Glu Ser Gly Lys Asn Gly Pro His Val 565 570 575
Tyr Gln Asp Leu Leu Leu Ser Leu Gly Thr Thr Asn Ser Thr Leu Pro 580
585 590 Pro Pro Phe Ser Leu Gln Ser Gly Ile Leu Thr Leu Asn Pro Val
Ala 595 600 605 Gln Gly Gln Pro Ile Leu Thr Ser Leu Gly Ser Asn Gln
Glu Glu Ala 610 615 620 Tyr Val Thr Met Ser Ser Phe Tyr Gln Asn Gln
625 630 635 <210> SEQ ID NO 18
<211> LENGTH: 1905 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polynucleotide <400> SEQUENCE: 18 atggctctgc ctgttacagc
tctgctgctg cctctggctc tgcttctgca tgccgccaga 60 cctgactgtg
acatcgaggg caaagacggc aagcagtacg agagcgtgct gatggtgtcc 120
atcgaccagc tgctggacag catgaaggaa atcggcagca actgcctgaa caacgagttc
180 aacttcttca agcggcacat ctgcgacgcc aacaaagaag gcatgttcct
gttcagagcc 240 gccagaaagc tgcggcagtt cctgaagatg aacagcaccg
gcgacttcga cctgcatctg 300 ctgaaagtgt ctgagggcac caccatcctg
ctgaattgca ccggccaagt gaagggcaga 360 aagcctgctg ctctgggaga
agcccagcct accaagagcc tggaagagaa caagtccctg 420 aaagagcaga
agaagctgaa cgacctctgc ttcctgaagc ggctgctgca agagatcaag 480
acctgctgga acaagatcct gatgggcacc aaagagcacg gcggaggatc tggcggaggt
540 ggaagcggcg gaggcggtag cggtggcgga ggaagtggtg gcggatctga
atctggctac 600 gcccagaacg gcgacctgga agatgccgag ctggacgact
acagcttcag ctgctacagc 660 cagctggaag tgaacggcag ccagcactct
ctgacctgcg cctttgaaga tcccgacgtg 720 aacatcacca accttgagtt
cgagatttgt ggcgccctgg tggaagtcaa gtgcctgaat 780 ttccggaagc
tgcaagaaat ctactttatc gagacaaaga agttcctgct gatcggcaag 840
agcaacatct gtgtgaaagt gggcgagaaa agcctgacct gcaagaagat cgacctgacc
900 accatcgtga agcccgaggc tcctttcgat ctgagcgtgg tgtatagaga
gggcgccaac 960 gacttcgtgg tcaccttcaa caccagccac ctccaaaaga
aatacgtgaa ggtgctgatg 1020 cacgacgtgg cctaccggca agagaaggac
gagaacaaat ggacccacgt gaacctgagc 1080 agcaccaagc tgaccctgct
gcagagaaaa ctgcagcctg ccgctatgta cgagatcaaa 1140 gtgcggagca
tccccgacca ctactttaaa ggcttttgga gcgagtggtc ccctagctac 1200
tacttcagaa cccctgagat caacaactcc agcggcgaga tggaccccat tctgctgaca
1260 atcagcatcc tgagcttttt cagcgtggcc ctgctggtca tcctggcctg
tgtgctgtgg 1320 aagaagcgga tcaagcccat cgtgtggccc agcctgcctg
accacaagaa aaccctggaa 1380 cacctgtgca agaagccccg gaaaaacctg
aacgtgtcct tcaatcccga gagcttcctg 1440 gactgccaga tccacagagt
ggacgacatc caggccaggg acgaagtgga aggatttctg 1500 caggacacat
tccctcagca gctcgaagag agcgagaagc aaagactcgg aggcgacgtg 1560
cagagcccta attgcccttc tgaggacgtg gtcatcaccc cagagagctt cggcagagat
1620 agcagcctga catgtctggc cggcaatgtg tccgcctgtg atgcccctat
cctgtcctct 1680 agcagaagcc tggattgcag agagagcggc aagaacggcc
ctcacgtgta ccaggatctg 1740 ctcctgtctc tgggcaccac aaacagcaca
ctgcctccac cattcagcct gcagagcggc 1800 atcctgacac tgaaccctgt
tgctcagggc cagcctatcc tgacaagcct gggcagcaat 1860 caagaagagg
cctacgtcac catgagcagc ttctaccaga accag 1905 <210> SEQ ID NO
19 <400> SEQUENCE: 19 000 <210> SEQ ID NO 20
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide <400> SEQUENCE: 20 ttcggaaccc aatcactgac 20
<210> SEQ ID NO 21 <211> LENGTH: 20 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic oligonucleotide <400> SEQUENCE: 21 tcagggttct
ggatatctgt 20 <210> SEQ ID NO 22 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic oligonucleotide <400>
SEQUENCE: 22 aagttcctgt gatgtcaagc 20 <210> SEQ ID NO 23
<400> SEQUENCE: 23 000 <210> SEQ ID NO 24 <400>
SEQUENCE: 24 000 <210> SEQ ID NO 25 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic oligonucleotide <400>
SEQUENCE: 25 gaggtcaatg tctacggctc 20 <210> SEQ ID NO 26
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide <400> SEQUENCE: 26 atcacggagg tcaatgtcta 20
<210> SEQ ID NO 27 <211> LENGTH: 20 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic oligonucleotide <400> SEQUENCE: 27 gtagacattg
acctccgtga 20 <210> SEQ ID NO 28 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic oligonucleotide <400>
SEQUENCE: 28 ggagcaggtg atgttgacgg 20 <210> SEQ ID NO 29
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide <400> SEQUENCE: 29 caaagagatt acgaatgcct 20
<210> SEQ ID NO 30 <211> LENGTH: 20 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic oligonucleotide <400> SEQUENCE: 30 gtgccacaaa
gaccatcaag 20 <210> SEQ ID NO 31 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic oligonucleotide <400>
SEQUENCE: 31 agagggtcat cacacacaag 20 <210> SEQ ID NO 32
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide <400> SEQUENCE: 32 cttgtagata tcctgatcat 20
<210> SEQ ID NO 33
<400> SEQUENCE: 33 000 <210> SEQ ID NO 34 <211>
LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic oligonucleotide
<400> SEQUENCE: 34 gaggtcaatg tctacggctc 20 <210> SEQ
ID NO 35 <211> LENGTH: 1461 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polynucleotide <400> SEQUENCE: 35 atggcactcc ctgtaactgc
acttcttttg ccacttgcct tgctcctgca cgcagcgcgg 60 ccggacatcg
agctgaccca gagccccgcc atcatgagcg ccagcctggg cgaggagatc 120
accctgacct gcagcgccag cagcagcgtg agctacatgc actggtacca gcagaagagc
180 ggcaccagcc ccaagctgct gatctacagc accagcaacc tggccagcgg
cgtgcccagc 240 aggttcagcg gcagcggcag cggcaccttc tacagcctga
ccatcagcag cgtggaggcc 300 gaggacgccg ccgactacta ctgccaccag
tggagcagct acaccttcgg cggcggcacc 360 aagctggaga tcaagagggg
cggcggcggc agcggcggcg gcggcagcgg cggcggcggc 420 agccaggtga
agctgcagga gagcggcggc ggcctggtga agcccggcgg cagcctgaag 480
ctgagctgcg ccgccagcgg cttcaccttc agcagctacg ccatgagctg ggtgaggcag
540 acccccgaga agaggctgga gtgggtggcc accatcagca gcggcggcag
ctacacctac 600 taccccgaca gcgtgaaggg caggttcacc atcagcaggg
acaacgccaa gaacaccctg 660 tacctgcaga tgagcagcct gaggagcgag
gacaccgcca tgtactactg cgccaggcag 720 gacggctact accccggctg
gttcgccaac tggggccagg gcaccaccgt gaccgtgagc 780 agctccggaa
caacgacacc agcaccacgg ccacccactc ctgctccgac aattgcgtct 840
cagccccttt cccttcgacc cgaagcttgt cgccctgctg cgggaggagc ggtccacacg
900 cgcgggcttg acttcgcttg cgacatctac atttgggcac ccttggccgg
gacatgcggc 960 gtcttgctcc tgagtctggt tataacgctg tattgtaagc
gaggtcggaa gaagcttttg 1020 tatatcttta aacagccctt tatgaggccc
gtacaaacca cacaagagga ggatgggtgc 1080 tcatgcagat ttcctgaaga
ggaagagggc ggttgcgaac ttagagtcaa attcagccgc 1140 tccgcagatg
cacctgctta taaacagggt cagaatcaat tgtataatga acttaatctc 1200
gggaggcgcg aggagtatga tgtgctggac aagcgacggg gtcgagaccc agagatgggc
1260 ggtaaacccc gccgaaagaa cccccaggag ggactgtata atgagctgca
aaaggacaaa 1320 atggcagaag cctattccga aatagggatg aagggagagc
ggcggcgagg taagggacat 1380 gacggtcttt atcaaggtct tagtactgca
actaaggaca cctatgacgc gctgcatatg 1440 caggctctcc cacctagata a 1461
<210> SEQ ID NO 36 <211> LENGTH: 486 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 36 Met Ala Leu Pro Val
Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala
Arg Pro Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met 20 25 30 Ser
Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser 35 40
45 Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro
50 55 60 Lys Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val
Pro Ser 65 70 75 80 Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser
Leu Thr Ile Ser 85 90 95 Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr
Tyr Cys His Gln Trp Ser 100 105 110 Ser Tyr Thr Phe Gly Gly Gly Thr
Lys Leu Glu Ile Lys Arg Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gln Val Lys 130 135 140 Leu Gln Glu Ser
Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys 145 150 155 160 Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser 165 170
175 Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile
180 185 190 Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys
Gly Arg 195 200 205 Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu
Tyr Leu Gln Met 210 215 220 Ser Ser Leu Arg Ser Glu Asp Thr Ala Met
Tyr Tyr Cys Ala Arg Gln 225 230 235 240 Asp Gly Tyr Tyr Pro Gly Trp
Phe Ala Asn Trp Gly Gln Gly Thr Thr 245 250 255 Val Thr Val Ser Ser
Ser Gly Thr Thr Thr Pro Ala Pro Arg Pro Pro 260 265 270 Thr Pro Ala
Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu 275 280 285 Ala
Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp 290 295
300 Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly
305 310 315 320 Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys
Arg Gly Arg 325 330 335 Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe
Met Arg Pro Val Gln 340 345 350 Thr Thr Gln Glu Glu Asp Gly Cys Ser
Cys Arg Phe Pro Glu Glu Glu 355 360 365 Glu Gly Gly Cys Glu Leu Arg
Val Lys Phe Ser Arg Ser Ala Asp Ala 370 375 380 Pro Ala Tyr Lys Gln
Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu 385 390 395 400 Gly Arg
Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp 405 410 415
Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 420
425 430 Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
Ile 435 440 445 Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
Gly Leu Tyr 450 455 460 Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr
Asp Ala Leu His Met 465 470 475 480 Gln Ala Leu Pro Pro Arg 485
<210> SEQ ID NO 37 <211> LENGTH: 2721 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polynucleotide <400> SEQUENCE: 37 atggcactcc
ctgtaactgc acttcttttg ccacttgcct tgctcctgca cgcagcgcgg 60
ccggacatcg agctgaccca gagccccgcc atcatgagcg ccagcctggg cgaggagatc
120 accctgacct gcagcgccag cagcagcgtg agctacatgc actggtacca
gcagaagagc 180 ggcaccagcc ccaagctgct gatctacagc accagcaacc
tggccagcgg cgtgcccagc 240 aggttcagcg gcagcggcag cggcaccttc
tacagcctga ccatcagcag cgtggaggcc 300 gaggacgccg ccgactacta
ctgccaccag tggagcagct acaccttcgg cggcggcacc 360 aagctggaga
tcaagagggg cggcggcggc agcggcggcg gcggcagcgg cggcggcggc 420
agccaggtga agctgcagga gagcggcggc ggcctggtga agcccggcgg cagcctgaag
480 ctgagctgcg ccgccagcgg cttcaccttc agcagctacg ccatgagctg
ggtgaggcag 540 acccccgaga agaggctgga gtgggtggcc accatcagca
gcggcggcag ctacacctac 600 taccccgaca gcgtgaaggg caggttcacc
atcagcaggg acaacgccaa gaacaccctg 660 tacctgcaga tgagcagcct
gaggagcgag gacaccgcca tgtactactg cgccaggcag 720 gacggctact
accccggctg gttcgccaac tggggccagg gcaccaccgt gaccgtgagc 780
agctccggaa caacgacacc agcaccacgg ccacccactc ctgctccgac aattgcgtct
840 cagccccttt cccttcgacc cgaagcttgt cgccctgctg cgggaggagc
ggtccacacg 900 cgcgggcttg acttcgcttg cgacatctac atttgggcac
ccttggccgg gacatgcggc 960 gtcttgctcc tgagtctggt tataacgctg
tattgtaagc gaggtcggaa gaagcttttg 1020 tatatcttta aacagccctt
tatgaggccc gtacaaacca cacaagagga ggatgggtgc 1080 tcatgcagat
ttcctgaaga ggaagagggc ggttgcgaac ttagagtcaa attcagccgc 1140
tccgcagatg cacctgctta taaacagggt cagaatcaat tgtataatga acttaatctc
1200 gggaggcgcg aggagtatga tgtgctggac aagcgacggg gtcgagaccc
agagatgggc 1260 ggtaaacccc gccgaaagaa cccccaggag ggactgtata
atgagctgca aaaggacaaa 1320 atggcagaag cctattccga aatagggatg
aagggagagc ggcggcgagg taagggacat 1380 gacggtcttt atcaaggtct
tagtactgca actaaggaca cctatgacgc gctgcatatg 1440 caggctctcc
cacctagacg agctaaacga ggctcaggcg cgacgaactt tagtttgctg 1500
aagcaagctg gggatgtaga ggaaaatccg ggtcccatgg attggacttg gattttgttc
1560 ctcgttgccg cagcgactcg cgtccatagt aattgggtga acgtaattag
tgacttgaaa 1620
aaaattgagg accttataca aagtatgcat atcgatgcaa cactgtacac ggagtccgac
1680 gtgcacccaa gctgcaaggt caccgcaatg aaatgctttt tgctcgaatt
gcaagttatc 1740 tcacttgagt caggggacgc ttcaatccat gatactgtgg
agaatttgat aatcctggcg 1800 aacaatagcc ttagttcaaa tggcaacgtc
actgagtcag gctgcaagga atgtgaggaa 1860 ttggaagaaa aaaatatcaa
ggaatttttg caatcttttg ttcacatagt tcagatgttc 1920 attaacacta
gttccggggg cggcagtgga ggtggcggta gcggcggggg tggctctggt 1980
ggaggcggct ctgggggcgg aagtctgcag ataacatgcc ccccacctat gagtgttgaa
2040 catgctgata tctgggttaa atcttactcc ctttacagtc gagaaaggta
catttgcaac 2100 tccggcttta aacgcaaagc cgggactagt tcactgactg
aatgtgtatt gaataaagcg 2160 acaaatgtcg cacactggac taccccttcc
ctcaaatgca ttcgcgatcc tgccttggtg 2220 catcagcgac cagcaccgcc
gtccacggta actaccgcag gagtaacacc gcagcccgag 2280 agcctttccc
cctcaggcaa agagccggcc gcatcctccc catcttccaa taataccgca 2340
gctaccaccg cagcaatcgt acccggatcc cagctgatgc ccagcaaaag tccgagtact
2400 ggaacgactg aaatctccag tcacgagtct tctcatggaa ctccgagtca
aactacagca 2460 aagaattggg agctgactgc ttccgcttca caccagccgc
caggcgttta tcctcaggga 2520 cactcagata ccacggtggc gattagcaca
agcaccgtcc tcctgtgtgg gctgagtgca 2580 gtgtcacttc tcgcctgcta
ccttaagtcc agacagacac cccctttggc aagcgttgaa 2640 atggaagcca
tggaagcctt gcctgtcaca tgggggactt catcccgcga tgaagacttg 2700
gagaactgct cacaccatct t 2721 <210> SEQ ID NO 38 <211>
LENGTH: 907 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 38 Met Ala Leu Pro Val Thr Ala Leu Leu Leu
Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Asp Ile Glu
Leu Thr Gln Ser Pro Ala Ile Met 20 25 30 Ser Ala Ser Leu Gly Glu
Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser 35 40 45 Ser Val Ser Tyr
Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro 50 55 60 Lys Leu
Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser 65 70 75 80
Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser 85
90 95 Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp
Ser 100 105 110 Ser Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
Arg Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gln Val Lys 130 135 140 Leu Gln Glu Ser Gly Gly Gly Leu Val
Lys Pro Gly Gly Ser Leu Lys 145 150 155 160 Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser 165 170 175 Trp Val Arg Gln
Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile 180 185 190 Ser Ser
Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg 195 200 205
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met 210
215 220 Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg
Gln 225 230 235 240 Asp Gly Tyr Tyr Pro Gly Trp Phe Ala Asn Trp Gly
Gln Gly Thr Thr 245 250 255 Val Thr Val Ser Ser Ser Gly Thr Thr Thr
Pro Ala Pro Arg Pro Pro 260 265 270 Thr Pro Ala Pro Thr Ile Ala Ser
Gln Pro Leu Ser Leu Arg Pro Glu 275 280 285 Ala Cys Arg Pro Ala Ala
Gly Gly Ala Val His Thr Arg Gly Leu Asp 290 295 300 Phe Ala Cys Asp
Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly 305 310 315 320 Val
Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg 325 330
335 Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln
340 345 350 Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu
Glu Glu 355 360 365 Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg
Ser Ala Asp Ala 370 375 380 Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu
Tyr Asn Glu Leu Asn Leu 385 390 395 400 Gly Arg Arg Glu Glu Tyr Asp
Val Leu Asp Lys Arg Arg Gly Arg Asp 405 410 415 Pro Glu Met Gly Gly
Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 420 425 430 Tyr Asn Glu
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile 435 440 445 Gly
Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr 450 455
460 Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met
465 470 475 480 Gln Ala Leu Pro Pro Arg Arg Ala Lys Arg Gly Ser Gly
Ala Thr Asn 485 490 495 Phe Ser Leu Leu Lys Gln Ala Gly Asp Val Glu
Glu Asn Pro Gly Pro 500 505 510 Met Asp Trp Thr Trp Ile Leu Phe Leu
Val Ala Ala Ala Thr Arg Val 515 520 525 His Ser Asn Trp Val Asn Val
Ile Ser Asp Leu Lys Lys Ile Glu Asp 530 535 540 Leu Ile Gln Ser Met
His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp 545 550 555 560 Val His
Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu 565 570 575
Leu Gln Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr 580
585 590 Val Glu Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn
Gly 595 600 605 Asn Val Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu
Glu Glu Lys 610 615 620 Asn Ile Lys Glu Phe Leu Gln Ser Phe Val His
Ile Val Gln Met Phe 625 630 635 640 Ile Asn Thr Ser Ser Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly 645 650 655 Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Ser Leu Gln Ile Thr 660 665 670 Cys Pro Pro Pro
Met Ser Val Glu His Ala Asp Ile Trp Val Lys Ser 675 680 685 Tyr Ser
Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly Phe Lys 690 695 700
Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn Lys Ala 705
710 715 720 Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile
Arg Asp 725 730 735 Pro Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser
Thr Val Thr Thr 740 745 750 Ala Gly Val Thr Pro Gln Pro Glu Ser Leu
Ser Pro Ser Gly Lys Glu 755 760 765 Pro Ala Ala Ser Ser Pro Ser Ser
Asn Asn Thr Ala Ala Thr Thr Ala 770 775 780 Ala Ile Val Pro Gly Ser
Gln Leu Met Pro Ser Lys Ser Pro Ser Thr 785 790 795 800 Gly Thr Thr
Glu Ile Ser Ser His Glu Ser Ser His Gly Thr Pro Ser 805 810 815 Gln
Thr Thr Ala Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser His Gln 820 825
830 Pro Pro Gly Val Tyr Pro Gln Gly His Ser Asp Thr Thr Val Ala Ile
835 840 845 Ser Thr Ser Thr Val Leu Leu Cys Gly Leu Ser Ala Val Ser
Leu Leu 850 855 860 Ala Cys Tyr Leu Lys Ser Arg Gln Thr Pro Pro Leu
Ala Ser Val Glu 865 870 875 880 Met Glu Ala Met Glu Ala Leu Pro Val
Thr Trp Gly Thr Ser Ser Arg 885 890 895 Asp Glu Asp Leu Glu Asn Cys
Ser His His Leu 900 905 <210> SEQ ID NO 39 <211>
LENGTH: 3063 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polynucleotide
<400> SEQUENCE: 39 atggcactcc ctgtaactgc acttcttttg
ccacttgcct tgctcctgca cgcagcgcgg 60 ccggacatcg agctgaccca
gagccccgcc atcatgagcg ccagcctggg cgaggagatc 120 accctgacct
gcagcgccag cagcagcgtg agctacatgc actggtacca gcagaagagc 180
ggcaccagcc ccaagctgct gatctacagc accagcaacc tggccagcgg cgtgcccagc
240 aggttcagcg gcagcggcag cggcaccttc tacagcctga ccatcagcag
cgtggaggcc 300 gaggacgccg ccgactacta ctgccaccag tggagcagct
acaccttcgg cggcggcacc 360 aagctggaga tcaagagggg cggcggcggc
agcggcggcg gcggcagcgg cggcggcggc 420 agccaggtga agctgcagga
gagcggcggc ggcctggtga agcccggcgg cagcctgaag 480 ctgagctgcg
ccgccagcgg cttcaccttc agcagctacg ccatgagctg ggtgaggcag 540
acccccgaga agaggctgga gtgggtggcc accatcagca gcggcggcag ctacacctac
600 taccccgaca gcgtgaaggg caggttcacc atcagcaggg acaacgccaa
gaacaccctg 660 tacctgcaga tgagcagcct gaggagcgag gacaccgcca
tgtactactg cgccaggcag 720 gacggctact accccggctg gttcgccaac
tggggccagg gcaccaccgt gaccgtgagc 780 agctccggaa caacgacacc
agcaccacgg ccacccactc ctgctccgac aattgcgtct 840 cagccccttt
cccttcgacc cgaagcttgt cgccctgctg cgggaggagc ggtccacacg 900
cgcgggcttg acttcgcttg cgacatctac atttgggcac ccttggccgg gacatgcggc
960 gtcttgctcc tgagtctggt tataacgctg tattgtaagc gaggtcggaa
gaagcttttg 1020 tatatcttta aacagccctt tatgaggccc gtacaaacca
cacaagagga ggatgggtgc 1080 tcatgcagat ttcctgaaga ggaagagggc
ggttgcgaac ttagagtcaa attcagccgc 1140 tccgcagatg cacctgctta
taaacagggt cagaatcaat tgtataatga acttaatctc 1200 gggaggcgcg
aggagtatga tgtgctggac aagcgacggg gtcgagaccc agagatgggc 1260
ggtaaacccc gccgaaagaa cccccaggag ggactgtata atgagctgca aaaggacaaa
1320 atggcagaag cctattccga aatagggatg aagggagagc ggcggcgagg
taagggacat 1380 gacggtcttt atcaaggtct tagtactgca actaaggaca
cctatgacgc gctgcatatg 1440 caggctctcc cacctagagg ctcaggcgcg
acgaacttta gtttgctgaa gcaagctggg 1500 gatgtagagg aaaatccggg
tcccatgttg gtgcgccgag gcgcacgagc aggacctcgg 1560 atgccgcgag
gctggacagc cctctgtctc ctctctttgc ttccatccgg gttcatgagt 1620
ctcgacaata atggtacggc aaccccggaa ctcccgaccc aaggaacctt tagtaacgtt
1680 tcaaccaatg tgtcctatca ggagacaaca accccttcta cactgggcag
taccagcttg 1740 catcccgtca gccaacacgg caacgaggca acaactaaca
tcacagagac tacggtcaag 1800 tttactagta cttccgtaat cacgtctgtg
tacgggaata caaattcatc agttcagagt 1860 caaacgtcag ttatatctac
agtcttcact actcccgcga atgtatccac cccagaaacc 1920 accctcaaac
cttctcttag tccaggaaat gttagcgatt tgtcaacgac gagcacgagt 1980
ttggcgacta gtccaacgaa accgtacact tccagcagtc ccatactgtc cgacattaag
2040 gcagaaataa aatgttctgg gatcagggag gtcaagctta cgcagggaat
atgtcttgag 2100 caaaataaga cgtcctcatg cgcagaattc aagaaagatc
gcggcgaagg tctggccaga 2160 gtcctctgtg gagaggagca ggcggatgct
gacgcaggag cgcaggtttg tagtctcctg 2220 ctcgcgcaaa gtgaagttag
gccccaatgt ctcttgttgg tactggctaa ccgaactgaa 2280 attagcagca
agcttcaact catgaaaaaa caccagagtg atttgaaaaa acttgggata 2340
cttgacttca cggagcaaga cgttgcgtct caccaatcct actcacagaa aaccccgata
2400 ctgttgacat gccccaccat atcaatcttg tctttcttca gtgtggctct
tctggtgatc 2460 ttggcgtgcg tgctgtggaa aaaaaggatt aaaccgatcg
tttggcctag tctgccggat 2520 cacaaaaaga cactggagca cctctgcaag
aagccacgaa aaaacctgaa tgtgagcttt 2580 aaccccgagt cttttttgga
ctgtcagata caccgagtcg acgatataca ggcaagagat 2640 gaggttgagg
gtttcctgca agacacattc ccgcaacaac tcgaagaatc cgagaaacag 2700
cgccttggtg gagatgtcca gtctccgaac tgtccgagcg aggacgtagt aattacccca
2760 gaaagcttcg gtcgagatag tagccttacg tgtctcgccg ggaacgtgtc
agcgtgtgac 2820 gcgcctattc tttcaagttc acgcagtttg gactgtcgag
aatcagggaa aaacggacct 2880 cacgtgtatc aggatctcct tctcagcctg
ggcacgacaa acagtacctt gcctcctccg 2940 ttttccctgc agtcaggtat
tctgacgctc aatccagtcg cacaagggca acctatcctg 3000 acctccttgg
gttctaacca ggaagaggca tacgtcacta tgtccagctt ctatcagaat 3060 cag
3063 <210> SEQ ID NO 40 <211> LENGTH: 1021 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic polypeptide <400> SEQUENCE: 40 Met Ala
Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15
His Ala Ala Arg Pro Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met 20
25 30 Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser
Ser 35 40 45 Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly
Thr Ser Pro 50 55 60 Lys Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala
Ser Gly Val Pro Ser 65 70 75 80 Arg Phe Ser Gly Ser Gly Ser Gly Thr
Phe Tyr Ser Leu Thr Ile Ser 85 90 95 Ser Val Glu Ala Glu Asp Ala
Ala Asp Tyr Tyr Cys His Gln Trp Ser 100 105 110 Ser Tyr Thr Phe Gly
Gly Gly Thr Lys Leu Glu Ile Lys Arg Gly Gly 115 120 125 Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Lys 130 135 140 Leu
Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys 145 150
155 160 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
Ser 165 170 175 Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
Ala Thr Ile 180 185 190 Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp
Ser Val Lys Gly Arg 195 200 205 Phe Thr Ile Ser Arg Asp Asn Ala Lys
Asn Thr Leu Tyr Leu Gln Met 210 215 220 Ser Ser Leu Arg Ser Glu Asp
Thr Ala Met Tyr Tyr Cys Ala Arg Gln 225 230 235 240 Asp Gly Tyr Tyr
Pro Gly Trp Phe Ala Asn Trp Gly Gln Gly Thr Thr 245 250 255 Val Thr
Val Ser Ser Ser Gly Thr Thr Thr Pro Ala Pro Arg Pro Pro 260 265 270
Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu 275
280 285 Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu
Asp 290 295 300 Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly
Thr Cys Gly 305 310 315 320 Val Leu Leu Leu Ser Leu Val Ile Thr Leu
Tyr Cys Lys Arg Gly Arg 325 330 335 Lys Lys Leu Leu Tyr Ile Phe Lys
Gln Pro Phe Met Arg Pro Val Gln 340 345 350 Thr Thr Gln Glu Glu Asp
Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu 355 360 365 Glu Gly Gly Cys
Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala 370 375 380 Pro Ala
Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu 385 390 395
400 Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp
405 410 415 Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu
Gly Leu 420 425 430 Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
Tyr Ser Glu Ile 435 440 445 Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
Gly His Asp Gly Leu Tyr 450 455 460 Gln Gly Leu Ser Thr Ala Thr Lys
Asp Thr Tyr Asp Ala Leu His Met 465 470 475 480 Gln Ala Leu Pro Pro
Arg Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu 485 490 495 Lys Gln Ala
Gly Asp Val Glu Glu Asn Pro Gly Pro Met Leu Val Arg 500 505 510 Arg
Gly Ala Arg Ala Gly Pro Arg Met Pro Arg Gly Trp Thr Ala Leu 515 520
525 Cys Leu Leu Ser Leu Leu Pro Ser Gly Phe Met Ser Leu Asp Asn Asn
530 535 540 Gly Thr Ala Thr Pro Glu Leu Pro Thr Gln Gly Thr Phe Ser
Asn Val 545 550 555 560 Ser Thr Asn Val Ser Tyr Gln Glu Thr Thr Thr
Pro Ser Thr Leu Gly 565 570 575 Ser Thr Ser Leu His Pro Val Ser Gln
His Gly Asn Glu Ala Thr Thr 580 585 590 Asn Ile Thr Glu Thr Thr Val
Lys Phe Thr Ser Thr Ser Val Ile Thr 595 600 605 Ser Val Tyr Gly Asn
Thr Asn Ser Ser Val Gln Ser Gln Thr Ser Val 610 615 620 Ile Ser Thr
Val Phe Thr Thr Pro Ala Asn Val Ser Thr Pro Glu Thr 625 630 635 640
Thr Leu Lys Pro Ser Leu Ser Pro Gly Asn Val Ser Asp Leu Ser Thr 645
650 655 Thr Ser Thr Ser Leu Ala Thr Ser Pro Thr Lys Pro Tyr Thr Ser
Ser 660 665 670 Ser Pro Ile Leu Ser Asp Ile Lys Ala Glu Ile Lys Cys
Ser Gly Ile 675 680 685 Arg Glu Val Lys Leu Thr Gln Gly Ile Cys Leu
Glu Gln Asn Lys Thr 690 695 700 Ser Ser Cys Ala Glu Phe Lys Lys Asp
Arg Gly Glu Gly Leu Ala Arg 705 710 715 720 Val Leu Cys Gly Glu Glu
Gln Ala Asp Ala Asp Ala Gly Ala Gln Val 725 730 735 Cys Ser Leu Leu
Leu Ala Gln Ser Glu Val Arg Pro Gln Cys Leu Leu 740 745 750 Leu Val
Leu Ala Asn Arg Thr Glu Ile Ser Ser Lys Leu Gln Leu Met 755 760 765
Lys Lys His Gln Ser Asp Leu Lys Lys Leu Gly Ile Leu Asp Phe Thr 770
775 780 Glu Gln Asp Val Ala Ser His Gln Ser Tyr Ser Gln Lys Thr Pro
Ile 785 790 795 800 Leu Leu Thr Cys Pro Thr Ile Ser Ile Leu Ser Phe
Phe Ser Val Ala 805 810 815
Leu Leu Val Ile Leu Ala Cys Val Leu Trp Lys Lys Arg Ile Lys Pro 820
825 830 Ile Val Trp Pro Ser Leu Pro Asp His Lys Lys Thr Leu Glu His
Leu 835 840 845 Cys Lys Lys Pro Arg Lys Asn Leu Asn Val Ser Phe Asn
Pro Glu Ser 850 855 860 Phe Leu Asp Cys Gln Ile His Arg Val Asp Asp
Ile Gln Ala Arg Asp 865 870 875 880 Glu Val Glu Gly Phe Leu Gln Asp
Thr Phe Pro Gln Gln Leu Glu Glu 885 890 895 Ser Glu Lys Gln Arg Leu
Gly Gly Asp Val Gln Ser Pro Asn Cys Pro 900 905 910 Ser Glu Asp Val
Val Ile Thr Pro Glu Ser Phe Gly Arg Asp Ser Ser 915 920 925 Leu Thr
Cys Leu Ala Gly Asn Val Ser Ala Cys Asp Ala Pro Ile Leu 930 935 940
Ser Ser Ser Arg Ser Leu Asp Cys Arg Glu Ser Gly Lys Asn Gly Pro 945
950 955 960 His Val Tyr Gln Asp Leu Leu Leu Ser Leu Gly Thr Thr Asn
Ser Thr 965 970 975 Leu Pro Pro Pro Phe Ser Leu Gln Ser Gly Ile Leu
Thr Leu Asn Pro 980 985 990 Val Ala Gln Gly Gln Pro Ile Leu Thr Ser
Leu Gly Ser Asn Gln Glu 995 1000 1005 Glu Ala Tyr Val Thr Met Ser
Ser Phe Tyr Gln Asn Gln 1010 1015 1020 <210> SEQ ID NO 41
<211> LENGTH: 2181 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polynucleotide <400> SEQUENCE: 41 atggcactcc ctgtaactgc
acttcttttg ccacttgcct tgctcctgca cgcagcgcgg 60 ccggatattc
aaatgacaca aactaccagc tccctttcag catctttggg cgatagagta 120
actataagtt gccgcgcgtc ccaagacatc tctaagtacc ttaactggta tcaacaaaaa
180 ccggacggga cggtcaaact gttgatctat cacacatcca gattgcactc
aggcgtgccg 240 agcaggttca gtgggagtgg gtcaggaacg gattacagct
tgacgattag taacctggag 300 caagaagaca ttgccaccta cttctgccag
caaggtaaca ctctcccata tacgttcggg 360 ggtggcacca agctggaaat
cactggcggc ggaggatccg aggtgcagct ggtgcagagc 420 ggcgccgagg
tgaagaagcc cggcgagagc ctgaggatca gctgcaaggg cagcggctac 480
agcttcagca cctactggat cagctgggtg aggcagatgc ccggcaaggg cctggagtgg
540 atgggcaaga tctaccccgg cgacagctac accaactaca gccccagctt
ccagggccag 600 gtgaccatca gcgccgacaa gagcatcagc accgcctacc
tgcagtggag cagcctgaag 660 gccagcgaca ccgccatgta ctactgcgcc
aggggctacg gcatcttcga ctactggggc 720 cagggcaccc tggtgaccgt
gagcagcggc agcacaagcg gctctggcaa gcctggatct 780 ggcgagggct
ctaccaaggg catgagctac gagctgaccc agccccccag cgtgagcgtg 840
agccccggcc agaccgccag catcacctgc agcggcgaca acatcggcga ccagtacgcc
900 cactggtacc agcagaagcc cggccagagc cccgtgctgg tgatctacca
ggacaagaac 960 aggcccagcg gcatccccga gaggttcagc ggcagcaaca
gcggcaacac cgccaccctg 1020 accatcagcg gcacccaggc catggacgag
gccgactact actgcgccac ctacaccggc 1080 ttcggcagcc tggccgtgtt
cggcggcggc accaagctga ccgtgctggg gggaggcggc 1140 agcgaggtga
aactgcagga gtccgggccc ggtctcgtgg caccttccca gtcactgtcc 1200
gtgacctgca ccgtatctgg ggtaagtctg ccggattatg gggtttcatg gatccggcaa
1260 cctccgagga aagggttgga atggctggga gtcatctggg gaagcgagac
aacttattat 1320 aattctgctt tgaagagccg cttgacgata atcaaggaca
acagtaagag tcaggttttc 1380 ttgaagatga attctcttca gacagatgac
accgctattt attattgtgc aaaacattat 1440 tattacggag gatcctacgc
gatggactat tggggacagg gtacctctgt tacggtgtcc 1500 tcatccggaa
caacgacacc agcaccacgg ccacccactc ctgctccgac aattgcgtct 1560
cagccccttt cccttcgacc cgaagcttgt cgccctgctg cgggaggagc ggtccacacg
1620 cgcgggcttg acttcgcttg cgacatctac atttgggcac ccttggccgg
gacatgcggc 1680 gtcttgctcc tgagtctggt tataacgctg tattgtaagc
gaggtcggaa gaagcttttg 1740 tatatcttta aacagccctt tatgaggccc
gtacaaacca cacaagagga ggatgggtgc 1800 tcatgcagat ttcctgaaga
ggaagagggc ggttgcgaac ttagagtcaa attcagccgc 1860 tccgcagatg
cacctgctta taaacagggt cagaatcaat tgtataatga acttaatctc 1920
gggaggcgcg aggagtatga tgtgctggac aagcgacggg gtcgagaccc agagatgggc
1980 ggtaaacccc gccgaaagaa cccccaggag ggactgtata atgagctgca
aaaggacaaa 2040 atggcagaag cctattccga aatagggatg aagggagagc
ggcggcgagg taagggacat 2100 gacggtcttt atcaaggtct tagtactgca
actaaggaca cctatgacgc gctgcatatg 2160 caggctctcc cacctagata a 2181
<210> SEQ ID NO 42 <400> SEQUENCE: 42 000 <210>
SEQ ID NO 43 <400> SEQUENCE: 43 000 <210> SEQ ID NO 44
<400> SEQUENCE: 44 000 <210> SEQ ID NO 45 <211>
LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic oligonucleotide
<400> SEQUENCE: 45 aacgtggcat ctgtcgaccc 20 <210> SEQ
ID NO 46 <211> LENGTH: 20 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide <400> SEQUENCE: 46 gcgctggaga aactatttgg 20
<210> SEQ ID NO 47 <211> LENGTH: 20 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic oligonucleotide <400> SEQUENCE: 47 acatttaacg
atcagaaacg 20 <210> SEQ ID NO 48 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic oligonucleotide <400>
SEQUENCE: 48 ggtcctttgt ccacctgcgc 20 <210> SEQ ID NO 49
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide <400> SEQUENCE: 49 gagaaactat ttggaggaca 20
<210> SEQ ID NO 50 <211> LENGTH: 20 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic oligonucleotide <400> SEQUENCE: 50 ggagaaacta
tttggaggac 20 <210> SEQ ID NO 51 <211> LENGTH: 254
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 51
Met Glu Tyr Ala Ser Asp Ala Ser Leu Asp Pro Glu Ala Pro Trp Pro 1 5
10 15 Pro Ala Pro Arg Ala Arg Ala Cys Arg Val Leu Pro Trp Ala Leu
Val 20 25 30 Ala Gly Leu Leu Leu Leu Leu Leu Leu Ala Ala Ala Cys
Ala Val Phe 35 40 45
Leu Ala Cys Pro Trp Ala Val Ser Gly Ala Arg Ala Ser Pro Gly Ser 50
55 60 Ala Ala Ser Pro Arg Leu Arg Glu Gly Pro Glu Leu Ser Pro Asp
Asp 65 70 75 80 Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala
Gln Leu Val 85 90 95 Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu
Ser Trp Tyr Ser Asp 100 105 110 Pro Gly Leu Ala Gly Val Ser Leu Thr
Gly Gly Leu Ser Tyr Lys Glu 115 120 125 Asp Thr Lys Glu Leu Val Val
Ala Lys Ala Gly Val Tyr Tyr Val Phe 130 135 140 Phe Gln Leu Glu Leu
Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser 145 150 155 160 Val Ser
Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala 165 170 175
Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala 180
185 190 Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser
Ala 195 200 205 Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg
Ala Arg His 210 215 220 Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu
Gly Leu Phe Arg Val 225 230 235 240 Thr Pro Glu Ile Pro Ala Gly Leu
Pro Ser Pro Arg Ser Glu 245 250 <210> SEQ ID NO 52
<211> LENGTH: 116 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 52 Glu Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Arg Ile Ser
Cys Lys Gly Ser Gly Tyr Ser Phe Ser Thr Tyr 20 25 30 Trp Ile Ser
Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly
Lys Ile Tyr Pro Gly Asp Ser Tyr Thr Asn Tyr Ser Pro Ser Phe 50 55
60 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr
Tyr Cys 85 90 95 Ala Arg Gly Tyr Gly Ile Phe Asp Tyr Trp Gly Gln
Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> SEQ ID
NO 53 <211> LENGTH: 109 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 53 Met Ser Tyr Glu Leu Thr Gln
Pro Pro Ser Val Ser Val Ser Pro Gly 1 5 10 15 Gln Thr Ala Ser Ile
Thr Cys Ser Gly Asp Asn Ile Gly Asp Gln Tyr 20 25 30 Ala His Trp
Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile 35 40 45 Tyr
Gln Asp Lys Asn Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly 50 55
60 Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala
65 70 75 80 Met Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Tyr Thr Gly Phe
Gly Ser 85 90 95 Leu Ala Val Phe Gly Gly Gly Thr Lys Leu Thr Val
Leu 100 105 <210> SEQ ID NO 54 <211> LENGTH: 121
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 54
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 1 5
10 15 Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly
Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Ser Pro Glu Lys Gly Leu
Glu Trp Ile 35 40 45 Gly Glu Ile Asn His Gly Gly Tyr Val Thr Tyr
Asn Pro Ser Leu Glu 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr
Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala
Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Tyr Gly Pro
Gly Asn Tyr Asp Trp Tyr Phe Asp Leu Trp Gly 100 105 110 Arg Gly Thr
Leu Val Thr Val Ser Ser 115 120 <210> SEQ ID NO 55
<211> LENGTH: 110 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 55 Glu Ile Val Leu Thr Gln Ser
Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu
Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr
Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55
60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp
Pro Pro 85 90 95 Ala Leu Thr Phe Cys Gly Gly Thr Lys Val Glu Ile
Lys Arg 100 105 110 <210> SEQ ID NO 56 <211> LENGTH:
489 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 56
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5
10 15 His Ala Ala Arg Pro Met Ser Tyr Glu Leu Thr Gln Pro Pro Ser
Val 20 25 30 Ser Val Ser Pro Gly Gln Thr Ala Ser Ile Thr Cys Ser
Gly Asp Asn 35 40 45 Ile Gly Asp Gln Tyr Ala His Trp Tyr Gln Gln
Lys Pro Gly Gln Ser 50 55 60 Pro Val Leu Val Ile Tyr Gln Asp Lys
Asn Arg Pro Ser Gly Ile Pro 65 70 75 80 Glu Arg Phe Ser Gly Ser Asn
Ser Gly Asn Thr Ala Thr Leu Thr Ile 85 90 95 Ser Gly Thr Gln Ala
Met Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Tyr 100 105 110 Thr Gly Phe
Gly Ser Leu Ala Val Phe Gly Gly Gly Thr Lys Leu Thr 115 120 125 Val
Leu Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly 130 135
140 Ser Thr Lys Gly Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys
145 150 155 160 Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser
Gly Tyr Ser 165 170 175 Phe Ser Thr Tyr Trp Ile Ser Trp Val Arg Gln
Met Pro Gly Lys Gly 180 185 190 Leu Glu Trp Met Gly Lys Ile Tyr Pro
Gly Asp Ser Tyr Thr Asn Tyr 195 200 205 Ser Pro Ser Phe Gln Gly Gln
Val Thr Ile Ser Ala Asp Lys Ser Ile 210 215 220 Ser Thr Ala Tyr Leu
Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala 225 230 235 240 Met Tyr
Tyr Cys Ala Arg Gly Tyr Gly Ile Phe Asp Tyr Trp Gly Gln 245 250 255
Gly Thr Leu Val Thr Val Ser Ser Ser Gly Thr Thr Thr Pro Ala Pro 260
265 270 Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser
Leu 275 280 285 Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val
His Thr Arg 290 295 300 Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp
Ala Pro Leu Ala Gly 305 310 315 320 Thr Cys Gly Val Leu Leu Leu Ser
Leu Val Ile Thr Leu Tyr Cys Lys
325 330 335 Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe
Met Arg 340 345 350 Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser
Cys Arg Phe Pro 355 360 365 Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg
Val Lys Phe Ser Arg Ser 370 375 380 Ala Asp Ala Pro Ala Tyr Lys Gln
Gly Gln Asn Gln Leu Tyr Asn Glu 385 390 395 400 Leu Asn Leu Gly Arg
Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg 405 410 415 Gly Arg Asp
Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln 420 425 430 Glu
Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr 435 440
445 Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
450 455 460 Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr
Asp Ala 465 470 475 480 Leu His Met Gln Ala Leu Pro Pro Arg 485
<210> SEQ ID NO 57 <211> LENGTH: 1470 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polynucleotide <400> SEQUENCE: 57 atggccctgc
ccgtgaccgc cctgctgctg cccctggccc tgctgctgca cgccgccagg 60
cccatgagct acgagctgac ccagcccccc agcgtgagcg tgagccccgg ccagaccgcc
120 agcatcacct gcagcggcga caacatcggc gaccagtacg cccactggta
ccagcagaag 180 cccggccaga gccccgtgct ggtgatctac caggacaaga
acaggcccag cggcatcccc 240 gagaggttca gcggcagcaa cagcggcaac
accgccaccc tgaccatcag cggcacccag 300 gccatggacg aggccgacta
ctactgcgcc acctacaccg gcttcggcag cctggccgtg 360 ttcggcggcg
gcaccaagct gaccgtgctg ggcagcacca gcggcagcgg caagcccggc 420
agcggcgagg gcagcaccaa gggcgaggtg cagctggtgc agagcggcgc cgaggtgaag
480 aagcccggcg agagcctgag gatcagctgc aagggcagcg gctacagctt
cagcacctac 540 tggatcagct gggtgaggca gatgcccggc aagggcctgg
agtggatggg caagatctac 600 cccggcgaca gctacaccaa ctacagcccc
agcttccagg gccaggtgac catcagcgcc 660 gacaagagca tcagcaccgc
ctacctgcag tggagcagcc tgaaggccag cgacaccgcc 720 atgtactact
gcgccagggg ctacggcatc ttcgactact ggggccaggg caccctggtg 780
accgtgagca gcagcggcac caccaccccc gcccccaggc cccccacccc cgcccccacc
840 atcgccagcc agcccctgag cctgaggccc gaggcctgca ggcccgccgc
cggcggcgcc 900 gtgcacacca ggggcctgga cttcgcctgc gacatctaca
tctgggcccc cctggccggc 960 acctgcggcg tgctgctgct gagcctggtg
atcaccctgt actgcaagag gggcaggaag 1020 aagctgctgt acatcttcaa
gcagcccttc atgaggcccg tgcagaccac ccaggaggag 1080 gacggctgca
gctgcaggtt ccccgaggag gaggagggcg gctgcgagct gagggtgaag 1140
ttcagcagga gcgccgacgc ccccgcctac aagcagggcc agaaccagct gtacaacgag
1200 ctgaacctgg gcaggaggga ggagtacgac gtgctggaca agaggagggg
cagggacccc 1260 gagatgggcg gcaagcccag gaggaagaac ccccaggagg
gcctgtacaa cgagctgcag 1320 aaggacaaga tggccgaggc ctacagcgag
atcggcatga agggcgagag gaggaggggc 1380 aagggccacg acggcctgta
ccagggcctg agcaccgcca ccaaggacac ctacgacgcc 1440 ctgcacatgc
aggccctgcc ccccaggtga 1470 <210> SEQ ID NO 58 <211>
LENGTH: 1470 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polynucleotide
<400> SEQUENCE: 58 atggccctgc ccgtgaccgc cctgctgctg
cccctggccc tgctgctgca cgccgccagg 60 cccgaggtgc agctggtgca
gagcggcgcc gaggtgaaga agcccggcga gagcctgagg 120 atcagctgca
agggcagcgg ctacagcttc agcacctact ggatcagctg ggtgaggcag 180
atgcccggca agggcctgga gtggatgggc aagatctacc ccggcgacag ctacaccaac
240 tacagcccca gcttccaggg ccaggtgacc atcagcgccg acaagagcat
cagcaccgcc 300 tacctgcagt ggagcagcct gaaggccagc gacaccgcca
tgtactactg cgccaggggc 360 tacggcatct tcgactactg gggccagggc
accctggtga ccgtgagcag cggcagcacc 420 agcggcagcg gcaagcccgg
cagcggcgag ggcagcacca agggcatgag ctacgagctg 480 acccagcccc
ccagcgtgag cgtgagcccc ggccagaccg ccagcatcac ctgcagcggc 540
gacaacatcg gcgaccagta cgcccactgg taccagcaga agcccggcca gagccccgtg
600 ctggtgatct accaggacaa gaacaggccc agcggcatcc ccgagaggtt
cagcggcagc 660 aacagcggca acaccgccac cctgaccatc agcggcaccc
aggccatgga cgaggccgac 720 tactactgcg ccacctacac cggcttcggc
agcctggccg tgttcggcgg cggcaccaag 780 ctgaccgtgc tgagcggcac
caccaccccc gcccccaggc cccccacccc cgcccccacc 840 atcgccagcc
agcccctgag cctgaggccc gaggcctgca ggcccgccgc cggcggcgcc 900
gtgcacacca ggggcctgga cttcgcctgc gacatctaca tctgggcccc cctggccggc
960 acctgcggcg tgctgctgct gagcctggtg atcaccctgt actgcaagag
gggcaggaag 1020 aagctgctgt acatcttcaa gcagcccttc atgaggcccg
tgcagaccac ccaggaggag 1080 gacggctgca gctgcaggtt ccccgaggag
gaggagggcg gctgcgagct gagggtgaag 1140 ttcagcagga gcgccgacgc
ccccgcctac aagcagggcc agaaccagct gtacaacgag 1200 ctgaacctgg
gcaggaggga ggagtacgac gtgctggaca agaggagggg cagggacccc 1260
gagatgggcg gcaagcccag gaggaagaac ccccaggagg gcctgtacaa cgagctgcag
1320 aaggacaaga tggccgaggc ctacagcgag atcggcatga agggcgagag
gaggaggggc 1380 aagggccacg acggcctgta ccagggcctg agcaccgcca
ccaaggacac ctacgacgcc 1440 ctgcacatgc aggccctgcc ccccaggtga 1470
<210> SEQ ID NO 59 <211> LENGTH: 120 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 59 Glu Val Lys Leu Gln
Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 1 5 10 15 Ser Leu Ser
Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr 20 25 30 Gly
Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu 35 40
45 Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys
50 55 60 Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val
Phe Leu 65 70 75 80 Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile
Tyr Tyr Cys Ala 85 90 95 Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala
Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Ser Val Thr Val Ser Ser
115 120 <210> SEQ ID NO 60 <211> LENGTH: 107
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 60
Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5
10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys
Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys
Leu Leu Ile 35 40 45 Tyr His Thr Ser Arg Leu His Ser Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu
Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe
Cys Gln Gln Gly Asn Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly
Thr Lys Leu Glu Ile Thr 100 105 <210> SEQ ID NO 61
<211> LENGTH: 491 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 61 Met Ala Leu Pro Val Thr Ala
Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro
Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu 20 25 30 Ser Ala Ser
Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln 35 40 45 Asp
Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr 50 55
60 Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Val Pro
65 70 75 80
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile 85
90 95 Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln
Gly 100 105 110 Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu
Glu Ile Thr 115 120 125 Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser
Gly Glu Gly Ser Thr 130 135 140 Lys Gly Glu Val Lys Leu Gln Glu Ser
Gly Pro Gly Leu Val Ala Pro 145 150 155 160 Ser Gln Ser Leu Ser Val
Thr Cys Thr Val Ser Gly Val Ser Leu Pro 165 170 175 Asp Tyr Gly Val
Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu 180 185 190 Trp Leu
Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala 195 200 205
Leu Lys Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val 210
215 220 Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr
Tyr 225 230 235 240 Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala
Met Asp Tyr Trp 245 250 255 Gly Gln Gly Thr Ser Val Thr Val Ser Ser
Ser Gly Thr Thr Thr Pro 260 265 270 Ala Pro Arg Pro Pro Thr Pro Ala
Pro Thr Ile Ala Ser Gln Pro Leu 275 280 285 Ser Leu Arg Pro Glu Ala
Cys Arg Pro Ala Ala Gly Gly Ala Val His 290 295 300 Thr Arg Gly Leu
Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu 305 310 315 320 Ala
Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr 325 330
335 Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe
340 345 350 Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser
Cys Arg 355 360 365 Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg
Val Lys Phe Ser 370 375 380 Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln
Gly Gln Asn Gln Leu Tyr 385 390 395 400 Asn Glu Leu Asn Leu Gly Arg
Arg Glu Glu Tyr Asp Val Leu Asp Lys 405 410 415 Arg Arg Gly Arg Asp
Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn 420 425 430 Pro Gln Glu
Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu 435 440 445 Ala
Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly 450 455
460 His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr
465 470 475 480 Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 485 490
<210> SEQ ID NO 62 <400> SEQUENCE: 62 000 <210>
SEQ ID NO 63 <400> SEQUENCE: 63 000 <210> SEQ ID NO 64
<400> SEQUENCE: 64 000 <210> SEQ ID NO 65 <400>
SEQUENCE: 65 000 <210> SEQ ID NO 66 <400> SEQUENCE: 66
000 <210> SEQ ID NO 67 <400> SEQUENCE: 67 000
<210> SEQ ID NO 68 <400> SEQUENCE: 68 000 <210>
SEQ ID NO 69 <400> SEQUENCE: 69 000 <210> SEQ ID NO 70
<400> SEQUENCE: 70 000 <210> SEQ ID NO 71 <400>
SEQUENCE: 71 000 <210> SEQ ID NO 72 <400> SEQUENCE: 72
000 <210> SEQ ID NO 73 <400> SEQUENCE: 73 000
<210> SEQ ID NO 74 <400> SEQUENCE: 74 000 <210>
SEQ ID NO 75 <211> LENGTH: 486 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 75 Met Ala Leu Pro Val
Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala
Arg Pro Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met 20 25 30 Ser
Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser 35 40
45 Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro
50 55 60 Lys Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val
Pro Ser 65 70 75 80 Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser
Leu Thr Ile Ser 85 90 95 Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr
Tyr Cys His Gln Trp Ser 100 105 110 Ser Tyr Thr Phe Gly Gly Gly Thr
Lys Leu Glu Ile Lys Arg Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gln Val Lys 130 135 140 Leu Gln Glu Ser
Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys 145 150 155 160 Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser 165 170
175 Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile
180 185 190 Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys
Gly Arg 195 200 205 Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu
Tyr Leu Gln Met 210 215 220 Ser Ser Leu Arg Ser Glu Asp Thr Ala Met
Tyr Tyr Cys Ala Arg Gln 225 230 235 240 Asp Gly Tyr Tyr Pro Gly Trp
Phe Ala Asn Trp Gly Gln Gly Thr Thr 245 250 255 Val Thr Val Ser Ser
Ser Gly Thr Thr Thr Pro Ala Pro Arg Pro Pro 260 265 270 Thr Pro Ala
Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu 275 280 285 Ala
Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp 290 295
300 Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly
305 310 315 320 Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys
Arg Gly Arg 325 330 335 Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe
Met Arg Pro Val Gln 340 345 350 Thr Thr Gln Glu Glu Asp Gly Cys Ser
Cys Arg Phe Pro Glu Glu Glu 355 360 365
Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala 370
375 380 Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
Leu 385 390 395 400 Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
Arg Gly Arg Asp 405 410 415 Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
Asn Pro Gln Glu Gly Leu 420 425 430 Tyr Asn Glu Leu Gln Lys Asp Lys
Met Ala Glu Ala Tyr Ser Glu Ile 435 440 445 Gly Met Lys Gly Glu Arg
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr 450 455 460 Gln Gly Leu Ser
Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met 465 470 475 480 Gln
Ala Leu Pro Pro Arg 485 <210> SEQ ID NO 76 <211>
LENGTH: 490 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 76 Met Ala Leu Pro Val Thr Ala Leu Leu Leu
Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Ala Ala Tyr
Lys Asp Ile Gln Met Thr Gln Thr 20 25 30 Thr Ser Ser Leu Ser Ala
Ser Leu Gly Asp Arg Val Thr Ile Ser Cys 35 40 45 Ser Ala Ser Gln
Gly Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys 50 55 60 Pro Asp
Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Ser Leu His 65 70 75 80
Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr 85
90 95 Ser Leu Thr Ile Ser Asn Leu Glu Pro Glu Asp Ile Ala Thr Tyr
Tyr 100 105 110 Cys Gln Gln Tyr Ser Lys Leu Pro Tyr Thr Phe Gly Gly
Gly Thr Lys 115 120 125 Leu Glu Ile Lys Arg Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly 130 135 140 Gly Gly Gly Ser Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val 145 150 155 160 Lys Pro Gly Gly Ser Leu
Lys Leu Ser Cys Ala Ala Ser Gly Leu Thr 165 170 175 Phe Ser Ser Tyr
Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg 180 185 190 Leu Glu
Trp Val Ala Ser Ile Ser Ser Gly Gly Phe Thr Tyr Tyr Pro 195 200 205
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn 210
215 220 Ile Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala
Met 225 230 235 240 Tyr Tyr Cys Ala Arg Asp Glu Val Arg Gly Tyr Leu
Asp Val Trp Gly 245 250 255 Ala Gly Thr Thr Val Thr Val Ser Ser Ser
Gly Thr Thr Thr Pro Ala 260 265 270 Pro Arg Pro Pro Thr Pro Ala Pro
Thr Ile Ala Ser Gln Pro Leu Ser 275 280 285 Leu Arg Pro Glu Ala Cys
Arg Pro Ala Ala Gly Gly Ala Val His Thr 290 295 300 Arg Gly Leu Asp
Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala 305 310 315 320 Gly
Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys 325 330
335 Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met
340 345 350 Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys
Arg Phe 355 360 365 Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val
Lys Phe Ser Arg 370 375 380 Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly
Gln Asn Gln Leu Tyr Asn 385 390 395 400 Glu Leu Asn Leu Gly Arg Arg
Glu Glu Tyr Asp Val Leu Asp Lys Arg 405 410 415 Arg Gly Arg Asp Pro
Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro 420 425 430 Gln Glu Gly
Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala 435 440 445 Tyr
Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His 450 455
460 Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
465 470 475 480 Ala Leu His Met Gln Ala Leu Pro Pro Arg 485 490
<210> SEQ ID NO 77 <211> LENGTH: 492 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 77 Met Ala Leu Pro Val
Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala
Arg Pro Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu 20 25 30 Ser
Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly 35 40
45 Asn Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser
50 55 60 Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly
Val Pro 65 70 75 80 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr
Ser Leu Lys Ile 85 90 95 Asn Ser Leu Gln Pro Glu Asp Phe Gly Ser
Tyr Tyr Cys Gln His Phe 100 105 110 Trp Thr Thr Pro Pro Trp Thr Phe
Gly Gly Gly Thr Lys Leu Glu Ile 115 120 125 Lys Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 130 135 140 Gln Ile Gln Leu
Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 145 150 155 160 Thr
Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 165 170
175 Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
180 185 190 Gly Trp Ile Asn Thr Tyr Asn Gly Glu Pro Thr Tyr Ala Asp
Asp Phe 195 200 205 Lys Gly Arg Phe Asp Phe Ser Leu Glu Thr Ser Ala
Ser Thr Ala Tyr 210 215 220 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp
Thr Ala Thr Tyr Phe Cys 225 230 235 240 Ala Arg Arg Gly Tyr Tyr Tyr
Gly Ser Arg Tyr Gly Ala Met Asp Tyr 245 250 255 Trp Gly Gln Gly Thr
Ser Val Thr Val Ser Ser Ser Gly Thr Thr Thr 260 265 270 Pro Ala Pro
Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro 275 280 285 Leu
Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val 290 295
300 His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro
305 310 315 320 Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val
Ile Thr Leu 325 330 335 Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr
Ile Phe Lys Gln Pro 340 345 350 Phe Met Arg Pro Val Gln Thr Thr Gln
Glu Glu Asp Gly Cys Ser Cys 355 360 365 Arg Phe Pro Glu Glu Glu Glu
Gly Gly Cys Glu Leu Arg Val Lys Phe 370 375 380 Ser Arg Ser Ala Asp
Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu 385 390 395 400 Tyr Asn
Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp 405 410 415
Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys 420
425 430 Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met
Ala 435 440 445 Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg
Arg Gly Lys 450 455 460 Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr
Ala Thr Lys Asp Thr 465 470 475 480 Tyr Asp Ala Leu His Met Gln Ala
Leu Pro Pro Arg 485 490 <210> SEQ ID NO 78 <211>
LENGTH: 492 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 78 Met Ala Leu Pro Val Thr Ala Leu Leu Leu
Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Gln Ile Gln
Leu Val Gln Ser Gly Pro Glu Leu 20 25 30
Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr 35
40 45 Thr Phe Thr Asn Tyr Gly Met Asn Trp Val Lys Gln Ala Pro Gly
Lys 50 55 60 Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Asn Gly
Glu Pro Thr 65 70 75 80 Tyr Ala Asp Asp Phe Lys Gly Arg Phe Asp Phe
Ser Leu Glu Thr Ser 85 90 95 Ala Ser Thr Ala Tyr Leu Gln Ile Asn
Asn Leu Lys Asn Glu Asp Thr 100 105 110 Ala Thr Tyr Phe Cys Ala Arg
Arg Gly Tyr Tyr Tyr Gly Ser Arg Tyr 115 120 125 Gly Ala Met Asp Tyr
Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 130 135 140 Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp 145 150 155 160
Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly Glu 165
170 175 Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile His Asn Tyr
Leu 180 185 190 Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu
Leu Val Tyr 195 200 205 Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
Arg Phe Ser Gly Ser 210 215 220 Gly Ser Gly Thr Gln Tyr Ser Leu Lys
Ile Asn Ser Leu Gln Pro Glu 225 230 235 240 Asp Phe Gly Ser Tyr Tyr
Cys Gln His Phe Trp Thr Thr Pro Pro Trp 245 250 255 Thr Phe Gly Gly
Gly Thr Lys Leu Glu Ile Lys Ser Gly Thr Thr Thr 260 265 270 Pro Ala
Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro 275 280 285
Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val 290
295 300 His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala
Pro 305 310 315 320 Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu
Val Ile Thr Leu 325 330 335 Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu
Tyr Ile Phe Lys Gln Pro 340 345 350 Phe Met Arg Pro Val Gln Thr Thr
Gln Glu Glu Asp Gly Cys Ser Cys 355 360 365 Arg Phe Pro Glu Glu Glu
Glu Gly Gly Cys Glu Leu Arg Val Lys Phe 370 375 380 Ser Arg Ser Ala
Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu 385 390 395 400 Tyr
Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp 405 410
415 Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
420 425 430 Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
Met Ala 435 440 445 Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
Arg Arg Gly Lys 450 455 460 Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
Thr Ala Thr Lys Asp Thr 465 470 475 480 Tyr Asp Ala Leu His Met Gln
Ala Leu Pro Pro Arg 485 490 <210> SEQ ID NO 79 <211>
LENGTH: 726 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 79 Met Ala Leu Pro Val Thr Ala Leu Leu Leu
Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Asp Ile Gln
Met Thr Gln Thr Thr Ser Ser Leu 20 25 30 Ser Ala Ser Leu Gly Asp
Arg Val Thr Ile Ser Cys Arg Ala Ser Gln 35 40 45 Asp Ile Ser Lys
Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr 50 55 60 Val Lys
Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Val Pro 65 70 75 80
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile 85
90 95 Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln
Gly 100 105 110 Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu
Glu Ile Thr 115 120 125 Gly Gly Gly Gly Ser Gln Val Lys Leu Gln Glu
Ser Gly Gly Gly Leu 130 135 140 Val Lys Pro Gly Gly Ser Leu Lys Leu
Ser Cys Ala Ala Ser Gly Phe 145 150 155 160 Thr Phe Ser Ser Tyr Ala
Met Ser Trp Val Arg Gln Thr Pro Glu Lys 165 170 175 Arg Leu Glu Trp
Val Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr 180 185 190 Tyr Pro
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala 195 200 205
Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr 210
215 220 Ala Met Tyr Tyr Cys Ala Arg Gln Asp Gly Tyr Tyr Pro Gly Trp
Phe 225 230 235 240 Ala Asn Trp Gly Gln Gly Thr Thr Val Thr Val Ser
Ser Gly Ser Thr 245 250 255 Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu
Gly Ser Thr Lys Gly Asp 260 265 270 Ile Glu Leu Thr Gln Ser Pro Ala
Ile Met Ser Ala Ser Leu Gly Glu 275 280 285 Glu Ile Thr Leu Thr Cys
Ser Ala Ser Ser Ser Val Ser Tyr Met His 290 295 300 Trp Tyr Gln Gln
Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr Ser 305 310 315 320 Thr
Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly 325 330
335 Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu Asp
340 345 350 Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Thr Phe
Gly Gly 355 360 365 Gly Thr Lys Leu Glu Ile Lys Arg Gly Gly Gly Gly
Ser Glu Val Lys 370 375 380 Leu Gln Glu Ser Gly Pro Gly Leu Val Ala
Pro Ser Gln Ser Leu Ser 385 390 395 400 Val Thr Cys Thr Val Ser Gly
Val Ser Leu Pro Asp Tyr Gly Val Ser 405 410 415 Trp Ile Arg Gln Pro
Pro Arg Lys Gly Leu Glu Trp Leu Gly Val Ile 420 425 430 Trp Gly Ser
Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu 435 440 445 Thr
Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn 450 455
460 Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys His Tyr
465 470 475 480 Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln
Gly Thr Ser 485 490 495 Val Thr Val Ser Ser Ser Gly Thr Thr Thr Pro
Ala Pro Arg Pro Pro 500 505 510 Thr Pro Ala Pro Thr Ile Ala Ser Gln
Pro Leu Ser Leu Arg Pro Glu 515 520 525 Ala Cys Arg Pro Ala Ala Gly
Gly Ala Val His Thr Arg Gly Leu Asp 530 535 540 Phe Ala Cys Asp Ile
Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly 545 550 555 560 Val Leu
Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg 565 570 575
Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln 580
585 590 Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu
Glu 595 600 605 Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser
Ala Asp Ala 610 615 620 Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr
Asn Glu Leu Asn Leu 625 630 635 640 Gly Arg Arg Glu Glu Tyr Asp Val
Leu Asp Lys Arg Arg Gly Arg Asp 645 650 655 Pro Glu Met Gly Gly Lys
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 660 665 670 Tyr Asn Glu Leu
Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile 675 680 685 Gly Met
Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr 690 695 700
Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met 705
710 715 720 Gln Ala Leu Pro Pro Arg 725 <210> SEQ ID NO 80
<211> LENGTH: 726 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 80 Met Ala Leu Pro Val Thr Ala
Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15 His Ala Ala Arg Pro Glu Val Lys Leu Gln Glu Ser Gly Pro
Gly Leu 20 25 30 Val Ala Pro Ser Gln Ser Leu Ser Val Thr Cys Thr
Val Ser Gly Val 35 40 45 Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile
Arg Gln Pro Pro Arg Lys 50 55 60 Gly Leu Glu Trp Leu Gly Val Ile
Trp Gly Ser Glu Thr Thr Tyr Tyr 65 70 75 80 Asn Ser Ala Leu Lys Ser
Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys 85 90 95 Ser Gln Val Phe
Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala 100 105 110 Ile Tyr
Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met 115 120 125
Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly Gly Gly 130
135 140 Gly Ser Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met Ser Ala
Ser 145 150 155 160 Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser
Ser Ser Val Ser 165 170 175 Tyr Met His Trp Tyr Gln Gln Lys Ser Gly
Thr Ser Pro Lys Leu Leu 180 185 190 Ile Tyr Ser Thr Ser Asn Leu Ala
Ser Gly Val Pro Ser Arg Phe Ser 195 200 205 Gly Ser Gly Ser Gly Thr
Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu 210 215 220 Ala Glu Asp Ala
Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Thr 225 230 235 240 Phe
Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Gly Ser Thr Ser Gly 245 250
255 Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln Val Lys
260 265 270 Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser
Leu Lys 275 280 285 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
Tyr Ala Met Ser 290 295 300 Trp Val Arg Gln Thr Pro Glu Lys Arg Leu
Glu Trp Val Ala Thr Ile 305 310 315 320 Ser Ser Gly Gly Ser Tyr Thr
Tyr Tyr Pro Asp Ser Val Lys Gly Arg 325 330 335 Phe Thr Ile Ser Arg
Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met 340 345 350 Ser Ser Leu
Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gln 355 360 365 Asp
Gly Tyr Tyr Pro Gly Trp Phe Ala Asn Trp Gly Gln Gly Thr Thr 370 375
380 Val Thr Val Ser Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln
385 390 395 400 Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val
Thr Ile Ser 405 410 415 Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr Leu
Asn Trp Tyr Gln Gln 420 425 430 Lys Pro Asp Gly Thr Val Lys Leu Leu
Ile Tyr His Thr Ser Arg Leu 435 440 445 His Ser Gly Val Pro Ser Arg
Phe Ser Gly Ser Gly Ser Gly Thr Asp 450 455 460 Tyr Ser Leu Thr Ile
Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr 465 470 475 480 Phe Cys
Gln Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr 485 490 495
Lys Leu Glu Ile Thr Ser Gly Thr Thr Thr Pro Ala Pro Arg Pro Pro 500
505 510 Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro
Glu 515 520 525 Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg
Gly Leu Asp 530 535 540 Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
Ala Gly Thr Cys Gly 545 550 555 560 Val Leu Leu Leu Ser Leu Val Ile
Thr Leu Tyr Cys Lys Arg Gly Arg 565 570 575 Lys Lys Leu Leu Tyr Ile
Phe Lys Gln Pro Phe Met Arg Pro Val Gln 580 585 590 Thr Thr Gln Glu
Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu 595 600 605 Glu Gly
Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala 610 615 620
Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu 625
630 635 640 Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly
Arg Asp 645 650 655 Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
Gln Glu Gly Leu 660 665 670 Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
Glu Ala Tyr Ser Glu Ile 675 680 685 Gly Met Lys Gly Glu Arg Arg Arg
Gly Lys Gly His Asp Gly Leu Tyr 690 695 700 Gln Gly Leu Ser Thr Ala
Thr Lys Asp Thr Tyr Asp Ala Leu His Met 705 710 715 720 Gln Ala Leu
Pro Pro Arg 725 <210> SEQ ID NO 81 <211> LENGTH: 746
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 81
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5
10 15 His Ala Ala Arg Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser
Leu 20 25 30 Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg
Ala Ser Gln 35 40 45 Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln
Lys Pro Asp Gly Thr 50 55 60 Val Lys Leu Leu Ile Tyr His Thr Ser
Arg Leu His Ser Gly Val Pro 65 70 75 80 Ser Arg Phe Ser Gly Ser Gly
Ser Gly Thr Asp Tyr Ser Leu Thr Ile 85 90 95 Ser Asn Leu Glu Gln
Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly 100 105 110 Asn Thr Leu
Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr 115 120 125 Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu 130 135
140 Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser
145 150 155 160 Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro
Asp Tyr Gly 165 170 175 Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly
Leu Glu Trp Leu Gly 180 185 190 Val Ile Trp Gly Ser Glu Thr Thr Tyr
Tyr Asn Ser Ala Leu Lys Ser 195 200 205 Arg Leu Thr Ile Ile Lys Asp
Asn Ser Lys Ser Gln Val Phe Leu Lys 210 215 220 Met Asn Ser Leu Gln
Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys 225 230 235 240 His Tyr
Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly 245 250 255
Thr Ser Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro 260
265 270 Gly Ser Gly Glu Gly Ser Thr Lys Gly Asp Ile Glu Leu Thr Gln
Ser 275 280 285 Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Glu Ile Thr
Leu Thr Cys 290 295 300 Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp
Tyr Gln Gln Lys Ser 305 310 315 320 Gly Thr Ser Pro Lys Leu Leu Ile
Tyr Ser Thr Ser Asn Leu Ala Ser 325 330 335 Gly Val Pro Ser Arg Phe
Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser 340 345 350 Leu Thr Ile Ser
Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys 355 360 365 His Gln
Trp Ser Ser Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 370 375 380
Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 385
390 395 400 Ser Gln Val Lys Leu Gln Glu Ser Gly Gly Gly Leu Val Lys
Pro Gly 405 410 415 Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe
Thr Phe Ser Ser 420 425 430 Tyr Ala Met Ser Trp Val Arg Gln Thr Pro
Glu Lys Arg Leu Glu Trp 435 440 445 Val Ala Thr Ile Ser Ser Gly Gly
Ser Tyr Thr Tyr Tyr Pro Asp Ser 450 455 460 Val Lys Gly Arg Phe Thr
Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu 465 470 475 480 Tyr Leu Gln
Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr 485 490 495 Cys
Ala Arg Gln Asp Gly Tyr Tyr Pro Gly Trp Phe Ala Asn Trp Gly 500 505
510 Gln Gly Thr Thr Val Thr Val Ser Ser Ser Gly Thr Thr Thr Pro Ala
515 520 525 Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro
Leu Ser 530 535 540
Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr 545
550 555 560 Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro
Leu Ala 565 570 575 Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile
Thr Leu Tyr Cys 580 585 590 Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile
Phe Lys Gln Pro Phe Met 595 600 605 Arg Pro Val Gln Thr Thr Gln Glu
Glu Asp Gly Cys Ser Cys Arg Phe 610 615 620 Pro Glu Glu Glu Glu Gly
Gly Cys Glu Leu Arg Val Lys Phe Ser Arg 625 630 635 640 Ser Ala Asp
Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn 645 650 655 Glu
Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg 660 665
670 Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
675 680 685 Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
Glu Ala 690 695 700 Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
Gly Lys Gly His 705 710 715 720 Asp Gly Leu Tyr Gln Gly Leu Ser Thr
Ala Thr Lys Asp Thr Tyr Asp 725 730 735 Ala Leu His Met Gln Ala Leu
Pro Pro Arg 740 745 <210> SEQ ID NO 82 <211> LENGTH:
743 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 82
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5
10 15 His Ala Ala Arg Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser
Leu 20 25 30 Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg
Ala Ser Gln 35 40 45 Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln
Lys Pro Asp Gly Thr 50 55 60 Val Lys Leu Leu Ile Tyr His Thr Ser
Arg Leu His Ser Gly Val Pro 65 70 75 80 Ser Arg Phe Ser Gly Ser Gly
Ser Gly Thr Asp Tyr Ser Leu Thr Ile 85 90 95 Ser Asn Leu Glu Gln
Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly 100 105 110 Asn Thr Leu
Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr 115 120 125 Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu 130 135
140 Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser
145 150 155 160 Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro
Asp Tyr Gly 165 170 175 Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly
Leu Glu Trp Leu Gly 180 185 190 Val Ile Trp Gly Ser Glu Thr Thr Tyr
Tyr Asn Ser Ala Leu Lys Ser 195 200 205 Arg Leu Thr Ile Ile Lys Asp
Asn Ser Lys Ser Gln Val Phe Leu Lys 210 215 220 Met Asn Ser Leu Gln
Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys 225 230 235 240 His Tyr
Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly 245 250 255
Thr Ser Val Thr Val Ser Ser Glu Ala Ala Ala Lys Glu Ala Ala Ala 260
265 270 Lys Glu Ala Ala Ala Lys Asp Ile Glu Leu Thr Gln Ser Pro Ala
Ile 275 280 285 Met Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys
Ser Ala Ser 290 295 300 Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln
Lys Ser Gly Thr Ser 305 310 315 320 Pro Lys Leu Leu Ile Tyr Ser Thr
Ser Asn Leu Ala Ser Gly Val Pro 325 330 335 Ser Arg Phe Ser Gly Ser
Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile 340 345 350 Ser Ser Val Glu
Ala Glu Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp 355 360 365 Ser Ser
Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Gly 370 375 380
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val 385
390 395 400 Lys Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
Ser Leu 405 410 415 Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser
Ser Tyr Ala Met 420 425 430 Ser Trp Val Arg Gln Thr Pro Glu Lys Arg
Leu Glu Trp Val Ala Thr 435 440 445 Ile Ser Ser Gly Gly Ser Tyr Thr
Tyr Tyr Pro Asp Ser Val Lys Gly 450 455 460 Arg Phe Thr Ile Ser Arg
Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln 465 470 475 480 Met Ser Ser
Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg 485 490 495 Gln
Asp Gly Tyr Tyr Pro Gly Trp Phe Ala Asn Trp Gly Gln Gly Thr 500 505
510 Thr Val Thr Val Ser Ser Ser Gly Thr Thr Thr Pro Ala Pro Arg Pro
515 520 525 Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu
Arg Pro 530 535 540 Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
Thr Arg Gly Leu 545 550 555 560 Asp Phe Ala Cys Asp Ile Tyr Ile Trp
Ala Pro Leu Ala Gly Thr Cys 565 570 575 Gly Val Leu Leu Leu Ser Leu
Val Ile Thr Leu Tyr Cys Lys Arg Gly 580 585 590 Arg Lys Lys Leu Leu
Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val 595 600 605 Gln Thr Thr
Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu 610 615 620 Glu
Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp 625 630
635 640 Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu
Asn 645 650 655 Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
Arg Gly Arg 660 665 670 Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
Asn Pro Gln Glu Gly 675 680 685 Leu Tyr Asn Glu Leu Gln Lys Asp Lys
Met Ala Glu Ala Tyr Ser Glu 690 695 700 Ile Gly Met Lys Gly Glu Arg
Arg Arg Gly Lys Gly His Asp Gly Leu 705 710 715 720 Tyr Gln Gly Leu
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His 725 730 735 Met Gln
Ala Leu Pro Pro Arg 740 <210> SEQ ID NO 83 <211>
LENGTH: 746 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 83 Met Ala Leu Pro Val Thr Ala Leu Leu Leu
Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Asp Ile Glu
Leu Thr Gln Ser Pro Ala Ile Met 20 25 30 Ser Ala Ser Leu Gly Glu
Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser 35 40 45 Ser Val Ser Tyr
Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro 50 55 60 Lys Leu
Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser 65 70 75 80
Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser 85
90 95 Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp
Ser 100 105 110 Ser Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
Arg Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gln Val Lys 130 135 140 Leu Gln Glu Ser Gly Gly Gly Leu Val
Lys Pro Gly Gly Ser Leu Lys 145 150 155 160 Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser 165 170 175 Trp Val Arg Gln
Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile 180 185 190 Ser Ser
Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg 195 200 205
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met 210
215 220 Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg
Gln 225 230 235 240 Asp Gly Tyr Tyr Pro Gly Trp Phe Ala Asn Trp Gly
Gln Gly Thr Thr 245 250 255
Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser 260
265 270 Gly Glu Gly Ser Thr Lys Gly Asp Ile Gln Met Thr Gln Thr Thr
Ser 275 280 285 Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser
Cys Arg Ala 290 295 300 Ser Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr
Gln Gln Lys Pro Asp 305 310 315 320 Gly Thr Val Lys Leu Leu Ile Tyr
His Thr Ser Arg Leu His Ser Gly 325 330 335 Val Pro Ser Arg Phe Ser
Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu 340 345 350 Thr Ile Ser Asn
Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln 355 360 365 Gln Gly
Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu 370 375 380
Ile Thr Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 385
390 395 400 Ser Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala
Pro Ser 405 410 415 Gln Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val
Ser Leu Pro Asp 420 425 430 Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro
Arg Lys Gly Leu Glu Trp 435 440 445 Leu Gly Val Ile Trp Gly Ser Glu
Thr Thr Tyr Tyr Asn Ser Ala Leu 450 455 460 Lys Ser Arg Leu Thr Ile
Ile Lys Asp Asn Ser Lys Ser Gln Val Phe 465 470 475 480 Leu Lys Met
Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys 485 490 495 Ala
Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly 500 505
510 Gln Gly Thr Ser Val Thr Val Ser Ser Ser Gly Thr Thr Thr Pro Ala
515 520 525 Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro
Leu Ser 530 535 540 Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly
Ala Val His Thr 545 550 555 560 Arg Gly Leu Asp Phe Ala Cys Asp Ile
Tyr Ile Trp Ala Pro Leu Ala 565 570 575 Gly Thr Cys Gly Val Leu Leu
Leu Ser Leu Val Ile Thr Leu Tyr Cys 580 585 590 Lys Arg Gly Arg Lys
Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met 595 600 605 Arg Pro Val
Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe 610 615 620 Pro
Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg 625 630
635 640 Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr
Asn 645 650 655 Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
Asp Lys Arg 660 665 670 Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
Arg Arg Lys Asn Pro 675 680 685 Gln Glu Gly Leu Tyr Asn Glu Leu Gln
Lys Asp Lys Met Ala Glu Ala 690 695 700 Tyr Ser Glu Ile Gly Met Lys
Gly Glu Arg Arg Arg Gly Lys Gly His 705 710 715 720 Asp Gly Leu Tyr
Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp 725 730 735 Ala Leu
His Met Gln Ala Leu Pro Pro Arg 740 745 <210> SEQ ID NO 84
<211> LENGTH: 746 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 84 Met Ala Leu Pro Val Thr Ala
Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro
Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met 20 25 30 Ser Ala Ser
Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser 35 40 45 Ser
Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro 50 55
60 Lys Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser
65 70 75 80 Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr
Ile Ser 85 90 95 Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys
His Gln Trp Ser 100 105 110 Ser Tyr Thr Phe Gly Gly Gly Thr Lys Leu
Glu Ile Lys Arg Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gln Val Lys 130 135 140 Leu Gln Glu Ser Gly Gly
Gly Leu Val Lys Pro Gly Gly Ser Leu Lys 145 150 155 160 Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser 165 170 175 Trp
Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile 180 185
190 Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg
195 200 205 Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu
Gln Met 210 215 220 Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr
Cys Ala Arg Gln 225 230 235 240 Asp Gly Tyr Tyr Pro Gly Trp Phe Ala
Asn Trp Gly Gln Gly Thr Thr 245 250 255 Val Thr Val Ser Ser Gly Ser
Thr Ser Gly Ser Gly Lys Pro Gly Ser 260 265 270 Gly Glu Gly Ser Thr
Lys Gly Glu Val Lys Leu Gln Glu Ser Gly Pro 275 280 285 Gly Leu Val
Ala Pro Ser Gln Ser Leu Ser Val Thr Cys Thr Val Ser 290 295 300 Gly
Val Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro 305 310
315 320 Arg Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Gly Ser Glu Thr
Thr 325 330 335 Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu Thr Ile Ile
Lys Asp Asn 340 345 350 Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser
Leu Gln Thr Asp Asp 355 360 365 Thr Ala Ile Tyr Tyr Cys Ala Lys His
Tyr Tyr Tyr Gly Gly Ser Tyr 370 375 380 Ala Met Asp Tyr Trp Gly Gln
Gly Thr Ser Val Thr Val Ser Ser Gly 385 390 395 400 Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile 405 410 415 Gln Met
Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg 420 425 430
Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr Leu Asn 435
440 445 Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr
His 450 455 460 Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser
Gly Ser Gly 465 470 475 480 Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser
Asn Leu Glu Gln Glu Asp 485 490 495 Ile Ala Thr Tyr Phe Cys Gln Gln
Gly Asn Thr Leu Pro Tyr Thr Phe 500 505 510 Gly Gly Gly Thr Lys Leu
Glu Ile Thr Ser Gly Thr Thr Thr Pro Ala 515 520 525 Pro Arg Pro Pro
Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser 530 535 540 Leu Arg
Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr 545 550 555
560 Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala
565 570 575 Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu
Tyr Cys 580 585 590 Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys
Gln Pro Phe Met 595 600 605 Arg Pro Val Gln Thr Thr Gln Glu Glu Asp
Gly Cys Ser Cys Arg Phe 610 615 620 Pro Glu Glu Glu Glu Gly Gly Cys
Glu Leu Arg Val Lys Phe Ser Arg 625 630 635 640 Ser Ala Asp Ala Pro
Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn 645 650 655 Glu Leu Asn
Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg 660 665 670 Arg
Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro 675 680
685 Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
690 695 700 Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
Gly His 705 710 715 720 Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
Lys Asp Thr Tyr Asp 725 730 735 Ala Leu His Met Gln Ala Leu Pro Pro
Arg 740 745 <210> SEQ ID NO 85 <211> LENGTH: 1261
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 85 Met Ala Leu Pro Val
Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala
Arg Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu 20 25 30 Ser
Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln 35 40
45 Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr
50 55 60 Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly
Val Pro 65 70 75 80 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr
Ser Leu Thr Ile 85 90 95 Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr
Tyr Phe Cys Gln Gln Gly 100 105 110 Asn Thr Leu Pro Tyr Thr Phe Gly
Gly Gly Thr Lys Leu Glu Ile Thr 115 120 125 Gly Gly Gly Gly Ser Gln
Val Lys Leu Gln Glu Ser Gly Gly Gly Leu 130 135 140 Val Lys Pro Gly
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe 145 150 155 160 Thr
Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys 165 170
175 Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr
180 185 190 Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala 195 200 205 Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg
Ser Glu Asp Thr 210 215 220 Ala Met Tyr Tyr Cys Ala Arg Gln Asp Gly
Tyr Tyr Pro Gly Trp Phe 225 230 235 240 Ala Asn Trp Gly Gln Gly Thr
Thr Val Thr Val Ser Ser Gly Ser Thr 245 250 255 Ser Gly Ser Gly Lys
Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Asp 260 265 270 Ile Glu Leu
Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu 275 280 285 Glu
Ile Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His 290 295
300 Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr Ser
305 310 315 320 Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser
Gly Ser Gly 325 330 335 Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser
Val Glu Ala Glu Asp 340 345 350 Ala Ala Asp Tyr Tyr Cys His Gln Trp
Ser Ser Tyr Thr Phe Gly Gly 355 360 365 Gly Thr Lys Leu Glu Ile Lys
Arg Gly Gly Gly Gly Ser Glu Val Lys 370 375 380 Leu Gln Glu Ser Gly
Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser 385 390 395 400 Val Thr
Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser 405 410 415
Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly Val Ile 420
425 430 Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser Arg
Leu 435 440 445 Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu
Lys Met Asn 450 455 460 Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr
Cys Ala Lys His Tyr 465 470 475 480 Tyr Tyr Gly Gly Ser Tyr Ala Met
Asp Tyr Trp Gly Gln Gly Thr Ser 485 490 495 Val Thr Val Ser Ser Ser
Gly Thr Thr Thr Pro Ala Pro Arg Pro Pro 500 505 510 Thr Pro Ala Pro
Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu 515 520 525 Ala Cys
Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp 530 535 540
Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly 545
550 555 560 Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg
Gly Arg 565 570 575 Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met
Arg Pro Val Gln 580 585 590 Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys
Arg Phe Pro Glu Glu Glu 595 600 605 Glu Gly Gly Cys Glu Leu Arg Val
Lys Phe Ser Arg Ser Ala Asp Ala 610 615 620 Pro Ala Tyr Lys Gln Gly
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu 625 630 635 640 Gly Arg Arg
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp 645 650 655 Pro
Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 660 665
670 Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile
675 680 685 Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly
Leu Tyr 690 695 700 Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
Ala Leu His Met 705 710 715 720 Gln Ala Leu Pro Pro Arg Gly Ser Gly
Ala Thr Asn Phe Ser Leu Leu 725 730 735 Lys Gln Ala Gly Asp Val Glu
Glu Asn Pro Gly Pro Met Leu Val Arg 740 745 750 Arg Gly Ala Arg Ala
Gly Pro Arg Met Pro Arg Gly Trp Thr Ala Leu 755 760 765 Cys Leu Leu
Ser Leu Leu Pro Ser Gly Phe Met Ser Leu Asp Asn Asn 770 775 780 Gly
Thr Ala Thr Pro Glu Leu Pro Thr Gln Gly Thr Phe Ser Asn Val 785 790
795 800 Ser Thr Asn Val Ser Tyr Gln Glu Thr Thr Thr Pro Ser Thr Leu
Gly 805 810 815 Ser Thr Ser Leu His Pro Val Ser Gln His Gly Asn Glu
Ala Thr Thr 820 825 830 Asn Ile Thr Glu Thr Thr Val Lys Phe Thr Ser
Thr Ser Val Ile Thr 835 840 845 Ser Val Tyr Gly Asn Thr Asn Ser Ser
Val Gln Ser Gln Thr Ser Val 850 855 860 Ile Ser Thr Val Phe Thr Thr
Pro Ala Asn Val Ser Thr Pro Glu Thr 865 870 875 880 Thr Leu Lys Pro
Ser Leu Ser Pro Gly Asn Val Ser Asp Leu Ser Thr 885 890 895 Thr Ser
Thr Ser Leu Ala Thr Ser Pro Thr Lys Pro Tyr Thr Ser Ser 900 905 910
Ser Pro Ile Leu Ser Asp Ile Lys Ala Glu Ile Lys Cys Ser Gly Ile 915
920 925 Arg Glu Val Lys Leu Thr Gln Gly Ile Cys Leu Glu Gln Asn Lys
Thr 930 935 940 Ser Ser Cys Ala Glu Phe Lys Lys Asp Arg Gly Glu Gly
Leu Ala Arg 945 950 955 960 Val Leu Cys Gly Glu Glu Gln Ala Asp Ala
Asp Ala Gly Ala Gln Val 965 970 975 Cys Ser Leu Leu Leu Ala Gln Ser
Glu Val Arg Pro Gln Cys Leu Leu 980 985 990 Leu Val Leu Ala Asn Arg
Thr Glu Ile Ser Ser Lys Leu Gln Leu Met 995 1000 1005 Lys Lys His
Gln Ser Asp Leu Lys Lys Leu Gly Ile Leu Asp Phe 1010 1015 1020 Thr
Glu Gln Asp Val Ala Ser His Gln Ser Tyr Ser Gln Lys Thr 1025 1030
1035 Pro Ile Leu Leu Thr Cys Pro Thr Ile Ser Ile Leu Ser Phe Phe
1040 1045 1050 Ser Val Ala Leu Leu Val Ile Leu Ala Cys Val Leu Trp
Lys Lys 1055 1060 1065 Arg Ile Lys Pro Ile Val Trp Pro Ser Leu Pro
Asp His Lys Lys 1070 1075 1080 Thr Leu Glu His Leu Cys Lys Lys Pro
Arg Lys Asn Leu Asn Val 1085 1090 1095 Ser Phe Asn Pro Glu Ser Phe
Leu Asp Cys Gln Ile His Arg Val 1100 1105 1110 Asp Asp Ile Gln Ala
Arg Asp Glu Val Glu Gly Phe Leu Gln Asp 1115 1120 1125 Thr Phe Pro
Gln Gln Leu Glu Glu Ser Glu Lys Gln Arg Leu Gly 1130 1135 1140 Gly
Asp Val Gln Ser Pro Asn Cys Pro Ser Glu Asp Val Val Ile 1145 1150
1155 Thr Pro Glu Ser Phe Gly Arg Asp Ser Ser Leu Thr Cys Leu Ala
1160 1165 1170 Gly Asn Val Ser Ala Cys Asp Ala Pro Ile Leu Ser Ser
Ser Arg 1175 1180 1185 Ser Leu Asp Cys Arg Glu Ser Gly Lys Asn Gly
Pro His Val Tyr 1190 1195 1200 Gln Asp Leu Leu Leu Ser Leu Gly Thr
Thr Asn Ser Thr Leu Pro 1205 1210 1215 Pro Pro Phe Ser Leu Gln Ser
Gly Ile Leu Thr Leu Asn Pro Val 1220 1225 1230 Ala Gln Gly Gln Pro
Ile Leu Thr Ser Leu Gly Ser Asn Gln Glu 1235 1240 1245 Glu Ala Tyr
Val Thr Met Ser Ser Phe Tyr Gln Asn Gln 1250 1255 1260 <210>
SEQ ID NO 86 <211> LENGTH: 1263
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 86
Met Ala Ser Arg Ile Leu Trp His Glu Met Trp His Glu Gly Leu Glu 1 5
10 15 Glu Ala Ser Arg Leu Tyr Phe Gly Glu Arg Asn Val Lys Gly Met
Phe 20 25 30 Glu Val Leu Glu Pro Leu His Ala Met Met Glu Arg Gly
Pro Gln Thr 35 40 45 Leu Lys Glu Thr Ser Phe Asn Gln Ala Tyr Gly
Arg Asp Leu Met Glu 50 55 60 Ala Gln Glu Trp Cys Arg Lys Tyr Met
Lys Ser Gly Asn Val Lys Asp 65 70 75 80 Leu Leu Gln Ala Trp Asp Leu
Tyr Tyr His Val Phe Arg Arg Ile Ser 85 90 95 Lys Leu Glu Tyr Ser
Gly Gly Gly Ser Leu Glu Gly Val Gln Val Glu 100 105 110 Thr Ile Ser
Pro Gly Asp Gly Arg Thr Phe Pro Lys Arg Gly Gln Thr 115 120 125 Cys
Val Val His Tyr Thr Gly Met Leu Glu Asp Gly Lys Lys Phe Asp 130 135
140 Ser Ser Arg Asp Arg Asn Lys Pro Phe Lys Phe Met Leu Gly Lys Gln
145 150 155 160 Glu Val Ile Arg Gly Trp Glu Glu Gly Val Ala Gln Met
Ser Val Gly 165 170 175 Gln Arg Ala Lys Leu Thr Ile Ser Pro Asp Tyr
Ala Tyr Gly Ala Thr 180 185 190 Gly His Pro Gly Ile Ile Pro Pro His
Ala Thr Leu Val Phe Asp Val 195 200 205 Glu Leu Leu Lys Leu Glu Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly 210 215 220 Ser Gly Gly Gly Gly
Ser Gly Val Asp Gly Phe Gly Asp Val Gly Ala 225 230 235 240 Leu Glu
Ser Leu Arg Gly Asn Ala Asp Leu Ala Tyr Ile Leu Ser Met 245 250 255
Glu Pro Cys Gly His Cys Leu Ile Ile Asn Asn Val Asn Phe Cys Arg 260
265 270 Glu Ser Gly Leu Arg Thr Arg Thr Gly Ser Asn Ile Asp Cys Glu
Lys 275 280 285 Leu Arg Arg Arg Phe Ser Ser Leu His Phe Met Val Glu
Val Lys Gly 290 295 300 Asp Leu Thr Ala Lys Lys Met Val Leu Ala Leu
Leu Glu Leu Ala Gln 305 310 315 320 Gln Asp His Gly Ala Leu Asp Cys
Cys Val Val Val Ile Leu Ser His 325 330 335 Gly Cys Gln Ala Ser His
Leu Gln Phe Pro Gly Ala Val Tyr Gly Thr 340 345 350 Asp Gly Cys Pro
Val Ser Val Glu Lys Ile Val Asn Ile Phe Asn Gly 355 360 365 Thr Ser
Cys Pro Ser Leu Gly Gly Lys Pro Lys Leu Phe Phe Ile Gln 370 375 380
Ala Cys Gly Gly Glu Gln Lys Asp His Gly Phe Glu Val Ala Ser Thr 385
390 395 400 Ser Pro Glu Asp Glu Ser Pro Gly Ser Asn Pro Glu Pro Asp
Ala Thr 405 410 415 Pro Phe Gln Glu Gly Leu Arg Thr Phe Asp Gln Leu
Asp Ala Ile Ser 420 425 430 Ser Leu Pro Thr Pro Ser Asp Ile Phe Val
Ser Tyr Ser Thr Phe Pro 435 440 445 Gly Phe Val Ser Trp Arg Asp Pro
Lys Ser Gly Ser Trp Tyr Val Glu 450 455 460 Thr Leu Asp Asp Ile Phe
Glu Gln Trp Ala His Ser Glu Asp Leu Gln 465 470 475 480 Ser Leu Leu
Leu Arg Val Ala Asn Ala Val Ser Val Lys Gly Ile Tyr 485 490 495 Lys
Gln Met Pro Gly Cys Phe Asn Phe Leu Arg Lys Lys Leu Phe Phe 500 505
510 Lys Thr Ser Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala
515 520 525 Gly Asp Val Glu Glu Asn Pro Gly Pro Met Ala Leu Pro Val
Thr Ala 530 535 540 Leu Leu Leu Pro Leu Ala Leu Leu Leu His Ala Ala
Arg Pro Asp Ile 545 550 555 560 Gln Met Thr Gln Thr Thr Ser Ser Leu
Ser Ala Ser Leu Gly Asp Arg 565 570 575 Val Thr Ile Ser Cys Arg Ala
Ser Gln Asp Ile Ser Lys Tyr Leu Asn 580 585 590 Trp Tyr Gln Gln Lys
Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr His 595 600 605 Thr Ser Arg
Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly 610 615 620 Ser
Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp 625 630
635 640 Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr Thr
Phe 645 650 655 Gly Gly Gly Thr Lys Leu Glu Ile Thr Gly Gly Gly Gly
Ser Gln Val 660 665 670 Lys Leu Gln Glu Ser Gly Gly Gly Leu Val Lys
Pro Gly Gly Ser Leu 675 680 685 Lys Leu Ser Cys Ala Ala Ser Gly Phe
Thr Phe Ser Ser Tyr Ala Met 690 695 700 Ser Trp Val Arg Gln Thr Pro
Glu Lys Arg Leu Glu Trp Val Ala Thr 705 710 715 720 Ile Ser Ser Gly
Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly 725 730 735 Arg Phe
Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln 740 745 750
Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg 755
760 765 Gln Asp Gly Tyr Tyr Pro Gly Trp Phe Ala Asn Trp Gly Gln Gly
Thr 770 775 780 Thr Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser Gly
Lys Pro Gly 785 790 795 800 Ser Gly Glu Gly Ser Thr Lys Gly Asp Ile
Glu Leu Thr Gln Ser Pro 805 810 815 Ala Ile Met Ser Ala Ser Leu Gly
Glu Glu Ile Thr Leu Thr Cys Ser 820 825 830 Ala Ser Ser Ser Val Ser
Tyr Met His Trp Tyr Gln Gln Lys Ser Gly 835 840 845 Thr Ser Pro Lys
Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly 850 855 860 Val Pro
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu 865 870 875
880 Thr Ile Ser Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys His
885 890 895 Gln Trp Ser Ser Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu
Ile Lys 900 905 910 Arg Gly Gly Gly Gly Ser Glu Val Lys Leu Gln Glu
Ser Gly Pro Gly 915 920 925 Leu Val Ala Pro Ser Gln Ser Leu Ser Val
Thr Cys Thr Val Ser Gly 930 935 940 Val Ser Leu Pro Asp Tyr Gly Val
Ser Trp Ile Arg Gln Pro Pro Arg 945 950 955 960 Lys Gly Leu Glu Trp
Leu Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr 965 970 975 Tyr Asn Ser
Ala Leu Lys Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser 980 985 990 Lys
Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr 995
1000 1005 Ala Ile Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser
Tyr 1010 1015 1020 Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr
Val Ser Ser 1025 1030 1035 Ser Gly Thr Thr Thr Pro Ala Pro Arg Pro
Pro Thr Pro Ala Pro 1040 1045 1050 Thr Ile Ala Ser Gln Pro Leu Ser
Leu Arg Pro Glu Ala Cys Arg 1055 1060 1065 Pro Ala Ala Gly Gly Ala
Val His Thr Arg Gly Leu Asp Phe Ala 1070 1075 1080 Cys Asp Ile Tyr
Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val 1085 1090 1095 Leu Leu
Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg 1100 1105 1110
Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val 1115
1120 1125 Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro
Glu 1130 1135 1140 Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe
Ser Arg Ser 1145 1150 1155 Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln
Asn Gln Leu Tyr Asn 1160 1165 1170 Glu Leu Asn Leu Gly Arg Arg Glu
Glu Tyr Asp Val Leu Asp Lys 1175 1180 1185 Arg Arg Gly Arg Asp Pro
Glu Met Gly Gly Lys Pro Arg Arg Lys 1190 1195 1200 Asn Pro Gln Glu
Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met 1205 1210 1215 Ala Glu
Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg 1220 1225 1230
Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr 1235
1240 1245 Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro
Arg 1250 1255 1260 <210> SEQ ID NO 87
<211> LENGTH: 107 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 87 Asp Ile Gln Met Thr Gln Thr
Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile
Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp
Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr
His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55
60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln
65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu
Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr 100
105 <210> SEQ ID NO 88 <211> LENGTH: 120 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic polypeptide <400> SEQUENCE: 88 Glu Val
Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 1 5 10 15
Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr 20
25 30 Gly Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp
Leu 35 40 45 Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser
Ala Leu Lys 50 55 60 Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys
Ser Gln Val Phe Leu 65 70 75 80 Lys Met Asn Ser Leu Gln Thr Asp Asp
Thr Ala Ile Tyr Tyr Cys Ala 85 90 95 Lys His Tyr Tyr Tyr Gly Gly
Ser Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Ser Val Thr
Val Ser Ser 115 120 <210> SEQ ID NO 89 <211> LENGTH:
491 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 89
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5
10 15 His Ala Ala Arg Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser
Leu 20 25 30 Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg
Ala Ser Gln 35 40 45 Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln
Lys Pro Asp Gly Thr 50 55 60 Val Lys Leu Leu Ile Tyr His Thr Ser
Arg Leu His Ser Gly Val Pro 65 70 75 80 Ser Arg Phe Ser Gly Ser Gly
Ser Gly Thr Asp Tyr Ser Leu Thr Ile 85 90 95 Ser Asn Leu Glu Gln
Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly 100 105 110 Asn Thr Leu
Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr 115 120 125 Gly
Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr 130 135
140 Lys Gly Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro
145 150 155 160 Ser Gln Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val
Ser Leu Pro 165 170 175 Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro
Arg Lys Gly Leu Glu 180 185 190 Trp Leu Gly Val Ile Trp Gly Ser Glu
Thr Thr Tyr Tyr Asn Ser Ala 195 200 205 Leu Lys Ser Arg Leu Thr Ile
Ile Lys Asp Asn Ser Lys Ser Gln Val 210 215 220 Phe Leu Lys Met Asn
Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr 225 230 235 240 Cys Ala
Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp 245 250 255
Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ser Gly Thr Thr Thr Pro 260
265 270 Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro
Leu 275 280 285 Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly
Ala Val His 290 295 300 Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr
Ile Trp Ala Pro Leu 305 310 315 320 Ala Gly Thr Cys Gly Val Leu Leu
Leu Ser Leu Val Ile Thr Leu Tyr 325 330 335 Cys Lys Arg Gly Arg Lys
Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe 340 345 350 Met Arg Pro Val
Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg 355 360 365 Phe Pro
Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser 370 375 380
Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr 385
390 395 400 Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
Asp Lys 405 410 415 Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
Arg Arg Lys Asn 420 425 430 Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln
Lys Asp Lys Met Ala Glu 435 440 445 Ala Tyr Ser Glu Ile Gly Met Lys
Gly Glu Arg Arg Arg Gly Lys Gly 450 455 460 His Asp Gly Leu Tyr Gln
Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr 465 470 475 480 Asp Ala Leu
His Met Gln Ala Leu Pro Pro Arg 485 490 <210> SEQ ID NO 90
<211> LENGTH: 105 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 90 Asp Ile Glu Leu Thr Gln Ser
Pro Ala Ile Met Ser Ala Ser Leu Gly 1 5 10 15 Glu Glu Ile Thr Leu
Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 20 25 30 His Trp Tyr
Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr 35 40 45 Ser
Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 50 55
60 Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu
65 70 75 80 Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Thr
Phe Gly 85 90 95 Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105
<210> SEQ ID NO 91 <211> LENGTH: 120 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 91 Gln Val Lys Leu Gln
Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Lys
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala
Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 35 40
45 Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val
50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr
Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala
Met Tyr Tyr Cys 85 90 95 Ala Arg Gln Asp Gly Tyr Tyr Pro Gly Trp
Phe Ala Asn Trp Gly Gln 100 105 110 Gly Thr Thr Val Thr Val Ser Ser
115 120 <210> SEQ ID NO 92 <211> LENGTH: 5 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic peptide
<400> SEQUENCE: 92 Glu Ala Ala Ala Lys 1 5 <210> SEQ ID
NO 93 <211> LENGTH: 30 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <220> FEATURE: <221> NAME/KEY: SITE
<222> LOCATION: (1)..(30) <223> OTHER INFORMATION: This
sequence may encompass 2-6 "Gly Gly Gly Gly Ser" repeating units
<400> SEQUENCE: 93 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly 1 5 10 15 Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser 20 25 30 <210> SEQ ID NO 94
<211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 94 Arg Gly Asp Ser 1 <210> SEQ ID NO 95
<211> LENGTH: 116 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 95 Gln Leu Gln Gln Pro Gly Ala
Glu Leu Val Arg Pro Gly Ser Ser Val 1 5 10 15 Lys Leu Ser Cys Lys
Ala Ser Gly Tyr Thr Phe Thr Arg Tyr Trp Ile 20 25 30 His Trp Val
Lys Gln Arg Pro Ile Gln Gly Leu Glu Trp Ile Gly Asn 35 40 45 Ile
Asp Pro Ser Asp Ser Glu Thr His Tyr Asn Gln Lys Phe Lys Asp 50 55
60 Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Gly Thr Ala Tyr Met Gln
65 70 75 80 Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
Ala Thr 85 90 95 Glu Asp Leu Tyr Tyr Ala Met Glu Tyr Trp Gly Gln
Gly Thr Ser Val 100 105 110 Thr Val Ser Ser 115 <210> SEQ ID
NO 96 <211> LENGTH: 113 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 96 Asp Ile Met Met Thr Gln Ser
Pro Ser Ser Leu Ala Val Ser Ala Gly 1 5 10 15 Glu Lys Val Thr Met
Thr Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser 20 25 30 Ser Asn Gln
Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Ser
Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55
60 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80 Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Val Tyr Tyr Cys
His Gln 85 90 95 Tyr Leu Ser Ser His Thr Phe Gly Gly Gly Thr Lys
Leu Glu Ile Lys 100 105 110 Arg <210> SEQ ID NO 97
<211> LENGTH: 120 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 97 Gln Val Gln Leu Gln Gln Pro
Gly Thr Glu Leu Val Arg Pro Gly Ser 1 5 10 15 Ser Val Lys Leu Ser
Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Val Asn
Trp Val Lys Gln Arg Pro Asp Gln Gly Leu Glu Trp Ile 35 40 45 Gly
Arg Ile Asp Pro Tyr Asp Ser Glu Thr His Tyr Asn Gln Lys Phe 50 55
60 Thr Asp Lys Ala Ile Ser Thr Ile Asp Thr Ser Ser Asn Thr Ala Tyr
65 70 75 80 Met Gln Leu Ser Thr Leu Thr Ser Asp Ala Ser Ala Val Tyr
Tyr Cys 85 90 95 Ser Arg Ser Pro Arg Asp Ser Ser Thr Asn Leu Ala
Asp Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120
<210> SEQ ID NO 98 <211> LENGTH: 108 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 98 Asp Ile Val Met Thr
Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly 1 5 10 15 Asp Arg Val
Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Asp Tyr 20 25 30 Leu
His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile 35 40
45 Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly
50 55 60 Ser Gly Ser Gly Ser Asp Phe Thr Leu Ser Ile Asn Ser Val
Glu Pro 65 70 75 80 Glu Asp Val Gly Val Tyr Tyr Cys Gln Asn Gly His
Ser Phe Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu
Arg Arg 100 105 <210> SEQ ID NO 99 <211> LENGTH: 903
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 99
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5
10 15 His Ala Ala Arg Pro Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile
Met 20 25 30 Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser
Ala Ser Ser 35 40 45 Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys
Ser Gly Thr Ser Pro 50 55 60 Lys Leu Leu Ile Tyr Ser Thr Ser Asn
Leu Ala Ser Gly Val Pro Ser 65 70 75 80 Arg Phe Ser Gly Ser Gly Ser
Gly Thr Phe Tyr Ser Leu Thr Ile Ser 85 90 95 Ser Val Glu Ala Glu
Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser 100 105 110 Ser Tyr Thr
Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Gly Gly 115 120 125 Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Lys 130 135
140 Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys
145 150 155 160 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
Ala Met Ser 165 170 175 Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu
Trp Val Ala Thr Ile 180 185 190 Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr
Pro Asp Ser Val Lys Gly Arg 195 200 205 Phe Thr Ile Ser Arg Asp Asn
Ala Lys Asn Thr Leu Tyr Leu Gln Met 210 215 220 Ser Ser Leu Arg Ser
Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gln 225 230 235 240 Asp Gly
Tyr Tyr Pro Gly Trp Phe Ala Asn Trp Gly Gln Gly Thr Thr 245 250 255
Val Thr Val Ser Ser Ser Gly Thr Thr Thr Pro Ala Pro Arg Pro Pro 260
265 270 Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro
Glu 275 280 285 Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg
Gly Leu Asp
290 295 300 Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr
Cys Gly 305 310 315 320 Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
Cys Lys Arg Gly Arg 325 330 335 Lys Lys Leu Leu Tyr Ile Phe Lys Gln
Pro Phe Met Arg Pro Val Gln 340 345 350 Thr Thr Gln Glu Glu Asp Gly
Cys Ser Cys Arg Phe Pro Glu Glu Glu 355 360 365 Glu Gly Gly Cys Glu
Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala 370 375 380 Pro Ala Tyr
Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu 385 390 395 400
Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp 405
410 415 Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
Leu 420 425 430 Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr
Ser Glu Ile 435 440 445 Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly
His Asp Gly Leu Tyr 450 455 460 Gln Gly Leu Ser Thr Ala Thr Lys Asp
Thr Tyr Asp Ala Leu His Met 465 470 475 480 Gln Ala Leu Pro Pro Arg
Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu 485 490 495 Lys Gln Ala Gly
Asp Val Glu Glu Asn Pro Gly Pro Met Asp Trp Thr 500 505 510 Trp Ile
Leu Phe Leu Val Ala Ala Ala Thr Arg Val His Ser Asn Trp 515 520 525
Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile Gln Ser 530
535 540 Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val His Pro
Ser 545 550 555 560 Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu
Leu Gln Val Ile 565 570 575 Ser Leu Glu Ser Gly Asp Ala Ser Ile His
Asp Thr Val Glu Asn Leu 580 585 590 Ile Ile Leu Ala Asn Asn Ser Leu
Ser Ser Asn Gly Asn Val Thr Glu 595 600 605 Ser Gly Cys Lys Glu Cys
Glu Glu Leu Glu Glu Lys Asn Ile Lys Glu 610 615 620 Phe Leu Gln Ser
Phe Val His Ile Val Gln Met Phe Ile Asn Thr Ser 625 630 635 640 Ser
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 645 650
655 Gly Gly Gly Ser Gly Gly Gly Ser Leu Gln Ile Thr Cys Pro Pro Pro
660 665 670 Met Ser Val Glu His Ala Asp Ile Trp Val Lys Ser Tyr Ser
Leu Tyr 675 680 685 Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly Phe Lys
Arg Lys Ala Gly 690 695 700 Thr Ser Ser Leu Thr Glu Cys Val Leu Asn
Lys Ala Thr Asn Val Ala 705 710 715 720 His Trp Thr Thr Pro Ser Leu
Lys Cys Ile Arg Asp Pro Ala Leu Val 725 730 735 His Gln Arg Pro Ala
Pro Pro Ser Thr Val Thr Thr Ala Gly Val Thr 740 745 750 Pro Gln Pro
Glu Ser Leu Ser Pro Ser Gly Lys Glu Pro Ala Ala Ser 755 760 765 Ser
Pro Ser Ser Asn Asn Thr Ala Ala Thr Thr Ala Ala Ile Val Pro 770 775
780 Gly Ser Gln Leu Met Pro Ser Lys Ser Pro Ser Thr Gly Thr Thr Glu
785 790 795 800 Ile Ser Ser His Glu Ser Ser His Gly Thr Pro Ser Gln
Thr Thr Ala 805 810 815 Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser His
Gln Pro Pro Gly Val 820 825 830 Tyr Pro Gln Gly His Ser Asp Thr Thr
Val Ala Ile Ser Thr Ser Thr 835 840 845 Val Leu Leu Cys Gly Leu Ser
Ala Val Ser Leu Leu Ala Cys Tyr Leu 850 855 860 Lys Ser Arg Gln Thr
Pro Pro Leu Ala Ser Val Glu Met Glu Ala Met 865 870 875 880 Glu Ala
Leu Pro Val Thr Trp Gly Thr Ser Ser Arg Asp Glu Asp Leu 885 890 895
Glu Asn Cys Ser His His Leu 900 <210> SEQ ID NO 100
<211> LENGTH: 1065 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 100 Met Ala Leu Pro Val Thr Ala
Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro
Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met 20 25 30 Ser Ala Ser
Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser 35 40 45 Ser
Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro 50 55
60 Lys Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser
65 70 75 80 Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr
Ile Ser 85 90 95 Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys
His Gln Trp Ser 100 105 110 Ser Tyr Thr Phe Gly Gly Gly Thr Lys Leu
Glu Ile Lys Arg Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gln Val Lys 130 135 140 Leu Gln Glu Ser Gly Gly
Gly Leu Val Lys Pro Gly Gly Ser Leu Lys 145 150 155 160 Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser 165 170 175 Trp
Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile 180 185
190 Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg
195 200 205 Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu
Gln Met 210 215 220 Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr
Cys Ala Arg Gln 225 230 235 240 Asp Gly Tyr Tyr Pro Gly Trp Phe Ala
Asn Trp Gly Gln Gly Thr Thr 245 250 255 Val Thr Val Ser Ser Ser Gly
Thr Thr Thr Pro Ala Pro Arg Pro Pro 260 265 270 Thr Pro Ala Pro Thr
Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu 275 280 285 Ala Cys Arg
Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp 290 295 300 Phe
Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly 305 310
315 320 Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly
Arg 325 330 335 Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg
Pro Val Gln 340 345 350 Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg
Phe Pro Glu Glu Glu 355 360 365 Glu Gly Gly Cys Glu Leu Arg Val Lys
Phe Ser Arg Ser Ala Asp Ala 370 375 380 Pro Ala Tyr Lys Gln Gly Gln
Asn Gln Leu Tyr Asn Glu Leu Asn Leu 385 390 395 400 Gly Arg Arg Glu
Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp 405 410 415 Pro Glu
Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 420 425 430
Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile 435
440 445 Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
Tyr 450 455 460 Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala
Leu His Met 465 470 475 480 Gln Ala Leu Pro Pro Arg Gly Ser Gly Ala
Thr Asn Phe Ser Leu Leu 485 490 495 Lys Gln Ala Gly Asp Val Glu Glu
Asn Pro Gly Pro Met Leu Leu Leu 500 505 510 Val Thr Ser Leu Leu Leu
Cys Glu Leu Pro His Pro Ala Phe Leu Leu 515 520 525 Ile Pro Arg Lys
Val Cys Asn Gly Ile Gly Ile Gly Glu Phe Lys Asp 530 535 540 Ser Leu
Ser Ile Asn Ala Thr Asn Ile Lys His Phe Lys Asn Cys Thr 545 550 555
560 Ser Ile Ser Gly Asp Leu His Ile Leu Pro Val Ala Phe Arg Gly Asp
565 570 575 Ser Phe Thr His Thr Pro Pro Leu Asp Pro Gln Glu Leu Asp
Ile Leu 580 585 590 Lys Thr Val Lys Glu Ile Thr Gly Phe Leu Leu Ile
Gln Ala Trp Pro 595 600 605 Glu Asn Arg Thr Asp Leu His Ala Phe Glu
Asn Leu Glu Ile Ile Arg 610 615 620 Gly Arg Thr Lys Gln His Gly Gln
Phe Ser Leu Ala Val Val Ser Leu 625 630 635 640 Asn Ile Thr Ser Leu
Gly Leu Arg Ser Leu Lys Glu Ile Ser Asp Gly 645 650 655
Asp Val Ile Ile Ser Gly Asn Lys Asn Leu Cys Tyr Ala Asn Thr Ile 660
665 670 Asn Trp Lys Lys Leu Phe Gly Thr Ser Gly Gln Lys Thr Lys Ile
Ile 675 680 685 Ser Asn Arg Gly Glu Asn Ser Cys Lys Ala Thr Gly Gln
Val Cys His 690 695 700 Ala Leu Cys Ser Pro Glu Gly Cys Trp Gly Pro
Glu Pro Arg Asp Cys 705 710 715 720 Val Ser Cys Arg Asn Val Ser Arg
Gly Arg Glu Cys Val Asp Lys Cys 725 730 735 Asn Leu Leu Glu Gly Glu
Pro Arg Glu Phe Val Glu Asn Ser Glu Cys 740 745 750 Ile Gln Cys His
Pro Glu Cys Leu Pro Gln Ala Met Asn Ile Thr Cys 755 760 765 Thr Gly
Arg Gly Pro Asp Asn Cys Ile Gln Cys Ala His Tyr Ile Asp 770 775 780
Gly Pro His Cys Val Lys Thr Cys Pro Ala Gly Val Met Gly Glu Asn 785
790 795 800 Asn Thr Leu Val Trp Lys Tyr Ala Asp Ala Gly His Val Cys
His Leu 805 810 815 Cys His Pro Asn Cys Thr Tyr Gly Cys Thr Gly Pro
Gly Leu Glu Gly 820 825 830 Cys Pro Thr Asn Gly Pro Lys Ile Pro Ser
Pro Ile Leu Leu Thr Cys 835 840 845 Pro Thr Ile Ser Ile Leu Ser Phe
Phe Ser Val Ala Leu Leu Val Ile 850 855 860 Leu Ala Cys Val Leu Trp
Lys Lys Arg Ile Lys Pro Ile Val Trp Pro 865 870 875 880 Ser Leu Pro
Asp His Lys Lys Thr Leu Glu His Leu Cys Lys Lys Pro 885 890 895 Arg
Lys Asn Leu Asn Val Ser Phe Asn Pro Glu Ser Phe Leu Asp Cys 900 905
910 Gln Ile His Arg Val Asp Asp Ile Gln Ala Arg Asp Glu Val Glu Gly
915 920 925 Phe Leu Gln Asp Thr Phe Pro Gln Gln Leu Glu Glu Ser Glu
Lys Gln 930 935 940 Arg Leu Gly Gly Asp Val Gln Ser Pro Asn Cys Pro
Ser Glu Asp Val 945 950 955 960 Val Ile Thr Pro Glu Ser Phe Gly Arg
Asp Ser Ser Leu Thr Cys Leu 965 970 975 Ala Gly Asn Val Ser Ala Cys
Asp Ala Pro Ile Leu Ser Ser Ser Arg 980 985 990 Ser Leu Asp Cys Arg
Glu Ser Gly Lys Asn Gly Pro His Val Tyr Gln 995 1000 1005 Asp Leu
Leu Leu Ser Leu Gly Thr Thr Asn Ser Thr Leu Pro Pro 1010 1015 1020
Pro Phe Ser Leu Gln Ser Gly Ile Leu Thr Leu Asn Pro Val Ala 1025
1030 1035 Gln Gly Gln Pro Ile Leu Thr Ser Leu Gly Ser Asn Gln Glu
Glu 1040 1045 1050 Ala Tyr Val Thr Met Ser Ser Phe Tyr Gln Asn Gln
1055 1060 1065 <210> SEQ ID NO 101 <211> LENGTH: 851
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
101 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15 His Ala Ala Arg Pro Asp Ile Glu Leu Thr Gln Ser Pro Ala
Ile Met 20 25 30 Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys
Ser Ala Ser Ser 35 40 45 Ser Val Ser Tyr Met His Trp Tyr Gln Gln
Lys Ser Gly Thr Ser Pro 50 55 60 Lys Leu Leu Ile Tyr Ser Thr Ser
Asn Leu Ala Ser Gly Val Pro Ser 65 70 75 80 Arg Phe Ser Gly Ser Gly
Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser 85 90 95 Ser Val Glu Ala
Glu Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser 100 105 110 Ser Tyr
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Gly Gly 115 120 125
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Lys 130
135 140 Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu
Lys 145 150 155 160 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
Tyr Ala Met Ser 165 170 175 Trp Val Arg Gln Thr Pro Glu Lys Arg Leu
Glu Trp Val Ala Thr Ile 180 185 190 Ser Ser Gly Gly Ser Tyr Thr Tyr
Tyr Pro Asp Ser Val Lys Gly Arg 195 200 205 Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met 210 215 220 Ser Ser Leu Arg
Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gln 225 230 235 240 Asp
Gly Tyr Tyr Pro Gly Trp Phe Ala Asn Trp Gly Gln Gly Thr Thr 245 250
255 Val Thr Val Ser Ser Ser Gly Thr Thr Thr Pro Ala Pro Arg Pro Pro
260 265 270 Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg
Pro Glu 275 280 285 Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr
Arg Gly Leu Asp 290 295 300 Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro
Leu Ala Gly Thr Cys Gly 305 310 315 320 Val Leu Leu Leu Ser Leu Val
Ile Thr Leu Tyr Cys Lys Arg Gly Arg 325 330 335 Lys Lys Leu Leu Tyr
Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln 340 345 350 Thr Thr Gln
Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu 355 360 365 Glu
Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala 370 375
380 Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu
385 390 395 400 Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg
Gly Arg Asp 405 410 415 Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn
Pro Gln Glu Gly Leu 420 425 430 Tyr Asn Glu Leu Gln Lys Asp Lys Met
Ala Glu Ala Tyr Ser Glu Ile 435 440 445 Gly Met Lys Gly Glu Arg Arg
Arg Gly Lys Gly His Asp Gly Leu Tyr 450 455 460 Gln Gly Leu Ser Thr
Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met 465 470 475 480 Gln Ala
Leu Pro Pro Arg Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu 485 490 495
Lys Gln Ala Gly Asp Val Glu Glu Asn Pro Gly Pro Met Leu Leu Leu 500
505 510 Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro Ala Phe Leu
Leu 515 520 525 Ile Pro Cys His Pro Glu Cys Gln Pro Gln Asn Gly Ser
Val Thr Cys 530 535 540 Phe Gly Pro Glu Ala Asp Gln Cys Val Ala Cys
Ala His Tyr Lys Asp 545 550 555 560 Pro Pro Phe Cys Val Ala Arg Cys
Pro Ser Gly Val Lys Pro Asp Leu 565 570 575 Ser Tyr Met Pro Ile Trp
Lys Phe Pro Asp Glu Glu Gly Ala Cys Gln 580 585 590 Pro Cys Pro Ile
Asn Cys Thr His Ser Cys Val Asp Leu Asp Asp Lys 595 600 605 Gly Cys
Pro Ala Glu Gln Arg Ala Ser Pro Leu Thr Gly Gly Gly Ser 610 615 620
Gly Gly Gly Ser Pro Ile Leu Leu Thr Cys Pro Thr Ile Ser Ile Leu 625
630 635 640 Ser Phe Phe Ser Val Ala Leu Leu Val Ile Leu Ala Cys Val
Leu Trp 645 650 655 Lys Lys Arg Ile Lys Pro Ile Val Trp Pro Ser Leu
Pro Asp His Lys 660 665 670 Lys Thr Leu Glu His Leu Cys Lys Lys Pro
Arg Lys Asn Leu Asn Val 675 680 685 Ser Phe Asn Pro Glu Ser Phe Leu
Asp Cys Gln Ile His Arg Val Asp 690 695 700 Asp Ile Gln Ala Arg Asp
Glu Val Glu Gly Phe Leu Gln Asp Thr Phe 705 710 715 720 Pro Gln Gln
Leu Glu Glu Ser Glu Lys Gln Arg Leu Gly Gly Asp Val 725 730 735 Gln
Ser Pro Asn Cys Pro Ser Glu Asp Val Val Ile Thr Pro Glu Ser 740 745
750 Phe Gly Arg Asp Ser Ser Leu Thr Cys Leu Ala Gly Asn Val Ser Ala
755 760 765 Cys Asp Ala Pro Ile Leu Ser Ser Ser Arg Ser Leu Asp Cys
Arg Glu 770 775 780 Ser Gly Lys Asn Gly Pro His Val Tyr Gln Asp Leu
Leu Leu Ser Leu 785 790 795 800 Gly Thr Thr Asn Ser Thr Leu Pro Pro
Pro Phe Ser Leu Gln Ser Gly 805 810 815 Ile Leu Thr Leu Asn Pro Val
Ala Gln Gly Gln Pro Ile Leu Thr Ser 820 825 830 Leu Gly Ser Asn Gln
Glu Glu Ala Tyr Val Thr Met Ser Ser Phe Tyr 835 840 845 Gln Asn Gln
850
<210> SEQ ID NO 102 <211> LENGTH: 15 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 102 Glu Ala Ala Ala Lys Glu
Ala Ala Ala Lys Glu Ala Ala Ala Lys 1 5 10 15 <210> SEQ ID NO
103 <211> LENGTH: 368 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 103 Met Leu Leu Leu Val Thr Ser
Leu Leu Leu Cys Glu Leu Pro His Pro 1 5 10 15 Ala Phe Leu Leu Ile
Pro Gln Leu Leu Phe Asn Lys Thr Lys Ser Val 20 25 30 Glu Phe Thr
Phe Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr 35 40 45 Asn
Met Glu Ala Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe 50 55
60 Lys Gly Arg Asp Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr
65 70 75 80 Val Pro Thr Asp Phe Ser Ser Ala Lys Ile Glu Val Ser Gln
Leu Leu 85 90 95 Lys Gly Asp Ala Ser Leu Lys Met Asp Lys Ser Asp
Ala Val Ser His 100 105 110 Thr Gly Asn Tyr Thr Cys Glu Val Thr Glu
Leu Thr Arg Glu Gly Glu 115 120 125 Thr Ile Ile Glu Leu Lys Tyr Arg
Val Val Ser Trp Phe Ser Pro Asn 130 135 140 Glu Pro Ile Leu Leu Thr
Cys Pro Thr Ile Ser Ile Leu Ser Phe Phe 145 150 155 160 Ser Val Ala
Leu Leu Val Ile Leu Ala Cys Val Leu Trp Lys Lys Arg 165 170 175 Ile
Lys Pro Ile Val Trp Pro Ser Leu Pro Asp His Lys Lys Thr Leu 180 185
190 Glu His Leu Cys Lys Lys Pro Arg Lys Asn Leu Asn Val Ser Phe Asn
195 200 205 Pro Glu Ser Phe Leu Asp Cys Gln Ile His Arg Val Asp Asp
Ile Gln 210 215 220 Ala Arg Asp Glu Val Glu Gly Phe Leu Gln Asp Thr
Phe Pro Gln Gln 225 230 235 240 Leu Glu Glu Ser Glu Lys Gln Arg Leu
Gly Gly Asp Val Gln Ser Pro 245 250 255 Asn Cys Pro Ser Glu Asp Val
Val Ile Thr Pro Glu Ser Phe Gly Arg 260 265 270 Asp Ser Ser Leu Thr
Cys Leu Ala Gly Asn Val Ser Ala Cys Asp Ala 275 280 285 Pro Ile Leu
Ser Ser Ser Arg Ser Leu Asp Cys Arg Glu Ser Gly Lys 290 295 300 Asn
Gly Pro His Val Tyr Gln Asp Leu Leu Leu Ser Leu Gly Thr Thr 305 310
315 320 Asn Ser Thr Leu Pro Pro Pro Phe Ser Leu Gln Ser Gly Ile Leu
Thr 325 330 335 Leu Asn Pro Val Ala Gln Gly Gln Pro Ile Leu Thr Ser
Leu Gly Ser 340 345 350 Asn Gln Glu Glu Ala Tyr Val Thr Met Ser Ser
Phe Tyr Gln Asn Gln 355 360 365
* * * * *
References